Rank	NCT Number	Title	Acronym	Status	Study Results	Conditions	Interventions	Outcome Measures	Sponsor/Collaborators	Gender	Age	Phases	Enrollment	Funded Bys	Study Type	Study Designs	Other IDs	Start Date	Primary Completion Date	Completion Date	First Posted	Results First Posted	Last Update Posted	Locations	Study Documents	URL
1	NCT01851772	Feasibility Study of the Xoft® Axxent® Electronic Brachytherapy System for the Treatment of Cervical Cancer		Completed	Has Results	Cervical Cancer	Device: Treatment with Electronic Brachytherapy	Safety|Device Performance	Xoft, Inc.|Icad, Inc.	Female	Child, Adult, Older Adult	Not Applicable	3	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CTRP-0010	November 2013	June 2015	June 2015	May 10, 2013	June 24, 2016	June 24, 2016	Oklahoma University, Oklahoma City, Oklahoma, United States		https://ClinicalTrials.gov/show/NCT01851772
2	NCT03166553	Clinical Trial of Elemene in Combination With Oxaliplatinin the Treatment of Advanced Primary Liver Cancer		Recruiting	No Results Available	Advanced Primary Liver Cancer	Drug: Elemene	Objective response rate and/or 1-year survival rate|Disease control rate(DCR)|Progression-free survival(PFS)|Overall survival(OS)|Quality of Life Questionnaire (QLQ)|the rate of incidence of adverse events	BeiJing Yijiayi Medicine Techonoloy Co., Ltd.|Dalian Holley Kingkong Pharmaceutical Co., Ltd	All	18 Years to 75 Years   (Adult, Older Adult)	Not Applicable	150	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	81YY-ZLLL-16-20	November 28, 2016	May 28, 2019	November 27, 2019	May 25, 2017		May 25, 2017	302 Military Hospital of China, Beijing, Beijing, China|The First Hospital of Lanzhou University, Lanzhou, Gansu, China|The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China|Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China|Henan Medical University Cancer Hospital, Zhengzhou, Henan, China|Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China|Xiehe University of Science and Technology Affiliate Tongji Hospital, Wuhan, Hubei, China|Jinan Military General Hospital, Jinan, Shandong, China|The Affiliated Hospital of Qindao University, Qindao, Shandong, China|Shanghai Oriental Hospital, Shanghai, Shanghai, China		https://ClinicalTrials.gov/show/NCT03166553
3	NCT03167775	Clinical Trial of Elemene Injection/Elemene Oral Emulusion in Combination With the Best Supportive Treatment in the Treatment of Advanced Primary Liver Cancer		Recruiting	No Results Available	Advanced Primary Liver Cancer	Drug: Elemene Injection/Elemene Oral Emulusion	DCR and/or 6-months survival rate|ORR|PFS|OS|QLQ|the rate of incidence of adverse events	BeiJing Yijiayi Medicine Techonoloy Co., Ltd.|Dalian Holley Kingkong Pharmaceutical Co., Ltd	All	18 Years to 75 Years   (Adult, Older Adult)	Not Applicable	30	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	81YY-ZLLL-16-19	November 28, 2016	May 27, 2019	November 27, 2019	May 30, 2017		May 30, 2017	Henan Medical University Cancer Hospital, Zhengzhou, Henan, China		https://ClinicalTrials.gov/show/NCT03167775
4	NCT03272971	Feasibility Study of the RF Ablation Catheter to Ablate Lung Tumors		Recruiting	No Results Available	Lung Cancer|Lung Cancer Metastatic|Lung Cancer, Non-small Cell	Device: Radio-frequency Ablation	RFA relate AEs/SAEs|Feasibility - Ablated Tissue|Feasibility - Delivery of Ablation	Broncus Medical Inc|Uptake Medical Technology, Inc.	All	21 Years to 75 Years   (Adult, Older Adult)	Not Applicable	10	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility	Protocol 45	December 5, 2017	June 30, 2018	July 5, 2018	September 6, 2017		January 30, 2018	The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China		https://ClinicalTrials.gov/show/NCT03272971
5	NCT03085238	Metastatic Tumor Cell Trap Device in Patients With Advanced Ovarian Cancer		Active, not recruiting	No Results Available	Ovarian Cancer Stage IIIC	Device: M-Trap	Safety: Freedom from device and procedure related major adverse events|Performance: Histological evidence of tumor cell capture|Safety: Long-term adverse event reporting|Performance: Disease focalization score	MTrap, Inc.|MedPass International	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	23	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MTRAP-2016-01	March 9, 2017	September 12, 2018	August 2019	March 21, 2017		March 6, 2019	Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Castellon University General Hospital, Castelló, Spain|MD Anderson Cancer Center, Madrid, Spain|Hospital La Paz Madrid, Madrid, Spain|Complexo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain|Valencia-Hospital General, Valencia, Spain|Hospital Universitrio y Politècnico La Fe, Valencia, Spain		https://ClinicalTrials.gov/show/NCT03085238
6	NCT03161600	Improving Surgical/Medical Oncology Collaboration for Breast Cancer Treatment Planning: Pilot Testing the Impact of Continuing Education and Patient Care Planning		Completed	No Results Available	Breast Cancer	Behavioral: Carevive CPS	Rates of provider self-report and actual percent of eligible patients referred to medical oncology for discussion of neoadjuvant therapy.|Rates of actual prescription of neoadjuvant therapy to eligible patients	Carevive Systems, Inc.	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	25	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening	G402	May 18, 2017	December 31, 2018	December 31, 2018	May 22, 2017		January 30, 2019	Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT03161600
7	NCT02666079	The LightPath® Breast Cancer Study		Recruiting	No Results Available	Breast Cancer	Device: LightPath® Imaging System.	Diagnostic performance of the LightPath® Imaging System|The recommendation by the study site's multidisciplinary team (MDT) to re-operate at the index location (breast) within 1 to 6 weeks post-initial surgery according to local practice.|Rate of re-operation at the index location|Volume of tissue excised|Radiation dosimetry|Safety - adverse events (related to breast surgery)	Lightpoint Medical Limited|European Commission	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	170	Industry|Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	LPM-007	May 1, 2017	November 2018	December 2018	January 28, 2016		June 20, 2018	Klinika Chirurgii Onkologicznej i Rekonstrukcyjnej Centrum Onkologii- Instytut oddział w Gliwicach, ul. Wybrzeże Armii Krajowej 15,, Gliwice, Poland|Szpital Uniwersytecki w Krakowie, Oddział Kliniczny Endokrynologii, ul. Mikołaja Kopernika 17,, Kraków, Poland|Centrum Onkologii - Instytut, im Marii Skłodowskiej-Curie, Klinika Nowotworów Piersi i Chirurgii Rekonstrukcyjnej ul. Roetgena 5, Warszawa, Poland|Royal Liverpool Hospital, Liverpool, United Kingdom|Cardiff Breast Centre, LLandough Hospital, Llandough, United Kingdom		https://ClinicalTrials.gov/show/NCT02666079
8	NCT03524430	RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy BREVITY	BREVITY	Recruiting	No Results Available	Breast Neoplasm Female	Procedure: Core needle biopsy	Pathological complete response (pCR)|Disease-free survival	Rna Diagnostics Inc.	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	725	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	RnaDx-BRV-BC- 01	April 26, 2018	April 26, 2025	October 26, 2025	May 14, 2018		July 4, 2019	Washington University School of Medicine - Siteman Cancer Center, Saint Louis, Missouri, United States|Grand River Hospital, Kitchener, Ontario, Canada|Health Sciences North, Sudbury, Ontario, Canada|Sunnybrook Research Institute, Toronto, Ontario, Canada|Hochtaunus-Klinikum GmbH, Bad Homburg, Germany|HELIOS Klinikum Bad Saarow Klinik für Hämatologie, Onkologie und Palliativmedizin Studienzentrale Haus 39, Bad Saarow, Germany|Charité Campus Mitte Klinik für Gynäkologie / Brustzentrum, Berlin, Germany|Evangelisches Waldkrankenhaus Spandau, Berlin, Germany|Marienhospital Bottrop gGmbH Klinik für Gynäkologie und Geburtshilfe, Bottrop, Germany|Kliniken der Stadt Köln Brustzentrum Holweide, Köln, Germany|St. Elisabeth Krankenhaus Brustzentrum/Senologie Interdisziplinäres Studienzentrum, Köln, Germany|Uniklinik Köln Klinik für Frauenheilkunde und Geburtshilfe, Köln, Germany|Katholisches Klinikum Mainz Gynäkologie und Geburtshilfe, Mainz, Germany|Rotkreuzklinikum München gGmbH Frauenklinik, München, Germany|Klinikum für Frauenheilkunde und Geburtshilfe Frauenklinik, Münster, Germany|Klinikum Nürnberg Nord Gynecology / Breast cancer, Nürnberg, Germany|Horst-Schmidt-Kliniken Gynäkologie und Gynäkologische Onkologie, Wiesbaden, Germany|IRCCS Istituto Tumori "Giovanni Paolo II" - Oncologia Medica, Bari, Italy|Policlinico S. Orsola-Malpighi, Bologna, Italy|Azienda Ospedaliero Universitaria Ferrara Clinical Oncology, Cona, Italy|ASST di Cremona U.O. Multidisciplinare di Patologia Mammaria e Ricerca Traslazionale, Cremona, Italy|Azienda Ospedaliero Universitaria di Modena, Modena, Italy|Ospedale San Gerardo - ASST Monza, Monza, Italy|Azienda Ospedaliero Universitaria di Parma - UO Oncologia Medica, Parma, Italy|Presidio Ospedaliero di Pordenone, Pordenone, Italy		https://ClinicalTrials.gov/show/NCT03524430
9	NCT02200705	Cryoablation of Low Risk Small Breast Cancer- Ice3 Trial		Active, not recruiting	No Results Available	Breast Cancer	Device: Ice-Sense3TM	local Inbreast Breast Tumor Recurrence (IBTR) rate.|Complete ablation of primary tumor up to 60 months after cryoablation|Improvement or maintenance of subject's quality of life.|Breast cosmetics satisfaction.|Regional and distant Invasive breast tumor recurrence rate.|Disease-free Survival (DFS),Overall survival including breast Cancer Survival.	IceCure Medical Ltd.	Female	50 Years and older   (Adult, Older Adult)	Not Applicable	200	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ICMBC-02	October 2014	December 2023	December 2024	July 25, 2014		March 5, 2019	Ironwood Cancer & Research Centers, Glendale, Arizona, United States|BreastLink, Santa Ana, California, United States|Bridgeport Hospital, Yale Medical School, Trumbull, Connecticut, United States|Dalton Surgical Group, Dalton, Georgia, United States|Indiana University, Indianapolis, Indiana, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Regional Medical Imaging, Flint, Michigan, United States|Comprehensive Breast Care, Troy, Michigan, United States|CentraState Medical Center, Freehold, New Jersey, United States|Breast Specialty care/ Presbyterian Hospital, Albuquerque, New Mexico, United States|Mount Sinai Beth Israel, New York, New York, United States|Columbia University/ NY Presbyterian hospital, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Montefiore Medical Center, New York, New York, United States|Cincinnati Breast Surgeons Inc., Cincinnati, Ohio, United States|University hospitals cleveland medical center, Cleveland, Ohio, United States|Thomas Jefferson University hospital, Philadelphia, Pennsylvania, United States|West Clinic, Germantown, Tennessee, United States|Complete Breast Care, Plano, Texas, United States		https://ClinicalTrials.gov/show/NCT02200705
10	NCT02729493	Study Evaluating the Efficacy and Safety With CAR-T for Liver Cancer	EECLC	Recruiting	No Results Available	Liver Neoplasms	Biological: EPCAM-targeted CAR-T cells	Disease control rates	Sinobioway Cell Therapy Co., Ltd.	All	up to 75 Years   (Child, Adult, Older Adult)	Not Applicable	25	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ACCO-2015-06-03	November 14, 2015	November 2019	November 2019	April 6, 2016		March 15, 2017	Anhui No.2 Province People's Hospital, Hefei, Anhui, China		https://ClinicalTrials.gov/show/NCT02729493
11	NCT03196609	Characteristics of the Intestinal Microbiota in Patients With Cancer	Catalogue-Onco	Recruiting	No Results Available	Oncology	Biological: Collection of stool and serum samples	Microbial DNA	Centre Georges Francois Leclerc|Enterome	All	18 Years to 75 Years   (Adult, Older Adult)	Not Applicable	55	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	Catalogue-Onco	February 6, 2017	February 6, 2017	February 6, 2019	June 23, 2017		August 9, 2018	Centre Georges-François Leclerc, Dijon, France|Hopital Universitaire Paul Brousse, Villejuif, France		https://ClinicalTrials.gov/show/NCT03196609
12	NCT02336737	SentiMag® Intraoperative Comparison in Breast Cancer	SentiMagIC	Completed	No Results Available	Breast Cancer	Device: SiennaXP|Drug: Technetium Tc99m Sulfur Colloid|Drug: Isosulfan blue dye	The lymph node detection rate identified by a specific method|To provide evidence of the safety of SiennaXP and SentiMag® as indicated by adverse events and serious adverse events and their relatedness to the detection method or procedure.|Nodal concordance: number of nodes identified by both test and control out of nodes identified by control|Overall per subject detection rate	Endomagnetics Inc|Regulatory and Clinical Research Institute Inc	All	18 Years and older   (Adult, Older Adult)	Not Applicable	160	Industry|Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	US-001	January 2015	December 2015	December 2015	January 13, 2015		February 7, 2017	University of California San Diego Moores Cancer Center, La Jolla, California, United States|University of California Davis Comprehensive Cancer Center, Sacramento, California, United States|UCSF Carol Franc Buck Breast Care Center, San Francisco, California, United States|Coordinated Health Breast Care Specialists, Allentown, Pennsylvania, United States|Dallas Surgical Group, Dallas, Texas, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT02336737
13	NCT02725125	Study Evaluating the Efficacy and Safety With CAR-T for Stomach Cancer	EECSC	Recruiting	No Results Available	Stomach Neoplasms	Biological: EPCAM-targeted CAR-T cells	Disease control rates|Duration of remission	Sinobioway Cell Therapy Co., Ltd.	All	up to 75 Years   (Child, Adult, Older Adult)	Not Applicable	19	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ACCO-2015-06-04	November 2015	November 2019	November 2019	March 31, 2016		March 23, 2017	Anhui Provincial Cancer Hospital, Hefei, Anhui, China		https://ClinicalTrials.gov/show/NCT02725125
14	NCT02244580	Re-Evaluation of Tumor Samples From Women With Breast Cancer With the in Vitro Diagnostic Kit "MammaTyperTM"		Completed	Has Results	Invasive Breast Cancer	Device: MammaTyper™	5 Year Distant Disease Free Survival (DDFS) Assessed as Rate of Patients Without Distant Metastases in Subgroup Luminal A vs. Combined Subgroup (Luminal B, HER2 Positive, Triple Negative), Based on Subtyping With MammaTyper™|Number of Patients With High Ki-67 and Prognosis on Outcome for DDFS and OS (Measured by Hazard Ratio)|Number of Patients With Ki-67 Determined by MammaTyper™ Compared to Local Ki-67 Eyeballed Assessment for Luminal Tumors and Correlation to Rate of Patients With Regard to OS and DDFS	Biontech Diagnostics GmbH	Female	18 Years to 65 Years   (Adult, Older Adult)	Not Applicable	1010	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	MammaTyper-FinHer	August 2014	August 2014	August 2014	September 19, 2014	November 7, 2016	November 7, 2016			https://ClinicalTrials.gov/show/NCT02244580
15	NCT03441464	Feasibility of the LUM Imaging System for Detection of Prostate Cancer		Recruiting	No Results Available	Prostate Cancer|Neoplasm, Residual	Combination Product: LUM Imaging System	Determine initial efficacy of LUM015 in labeling prostate cancer by molecular imaging by comparing imaging results with pathology|Number of patients with reported adverse events	Lumicell, Inc.	Male	40 Years and older   (Adult, Older Adult)	Not Applicable	12	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Other	CL0005	March 20, 2019	November 2019	December 2019	February 21, 2018		May 13, 2019	Icahn School of Medicine at Mount Sinai, New York, New York, United States		https://ClinicalTrials.gov/show/NCT03441464
16	NCT01142661	Compassionate Use of Eribulin for the Treatment of Advanced Breast Cancer Refractory to All Other Marketed Therapies		Completed	Has Results	Breast Cancer	Drug: Eribulin Mesylate	Safety	Eisai Inc.	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	9	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	E7389-G000-399	August 2010	August 2011		June 11, 2010	September 20, 2013	September 20, 2013	La Verne, California, United States|Nyack, New York, United States|Raleigh, North Carolina, United States|Bismark, North Dakota, United States|Dallas, Texas, United States		https://ClinicalTrials.gov/show/NCT01142661
17	NCT02323854	The EMPrint™ Ablate and RESect Study in Patients With Metastatic Lung Tumors (EMPRESS)	EMPRESS	Completed	Has Results	Lung Cancer	Device: Ablation|Procedure: Surgical Resection	Dose Response|Ablation Zone Shape|Number of Participants With Complete or Incomplete Tumor Ablation	Medtronic - MITG	All	18 Years and older   (Adult, Older Adult)	Not Applicable	15	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	COVEMPR0437	January 2015	March 13, 2017	November 2017	December 24, 2014	April 5, 2018	April 5, 2018	Mayo Clinic, Rochester, Minnesota, United States|Weill Cornell Medical College, New York, New York, United States|Rhode Island Hospital, Providence, Rhode Island, United States|University Hospital Frankfurt, Frankfurt, Germany	"Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/54/NCT02323854/SAP_000.pdf|"Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/54/NCT02323854/Prot_001.pdf	https://ClinicalTrials.gov/show/NCT02323854
18	NCT01957787	Study of Cryoablation for Metastatic Lung Tumors	SOLSTICE	Completed	No Results Available	Neoplasm Metastasis	Device: Cryoablation	Local tumor control for each index tumor as measured by imaging|Safety assessment	Galil Medical	All	18 Years and older   (Adult, Older Adult)	Not Applicable	134	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CUC13-LNG079	March 2014	August 7, 2017	August 20, 2018	October 8, 2013		February 8, 2019	UCLA Ronald Reagan Medical Center, Los Angeles, California, United States|Cancer Treatment Centers of America at Southeastern Regional Medical Center, Newnan, Georgia, United States|Mayo Clinic Rochester, Rochester, Minnesota, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|New York Presbyterian Hospital - Cornell Medical Center, New York, New York, United States|State University of New York at Stony Brook, Stony Brook, New York, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Inova Alexandria Hospital CVIR, Alexandria, Virginia, United States|Institut Bergonié, Bordeaux, Aquitaine, France|Institut Gustave Roussy, Villejuif, Ile-de-France, France		https://ClinicalTrials.gov/show/NCT01957787
19	NCT00847509	A Multi - Center Study Of PET Imaging With [F-18] FLT & [F-18] FDG in Cancer Patients for Treatment Evaluation	FLT101	Completed	Has Results	Lung Cancer|Head and Neck Cancer	Drug: [F-18]FLT	[F-18]FLT PET Scan for Early Assessment of Tumor Response to Radiation or Chemoradiotherapy Compared to [F-18] FDG PET Scan	Siemens Molecular Imaging	All	18 Years and older   (Adult, Older Adult)	Not Applicable	49	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	FLT101	February 2009	August 2010	September 2010	February 19, 2009	September 27, 2013	September 27, 2013	Hoag Memorial Hospital, Newport Beach, California, United States|Excel Diagnostics Imaging Clinics, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT00847509
20	NCT01819948	Changes in Biomarkers of Cancer in Women With Breast Cancer and Without Evidence of Disease Who Were Given PhytoMed™		Completed	No Results Available	Breast Cancer	Dietary Supplement: PhytoMed™	Reduction in the levels of CRP|Reduction in IL-6|Increase in the levels of IL-10|Safety and tolerability (Gastrointestinal symptoms)|Pain intensity score measured with the BPI scale|Effect on lipid profile|Reduction SAA (serum amyloid A)|Reduction IFNgamma|Reduction TNF-alpha|Increase in the levels of TGFbeta (transforming growth factor beta)|Reduction in IGF (insulin growth factor)	Phytogen Medical Foods S.L.	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	46	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	Phytomed	June 2012	December 2015		March 28, 2013		February 25, 2016	Hospital Quirón, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Puerta de Hierro, Madrid, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|MD Anderson Cancer Center, Madrid, Spain		https://ClinicalTrials.gov/show/NCT01819948
21	NCT00848042	Pilot Study of AuroLase(tm) Therapy in Refractory and/or Recurrent Tumors of the Head and Neck		Completed	Has Results	Head and Neck Cancer	Device: AuroLase Therapy	Number of Participants With Any Adverse Device Effects Considered Attributable to AuroShell Particle Administration|Response in Targeted Tumors.	Nanospectra Biosciences, Inc.	All	18 Years to 130 Years   (Adult, Older Adult)	Not Applicable	11	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NBI-07-001	April 2008	August 2014	August 2014	February 20, 2009	July 18, 2016	February 9, 2017	Cancer Treatment Centers of American Western Regional Medical Center, Goodyear, Arizona, United States|Baylor College of Medicine, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT00848042
22	NCT02997241	Colon Cancer Treatment Decisions and Recurrence Predicting	CCTDRP	Not yet recruiting	No Results Available	Colonic Neoplasms	Biological: OncoCare|Drug: chemotherapy for colorectal carcinoma	patients treated with chemotherapy based on clinical prognosis compared to Oncocare detection prognosis|the rate of gene copies change from primary detection to recurrence|Overall survival at 5 years	MyGenostics Inc., Beijing|Chinese PLA General Hospital	All	18 Years and older   (Adult, Older Adult)	Not Applicable	500	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Supportive Care	MG-WXu	January 2017	December 2017	September 2022	December 20, 2016		December 20, 2016	Chinese PLA General Hospital, Beijing, Beijing, China		https://ClinicalTrials.gov/show/NCT02997241
23	NCT03832686	Validation of Smartphone App for Head and Neck Cancer Control and Patient Support		Recruiting	No Results Available	Head Neck Cancer	Other: Virtual Coach	Overall adherence to prescribed exercise protocol measured as percentage of prescribed exercises completed|Patient perceived swallowing impairment as measured by the MD Anderson Dysphagia Inventory|Diet level as defined by the Functional Oral Intake Scale|Diet restrictions as measured by the Performance Status Scale Head and Neck|Physiological oropharyngeal swallowing impairment as measured by the Modified Barium Swallow Impairment Profile (MBS-ImP)|Depth of bolus entry into the laryngeal vestibule as measured using the Penetration-Aspiration Scale (PAS)|Severity of impairment of swallowing safety and efficiency as measured using the Dynamic Imaging Grade of Swallowing Toxicity scale	Vibrent Health|Stanford University|Johns Hopkins University|Massachusetts General Hospital	All	18 Years and older   (Adult, Older Adult)	Not Applicable	176	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	HHSN261201700003C_SBIR342	April 24, 2019	October 2019	January 2020	February 6, 2019		May 13, 2019	Stanford Cancer Institute, Palo Alto, California, United States		https://ClinicalTrials.gov/show/NCT03832686
24	NCT03694054	Care Coordination in Oncology, Quality Among Patients With Lung Cancer and Their Caregivers		Completed	No Results Available	Lung Cancer	Other: Care coordination tool	Patient Satisfaction|Caregiver Satisfaction|Patient Quality of Life|Caregiver Quality of Life|Family Centered Care|Patient Experience|Caregiver Burden	Geisinger Clinic|Merck Sharp & Dohme Corp.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	57	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	2018-0172	June 4, 2018	February 28, 2019	March 31, 2019	October 3, 2018		April 9, 2019	Geisinger Health System, Danville, Pennsylvania, United States	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/54/NCT03694054/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT03694054
25	NCT01446185	Treatment Decision Impact of OncotypeDX™ in HR+, N- Breast Cancer Patients	SWITCH	Completed	No Results Available	Breast Cancer	Device: Oncotype DX breast cancer test	impact of the Oncotype DX Recurrence Score on the treatment recommendation made|Level of confidence of the physicians relating to their treatment recommendation before and after Oncotype DX RS results|Physicians' perceptions regarding the utility of the Oncotype DX.	Genomic Health®, Inc.|Registrat-Mapi	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	100	Industry|Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)	2010-A00577-32	January 2011	February 2012	May 2012	October 5, 2011		April 18, 2013	CHRU Besançon, Besançon, France|Centre Jean Perrin, Clermont-Ferrand, France|Centre Val d'Aurelle, Montpellier, France|Centre Azuréen de Cancérologie, Mougins, France|Centre d'Oncologie Médicale de Gentilly, Nancy, France|Hôpital TENON, Paris, France		https://ClinicalTrials.gov/show/NCT01446185
26	NCT02968784	Focal ExAblate MR-Guided Focused Ultrasound Treatment for Management of Organ-Confined Intermediate Risk Prostate Cancer		Recruiting	No Results Available	Prostate Cancer	Device: ExAblate MRgFUS	The primary efficacy endpoint in this trial measured with whole-gland extended imaging-guided mapping biopsy, is Response scored dichotomously; success vs. failure|Adverse events|Percent of patients with negative biopsy|Quality of Life - urinary symptoms - IPSS questionnaire score|Quality of Life - urinary continence - ICIQ-SF questionnaire score|Quality of Life - sexual function - IIEF-15 questionnaire score|Prostate Specific Antigen (PSA)	InSightec	Male	50 Years and older   (Adult, Older Adult)	Not Applicable	68	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PCa006	June 2016	June 2022	June 2022	November 21, 2016		May 24, 2019	Toronto General Hospital, Toronto, Ontario, Canada|Shanghai Jiaotong University No.1 Hospital, Shanghai, HongKou District, China|Changhai Hospital of Shanghai, Shanghai, Shanghai, China|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|St. Mary's Hospital, London, United Kingdom		https://ClinicalTrials.gov/show/NCT02968784
27	NCT02064829	Bioequivalence Study of IG-001 Versus Nab-paclitaxel in Metastatic or Locally Recurrent Breast Cancer	TRIBECA	Completed	No Results Available	Metastatic Breast Cancer|Locally Recurrent Breast Cancer	Drug: Nab-paclitaxel|Drug: IG-001	Maximum observed concentration of paclitaxel (Cmax)|Area under the concentration-time curve from time zero to infinite time of paclitaxel (AUC 0-inf)	Sorrento Therapeutics, Inc.	Female	30 Years and older   (Adult, Older Adult)	Not Applicable	111	Industry	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	STI-102	March 2014	February 2015	July 2015	February 17, 2014		March 25, 2016	Sorrento investigational site, Fayetteville, Arkansas, United States|Sorrento investigational site, Chattanooga, Tennessee, United States|Sorrento investigational site, Memphis, Tennessee, United States|Sorrento investigational site, Flower Mound, Texas, United States|Sorrento investigational site, Batumi, Georgia|Sorrento investigational site, Tbilisi, Georgia|Sorrento investigational site, Chisinau, Moldova, Republic of|Sorrento investigational site, Bucharest, Romania|Sorrento investigational site, Belgrade, Serbia|Sorrento investigational site, Kragujevac, Serbia|Sorrento investigational site, Sremska Kamenica, Serbia|Sorrento investigational site, Zrenjanin, Serbia|Sorrento investigational site, Singapore, Singapore|Sorrento investigational site, Cherkasy, Ukraine|Sorrento investigational site, Dnipropetrovsk, Ukraine|Sorrento investigational site, Kharkiv, Ukraine|Sorrento investigational site, Kyiv, Ukraine|Sorrento investigational site, Lviv, Ukraine|Sorrento investigational site, Sumy, Ukraine|Sorrento investigational site, Vinnytsya, Ukraine		https://ClinicalTrials.gov/show/NCT02064829
28	NCT02612532	Lung Cancer Indicator Detection	LuCID	Recruiting	No Results Available	Lung Cancer	Device: ReCIVA breath sampler	Area Under the Curve for the diagnostic algorithm for lung cancer with optimal point sensitivity, specificity negative and positive predictive values.|Fraction of within group variability in exhaled VOCs explained by factors not primarily related to disease proces|Identified exhaled biomarkers associated with tumor stage and size.	Owlstone Ltd|Papworth Hospital|University Hospitals, Leicester|University College, London|Universitätsklinikum Leipzig|University Hospital, Antwerp|University Hospital, Ghent|University of Bari|University of Athens|Glenfield Hospital|Peterborough and Stamford Hospitals NHS Foundation Trust|University Hospitals of North Midlands NHS Trust|Manchester University NHS Foundation Trust|University Hospital Southampton NHS Foundation Trust|Buckinghamshire Healthcare NHS Trust|Wirral University Teaching Hospital NHS Trust|South Tyneside and Sunderland NHS Foundation Trust|Aintree University Hospitals NHS Foundation Trust|Clinical Research and Trials Unit (Norfolk & Norwich University Hospital, UK)|Barnet and Chase Farm Hospitals NHS Trust|Liverpool Heart and Chest Hospital NHS Foundation Trust	All	18 Years and older   (Adult, Older Adult)	Not Applicable	520	Industry|Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	LuCID-2	October 2015	August 2019	August 2020	November 24, 2015		June 1, 2017	UZA University Hospital Antwerp, Antwerp, Belgium|UZG University Hospital Gent, Gent, Belgium|University Hospital Leipzig, Leipzig, Germany|University Hospital Bari, Bari, Italy|PapworthHospital, Cambridge, Cambridgeshire, United Kingdom|Buckinghamshire Healthcare Trusts, Buckinghamshire, United Kingdom|West Hertfordshire Hospital NHS Trust, Hertfordshire, United Kingdom|University Hospital of Leicester, Leicester, United Kingdom|University Hospital Aintree NHS Foundation Trust, Liverpool, United Kingdom|University College London, London, United Kingdom|University Hospital of South Manchester NHs Foundation Trust, Manchester, United Kingdom|Nottingham University Hospital NHS Trust, Nottingham, United Kingdom|Peterborough and Stamford Hospital, Peterborough, United Kingdom|South Tyneside District Hospital, South Shields, United Kingdom|Southampton General Hospital, Southampton, United Kingdom|Royal Stoke University Hospital NHS Trust, Stoke, United Kingdom|Wirral University Teaching Hospital NHS Foundation Trust, Upton, United Kingdom		https://ClinicalTrials.gov/show/NCT02612532
29	NCT03740984	Effects of Music or Hypnotherapy on Cancer Patients During Chemotherapy	F-Chem	Recruiting	No Results Available	Breast Neoplasm|Ovary Cancer	Other: Interventions are self controlled by the patient via a mp3 player and noise reduction headphones.	ZSDS = Zung Self-rating Depression Scale|Quality of life questionnaire - Core30|Patient diary, number of emetic episodes, the intensity of Nausea and QoL evaluation (functional living index-emesis questionnaire)|Fatigue assessment questionnaire (FAQ)|Screening Scale for Taste Alteration (TA)|Change of heart rate	Dr. Horst Schmidt Klinik GmbH|Deutsche Gesellschaft für hypnose und hypnotherapie E.V.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	183	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care	Gyn F-Chem	February 1, 2018	February 1, 2022	September 1, 2023	November 14, 2018		February 22, 2019	Klinik für Gynäkologie und gynäkologischen Onkologie, Wiesbaden, Hessen, Germany|Helios Berlin Buch, Berlin, Germany|Zentrum für ambulante gynäkologische Onkologie (ZAGO), Krefeld, Germany|Helios Kliniken Schwerin GmbH, Schwerin, Germany		https://ClinicalTrials.gov/show/NCT03740984
30	NCT01045187	Feasibility Study Using the Xoft System for the Treatment of Endometrial Cancer		Completed	Has Results	Endometrial Cancer	Radiation: brachytherapy|Radiation: Xoft Axxent Electronic Brachytherapy System	Assess Number of Patients Who Were Able to Complete Treatment Delivery Using the Axxent Electronic Brachytherapy System|Assess Acute Safety Outcomes in Patients During and After Vaginal Cuff Brachytherapy Treatment With the Axxent Electronic Brachytherapy System as Incorporated in to the Physician's Current Standard of Practice|Assess Occurence Rate of Toxicities	Xoft, Inc.	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	15	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	TPR-0209	October 2008	January 2010	April 2010	January 8, 2010	February 21, 2011	August 1, 2012	Cancer Treatment Services Arizona, Casa Grande, Arizona, United States|Southwest Oncology Center, Phoenix, Arizona, United States|Beverly Oncology & Imaging Medical Center, Inc, Montebello, California, United States|Swedish Covenant Hospital, Chicago, Illinois, United States|Little Company of Mary Hospital, Evergreen Park, Illinois, United States|Rhode Island Hospital, Providence, Rhode Island, United States		https://ClinicalTrials.gov/show/NCT01045187
31	NCT03243734	trūFreeze® Palliative Esophageal Cancer		Recruiting	No Results Available	Esophageal Cancer	Device: trūFreeze® System spray cryotherapy	Change from baseline EORTC at 14 days post cryotherapy procedure|Change from baseline dysphagia scale at 14 days post cryotherapy procedure|Time to additional interventional procedure(s) other than spray cryotherapy (e.g. stent placement)|Overall Survival|Mean change in the amount of residual tumor from baseline to follow-up cryospray delivery session	CSA Medical, Inc.	All	18 Years to 89 Years   (Adult, Older Adult)	Not Applicable	50	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	017	November 6, 2017	November 2021	November 2022	August 9, 2017		July 30, 2019	Cancer Treatment Centers of America Western Regional Medical Center, Goodyear, Arizona, United States|Scripps Clinic Torrey Pines, La Jolla, California, United States|University of California at Irvine, Orange, California, United States|Emory University, Atlanta, Georgia, United States|Cancer Treatment Centers of America Midwestern Regional Medical Center, Zion, Illinois, United States|Parkview Comprehensive Cancer Center, Fort Wayne, Indiana, United States|Spectrum Health, Grand Rapids, Michigan, United States|Dartmouth-Hotchcock Medical Center, Lebanon, New Hampshire, United States|North Shore-Long Island Jewish Medical Center, Manhasset, New York, United States|University of Rochester, Rochester, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Virginia Commonwealth University, Richmond, Virginia, United States		https://ClinicalTrials.gov/show/NCT03243734
32	NCT03908671	Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Patients With Advanced Esophageal Cancer and Non-small Cell Lung Cancer		Not yet recruiting	No Results Available	Esophageal Cancer|Non Small Cell Lung Cancer	Biological: Personalized mRNA Tumor Vaccine	Number of participants with treatment-related adverse events as assessed by CTCAE v4.03|Disease Control Rate (DCR)|Progression-free Survival (PFS)|Time to Tumor Progression (TTP)|Overall Survival (OS)	Stemirna Therapeutics|The First Affiliated Hospital of Zhengzhou University	All	18 Years to 75 Years   (Adult, Older Adult)	Not Applicable	24	Industry|Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	STZD-1801	May 2019	September 2020	September 2022	April 9, 2019		April 9, 2019			https://ClinicalTrials.gov/show/NCT03908671
33	NCT03491917	Fujifilm DBT Plus S-View Versus FFDM Alone in the Detection of Breast Cancer		Completed	No Results Available	Breast Cancer	Device: DBT plus S-View|Device: FFDM alone	Non-inferior per subject AUC	Fujifilm Medical Systems USA, Inc.	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	100	Industry	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	FMSU2017-002A	November 3, 2017	December 31, 2017	February 15, 2018	April 9, 2018		April 12, 2018	International HealthCare, LLC, Norwalk, Connecticut, United States		https://ClinicalTrials.gov/show/NCT03491917
34	NCT00147056	MRI-Guided Focused Ultrasound Feasibility Study for Brain Tumors		Recruiting	No Results Available	Brain Tumor	Device: ExAblate transcranial system	Number of subjects with Serious and Non-Serious Adverse Events after MRI Guided Focused ultrasound treatment for brain tumors	InSightec	All	18 Years to 70 Years   (Adult, Older Adult)	Not Applicable	10	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	BT002	August 2012	December 2022	December 2022	September 7, 2005		January 10, 2019	Brigham and Women's Hospital, Boston, Massachusetts, United States|Swedish Medical Center, Seattle, Washington, United States		https://ClinicalTrials.gov/show/NCT00147056
35	NCT03501693	Fujifilm DBT Plus S-View Versus FFDM Alone in the Detection of Breast Cancer - A Pivotal Study		Completed	No Results Available	Breast Cancer	Device: DBT plus S-View|Device: FFDM Alone	Non-inferior per subject AUC|Non-inferior per-subject average recall rate for all non-cancer cases for DBT plus S-View versus FFDM|Non-inferior per-subject average recall rate for DBT plus S-View versus FFDM for all cancer cases|Non-inferior per-subject average sensitivity for DBT plus S-View versus FFDM	Fujifilm Medical Systems USA, Inc.	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	300	Industry	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	FMSU2017-002B	April 6, 2018	May 24, 2018	August 31, 2018	April 18, 2018		October 16, 2018	International HealthCare, LLC, Norwalk, Connecticut, United States		https://ClinicalTrials.gov/show/NCT03501693
36	NCT03039127	Immunostimulating Interstitial Laser Thermotherapy in Breast Cancer		Completed	No Results Available	Breast Neoplasms	Device: Immunostimulating Interstitial Laser Thermotherapy	Treatment effect by radiology|Safety (adverse events)|Usability (user evaluation of instrument)	Clinical Laserthermia Systems AB|Nottingham University Hospitals NHS Trust	All	Child, Adult, Older Adult	Not Applicable	3	Industry|Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CTP-2015-009	June 2016	July 2018	August 2018	February 1, 2017		January 30, 2019	Nottingham Breast Cancer Institute, Nottingham, United Kingdom		https://ClinicalTrials.gov/show/NCT03039127
37	NCT03296683	Evaluation of a 3D Functional Metabolic Imaging and Risk Assessment System in Classifying Women for Likelihood of Breast Cancer		Recruiting	No Results Available	Breast Cancer	Device: MIRA device imaging	Increase in incremental cancer detection rate	Real Imaging Ltd.	Female	24 Years and older   (Adult, Older Adult)	Not Applicable	1200	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening	960-CLP-ITL_RI8 _ITS1	May 23, 2017	September 2019	September 2021	September 28, 2017		June 19, 2018	Policlinico San Donato, San Donato Milanese, Italy		https://ClinicalTrials.gov/show/NCT03296683
38	NCT02388074	Sputum Labeling Utilizing Synthetic Meso-Tetra (4-Carboxyphenyl) Porphine (TCPP) for Detection of Lung Cancer		Completed	Has Results	Lung Cancer	Device: CyPath®	Number of Red Fluorescent [i.e., Cancer] Cells (RFCs) in Sputum From Healthy Participants	bioAffinity Technologies Inc.|Radiology Associates of Albuquerque	All	18 Years and older   (Adult, Older Adult)	Not Applicable	25	Industry|Other	Interventional	Intervention Model: Single Group Assignment|Masking: Single (Investigator)|Primary Purpose: Diagnostic	MODA-002	March 2015	April 2015	April 2015	March 13, 2015	June 17, 2015	July 14, 2015	Radiology Associates of Albuquerque (RAA), Albuquerque, New Mexico, United States		https://ClinicalTrials.gov/show/NCT02388074
39	NCT02438358	Feasibility Study of Intraoperative Imaging in Breast Cancer		Completed	No Results Available	Breast Cancer	Drug: LUM015|Device: LUM 2.6 Imaging Device	To evaluate the detection algorithm for identifying residual cancer in the tumor|Number of patients with Adverse Events as a measure of safety of the LUM Imaging System in breast cancer subjects.|To determine the dose of LUM015 to be used in the pivotal trial	Lumicell, Inc.|National Cancer Institute (NCI)|Massachusetts General Hospital|Dana-Farber Cancer Institute	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	60	Industry|NIH|Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	LUM-015/2.6-001|1R21CA173762	June 2015	September 2017	October 2017	May 8, 2015		November 2, 2018	Massachusetts General Hospital, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT02438358
40	NCT03080155	Evaluation of a Three Dimensional Functional Metabolic Imaging and Risk Assessment System in Classifying Women for Likelihood of Breast Cancer		Recruiting	No Results Available	Breast Cancer	Device: MIRA device imaging	determining MIRA's PPV (positive predictive value)	Real Imaging Ltd.	Female	30 Years to 79 Years   (Adult, Older Adult)	Not Applicable	680	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	960-CLP-GER_Multimodality_GER1	September 2016	September 2018	October 2018	March 15, 2017		June 19, 2018	BrustZentrum, Göttingen, Germany		https://ClinicalTrials.gov/show/NCT03080155
41	NCT03375827	Feasibility of an Individualized Goals of Care Discussion Guide for Advanced Breast Cancer		Active, not recruiting	No Results Available	Breast Cancer	Other: IGCDG	Recruitment rate|Attrition rate|Change in distress|Evaluate baseline preferences for care among patients with metastatic breast cancer via the Individualized Goals of Care Discussion Guide (IGCDG) questionnaire|The Satisfaction with Decision Making Scale|The Decisional Conflict Scale|Modified Control Preferences Scale|Patient Satisfaction with Cancer Care	Massachusetts General Hospital|Pfizer	All	18 Years and older   (Adult, Older Adult)	Not Applicable	45	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research	17-398	January 22, 2018	November 30, 2020	November 30, 2020	December 18, 2017		December 24, 2018	Massachusetts General Hospital, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT03375827
42	NCT00770822	Clinical Study of the Sonablate® 500 to Treat Localized (T1c/T2a) Prostate Cancer	SetPace	Active, not recruiting	No Results Available	Prostate Cancer	Device: HIFU (Sonablate® 500)|Device: Brachytherapy	The primary endpoint will be the absence of biochemical failure, which is defined as a rise of 2.0 ng/mL or more above the PSA nadir and negative biopsy at 24 months.	SonaCare Medical	Male	40 Years to 75 Years   (Adult, Older Adult)	Not Applicable	466	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	FSI-002	April 2007	July 2020	December 2020	October 10, 2008		April 10, 2019	Brachytherapy Site: Urology Centers of Alabama, Birmingham, Alabama, United States|Brachytherapy Site: Specialists in Urology, Naples, Florida, United States|Brachytherapy Site: Grand Strand Urology, Myrtle Beach, South Carolina, United States|HIFU Site: Southeast Urology Network, Memphis, Tennessee, United States|HIFU Site: Urology Associates, Nashville, Tennessee, United States|HIFU Site: Urology of San Antonio, San Antonio, Texas, United States		https://ClinicalTrials.gov/show/NCT00770822
43	NCT03463954	Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors		Not yet recruiting	No Results Available	Malignant Neoplasm of Breast	Device: Novilase Laser ablation	Percentage of target tumors completely ablated in one procedure|Frequency of adverse events (categorized using the NCI Common Terminology for Adverse Events (CTCAE) v4.0 guidelines) post-laser ablation and post-surgery|Patient reported rate of return to activities of daily living post-laser ablation and post-surgery|Physician reported cosmetic satisfaction, utilizing the 4-point scoring system of breast cosmesis in protocol (e.g., excellent, good, fair, poor) post-laser ablation and post-surgery (4-6 weeks)|Health related quality of life outcome measures at three timepoints via EORTC QLQ-C30 & QLQ-BR23 questionnaire (baseline and 4-6 weeks post-laser ablation and post-surgery)	Novian Health Inc.	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	122	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	BR-003	October 2019	October 2021	December 2021	March 13, 2018		March 14, 2019			https://ClinicalTrials.gov/show/NCT03463954
44	NCT01992250	Cryoablation of Small Breast Tumors in Early Stage Breast Cancer	FROST	Recruiting	No Results Available	Breast Cancer	Device: Visica 2 Treatment System	Tumor ablation occurence|Local tumor recurrence|Satisfactory breast cosmesis results|Adverse event assessment	Sanarus Technologies, Inc.	Female	50 Years and older   (Adult, Older Adult)	Not Applicable	200	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CP-00-0011	November 2013	December 2021	June 2023	November 25, 2013		April 20, 2018	Arizona Breastnet, Scottsdale, Arizona, United States|90210 Surgery Medical Center, Beverly Hills, California, United States|City of Hope, Duarte, California, United States|Epic Care, Emeryville, California, United States|Diagnostic Center for Women, LLC, Miami, Florida, United States|Naples Community Hospital, Naples, Florida, United States|Ascension Crittenton Hospital, Rochester, Michigan, United States|Lankenau Medical Center, Wynnewood, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Knoxville Comprehensive Breast Center, Knoxville, Tennessee, United States|Texas Tech University Health Sciences Center, Lubbock, Texas, United States|Ogden Regional Hospital, Ogden, Utah, United States		https://ClinicalTrials.gov/show/NCT01992250
45	NCT03780582	Evaluation of Use of Diagnostic AI for Lung Cancer in Practice		Active, not recruiting	No Results Available	Lung Cancer	Behavioral: AI-human interaction	Classification accuracy|detection concordance	Ensemble Group Holdings, LLC	All	Child, Adult, Older Adult	Not Applicable	15	Industry	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Diagnostic	EN-122018	December 14, 2018	December 15, 2019	December 15, 2019	December 19, 2018		July 23, 2019	University of Hong Kong, Hong Kong, Hong Kong		https://ClinicalTrials.gov/show/NCT03780582
46	NCT02039635	Korean Red Ginseng in Treating Patients With Fatigue Caused by Chemotherapy for Colorectal Cancer	KRG	Completed	No Results Available	Colorectal Cancer	Dietary Supplement: Korean Red Ginseng|Dietary Supplement: Placebo	Area Under Curve (AUC) of Brief Fatigue Index (BFI) on the intake trial drugs up to 16 weeks|Area Under Curve (AUC) of Brief Fatigue Index (BFI) on the intake of trial drugs up to 8 weeks|Change in Functional Assessment of Chronic Illness Therapy-Fatigue Trial Outcome Index (FACIT-F TOI) after 8 and 16 weeks of trial drug intake|Change in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) total score after 8 and 16 weeks of trial drug in take|The percentage of subjects whom the Functional Assessment of Cancer Therapy-General (FACT-G) score decreased more than 20 scores after 8 and 16 weeks of trial drug intake|Change in blood cytokine (IL-1, IL-6, TNF-alpha) level after 16 weeks of trial drug intake|Change in blood cortisol level after 16 weeks of trial drug intake|Perceived Stress Scale (PSS) change after 16 weeks of trial drug intake|adverse events	Korea Ginseng Corporation	All	20 Years and older   (Adult, Older Adult)	Not Applicable	438	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care	KGC-S-02	December 2013	August 2016	March 2017	January 17, 2014		August 11, 2017	Korea Ginseng Corporation, Shinseongdong, Daejeon, Korea, Republic of		https://ClinicalTrials.gov/show/NCT02039635
47	NCT03665714	Effects of Immunonutrition (Impact Oral®) in Patients Undergoing Surgery for Gastrointestinal Cancer		Recruiting	No Results Available	Gastrointestinal Cancer	Other: Impact Oral|Other: Enteral Nutrition Emulsion(TPF-T)	Change of Serum Prealbumin level|Change of Albumin|Change of C-reactive protein|Change of Interleukin-6 (IL-6)|Change of CD4+/CD8+|Incidence of postoperative Infections	Nestlé	All	18 Years to 75 Years   (Adult, Older Adult)	Not Applicable	240	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	17.01. CN. NHS	October 23, 2018	August 2019	September 2019	September 11, 2018		November 7, 2018	Peiking Union Medical College Hospital, Beijing, Beijing, China		https://ClinicalTrials.gov/show/NCT03665714
48	NCT00918229	Pilot Study to Assess the Safety and Efficacy of BioProtect Balloon in Prostate Cancer Subjects		Completed	Has Results	Prostate Cancer	Device: balloon implant|Procedure: Balloon implantation	Proportion of Subjects Achieving a Reduction of at Least 25% of the Volume of the Rectum Receiving at Least 70 Gy.|Rate of Occurrence of Grade 2 or Greater Rectal Adverse Event or Procedure Related Adverse Events.	BioProtect	Male	45 Years to 85 Years   (Adult, Older Adult)	Not Applicable	24	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	BPI-01 (USA)	June 2009	May 2011	May 2011	June 11, 2009	November 20, 2018	November 20, 2018	Virginia Commonwealth University School of Medicine, Massey Cancer Center, Richmond, Virginia, United States		https://ClinicalTrials.gov/show/NCT00918229
49	NCT00436189	Assess Cancer in Ovarian Tumors With Biomarkers.		Completed	No Results Available	Ovarian Tumor	Procedure: Blood Draw	Proportion of actual ovarian cancer cases among OvaRl positive patients is higher than the proportion of actual ovarian cancer cases among referred patients.|Evaluate OvaRl assay plus standard clinical practice.	Ciphergen Biosystems	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	1000	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	OVA-001-C01	February 2007	April 2008	April 2008	February 16, 2007		April 30, 2008	Clinical Research Consultants, Hoover, Alabama, United States|Women's Health Research, Phoenix, Arizona, United States|Precision Trials, Phoenix, Arizona, United States|Gynecologic Oncology Associates, Newport Beach, California, United States|North Coast Women's Care Medical Group Inc, Vista, California, United States|Farmington Obstetrics and Gynecology Group, Avon, Connecticut, United States|The GYN Center for Women's Health, Waterbury, Connecticut, United States|Florida Hospital Cancer Institute, Orlando, Florida, United States|OB/GYN Specialists of the Palm Beaches, West Palm Beach, Florida, United States|University of Kentucky - Whitney Facility, Lexington, Kentucky, United States|Maine Medical Center, Scarborough, Maine, United States|Eastern Carolina Women's Center, New Bern, North Carolina, United States|HWC Women's Research Center, Miamisburg, Ohio, United States|Advanced Clinical Research, Medford, Oregon, United States|Chattanooga Gyn-Oncology, Chattanooga, Tennessee, United States|SWRCC, Austin, Texas, United States|UT South Western Medical Center at Dallas, Dallas, Texas, United States|Tacoma Women's Specialists, Tacoma, Washington, United States		https://ClinicalTrials.gov/show/NCT00436189
50	NCT02275871	Comparison of Contrast-enhanced Spectral Mammography (CESM) to MRI in Screening High Risk Women for Breast Cancer		Active, not recruiting	No Results Available	Breast Cancer	Other: MRI|Other: CESM	Number of cancers and false positive findings identified on CESM versus MRI as a measure of sensitivity and specificity	Beth Israel Deaconess Medical Center|GE Healthcare|Dana-Farber Cancer Institute	Female	30 Years and older   (Adult, Older Adult)	Not Applicable	220	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	14-225	November 2014	January 2020	January 2021	October 27, 2014		February 15, 2019	Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT02275871
51	NCT02853500	Effect of Surefire Infusion Device on Tumor Response to Regional Intra-arterial Therapy for Primary Liver Malignancies		Recruiting	No Results Available	Liver Cancer	Device: Surefire|Device: Traditional Delivery|Drug: Doxorubicin	Capillary permeability (Ktrans) calculated by software that analyzes enhancement on post-contrast MRI.|Extravascular extracellular volume fraction (ve) calculated by software that analyzes enhancement on post-contrast MRI.|Rate constant (kep)|Plasma volume (vp) calculated by software that analyzes enhancement on post-contrast MRI.|Time To Tumor Progression	Dana-Farber Cancer Institute|Surefire Medical, Inc.	All	18 Years to 75 Years   (Adult, Older Adult)	Not Applicable	10	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	16-077	July 2016	July 2020	July 2022	August 3, 2016		November 12, 2018	Brigham and Women's Hospital, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT02853500
52	NCT00772317	A Multicenter Clinical Study of the Sonablate®450 for the TreAtment of Locally Recurrent Prostate Cancer With HIFU (STAR Trial)	STAR	Active, not recruiting	No Results Available	Recurrent Prostate Cancer	Device: High Intensity Focused Ultrasound	absence of biochemical failure, defined as achieving a PSA nadir of ≤ 0.5 ng/mL within 12 months of treatment|negative prostate biopsy at the 12 month time point	SonaCare Medical	Male	40 Years to 85 Years   (Adult, Older Adult)	Not Applicable	117	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	FSI-003	July 2008	December 2020	December 2021	October 15, 2008		April 10, 2019	Tower Urology, Los Angeles, California, United States|David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California, United States|Walter Reed National Military Medical Center (Military Personnel Only), Washington, District of Columbia, United States|Specialists in Urology, P.A., Naples, Florida, United States|Indiana University, Indianapolis, Indiana, United States|Metropolitan Urology, PSC, Jeffersonville, Indiana, United States|Tulane University, New Orleans, Louisiana, United States|New York University School of Medicine, New York, New York, United States|University of Cincinnati, Cincinnati, Ohio, United States|University Hospitals of Cleveland Case Medical Center, Cleveland, Ohio, United States|Urologic Consultants of SE PA, LLP, Bala-Cynwyd, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States|University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States|London Health Sciences Centre, London, Ontario, Canada|CAN-AM, Toronto, Ontario, Canada		https://ClinicalTrials.gov/show/NCT00772317
53	NCT00462124	Evaluation of the Safety and Efficacy of the BioProtect Balloon in Prostate Cancer Subjects Undergoing Radiotherapy		Completed	Has Results	Prostate Cancer	Device: Absorbable perirectal spacer	Safety of Balloon Implant|Efficacy Will be Measured in Terms of: Number of Participants With a Reduction in Radiation to the Rectum	BioProtect	Male	up to 80 Years   (Child, Adult, Older Adult)	Not Applicable	7	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	BP-01	June 2007	March 2009	May 2009	April 18, 2007	August 8, 2019	August 8, 2019	Ichilov Medical Center, Tel Aviv, Israel		https://ClinicalTrials.gov/show/NCT00462124
54	NCT03740191	Spot-Scanning Based Hypofractionated Proton Therapy for Low and Intermediate Risk Prostate Cancer		Recruiting	No Results Available	Low Risk Prostate Cancer|Intermediate Risk Prostate Cancer	Other: EPIC questionnaire|Radiation: kV x-ray images|Radiation: Conebeam CT	freedom from biochemical failure|Determination of the intra-fraction target movement using planar kilovoltage (kV) x-ray Imaging 5x/week or at each day of ion therapy.|Determination of the inter-fraction target and organ at risk movement using Conebeam CT 5x/week or at each day of ion therapy.|Determination of the incidence of gastrointestinal and genitourinary toxicities acute during treatment|Determination of the incidence of gastrointestinal and genitourinary toxicities late at 2 years|Determination of the incidence of gastrointestinal and genitourinary toxicities late at 5 years|Assessment of the quality of life and sexual function following proton therapy.|Correlation of adverse events (toxicity), quality of life (QoL) and sexual function with dosevolume histogram parameters adjusted according to actual dose delivered.|Determine disease specific survival at 5 years.|Determine overall survival at 5 years.|Determination of the intra- and inter- mobility of prostate, seminal vesicles and rectum in order to further define and refine planning target volume parameters for future applications.	EBG MedAustron GmbH	Male	18 Years and older   (Adult, Older Adult)	Not Applicable	297	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	PRLI-MA-012016|PRLI	July 3, 2018	July 2027	December 2027	November 14, 2018		November 14, 2018	EBG MedAustron GmbH, Wiener Neustadt, Niederösterreich, Austria		https://ClinicalTrials.gov/show/NCT03740191
55	NCT03638193	Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer		Recruiting	No Results Available	Pancreatic Cancer	Biological: CART-meso cells	Safety of CART-meso infusion: number of adverse events|Clinical response of CART-meso|CAR-T cell detection	Shenzhen BinDeBio Ltd.|The First Affiliated Hospital with Nanjing Medical University	All	18 Years to 70 Years   (Adult, Older Adult)	Not Applicable	10	Industry|Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2017NJYY-Meso	July 11, 2018	February 1, 2022	February 1, 2022	August 20, 2018		December 27, 2018	Nanjing First Hospital, Nanjing, Jiangsu, China		https://ClinicalTrials.gov/show/NCT03638193
56	NCT03589781	Investigating the Effects of Mikei® Red Reishi Essence EX on the Immune System of Prostate Cancer Patients and Patients With Non-cancerous Conditions of the Prostate		Not yet recruiting	No Results Available	Prostate Cancer	Dietary Supplement: Mikei Red Reishi Essence EX|Dietary Supplement: Placebo	Changes in tumor size as determined by Digital Rectal Examination (DRE) tests results.|Decrease of PSA level or no further increase of PSA level|Gleason scores changes on prostate biopsy|Immune response changes as determine by the D2Dx blood test of tumor-elicited total autoantibodies. The immune activity will be tested using D2Dx blood test by measuring the relative quantity of tumor-elicited IgG autoantibodies in the blood.|Relationship between immune response and tumor size and/or Gleason score.	Nikkei (Canada) Marketing Limited	Male	50 Years to 85 Years   (Adult, Older Adult)	Not Applicable	50	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	RM5160	April 2019	October 2020	October 2020	July 18, 2018		March 13, 2019	Florida Urology Associates, Orlando, Florida, United States		https://ClinicalTrials.gov/show/NCT03589781
57	NCT03998566	Radiopaque Hydrogel Spacer in Patients Undergoing Radiotherapy for Pancreatic Cancer		Recruiting	No Results Available	Pancreatic Cancer	Device: TraceIT Tissue Spacer implantation	The ability to place TraceIT Tissue Spacer and create space between the duodenum and head of pancreas in patients undergoing image-guided radiotherapy for pancreatic adenocarcinoma.	Boston Scientific Corporation	All	18 Years and older   (Adult, Older Adult)	Not Applicable	6	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	AgX17-001-US	October 5, 2018	April 2020	April 2021	June 26, 2019		July 29, 2019	Johns Hopkins Medicine, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT03998566
58	NCT04042870	Effect of Sukshma Vyayama Yoga on Aromatase Inhibitor-Induced Arthralgia in Breast Cancer Survivors		Completed	No Results Available	Breast Cancer	Behavioral: Joint Loosening Yoga	Change in Patient-Reported Arthralgia Inventory (PRAI) Measure for Joint Arthralgia|Change in Brief Pain Inventory Short Form (BPI SF) Measure for Body Pain|Change in Brief Pain Inventory Short Form (BPI SF) Measure for Quality of Life|Change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Measure for Pain, Stiffness, and Physical Function of Knee and Hip|Change in Disability of the Arm, Shoulder and Hand (DASH) Measure of Ability to Use Arm, Shoulder, and Hand|Effectiveness of Delivering Intervention on Facebook	AshtaYoga, LLC|Columbia University|Swami Vivekananda Yoga Anusandhana Samsthana	Female	35 Years to 70 Years   (Adult, Older Adult)	Not Applicable	38	Industry|Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	AI Yoga Study on Facebook - 1	September 4, 2018	September 28, 2018	October 19, 2018	August 2, 2019		August 2, 2019	Columbia University Medical Center, New York, New York, United States		https://ClinicalTrials.gov/show/NCT04042870
59	NCT01307501	Safety and Efficacy of Cryoablation for Metastatic Lung Tumors	ECLIPSE	Completed	No Results Available	Metastatic Lung Cancer	Device: Cryoablation	Local tumor control as measured by imaging|Metastatic disease spread as measured by imaging|Overall disease specific survival|Time to disease recurrence or progression|Changes in physical function and quality of life over time|Cryoablation technical success|Safety assessment	Galil Medical	All	18 Years and older   (Adult, Older Adult)	Not Applicable	40	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CUC10-LNG06	August 2011	August 30, 2018	August 30, 2018	March 3, 2011		February 8, 2019	Ronald Regan UCLA Medical Center, Los Angeles, California, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Mayo Clinic Rochester, Rochester, Minnesota, United States|Institut Gustave Roussy, Villejuif, Cedex, France		https://ClinicalTrials.gov/show/NCT01307501
60	NCT01669148	Breast Cancer Detection: Comparison of Breast Tomosynthesis and Conventional Mammography		Completed	Has Results	Breast Cancer	Device: Tomosynthesis|Device: Conventional	Detection of Breast Cancer (Sensitivity)	Massachusetts General Hospital|Hologic, Inc.	Female	35 Years and older   (Adult, Older Adult)	Not Applicable	496	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	2007p-001197	November 2007	June 2011	October 2012	August 20, 2012	June 14, 2017	June 14, 2017	MGH, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT01669148
61	NCT03715660	Xpert Bladder Cancer Monitor; Prospective, Single, Tertiary-care Center Implementation Study		Recruiting	No Results Available	Bladder Cancer	Diagnostic Test: Xpert bladder cancer monitor	Accuracy of Xpert Bladder Cancer Monitor in monitoring of non muscle invasive bladder cancer by comparing its results to the results of the standard tool of monitoring of bladder cancer (diagnostic cystoscopy)	Mansoura University|Cepheid	All	Child, Adult, Older Adult	Not Applicable	200	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	AE 2395	September 1, 2018	August 1, 2019	September 1, 2019	October 23, 2018		October 23, 2018	Urology and Nephrology Center, Mansourah, Egypt		https://ClinicalTrials.gov/show/NCT03715660
62	NCT03940196	Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Platinum-resistant Ovarian Cancer (PROC) (ENGOT-ov50 / GOG-3029 / INNOVATE-3)		Recruiting	No Results Available	Ovarian Cancer	Device: NovoTTF-100L(O)|Drug: Paclitaxel	Overall survival|Progression-free survival|Objective response rate|Next progression-free survival|Time to undisputable deterioration in health-related quality of life (HRQoL)|Time to first and second subsequent treatment|Quality of life using the EORTC QLQ C30 questionnaire with the ovarian cancer symptom OV28 module.|Severity and frequency of adverse events	NovoCure Ltd.	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	540	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	EF-28	March 22, 2019	December 2024	December 2024	May 7, 2019		August 9, 2019	KH der Barmherzigen Brüder Graz, Graz, Austria|Univ.-Klinik für Gynäkologie und Geburtshilfe, Innsbruck, Innsbruck, Austria|University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium|CHU UCL Namur - Site Ste Elisabeth, Namur, Belgium|Onkologická Klinika Fakultní nemocnice Olomouc, Olomouc, Czechia|Gynekologicko-porodnická klinika 1. LF UK a VFN, Praha 2, Czechia|Hillel Yaffe Medical Center, Hadera, Israel|Oncology Institute, Galilee Medical Center, Nahariya, Israel|Gynecological Tumor Center, University Hospital Basel, Basel, Switzerland|Kantonsspital Frauenfeld - Frauenklinik, Frauenfeld, Switzerland|UniversitätsSpital Zürich - Klinik für Gynäkologie, Zürich, Switzerland		https://ClinicalTrials.gov/show/NCT03940196
63	NCT02209532	A Study Assessing the Safety and Utility of PINPOINT® Near Infrared Fluorescence Imaging in the Identification of Lymph Nodes in Patients With Uterine and Cervical Malignancies Who Are Undergoing Lymph Node Mapping	FILM	Completed	Has Results	Endometrial Cancer|Uterine Cancer|Cervical Cancer	Device: PINPOINT	Effectiveness of PINPOINT and IC2000 in the Identification of Lymph Nodes Defined as the Proportion of Confirmed Lymph Nodes Identified|Effectiveness of PINPOINT and Blue Dye in the Identification of at Least One Lymph Node Defined as the Number of Subjects in Which at Least One Confirmed Lymph Node Was Identified With Either PINPOINT or Blue Dye|Effectiveness of PINPOINT and Blue Dye in the Identification of Bilateral Lymph Nodes Defined as the Number of Subjects in Which Lymph Nodes Were Identified Bilaterally With Either PINPOINT or Blue Dye.|Identification of Lymph Nodes Following Lymphatic Channels Defined as the Number of Subjects in Which Confirmed Lymph Nodes Were Identified by Following a Lymphatic Channel With Either PINPOINT or Blue Dye.|Safety of Interstitial Injection of ICG Defined as the Number of Adverse Effects Related to ICG|Anatomic Distribution of Lymph Nodes	Novadaq Technologies ULC, now a part of Stryker	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	180	Industry	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PP LNM 01	December 2015	June 2017	June 2017	August 6, 2014	March 25, 2019	March 25, 2019	O'Connor Hospital, San Jose, California, United States|Lee Memorial Hospital, Fort Myers, Florida, United States|Memorial Sloan Kettering, New York, New York, United States|Duke Cancer Institute, Durham, North Carolina, United States|MD Anderson Cancer Center, Houston, Texas, United States|Sunnybrook Health Science Centre, Toronto, Ontario, Canada|CHU de Québec - Université Laval, Quebec City, Quebec, Canada|Hospital HIMA San Pablo, Caguas, Puerto Rico	"Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/32/NCT02209532/Prot_000.pdf|"Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/32/NCT02209532/SAP_001.pdf	https://ClinicalTrials.gov/show/NCT02209532
64	NCT01567462	PlasmaKinetic (PK) Button Vaporization Electrode for Treatment of Bladder Tumors	PK Button	Completed	Has Results	Bladder Cancer	Device: Monopolar electrocautery loop in Transurethral resection of bladder tumors|Device: PK Button Vaporization Electrode in transurethral resection of bladder tumors	Number of Procedural Complications|Mean Operative Time|Mean Catheterization Time|Number of Participants With Disease Recurrence	Emory University|Olympus	All	18 Years to 89 Years   (Adult, Older Adult)	Not Applicable	95	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	IRB00053735|PK Button and Bladder Tumors	September 2012	March 28, 2017	March 28, 2017	March 30, 2012	December 8, 2017	December 8, 2017	Emory University Department of Urology, Atlanta, Georgia, United States	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/62/NCT01567462/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT01567462
65	NCT03155516	Effect of Good Pain Management (GPM) Ward Program on Moderate to Severe Cancer Pain Patients	GPM	Recruiting	No Results Available	Cancer|Pain	Other: Good pain management (GPM) procedure|Other: Current practice procedure	Pain management index (PMI) assessment|Satisfaction of pain control during admission|Patient outcome questionnaire (APS-POQ) analysis|SF-36 Questionnaire analysis	Taiwan Mundipharma Pharmaceuticals Ltd.	All	20 Years and older   (Adult, Older Adult)	Not Applicable	150	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care	GPM16-TW-401	August 30, 2016	August 29, 2019	August 29, 2019	May 16, 2017		May 16, 2017	Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung, Taiwan|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan|Kaohsiung Municipal Siaogang Hospital, Kaohsiung, Taiwan		https://ClinicalTrials.gov/show/NCT03155516
66	NCT03514329	Vapor Ablation for Localized Cancer Lesions	VAPORIZED	Not yet recruiting	No Results Available	Non Small Cell Lung Cancer|Metastatic Lung Cancer|Lung Cancer	Device: Bronchoscopic Thermal Vapor Ablation	BTVA-C related AEs/SAEs|Successful BTVA-C Treatment Delivery|Local Control Evaluation per RECIST	Uptake Medical Technology, Inc.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	10	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CSP-2315	March 1, 2019	December 30, 2020	March 30, 2021	May 2, 2018		January 25, 2019	Otto-Wagner Hospital, Vienna, Austria|Azienda Ospedaliero - Universitaria, Ancona, Italy		https://ClinicalTrials.gov/show/NCT03514329
67	NCT01226576	Focal MR-Guided Focused Ultrasound Treatment of Localized Low-Intermediate Risk Prostate Cancer: Feasibility Study		Completed	No Results Available	Localized Low-Intermediate Risk Prostate Cancer	Device: MRgFUS Treatment	Safety and initial Effectiveness|Safety|Effectiveness|QOL	InSightec	Male	50 Years to 75 Years   (Adult, Older Adult)	Not Applicable	8	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PCa004	October 2010	December 2018	December 2018	October 22, 2010		March 13, 2019	University Health Network, Toronto, Ontario, Canada|Sheba Medical Center, Tel Hashomer, Israel|Sapienza University Hospital, Rome, Italy|National Cancer Center Singapore, Singapore, Singapore|St. Mary's Hospital, London, United Kingdom		https://ClinicalTrials.gov/show/NCT01226576
68	NCT00921193	Evaluation of Radiation Therapy Positioning System (RTPS) in Patients With Localized Prostate Cancer		Completed	No Results Available	Prostate Cancer	Device: Radiation Therapy Positioning System (RTPS)	Device related adverse events by evaluation of the type, frequency and severity of the device, implantation device and/or implantation procedure related adverse events|International Prostate Symptom Score (IPSS) questionnaire at baseline, at CT planning and on first week of Radiation Therapy.|Successful implantation of the Blip in the prostate|Non migration of the Blip as evaluated by measuring the average absolute change in inter-marker distances measured during and at the end of radiotherapy treatment|Performance of the RTPS in at least five of approximately 40 radiation therapy sessions|Record target volume movement during at least 5 radiation therapy sessions	Navotek Medical, Ltd.	Male	45 Years and older   (Adult, Older Adult)	Not Applicable	20	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	20-14-001	May 2009	January 2011	January 2011	June 16, 2009		March 30, 2011	Leuvens Kankerinstituut, Leuven, Belgium|Dr. Bernard Verbeeten Institute, Tilburg, Netherlands		https://ClinicalTrials.gov/show/NCT00921193
69	NCT00303654	Loop Resectoscope in Treating Patients With Bladder Cancer or Benign Prostatic Hyperplasia Who Are Undergoing Transurethral Resection		Completed	No Results Available	Bladder Cancer	Procedure: biopsy|Procedure: therapeutic conventional surgery	Surgeon satisfaction with usage of Roei loop resectoscope measured by a questionnaire after the surgical procedure	Roei Medical Technologies Ltd.|National Cancer Institute (NCI)	All	Child, Adult, Older Adult	Not Applicable	24	Industry	Interventional	Masking: None (Open Label)|Primary Purpose: Treatment	CDR0000446284|UCLA-0506127-01	August 2005		June 2007	March 17, 2006		March 26, 2013	Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States		https://ClinicalTrials.gov/show/NCT00303654
70	NCT03198468	Vapor Ablation for Localized Cancer Lesions of the Lung (VAPORIZE)	VAPORIZE	Recruiting	No Results Available	Non Small Cell Lung Cancer|Metastatic Lung Cancer|Lung Cancer	Device: Bronchoscopic Thermal Vapor Ablation	BTVA-C related AEs/SAEs|Successful BTVA-C Treatment Delivery|Ischemic tissue assessment|Tissue necrosis evaluated by semi-quantitative histological analysis	Uptake Medical Technology, Inc.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	8	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CSP-2313	December 1, 2018	November 30, 2019	February 28, 2020	June 26, 2017		January 25, 2019	Macquarie University Hospital, Sydney, New South Wales, Australia|The Royal Melbourne Hospital, Melbourne, Victoria, Australia		https://ClinicalTrials.gov/show/NCT03198468
71	NCT03482557	Contrast Enhanced Spectral Mammography vs. MRI for Breast Cancer Screening		Recruiting	No Results Available	Breast Cancer	Device: CESM|Device: MRI	Diagnostic accuracy of CESM compared with breast MRI for breast cancer screening|Diagnostic accuracy of CESM compared with abbreviated MRI for breast cancer detection|Diagnostic accuracy of CESM compared with conventional mammography for breast cancer screening|Patient preference for breast MRI versus CESM for breast cancer screening	Dana-Farber Cancer Institute|GE Healthcare	Female	30 Years to 110 Years   (Adult, Older Adult)	Not Applicable	96	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening	17-689	May 17, 2018	April 30, 2021	April 30, 2021	March 29, 2018		January 10, 2019	Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT03482557
72	NCT00573586	Treatment of Localized Prostate Cancer With High Intensity Focused Ultrasound Using the Sonablate® 500 System in Canada		Not yet recruiting	No Results Available	Prostate Cancer	Device: Sonablate 500 (SB-500)	PSA level	SonaCare Medical	Male	40 Years to 80 Years   (Adult, Older Adult)	Not Applicable	20	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	USHIFU-CABC-PC002	December 2020	December 2020	December 2020	December 14, 2007		May 3, 2019	Abbotsford Regional Hospital Cancer Center, Abbotsford, British Columbia, Canada		https://ClinicalTrials.gov/show/NCT00573586
73	NCT04020523	Advanced MR Techniques for Breast Cancer Detection	RAPIDIRM	Not yet recruiting	No Results Available	Breast Cancer	Other: MRI sequence	Mammary lesions Visualization on ultrafast injected dynamic MRI: Yes/No|Mammary lesions Visualization with a diffusion sequence|Quantitative perfusion parameters : Enhancement Integral (EI (%))|Quantitative perfusion parameters : Maximum Slope of Increase (MSI (%/sec))|Quantitative perfusion parameters : Maximum of enhancement (Rmax (%))|Quantitative perfusion parameters : Timing of Maximum of enhancement (RmaxTiming (sec))|Quantitative perfusion parameters : Wash-inrate (WIR (%/sec)|Correlate diffusion MRI parameters with immunochemical markers of tumor angiogenesis on anatomopathological specimen Quantitative diffusion parameter : Apparent Coefficient Diffusion|Evaluate the reduction in the time required to acquire and interpret the new breast MR protocol compared to the standard one	Assistance Publique - Hôpitaux de Paris|GE Healthcare	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	655	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	K180603J|2018-A01647-48	July 2019	November 2022	July 2024	July 16, 2019		July 16, 2019	Service de Radiologie Hôpital Tenon (APHP), Paris, France		https://ClinicalTrials.gov/show/NCT04020523
74	NCT02965755	Personalized Molecular Profiling in Cancer Treatment at Johns Hopkins	IMAGE-II	Recruiting	No Results Available	Metastatic Breast Cancer	Other: Treatment recommendation	Ability of genetically profiling of ptDNA as assessed by identifying the proportion of genetic alterations in tumor tissue|Percentage of patients who cannot have NGS of metastatic site biopsy but have clinically actionable mutations detected via genetic profiling of ptDNA|Response as assessed by change in ptDNA level up to 2 weeks post-intervention. To determine whether a 10-fold decrease in allelic frequency of a given mutation in ptDNA after initiating new systemic therapy can predict for response to treatment.|Response as assessed by Change in Circulating tumor cell (CTC) counts	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Foundation Medicine	All	18 Years to 100 Years   (Adult, Older Adult)	Not Applicable	200	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	J16146|IRB00117742	January 26, 2018	July 2020	July 2022	November 17, 2016		February 5, 2019	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States		https://ClinicalTrials.gov/show/NCT02965755
75	NCT00656669	Exploratory Study of Sunitinib Malate as a Component of Neoadjuvant Therapy for Breast Cancer		Completed	Has Results	Breast Cancer	Drug: sunitinib alone|Drug: sunitinib plus paclitaxel|Drug: doxorubicin and cyclophosphamide	Change in Interstitial Fluid Pressure (IFP) Induced by Sunitinib Monotherapy|Change in Interstitial Fluid Pressure (IFP) Induced by Paclitaxel Plus Sunitinib After Sunitinib Monotherapy|Pathological Complete Response (pCR) Rate for Patients Treated With Sunitinib/Paclitaxel Followed by AC as Neoadjuvant Therapy for Breast Cancer|To Evaluate the Safety of Paclitaxel Plus Sunitinib When Given in Combination as Neoadjuvant Therapy	Indiana University|Pfizer	All	18 Years and older   (Adult, Older Adult)	Not Applicable	23	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	0802-15/1011003564; IUCRO-0215	April 2008	September 2010	September 2010	April 11, 2008	August 12, 2014	August 12, 2014	Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States		https://ClinicalTrials.gov/show/NCT00656669
76	NCT02441140	Detection of Tumor Associated Cell-free DNA in Peritoneal Fluid Obtained by Culdocentesis		Recruiting	No Results Available	Stage III Ovarian Cancer|Stage IV Ovarian Cancer	Procedure: Culdocentesis|Procedure: Vaginal Swab|Procedure: Chromopertubation|Procedure: Blood collection|Procedure: Tissue collection	Number of completed peritoneal fluid collection by culdocentesis after chromopertubation as an assessment of feasibility of peritoneal fluid collection in women with ovarian cancer.|Measure the concentration of cell free DNA in various biologic fluids and compare it to primary tumor DNA.	Dana-Farber Cancer Institute|Celula, Inc.	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	10	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	15-029	May 2015	August 2018	April 2020	May 12, 2015		July 11, 2018	Brigham and Women's Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT02441140
77	NCT00235794	An Open Label Exploratory Study in Newly Diagnosed Prostate Cancer Patients		Completed	No Results Available	Prostatic Neoplasms	Drug: temsirolimus	To determine the effects of oral temsirolimus on changes in phosphorylation state of proteins in the mTOR signaling pathway in tumor tissue and on phosphorylation state of mTOR pathway proteins and on global and targeted gene expression pattern PBMCs|Determine effects of oral temsirolimus on global and targeted gene expression; compare effects in the tumor and PBMCs; obtain preliminary information on potential antitumor effects; evaluate PK using whole blood and tumor tissue.|To evaluate the relationship between PTEN status and the pharmacodynamic/pharmacogenomic effects of temsirolimus and to determine the effects of temsirolimus on changes in protein expression patterns in the plasma	Wyeth is now a wholly owned subsidiary of Pfizer	Male	18 Years and older   (Adult, Older Adult)	Not Applicable	50	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	3066A1-132	January 2004		September 2007	October 10, 2005		December 27, 2007	Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT00235794
78	NCT00003763	Radiolabeled Folic Acid and Imaging to Detect Ovarian Cancer		Completed	No Results Available	Ovarian Cancer	Procedure: radionuclide imaging|Radiation: indium In 111 folic acid		Endocyte	Female	18 Years to 120 Years   (Adult, Older Adult)	Not Applicable		Industry	Interventional	Primary Purpose: Diagnostic	ENDOCYTE-EC.OV.53.958|CDR0000066889|ENDOCYTE-96-286|ENDOCYTE-98-0409	January 1999			July 22, 2004		April 4, 2017	Indiana University Cancer Center, Indianapolis, Indiana, United States|Washington University - St. Louis, St. Louis, Missouri, United States|University of Texas - MD Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT00003763
79	NCT01478438	A Multicenter "Ablate and Resect" Study of Novilase® Interstitial Laser Therapy for the Ablation of Small Breast Cancers		Active, not recruiting	No Results Available	Malignant Tumor	Device: Novilase Interstitial Laser Therapy	Collect information on the proportion of tumors ablated for sample size calculations in the pivotal trial|To gain experience with the cosmetic outcome and rate of recovery tools	Novian Health Inc.	Female	18 Years to 80 Years   (Adult, Older Adult)	Not Applicable	60	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	BR-002	April 2012	December 2015	December 2020	November 23, 2011		March 14, 2019	The Breast Center of Southern Arizona, Tucson, Arizona, United States|Rose Medical Center - Rose Breast Center, Denver, Colorado, United States|St. Alexius Breast Care of St. Alexius Medical Center, Bartlett, Illinois, United States|Advocate Lutheran General Hospital - Caldwell Breast Center, Park Ridge, Illinois, United States|Walter Reed National Military Medical Center, Bethesda, Maryland, United States|Columbia University Medical Center - Department of Surgery, New York, New York, United States|University of Toledo - Eleanor N. Dana Cancer Center Breast Care, Toledo, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Wheaton Franciscan Health System, Wauwatosa, Wisconsin, United States|North Bristol NHS Trust: Southmead Hospital - The Breast Care Centre, Bristol, United Kingdom|Mid Essex Hospital Services NHS Trust: Broomfield Hospital - Breast Unit, Chelmsford, United Kingdom|Norfolk & Norwich University NHS Foundation Trusts: Norfolk and Norwich University Hospital, Norwich, United Kingdom		https://ClinicalTrials.gov/show/NCT01478438
80	NCT03028246	A Feasibility Safety Study of Benign Centrally-Located Intracranial Tumors in Pediatric and Young Adult Subjects		Recruiting	No Results Available	Benign Centrally-Located Intracranial Tumors	Device: ExAblate 4000 System	Incidence of Treatment-Emergent Adverse Events Safety and Tolerability|Measurement of Tumor Volume|Changes in the General Physical Exam|Changes in the Neurological Exam|Confrontational Visual Field Testing|Global Impression of Change-Clinician|Patient Global Impression of Change	InSightec	All	8 Years to 22 Years   (Child, Adult)	Not Applicable	10	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	BT005	February 28, 2017	March 31, 2021	December 31, 2022	January 23, 2017		May 24, 2019	Miami Children's Research Institute - Nicklaus Children's Hospital, Miami, Florida, United States		https://ClinicalTrials.gov/show/NCT03028246
81	NCT01939847	IMAGE Study: Personalized Molecular Profiling in Cancer Treatment at Johns Hopkins		Completed	No Results Available	Metastatic Breast Cancer	Other: Treatment suggestion	Time to report molecular profiling in tissue|Time to report molecular profiling in blood|Ability to make treatment suggestions|Decisions about Molecular Profiling Tumor Board (MPTB) suggestion|Progression-free survival|Changes in plasma tumor DNA (ptDNA)|Similarities and differences of the profiling results with the different assays in tissue	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Foundation Medicine	All	18 Years and older   (Adult, Older Adult)	Not Applicable	32	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	J12129|NA_00080409	September 19, 2013	May 14, 2015	February 1, 2017	September 11, 2013		February 28, 2019	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States		https://ClinicalTrials.gov/show/NCT01939847
82	NCT01896713	The Value of MultiSpectral 3 Tesla MRI in Active Surveillance of Prostate Cancer		Completed	No Results Available	Prostate Cancer	Other: MS3TMRI	The Positive Predictive Value (PPV) of MS3TMRI-TRUSBx for detection of a patient with a cancer burden requiring consideration of immediate therapy.|The number of cores required for diagnosis of prostate cancer for MS3TMRI-TRUSBx versus TRUSBx alone	Sunnybrook Health Sciences Centre|Philips Healthcare	Male	18 Years and older   (Adult, Older Adult)	Not Applicable	81	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	154-2009	April 2010	December 2012	December 2012	July 11, 2013		July 11, 2013	Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada		https://ClinicalTrials.gov/show/NCT01896713
83	NCT03886181	Alpha Radiation Emitters Device for the Treatment of Cutaneous, Mucosal and Superficial Soft Tissue Neoplasia (DaRT)		Not yet recruiting	No Results Available	Skin Cancer|Mucosal Neoplasm of Oral Cavity|Soft Tissue Neoplasm	Device: Device: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)	Evaluate the safety of the DaRT treatment|Evaluation the effectiveness of the treatment.	Alpha Tau Medical LTD.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	35	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CTP-CMN-01	June 2019	June 2021	August 2021	March 22, 2019		March 22, 2019	IRCCS Istituto Dermatologico S. Gallicano, IFO - Istituti Fisioterapici Ospitalieri - Dermatologia Oncologica e Prevenzione, Rome, Lazio, Italy		https://ClinicalTrials.gov/show/NCT03886181
84	NCT03889899	Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia.		Not yet recruiting	No Results Available	Skin Cancer|Mucosal Neoplasm of Oral Cavity|Soft Tissue Neoplasm	Device: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)	Tumor response to DaRT|Adverse Events|Assessment of the reduction in tumor volume|DaRT seeds placement.|Change in quality of life	Alpha Tau Medical LTD.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	30	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CTP-CMN-03	June 2019	June 2021	September 2021	March 26, 2019		June 4, 2019	RAMBAM Health Care Campus, Haifa, Israel		https://ClinicalTrials.gov/show/NCT03889899
85	NCT03737734	Alpha Radiation Emitters Device for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia (DaRT)		Recruiting	No Results Available	Skin Cancer|Mucosal Neoplasm of Oral Cavity|Soft Tissue Neoplasm	Device: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)	Tumor response to DaRT|Adverse Events|Reduction in tumor volume|DaRT seeds placement|Change in quality of life|Progression Free Survival	Alpha Tau Medical LTD.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	30	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CTP-CMN-02	December 31, 2018	December 2020	December 2022	November 9, 2018		January 10, 2019	Davidof Cancer Institution at the Rabin Medical Center Israel, Petah tikva, Israel		https://ClinicalTrials.gov/show/NCT03737734
86	NCT02079025	Multi-Center Trial of High-resolution Transrectal Ultrasound Versus Standard Low-resolution Transrectal Ultrasound for the Identification of Clinically Significant Prostate Cancer		Completed	Has Results	Prostatic Neoplasms|Prostate Cancer|Cancer of the Prostate	Device: High-resolution ultrasound guided prostate biopsy|Device: Standard ultrasound guided prostate biopsy	Percentage of Participants With Clinically Significant Prostate Cancer|Improvement of an Investigator's Ability to Detect Clinically Significant Cancer Using UHR-TRUS Post-training When Compared to Pre-training|Combined Sensitivity and Specificity in Determining Cancer Detection Overall for Image-guided Biopsy	Exact Imaging	Male	40 Years to 79 Years   (Adult, Older Adult)	Not Applicable	1676	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other	2013-UHR-002	December 2013	December 2016	February 2018	March 5, 2014	January 8, 2019	February 26, 2019	Johns Hopkins Brady Urological Institution, Baltimore, Maryland, United States|Urology of Virgina, Virginia Beach, Virginia, United States|Prostate Cancer Centre, Calgary, Alberta, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Centre de Recherche sur le Cancer ("CRCEO"), Quebec City, Quebec, Canada		https://ClinicalTrials.gov/show/NCT02079025
87	NCT01166763	Modulation of Breast Cancer Risk Biomarkers by High Dose Vitamin D		Completed	Has Results	Breast Cancer	Drug: vitamin D3	Change in Mammographic Breast Density Over Course of Study|Change in Proliferation (as Assessed by Ki-67) Examined in Breast Epithelial Cells.|OH Vitamin D Levels in Serum	Carol Fabian, MD|BTR Group|University of Kansas Medical Center	Female	up to 55 Years   (Child, Adult)	Not Applicable	30	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	11657	May 2009	June 2011	June 2011	July 21, 2010	March 10, 2014	July 18, 2016	University of Kansas Medical Center, Kansas City, Kansas, United States		https://ClinicalTrials.gov/show/NCT01166763
88	NCT01344564	Initiation of Androgen Deprivation Therapy for Prostate Cancer Using Degarelix Followed by Leuprolide		Completed	No Results Available	Prostate Cancer	Drug: Degarelix acetate, Leuprolide acetate	Testosterone measurement	Urology of Virginia|Ferring Pharmaceuticals	Male	18 Years and older   (Adult, Older Adult)	Not Applicable	50	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	UVA002	April 2011	August 2012	August 2012	April 29, 2011		March 18, 2013	Urology of Virginia, Virginia Beach, Virginia, United States		https://ClinicalTrials.gov/show/NCT01344564
89	NCT00200174	Combined Estrogen Blockade of the Breast With Exemestane and Raloxifene in Postmenopausal Women With a History of Breast Cancer Who Have No Clinical Evidence of Disease		Completed	No Results Available	Breast Cancer	Drug: Raloxifene followed by combination therapy|Drug: Exemestane followed by combination therapy	To evaluate the clinical safety and toxicity of raloxifene in combination with exemestane in postmenopausal women with a hx of AJCC Stage 0, I, II, or III breast cancer, who have no clinical evidence of disease, after completion of all planned adjuvant|To determine the feasibility of using mammography and breast MRI imaging to assess the effects of raloxifene plus exemestane on radiographic breast density.	Memorial Sloan Kettering Cancer Center|Pharmacia	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	11	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	99-017	July 1999	July 2003	August 2008	September 20, 2005		December 23, 2015	Memorial Sloan-Kettering Cancer Center, New York, New York, United States		https://ClinicalTrials.gov/show/NCT00200174
90	NCT02303054	MRI-Targeted Focal Ablation of the Prostate in Men With Prostate Cancer	FUSAblate	Completed	No Results Available	Prostate Cancer	Procedure: Bipolar Radiofrequency Focal Ablation	Number of Subjects Resulting in Negative Biopsy as a Measure of Efficacy|International Prostate Symptom Score to Measure Quality of Life Post Focal Ablation|Expanded Prostate Cancer Index Composite (EPIC) Score to Measure Quality of Life Post Focal Ablation|International Index of Erectile Function questionnaires Score (IEFF) to Measure Quality of Life Post Focal Ablation|Short Form - 12 (SF-12) to Measure Quality of Life Post Focal Ablation	NYU Langone Health|Trod Medical N.V.	Male	40 Years to 80 Years   (Adult, Older Adult)	Not Applicable	21	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	14-00903	September 2014	March 2016	March 2016	November 27, 2014		October 11, 2017	Smilow Comprehensive Prostate Cancer Center, New York, New York, United States		https://ClinicalTrials.gov/show/NCT02303054
91	NCT01473485	ExAblate (Magnetic Resonance-guided Focused Ultrasound Surgery) Treatment of Brain Tumors		Recruiting	No Results Available	Glioma|Metastatic Brain Cancer	Device: ExAblate Transcranial System	Evaluate Safety of ExAblate Transcranial Device	InSightec	All	18 Years to 75 Years   (Adult, Older Adult)	Not Applicable	10	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	BT003	April 2011	December 2022	December 2022	November 17, 2011		January 10, 2019	Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada		https://ClinicalTrials.gov/show/NCT01473485
92	NCT02953418	RFA for Flat Type High-grade and Medium-grade Intraepithelial Squamous Neoplasia	REACH	Active, not recruiting	No Results Available	Esophageal Squamous Cell Neoplasia (ESCN)	Device: Radiofrequency ablation	percentage of subjects with complete response (CR)|Proportion of patients with a CR after primary RFA, defined as absence of MGIN or worse in any of the biopsies from the treatment area at the three months visit|Proportion of patients demonstrating neoplastic progression, defined as detection of a more severe histological grade compared to the baseline at any follow-up visit|Proportion of patients demonstrating MGIN or worse outside the TA during treatment phase or follow-up|Proportion of patients requiring endoscopic resection of visible abnormalities in the TA during treatment phase or follow-up.	Medtronic - MITG	All	18 Years to 85 Years   (Adult, Older Adult)	Not Applicable	150	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	COVB3050540	April 20, 2017	July 2019	July 2019	November 2, 2016		June 12, 2019	Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China		https://ClinicalTrials.gov/show/NCT02953418
93	NCT02321527	Feasibility of Ultrasound Microbubble Contrast-Enhanced (CEUS) Sentinel Lymph Node Imaging With Guided Biopsy in Breast Cancer Patients		Completed	Has Results	Breast Cancer	Drug: Perflutren Protein-Type A Microspheres Injectable Suspension|Device: Contrast-Enhanced Ultrasound (CEUS)|Procedure: Biopsy + Radioactive Seed Placement|Behavioral: Phone Call	Number of Breast Cancer Participants With Sentinel Lymph Nodes (SLN) Identification Using the CEUS Technique	M.D. Anderson Cancer Center|GE Healthcare	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	21	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening	2014-0611|NCI-2015-00066	July 2015	May 2016	May 2016	December 22, 2014	June 20, 2017	June 20, 2017	University of Texas MD Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT02321527
94	NCT01755130	Multimode Laser Optoacoustic Ultrasonic Tomography System for Breast Cancer Care - LOUIS-3D Breast Study		Active, not recruiting	No Results Available	Breast Cancer	Procedure: LOUIS-3D Imaging Procedure	LOUIS 3D Capability to Detect and Differentiate Breast Tumors|Comparison of False Positive Rate of LOUIS-3D Compared to Ultrasound for Breast Cancer Detection	M.D. Anderson Cancer Center|TomoWave Laboratories, Inc.	Female	20 Years to 85 Years   (Adult, Older Adult)	Not Applicable	96	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	2012-0210|NCI-2014-01243	May 2014	May 2020	May 2020	December 24, 2012		January 11, 2019	University of Texas MD Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT01755130
95	NCT03790813	Informative Tools to Optimize Neoadjuvant Therapy in ER Positive, HER2 Negative Breast Cancers	ER	Not yet recruiting	No Results Available	Breast Cancer	Diagnostic Test: Intervention 1|Diagnostic Test: Intervention 2	Feasibility of neoajduvant Ki-67 and Oncotype DX, defined as >=75% enrollment rate for all screened patients|Turnaround time of Ki-67 and Oncotype DX, defined as time from patient consent to date results are obtained|Feasibility of MRI prior to neoadjuvant systemic treatment, defined as >=75% of patients who receive an MRI before the start of neoadjuvant treatment|Turnaround time of MRI prior to neoadjuvant systemic treatment, defined as time from patient consent to date of 1st MRI|Correlation of Ki-67 and Oncotype DX to each other and to the outcome of neoadjuvant systemic treatment.|Predictive association of Ki-67 and Oncotype to invasive locoregional or systemic relapse|Predictive association of Ki-67 and Oncotype to overall survival|Impact of serial MRI on changes to surgical planning|Correlation of serial MRI to clinical and pathological response|Patient reported outcomes assessed by questionnaire	British Columbia Cancer Agency|Genomic Health®, Inc.	Female	18 Years to 89 Years   (Adult, Older Adult)	Not Applicable	50	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	H18-02581	January 7, 2019	December 31, 2019	December 31, 2023	January 1, 2019		January 1, 2019			https://ClinicalTrials.gov/show/NCT03790813
96	NCT03478384	Self-efficacy Coaching for Women With Breast Cancer	SECOM-PSWE	Recruiting	No Results Available	Breast Cancer	Behavioral: Patient coaching	Overall perceived self-efficacy|Overall quality of life|Disease-related quality of life|Active coping with the disease|Physical activity|Duration of hormone therapy|Anxiety levels|Use of complementary medicine|Rate of Relapse|Change of perceived self-efficacy|Change of quality of life|Change of disease-related quality of life|Depression|Use of micronutrients	Stiftung Patientenkompetenz|iOMEDICO AG	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	150	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	iOM-110393	March 16, 2018	February 2020	February 2020	March 27, 2018		April 6, 2018	Tumorzentrum ZeTuP Rapperswil-Jona, Rapperswil-Jona, Saint Gallen, Switzerland|Prolindo, Onkologie & Hämatologie, Team am Lindenhofspital, Bern, Switzerland|Spital Thurgau AG - Kantonsspital Frauenfeld, Frauenfeld, Switzerland|Hirslanden Klinik St. Anna, Luzern, Switzerland|Tumor-und Brustzentrum ZeTuP AG St. Gallen, St. Gallen, Switzerland|Stadtspital Triemli, Zürich, Switzerland		https://ClinicalTrials.gov/show/NCT03478384
97	NCT00208871	An Evaluation of Stereoscopic Digital Mammography for Earlier Detection of Breast Cancer and Reduced Rate of Recall		Completed	No Results Available	Breast Cancer	Procedure: Stereoscopic Digital Mammography	sensitivity/specificity|Recall rate	Emory University|BBN Technologies	Female	Child, Adult, Older Adult	Not Applicable	1467	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	IRB00045816	December 2004	December 2007	March 2011	September 21, 2005		November 20, 2013	Emory University Hospital, Atlanta, Georgia, United States		https://ClinicalTrials.gov/show/NCT00208871
98	NCT03036943	Fluciclovine (18F) Imaging of Breast Cancer	FRONTIER	Completed	No Results Available	Breast Cancer	Radiation: Fluciclovine	Tumour standardised uptake values (SUV) in invasive breast cancer, classified by molecular type, on fluciclovine (18F) PET imaging.|Amino acid transporter (AAT) and related growth pathway expression levels quantitatively assessed by immunohistochemistry using the H-score method, and correlated to fluciclovine (18F) uptake (SUV).|Tumour metabolite levels characterized by fold change compared to metabolite levels in the adjacent normal tissue, and correlated to fluciclovine (18F) uptake.	University of Oxford|Blue Earth Diagnostics	Female	40 Years and older   (Adult, Older Adult)	Not Applicable	40	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	OCTO_078	February 15, 2017	December 4, 2018	December 4, 2018	January 31, 2017		December 19, 2018	Churchill Hospital, Oxford, United Kingdom		https://ClinicalTrials.gov/show/NCT03036943
99	NCT00606931	Pilot Study to Evaluate High Resolution PET Image-Guidance for Sampling of Breast Abnormalities	PEM-BX	Completed	Has Results	Breast Cancer	Device: Stereo Navigator Accessory to PEM Flex PET Scanner	Number of Lesions That Were Successfully Biopsied Using the PET-Guided Biopsy Method.|Number of Participants Who Reported Serious Adverse Events After the PET-Guided Biopsy	Naviscan PET Systems|American Radiology Services, Inc|Boca Raton community Hospital, FL|Diversified Specialty Institutes, Bensalem, PA|Advanced Breast Care Imaging|Epic Imaging	Female	25 Years and older   (Adult, Older Adult)	Not Applicable	22	Industry|Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	PEM-07-02|NIH/NCI 5 R44 CA082042-03	January 2008	July 2008	August 2008	February 5, 2008	July 7, 2009	July 7, 2009	Boca Raton Community Hospital, Boca Raton, Florida, United States|American Radiology Services, Greenspring, Timonium, Maryland, United States|Epic Imaging, Portland, Oregon, United States|Advanced Breast Care Imaging, Allentown, Pennsylvania, United States|Diversified Specialty Institutes, Bensalem, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT00606931
100	NCT02332863	Comparison of Back-loaded vs Preloaded Fiducial Needles in EUS-guided Fiducial Marker Placement in Pancreatic Cancer.		Recruiting	No Results Available	Pancreatic Cancer	Device: Back-loaded Needle (Device)|Device: Preloaded Needle (Device)	Duration of Procedure time (Composite of multiple aspects of procedure)|Ease of fiducial deployment|EUS visualization of the delivery system needle|EUS visual appearance of fiducials|Visualization of fiducials as assessed by radiation oncology|Inadvertent deployment of fiducials|Ease of passage of delivery system|Adverse Event (AE) rates	University of Colorado, Denver|Cook Group Incorporated	All	18 Years and older   (Adult, Older Adult)	Not Applicable	40	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	14-1711.cc	August 3, 2016	April 2020	April 2020	January 7, 2015		October 29, 2018	University of Colorado Hospital, Aurora, Colorado, United States|Moffitt Cancer Center, Tampa, Florida, United States		https://ClinicalTrials.gov/show/NCT02332863
101	NCT03650595	MRI Guided Focal Laser Ablation of Prostate Cancer	MRgFLA	Recruiting	No Results Available	Prostate Cancer|Low and Intermediate Risk Prostate Cancer	Device: The TRANBERGCLS Thermal Therapy	The proportion of study patients clinically free of clinically significant PCa (i.e. requires definitive treatment)|Treatment effect on patients' Quality of Life (QoL), the following validated self-reported urogenital functioning assessment instruments will be used before and following treatment at pre-specified interval	University Health Network, Toronto|Clinical Laserthermia Systems AB	Male	40 Years to 80 Years   (Adult, Older Adult)	Not Applicable	23	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	15-9002	March 29, 2018	June 30, 2021	June 30, 2022	August 28, 2018		August 28, 2018	Sangeet Ghai, MD, Toronto, Ontario, Canada		https://ClinicalTrials.gov/show/NCT03650595
102	NCT02833233	A Study of Pre-Operative Treatment With Cryoablation and Immune Therapy in Early Stage Breast Cancer		Active, not recruiting	No Results Available	Breast Cancer	Procedure: Cryoablation|Drug: Ipilimumab|Drug: Nivolumab	Number of adverse events	Memorial Sloan Kettering Cancer Center|Bristol-Myers Squibb	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	5	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	16-495	June 2016	June 2020	June 2020	July 14, 2016		July 17, 2019	Memorial Sloan Kettering Cancer Center, New York, New York, United States		https://ClinicalTrials.gov/show/NCT02833233
103	NCT01576939	Feasibility of IMRT Modulation to Account for Scattered Radiation From Dental Fillings in Head and Neck Cancer		Completed	Has Results	Head and Neck Cancer	Radiation: Intensity Modulated Radiation Therapy	Time Until the Maximum Oral Mucositis Measured From the Start of Radiation Treatment.|Duration of Grade 2 or Higher Oral Mucositis After First Oral Mucositis Was Observed.|Relationship Between the Measured Lateral Tongue Mucosal Dose and the Amount of Narcotic Use|How Does Increase in Soreness Scores Affect Quality of Life Questionnaire While Adjusting for the Measured Lateral Tongue Mucosal Dose|How Does Increase in Pain Scores Affect Quality of Life Questionnaire While Adjusting for the Measured Lateral Tongue Mucosal Dose?	Stanford University|Varian Medical Systems	All	18 Years and older   (Adult, Older Adult)	Not Applicable	30	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IRB-21777|SU-08102011-8266|ENT0032	August 2011	January 2014	April 2016	April 13, 2012	June 14, 2017	June 14, 2017	Stanford University School of Medicine, Stanford, California, United States		https://ClinicalTrials.gov/show/NCT01576939
104	NCT00463489	Lifestyle Intervention Study in Adjuvant Treatment of Early Breast Cancer	LISA	Completed	No Results Available	Breast Cancer	Behavioral: Lifestyle intervention|Behavioral: Mail-based	Disease-free survival|Overall survival|Distant disease-free survival|Weight at 6, 12, 24, 36, 48 and 60 months compared to baseline|Health-related quality of life at 6, 12, 24, 36, 48 and 60 months compared to baseline|Other medical endpoints such as diabetes, cardiovascular disease, arthritis, fasting biomarkers at 12 months compared to baseline (for women participating in a biospecimen substudy)|Compliance with study procedures.	Ontario Clinical Oncology Group (OCOG)|Novartis Pharmaceuticals	Female	Child, Adult, Older Adult	Not Applicable	338	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	OCOG-2007-LISA	August 2007	June 2018	June 2018	April 20, 2007		September 26, 2018	Los Angeles Biomedical (LABIOMED) Research Institue at Harbor-UCLA Medical Center, Torrance, California, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Centre, Boston, Massachusetts, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Bcca - Csi, Kelowna, British Columbia, Canada|Cambridge Memorial Hospital, Cambridge, Ontario, Canada|Juravinski Cancer Centre, Hamilton, Ontario, Canada|Grand River Regional Cancer Centere, Kitchener, Ontario, Canada|London Regional Cancer Centre, London, Ontario, Canada|Ottawa Hospital Regional Cancer Centre, Ottawa, Ontario, Canada|Algoma District Cancer Program, Sault Ste. Marie, Ontario, Canada|Scarborough Hospital, Scarborough, Ontario, Canada|Niagara Health System, St. Catharines, Ontario, Canada|Thunder Bay Regional Health Science Centre, Thunder Bay, Ontario, Canada|Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Mount Sinai Hospital, Toronto, Ontario, Canada|Trillium Healthcare Centre, Toronto, Ontario, Canada|Windsor Regional Cancer Centre, Windsor, Ontario, Canada|Hopital Charles LeMoyne, Greenfield Park, Quebec, Canada|CHUM - Hotel Dieu de Montreal, Montreal, Quebec, Canada		https://ClinicalTrials.gov/show/NCT00463489
105	NCT02030769	Pronase Improves Efficacy of Chromoendoscopy Screening on Esophageal Cancer		Completed	No Results Available	Esophageal Neoplasms	Drug: Pronase|Drug: Control	Detection rate of high grade dysplasia and carcinoma in iodine void lesion|Average Esophageal Visibility Score Before iodine staining|Average Esophageal Visibility Score After iodine staining|Detection Rate of lesions with pink sign|overall detection rate of iodine void lesion	Xijing Hospital of Digestive Diseases|Beijing Tide Pharmaceutical Co., Ltd	All	18 Years to 75 Years   (Adult, Older Adult)	Not Applicable	1000	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	20130925-4	January 2014	December 2014	December 2014	January 9, 2014		March 29, 2016	Xijing Hospital of Digestive Disease, Xi'an, Shaanxi, China		https://ClinicalTrials.gov/show/NCT02030769
106	NCT01874678	A Study of TS-1 Plus Cisplatin in Patients With Advanced Non-small-cell Lung Cancer		Completed	No Results Available	Non-small-cell Lung Cancer (NSCLC)	Drug: TS-1/Cisplatin	overall response rate|To assess progression free survival To assess overall survival To bridge the safety profile by assessing the toxicities and tolerability	TTY Biopharm	All	20 Years to 74 Years   (Adult, Older Adult)	Not Applicable	45	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	TTYTG0904	March 2011	December 2015	December 2015	June 11, 2013		January 12, 2016	Dalin Tzu Chi General Hospital, Chiayi, Taiwan|E-Da Hospital, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan		https://ClinicalTrials.gov/show/NCT01874678
107	NCT04004312	Single Fractions SBRT for Prostate Cancer		Recruiting	No Results Available	Prostate Cancer	Radiation: Stereotactic Body Radiation Therapy (SBRT)	Small bowel or rectal irritation,|Bladder complications|To assess late GI and GU toxicity|PSA control	Fabio Cury|Boston Scientific Corporation|McGill University Health Center	Male	18 Years and older   (Adult, Older Adult)	Not Applicable	12	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2019-4650	November 7, 2018	September 15, 2021	December 20, 2024	July 2, 2019		July 2, 2019	McGill University Health Centre-Cedars Cancer Centre, Montréal, Quebec, Canada		https://ClinicalTrials.gov/show/NCT04004312
108	NCT00544167	Adjuvant Doxorubicin/Cyclophosphamide and Paclitaxel Plus Sorafenib Breast Cancer		Completed	Has Results	Breast Cancer	Drug: Doxorubicin|Drug: Cyclophosphamide|Drug: Paclitaxel|Drug: Sorafenib	The Safety and Tolerability of Protocol Treatment, Defined as the Percentage of Patients Experiencing Severe or Life-threatening Side Effects Per CTCAE Version 3.0.	SCRI Development Innovations, LLC|Bayer	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	45	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	SCRI BRE 112	May 2007	January 2008	April 2011	October 16, 2007	January 25, 2013	April 1, 2013	Integrated Community Oncology Network, Jacksonville, Florida, United States|Florida Hospital Cancer Institute, Orlando, Florida, United States|Consultants in Blood Disorders and Cancer, Louisville, Kentucky, United States|Grand Rapids Clinical Oncology Program, Grand Rapids, Michigan, United States|Methodist Cancer Center, Omaha, Nebraska, United States|Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Peninsula Cancer Institute, Newport News, Virginia, United States		https://ClinicalTrials.gov/show/NCT00544167
109	NCT00548626	Evaluation of Multiple Needle Use in EUS-FNA for Pancreatic Cancer	EMUNE-07	Completed	No Results Available	Pancreatic Cancer	Procedure: Single needle|Procedure: Multiple needle	Evaluate if the early change of needle during EUS-FNA for suspected pancreatic cancer can reduce the number of passes needed to obtain a preliminary cytological diagnosis of neoplasia.|Rate of complications related with EUS-FNA|Influence of different factors in obtaining a positive cytological result	University of Chicago|Cook Group Incorporated	All	18 Years and older   (Adult, Older Adult)	Not Applicable	47	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Diagnostic	15497A	October 2007	November 2015	November 2015	October 24, 2007		December 21, 2015	University of Chicago Medical Center, Chicago, Illinois, United States		https://ClinicalTrials.gov/show/NCT00548626
110	NCT02773004	Prospective Study Assessing EndoPredict® Genomic Test Impact on Shared Decision of Adjuvant Chemotherapy in Patients With ER-positive, Her2-negative Early Breast Cancer	ADENDOM	Completed	No Results Available	Breast Cancer	Other: EPClin genomic test	The proportion of patients whose choice of treatment is changed as a result of receiving the EPclin genomic test result|Impact of genomic test results on patient's quality of life (QoL), anxiety levels and satisfaction results using standardized "State-Trait-Anxiety Inventory" questionnaires compared with general condition at baseline.|Time required by the centralized platform to perform the test (calculated from the biological sample receipt to the genomic test results).	UNICANCER|Myriad Genetics, Inc.	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	203	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	UC-0140/1505 - ADENDOM|2015-A00528-41|PACS14|ADENDOM|UCBG 2-14	September 2016	September 2017	December 2017	May 16, 2016		September 7, 2018			https://ClinicalTrials.gov/show/NCT02773004
111	NCT00551044	Bicalutamide Monotherapy Has Significant Quality of Life Benefits for Men With Advanced Prostate Cancer		Completed	No Results Available	Prostatic Neoplasms	Drug: Bicalutamide	Quality of life (using Rand 36-Item Health Survey SF-36)|Renal & liver function tests, PSA, testosterone, estradiol|Body Mass Index, arm anthropometry (mid-upper arm circumference and triceps skin fold thickness), dynamometry (quadriceps muscle strength)|Bone turnover markers (bone-specific alkaline phosphatase, N-terminal propeptide of type I collagen, C-telopeptide crosslinks of type I collagen, urine N-telopeptide of tyoe I collagen corrected for creatinine|Peripheral bone densitometry of non-dominant forearm	Wirral University Teaching Hospital NHS Trust|AstraZeneca	Male	Child, Adult, Older Adult	Not Applicable	42	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	96/02	August 2003		August 2005	October 30, 2007		October 30, 2007	Wirral University Teaching Hospitals NHS Trust, Upton, Wirral, Merseyside, United Kingdom		https://ClinicalTrials.gov/show/NCT00551044
112	NCT02563925	Brain Irradiation and Tremelimumab in Metastatic Breast Cancer		Active, not recruiting	No Results Available	Metastatic Breast Cancer	Radiation: Brain radiotherapy or Stereotactic Radiosurgery|Drug: Tremelimumab|Drug: HER2 directed therapy|Drug: Durvalumab	non-CNS disease control rate|Immune-related progression free survival (irPFS)|safety profile assessed with regular physical examination and toxicity assessment using the NCI CTCAE 4.0. Subjects will be followed with regular radiation oncology assessments as per the standard of care.	Memorial Sloan Kettering Cancer Center|MedImmune LLC	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	28	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	15-038	September 2015	September 2020	September 2020	September 30, 2015		July 17, 2019	Memorial Sloan Kettering Cancer Center, New York, New York, United States		https://ClinicalTrials.gov/show/NCT02563925
113	NCT03475992	Pilot Clinical Study on a Low-power Electromagnetic Wave Breast Imaging Device for Cancer Screening Purposes.		Recruiting	No Results Available	Breast Cancer|Breast Cyst	Device: Low-power microwave breast imaging system	Number of Serious Adverse Events, directly related to normal functioning of the device	MVG Industries SAS|HRB Clinical Research Facility, Galway (CRFG)	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	30	Industry|Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	TN.32.1.17.SATF.D	October 10, 2018	June 2019	June 2019	March 23, 2018		October 16, 2018	HRB Clinical Research Facility Galway, Galway, Ireland		https://ClinicalTrials.gov/show/NCT03475992
114	NCT01185314	To Study the Changes in Protein in Lung Cells of Asian Patients With Advanced Non-small Cell Lung Cancer (NSCLC)	PIONEER	Completed	No Results Available	Non Small Cell Lung Cancer	Procedure: Testing for mutation status	EGFR mutation status of Asian patients with advanced NSCLC	AstraZeneca	All	20 Years and older   (Adult, Older Adult)	Not Applicable	1270	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening	D7913L00086	September 2010	July 2011	July 2011	August 19, 2010		August 8, 2011	Research Site, Beijing, Beijing, China|Research Site, Guangzhou, Guangdong, China|Research Site, Shijiazhuang, Hebei, China|Research Site, Zhengzhou, Henan, China|Research Site, Wuhan, Hubei, China|Research Site, Changchun, Jilin, China|Research Site, Shenyang, Liaoning, China|Research Site, Jinan, Shandong, China|Research Site, Shanghai, Shanghai, China|Research Site, Taiyuan, Shanxi, China|Research Site, Chengdu, Sichuan, China|Research Site, Tianjin, Tianjin, China|Research Site, Hong Kong, Hong Kong|Research Site, Rohini, Delhi, India|Research Site, Vadodara, Gujarat, India|Research Site, Kochi, Kerala, India|Research Site, Mumbai, Maharashtra, India|Research Site, Pune, Maharashtra, India|Research Site, Chennai, India|Research Site, Kolkata, India|Research Site, Cebu City, Philippines|Research Site, Manila City, Philippines|Research Site, Pasay City, Philippines|Research Site, Quezon City, Philippines|Research Site, Taguig City, Philippines|Research Site, Chiayi, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei, Taiwan|Research Site, Tao-Yuan, Taiwan|Research Site, Bangkok, Thailand|Research Site, Chiang Mai, Thailand|Research Site, Songkla, Thailand|Research Site, Hanoi, Vietnam|Research Site, Ho Chi Minh City, Vietnam		https://ClinicalTrials.gov/show/NCT01185314
115	NCT03714243	Blood Brain Barrier Disruption (BBBD) Using MRgFUS in the Treatment of Her2-positive Breast Cancer Brain Metastases	BBBD	Not yet recruiting	No Results Available	Breast Cancer|Brain Metastases	Device: ExAblate BBBD	Adverse events|Feasibility of BBBD	InSightec	All	18 Years to 80 Years   (Adult, Older Adult)	Not Applicable	10	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility	BT006|277990	September 2019	January 2020	May 2020	October 22, 2018		July 25, 2019			https://ClinicalTrials.gov/show/NCT03714243
116	NCT01153035	Excision Followed by Radiofrequency Ablation for Breast Cancer	ABLATE	Active, not recruiting	No Results Available	Breast Cancer	Device: Radiofrequency Ablation	Estimate the re-excision rate for close (<3mm) or positive margins|Decrease local recurrence	University of Arkansas|Angiodynamics, Inc.	Female	50 Years to 100 Years   (Adult, Older Adult)	Not Applicable	104	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	104603	June 2010	December 2020	June 2021	June 29, 2010		July 3, 2019	University of Arizona, Tucson, Arizona, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Sharp Oncology (Comprehensive Breast Care of San Diego), San Diego, California, United States|Comprehensive Breast Care of Denver, Denver, Colorado, United States|The University of Kansas Cancer Center, Westwood, Kansas, United States|Columbia, New York, New York, United States		https://ClinicalTrials.gov/show/NCT01153035
117	NCT01086514	Digital Mammography for the Detection and Preoperative Staging of Breast Cancer		Completed	No Results Available	Breast Cancer	Procedure: Dual Energy Contrast Enhanced Digital Mammography (DE CEDM)	To estimate additional measures of accuracy of DE CEDM and MRI, such as the predictive values and ROC curves where applicable, for detecting multifocal or multicentric disease in the ipsilateral breast.|To compare the sensitivity and specificity of DE CEDM with that of breast MRI in the detection of disease in the contralateral breast.|To estimate the interobserver variability of DE CEDM.	Memorial Sloan Kettering Cancer Center|GE Healthcare	Female	21 Years and older   (Adult, Older Adult)	Not Applicable	82	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	10-024	March 2010	October 2012	October 2012	March 15, 2010		September 30, 2015	Memorial Sloan Kettering Cancer Center, New York, New York, United States		https://ClinicalTrials.gov/show/NCT01086514
118	NCT03072641	Using Probiotics to Reactivate Tumor Suppressor Genes in Colon Cancer		Completed	No Results Available	Colon Cancer	Dietary Supplement: ProBion Clinica	Changes in microbiota composition after probiotics use|Epigenetic changes after probiotics use	Vastra Gotaland Region|DuPont Nutrition and Health	All	18 Years and older   (Adult, Older Adult)	Not Applicable	20	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	ALFGBG-542821	June 3, 2010	March 2016	March 2016	March 7, 2017		March 7, 2017			https://ClinicalTrials.gov/show/NCT03072641
119	NCT01996969	Identification of Predictive Biomarker of Regorafenib in Refractory Colorectal Cancer		Completed	No Results Available	Metastatic Colorectal Cancer	Drug: Regorafenib	Predictive biomarker in terms of disease control rate|Disease control rate|Progression-free survival|Overall survival|number of participants with adverse events|Progression-free survival according to biomarker status|Overall survival according to biomarker status|Assessment of adequate response evaluation modality after regorafenib treatment	Seoul National University Hospital|Bayer	All	20 Years and older   (Adult, Older Adult)	Not Applicable	117	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening	Regorafenib biomarker	October 2013	June 2015	May 2016	November 27, 2013		February 22, 2019	Seoul National University Hospital, Seoul, Korea, Republic of		https://ClinicalTrials.gov/show/NCT01996969
120	NCT04014478	A Clinical Trial to Evaluate Safety and Efficacy of Endovascualr Denervation in Treatment of Cancer Pain		Not yet recruiting	No Results Available	Liver Cancer|Pancreas Cancer|Stomach Cancer|Bile Duct Cancer	Device: Endovascular Denervation	Visual Analog Scale Changes over the time|Morphine Equivalent Changes over the time|Quality of Life Score Changes over the time	Shanghai Golden Leaf MedTec Co. Ltd	All	25 Years to 75 Years   (Adult, Older Adult)	Not Applicable	110	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GL-CT-20161201	July 15, 2019	July 15, 2021	July 15, 2021	July 10, 2019		July 10, 2019			https://ClinicalTrials.gov/show/NCT04014478
121	NCT03946033	Impact of Immunoscore Colon Test on Adjuvant Therapeutic Strategy in Non-Metastatic Colon Cancer	PROSCORE	Not yet recruiting	No Results Available	Colonic Neoplasms	Diagnostic Test: Immunoscore Colon Test	Modification rate of adjuvant therapeutic strategy	UNICANCER|HalioDx	All	18 Years and older   (Adult, Older Adult)	Not Applicable	280	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	UC-0110/1813|2018-A03339-46	May 2019	December 2020	February 2021	May 10, 2019		May 10, 2019	Hôpital Simone Veil, Blois, France|Hospices civils de Colmar, Colmar, France|CHU de Dijon, Dijon, France|CHD de Vendée, La Roche-sur-Yon, France|Centre Oscar Lambret, Lille, France|CHU de Limoges, Limoges, France|Centre Léon Bérard, Lyon, France|Hôpital Jean Mermoz, Lyon, France|Hôpital Européen Marseille, Marseille, France|Institut Régional du Cancer de Montpellier, Montpellier, France|CHU Hôtel-Dieu, Nantes, France|Hôpital Saint-Louis, Paris, France|CHU de Bordeaux - Haut Lévêque, Pessac, France|CHU de Poitiers, Poitiers, France|Centre Hospitalier Annecy Genevois, Pringy, France|CHU de Reims, Reims, France|Centre Eugène Marquis, Rennes, France|Institut de Cancérologie de l'Ouest, Saint-Herblain, France|Hôpital du Léman, Thonon-les-Bains, France|Institut Gustave Roussy, Villejuif, France|Hôpital privé de Villeneuve d'Ascq, Villeneuve-d'Ascq, France		https://ClinicalTrials.gov/show/NCT03946033
122	NCT01192438	Laser Based Focal Ablation of Low Grade Prostate Cancer		Completed	No Results Available	Low Grade Prostate Cancer	Procedure: Laser-based thermotherapy	Number of patients with adverse events	University of Chicago|Visualase, Inc.	Male	45 Years and older   (Adult, Older Adult)	Not Applicable	9	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	09-364A	January 2010	September 2011	September 2011	September 1, 2010		March 27, 2014	University of Chicago, Chicago, Illinois, United States		https://ClinicalTrials.gov/show/NCT01192438
123	NCT03057288	Prospective Study Evaluating the Feasibility of Fiducial Markers Placement for Patients With Esophageal or Rectal Cancer	FIDECHO	Recruiting	No Results Available	Esophageal Neoplasm|Rectal Neoplasms	Device: fiducial markers placement	Success rate evaluation of the placement of two fiducial markers|Complications (early within 24 hours and late complications) such as pain, bleeding, perforation, infection, migration of the markers|The length of the procedure|The costs (procedure, hospitalization)|The clinical efficacy, by studying the decrease of the estimated target volume, the decrease of the dose delivered to the healthy tissue|The presence of the markers at the end of the radiotherapy	Société Française d'Endoscopie Digestive|Cook Group Incorporated	All	18 Years and older   (Adult, Older Adult)	Not Applicable	40	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	Etude SFED 115	February 3, 2017	April 3, 2020	November 28, 2020	February 20, 2017		April 11, 2019	Ulriikka CHAPUT, Paris, France		https://ClinicalTrials.gov/show/NCT03057288
124	NCT00792961	Real Time Microscopic Imaging During Robot Assisted Prostate Cancer Surgery		Completed	No Results Available	Prostate Cancer	Device: Endomicroscopy	Endomicroscopy images captured from prostate and surrounding tissues|Comparison with conventional histology from corresponding biopsies or resection specimens	Peter Delaney|Hospital at Westlake|Optiscan Pty Ltd	Male	18 Years and older   (Adult, Older Adult)	Not Applicable	10	Industry|Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	13082008	November 2008	December 2009	December 2009	November 18, 2008		April 9, 2014	The Hospital at Westlake Medical Center, Austin, Texas, United States		https://ClinicalTrials.gov/show/NCT00792961
125	NCT00615901	Dose Dense Adjuvant CMF (Cyclophosphamide, Methotrexate, Fluorouracil) at 14 and 10-11 Day Intervals for Women With Early Stage Breast Cancer		Completed	Has Results	Breast Cancer	Drug: cyclophosphamide, methotrexate, fluorouracil, PEG-filgrastim	The Number of Patients Who Completed 8 Cycles.	Memorial Sloan Kettering Cancer Center|Amgen	Female	18 Years to 70 Years   (Adult, Older Adult)	Not Applicable	38	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	07-133	January 2008	June 2010	June 2010	February 14, 2008	March 3, 2017	March 3, 2017	Memorial Sloan-Kettering at Basking Ridge, Basking Ridge, New Jersey, United States|Memorial Sloan-Kettering Cancer Center at Commack, Commack, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Memorial Sloan-Kettering Cancer Center at Mercy, Rockville Centre, New York, United States|Memoral Sloan-Kettering Cancer Center at Phelps, Sleepy Hollow, New York, United States		https://ClinicalTrials.gov/show/NCT00615901
126	NCT00567684	Computed Tomography Urography (CTU) vs Intravenous Urography (IVU) on Patients at Risk of Urothelial Tumors		Active, not recruiting	No Results Available	Bladder Cancer	Other: Computed Tomography Urography (CTU)|Other: Intravenous Urography (IVU)	CTU to IVU Technical Performance Comparison: Opacification + Ability to Visualize Urothelial Segments	M.D. Anderson Cancer Center|GE Healthcare	All	18 Years and older   (Adult, Older Adult)	Not Applicable	135	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	2007-0381|NCI-2014-01374	November 2007	November 2019	November 2019	December 5, 2007		May 10, 2019	University of Texas MD Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT00567684
127	NCT01028352	Study to Assess Effect of 8 Wks of Duloxetine Therapy on Breast Cancer Patients With Aromatase-Inhibitor Associated Pain		Completed	Has Results	Breast Cancer	Drug: Duloxetine	Percentage of Patients Who Experience 30% Reduction in Average Pain Score From Baseline to 8 Weeks Due to Duloxetine Therapy.|Decrease in Average Pain With 8 Weeks of Duloxetine Therapy. (Sustained)	University of Michigan Rogel Cancer Center|Eli Lilly and Company	Female	21 Years and older   (Adult, Older Adult)	Not Applicable	35	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	UMCC 2008.062|HUM00022455	October 2008	November 2010	October 2011	December 9, 2009	August 17, 2012	August 8, 2013	University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States		https://ClinicalTrials.gov/show/NCT01028352
128	NCT01024959	Clinical Evaluation of the PROGENSA(Registered Trademark) Prostate Cancer Gene 3 (PCA3) Assay in Men With a Previous Negative Biopsy Result	PCA3	Completed	Has Results	Prostatic Neoplasms	Other: PCA3 Assay	Association of PCA3 Score With Prostate Biopsy Outcome (PCA3 Score Using Cutoff of 25.)	Gen-Probe, Incorporated	Male	40 Years and older   (Adult, Older Adult)	Not Applicable	507	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	2009PCA301	August 2009	April 2010	April 2010	December 3, 2009	November 7, 2012	November 12, 2012	HealthCare Partners Medical Group, Los Angeles, California, United States|San Diego Clinical Trials, San Diego, California, United States|South Florida Medical Research, Aventura, Florida, United States|Specialists in Urology, Naples, Florida, United States|Florida Urology Specialists, Sarasota, Florida, United States|Metropolitan Urology, PSC, Jeffersonville, Indiana, United States|Regional Urology Specialists, LLC, Shreveport, Louisiana, United States|AccuMed Research Associates, Garden City, New York, United States|TriState Urologic Services PSC Inc. dba The Urology Group, Cincinnati, Ohio, United States|Columbus Urology Research, LLC, Columbus, Ohio, United States|MD Anderson Cancer Center, Houston, Texas, United States|Urology San Antonio Research, San Antonio, Texas, United States|Virginia Urology, Richmond, Virginia, United States		https://ClinicalTrials.gov/show/NCT01024959
129	NCT00489905	Study on Evaluation of Zoledronic Acid to Prevent Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer		Completed	No Results Available	Prostatic Neoplasms|Bone Density	Drug: Zolderonic acid (Zometa)	Bone mineral density of lumber spine|Bone mineral density of femoral neck|Change in serum creatinine, calcium, phosphate and alkaline phosphatase|Change in creatinine clearance	Hospital Authority, Hong Kong|Baxter Healthcare Corporation	Male	50 Years to 80 Years   (Adult, Older Adult)	Not Applicable	24	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CRE-2005.137-T|HARECCTR0500010	April 2005		May 2008	June 21, 2007		October 23, 2013	Department of Urology, Prince of Wales Hospital, Hong Kong, China		https://ClinicalTrials.gov/show/NCT00489905
130	NCT02294903	Focal Prostate Radiofrequency Ablation	ProRAFT	Active, not recruiting	No Results Available	Prostate Cancer	Procedure: Coiled Bipolar Radiofrequency Ablation	Cancer control outcome	Trod Medical N.V.	Male	40 Years and older   (Adult, Older Adult)	Not Applicable	20	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	TM-105	March 2015	April 2018	May 30, 2018	November 19, 2014		April 24, 2018	University College London Hospitals, London, United Kingdom		https://ClinicalTrials.gov/show/NCT02294903
131	NCT02357992	Lung Cancer STARS Trial - STARS Revised Clinical Trial Protocol: Stereotactic Ablative Radiotherapy (SABR) in Stage I Non-small Cell Lung Cancer Patients Who Can Undergo Lobectomy		Active, not recruiting	No Results Available	Lung Cancer	Radiation: Stereotactic Body Radiotherapy (SABR)	Overall Survival (OS) for Stage I Non-small Cell Lung Cancer Patients Treated with Stereotactic Body Radiotherapy (SABR)	M.D. Anderson Cancer Center|Varian Medical Systems	All	18 Years and older   (Adult, Older Adult)	Not Applicable	122	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2007-0870|NCI-2015-00536	April 5, 2010	April 2025	April 2025	February 6, 2015		May 15, 2019	University of Texas MD Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT02357992
132	NCT01876069	Comparing Newly Developed PreCore Needle With Conventional Fine Needle in Suspected Unresectable Pancreatic Cancer		Completed	No Results Available	Pancreatic Cancer	Device: 22 gauge ProCore needle aspiration|Device: 22 gauge Fine needle aspiration	The rates of diagnostic sufficiency|The presence of histologic core	Samsung Medical Center|Olympus	All	18 Years to 80 Years   (Adult, Older Adult)	Not Applicable	65	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	2013-02-018	July 2013	February 2015	February 2015	June 12, 2013		April 27, 2016	Samsung Medical Center, Seoul, Korea, Republic of		https://ClinicalTrials.gov/show/NCT01876069
133	NCT02528175	Magnetic Resonance-Guided High Intensity Focused Ultrasound for Recurrent Rectal Cancer		Recruiting	No Results Available	Recurrent Rectal Cancer	Device: Magnetic resonance-guided focused ultrasound|Radiation: Standard Radiation|Drug: Chemotherapy	Acute toxicities|Late toxicities|The efficacy of MRg-FU in reducing pain|Patient quality of life|Assessment of radiologic response following treatment.	Dr. William Chu|Philips Medical Systems|Sunnybrook Health Sciences Centre	All	18 Years and older   (Adult, Older Adult)	Not Applicable	20	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	273-2011|226861	April 2015	April 2020	April 2022	August 19, 2015		July 8, 2019	Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada		https://ClinicalTrials.gov/show/NCT02528175
134	NCT04002479	Alpha Radiation Emitters Device for the Treatment of Advanced Pancreatic Cancer		Not yet recruiting	No Results Available	Pancreatic Cancer|Unresectable Pancreatic Cancer|Metastatic Pancreatic Cancer|Pancreatic Adenocarcinoma	Device: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)	Feasibility - DaRT seed placement|Safety - Adverse events|Efficiency - Short-term effect|Tissue damage evaluation|Efficiency - Long-term effect|Stent durability|Change in quality of life: EORTC-QLQ-C30|Change in quality of life: QLQ-PAN26	Alpha Tau Medical LTD.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	30	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	AT-PANC-101	October 2019	October 2021	October 2023	June 28, 2019		August 7, 2019			https://ClinicalTrials.gov/show/NCT04002479
135	NCT03564054	Trial of Photodynamic Therapy Versus Argon Plasma Coagulation for Lung Cancer With Endobronchial Obstruction		Active, not recruiting	No Results Available	Non Small Cell Lung Cancer	Procedure: Photodynamic Therapy|Procedure: Argon Plasma Coagulation	Treatment time until failure|Change in mean score of quality of life using the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire and Lung Cancer Module (EORTC QLQ-LC13) at 30, 90 and 180 days after the last PDT or APC|Need for additional bronchoscopic therapies for either endobronchial obstruction at the treated site or for recurrent obstruction with no additional therapies offered at 30, 90, and 180 days following the last PDT or APC treatment|Median survival time|Percent reduction in airway obstruction as measured by bronchoscopy at 30 and 90 days after the last PDT or APC treatment|Resolution of atelectasis, if present, at 30, 45, 60, 75, 90, and 180 days after the last PDT or APC treatment|Resolution of post-obstructive pneumonia, if present, at 30, 45, 60, 75, 90, and 180 days after the last PDT or APC treatment|Change in dyspnea (as measured by the transitional dyspnea index (TDI), using the score obtained from the Baseline Dyspnea Index (BDI) as the baseline comparator) at 30, 60, 90, and 180 days after the last PDT or APC treatment|Change in hemoptysis, if present, at 30, 45, 60, 75, 90, and 180 days after the last PDT or APC treatment using categorical measures (worsened, unchanged, improved, resolved)|Change in cough, if present, at 30, 45, 60, 75, 90, and 180 days after the last PDT or APC treatment using categorical measures (worsened, unchanged, improved, resolved)|Change in Karnofsky performance status, if present, at 30, 60, 90, and 180 days after the last PDT or APC treatment using categorical measures (worsened, unchanged, improved, resolved).|Proportion of patients experiencing treatment failure at 90 days	University of Florida|Concordia Laboratories Inc.	All	18 Years to 99 Years   (Adult, Older Adult)	Not Applicable	3	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	UF-THO-001|RGA030|UF-PDO-THO-1001|OCR17811	October 11, 2018	November 2019	November 2019	June 20, 2018		August 9, 2019	University of Florida, Gainesville, Florida, United States		https://ClinicalTrials.gov/show/NCT03564054
136	NCT02875561	Ultrasonic Aspiration Versus CO2 Laser Ablation for the Treatment of Vulvar Intraepithelial Neoplasia		Recruiting	No Results Available	Vulvar Intraepithelial Neoplasia (VIN)	Device: Sonopet Ultrasonic Aspirator|Device: CO2 Laser Ablation	Incidence of recurrence of dysplasia|Incidence of pain|Incidence of scarring|Changes in Sexual Function|Changes in Mental and Physical Wellness	University of Colorado, Denver|Stryker Instruments	Female	18 Years to 89 Years   (Adult, Older Adult)	Not Applicable	150	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	16-0701.cc	March 26, 2017	December 2019	December 2019	August 23, 2016		August 1, 2019	University of Colorado Denver, Aurora, Colorado, United States		https://ClinicalTrials.gov/show/NCT02875561
137	NCT01096134	Mother - Daughter Initiative (MDI) in Cervical Cancer Prevention	MDI	Completed	No Results Available	Cervical Cancer	Biological: HPV Vaccine (Gardasil)	Determine the population coverage of HPV vaccination of girls aged 9-13 offered within the context of cervical cancer screening and treatment of mothers|Assess mothers' acceptability of having their daughters receive the full course of HPV vaccine after mothers receive screening and treatment services for cervical pre-cancer|Inform future programs that aim to introduce the HPV vaccine in the context of secondary screening for cervical cancer by determining the factors related to screened women bringing daughters for HPV vaccination and the costs of vaccine introduction	Jhpiego|Merck Sharp & Dohme Corp.	Female	9 Years to 13 Years   (Child)	Not Applicable	8000	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	36448	January 2011	November 2012	November 2012	March 30, 2010		October 12, 2015	Minglanilla, Cebu, Philippines|Los Banos, Quezon, Philippines|Pagbilao Health Center, Quezon, Philippines|Health promotion Clinic Number 11, Nakhon Si Thammarat, Nakisron, Thailand|Ban Pak Poon Health Center, Nakhon Si Thammarat, Nakornsri, Thailand|Maharat Nakhonsithammarat Primary Care Unit, Nakhon Si Thammarat, Nakornsri, Thailand|Pak-Panung District Health Center, Nakhon Si Thammarat, Nakornsri, Thailand|Ban Yuanlae District Health Center, Ban Phon Ko, Thailand|Ban Mai Daeng, Nakhon Si Thammarat, Nakornsri, Thailand|Ban Pai Ta Health Center, Nakhon Si Thammarat, Nakornsri, Thailand		https://ClinicalTrials.gov/show/NCT01096134
138	NCT03776604	PEG-rhG-CSF in Elderly Patients With Small Cell Lung Cancer Receiving Chemotherapy		Recruiting	No Results Available	Small Cell Lung Cancer|PEG-rhG-CSF	Drug: PEG-rhG-CSF	The incidence of grade III/IV neutropenia in the first cycle of PEG-rhG-CSF.|The incidence of grade III/IV neutropenia in the second cycle of PEG-rhG-CSF.|The incidence of febrile neutropenia in cycles 1 and 2|The ANC recovery time in cycles 1 and 2|The incidence of infection|The incidence of antibiotic use|Incidence of chemotherapy dose adjustment due to neutropenia|Chemotherapy delay time|Incidence of chemotherapy delay caused by neutropenia|The duration of febrile neutropenia in cycles 1 and 2	CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.|Beijing Cancer Hospital	All	70 Years and older   (Older Adult)	Not Applicable	61	Industry|Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	CSPC-JYL-SCLC-01	December 5, 2018	December 2019	February 2020	December 17, 2018		December 18, 2018	Bejing Cancer Hospital, Beijing, Beijing, China		https://ClinicalTrials.gov/show/NCT03776604
139	NCT03632980	Dynamic Focusing Evaluation for Prostate Cancer Treatment	FOC/DYN	Active, not recruiting	No Results Available	Cancer of Prostate	Device: "Ablatherm Foc/Dyn" or "Focal One" HIFU treatment	Necrosis measurement (immediate efficacy)|Histological marker measurement (mid term efficacy)|Biochemical marker measurement (mid term efficacy)|Rectal wall preservation (immediate safety and morbidity)|Adverse events reporting rates (safety and the morbidity) at 6 months|Adverse events reporting rates (safety and the morbidity) at 24 months|Quality of life score|IPSS score|IIEF-5 score	EDAP TMS S.A.	Male	70 Years and older   (Older Adult)	Not Applicable	180	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HIFU/F/10.08|2011-A00313-38	June 2011	December 2019	December 2019	August 16, 2018		August 16, 2018	Edouard Herriot Hospital, Lyon, France		https://ClinicalTrials.gov/show/NCT03632980
140	NCT02189161	A Safety and Tolerability of Circumferential Anal Canal Radiofrequency Ablation For Anal Intraepithelial Neoplasia		Completed	Has Results	Anal Intraepithelial Neoplasia (AIN)|High-grade Squamous Intraepithelial Lesions (HSIL)	Device: Radiofrequency Ablation (Barrx™)	Related Adverse Events|Subject Tolerability: Post -Ablation Anal Pain|Quality of Life Assessment: Subject Score for Worry About Anal Canal Condition	Medtronic - MITG	All	18 Years to 75 Years   (Adult, Older Adult)	Not Applicable	10	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	B-253	July 2014	August 2015	August 2015	July 14, 2014	July 14, 2016	July 14, 2016	Laser Surgery Care, New York, New York, United States		https://ClinicalTrials.gov/show/NCT02189161
141	NCT02681237	A Study of Cediranib and Olaparib at Disease Worsening in Ovarian Cancer		Active, not recruiting	No Results Available	Ovarian Cancer	Drug: Cediranib|Drug: Olaparib	Objective Response Rate|Progression-Free Survival Rate|CA125 response rate|Disease control rate|Overall survival rate|Number of Adverse Events Experienced	University Health Network, Toronto|AstraZeneca	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	34	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	e-Volve 1	April 29, 2016	April 2021	October 2021	February 12, 2016		May 10, 2019	Princess Margaret Cancer Centre, Toronto, Ontario, Canada		https://ClinicalTrials.gov/show/NCT02681237
142	NCT04009122	Evaluation of the Quality of Life of Patients With Metastatic Non-small Cell Lung Cancer With Supplementary Therapy With IGEN-0206		Recruiting	No Results Available	Quality of Life of Patients|Non-small Cell Lung Cancer Metastatic	Dietary Supplement: IGEN0206|Other: Placebo	Impact of IGEN-0206 on quality of life in patients with metastatic lung cancer according to the EORTC QLQ-C30.|Impact of IGEN-0206 on quality of life in patients with metastatic lung cancer according to the EORTC QLQ-L13|BMI|Changes in the microbiota|Interleukin levels|Cytokines levels	Igen BioLab SLU	All	18 Years and older   (Adult, Older Adult)	Not Applicable	280	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	IGEN0206-15	June 11, 2019	December 12, 2019	December 12, 2020	July 4, 2019		July 4, 2019	Hospital Público Virgen de los Lirios, Alcoi, Alicante, Spain|Hospital General Universitario de Elche, Elche, Alicante, Spain|Hospital General Universitario de Elda, Elda, Alicante, Spain|Complexo Hospitalario Universitario A Coruña, A Coruña, La Coruña, Spain|Hospital del Henares, Coslada, Madrid, Spain|Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain|Hospital Universitario de Móstoles, Móstoles, Madrid, Spain|Hospital Universitario Infanta Sofía, San Sebastián De Los Reyes, Madrid, Spain|Complexo Hospitalario Universitario de Ourense, Orense, Ourense, Spain|Hospital de Sagunto, Sagunto, Valencia, Spain|Hospital Universitario San Juan De Alicante, Alicante, Spain|Instituto Oncológico Teknon Dr. Rosell, Barcelona, Spain|Hospital LUcus Augusti, Lugo, Spain|GenesisCare Madrid, Hospital La Milagrosa, Madrid, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain|Hospital Universitari i Politècnic La Fe, Valencia, Spain		https://ClinicalTrials.gov/show/NCT04009122
143	NCT01970787	A Trial of Radiofrequency Ablation for Anal Intraepithelial Neoplasia Using the HALO Ablation System	AIN	Completed	Has Results	HIV-negative Subjects With Intra-anal Intraepithelial Neoplasia Containing High-Grade Squamous Intraepithelial Lesions	Device: Radiofrequency Ablation (RFA) using the HALO Ablation System	Clearance of Anal HSIL (High Grade Squamous Intraepithelial Lesion (HSIL)|Feasibility and Ease of Technique|Tolerability|Adverse Events|Progression of HSIL to Cancer	Medtronic - MITG	All	18 Years to 75 Years   (Adult, Older Adult)	Not Applicable	22	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	B-250	March 2013	June 2015	June 2015	October 28, 2013	July 14, 2016	February 6, 2017	Laser Surgery Center, New York, New York, United States		https://ClinicalTrials.gov/show/NCT01970787
144	NCT02487524	Biomarkers of Neuropathic Pain in Women Treated for Breast Cancer		Active, not recruiting	No Results Available	Neuropathic Pain|Breast Cancer	Other: Cold water test|Other: Autonomic nervous system monitoring|Other: QST	Composite factors related to the persistence of pain after nerve injury	Helsinki University Central Hospital|deCODE genetics	Female	18 Years to 75 Years   (Adult, Older Adult)	Not Applicable	402	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Other	149/13/03/00/14	October 28, 2014	December 2018	December 2020	July 1, 2015		February 28, 2018	Helsinki University Central Hospital, Helsinki, HUS, Finland		https://ClinicalTrials.gov/show/NCT02487524
145	NCT00738998	Longitudinal Assessment of Arthralgia and Related Symptoms in Breast Cancer Patients Receiving Aromatase Inhibitors		Active, not recruiting	No Results Available	Breast Cancer	Behavioral: Questionnaire|Other: Phone Calls	Incidence, onset and severity of arthralgia during anastrozole treatment	M.D. Anderson Cancer Center|AstraZeneca	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	102	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	2006-1038	June 2008	June 2019	June 2020	August 21, 2008		May 15, 2019	University of Texas MD Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT00738998
146	NCT00629447	Innohep for Prophylaxis of Venous Thromboembolism in Brain Tumor Patients		Completed	No Results Available	Primary Brain Tumor	Drug: Innohep	Neurologic evaluation, CBC, Coagulation test (PT w/ INR, aPTT),Karnofsky performance status, Thrombosis panel, Adverse events assessment|Bone densitometry study (DEXA-Scan)d	Duke University|Celgene Corporation	All	18 Years and older   (Adult, Older Adult)	Not Applicable	40	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	Pro00008486|4930	February 2004	March 2007	October 2009	March 6, 2008		January 7, 2013	Duke University Health Systems, Durham, North Carolina, United States		https://ClinicalTrials.gov/show/NCT00629447
147	NCT00336934	Pomegranate Extract in Treating Patients With Rising Prostate-Specific Antigen Levels After Surgery or Radiation Therapy for Localized Prostate Cancer		Completed	No Results Available	Prostate Cancer	Dietary Supplement: pomegranate juice|Other: placebo	Objective response|Response duration|Effects of pomegranate extract on prostate-specific antigen (PSA) doubling and velocity times	Roll International Corporation|National Cancer Institute (NCI)	Male	18 Years and older   (Adult, Older Adult)	Not Applicable	183	Industry|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	CDR0000480402|P30CA016042|ROLL-GUP-0205-1|UCLA-0507059-01	November 2005	July 2010	December 2010	June 15, 2006		August 15, 2011			https://ClinicalTrials.gov/show/NCT00336934
148	NCT02055833	Intensive Nutritional Counseling in Head-neck Cancer Patients Undergoing Radiotherapy		Completed	No Results Available	Head-neck Cancer	Dietary Supplement: Intensive nutritional counseling|Other: Nutritional counseling	Body weight|Quality of life|Handgrip strength|Phase angle	IRCCS Policlinico S. Matteo|Nestlé Health Science Spain|Akern Srl	All	18 Years and older   (Adult, Older Adult)	Not Applicable	159	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	20120001310	September 2013	June 2016	August 2016	February 5, 2014		August 30, 2016	Nutrition and Dietetics Service, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy		https://ClinicalTrials.gov/show/NCT02055833
149	NCT02734433	Study of Pexidartinib in Asian Subjects With Advanced Solid Tumors		Active, not recruiting	No Results Available	Advanced Solid Tumors	Drug: Pexidartinib	Number and severity of adverse events|Number and severity of laboratory abnormalities|Maximum concentration (Cmax)|Time of maximum concentration (Tmax)|Area under plasma-concentration curve (AUC)|Level of macrophage colony stimulating factor (CSF-1)|Level of Adiponectin|Tumor response by radiological scan	Daiichi Sankyo Co., Ltd.|Daiichi Sankyo, Inc.	All	20 Years and older   (Adult, Older Adult)	Not Applicable	11	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PL3397-A-A103	June 2016	June 13, 2017	August 2020	April 12, 2016		July 10, 2019	Investigator Site, Taipei, Taiwan		https://ClinicalTrials.gov/show/NCT02734433
150	NCT03954548	CB-17-08 Augmented Endoscopy System for Mucosal Lesion Detection During Colonoscopy for Colon Rectal Cancer.		Not yet recruiting	No Results Available	Colorectal Cancer	Device: CB-17-08 SaMD	Adenoma per colonoscopy [APC]|Adenoma miss rate [AMR]|Positive Predictive Value [PPV]	Cosmo Technologies Ltd	All	45 Years and older   (Adult, Older Adult)	Not Applicable	532	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	CB-17-08/03	September 2019	January 2020	March 2020	May 17, 2019		July 23, 2019			https://ClinicalTrials.gov/show/NCT03954548
151	NCT03785665	Motility of the Check-cap's MD1 Colon Capsule in Subjects Following Colon Rectal Cancer Screening by Colonoscopy		Recruiting	No Results Available	Colo-rectal Cancer	Device: MDI	Measure the variability of the motility (Whole gut transit time from ingestion to excretion {hours}) of the MD1 (Motility dummy 1) capsules in the Gastrointestinal tract of human subjects with and w/out polyps in previous Colonoscopy.	Ceck Cap Ltd.	All	40 Years to 80 Years   (Adult, Older Adult)	Not Applicable	100	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	CL-MD1-01-0097	June 15, 2019	August 1, 2019	December 1, 2019	December 24, 2018		July 24, 2019	Bnai Zion Medical Center, Haifa, North, Israel		https://ClinicalTrials.gov/show/NCT03785665
152	NCT00675597	Docetaxel (Taxotere), Vinorelbine, and Bevacizumab, as Adjuvant Chemotherapy for Patients With Resected Stage I-III Non-small Cell Lung Cancer		Completed	Has Results	Lung Cancer	Drug: Bevacizumab (Avastin), Taxotere (Docetaxel), Vinorelbine Tartrate (Navelbine)	To Measure the Number of Cycles	Memorial Sloan Kettering Cancer Center|Sanofi	All	18 Years and older   (Adult, Older Adult)	Not Applicable	25	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	07-178	May 2008	February 2012	February 2012	May 9, 2008	November 20, 2015	November 20, 2015	Memorial Sloan-Kettering at Basking Ridge, Basking Ridge, New Jersey, United States|Memorial Sloan-Kettering Cancer Center @ Suffolk, Commack, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan-Kettering at Mercy Medical Center, Rockville Centre, New York, United States|Memorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital Center, Sleepy Hollow, New York, United States		https://ClinicalTrials.gov/show/NCT00675597
153	NCT02835807	Engaging Moms on Teen Indoor Tanning Through Social Media		Recruiting	No Results Available	Skin Cancer	Behavioral: Health Chat including Indoor Tanning|Behavioral: Health Chat excluding Indoor Tanning	Change in Mothers' Permissiveness for Daughters to Indoor Tan|Change in Mothers' Indoor Tanning Prevalence|Change in Daughters' Indoor Tanning Prevalence|Mothers' Support for Stricter Bans on Indoor Tanning by Minors	Klein Buendel, Inc.|East Tennessee State University|Colorado State University|University of Connecticut	All	18 Years and older   (Adult, Older Adult)	Not Applicable	4200	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention	5R01CA192652-02|0301	June 2015	September 2019	May 2020	July 18, 2016		March 26, 2019	Colorado State University, Fort Collins, Colorado, United States|Klein Buendel, Inc., Golden, Colorado, United States|University of Connecticut, Storrs, Connecticut, United States|East Tennessee State University, Johnson City, Tennessee, United States		https://ClinicalTrials.gov/show/NCT02835807
154	NCT00056654	Study of a 6-Month Sustained-Release Formulation of Leuprolide Acetate in Prostate Cancer		Completed	No Results Available	Prostatic Neoplasms	Drug: Leuprolide acetate	Suppression of serum testosterone (<=50 ng/dL) and maintenance of serum testosterone suppression once suppression is achieved for individual subjects.|Change from baseline in Eastern Cooperative Oncology Group (ECOG) performance status.|Change from baseline in symptom severity (bone pain, pain on urination, urination difficulty).|Change from baseline in prostate specific antigen (PSA).|Change from baseline in prostatic acid phosphatase (PAP).	Abbott	Male	Child, Adult, Older Adult	Not Applicable	164	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	C02-008	March 2003	July 2004	July 2004	March 21, 2003		September 17, 2008	Urology Centers of Alabama, Homewood, Alabama, United States|Medical Affiliated Research Center, Huntsville, Alabama, United States|Alaska Clinical Research Center, LLC, Anchorage, Alaska, United States|Arkansas Urology, Little Rock, Arkansas, United States|Pacific Clinical Center, Encino, California, United States|Los Angeles Clinical Research Center, Encino, California, United States|Urology Associates of Central California, Fresno, California, United States|Center for Urologic Research, La Mesa, California, United States|South Orange County Medical Research Center, Laguna Woods, California, United States|San Diego Uro-Research, San Diego, California, United States|Western Clinical Research, Torrance, California, United States|Urology Research Options, Aurora, Colorado, United States|Connecticut Clinical Research Center, Waterbury, Connecticut, United States|South Florida Medical Research, Aventura, Florida, United States|Atlantic Urological Associates, Daytona Beach, Florida, United States|UroSearch, Inverness, Florida, United States|Advanced Research Institute, New Port Richey, Florida, United States|Atlantic Urological Associates, New Smyrna Beach, Florida, United States|UroSearch, Ocala, Florida, United States|Florida Foundation for Healthcare Research, Ocala, Florida, United States|Atlantic Urological Associates, Orange City, Florida, United States|Atlantic Urological Associates, St. Augustine, Florida, United States|Emory University, Atlanta, Georgia, United States|Georgia Urology, PA, Atlanta, Georgia, United States|West Side Veteran Administration Medical Center, Chicago, Illinois, United States|Kankakee Urological Associates, Kankakee, Illinois, United States|Specialty Care Research, Peoria, Illinois, United States|Welborn Clinic East, Evansville, Indiana, United States|Northeast Indiana Research, Fort Wayne, Indiana, United States|Urology of Indiana, LLC, Indianapolis, Indiana, United States|Urological Associates, PC, Davenport, Iowa, United States|206 Research Associates, Greenbelt, Maryland, United States|Lawrenceville Urology, St Joseph, Michigan, United States|Kansas City Urology Care, Kansas City, Missouri, United States|Saint Louis Urological Surgeons, Inc, St Louis, Missouri, United States|Sheldon J. Freedman, MD, LTD, Las Vegas, Nevada, United States|Nevada Urology Associates, Reno, Nevada, United States|Urological Surgical Associates, Edison, New Jersey, United States|Lawrenceville Urology, Lawrenceville, New Jersey, United States|Associated Urologic Specialists, PA, Marlton, New Jersey, United States|Suffolk Urology Associates, Bay Shore, New York, United States|Urological Surgeons of Long Island, Garden City, New York, United States|Hudson Valley Urology, Poughkeepsie, New York, United States|Center for Urologic Research of Western New York, Williamsville, New York, United States|Northeast Urology Research, Concord, North Carolina, United States|The Urology Group, Cincinnati, Ohio, United States|University Urological Research Institute, Providence, Rhode Island, United States|Grand Strand Urology, Myrtle Beach, South Carolina, United States|Vanderbilt Medical Center Dept of Urologic Surgery, Nashville, Tennessee, United States|Urology Specialists & Associates, Dallas, Texas, United States|Urology Associates of North Texas, Fort Worth, Texas, United States|Urology San Antonio Research, San Antonio, Texas, United States|Salt Lake Research, Salt Lake City, Utah, United States|Devine-Tidewater Urology, Virginia Beach, Virginia, United States|Madigan Army Medical Center, Tacoma, Washington, United States		https://ClinicalTrials.gov/show/NCT00056654
155	NCT03111914	Applications of Dual Energy CT in Patients With Osseous Metastases From Castrate-resistant Prostate Cancer		Recruiting	No Results Available	Dual Energy CT (DECT)|Prostate Cancer	Diagnostic Test: Dual Energy Computed Tomography	Optimal threshold for iodine uptake to differentiate between therapy response and progression of metastatic bone disease|sensitivity of optimal threshold for iodine uptake to differentiate between therapy response and progression of metastatic bone disease|Specificity of optimal threshold for iodine uptake to differentiate between therapy response and progression of metastatic bone disease|Accuracy of optimal threshold for iodine uptake to differentiate between therapy response and progression of metastatic bone disease|Reader performance for iodine maps and fused images to differentiate between therapy response and progression of metastatic bone disease|Sensitivity of imaging approach|Specificity of imaging approach|Accuracy of imaging approach|Optimal threshold for iodine uptake to diagnose of metastatic bone disease.|Reader performance for iodine maps and fused images to diagnose metastatic bone disease|Sensitivity of optimal threshold for iodine uptake to diagnose of metastatic bone disease|Specificity of optimal threshold for iodine uptake to diagnose of metastatic bone disease|Accuracy of optimal threshold for iodine uptake to diagnose of metastatic bone disease|Optimal threshold for iodine uptake to diagnose metastatic lymph nodes|Sensitivity of optimal threshold for iodine uptake to diagnose metastatic lymph nodes|Specificity of optimal threshold for iodine uptake to diagnose metastatic lymph nodes|Accuracy of optimal threshold for iodine uptake to diagnose metastatic lymph nodes	Duke University|Siemens Medical Solutions	Male	18 Years and older   (Adult, Older Adult)	Not Applicable	100	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	Pro00078046	July 3, 2017	April 2020	April 2020	April 13, 2017		May 27, 2019	Duke University Hospital, Durham, North Carolina, United States		https://ClinicalTrials.gov/show/NCT03111914
156	NCT02626195	Preoperative Nutritional Support in Malnutritional Cancer Patients		Completed	No Results Available	Pancreatic Cancer|Biliary Cancer|Malnutrition	Dietary Supplement: nutritional support program	postoperative complication|postoperative hospital stay|quality of life|postoperative cost( + nutritional support cost)	National Cancer Center, Korea|Fresenius Kabi	All	20 Years to 80 Years   (Adult, Older Adult)	Not Applicable	50	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCCCTS-13-676	October 2013	November 27, 2013	April 5, 2017	December 10, 2015		June 11, 2018	National Cancer Center, Goyang-si, Gyeonggi-do, Korea, Republic of		https://ClinicalTrials.gov/show/NCT02626195
157	NCT01048099	Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast Cancer		Completed	Has Results	Breast Cancer	Procedure: PRO Onc Assay and Treatment|Drug: Trastuzumab|Drug: Pertuzumab	Part II: Objective Response Rate of HER2-negative Metastatic Breast Cancer (by FISH Testing)|Part II: Objective Response Rate of Trastuzumab Therapy|Part II: Objective Response Rate of Pertuzumab Therapy|Part 1: The Incidence of HER2 Overexpression/Activation as Measured by the PRO Onc Assay|Part I: The Incidence of Isolation of Circulating Tumor Cells (CTCs) From Blood Specimens	SCRI Development Innovations, LLC|Prometheus Laboratories|Genentech, Inc.	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	283	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	SCRI BRE 166	January 2011	July 2014	July 2014	January 13, 2010	January 29, 2016	January 29, 2016	Florida Cancer Specialists, Fort Myers, Florida, United States|Florida Cancer Specialists, St. Petersburg, Florida, United States|Oncology Hematology Care, Inc., Cincinnati, Ohio, United States|Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Center for Cancer and Blood Disorders, Fort Worth, Texas, United States|Virginia Cancer Institute, Richmond, Virginia, United States		https://ClinicalTrials.gov/show/NCT01048099
158	NCT03669263	A Dose Titration Study of Fentanyl Buccal Soluble Film for Breakthrough Cancer Pain in Taiwan		Completed	No Results Available	Breakthrough Cancer Pain	Drug: Fentanyl buccal soluble film (FBSF)	Optimal dose calculation of Painkyl®|Efficacy Phase : Pain intensity difference at 30 minutes (PID30) after treatment|Efficacy Phase : Subjects' satisfaction score at 30 minutes after treatment|The percentage of episodes requiring rescue medications.|Incidence of adverse events (AEs), serious adverse events (SAEs) [Safety and Tolerability]	Chang Gung Memorial Hospital|TTY Biopharm	All	20 Years and older   (Adult, Older Adult)	Not Applicable	36	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PK1302	November 25, 2014	June 23, 2016	July 1, 2016	September 13, 2018		September 13, 2018	Chang Gung Memorial Hospital, Keelung, Taiwan		https://ClinicalTrials.gov/show/NCT03669263
159	NCT03381430	Gefitinib Combine Radiotherapy as Therapy for Patients With NSCLC Harbouring Sensitive Mutations of EGFR		Not yet recruiting	No Results Available	Lung Cancer	Drug: Gefitinib	Disease free survival|Overall survival|3 yeas DFS rate|5 years DFS rate|5 years OS rate|Number of Participants with Adverse Events	Qilu Pharmaceutical Co., Ltd.|China-Japan Friendship Hospital|Beijing Cancer Hospital|Cancer Institute and Hospital, Chinese Academy of Medical Sciences|Chinese PLA General Hospital	All	18 Years to 75 Years   (Adult, Older Adult)	Not Applicable	50	Industry|Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GRAY	June 2018	March 2023	December 2025	December 22, 2017		December 22, 2017	China-Japan Friendship Hospital, Beijing, China		https://ClinicalTrials.gov/show/NCT03381430
160	NCT01817192	Adjuvant Chemotherapy in Patients With High Risk Stage I Non-squamous Non-Small Cell Lung Cancer		Active, not recruiting	No Results Available	Non-Small Cell Lung Cancer	Drug: Adjuvant Chemotherapy|Other: Radiographic surveillance|Other: Pervenio™ Lung RS Assay	Overall Survival|Disease-Free Survival	Encore Clinical|Life Technologies Corporation	All	18 Years and older   (Adult, Older Adult)	Not Applicable	700	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	EC-120888	May 2013	April 2021		March 25, 2013		March 21, 2014	Highlands Oncology Group, Fayetteville, Arkansas, United States|University of California, Davis Cancer Center, Sacramento, California, United States|University Park Hematology/Oncology, Englewood, Colorado, United States|Inova Fairfax Hospital, Falls Church, Virginia, United States|Huaxi Hospital, Chengdu, Sichuan, China|Beijing Cancer Hospital, Beijing, China|Xuanwu Hospital, Beijing, China|Shanghai Pulmonary Hospital, Shanghai, China|Zhong Shan Hospital, Shanghai, China		https://ClinicalTrials.gov/show/NCT01817192
161	NCT03547557	MR Guided Focused Ultrasound Surgery in the Treatment of Pain From Bone Tumors w/ the ExAblate 2000 Strappable System	BM005	Completed	No Results Available	Bone Metastases	Device: Exablate 2000 strappable system	Number of participants with treatment-related adverse events|Change in pain Numerical Rating Scale (NRS) from pre-treatment to post treatment	InSightec	All	18 Years and older   (Adult, Older Adult)	Not Applicable	10	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	BM005	January 2007	February 2009	March 2009	June 6, 2018		June 6, 2018	Sheba Medical Center Oncology Department, Tel Hashomer, Israel		https://ClinicalTrials.gov/show/NCT03547557
162	NCT00087659	A Prostate Cancer Study in Men Undergoing Androgen Deprivation Therapy		Completed	No Results Available	Prostate Cancer	Drug: zoledronic acid	Percent change in bone mineral density of the lumbar spine (L2-L4) at 6 and 12 months.|Percent change in bone mineral density of the total hip (including femoral neck, trachanteric region, and Ward's triangle) following one year of therapy.	Novartis Pharmaceuticals|Novartis	Male	18 Years and older   (Adult, Older Adult)	Not Applicable		Industry	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CZOL446GUS63|US63, US72 H014	December 2003		May 2007	July 14, 2004		November 23, 2009	Tucson VA Medical Center, Tucson, Arizona, United States|VA Medical Center - Long Beach, Long Beach, California, United States|Washington VA Medical Center, Washington, District of Columbia, United States|Veterans Affairs Medical Center, Augusta, Georgia, United States|Atlanta VA Medical Center, Decatur, Georgia, United States|West Sde Vamc, Chicago, Illinois, United States|Hines VA Medical Center, Hines, Illinois, United States|Louisville VAMC, Louisville, Kentucky, United States|West Roxbury VAMC, West Roxbury, Massachusetts, United States|John D. Dingell VA Medical Center, Detroit, Michigan, United States|Department of Veterans Affairs, Minneapolis, Minnesota, United States|Kansas City VAMC, Kansas City, Missouri, United States|Department of Veterans Affairs, East Orange, New Jersey, United States|VAWNY, Buffalo, Buffalo, New York, United States|Portland/Vancouver, Portland, Oregon, United States|WJB Dorn Veteran Affairs Medical Center, Columbia, South Carolina, United States		https://ClinicalTrials.gov/show/NCT00087659
163	NCT02080689	Prospective Clinical Utility Study to Assess the Impact of Decipher on Treatment Decisions After Surgery	PRO-IMPACT	Completed	No Results Available	Prostate Cancer	Other: Decipher	Number of participants for which the Decipher test changes the urologist's and patient's treatment plan choices|Measure the number of participants for which treatment was Increased or decreased in the intensity.|The number of different treatment plans most influenced by Decipher as a measure of clinical utility|Comparison of type of treatment plans between high risk and low risk patients|Account for the number of specific treatment assignments that correlated with a change in treatment recommendation|Frequency of follow visits as a measure of reproducibility|Measure the urologist's and patient's Level of confidence in their selected treatment plan through the use of a share decision making tool|Assess the number of physicians that assigned the same treatment treatment recommendations for patient of the same pathological profile as a measure of concordance|A measure of the patient's quality of life (QOL) as a measure of Decipher's clinical utility for patients|Evaluate number of participants which show coherence to treatment decisions	GenomeDx Biosciences Corp|Society of Urologic Oncology (SUO)	Male	Child, Adult, Older Adult	Not Applicable	286	Industry|Other	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	CU 004	May 2014	February 1, 2017	February 1, 2017	March 6, 2014		February 27, 2017	Alaska Urology Institute Alaska Clinical Research Center, Anchorage, Alaska, United States|Cedars-Sinai Medical Center, Los Angeles,, California, United States|University of Colorado, Denver Medical Campus, Aurora, Colorado, United States|The Urology Center of Colorado, Denver, Colorado, United States|Urological Research Network, Hialeah, Florida, United States|Lakeland Regional Health Systems, Lakeland, Florida, United States|University of Miami Miller School of Medicine, Miami, Florida, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Spectrum Health Medical Group, Grand Rapids, Michigan, United States|Delaware Valley Urology, LLC, Voorhees, New Jersey, United States|Carolina Urology Partners, Gastonia, North Carolina, United States|Lancaster Urology, Lancaster, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Huntsman Cancer Hospital, Salt Lake City, Utah, United States|University of Vermont Medical Center, Burlington, Vermont, United States|Virginia Urology, Richmond, Virginia, United States|University of Washington, Seattle, Washington, United States		https://ClinicalTrials.gov/show/NCT02080689
164	NCT03304145	Shared Decision Making in Pain Management Planning in Patients With Cancer		Recruiting	No Results Available	Cancer	Other: The Carevive CPS	Effect of pain care plan on pain outcomes|Contribution of shared-decision-making on pain outcomes will be evaluated using the PainCQ© surveys|Feasibility of the proposed shared decision-making model to effectively manage chronic pain experienced by patients with cancer	Carevive Systems, Inc.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	105	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	G414	October 1, 2017	October 30, 2018	April 30, 2019	October 6, 2017		January 30, 2019	Billings Clinic, Billings, Montana, United States		https://ClinicalTrials.gov/show/NCT03304145
165	NCT03049280	Prospective, Multicenter da Vinci® SP™ Surgical System TORS Study		Completed	No Results Available	Oropharyngeal Cancer	Device: Transoral robotic surgery	Performance|Number of subjects with device-related serious adverse events|Positive surgical margin	Intuitive Surgical	All	18 Years and older   (Adult, Older Adult)	Not Applicable	33	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ISI dV SP-TORS - 01	April 17, 2017	November 14, 2017	December 26, 2017	February 10, 2017		August 8, 2018	Board of Trustees of the Leland Stanford Junior University, Palo Alto, California, United States|Florida Hospital, Celebration, Florida, United States|Trustees of the University of Pennsylvania, Philadelphia, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT03049280
166	NCT02343991	Blood-Brain Barrier Disruption Using Transcranial MRI-Guided Focused Ultrasound		Active, not recruiting	No Results Available	Brain Tumor	Device: Transcranial ExABlate	Number of Device and Procedure related adverse events|Severity of Device and Procedure related adverse events	InSightec	All	18 Years to 70 Years   (Adult, Older Adult)	Not Applicable	10	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	BBB001|215600	October 2014	December 2019	December 2019	January 22, 2015		January 10, 2019	Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada		https://ClinicalTrials.gov/show/NCT02343991
167	NCT02494206	Immunotherapy for the Treatment of Breast Cancer Related Upper Extremity Lymphedema (BCRL)		Completed	Has Results	Breast Cancer|Upper Extremity Lymphedema	Drug: QBX258	Volume Changes as Measured by Perometry	Memorial Sloan Kettering Cancer Center|Novartis	Female	18 Years to 70 Years   (Adult, Older Adult)	Not Applicable	9	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	15-085	July 2015	May 2018	May 2018	July 10, 2015	October 11, 2018	November 8, 2018	Memorial Sloan-Kettering Cancer Center, New York, New York, United States	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/06/NCT02494206/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT02494206
168	NCT03096548	Sun Safety Ink! A Sun Safety Program for the Tattoo Community		Recruiting	No Results Available	Skin Cancer	Behavioral: Sun Safety Ink! Program|Behavioral: Attention Control	Change in Sun Protection by Client (online survey)|Change in Number of Sunburns|Change in Tanning Behaviors (online survey)|Change in Tanning Attitudes (online survey)	Klein Buendel, Inc.|National Cancer Institute (NCI)|University of Colorado, Denver	All	18 Years and older   (Adult, Older Adult)	Not Applicable	1820	Industry|NIH|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	1R01CA206569-01A1|R01CA206569-01A1|315	June 15, 2017	January 1, 2021	January 1, 2021	March 30, 2017		July 26, 2018	University of Colorado Denver, Aurora, Colorado, United States|Klein Buendel, Inc., Golden, Colorado, United States		https://ClinicalTrials.gov/show/NCT03096548
169	NCT01671943	Cryotherapy for Breast Cancer Trial	ICE-BREACCER	Completed	No Results Available	Breast Carcinoma	Device: Ice-Sense3TM	The rate of complete tumor ablation in patients treated with cryoablation, with complete tumor ablation defined as no remaining invasive or in-situ carcinoma present upon pathological examination of the surgical resection specimen|Adverse events|Pain assessment	IceCure Medical Ltd.	Female	Child, Adult, Older Adult	Not Applicable	4	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ICMBC-01	August 2012	July 2014	July 2014	August 24, 2012		February 6, 2015	Oncogynecological Center, Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague Prague, Czech Republic, Prague, Czech Republic		https://ClinicalTrials.gov/show/NCT01671943
170	NCT03510143	Effect of Polyglycolic Acid Mesh (Neoveil) in Thyroid Cancer Surgery		Not yet recruiting	No Results Available	Thyroid Gland Carcinoma|Thyroid Cancer|Thoracic Duct Leak	Device: Neoveil (Polyglycolic Acid Mesh)	Change of triglyceride(TG) level in drained fluid|Drain amount	Seoul National University Hospital|Green Cross Corporation	All	20 Years to 70 Years   (Adult, Older Adult)	Not Applicable	330	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	1802-087-923	May 1, 2018	May 1, 2020	December 31, 2020	April 27, 2018		April 27, 2018	Jin Wook Yi, Seoul, Korea, Republic of		https://ClinicalTrials.gov/show/NCT03510143
171	NCT01091883	Study Comparing the Safety and Effectiveness of Magnetic Resonance Guided Focused Ultrasound (MRgFUS) and External Beam Radiation (EBRT) for Treatment of Metastatic Bone Tumors and Multiple Myeloma		Completed	No Results Available	Bone Cancer|Bone Metastases|Pain	Device: Exablate treatment|Radiation: Radiation	Safety of treatment|NRS score|Pain Medication dose and quantity|Quality of Life score	InSightec	All	18 Years and older   (Adult, Older Adult)	Not Applicable	60	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	BM016	May 2010	January 2019	March 2019	March 24, 2010		March 13, 2019	Taipei Medical University Hospital, Taipei city, Taipei, Taiwan		https://ClinicalTrials.gov/show/NCT01091883
172	NCT02794558	Safety and Effectiveness of MR Guided Focused Ultrasound Surgery in the Treatment of Early Breast Carcinomas		Completed	No Results Available	Breast Cancer	Device: ExAblate MRgFUS	Incidence and severity of Adverse events|Post treatment local recurrence	InSightec	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	100	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	BC004	June 2005	March 1, 2019	March 1, 2019	June 9, 2016		July 1, 2019			https://ClinicalTrials.gov/show/NCT02794558
173	NCT03870919	Locoregional Treatment and Palbociclib in de Novo, Treatment Naive, Stage IV ER+, HER2- Breast Cancer Patients	PALATINE	Not yet recruiting	No Results Available	Breast Cancer Stage IV|Radiotherapy|Surgery	Drug: Palbociclib|Other: locoregional treatment	Overall survival rate in patients receiving the letrozole plus palbociclib combination plus locoregional treatment|Clinical response rate on both primary tumour and metastasis disease|Pathological response rate in primary tumour|Conversion rate of breast surgery (conservative-radical)|Locoregional control rate|Progression-free survival (PFS)|Overall survival|Incidence of combined therapies in terms of adverse events|Registration of post letrozole-CDKi therapies|Evolution of quality of life during treatment	UNICANCER|Pfizer	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	200	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	UC 0140-1814|2019-A00570-57	May 15, 2019	May 15, 2023	May 15, 2026	March 12, 2019		March 14, 2019			https://ClinicalTrials.gov/show/NCT03870919
174	NCT00664482	A Single-Patient Study Using AGS 006		Completed	No Results Available	Pancreatic Cancer	Biological: AGS-006	Treatment-emergent changes in vital signs (blood pressure, heart rate, respiratory rate, and body temperature) from baseline values obtained prior to each investigative treatment|Incidence of treatment-emergent adverse events graded according to the Common Terminology Criteria for Adverse Events|Treatment-emergent adenopathy, tenderness, or inflammation (inguinal and axillary) assessed before and after each dose|Treatment-emergent changes in autoimmunity evaluations as measured by clinical signs and symptoms and laboratory assessments at periodic intervals during the Treatment Period.|Treatment-emergent changes in localized injection site reactions following each dose|Assessment of progression-free survival (PFS) estimated from the date of subject registration - Standard Response Evaluation Criteria in Solid Tumors (RECIST) definitions of progressive disease (PD) will contribute to estimating the interval for PFS.|T cell response to RNA-electroporated DCs will be assessed by flow cytometry using blood cells collected according to protocol time and events|Positive immune response|Feasibility	Argos Therapeutics	Male	18 Years and older   (Adult, Older Adult)	Not Applicable	1	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	AGS-006-001	May 2007	October 2011	October 2011	April 23, 2008		January 29, 2013	Rockefeller University, New York, New York, United States		https://ClinicalTrials.gov/show/NCT00664482
175	NCT02111681	Calypso-based Deep Inspiration Breath Hold (DIBH) Radiation Treatments of Lung Cancer		Recruiting	No Results Available	Non-small Cell Lung Cancer (NSCLC)	Device: Calypso Beacon Implantation	feasibility of Calypso transponders|reproducibility|measure the residual intrafraction tumor motion	Memorial Sloan Kettering Cancer Center|Varian Medical Systems	All	18 Years and older   (Adult, Older Adult)	Not Applicable	55	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	13-174	April 2014	April 2020	April 2020	April 11, 2014		April 9, 2019	Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Commack, Commack, New York, United States|Memorial Sloan Kettering West Harrison, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States		https://ClinicalTrials.gov/show/NCT02111681
176	NCT02809846	Quell Opioid Reduction and Pain Relief in Patients With Cancer		Completed	No Results Available	Pain|Metastatic Breast Cancer|Prostate Cancer|Colorectal Cancer	Device: Quell|Device: Sham Quell	Reduction in daily opioid use assessed as recorded by the subject in their analgesia diary.	Scripps Translational Science Institute|NeuroMetrix, Inc.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	33	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care	IRB-16-6815	July 2016	August 2017	October 2017	June 22, 2016		September 10, 2018			https://ClinicalTrials.gov/show/NCT02809846
177	NCT03834272	Feasibility of the LUM Imaging System for Peritoneal Surface Malignancies		Recruiting	No Results Available	Peritoneal Metastases	Combination Product: LUM Imaging System	Initial efficacy of LUM015 in labeling peritoneal surface malignancies by molecular imaging by comparing imaging results with pathology|Number of patients with reported adverse events	Lumicell, Inc.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	18	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Other	CLP-00010	March 18, 2019	November 1, 2019	December 1, 2019	February 7, 2019		May 13, 2019	Massachusetts General Hospital, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT03834272
178	NCT01542021	Androgen Deprivation Therapy Prior to Prostatectomy for Patients With Intermediate and High Risk Prostate Cancer		Active, not recruiting	No Results Available	Prostate Cancer|Prostatic Adenocarcinoma	Drug: degarelix injection|Drug: androgen deprivation therapy	To assess between the time to determine the time of the maximal change in prostate cancer cell proliferation (Ki-67) and apoptosis rates (cleaved caspase-3)|To explore the association between PTEN status and maximal changes in prostate cancer proliferation and apoptosis rates in patients treated with androgen deprivation therapy|To explore the association between PI3K pathway (pAKT and pS6) and prostate cancer proliferation and apoptosis rates after treatment with androgen deprivation therapy in relation to other markers of prostate cancer (ERG, AR and NCOA2).|To discover novel biomarkers and correlates of response	Memorial Sloan Kettering Cancer Center|Ferring Pharmaceuticals	Male	18 Years and older   (Adult, Older Adult)	Not Applicable	41	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	11-182	February 2012	February 2020	February 2020	March 1, 2012		February 26, 2019	Memorial Sloan Kettering Cancer Center, New York, New York, United States		https://ClinicalTrials.gov/show/NCT01542021
179	NCT00735826	A Clinical Trial to Validate Molecular Targets of Vorinostat in Patients With Aerodigestive Tract Cancer		Completed	Has Results	Aerodigestive Tract Cancer|Lung Cancer|Esophageal Cancer|Head and Neck Cancer	Drug: Vorinostat	Changes in Tumor Markers on Tumors of the Lung, Esophagus, or Head and Neck, After 7 Days of Treatment With Vorinostat|Concentration of Vorinostat in Tumor Tissue|Effects of Vorinostat Treatment on Induction of Apoptosis or Necrosis in Treated vs. Untreated Tumors	Dartmouth-Hitchcock Medical Center|Merck Sharp & Dohme Corp.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	10	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	D-0828	March 2009	July 2012	July 2012	August 15, 2008	October 12, 2018	October 12, 2018	Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States		https://ClinicalTrials.gov/show/NCT00735826
180	NCT03796559	Magseed Enabled Long-Term Localization of Axillary Lymph Nodes	MAGELLAN	Recruiting	No Results Available	Breast Cancer|Axillary Lymph Nodes	Device: Magseed Marker	Retrieval rate of clipped node and Magseed in the excised specimen|Rates of device and serious device-related events|Radiologic rated ease of Magseed placement|Radiologic placement accuracy|Radiologic seed position|Surgical nodes localized|Ease of surgical localization	Endomagnetics Inc|M.D. Anderson Cancer Center	All	18 Years and older   (Adult, Older Adult)	Not Applicable	65	Industry|Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	US-003	June 13, 2019	January 2021	April 2021	January 8, 2019		July 19, 2019	Cooper Health, MD Anderson Cancer Center, Camden, New Jersey, United States|MD Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT03796559
181	NCT00880022	Home-based Compression Therapy for Arm and Truncal Lymphedema in Breast Cancer		Completed	Has Results	Arm Lymphedema|Truncal Lymphedema|Breast Cancer	Device: Flexitouch System	Arm Volume at End of Study|Symptom Improvement	Vanderbilt University|Tactile Systems Technology, Inc.	All	21 Years and older   (Adult, Older Adult)	Not Applicable	47	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	supp930	May 2009	May 2010	May 2010	April 13, 2009	September 13, 2012	December 5, 2017	Vanderbilt Univeristy, Nashville, Tennessee, United States		https://ClinicalTrials.gov/show/NCT00880022
182	NCT02486497	Adjuvant Gemcitabine Versus 5-FU/Leucovorin Based on hENT1 Immunostaining		Completed	No Results Available	Pancreatic Cancer	Biological: hENT1	Recurrence free survival|Overall survival|Toxicity	Seoul National University Hospital|IlDong Pharmaceutical Co Ltd	All	18 Years to 75 Years   (Adult, Older Adult)	Not Applicable	40	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	SNUBH-IMGPB-2015-01	June 2015	May 2017	May 2017	July 1, 2015		September 25, 2017	Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Korea, Republic of		https://ClinicalTrials.gov/show/NCT02486497
183	NCT03163732	Evaluation of the Added Value of a Large Molecular Profiling Panel Versus a Limited Molecular Profiling Panel in Advanced Solid Tumors.	PROFILER 02	Recruiting	No Results Available	Advanced Solid Tumor	Genetic: Blood and tumor samples	Compare the proportion of patients for whom a genomically identified recommended therapy could be initiated using the large NGS panel from FoundationOne versus the limited CONTROL panel.|Compare in the 2 randomization arms the number of patients with at least one actionable alteration.|Compare in the 2 randomization arms the proportion of patients for which a genomically identified recommended therapy is effectively initiated.|Describe in both arms the number of patients for whom a genomically identified recommended therapy was available but not initiated.|Evaluate proportion of patients who could have been initiated a recommended therapy considering only the INCa panel.|Progression-Free Survival (PFS)|Overall response Rate (ORR)|Duration of response (DoR)|Patient Quality Of Life|Perform a health economic evaluation	Centre Leon Berard|Roche Pharma AG	All	18 Years and older   (Adult, Older Adult)	Not Applicable	300	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	ET16-115	June 29, 2017	March 2020	March 2020	May 23, 2017		June 6, 2019	Institut Bergonié, Bordeaux, France|Centre Jean PERRIN, Clermont-Ferrand, France|Centre Georges François LECLERC, Dijon, France|Centre Oscar Lambret, Lille, France|Centre Léon Bérard, Lyon, France|Institut Paoli Calmettes, Marseille, France|AP-HM MARSEILLE - Hôpital Nord, Marseille, France|Institut cancer Montpellier - ICM, Montpellier, France|Institut Curie, Paris, France|Hopital Tenon, Paris, France|Centre Eugène Marquis, Rennes, France|ICO site René Gauducheau, Saint-Herblain, France|Institut de Cancérologie Lucien NEUWIRTH, Saint-Priest-en-Jarez, France|Institut Claudius Regaud, Toulouse, France		https://ClinicalTrials.gov/show/NCT03163732
184	NCT00970359	Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244		Completed	Has Results	Thyroid Cancer	Biological: AZD6244	Number of Patients Whose Tumor(s) Acquire an Increased Propensity for Iodine Uptake as Detected on Iodine-124 Positron Emission Tomography Scan|Tumor Response Defined as Either a Complete Response or Partial Response|Change From Baseline in Serum Thyroglobulin Levels After Treatment With 131I	Memorial Sloan Kettering Cancer Center|Genzyme, a Sanofi Company|AstraZeneca	All	18 Years and older   (Adult, Older Adult)	Not Applicable	24	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	09-048	September 2009	April 2013	April 2013	September 2, 2009	April 12, 2017	April 12, 2017	Memorial Sloan-Kettering Cancer Center, New York, New York, United States		https://ClinicalTrials.gov/show/NCT00970359
185	NCT02824289	Sun Safe Workplaces: A Campaign on Sun Protection Policies for Outdoor Workers	SSW	Completed	No Results Available	Skin Cancer	Behavioral: Sun Safe Workplaces Program|Behavioral: Attention Control	Change in Presence of a Sun Protection Policy for Outdoor Workers|Workplace Actions on Occupational Sun Safety|Change in Awareness of a Sun Protection Policy for Outdoor Workers|Sun Protection Practices by Outdoor Workers|Change in Extent of Sun Protection Policy for Outdoor Workers|Change in Strength of Sun Protection Policy for Outdoor Workers	Klein Buendel, Inc.|University of Colorado, Denver|Kaiser Foundation Research Institute	All	18 Years and older   (Adult, Older Adult)	Not Applicable	1019	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	R01CA134705	July 1, 2009	April 30, 2015	December 31, 2015	July 6, 2016		July 26, 2017	Kaiser Foundation Research Institute, Oakland, California, United States|University of Colorado Denver, Aurora, Colorado, United States|Klein Buendel, Inc., Golden, Colorado, United States		https://ClinicalTrials.gov/show/NCT02824289
186	NCT03302819	London Investigation Into diElectric Scanning of Lesions	LIESL	Not yet recruiting	No Results Available	Breast Cancer	Diagnostic Test: MARIA scan	Proportion of patients with breast cancer in whom breast cancer is correctly identified by MARIA|Sensitivity and specificity of MARIA for a range of findings to include, simple cysts, fibroadenomata, and malignant lesions. As judged against the final diagnosis at discharge, which may be based on clinical findings, imaging and pathology data.|Proportion of post-operative patients treated with neo-adjuvant chemotherapy or endocrine therapy, correctly identified by MARIA with complete response or residual disease, as compared to surgical histology.|Compare the detection of breast cancer from MARIA with the detection from mammography by the sub-group of histology type.|Compare the detection of breast cancer from MARIA with the detection from mammography by sub-group of mammographic density.|Compare the detection of breast cancer from MARIA with the detection from mammography in the overall patient group.|Assessment of data repeatability (test re-test) of MARIA assessment results on patients with diagnostic follow-up imaging.|Investigate the performance of MARIA in the estimation of residual tumour size compared to the final surgical histology results in the case of patients receiving neo-adjuvant chemotherapy or endocrine therapy.|Patient tolerance of MARIA (a non-compressing, non-ionising modality)	Royal Marsden NHS Foundation Trust|Micrima, Ltd.	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	994	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	CCR4702	November 1, 2017	November 1, 2018	December 1, 2018	October 5, 2017		October 5, 2017			https://ClinicalTrials.gov/show/NCT03302819
187	NCT03012789	Surgical Intervention and the NETest	NETest_Sx	Recruiting	No Results Available	Neuroendocrine Tumor|Gastroenteropancreatic	Procedure: Surgery	Biomarker prediction of tumor recurrence|Biomarkers and clinical symptomatology	Wren Laboratories LLC	All	18 Years and older   (Adult, Older Adult)	Not Applicable	40	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Surgery_NETest	May 15, 2017	December 2019	June 2020	January 6, 2017		June 18, 2018	San Raffaele Hospital IRCCS, Milano, Italy		https://ClinicalTrials.gov/show/NCT03012789
188	NCT00437853	Neoadjuvant Hormonal Treatment of Postmenopausal Women Who Have Operable Breast Cancer		Completed	No Results Available	Breast Cancer	Drug: Anastrozole	The primary endpoint was to compare overall objective response (OR) determined by clinical (palpation) and ultrasound.|Secondary endpoint was the number of patients who qualified for BCS plus radiotherapy.	Instituto Nacional de Cancerologia de Mexico|AstraZeneca	Female	66 Years and older   (Older Adult)	Not Applicable	30	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	1033MX/0001	June 2003		February 2007	February 21, 2007		February 21, 2007	Instituto Nacional de Cancerologia de Mexico, Mexico D.F., Mexico, D.F., Mexico		https://ClinicalTrials.gov/show/NCT00437853
189	NCT00559013	Peri-Strips Dry (PSD) Veritas Collagen Matrix Staple Line Reinforcement for Colorectal Surgery		Completed	Has Results	Colorectal Cancer	Device: Staple line reinforcement	Number of Participants With Major Colorectal Related Adverse Events: Leak, Stricture and Hemorrhage.	Baxter Healthcare Corporation|Synovis Surgical Innovations	All	18 Years and older   (Adult, Older Adult)	Not Applicable	38	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	CP1011, Rev C	March 2007	December 2008	December 2008	November 16, 2007	May 24, 2012	May 10, 2017	Lahey Clinic, Burlington, Massachusetts, United States|Colon & Rectal Surgery Associates, St. Paul, Minnesota, United States		https://ClinicalTrials.gov/show/NCT00559013
190	NCT02831634	A Feasibility Study to Identify T-cell Responses to Neo-epitopes in Tumor Invaded Lymph Nodes (NeoEpitope)		Completed	No Results Available	Breast Cancer|Cutaneous Melanoma	Procedure: Blood sampling	Feasibility of a method allowing identification of tumor mutated epitopes in patients with breast cancer or cutaneous melanoma and quantification of CD8+ T cells specific for the tumor neo-antigens identified in the lymph nodes.|Quantification of CD4+ T lymphocytes specific for identified tumor neo-antigens in the lymph nodes.|Quantification of CD4+ and CD8+ T lymphocytes specific for identified neo-antigens in the blood and tumor.|Comparison of the frequency and relative amplitude of the T cell response specific for the tumor neo-epitopes with other immune responses and responses against known tumor antigens.	Institut Curie|Genentech, Inc.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	25	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	IC 2015-06	June 9, 2016	March 1, 2018	March 1, 2018	July 13, 2016		December 13, 2018	Institut Curie, Paris, France		https://ClinicalTrials.gov/show/NCT02831634
191	NCT03488472	Radiosurgery Plus NovoTTF-200A for Metastatic Small Cell Lung Cancer to the Brain	RAD 1704	Recruiting	No Results Available	Brain Metastases|Small Cell Lung Cancer	Device: NovoTTF-200A|Radiation: Stereotactic Radiosurgery (SRS)	Rate of Distant Metastases|Overall Survival|Local Recurrence|Distant CNS Progression	Drexell Hunter Boggs|NovoCure Ltd.|University of Alabama at Birmingham	All	18 Years to 99 Years   (Adult, Older Adult)	Not Applicable	20	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IRB-300001201	September 2019	April 2022	April 2022	April 5, 2018		August 14, 2019	University of Alabama at Birmingham (UAB), Hazelrig-Salter Radiation Oncology Center (HSROC), Birmingham, Alabama, United States		https://ClinicalTrials.gov/show/NCT03488472
192	NCT03601962	Effects of Aqualief® in Patients With Xerostomia as Consequence of Radiotherapy for Head and Neck Cancer		Recruiting	No Results Available	Xerostomia|Asialia|Hyposalivation|Mouth Dryness	Dietary Supplement: Aqualief|Other: Placebo	Saliva Production|pH of the mouth cavity evaluation|Xerostomia Evaluation (XQ-I questionnaire)|MD Anderson Dysphagia Inventory (MDADI) questionnaire|Adherence to the treatment by accountability|Patient's global satisfaction	Helsinn Healthcare SA|Latis S.r.l.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	100	Industry	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	HF07-16-31	July 31, 2017	October 31, 2019	December 31, 2019	July 26, 2018		February 21, 2019	Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy		https://ClinicalTrials.gov/show/NCT03601962
193	NCT03413358	Clinical Trial for Post-marketing Evaluation of Sheng Bai Oral Liquid		Recruiting	No Results Available	Non-small-Cell Lung Cancer	Drug: Sheng Bai oral liquid|Drug: Platinum-based two medicine (carboplatin / cisplatin) .	The incidence and degree of neutropenia after chemotherapy|The recovery time of neutropenia|The incidence of neutropenia associated with Fever (FN) in patients after chemotherapy|The incidence of Peripheral blood thrombocytopenia disease|The duration of Peripheral blood thrombocytopenia disease|THE incidence and duration of hemoglobin reduction in peripheral blood|THE duration of hemoglobin reduction in peripheral blood|THE incidence and duration of peripheral blood leukocyte reduction|The duration of peripheral blood leukocyte reduction|The time when the neutrophils were reduced to the lowest point after chemotherapy|Neutrophil value of neutrophils in patients with low to lowest level after chemotherapy|MDASI-TCM|Cancer-related fatigue|rhG-CSF dosage|Immune Index (optional)	BeiJing Yijiayi Medicine Techonoloy Co., Ltd.|Hubei Mon Yan Pharmaceutical Co., Ltd	All	18 Years and older   (Adult, Older Adult)	Not Applicable	240	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2017-133-KY-01	January 15, 2018	October 31, 2019	October 31, 2019	January 29, 2018		January 29, 2018	CHINA ACADENY OF CHINESE MEDICAL SCIENCES Guang'anmen Hospital, Beijing, Beijing, China		https://ClinicalTrials.gov/show/NCT03413358
194	NCT00211237	CAFE Study - Cancer Patient Fracture Evaluation	CAFE	Completed	Has Results	Cancer|Spinal Fractures	Device: Balloon Kyphoplasty|Other: Non Surgical Management	The Functional Status, as Measured by the Roland-Morris Disability Questionnaire (RDQ) at 1 Month|Change in Roland-Morris Disability Questionnaire Score|Change in Functional Status Assessed With the Karnofsky Performance Scale|Change in Back Pain|Change in Quality of Life.|Change in Quality of Life|Change in Activities of Daily Living - Activities Reduced Due to Back Pain in Previous 2 Weeks|Change in Activities of Daily Living - Number of Days With Reduced Activities Due to Back Pain in Previous 2 Weeks|Change in Activities of Daily Living - Number of Days in Bed Due to Back Pain in Previous 2 Weeks|Ambulatory Status Change From Baseline to One Month|Ambulatory Status Change|Index Spinal Deformity Change Measured by Index Vertebral Body Angles From Baseline to 1 Month|Index Spinal Deformity Change Measured by Index Vertebral Body Angles|Index Spinal Deformity Change Measured by Index Vertebral Body Height Ratio|Back Pain Analgesics Used|Change in Neurology Status From Baseline (Motor Strength)|Change in Neurology Status From Baseline (Motor Strength)-Per Protocol|Change in Neurological Status From Baseline (Sensory Examination)|Change in Neurological Status From Baseline (Reflex Strength)|Change in Neurological Status From Baseline (Limb Strength)|Rate of Study Treatment-related Adverse Events Within 30 Days of Baseline|Rate of Study Treatment-related Adverse Events Till Study Completion|Rate of Subsequent Vertebral Body Fractures	Medtronic Spine LLC|Medtronic Spinal and Biologics	All	21 Years and older   (Adult, Older Adult)	Not Applicable	134	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	SP0401 - CAFE Study	May 2005	April 2009	December 2009	September 21, 2005	May 14, 2010	December 8, 2017	Valley Radiology Inc., UCSD, Escondido, California, United States|Boulder Neurosurgical Associates, Boulder, Colorado, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, United States|Sibley Memorial Hospital, Chevy Chase, Maryland, United States|Greater Oncology Associates, Silver Spring, Maryland, United States|Karmanos Cancer Center, Detroit, Michigan, United States|Cleveland Clinic, Cleveland, Ohio, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|University of Utah, Salt Lake City, Utah, United States|St. Vincent's Hospital, Fitzroy, Victoria, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Institut Jules Bordet, Brussels, Belgium|Foothills Hospital, Calgary, Alberta, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|Montreal General Hospital, Montreal, Quebec, Canada|Charité Virchow-Klinikum, Berlin, Germany|Medizinische Hochschule, Hannover, Germany|National Center for Spinal Disorders, Budapest, Hungary|Akademiska Sjukhuset, Uppsala, Sweden|Royal London, London, United Kingdom		https://ClinicalTrials.gov/show/NCT00211237
195	NCT01973673	Healthy Bones Study		Completed	No Results Available	Locally Advanced Malignant Neoplasm	Behavioral: Bone health educational materials	Recruitment rate|Study completion and retention rate|Intervention efficacy|Clinical outcome|Clinical outcome capture rate|Questionnaire, and Osteoporosis Health Belief Scale|BMD monitoring	University Health Network, Toronto|Canadian Association of Radiation Oncology	Male	18 Years and older   (Adult, Older Adult)	Not Applicable	200	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	13-6050	September 2013	March 1, 2017	March 1, 2017	October 31, 2013		May 8, 2017	Princess Margaret Cancer Centre, Toronto, Ontario, Canada		https://ClinicalTrials.gov/show/NCT01973673
196	NCT03595722	Exploring HIFU as a Treatment for Rectal and Other Pelvic Cancers		Recruiting	No Results Available	Rectal Cancer|Rectal Neoplasms|Pelvic Cancer|Endometrial Cancer|Cervical Cancer	Device: High Intensity Focused Ultrasound	Complications|Symptom control|Histological tissue changes|Tumour marker changes|Inflammatory marker changes|Radiological changes	Imperial College London|SonaCare Medical	All	18 Years to 90 Years   (Adult, Older Adult)	Not Applicable	60	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	18SM4430	July 11, 2019	August 28, 2022	August 28, 2022	July 23, 2018		August 15, 2019	Imperial College London, London, United Kingdom		https://ClinicalTrials.gov/show/NCT03595722
197	NCT00036829	Improving Pain Management in Patients With Nonhematologic Cancer		Completed	No Results Available	Pain|Unspecified Adult Solid Tumor, Protocol Specific	Procedure: pain therapy		Inflexxion, Inc.|National Cancer Institute (NCI)	All	18 Years and older   (Adult, Older Adult)	Not Applicable		Industry|NIH	Interventional		INFLEXXION-50|CDR0000069327|NCI-V02-1698	March 2002		April 2003	January 27, 2003		July 18, 2013	Inflexxion, Newton, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT00036829
198	NCT03281161	Sun Safe Workplaces: Assessment of Benefits and Costs of a Policy Intervention	SSW2	Completed	No Results Available	Skin Cancer	Behavioral: Sun Safe Workplaces Program|Behavioral: Attention Control	Survey of sun protection practices by employees.|Observational checklist to review sun protections items within the workplace.|In-depth manager interview to assess relationship of employer sun safety actions to employee sun safety.|In-depth manager survey to assess relationship of employer sun safety actions to employee sun safety.|Extraction of costs from parent study ledgers to conduct economic analysis of the SSW intervention.|In-depth manager interview to conduct economic analysis of the SSW intervention.|Analysis of employee surveys to compare the impact of workplaces implementing education-only versus education plus policy adoption on employee sun safety practices.	Klein Buendel, Inc.|National Cancer Institute (NCI)|Kaiser Foundation Research Institute|University of Colorado, Denver	All	18 Years and older   (Adult, Older Adult)	Not Applicable	1990	Industry|NIH|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention	5R01CA187191-02|0284	February 27, 2015	April 30, 2017	July 31, 2017	September 13, 2017		October 26, 2017	Kaiser Foundation Research Institute, Oakland, California, United States|University of Colorado Denver, Aurora, Colorado, United States		https://ClinicalTrials.gov/show/NCT03281161
199	NCT03278340	Using Technology to Scale-Up an Occupational Sun Protection Policy Program	SSW-T	Enrolling by invitation	No Results Available	Skin Cancer	Behavioral: Sun Safe Workplaces - Technology|Behavioral: Sun Safe Workplaces -In Person	Implementation of Occupational Sun Protection Policy|Implementation of Sun Safety Education|Economic Evaluation of the SSW-IP and SSW-T Intervention Programs|Changes in Workplace Environment for Sun Safety|Other Policy-related Measures|Employees Sun Protection Practices	Klein Buendel, Inc.|Kaiser Permanente|University of Colorado, Denver|National Cancer Institute (NCI)	All	18 Years and older   (Adult, Older Adult)	Not Applicable	11394	Industry|Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention	R01CA210259|0316	May 30, 2018	June 30, 2022	July 31, 2022	September 11, 2017		June 13, 2019	Kaiser Foundation Research Institute, Oakland, California, United States|University of Colorado Denver, Aurora, Colorado, United States|Klein Buendel, Inc., Golden, Colorado, United States		https://ClinicalTrials.gov/show/NCT03278340
200	NCT02620228	Identification of Liver Tumours Using BIP - Biopsy System		Completed	No Results Available	Liver Biopsy	Device: BIP Biopsy System	Difference in mean between measured bioimpedance spectra from tumorous and nontumorous tissue	Injeq Ltd	All	18 Years and older   (Adult, Older Adult)	Not Applicable	26	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	INJ-LIVERB-01	June 9, 2016	December 31, 2017	November 2018	December 2, 2015		November 21, 2018	Helsinki University Hospital, Department of Radiology, Helsinki, HUS, Finland		https://ClinicalTrials.gov/show/NCT02620228
201	NCT03775473	PROgastrine COlon DEpistage		Recruiting	No Results Available	Colon Cancer Screening|Healthy Person	Diagnostic Test: progastrin	progastrin rate	ECS-Progastrin SA|Centre Hospitalier Princesse Grace	All	50 Years to 80 Years   (Adult, Older Adult)	Not Applicable	1100	Industry|Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	PROCODE	February 7, 2019	January 2021	March 2021	December 14, 2018		March 8, 2019	Centre Hospitalier Princesse Grace, Monaco, MC, France		https://ClinicalTrials.gov/show/NCT03775473
202	NCT02328807	Focal Prostate Radio-Frequency Ablation		Active, not recruiting	Has Results	Prostate Cancer	Procedure: Radio-Frequency Ablation (RFA)	Negative Biopsy Rate at 6 Months After Focal Bipolar Radio-Frequency Ablation (RFA)|Number of Participants With Treatment Related Adverse Events|Completion of Quality of Life (QOL) Assessment Questionnaires at Six Months	H. Lee Moffitt Cancer Center and Research Institute|Trod Medical N.V.	Male	18 Years and older   (Adult, Older Adult)	Not Applicable	6	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MCC-17753	December 29, 2014	May 10, 2018	April 2020	December 31, 2014	June 3, 2019	August 7, 2019	H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/07/NCT02328807/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT02328807
203	NCT02754661	Evaluation the Efficacy of Colon Capsule Endoscopy (CCE) Versus Computed Tomographic Colonography (CTC) in the Identification of Colonic Polyps in a Screening Population.	TOPAZ	Completed	No Results Available	Colorectal Cancer Screening	Device: COLON Capsule endoscopy|Device: Computed Tomographic Colonography	Diagnostic yield by CCE as compared to CTC. Diagnostic yield of CCE/CTC will be calculated in relation to the confirmatory Optical colonoscopy results|Accuracy measures of CCE versus CTC in the detection of polyps ≥6 mm will be assessed in relation to the confirmatory OC results on a "per subject" basis: Negative predictive value (NPV), Positive predictive value (PPV); Sensitivity; Specificity	Medtronic - MITG	All	50 Years to 75 Years   (Adult, Older Adult)	Not Applicable	320	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	COVGIC20543|MA-213	September 2016	August 7, 2018	August 7, 2018	April 28, 2016		January 29, 2019	University of South Alabama, Mobile, Alabama, United States|Borland-Groover Clinic, Jacksonville, Florida, United States|Loyola University Medical Center, Chicago, Illinois, United States|Indiana University Hospital, Indianapolis, Indiana, United States|Indianapolis Gastroenterology and Hepatology, Indianapolis, Indiana, United States|Baystate Hospital, Springfield, Massachusetts, United States|Mayo Clinic Rochester, Rochester, Minnesota, United States|Clinical Research Professionals, Saint Louis, Missouri, United States|NYU, New York, New York, United States|Columbia University, New York, New York, United States|Asheville Gastroenterology Associates, Asheville, North Carolina, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Virginia Gastroenterology institute, Suffolk, Virginia, United States		https://ClinicalTrials.gov/show/NCT02754661
204	NCT02248519	Laparoscopic Versus Open Gastrectomy for Gastric Cancer	LOGICA	Active, not recruiting	No Results Available	Gastric Cancer	Procedure: Open Gastrectomy|Procedure: Laparoscopic Gastrectomy	Post-operative hospital stay|Mortality|Post-operative morbidity|Cost-effectiveness|Quality of Life|Readmissions	UMC Utrecht|ZonMw: The Netherlands Organisation for Health Research and Development|Johnson & Johnson	All	18 Years and older   (Adult, Older Adult)	Not Applicable	210	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NL47444.041.14	December 2014	October 2023	October 2023	September 25, 2014		August 28, 2018	Zorggroep Twente Almelo, Almelo, Netherlands|Meander Medical Center, Amersfoort, Netherlands|VU University Medical Center, Amsterdam, Netherlands|Academic Medical Center, Amsterdam, Netherlands|Gelre Hospital, Apeldoorn, Netherlands|Catharina Hospital, Eindhoven, Netherlands|Leiden University Medical Center, Leiden, Netherlands|Erasmus Medical Center, Rotterdam, Netherlands|Orbis Medical Center, Sittard-Geleen, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands		https://ClinicalTrials.gov/show/NCT02248519
205	NCT03443258	Needs Assessment Tool Integrated in Clinical Practice of Head and Neck Cancer Rehabilitation	NEAT	Recruiting	No Results Available	Head and Neck Neoplasms	Other: Needs assesment tool integrated in nursing consultation.	Change in Health Related Quality of Life, from baseline to 9, 21 and until 67 days post surgery|Change in Symptom Burden from baseline to 2, 14 and 60 days post-surgery	Rigshospitalet, Denmark|Novo Nordisk A/S|Danish Nurses Organisation	All	16 Years and older   (Child, Adult, Older Adult)	Not Applicable	128	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	05781	June 11, 2018	July 31, 2019	September 30, 2019	February 23, 2018		September 3, 2018	Dept. Of Otorhinolaryngology, Head and Neck Surgery and Audiology, Copenhagen, Denmark	"Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/58/NCT03443258/Prot_000.pdf	https://ClinicalTrials.gov/show/NCT03443258
206	NCT03198117	Huaier Granule for Prevention of Recurrence and Metastasis of Stage II and III Non-small Cell Lung Cancer (NSCLC)		Active, not recruiting	No Results Available	Non-small Cell Lung Cancer	Drug: Huaier Granule|Other: placebo	disease-free survival|overall survivals|Quality of Life|KPS|ECOG-PS|CEA|CYFRA21-1|SCC	Qidong Gaitianli Medicines Co., Ltd	All	18 Years to 70 Years   (Adult, Older Adult)	Not Applicable	798	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	HE-201701	April 25, 2017	June 1, 2019	June 1, 2022	June 23, 2017		June 23, 2017	Du Ying Ying, Hefei, Anhui, China		https://ClinicalTrials.gov/show/NCT03198117
207	NCT02109913	Analysis of Tumor Tissue and Circulating Genetic Material in the Blood to Obtain Further Insight in the Effectiveness of Everolimus When Combined With Exemestane		Active, not recruiting	No Results Available	Hormone Receptor Positive Malignant Neoplasm of Breast|Metastatic Breast Cancer	Drug: Everolimus plus Exemestane	Biomarker Evaluation from Primary Tumor Tissue, New Tumor Biopsies and Blood Samples|Progression-free survival|Number of Participants with Adverse Events as a Measure of Safety and Tolerability	VU University Medical Center|Borstkanker Onderzoek Groep|Novartis	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	175	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	EudraCT 2013-004120-11|BOOG 2013-06	March 2014	January 2019	January 2019	April 10, 2014		May 10, 2018	VU University Medical Center, Amsterdam, Noord-Holland, Netherlands|Flevoziekenhuis, Almere, Netherlands|BovenIJ Ziekenhuis, Amsterdam, Netherlands|The Netherlands Cancer Institute, Amsterdam, Netherlands|Gelre, Apeldoorn, Netherlands|Rijnstate Ziekenhuis, Arnhem, Netherlands|Amphia Ziekenhuis, Breda, Netherlands|Reinier de Graaf Groep, Delft, Netherlands|Haga, Den Haag, Netherlands|MC Haaglanden, Den Haag, Netherlands|Gemini, Den Helder, Netherlands|Deventer Ziekenhuis, Deventer, Netherlands|Maxima Medisch Centrum, Eindhoven, Netherlands|Groene Hart Ziekenhuis, Gouda, Netherlands|Tergooi ziekenhuizen, Hilversum, Netherlands|Spaarne Ziekenuis, Hoofddorp, Netherlands|MC Leeuwarden, Leeuwarden, Netherlands|LUMC, Leiden, Netherlands|Canisius Ziekenhuis, Nijmegen, Netherlands|Bravis, Roosendaal And Bergen Op Zoom, Netherlands|Erasmus University Medical Center, Rotterdam, Netherlands|Ikazia, Rotterdam, Netherlands|Vlietland, Schiedam, Netherlands|Orbis MC, Sittard, Netherlands|Elisabeth - Tweesteden, Tilburg, Netherlands|UMC Utrecht, Utrecht, Netherlands|VieCuri, Venray, Netherlands|Isala, Zwolle, Netherlands		https://ClinicalTrials.gov/show/NCT02109913
208	NCT00462501	Combination Chemotherapy and Bevacizumab With or Without Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer		Completed	Has Results	Colorectal Cancer	Biological: bevacizumab|Drug: fluorouracil|Drug: leucovorin calcium|Drug: oxaliplatin|Procedure: conventional surgery|Radiation: radiation therapy	Complete Pathologic Response	Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI)|Genentech, Inc.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	35	Other|NIH|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	07-021|P30CA008748|MSKCC-07021	March 2007	February 2014	February 2014	April 19, 2007	January 20, 2016	January 20, 2016	Memorial Sloan-Kettering Cancer Center, New York, New York, United States		https://ClinicalTrials.gov/show/NCT00462501
209	NCT02101970	Weight Loss Plus Omega-3 Fatty Acids or Placebo in High Risk Women		Completed	No Results Available	Breast Cancer	Dietary Supplement: Omega-3 Fatty Acids|Other: Placebo Capsule|Other: Diet and Exercise	Dropout rate|Study design feasibility|Modulation of breast cancer risk biomarkers|Modulation of breast cancer risk biomarkers in benign breast tissue|Weight gain|Change in Gut Microbiome	Carol Fabian, MD|DSM Nutritional Products, Inc.|University of Kansas Medical Center	Female	45 Years to 70 Years   (Adult, Older Adult)	Not Applicable	46	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	STUDY00000703	March 2014	May 2016	August 27, 2018	April 2, 2014		February 6, 2019	University of Kansas Medical Center, Breast Cancer Prevention Center, Kansas City, Kansas, United States		https://ClinicalTrials.gov/show/NCT02101970
210	NCT02735252	PROMOTE: Identifying Predictive Markers of Response for Prostate Cancer		Recruiting	No Results Available	Prostate Cancer	Other: Systemic therapy	Progression-Free Survival|PSA Response Rate|Objective Response Rate|Overall Survival|Somatic Mutations	University of California, San Francisco|Prostate Cancer Foundation|Strata Oncology	Male	18 Years and older   (Adult, Older Adult)	Not Applicable	600	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	155518|NCI-2018-02052	April 2016	December 2020	December 2021	April 12, 2016		July 22, 2019	University of California, San Francisco, San Francisco, California, United States		https://ClinicalTrials.gov/show/NCT02735252
211	NCT03245411	Assessment of Multi-Level Interventions to Improve Adherence to Oral Medications in Cancer Patients		Recruiting	No Results Available	Cancer	Behavioral: Intervention	Adherence to oral chemotherapy|Frequency of medication refills|Adherence to scheduled follow-up medical care visits|Healthcare utilization	Albert Einstein Healthcare Network|Merck Sharp & Dohme Corp.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	110	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other	4950 EXP	July 20, 2017	December 20, 2018	July 20, 2019	August 10, 2017		June 26, 2018	Albert Einstein Healthcare Network, Philadelphia, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT03245411
212	NCT03249584	OsteoCool Tumor Ablation Post-Market Study	OPuS One	Recruiting	No Results Available	Metastasis Spine|Metastasis to Bone	Device: OsteoCool™ RF Ablation	Improvement of worst pain score|Change in worst pain score	MedtronicNeuro	All	18 Years and older   (Adult, Older Adult)	Not Applicable	250	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MDT16075	October 12, 2017	April 30, 2019	November 30, 2021	August 15, 2017		May 20, 2019	Banner - University Medical Center Phoenix, Phoenix, Arizona, United States|Saint Jude Medical Center, Fullerton, California, United States|Moffitt Cancer Center, Tampa, Florida, United States|Emory University School of Medicine, Atlanta, Georgia, United States|Northside Hospital, Cumming, Georgia, United States|University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Renown Regional Medical Center, Reno, Nevada, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|University of Texas (UT) Southwestern Medical Center, Dallas, Texas, United States|Vascular Institute of Virginia, Woodbridge, Virginia, United States|Sunnybrook Health Science Centre, Toronto, Canada|Hôpitaux Universitaires de Strasbourg - Nouvel Hôpital Civil, Strasbourg, France|Universitätsklinikum Leipzig AöR, Leipzig, Germany|Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg		https://ClinicalTrials.gov/show/NCT03249584
213	NCT02515006	Impact of Homeopathy for Persistent Insomnia in Patients With Cancer		Completed	No Results Available	Chronic Insomnia|Cancer	Other: Homeopathy Medicine	Changes in sleep efficiency on the Insomnia Severity Index|Change in Anxiety and Depression on Hospital Anxiety Depression Scale|Change in Quality of Life on Short Form-36 Scale	Adwin Life Care|Center For Homeopathy Research, India|Sonal Foundation, India	All	18 Years to 45 Years   (Adult)	Not Applicable	160	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	Adwin/chr/1121	September 2014	April 2015	June 2015	August 4, 2015		August 4, 2015	Center for Homeopathy Research, Ahmedabad, Gujarat, India|Center for Homeopathy Research, Jaipur, Rajasthan, India		https://ClinicalTrials.gov/show/NCT02515006
214	NCT02135484	Radium 223 in Castrate Resistant Prostate Cancer Bone Metastases		Active, not recruiting	No Results Available	Prostate Cancer	Drug: Alpharadin	Biomarkers in Predicting Overall Survival	M.D. Anderson Cancer Center|Bayer|Prostate Cancer Foundation	Male	18 Years and older   (Adult, Older Adult)	Not Applicable	25	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2013-0933|NCI-2014-02016	September 19, 2014	September 2019	September 2020	May 12, 2014		May 22, 2019	University of Texas MD Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT02135484
215	NCT03400748	ANET Electrosurgery Applicator Pilot Evaluation Study		Recruiting	No Results Available	Lung Cancer|Lung Cancer Metastatic	Device: RF Ablation	ANET related peri-procedural Adverse Events	Spiration, Inc.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	20	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility	15	April 23, 2018	December 2020	December 2020	January 17, 2018		June 21, 2019	Duke University Medical Center, Durham, North Carolina, United States|MD Anderson Cancer Center, Houston, Texas, United States|Toronto General Hospital, Toronto, Ontario, Canada		https://ClinicalTrials.gov/show/NCT03400748
216	NCT00981578	ExAblate Conformal Bone System Treatment of Metastatic Bone Tumors for the Palliation of Pain		Active, not recruiting	No Results Available	Bone Metastases	Device: ExAblate 2100	Adverse device effects|Change in scores from baseline|Change Brief Pain Inventory - Pain Interference|Changes in pain medications	InSightec	All	18 Years and older   (Adult, Older Adult)	Not Applicable	50	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	BM010	September 2009	June 2020	June 2020	September 22, 2009		August 2, 2019	City of Hope, Duarte, California, United States|University of California San Francisco, San Francisco, California, United States|Stanford University Medical Center, Stanford, California, United States|Methodist Hospital Research Institute, Houston, Texas, United States|University of Virginia, Charlottesville, Virginia, United States		https://ClinicalTrials.gov/show/NCT00981578
217	NCT02351089	Probiotics in Radiation-treated Gynecologic Cancer	ProRad	Recruiting	No Results Available	Gastrointestinal Toxicity|Gynecologic Cancer	Dietary Supplement: Capsules placebo|Dietary Supplement: Capsules probiotic powder and corn starch	Change in incidence of loose/watery stools	Probi AB	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	200	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	ProRad	February 2015	December 2018	December 2020	January 30, 2015		April 13, 2018	Dept of Oncology, Lund, Sweden		https://ClinicalTrials.gov/show/NCT02351089
218	NCT04037852	Robotic Versus Conventional or Endoscopic Nipple Sparing Mastectomy in the Management of Breast Cancer-Prospective Study	RCENSM-P	Not yet recruiting	No Results Available	Breast Cancer Female	Device: robotic assisted nipple sparing mastectomy|Procedure: Endoscopic assisted nipple sparing mastectomy|Procedure: Conventional nipple sparing mastectomy	Operation time|Morbidity and complications|Nipple areolar complex ischemia/necrosis grading|Surgical margin involvement|Aesthetic outcome evaluation-Patient reported cosmetic outcome results|Blood loss during operations|Hospital stay|Resection mastectomy weight|Reconstruction implant volume|Pain assessments|Cost- analysis of C-NSM versus R-NSM or E-NSM|Disease free survival|Overall Survival	Changhua Christian Hospital|Intuitive Surgical|Ministry of Science and Technology, Taiwan	Female	20 Years to 70 Years   (Adult, Older Adult)	Not Applicable	180	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CCH-IRB-190414-P|108-2314-B-371-006-	September 1, 2019	August 31, 2021	December 31, 2021	July 30, 2019		July 30, 2019	Changhua Christian Hospital, Changhua, Taiwan|Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan, Taichung, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan|Shuang-Ho Hospital - Taipei Medical University, Taipei, Taiwan|Taipei Municipal Wan Fang Hospital, Tawian, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Tri-Service General Hospital, Taipei, Taiwan|Chang Gung Memorial Hospital, Taoyuan, Taiwan, Taoyuan, Taiwan		https://ClinicalTrials.gov/show/NCT04037852
219	NCT00612560	Flaxseed, Aromatase Inhibitors and Breast Tumor Characteristics	FABrC	Completed	Has Results	Breast Cancer	Drug: Anastrozole|Dietary Supplement: flaxseed|Drug: Placebo	Expression of Estrogen Receptor (ER-beta)|Progesterone Receptor (PR) Expression|Human Epidermal Growth Factor Receptor 2 (Her2) Expression|Growth Hormone Serum Levels IGF-1	Roswell Park Cancer Institute|National Center for Complementary and Integrative Health (NCCIH)|AstraZeneca	Female	18 Years to 85 Years   (Adult, Older Adult)	Not Applicable	28	Other|NIH|Industry	Interventional	Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science	I 99507|I99507|R21AT004024-01	November 2007	January 2011	April 2014	February 11, 2008	August 16, 2017	October 12, 2017	Roswell Park Cancer Institute, Buffalo, New York, United States		https://ClinicalTrials.gov/show/NCT00612560
220	NCT03643640	Evaluating a Novel Web-based Intervention for Breast Cancer Survivors	OPTIMUNE	Recruiting	No Results Available	Breast Cancer	Behavioral: Optimune|Other: Care-As-Usual	Determination of Quality of Life using the WHOQOL-BREF|Determination of Physical Activity using the International Physical Activity Questionnaire|Determination of Diet Quality using the Food Quality Questionnaire|Determination of cancer-related fatigue using the Brief Fatigue Inventory Questionnaire|Determination of cancer-related emotional stress|Determination of depression|Determination of anxiety|Determination of fear of progression|Determination of insomnia|Determination of usefulness of the program|Determination of Negative Effects	Technical University of Dortmund|University of Leipzig|Gaia AG	Female	30 Years to 70 Years   (Adult, Older Adult)	Not Applicable	360	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	Optimune Trial Add-on	September 1, 2018	June 1, 2020	September 1, 2020	August 23, 2018		April 10, 2019	Technical University of Dortmund, Leibniz Research Centre for Working Environment and Human Factors, Dortmund, Germany|University Medical Center Leipzig, Department of Medical Psychology and Medical Sociology, Section Psychosocial Oncology, Leipzig, Germany		https://ClinicalTrials.gov/show/NCT03643640
221	NCT00894933	Performance Evaluation of the AMS CONTINUUM™ Device		Completed	Has Results	Prostate Cancer	Device: CONTINUUM™	Safety - Infection That Requires IV Antibiotics or Re-hospitalization|Successful Device Placement|Functionally Adequate Vesico-urethral Anastomosis Within 21 Days Post-Device Placement in Subjects With Successful Device Placement|Safety - Perforation of the Bowel or Bladder|Safety - Creation of a False Passage|Safety - Urinary Retention Requiring Catheterization Post-Device Removal|Safety - Mechanical Failure, Extrusion, Erosion, or Migration of the Device Requiring Surgical or Medical Intervention|Safety - Separation/Disruption of the Anastomosis Requiring Corrective Intervention|Safety - Bladder Neck Contracture|Intraoperative/Postoperative Parameters - Estimated Blood Loss|Extravasation During Post-placement Cystogram at Either the First or Second Device Removal Attempts|Intraoperative/Postoperative Parameters - Total Device Placement Time|Intraoperative/Postoperative Parameters - Total Radical Prostatectomy Operative Time	American Medical Systems	Male	40 Years and older   (Adult, Older Adult)	Not Applicable	33	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PE0814|G090011	May 2009	December 2010	December 2010	May 7, 2009	March 13, 2017	February 21, 2018	Arkansas Urology, Little Rock, Arkansas, United States|Lahey Clinic Medical Center, Burlington, Massachusetts, United States|Center for Urology, Rochester, New York, United States|Urologic Consultants of Southeastern Pennsylvania, Philadelphia, Pennsylvania, United States|Urology Clinics of North Texas, Dallas, Texas, United States|Urology San Antonio Research PA, San Antonio, Texas, United States		https://ClinicalTrials.gov/show/NCT00894933
222	NCT01951976	Yoga for Aromatase Inhibitor-associated Joint Pain		Completed	No Results Available	Breast Cancer	Other: Questionnaires|Other: Yoga Classes	Rate of Study Enrollment|Rate of Study Completion|Occurrence of Reduced Pain Severity|Occurrence of Relief from Other Side Effects	H. Lee Moffitt Cancer Center and Research Institute|Pfizer	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	16	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	MCC-17592	September 2013	March 2015	June 2016	September 27, 2013		July 4, 2016	H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States		https://ClinicalTrials.gov/show/NCT01951976
223	NCT03448250	Evaluating a Novel Web-based Intervention for Breast Cancer Survivors	OPTIMUNE	Recruiting	No Results Available	Breast Cancer	Behavioral: Optimune|Other: Care-As-Usual	concentration of C-reactive protein (CRP)|circulating Interleukin (IL) 6|circulating Tumor necrosis factor (TNF)-α|stimulated IL-6|stimulated TNF-α|Plasma Concentrations of Cytokines|Concentration of secreted Cytokines after Phorbol-12-myristate-13-acetate (PMA) stimulation of peripheral blood mononuclear cells|Concentration of secreted Cytokines after Lipopolysaccharide (LPS) Stimulation of peripheral blood mononuclear cells|Circulating numbers of Lymphocytes, Monocytes, Granulocytes|Phenotypic analysis of T and NK cell subsets|Cortisol awakening response (CAR)|Determination of cancer-related fatigue using the Brief Fatigue Inventory Questionnaire|Determination of cancer-related emotional stress|Determination of depression|Determination of anxiety|Determination of fear of progression|Determination of usefulness of the program|Determination of Negative Effects	Technical University of Dortmund|University of Leipzig|Gaia AG	Female	30 Years to 70 Years   (Adult, Older Adult)	Not Applicable	150	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	Optimune Trial	March 16, 2018	September 2019	March 2020	February 28, 2018		May 4, 2018	Technical University of Dortmund, Leibniz Research Centre for Working Environment and Human Factors, Dortmund, Germany|University Medical Center Leipzig, Department of Medical Psychology and Medical Sociology, Section Psychosocial Oncology, Leipzig, Germany		https://ClinicalTrials.gov/show/NCT03448250
224	NCT00862186	Self-Management of Cancer-Related Fatigue by Adolescents		Completed	Has Results	Neoplasms|Fatigue	Behavioral: 'Fatigue Facts & Fixes'	Change From Baseline in Fatigue Scale-Adolescent (FS-A) Score Categorized According to 1-5 Rating Scale of Resource Use and Resource Helpfulness.	Seattle Children's Hospital|Alex's Lemonade Stand Foundation	All	13 Years to 18 Years   (Child, Adult)	Not Applicable	15	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	SCH-12551	April 2009	December 2010	December 2010	March 16, 2009	May 9, 2012	January 15, 2013	Seattle Children's Hospital, Seattle, Washington, United States		https://ClinicalTrials.gov/show/NCT00862186
225	NCT02971709	Use of Shade in U.S. and Australian City Parks	Shade	Completed	No Results Available	Skin Cancer	Behavioral: Shade Sail	Observed Use of Passive Recreation Area by Adults|Solar Ultraviolet Radiation Level	Klein Buendel, Inc.|Cancer Council Victoria	All	18 Years and older   (Adult, Older Adult)	Not Applicable	144	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	CA140367|0265	July 2010	May 31, 2017	May 31, 2017	November 23, 2016		July 25, 2017	Klein Buendel, Inc., Golden, Colorado, United States|Cancer Council Victoria, Melbourne, Victoria, Australia		https://ClinicalTrials.gov/show/NCT02971709
226	NCT02359123	Cannabics Capsules as Treatment to Improve Cancer Related CACS in Advanced Cancer Patients		Completed	No Results Available	Cancer Cachexia|Atypical Anorexia Nervosa	Other: Cannabics capsules	weight gain of ≥10% from baseline weight assessed.|Improvement in appetite|Nutritional intake|Reduction in TNF-alpha|Correlation between THC levels and primary outcome,|QOL will be assessed using the European Organization of Research and Treatment of Cancer core questions on the Quality of Life Questionnaire, version 2 (QLQ-C30) and the Anorexia/Cachexia Therapy (FAACT) questionnaire.|Safety assessment for early psychiatric side-effects by the Community Assessment of Psychic Experiences|Evaluation of muscle strength	Cannabics Pharmaceuticals Inc.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	24	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CNBX-001	November 2016	April 1, 2018	April 1, 2018	February 9, 2015		April 10, 2018	Rambam MC, Haifa, Israel		https://ClinicalTrials.gov/show/NCT02359123
227	NCT00038012	rhTPO Mobilized Auto Cryo Platelets For GYN Patients Receiving Carboplatin		Completed	No Results Available	Neoplasms, Gynecologic	Drug: Thrombopoietin|Procedure: Platelet-pheresis|Drug: Carboplatin	Response Rate	M.D. Anderson Cancer Center|Pharmacia|LifeCell	Female	15 Years and older   (Child, Adult, Older Adult)	Not Applicable	33	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GYN97-310	July 23, 1999	June 2004	June 2004	May 27, 2002		November 1, 2018	MD Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT00038012
228	NCT02704104	Safety and Performance Evaluation of the Topical Hemostatic Device (AC5™) Following Excision of Skin Lesions		Completed	Has Results	Skin Neoplasms	Device: AC5 Topical Hemostatic Device	Number of Participants With Treatment-emergent Adverse Events Related to Clinical Investigation Product During the 30 Days of Follow-up|Median Time to Hemostasis (Seconds)|Time to Hemostasis in Seconds Per Square Centimeter Wound Area|Number of Wounds With ASEPSIS Wound Scores of 0 at Day 7 and Day 30	ARCH Therapuetics	All	18 Years to 85 Years   (Adult, Older Adult)	Not Applicable	46	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Supportive Care	AC5-1	February 2016	June 2016	June 2016	March 9, 2016	August 7, 2018	August 7, 2018	University College Hospital, Galway, Ireland		https://ClinicalTrials.gov/show/NCT02704104
229	NCT04049305	Robotic Versus Conventional or Endoscopic Nipple Sparing Mastectomy for Breast Cancer	RCENSM-R	Not yet recruiting	No Results Available	Breast Cancer Female	Device: Robotic assisted nipple sparing mastectomy (R-NSM)|Procedure: conventional nipple sparing mastectomy (C-NSM)|Procedure: Endoscopic assisted nipple sparing mastectomy (E-NSM)	Operation time|Wound healing status|Skin blister formation|Skin flap ischemia/necrosis rate|Implant loss rate|Post operation Bleeding/hematoma rate|Seroma formation rate|Grade of Nipple areolar complex ischemia/necrosis|Rate of Surgical margin involvement in specimen pathologic examination|Aesthetic outcome evaluation-Patient reported cosmetic outcome results|Blood loss during operation|Hospital stay|Mean mastectomy weight|Reconstruction implant volume|Cost- analysis of C-NSM versus R-NSM or E-NSM|Disease free Survival|Overall survival	Changhua Christian Hospital|Ministry of Science and Technology, Taiwan|Intuitive Surgical	Female	20 Years to 80 Years   (Adult, Older Adult)	Not Applicable	900	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CCH-IRB-190414-R|MOST 108-2314-B-371-006-	August 15, 2019	February 28, 2020	December 31, 2020	August 8, 2019		August 8, 2019	European Institute of Oncology, Milan, Italy|Severance Hospital, Seoul, Korea, Republic of|Changhua Christian Hospital, Changhua, Taiwan|Kaohsiung Medical University Hospital, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|Shuang-Ho Hospital - Taipei Medical University, Taipei county, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan|Taipei Municipal Wan Fang Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Tri-Service General Hospital, Taipei, Taiwan|Chang Gung Memorial Hospital, Taoyuan, Taiwan		https://ClinicalTrials.gov/show/NCT04049305
230	NCT03651037	Physical Activity Platform to Improve Bone Health in Cancer Survivors	THRIVORS+BH	Recruiting	No Results Available	Breast Cancer|Physical Activity|Bone Health	Behavioral: Thrivors+BH	Number of participants to complete exercise sessions and surveys	Thrivors Inc|Oregon Health and Science University|Masonic Cancer Center, University of Minnesota|National Cancer Institute (NCI)	Female	40 Years to 70 Years   (Adult, Older Adult)	Not Applicable	50	Industry|Other|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	THRIVORSBH-01|R43CA224412	January 21, 2019	August 19, 2019	August 19, 2019	August 29, 2018		January 23, 2019	Thrivors Inc, Saint Paul, Minnesota, United States		https://ClinicalTrials.gov/show/NCT03651037
231	NCT00617370	Dose-Dense Epirubicin and Cyclophosphamide (EC) Followed by Paclitaxel in Breast Cancer: Feasibility		Completed	No Results Available	Breast Cancer|Adenocarcinoma of the Breast	Drug: epirubicin, cyclophosphamide, Paclitaxel,	To evaluate the feasibility and safety of this dose-dense regimen.	Memorial Sloan Kettering Cancer Center|Amgen|Pfizer	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	38	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	04-065	November 2004	July 2005	June 2008	February 18, 2008		December 23, 2015	Memorial Sloan Kettering Cancer Center, New York, New York, United States		https://ClinicalTrials.gov/show/NCT00617370
232	NCT02291198	Measurement of NK Cell Activity in Whole Blood in Subjects Being Screened for Colorectal Cancer Using Colonoscopy		Completed	No Results Available	Natural Killer Cell Cytokine Production	Device: NK Vue: NK cell activity in stimulated whole blood	NK cell activity	ATGen Canada Inc|Maisonneuve-Rosemont Hospital	All	40 Years and older   (Adult, Older Adult)	Not Applicable	1081	Industry|Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening	ATG-001	October 2014	January 2016	March 2017	November 14, 2014		August 14, 2017	Hopital Maisonneuve-Rosemont, Montreal, Quebec, Canada		https://ClinicalTrials.gov/show/NCT02291198
233	NCT02419807	Comparison of Use of Indocyanine Green and 99mTc-labeled Radiotracer for Axillary Lymphatic Mapping in Patients With Breast Cancer		Completed	No Results Available	Stage I Breast Cancer|Stage II Breast Cancer	Drug: Indocyanine Green Solution|Radiation: Technetium Tc-99m Sulfur Colloid|Procedure: Lymphoscintigraphy|Procedure: Axillary Lymph Node Biopsy	Proportion of sentinel lymph nodes (SLNs) flagged by the two methods	Case Comprehensive Cancer Center|National Cancer Institute (NCI)|Mitaka USA, Inc.	Female	Child, Adult, Older Adult	Not Applicable	102	Other|NIH|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	CASE10114	February 17, 2015	February 2019	February 2019	April 17, 2015		March 12, 2019	Cleveland Clinic Taussig Cancer Instititute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States		https://ClinicalTrials.gov/show/NCT02419807
234	NCT03322072	Calypso Guided High Precision Stereotactic Ablative Radiosurgery for Lung TUmours Using Real-Time Tumour Tracking & Respiratory Gating	GPS	Recruiting	No Results Available	Lung Cancer Stage I|Lung Cancer Stage II|Lung Cancer, Nonsmall Cell|Lung Cancer Recurrent|Lung Cancer Stage IV	Device: Real-Time Position Transponder Beacons	Mean within patient difference in PTV volumes|Patient self-reported quality of life|Acute and late toxicity assessment using the Common Terminology Criteria for Adverse Events (CTCAE version 4.0)|RT doses to Thoracic Organs at Risk|Tumour Local Control|Progression Free Survival|Overall Survival	CancerCare Manitoba|Varian Medical Systems	All	18 Years to 85 Years   (Adult, Older Adult)	Not Applicable	28	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	RRIC 2017-014	November 23, 2017	December 2021	December 2024	October 26, 2017		June 12, 2019	CancerCare Manitoba, Winnipeg, Manitoba, Canada|Health Sciences Center, Winnipeg, Manitoba, Canada	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/72/NCT03322072/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT03322072
235	NCT01063283	Dose Escalation of Bevacizumab With Ambulatory Blood Pressure Monitoring in Patients With Advanced Non-squamous NSCLC	AVF4759	Completed	No Results Available	Advanced Non-squamous Non-Small Cell Lung Cancer	Drug: Carboplatin and Pemetrexed with Bevacizumab 7.5 mg/kg|Drug: Carboplatin and Pemetrexed with Bevacizumab 15 mg/kg	Does a higher dose of bevacizumab have any effect on changes in blood pressure|Response rate|Change in tumor size|Progression free survival	University of Chicago|Genentech, Inc.	All	18 Years to 89 Years   (Adult, Older Adult)	Not Applicable	70	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	10-014-B	March 2010	June 2016	June 2016	February 5, 2010		June 1, 2017	The University of Chicago Medical Center, Chicago, Illinois, United States|North Shore University Health System, Evanston, Illinois, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States		https://ClinicalTrials.gov/show/NCT01063283
236	NCT01831024	Efficacy and Safety of Dignicap System for Preventing Chemotherapy Induced Alopecia		Active, not recruiting	No Results Available	Chemotherapy Adjuvant|Breast Cancer	Device: Dignicap System	Hair loss|Tolerability|Adverse events|Hair regrowth|Quality of Life	Target Health Inc.	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	110	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	DIG-001	July 2013	October 2020	December 2020	April 15, 2013		October 19, 2016	UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States|Beth Israel Medical Center, Comprehensive Cancer Center, New York, New York, United States|Weill Cornell Breast Center, New York, New York, United States|Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States		https://ClinicalTrials.gov/show/NCT01831024
237	NCT03017183	Detection of Heterogeneity in Central Lung Cancer - EBUS-TBNA and ctDNA Analysis vs. Endobronchial Forceps Biopsy		Completed	No Results Available	Lung Neoplasms	Procedure: EBUS-TBNA|Procedure: Endobronchial forceps biopsy	Number of detected mutations	Wissenschaftliches Institut Bethanien e.V|AstraZeneca|Institute of Pathology, University Clinic Düsseldorf	All	18 Years to 84 Years   (Adult, Older Adult)	Not Applicable	30	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	WI_EBUS-TBNA_16-226	January 2, 2017	July 31, 2017	July 31, 2017	January 11, 2017		October 30, 2018	Krankenhaus Bethanien gGmbH, Solingen, NRW, Germany		https://ClinicalTrials.gov/show/NCT03017183
238	NCT00815685	A Pilot Study of Eicosapentaenoic Acid (EPA) in Patients With Cancer Cachexia		Completed	Has Results	Cancer Cachexia	Drug: Eicosapentaenoic Acid	Change in Serum Albumin|Number of Participants With Proteasome Activity That Was Inhibited in the Range of 6%-29%.	H. Lee Moffitt Cancer Center and Research Institute|GlaxoSmithKline	All	25 Years to 80 Years   (Adult, Older Adult)	Not Applicable	36	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MCC-15190	July 2007	March 2010	August 2010	December 30, 2008	September 8, 2011	March 23, 2017	Martin Memorial, Stuart, Florida, United States|H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States		https://ClinicalTrials.gov/show/NCT00815685
239	NCT01679483	Efficacy Study of FloSeal for Prevention of Lymphocele After Lymphadenectomy for Gynecologic Cancer		Completed	No Results Available	Gynecologic Cancer|Cervical Cancer|Endometrial Cancer|Ovarian Cancer|Fallopian Tubal Cancer	Drug: FloSeal application	Incidence of lymphocele an lymphatic ascites|Time interval from surgery to removal of closed drain system|Postoperative drain amount|Postoperative hospital stay|Postoperative bleeding incidence|Postoperative complication incidence|Quality of life|2-year disease free survival and overall survival	Asan Medical Center|Baxter Healthcare Corporation	Female	20 Years and older   (Adult, Older Adult)	Not Applicable	40	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	FloSeal-LND	September 2012	November 2015	November 2015	September 6, 2012		May 31, 2017	Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, Republic of		https://ClinicalTrials.gov/show/NCT01679483
240	NCT01480375	A Novel 3D Navigation Technology for Improved TRUS Prostate Biopsy	NaSBxP01	Completed	No Results Available	Prostate Cancer	Device: Smartbx™ system.	increased prostate cancer detection rate	UC Care, Ltd.	Male	18 Years and older   (Adult, Older Adult)	Not Applicable	524	Industry	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	0053-11-BNZ	September 22, 2011	November 15, 2017	November 15, 2017	November 28, 2011		April 19, 2019	Bnai Zion medical center, Haifa, Israel		https://ClinicalTrials.gov/show/NCT01480375
241	NCT02462226	Enhancing Management of Chronic Pain and Symptoms Among Women Treated for Breast Cancer (Lymph-Flow)	Lymph-Flow	Completed	No Results Available	Breast Cancer|Pain|Lymphedema	Behavioral: The-Optimal-Lymph-Flow|Behavioral: Arm Precaution	The Lymphedema and Breast Cancer Symptom Experience Index (BCLE-SEI|Limb Volume Difference by Infra-red Perometer.|The Pain Impact Questionnaire™ (PIQ-6™)|Body Weight and Body Mass Index [BMI]|Risk Reduction Behavior Checklist	NYU Langone Health|Pfizer	Female	21 Years to 89 Years   (Adult, Older Adult)	Not Applicable	120	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care	15-00221	May 1, 2015	December 1, 2016	December 1, 2016	June 4, 2015		April 20, 2017	NYU Cancer Center, New York, New York, United States		https://ClinicalTrials.gov/show/NCT02462226
242	NCT02102165	AURORA: Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer.	AURORA	Recruiting	No Results Available	Metastatic Breast Cancer	Procedure: metastatic lesion biopsy	Metastatic Breast Cancer (MBC) understanding|Building new therapeutic hypotheses|Patients' prognosis determination|Identification of "exceptional responders" and "rapid progressors"; the outlier patients|Feasibility of implementing a global molecular screening platform for MBC|Correlation between molecular alterations and standardly assessed efficacy endpoints|Patient identification to match with biomarker-driven clinical trials	Breast International Group|Breast European Adjuvant Studies Team|Frontier Science & Technology Research Foundation, Inc.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	1000	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening	BIG 14-01|1408-BCG|GBG 85|ICR-CTSU/2014/10050	April 2014	April 2019	January 2029	April 2, 2014		March 22, 2018	Institut Jules Bordet, Brussels, Belgium|Cliniques Universitaires St-Luc, Brussels, Belgium|Grand Hopital Charleroi, Charleroi, Belgium|UZA, Antwerp University Hospital, Edegem, Belgium|UZ Leuven, Leuven, Belgium|CHU de Liège, Liège, Belgium|Clinique et Maternité Sainte-Elisabeth (CMSE - Namur), Namur, Belgium|Sint-Augustinus, Wilrijk, Belgium|Luisenkrankenhaus, Düsseldorf, Germany|Kliniken Essen-Mitte, Klinik für Senologie/ Brustzentrum, Essen, Germany|University Medical Center Freiburg, Freiburg, Germany|University of Schleswig-Holstein / Campus Luebeck, Luebeck, Germany|Sana Klinikum Offenbach, Offenbach, Germany|Klinikum Oldenburg gGmbH, Oldenburg, Germany|Landspitali, Reykjavík, Iceland|Ospedale degli Infermi - S.O.C.Oncologia, Biella, Italy|Ospedale di Bolzano - Oncologia Medica, Bolzano, Italy|Ospedale Ramazzini di Carpi, Carpi, Italy|Az. Istituti Ospitalieri di Cremona, Cremona, Italy|IRCCS AOU San Martino-IST, Genova, Italy|ULSS 21 Legnago, Legnago, Italy|Istituto Europeo di Oncologia, Milano, Italy|UOC Oncologia Medica - AOU Parma, Parma, Italy|Fondazione Salvatore Maugeri, Pavia, Italy|IRCCS Az Ospedaliera S.Maria Nuova, Reggio Emilia, Italy|Centre Hospitalier, Luxembourg, Luxembourg|Centrum Onkologii - Instytut im. Marii Sklodowskiej-Curie, Warsaw, Poland|Champalimaud Foundation, Lisboa, Portugal|Complexo Hospitalario Universitario A Coruña, A Coruña, Spain|Hospital del Mar, Barcelona, Spain|Dr Rosell Oncology Institute, Quirón Dexeus University Hospital, Barcelona, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Consorcio Hospitalario Provincial de Castellón, Castellón, Spain|Hospital San Pedro de Alcantara, Cáceres, Spain|Hospital Universitari Arnau de Vilanova, Lleida, Spain|MD Anderson Cancer Center, Madrid, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Centro Integral Oncológico Clara Campa, Madrid, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Instituto Valenciano de Oncología, Valencia, Spain|Hospital Clinico Universitario de Valencia, Valencia, Spain|Hospital General Universitario de Valencia, Valencia, Spain|Sahlgrenska University Hospital, Gothenburg, Sweden|Ryhov County Hospital, Jönköping, Sweden|Kantonsspital Baden, Baden, Switzerland|Inselspital Bern, Bern, Switzerland|Kantonsspital Graubuenden, Chur, Switzerland|Luzerner Kantonsspital, Division of Medical Oncology, Lucerne, Switzerland|Queen Elizabeth Hospital - University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom|University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom|Royal Cornwall Hospital - Royal Cornwall Hospitals NHS Trust, Cornwall, United Kingdom|NHS Tayside, Ninewells Hospital, Dundee, United Kingdom|Edinburgh Cancer Centre - Western General Hospital, Edinburgh, United Kingdom|Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom|Christie NHS Foundation Trust, Manchester, United Kingdom|Nottingham University Hospital NHS Trust, Nottingham, United Kingdom|Velindre NHS Trust, South Glamorgan, United Kingdom|Singleton Hospital - ABM University Health Board, Swansea, United Kingdom|Yeovil District Hospital NHS Foundation Trust, Yeovil, Somerset, United Kingdom		https://ClinicalTrials.gov/show/NCT02102165
243	NCT03256084	Tumoral Circulating Cells and Colorectal Cancer Progression		Recruiting	No Results Available	Colorectal Cancer	Procedure: Blood and tumor samples	Evaluation of CTC features	Institut Paoli-Calmettes|Institut National de la Santé Et de la Recherche Médicale, France|Beckman Coulter, Inc.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	160	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	CTC-Côlon-IPC 2015-020	July 17, 2017	July 17, 2022	July 17, 2022	August 21, 2017		August 21, 2017	Institut Paoli Calmettes, Marseille, France		https://ClinicalTrials.gov/show/NCT03256084
244	NCT00580281	Effect of Imatinib on Bone Metabolism in Patients With Chronic Myelogenous Leukemia or Gastrointestinal Stromal Tumors		Completed	No Results Available	Gastric Cancer|Leukemia|Chronic Myelogenous Leukemia	Other: blood test, urine test, and bone density x-ray.	This pilot study will collect longitudinal data on bone metabolism for patients treated with imatinib. Sixty patients will be followed over a two-year period on this protocol, with bone marker assessments ascertained every 3 months (+2 weeks).	Memorial Sloan Kettering Cancer Center|Novartis	All	Child, Adult, Older Adult	Not Applicable	33	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	06-142	November 2006	October 2013	October 2013	December 24, 2007		October 24, 2013	Memorial Sloan-Kettering Cancer Center, New York, New York, United States		https://ClinicalTrials.gov/show/NCT00580281
245	NCT01223235	Polyvalent Vaccine-KLH Conjugate + Opt-821 Given in Combination With Bevacizumab		Completed	Has Results	Fallopian Tubes Cancer|Ovarian Cancer|Peritoneal Cancer	Biological: bevacizumab and the polyvalent vaccine-KLH conjugate + OPT-821	Number of Participants With Adverse Events|Percentage of Participants Who Met the Immunogenicity Criteria (>/=3 Antigens) of the Vaccine|Progression-free Survival as Assessed By Multiplex Biomarker Panel of Angiogenesis Markers	Memorial Sloan Kettering Cancer Center|Genentech, Inc.	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	22	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	10-099	October 2010	September 2017	September 2017	October 18, 2010	May 14, 2018	June 12, 2018	Memorial Sloan-Kettering Cancer Center, New York, New York, United States	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/35/NCT01223235/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT01223235
246	NCT02958449	Prospective Clinical Investigation Comparing Standard Wound Closure Technique With Drains (Control) to Standard Wound Closure Techniques With TissuGlu® and No Drains (Test) in Mastectomy		Completed	No Results Available	Cancer, Breast	Device: Test - Standard Closure with TissuGlu Surgical Adhesive	Number of Post-Operative Clinical Interventions|Wound healing related complications|Cumulative drain volume, aspiration volume, and total wound drainage (drain volume + aspiration volume)|Days to drain removal|Cumulative days of treatment (with drains or aspiration)|Days to discharge from hospital|Number of Clinically Relevant Seromas formation (number and aspiration volume)|Incidence and timing of initiation of adjuvant therapy related to the mastectomy procedure (such as radiation therapy, chemotherapy, endocrine therapy)|Patient Benefit Questionnaire	Cohera Medical, Inc.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	77	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PRO-100-0145	December 2016	February 2018	February 2018	November 8, 2016		March 29, 2018	University Hospital Cologne Holweide, Cologne, Germany|University Hospital Cologne St. Elisabeth, Cologne, Germany|University Hospital Erlangen, Erlangen, Germany|University Hospital Greifswald, Greifswald, Germany|Royal Cornwall Hospital, Cornwall, United Kingdom|Derby Teaching Hospitals NHS Foundation Trust, Derby, United Kingdom|University Hospitals of Leicester NHS Foundation Trust, Leicester, United Kingdom|Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom|Royal Hallamshire Hospital, Sheffield, United Kingdom|St. Helens & Knowsley Teaching Hospitals NHS Trust, St Helens, United Kingdom		https://ClinicalTrials.gov/show/NCT02958449
247	NCT03998085	Anlotinib Single Drug as the Maintenance Treatment for Advanced NSCLC		Recruiting	No Results Available	Non-Small Cell Lung Cancer	Drug: Anlotinib Hydrochloride	PFS|OS	First Hospital of Jilin University|Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	All	18 Years to 75 Years   (Adult, Older Adult)	Not Applicable	40	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	K2018065|ALTER-L011	March 5, 2019	December 31, 2020	December 31, 2021	June 25, 2019		June 25, 2019	First Hospital of Jilin University, Chang chun, Jilin, China		https://ClinicalTrials.gov/show/NCT03998085
248	NCT02647112	Utility of Bladder EpiCheck for Detection of Recurrent Urothelial Carcinoma		Recruiting	No Results Available	Bladder Cancer	Other: Bladder EpiCheck	Sensitivity (the proportion of positives that are correctly identified as such by the gold standard)|Specificity (the proportion of negatives that are correctly identified as such by the gold standard)	Nucleix Ltd.	All	22 Years to 100 Years   (Adult, Older Adult)	Not Applicable	350	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Investigator)|Primary Purpose: Diagnostic	UC-EpiCheck-EU-01	December 2015	December 2018	December 2018	January 6, 2016		September 13, 2017	Tubingen University Medical Center, Tubingen, Germany|Meir Medical Center, Kfar Saba, Israel|ZGT Medical Center, Hengelo, Netherlands|Radboud University Medical Center, Nijmegen, Netherlands|Vall D'Hebron Medical Center, Barcelona, Spain		https://ClinicalTrials.gov/show/NCT02647112
249	NCT02481219	Optimization of the Bowel Preparation Regimen for the PillCam® COLON 2 Capsule Endoscopy Procedure		Completed	Has Results	Colorectal Cancer Screening	Device: PillCam® COLON 2 procedure-CONTROL|Drug: Senna tablets|Drug: PEG|Drug: Metoclopramide|Drug: Erythromycin|Drug: SUPREP oral sulfate solution|Drug: Bisacodyl|Drug: SUPREP oral sulfate solution with Gastrografin	Bowel Cleansing Level of Two Different Bowel Preparation Methods for PillCam® Colon Capsule Endoscopy (CCE)|Comparing Polyp Detection Rate of Two Different Bowel Preparation Methods for PillCam CCE|Colonic Transit Time of Two Different Bowel Preparation Methods for PillCam CCE|Comparing of Completion Rate of Capsule of Two Different Bowel Preparation Methods for PillCam CCE|Excretion Rate of Capsule Within 12 Hours of Two Different Bowel Preparation Methods for PillCam CCE|Adverse Events Rate Between Two Different Bowel Preparation Methods for PillCam CCE	Medtronic - MITG	All	50 Years to 75 Years   (Adult, Older Adult)	Not Applicable	122	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	MA-205	May 2015	January 2016	February 2016	June 25, 2015	July 11, 2016	March 7, 2017	Pinnacle Research Group, LLC, Anniston, Alabama, United States|Indiana University Hospital, Indianapolis, Indiana, United States|Indianapolis Gastroenterology and Hepatology, Indianapolis, Indiana, United States|Dayton Gastroenterology, Dayton, Ohio, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Franklin Gastroenterology, PLLC, Franklin, Tennessee, United States		https://ClinicalTrials.gov/show/NCT02481219
250	NCT02891460	Pilot Study to Evaluate the Clinical Response to Mitomycin-C in Hydrogel (TC-3) Administered Intravesically in NMIBC Patients		Completed	No Results Available	Urinary Bladder Neoplasms|Urologic Neoplasms|Neoplasms|Urinary Bladder Diseases|Urologic Diseases	Device: 40 mg MMC in 40 mL TC-3.|Device: 80 mg MMC in 40 mL TC-3.	Subject's degree of response at 2-4 weeks post-treatment|Adverse events (AE) including serious adverse events (SAE)|Anesthesia information|Blood and urine tests|The degree of pain during treatment|Gel clearance and urinary patency|Tumor recurrence rate during 12 months post- 2-4 week follow-up visit in complete response (CR) subjects.|Lesion Mass by time point (Screening and 2-4 weeks post-treatment)	UroGen Pharma Ltd.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	18	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	TC-3 /2012 / P2	January 2013	February 2014	March 2015	September 7, 2016		September 8, 2016	Rajiv Gandhi Cancer Institute & Research Center, Delhi, New Delhi, India		https://ClinicalTrials.gov/show/NCT02891460
251	NCT02673021	MARK 1A Series: Percutaneous Microwave Ablation for Patients With Lung Tumor(s)	MARK 1A	Active, not recruiting	No Results Available	Lung Neoplasms|Cancer of Lung|Cancer of the Lung|Lung Cancer|Neoplasms, Lung|Neoplasms, Pulmonary|Pulmonary Cancer|Pulmonary Neoplasms|Metastatic Cancer to the Lung	Procedure: Microwave ablation	Efficacy of microwave ablation.|Assessment of patient adverse events as defined by CTCAE.|Pathological response in patients receiving microwave ablation.	Mayo Clinic|Medtronic - MITG	All	18 Years and older   (Adult, Older Adult)	Not Applicable	10	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	15-001758	February 2016	May 2020	May 2020	February 3, 2016		June 7, 2019	Mayo Clinic, Rochester, Minnesota, United States|Mayo Clinic in Rochester, Rochester, Minnesota, United States		https://ClinicalTrials.gov/show/NCT02673021
252	NCT02792959	Evaluation of Response to the Neoadjuvante Chemotherapy for Advanced Ovarian Cancer by Multimodal Functional Imaging	IMOVA	Completed	No Results Available	Ovarian Cancer	Device: Functional Imaging previous the second course|Device: Functional Imaging previous the surgery	Intra-rater reliability of positron emission tomography (PET) maximum standardized uptake value (SUVmax)|Inter-rater reliability of PET maximum standardized uptake value (SUVmax)|Intra-rater reliability of PET Metabolic Tumoral Volume (MTV)|Inter-rater reliability of PET Metabolic Tumoral Volume (MTV)|Intra-rater reliability of PET Magnetic Resonance Imaging (MRI) Apparent Diffusion Coefficient (ADC)|Inter-rater reliability of PET Magnetic Resonance Imaging (MRI) Apparent Diffusion Coefficient (ADC)|Inter-rater reliability of positron emission tomography (PET) maximum standardized uptake value (SUVmax)|Descriptive statistics (mean and standard deviation) of PET SUVmax by rate of complete surgery resection|Descriptive statistics (mean and standard deviation) of PET MTV by rate of complete surgery resection|Descriptive statistics (mean and standard deviation) of MRI ADC by rate of complete surgery resection|Descriptive statistics (mean and standard deviation) of PET SUVmax by pathology results|Descriptive statistics (mean and standard deviation) of PET MTV by pathology results surgery resection|Descriptive statistics (mean and standard deviation) of MRI ADC by pathology results surgery resection|Descriptive statistics (mean and standard deviation) of PET SUVmax by response as per RECIST V1.1 criteria|Descriptive statistics (mean and standard deviation) of PET MTV by response as per RECIST V1.1 criteria|Descriptive statistics (mean and standard deviation) of MRI ADC by response as per RECIST V1.1 criteria|Descriptive statistics (mean and standard deviation) of PET SUVmax by CA125 assay|Descriptive statistics (mean and standard deviation) of PET MTV by CA125 assay|Descriptive statistics (mean and standard deviation) of MRI ADC by CA125 assay|MRI tumor volume|Peritoneal Extent assessed by Fagotti score using MRI data|Peritoneal Extent assessed by Fagotti score using PET data|Progression¬free survival as per RECIST v1.1|Overall survival	Institut Bergonié|Roche Pharma AG|Ligue contre le cancer, France	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	10	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	IB 2013-03	August 2014	August 2017	August 2017	June 8, 2016		October 2, 2017	Institut Bergonié, Bordeaux, Gironde, France		https://ClinicalTrials.gov/show/NCT02792959
253	NCT02911259	Suction on Post-Operative Chest Tubes	SPOCT	Completed	No Results Available	Non-small Cell Lung Cancer	Device: Suction is set to -2 cmH2O|Device: Suction is set to -10 cmH2O	Chest tube duration through study completion, an average of 3 days.|Time to removal criteria have been fulfilled up to 24 hours|Number of participants with prolonged air leak|Number of participants requiring treatment for prolonged air leak.|Number of participants requiring treatment for subcutaneous emphysema.|Number of participants with pneumonia or empyema.|Length of stay.|Number of participants with other respiratory problems.|Number of participants requiring readmission for thoracic surgical complications.	Rigshospitalet, Denmark|Medela AG	All	18 Years and older   (Adult, Older Adult)	Not Applicable	230	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment	H-15008900	February 2016	November 14, 2017	November 14, 2017	September 22, 2016		April 27, 2018	Rigshospitalet, Copenhagen, Denmark		https://ClinicalTrials.gov/show/NCT02911259
254	NCT00847366	Open Label Trial of Perifosine in Patients Currently Being Treated on Perifosine Trials in Solid Tumors or Multiple Myeloma		Completed	No Results Available	Non Small Cell Lung Cancer|Solid Tumors|Metastatic Breast Cancer|Sarcomas	Drug: Perifosine|Drug: Trastuzumab|Drug: Tamoxifen	To evaluate the safety and tolerability	AEterna Zentaris	All	18 Years and older   (Adult, Older Adult)	Not Applicable	10	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Perifosine 534	May 2008	December 2012	December 2012	February 19, 2009		March 15, 2018			https://ClinicalTrials.gov/show/NCT00847366
255	NCT02608281	Evaluation of Diagnostic Accuracy of Contrast Enhanced Dual Energy Mammography Imaging in Comparison to CE-MRI	CEDEM	Completed	No Results Available	Breast Cancer Diagnosis	Device: CONTRAST ENHANCED DUAL ENERGY (CEDEM)	Diagnostic accuracy of contrast enhanced dual energy mammography for breast cancer diagnosis|sensitivity, specificity and the lesion-level ROC area.	Siemens Healthcare QT|Medical University of Vienna	Female	21 Years and older   (Adult, Older Adult)	Not Applicable	110	Industry|Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	C00215154	November 2015	August 1, 2017	August 1, 2017	November 18, 2015		August 11, 2017	Allgemeines Krankenhaus Wien, Wien, Austria		https://ClinicalTrials.gov/show/NCT02608281
256	NCT01269645	Facts and Attitudes About Clinical Trials	FACT	Completed	No Results Available	Cancer|Neoplasm	Behavioral: Clinical Trial educational materials	Change from baseline to follow-up in attitudes towards clinical trial participation|Impact of information on knowledge, self-efficacy, receptivity, and likelihood of participating|Impact of information on participation in clinical trials	H. Lee Moffitt Cancer Center and Research Institute|Pfizer	All	18 Years and older   (Adult, Older Adult)	Not Applicable	471	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	MCC-15820	July 2009	September 2011	July 2014	January 4, 2011		June 8, 2016	Hartford Hospital, Hartford, Connecticut, United States|University of Florida, Gainesville, Gainesville, Florida, United States|Center for Cancer Care & Research/Watson, Lakeland, Florida, United States|Ocala Oncology Center, Ocala, Florida, United States|H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States|Space Coast Medical Associates, Titusville, Florida, United States|Billings Clinic, Billings, Montana, United States		https://ClinicalTrials.gov/show/NCT01269645
257	NCT03995667	Tumor Treating Fields (TTFields) Therapy to Manage Brain Metastases in Small Cell Lung Cancer		Not yet recruiting	No Results Available	Small Cell Lung Cancer|Brain Metastases	Device: Optune®-Tumor Treating Fields (TTFields)	Incidence of Small Cell Lung Cancer (SCLC) brain metastases at 6 months|Incidence of SCLC brain metastases at 12 months|Overall survival|Incidence of TTfield related adverse events|Incidence of cognitive Adverse Events (AEs) using Mini Mental State Exam (MMSE)|Change in quality of life over time: EORTC QLQ-C30	OHSU Knight Cancer Institute|Oregon Health and Science University|NovoCure Ltd.	All	22 Years and older   (Adult, Older Adult)	Not Applicable	106	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	STUDY00018029	June 20, 2019	June 20, 2021	December 31, 2022	June 24, 2019		June 24, 2019	OHSU Knight Cancer Institute, Portland, Oregon, United States|University of Washington, Seattle, Washington, United States		https://ClinicalTrials.gov/show/NCT03995667
258	NCT01384838	Exercise Training in Postmenopausal Patients With Breast Cancer		Completed	No Results Available	Physical Activity	Behavioral: Counseling|Behavioral: physical activity	Individual maximum power output in watt (Pmax) on a bicycle ergometer after 6 months of controlled or unobserved physical activity.|Determination of feasibility of achieving 12 MET/week (metabolic units) on an outpatient basis|Evaluation of the influence of controlled/observed physical activity versus lifestyle counseling only on Fitness level, Quality of Life, rate of infections, weight, body mass index BMI, Body fat percentage	Arbeitsgemeinschaft medikamentoese Tumortherapie|Roche Pharma AG	Female	Child, Adult, Older Adult	Not Applicable	80	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research	AGMT_BC_Sports	June 2011	December 2014	April 2015	June 29, 2011		June 4, 2015	Universitätsklinik für Innere Medizin III mit Hämatologie, internistischer Onkologie, Infektologie, Rheumatologie und Onkologisches Zentrum, Salzburg, Austria		https://ClinicalTrials.gov/show/NCT01384838
259	NCT01648010	Safety and Tolerability Study Which Evaluate Intravesical Instillation With Mitomycin C Mixed With TC-3 Drug Retaining Hydrogel Device In Patients With Muscle Invasive Bladder Cancer		Completed	No Results Available	Carcinoma of Urinary Bladder, Invasive	Device: TC-3 gel|Device: TC-3 gel mixed with Mitomycin C (MMC)	Assessment of systemic and urine pharmacokinetics of MMC following intravesical instillation of TC-3 mixed with MMC for safety evaluation.|Assessment of the levels of MMC in patients urinary bladder following intravesical instillation of TC-3 mixed with MMC.	UroGen Pharma Ltd.	All	45 Years and older   (Adult, Older Adult)	Not Applicable	7	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)	TAS-4M-PR-H-127-1|HTA 5972	November 2011	May 2013	May 2013	July 24, 2012		May 7, 2013	Barzilai Hospital, Ashkelon, Israel|Wolfson, Holon, Israel|Beilinson, Petah-Tikva, Israel		https://ClinicalTrials.gov/show/NCT01648010
260	NCT03717142	Feasibility of the LUM Imaging System for Detection of Cancer to the Brain		Recruiting	No Results Available	Low Grade Glioma of Brain|Glioblastoma|Metastasis to Brain	Combination Product: LUM Imaging System	Correlation of fluorescence levels in normal and tumor tissue by dose of LUM015|Number of reported safety events	Lumicell, Inc.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	36	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Other	CL0004	May 3, 2019	January 2020	February 2020	October 24, 2018		May 13, 2019	Brigham and Women's Hospital, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT03717142
261	NCT03651921	Testing of the Cancer Thriving and Surviving Breast Cancer Program	COSS	Recruiting	No Results Available	Breast Neoplasm|Early-Stage Breast Cancer|Self-Management|Intervention|Cancer Survivorship	Behavioral: CTS-BC-CH	Reach of intervention assessed by ratio of eligible patients vs. participating patients|Changes in self-management skills assessed by heiQ|Change in patient-reported self-efficacy assessed by SES6G|Change in patient-reported health literacy assessed by HLS-EU-Q6|Change in patient-reported symptom burden assessed by BCPT Symptom Scales|Change in patient-reported health service navigation assessed by heiQ|Change in nurse-reported self-efficacy and self-management support practices assessed by SEPSS	Manuela Eicher|Swiss Cancer League|Lindenhof AG|University of Lausanne	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	72	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	ULausanne	December 12, 2017	July 27, 2019	July 27, 2019	August 29, 2018		August 29, 2018	Cantonal Hospital Aarau, Aarau, Switzerland|University Hospital Basel, Basel, Switzerland|University Inselspital Bern, Bern, Switzerland		https://ClinicalTrials.gov/show/NCT03651921
262	NCT02828150	Integrative Parenteral Nutrition in Cancer Patients		Completed	No Results Available	Neoplasms|Parenteral Nutrition	Dietary Supplement: Parenteral nutrition	Phase angle|body weight|body mass index|Handgrip strength|Number of participants with treatment-related adverse events as assessed by biochemistry	IRCCS Policlinico S. Matteo|Baxter Healthcare Corporation	All	18 Years and older   (Adult, Older Adult)	Not Applicable	131	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2015013559	July 2016	December 2017	December 2017	July 11, 2016		December 4, 2017	Fondazione IRCCS Policlinico San Matteo, Pavia, Italy		https://ClinicalTrials.gov/show/NCT02828150
263	NCT01044732	Third Eye Retroscope Randomized Clinical Evaluation	TERRACE	Completed	Has Results	Colorectal Neoplasms	Device: Third Eye Retroscope	Detection Rates for Adenomas and for Total Polyps|Times for Withdrawal Phase and for Complete Procedure	Avantis Medical Systems	All	Child, Adult, Older Adult	Not Applicable	448	Industry	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	Avantis TER-08-06	March 2009	February 2010	February 2010	January 8, 2010	October 1, 2015	July 25, 2017	Johns Hopkins Hospital, Baltimore, Maryland, United States|Kansas City Veterans Administration Medical Center, Kansas City, Missouri, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Bayside Endoscopy Center, Providence, Rhode Island, United States|Baylor University Medical Center, Dallas, Texas, United States|Cliniques Universitaires Saint-Luc, Brussels, Belgium|Istituto Clinico Humanitas, Milan, Italy|University Medical Center Utrecht, Utrecht, Netherlands|St. Mark's Hospital, London, United Kingdom		https://ClinicalTrials.gov/show/NCT01044732
264	NCT00153868	A Web-based Study of Quality of Life Benefits Associated Aranesp in Anemic Patients With Cancer		Active, not recruiting	No Results Available	Anemia|Cancer	Drug: darbepoetin alfa	A secure web-based assessment of cancer-related symptoms (LCSS), functional status (SF-36), and quality of life (FACT-An and PFS) will be obtained every 2 weeks (weeks 3, 5, 7, 9, 11, and 13).|A blood sample will be obtained to evaluate hemoglobin concentrations every 2 weeks (weeks 3, 5, 7, 9, 11, and 13).|A blood sample will be obtained to evaluate plasma cytokines every 4 weeks (weeks 5, 9, and 13).	Dartmouth-Hitchcock Medical Center|Amgen	All	18 Years and older   (Adult, Older Adult)	Not Applicable	43	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	D-0341	October 2003	December 2025	December 2025	September 12, 2005		August 24, 2018	Norris Cotton Cancer Center, Lebanon, New Hampshire, United States		https://ClinicalTrials.gov/show/NCT00153868
265	NCT00130143	Toxicities Associated With Subcutaneous Administration of Ethyol (Amifostine) for the Prevention of Radiation-Induced Toxicities		Completed	No Results Available	Head and Neck Cancer|Lung Cancer	Drug: Ethyol (Amifostine)	Primary endpoint: To evaluate how amifostine is given subcutaneously at each institution|To determine treatment related toxicities and safety of subcutaneous administration of amifostine for the prevention of radiation-induced toxicities|Secondary endpoints: Evaluate efficacy of amifostine in reducing radiation induced toxicities in these patients	The Dale & Frances Hughes Cancer Center|MedImmune LLC	All	18 Years and older   (Adult, Older Adult)	Not Applicable	20	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Ethyol Study #ETH156-03D	June 2003		September 2004	August 15, 2005		September 27, 2005	The Dale & Frances Hughes Cancer Center, East Stroudsburg, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT00130143
266	NCT00967148	Thromboprophylaxis for Patients Undergoing Surgical Resection for Colon Cancer	PERI-OP	Completed	No Results Available	Deep Vein Thrombosis|Pulmonary Embolism|Cancer	Drug: Tinzaparin	Recruitment rate|Refusal rate|Rate of non-compliance and lost to follow-up|Expression of sialylated fucosylated glycans (including CA19-9, sialyl Lewis X and CD24) in primary tumor specimens by immunohistochemistry (IHC).|Expression of TF. VEGF and microvessel density in primary tumor specimens by IHC.|Serum soluble TF and TFPI levels pre and postoperatively (postoperative day 0, 1, 4, 7±1, and 28±4) measured by enzyme linked immunosorbent assay (ELISA).|Platelet count and serum soluble P-selectin levels pre and postoperatively (postoperative day 0, 1, 4, 7±1, and 28±4) measured by hemocytometer and ELISA.|Serum VEGF levels pre and postoperatively (postoperative day 0, 1, 4, 7±1, and 28±4) measured by ELISA|Quantification and characterization of VPC pre and postoperatively (postoperative day 0, 1, 4, 7±1, and 28±4) measured by VPC cell culture assay and flow cytometry.	Ottawa Hospital Research Institute|LEO Pharma	All	18 Years and older   (Adult, Older Adult)	Not Applicable	18	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	2009121-01H	June 2009	September 2010	September 2010	August 27, 2009		October 22, 2014	Ottawa Health Research Institute, Ottawa, Ontario, Canada		https://ClinicalTrials.gov/show/NCT00967148
267	NCT02700464	The Efficacy of the Bladder EpiCheck for Detection of Recurrent Urothelial Cell Carcinoma		Recruiting	No Results Available	Bladder Cancer	Device: Bladder EpiCheck Urine Test|Procedure: Cystoscopy and pathology	Specificity of Bladder EpiCheck Urine Test Kit (the proportion of negatives that are correctly identified as such by the gold standard)|Sensitivity of Bladder EpiCheck Urine Test Kit (The proportion of positives that are correctly identified as such by the gold standard)	Nucleix Ltd.	All	22 Years and older   (Adult, Older Adult)	Not Applicable	500	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Diagnostic	UC-EpiCheck-FDA-01	September 2016	December 2019	March 2020	March 7, 2016		August 21, 2017	Chesapeake Urology Research Associates, Baltimore, Maryland, United States|Metro Urology, Woodbury, Minnesota, United States|Urological Surgeons of Long Island, Garden City, New York, United States|Duke University Health System, Durham, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Urology San Antonio, San Antonio, Texas, United States|University Of Washington, Seattle, Washington, United States|UHN, Princess Margret Cancer center, Toronto, Ontario, Canada		https://ClinicalTrials.gov/show/NCT02700464
268	NCT03972527	Photobiomodulation Therapy to Demonstrate Safety and Reduce Pain Associated With Oral Mucositis in Adult Patients With Head and Neck Cancer Receiving Concurrent Radiation and Chemotherapy		Not yet recruiting	No Results Available	Oral Mucositis (Ulcerative)|Oral Mucositis (Ulcerative) Due to Radiation|Oral Mucositis (Ulcerative) Due to Antineoplastic Therapy|Head and Neck Cancer	Device: Photobiomodulation|Other: Routine Oral Care and Analgesia	Change in pain from baseline|Oral Mucositis (OM) Grade and Incidence,|Analgesic Usage, Pain	MuReva Phototherapy Inc.|Ohio State University Comprehensive Cancer Center|Hackensack Meridian Health	All	22 Years and older   (Adult, Older Adult)	Not Applicable	50	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care	LLD-001	July 1, 2019	July 1, 2020	July 1, 2020	June 3, 2019		June 3, 2019			https://ClinicalTrials.gov/show/NCT03972527
269	NCT02065726	Whey Protein Supplementation in Cancer Patients		Completed	No Results Available	Solid Tumors	Dietary Supplement: Whey protein|Other: Nutritional counseling	Body composition|Body weight|Quality of life|Handgrip strength	IRCCS Policlinico S. Matteo|Norgine|Akern Srl	All	18 Years and older   (Adult, Older Adult)	Not Applicable	166	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	20130018046	February 25, 2014	June 2018	June 2018	February 19, 2014		June 8, 2018	Nutrition and Dietetics Service, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, Pavia, Italy		https://ClinicalTrials.gov/show/NCT02065726
270	NCT03630666	Comparison of Intermittent Androgen Deprivation Therapy With or Without Irradiation Recovery in Prostate Cancer Patients	OLIGOPELVIS2	Recruiting	No Results Available	Prostate Cancer|Oligometastasis	Drug: IADT|Combination Product: IADT + radiotherapy	progression-free survival|overall survival|time to castration-resistance|toxicity to IADT and radiation|quality of life during treatment|site of tumor progression	Institut Cancerologie de l'Ouest|Direction Générale de l'Offre de Soins|Astellas Pharma Inc	Male	18 Years and older   (Adult, Older Adult)	Not Applicable	256	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ICO-N-2017-13	December 4, 2018	June 2026	June 2026	August 15, 2018		May 13, 2019	Institut Sainte Catherine, Avignon, France|Institut Bergonie, Bordeaux, France|CHRU de Brest, Brest, France|Clinique Pasteur, Brest, France|Institut de Cancérologie de Bourgogne, Chalon-sur-Saône, France|Centre Jean Perrin, Clermont-Ferrand, France|Centre Georges François Leclerc, Dijon, France|Centre Oscar Lambret, Lille, France|Centre Léon Bérard, Lyon, France|Institut de Cancérologie de Montpellier, Montpellier, France|Centre Azureen de Cancerologie, Mougins, France|Institut de Cancérologie, Nantes, France|Hopital Privé du Confluent, Nantes, France|Clinique Mutualiste de l'Estuaire, Saint-Nazaire, France|ICL Lucien Neuwirth, Saint-Priest-en-Jarez, France|Centre Saint Yves, Vannes, France		https://ClinicalTrials.gov/show/NCT03630666
271	NCT02729753	Clinical Study to Evaluate CryoBalloon™ Full and Swipe Ablation Systems for Ablation of Human Esophageal Epithelium		Completed	Has Results	Esophageal Cancer	Device: CryoBalloon™ Full Ablation System|Device: CryoBalloon™ Swipe Ablation System	Safety of the CryoBalloon™ Full and Swipe Ablation System|Effect of Ablation to Submucosa at Different Depth of Tissue Ablation Using the CryoBalloon™ Full and Swipe Ablation Systems|Device Performance: Average Procedure Time|Device Performance: Ease of Deployment of Device	C2 Therapeutics, Inc.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	10	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	CP0014	April 2016	October 24, 2016	October 30, 2016	April 6, 2016	October 12, 2018	October 12, 2018	MD Anderson Cancer Center, Houston, Texas, United States|Swedish Medical Center and Cancer Institute, Seattle, Washington, United States		https://ClinicalTrials.gov/show/NCT02729753
272	NCT02729727	Clinical Study to Evaluate CryoBalloon™ Ablation System in Patients Undergoing Esophagectomy		Completed	No Results Available	Esophageal Cancer	Device: CryoBalloon Ablation System	Safety of CryoBalloon Ablation System|Device Performance	C2 Therapeutics, Inc.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	3	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	CP-0008	March 2016	June 24, 2016	June 30, 2016	April 6, 2016		January 25, 2018	Academic Medical Centre Amsterdam, Amsterdam, North Holland, Netherlands		https://ClinicalTrials.gov/show/NCT02729727
273	NCT02468726	Performance of NER1008 Enema Compared With Fleet® Enema in Bowel Cleansing		Completed	No Results Available	Colorectal Cancer	Device: NER1008 enema|Drug: Fleet	Success of bowel cleansing|Grade of bowel cleansing|Quality of cleansing in rectum|Quality of cleansing in sigmoid colon|Quality of cleansing in the descending colon|Depth of scope progression|Stool weight	Norgine	All	18 Years to 45 Years   (Adult)	Not Applicable	25	Industry	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Screening	NER1008-01/2011 (ENE)	November 2011	March 2012	December 2012	June 11, 2015		June 11, 2015	BioKinetic Europe Ltd, Belfast, United Kingdom		https://ClinicalTrials.gov/show/NCT02468726
274	NCT01572428	Narrow-Band Imaging Versus Standard White Light for the Detection of Serrated Lesions in the Proximal Colon		Completed	Has Results	Colon Cancer	Procedure: Inspection with Narrow-Band Imaging(NBI)|Procedure: Standard White Light	Total Number of Serrated Lesions Proximal to the Sigmoid Colon|Number of Serrated Lesions Proximal to the Sigmoid Colon Per Patient|Patients With 1 or More Serrated Lesions Proximal to the Sigmoid Colon|Total Number of Conventional Adenomas in Entire Colon|Number of Conventional Adenomas Per Patient in Entire Colon|Patients With 1 or More Conventional Adenomas	Indiana University|Olympus	All	50 Years to 85 Years   (Adult, Older Adult)	Not Applicable	898	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	1012-17	April 2011	July 7, 2014	July 7, 2014	April 6, 2012	August 8, 2019	August 8, 2019	Beltway Surgical Center, Indianapolis, Indiana, United States		https://ClinicalTrials.gov/show/NCT01572428
275	NCT00256789	Once Weekly Radiation for Lung Cancer With Chemotherapy		Completed	No Results Available	Carcinoma, Non-Small-Cell Lung	Procedure: Radiation|Drug: Chemotherapy	Feasibility|Toxicity, Safety, Efficacy	Clinical Oncology Research Associates|Aventis Pharmaceuticals	All	Child, Adult, Older Adult	Not Applicable	26	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Hypo 1	September 2002	December 2003	December 2004	November 22, 2005		February 11, 2014	Cancer Center and Mobile Infirmary Hospital, Mobile, Alabama, United States		https://ClinicalTrials.gov/show/NCT00256789
276	NCT03235687	Decision Impact Trial of the ExoDx Prostate (IntelliScore)		Active, not recruiting	No Results Available	Cancer of the Prostate	Diagnostic Test: ExoDx Prostate (IntelliScore)	Evaluate performance of the ExoDx Prostate(IntelliScore)	Exosome Diagnostics, Inc.|CareFirst BlueCross BlueShield|Chesapeake Urology Research Associates	Male	50 Years and older   (Adult, Older Adult)	Not Applicable	1000	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Screening	ECT2017-002	July 19, 2017	December 1, 2019	December 29, 2019	August 1, 2017		February 15, 2019	Chesapeake Urology Research Associates, Towson, Maryland, United States		https://ClinicalTrials.gov/show/NCT03235687
277	NCT01032044	CLE for Assessment of Neoplasia After Mucosal Ablation or Resection of Gastrointestinal Neoplasia	CLEAN-MARGIN	Completed	Has Results	Barrett Syndrome|Barrett's Syndrome|Barrett's Esophagus|Barrett Esophagus|Adenocarcinoma	Device: Standard endoscopic evaluation|Device: pCLE guided evaluation	Number of Barrett's Esophagus (BE) Participants With a Composite Outcome of "Optimally Treated"	Mauna Kea Technologies|Cellvizio Inc.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	164	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic	MKT-2009-BE-01	February 2010	April 2011	April 2011	December 15, 2009	April 22, 2016	April 22, 2016	Mayo Clinic, Jacksonville, Florida, United States|University of Chicago Hospital, Chicago, Illinois, United States|Veterans Affairs Hospital, Kansas City, Missouri, United States|University of Washington Medical Center, Seattle, Washington, United States|Centre Hospitalier Universitaire, Nantes, France|University College London Hospital, London, United Kingdom		https://ClinicalTrials.gov/show/NCT01032044
278	NCT03340857	Intelligent Electric Bicycle for Health (VELIS) to Optimize the Return to Physical Activity for Oncology Patients		Recruiting	No Results Available	Cancer|Oncology	Other: Intelligent electric bicycle (VELIS) sessions	Percentage of patients reaching the goal of 150 min equivalent of moderate physical activity per week (600 MET-min/week)|Quantitative analysis of kinetic physical activity evolution|Evaluate the VELIS sessions feasibility n°1|Evaluate the VELIS sessions feasibility n°2|Evaluate the VELIS sessions feasibility n°3|Evaluate the impact on the physical capacities n°1|Evaluate the impact on the physical capacities n°2|Evaluate the impact on the physical capacities n°3|Evaluate the impact on the physical capacities n°4|Evaluate the impact on the physical capacities n°5|Evaluate the impact on the physical capacities n°6|Evaluate the impact on the physical capacities n°7|Evaluate the impact on the physical capacities n°8|Evaluate the impact on the physical capacities n°9|Evaluate the impact on the physical capacities n°10|Evaluate the impact on the physical capacities n°11|Evaluate the impact on the physical capacities n°12|Improve quality of life|Improve fatigue n°1|Improve fatigue n°2|Improve chronic pain|Improve self-esteem|Improve patient satisfaction|Remove stereotypes that can lead to inhibition in the physical activity practice|Evolution of uses and performances during bicycle sessions at the beginning and the end of the intervention n°1|Evolution of uses and performances during bicycle sessions at the beginning and the end of the intervention n°2|Evolution of uses and performances during bicycle sessions at the beginning and the end of the intervention n°3|Evolution of uses and performances during bicycle sessions at the beginning and the end of the intervention n°4	Fondation Audavie|Floralis|eBikeLabs|Rocheplane Medical Center	All	18 Years and older   (Adult, Older Adult)	Not Applicable	16	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	ONCOVELIS version 2.0	October 9, 2017	August 30, 2018	October 30, 2018	November 14, 2017		February 19, 2018	Rocheplane Medical Center, Saint-Martin-d'Hères, Rhône-Alpes, France		https://ClinicalTrials.gov/show/NCT03340857
279	NCT02416336	Evaluation of Intraoperative Usage of Sentinella in Detecting Sentinel Lymph Nodes		Completed	No Results Available	Melanoma|Head and Neck Cancer|Breast Cancer	Device: Sentinella Intraoperative imaging protocol	The percentage of patients for whom Sentinella detects additional tumor-positive SLNs.|Mean percentage of SLNs detected using pre-operative lymphoscintigraphy and/or SPECT/CT|Additional SLNs per patient found using Sentinella|Mean Sentinella imaging time	Oncovision Inc|California Pacific Medical Center	All	Child, Adult, Older Adult	Not Applicable	100	Industry|Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	SLN-USA-1	July 2015	March 2017	March 2017	April 15, 2015		April 5, 2017	California Pacific Medical Center - Pacific Campus, San Francisco, California, United States		https://ClinicalTrials.gov/show/NCT02416336
280	NCT02286843	Can HER2 Targeted PET/CT Imaging Identify Unsuspected HER2 Positive Breast Cancer Metastases, Which Are Amenable to HER2 Targeted Therapy?		Recruiting	No Results Available	Breast Cancer Metastases|HER2 Positive Breast	Radiation: 89Zr-trastuzumab|Device: PET/CT scan|Radiation: 89Zr-pertuzumab	proportion of patients with HER2- primary breast cancer who develop imagable HER2+ metastases	Memorial Sloan Kettering Cancer Center|United States Department of Defense|Genentech, Inc.	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	50	Other|U.S. Fed|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	14-156	November 2014	November 2019	November 2019	November 10, 2014		October 29, 2018	Memorial Sloan Kettering Cancer Center, New York, New York, United States		https://ClinicalTrials.gov/show/NCT02286843
281	NCT01215071	Eingeschränkte vs Ausgedehnte Lymphadenektomie LEA		Completed	No Results Available	Bladder Cancer	Procedure: limited lymphadenectomy|Procedure: extended lymphadenectomy	Recurrence free Survival (RFS)|Cancer specific survival (CSS)|Overall survival (OS)|Determination of type and location of tumour progression(local recurrences and distant metastases)|Effect on histopathological stage (Will Rogers phenomenon)|Influence of adjuvant chemotherapy (by subgroup analysis)|Documentation of complications	Association of Urologic Oncology (AUO)|Eli Lilly and Company	All	18 Years and older   (Adult, Older Adult)	Not Applicable	401	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	AB 25/02	February 2006	August 2015	August 2015	October 6, 2010		January 24, 2018	Urological hospital, Städt. Kliniken Dortmund, Dortmund, Germany|Paracelsus Hospital, Düsseldorf, Germany|Heinrich Heine University, Düsseldorf, Germany|University of Essen, Essen, Germany|Department of urology, städt. Klinikum Fulda, Fulda, Germany|Saarland University, Homburg/Saar, Germany|Städt. Klinikum, Karlsruhe, Germany|Urological Hospital Kassel, Kassel, Germany|University of Cologne, Köln, Germany|Hospital Holweide, Köln, Germany|Klinikum Ludwigshafen, Ludwigshafen, Germany|Otto von Guericke University, Magdeburg, Germany|Klinikum r. d. Isar der TUM, München, Germany|Eberhard Karls University, Tübingen, Germany|Urological hospital, University Hospital Ulm, Ulm, Germany|Helios Klinikum Wuppertal, Wuppertal, Germany		https://ClinicalTrials.gov/show/NCT01215071
282	NCT03735407	Safety,Usability and Compliance of Using C-Scan System for Providing Information on Colonic Polypoid Lesions and Masses	C-Scan	Recruiting	No Results Available	Colo-rectal Cancer	Device: C-Scan procedure	Number of incidence of device and procedure related Serious Adverse Events (SAE)|Non-compliance rate of subjects (%)|To evaluate subject's satisfaction	Ceck Cap Ltd.	All	40 Years to 80 Years   (Adult, Older Adult)	Not Applicable	45	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	CL-SY-02-0096	February 1, 2019	August 1, 2019	September 1, 2019	November 8, 2018		June 4, 2019	Mayoclinic, Rochester, Minnesota, United States		https://ClinicalTrials.gov/show/NCT03735407
283	NCT00724503	FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer	SIRFLOX	Completed	Has Results	Colorectal Cancer|Colorectal Carcinoma|Liver Metastases	Device: SIR-Spheres yttrium-90 microspheres|Drug: Systemic chemotherapy (FOLFOX)	Progression-Free Survival (PFS) at Any Site|Percentage of Participants With Overall Response	Sirtex Medical	All	18 Years and older   (Adult, Older Adult)	Not Applicable	530	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	STX0206	August 2006	May 2015	May 2015	July 29, 2008	March 26, 2019	March 26, 2019	Pinnacle Oncology Hematology, Scottsdale, Arizona, United States|City of Hope Hospital, Duarte, California, United States|Florida International University College of Medicine Practice, North Miami Beach, Florida, United States|Vanguard Health, Berwyn, Illinois, United States|University of Illinois at Chicago, Chicago, Illinois, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|Adventist Hinsdale Hospital, Hinsdale, Illinois, United States|University of Louisville, Louisville, Kentucky, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|William Beaumont Hospital, Royal Oak, Michigan, United States|Virginia Piper Cancer Institute, Minneapolis, Minnesota, United States|Holy Name Hospital, Teaneck, New Jersey, United States|Montefiore Medical Center, Bronx, New York, United States|Carolinas Hematology-Oncology Associates, Charlotte, North Carolina, United States|Carolinas Medical Center, Charlotte, North Carolina, United States|Altru Health Systems, Grand Forks, North Dakota, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|St. Mark's Hospital, Salt Lake City, Utah, United States|University of Washington, Seattle, Washington, United States|Aurora St. Luke's Medical Center, Milwaukee, Wisconsin, United States|Medical College of Wisconsin/Froedtert Memorial Lutheran Hospital, Milwaukee, Wisconsin, United States|Concord Hospital, Concord, New South Wales, Australia|St. Vincent's Hospital, Darlinghurst, New South Wales, Australia|Nepean Cancer Care Centre, Kingswood, New South Wales, Australia|St. George Hospital, Kogarah, New South Wales, Australia|Royal North Shore Hospital, St Leonards, New South Wales, Australia|Sydney Adventist Hospital, Wahroonga, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Wesley Medical Centre, Auchenflower, Queensland, Australia|Cairns Private Hospital, Cairns, Queensland, Australia|Royal Brisbane and Women's Hospital, Herston, Queensland, Australia|Gold Coast Health Service District, Southport, Queensland, Australia|HOCA Gold Coast Centre, Southport, Queensland, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Ashford Cancer Centre, Ashford, South Australia, Australia|Flinders Medical Centre, Bedford Park, South Australia, Australia|Lyell McEwin Hospital, Elizabeth Vale, South Australia, Australia|Queen Elizabeth II Hospital, Woodville South, South Australia, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|Monash Medical Centre, Bentleigh East, Victoria, Australia|John Fawkner Private Hospital, Coburg, Victoria, Australia|Western Hospital, Footscray, Victoria, Australia|Peninsula Oncology Centre, Frankston, Victoria, Australia|South Eastern Private, Noble Park, Victoria, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|Maroondah Public, Ringwood East, Victoria, Australia|Ringwood/Knox Private, Ringwood, Victoria, Australia|Hollywood Private Hospital, Nedlands, Western Australia, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia|Mount Medical Centre, Perth, Western Australia, Australia|Royal Perth Hospital, Perth, Western Australia, Australia|OL Vrouw Ziekenhuis Aalst Gastro-Enterologie, Aalst, Belgium|ZNA Middelheim, Antwerpen, Belgium|Antwerp University Hospital, Antwerp, Belgium|Imelda Ziekenhuis GI Clinical Research Centre, Bonheiden, Belgium|Sint-Josef Ziekenhuie (Campus Bornem), Bornem, Belgium|Institut Jules Bordet - Centre de Tumeurs d'ULB, Brussels, Belgium|Universiteits Ziekenhuis Gent, Gent, Belgium|AZ Maria Middelares, Gent, Belgium|Hospital de Jolimont, Haine-Saint-Paul, Belgium|UZ Leuven, Campus Gasthuisberg, Leuven, Belgium|Centre Hospitalier Universitaire de Liege, Liege, Belgium|VZW Emmaus St. Maarten Ziekenhuis Mechelen and St. Marten Ziekenhuis Duffel, Mechelen, Belgium|AZ Heilige Familie, Reet, Belgium|Sint-Augustinus Ziekenhuis, Wilrijk, Belgium|CHU de Bordeau, Bordeaux, France|Hospitalier Universitaire de Grenoble C.H.U., La Tronche, France|Centre Hospitalier General de Longjumeau, Longjumeau, France|Hopital de l'Archet II, CHU de Nice, Nice, France|Hospital European Georges Pompidou, Paris, France|Centre Eugene Marquis, Rennes Cedex, France|Internistische Gemeinschaftspraxis, Altstadt, Germany|Charite Campus Virchow Klinikum, Berlin, Germany|Braxiskooperation Bonn, Fachartze fur Innere Medizin, Bonn, Germany|Johanniterkrankenhaus Bonn, Bonn, Germany|Universitaetsklinikum Bonn, Bonn, Germany|Kliniken Essen Mitte, Essen, Germany|Gemeinschaftspraxis Hamatologie und internistische Onkologie, Essen, Germany|Universitat Frankfurt Institute fur Diagnostic und Interventionelle Radiologie, Frankfurt, Germany|Asklepios Klinik Altona, Abt. Radiologie, Neuroradiologie, Nuklearmedizin, Hamburg, Germany|Universitastsklinikum Saarland, Hamburg, Germany|Praxisgemeinschaft Dr. med. Peter Sandor und Peter Kohl, Holzkirch, Germany|Onklogische Praxis Dr. Gerald Gehbauer, Ingolstadt, Germany|Klinikum Karlsruhe, Stadtisches Klinikum Karlsruhe, Zentralinstitut fur Bildgebende Diagnostik, Karlsruhe, Germany|Schwerpunktpraxis fur Hamatologie und Onkologie, Magdeburg, Germany|Klinikum Magdeburg GmbH, Klinik für Hämatologie/Onkologie, Magdeburg, Germany|Universitaetsklinikum Magdeburg, Magdeburg, Germany|Universitatsklinikum GieBen und Marburg, Marburg, Germany|Klinikum Bogenhausen, Muenchen, Germany|Klinikum der Universitaet Muenchen, Muenchen, Germany|Hamato-Onkologische Schwerpunktspraxis, Munchen, Germany|Klinikum rechts der Isar der TU Munchen, Munchen, Germany|Schwerpunktspraxis fur Hamatologie und Internistische Onkologie, Munchen, Germany|Praxis fur Hamatologie und Internnistische Onkologie, Velbert, Germany|Schwerpunktspraxis und Tagesklinik Dr. Perker/Dr. Sandherr, Weilheim, Germany|Rambam Medical Center, Haifa, Israel|Shaare-Zedek Medical Centre, Jerusalem, Israel|Rabin Medical Center, Beilinson Hospital, Petah Tiqva, Israel|Sheba Medical Center, Ramat Gan, Israel|TA Sourasky Medical Center, Tel Aviv, Israel|A.O.U. die Bologna, Bologna, Italy|University of Auckland, Auckland, New Zealand|Christchurch Hospital, Christchurch, New Zealand|Dunedin Hospital, Dunedin, New Zealand|Wellington Hospital, Newtown, New Zealand|Palmerston North Hospital, Palmerston, New Zealand|Wojskowy Instytut Medyczny (WIM), Warsaw, Poland|Clinica Universitaria de Navarra, Pamplona, Spain|Hospital de Navarra, Servicio de Ongoligia, Planta Baja, Pamplona, Spain|Universitatsspital Zurich, Zurich, Switzerland		https://ClinicalTrials.gov/show/NCT00724503
284	NCT00520052	Frequency of Zoledronic Acid to Prevent Further Bone Loss in Osteoporotic Patients Requiring Androgen Deprivation Therapy for Prostate Cancer		Completed	No Results Available	Osteoporosis	Drug: zoledronic acid	axial and peripheral bone mineral density|serum and urine bone turnover markers	Wirral University Teaching Hospital NHS Trust|Novartis	Male	Child, Adult, Older Adult	Not Applicable	58	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	57/03	August 2003		August 2005	August 23, 2007		August 23, 2007	Wirral Hospitals Universirt NHS Trust, Upton, Wirral, Merseyside, United Kingdom		https://ClinicalTrials.gov/show/NCT00520052
285	NCT02680535	MRI/US Fusion Imaging and Biopsy in Combination With Nanoparticle Directed Focal Therapy for Ablation of Prostate Tissue		Recruiting	No Results Available	Neoplasms of the Prostate	Device: AuroShell particle infusion	Evidence of efficacy of focal ablation of clinically significant targeted prostate lesion(s) confirmed using 3T MRI/Ultrasound guided biopsy 3 months after treatment.|Adverse Events|Evidence of efficacy of focal ablation of clinically significant targeted prostate lesion(s) confirmed using 3T MRI/Ultrasound guided biopsy one year after treatment.	Nanospectra Biosciences, Inc.	Male	45 Years and older   (Adult, Older Adult)	Not Applicable	45	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NBI-PC-002	February 2016	July 2019	December 2019	February 11, 2016		April 29, 2019	Johns Hopkins Hospital, Baltimore, Maryland, United States|University of Michigan, Ann Arbor, Michigan, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|The University of Texas Medical Branch, Galveston, Texas, United States|University of Texas Medical School at Houston, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT02680535
286	NCT03146338	Prophylaxis of Magnesium-rich Mineral Water to Prevent Hypomagnesemia Induced by an Anti-EGFR (OPTIMAG)	OPTIMAG	Recruiting	No Results Available	Metastatic Colorectal Cancer|Metastatic Head and Neck Cancer	Other: Magnesium-rich mineral water (Rozana)	Rate of patients with hypomagnesemia|Median rate of magnesium and hypomagnesemia grade III / IV|Proportion of patients with a 20% decrease in magnesemia|Incidence of hypomagnesemia after 2 cycles of anti-EGFR treatment|The fraction of urinary excretion over 24 hours of magnesium|Rate of patient requiring magnesium supplementation|Rate of hypomagnesemia at 5 months of treatment|Enteral intakes in magnesium|Quality of life|Compliance|Rate of diarrhea and cramps|Hypocalcaemia and hypokalemia rates|Time until hypomagnesemia occurrence, regardless of grade, and time until grade III / IV hypomagnesemia|Progression-free survival|Overall survival	Weprom|Neptune	All	18 Years and older   (Adult, Older Adult)	Not Applicable	166	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	ILC-2-2016|2016-A01091-50	July 4, 2017	November 2019	July 2021	May 9, 2017		July 31, 2019	GHBS Lorient, Lorient, Bretagne, France|CARIO-HPCA Plérin, Plérin, Bretagne, France|Centre Maurice TUBIANA, Caen, Normandie, France|CORT 37, Chambray-lès-Tours, France|Centre Hospitalier Départemental, La Roche-sur-Yon, France|Centre Hospitalier, Le Mans, France|Centre Jean Bernard, Le Mans, France|Polyclinique de Gentilly, Nancy, France|Centre Hospitalier, Niort, France|Centre Hospitalier Centre Bretagne, Pontivy, France|CHRU Tours, Tours, France|Centre d'Oncolgie Saint Yves, Vannes, France		https://ClinicalTrials.gov/show/NCT03146338
287	NCT00539253	Assessment of Liver Cancer Response to TACE Using MultiHance-Enhanced MRI.	TACE	Completed	Has Results	Hepatocellular Carcinoma	Drug: gadobenate dimeglumine (MultiHance)	Nodule Size|Nodule Enhancement	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Bracco Diagnostics, Inc	All	18 Years to 80 Years   (Adult, Older Adult)	Not Applicable	45	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	J06108|NA_00003943	September 2007	March 2013	December 2013	October 4, 2007	September 26, 2017	September 26, 2017	The Johns Hopkins Hospital, Baltimore, Maryland, United States		https://ClinicalTrials.gov/show/NCT00539253
288	NCT02306265	Assessment of Diagnostic Accuracy and Performance of Digital Breast Tomosynthesis Compared to Mammography	ADAPT	Completed	Has Results	Breast Cancer|Tumors, Breast|Cancer Screening	Device: FFDM|Device: DBT	Number of Participants With Imaging Data Collected	GE Healthcare	Female	30 Years and older   (Adult, Older Adult)	Not Applicable	250	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening	124.03-2014-GES-0010	May 2015	July 7, 2017	July 7, 2017	December 3, 2014	January 29, 2019	January 29, 2019	Beaumont Health System, Royal Oak, Michigan, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/65/NCT02306265/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT02306265
289	NCT00730808	Effectiveness and Tolerability of an Oral Nutritional Supplement (PreOP Booster) Given Before Surgery		Completed	No Results Available	Rectal Tumors	Dietary Supplement: PreOP Booster (food for special medical purposes)	Immunoinflammatory parameters|Antioxidant / oxidant parameters|Ischemia / reperfusion injury parameters|pre-and postoperative discomfort (well-being)|hand grip strength|GI tolerance|Safety	Fresenius Kabi	All	18 Years to 75 Years   (Adult, Older Adult)	Not Applicable	20	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care	N-POB-04-NL	December 2008	November 2009	November 2009	August 8, 2008		May 19, 2010	Medical Center Alkmaar, Alkmaar, Netherlands		https://ClinicalTrials.gov/show/NCT00730808
290	NCT02638935	Evaluation of Virtual Touch Tissue Imaging Quantification (VTIQ - 2D-SWE) in the Assessment of BI-RADS® 3 and 4 Lesions		Recruiting	No Results Available	Breast Neoplasms	Device: Ultrasound- Virtual Touch Tissue Imaging Quantification	Standard chi-square test at a two-sided significance level of 5% to test the diagnostic accuracy of Virtual Touch Tissue Imaging Quantification (VTIQ) in the differentiation of BI-RADS® 3 and 4a lesions|Standard Binomial-test according to Bonferroni-Holm to test the null hypothesis H0_2|Standard Binomial-test according to Bonferroni-Holm to test the null hypothesis H0_3|Corresponding chi-square tests for descriptive analysis of Virtual Touch Tissue Imaging Quantification (VTIQ) in the assessment of BI-RADS® 3, 4b, 4c lesions|BI-RADS® vs. BI-RADS® + Virtual Touch Tissue Imaging Quantification (VTIQ)|Corresponding chi-square tests for descriptive analysis of the strain ratio in the differentiation of BI-RADS® 3, 4a, 4b or 4c lesions|Robust regression models to test the INTRA-RATER reliability for the original continuous scale|Cohens's Kappa to test the INTRA-RATER reliability for the dichotomized values|Robust regression models to test the INTER-RATER reliability for the original continuous scale|Cohens's Kappa to test the INTER-RATER reliability for the dichotomized values|Descriptive analysis of predictive factors of the continuous VTIQ-value|Skin to breast lesion surface depth (cm)|Quality factor within the lesion assessed using a color coded scale|Breast density/ tissue composition assessed using the morphologic characteristics on US (homogeneous background texture fat, homogeneous background texture fibroglandular, heterogeneous background texture)|Lesion size in B-mode Ultrasound (in cm)|Normal fatty tissue shear wave velocity (ratio between measurement in the fatty tissue and in the lesion)|Pathology (fibroadenoma, lipoma, atypia, cyst condense, "non special type" (NST), invasive lobular carcinoma (ILC), invasive tubular carcinoma (ITC), carcinoma with medullary features, papillary cancer, ductal carcinoma in situ (DCIS), others)|Grading (G1, G2, G3, Gx)|Immunohistology (estrogen receptor (ER) status positive/ negative, progesterone receptor (PgR) status positive/ negative, human epidermal growth factor receptor 2 (HER2-neu) status positive/ negative, Ki-67 status (%))|Cohens's Kappa to determine the inter-rater reliability of BI-RADS® Assessment (local vs. central assessment)|Interclass correlation coefficient (ICC) values to determine the inter-rater reliability of BI-RADS® Assessment (local vs. central assessment)|BI-RADS® vs. histological results|Chi-square test to examine whether the cut-off value of ≥ 3.5 m/s (37kPa) might be increased by increasing the cut-off value step-by-step by a small amount and repeat the primary analysis	Heidelberg University|Siemens Medical Solutions	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	1000	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic	VTIQ	February 2016	August 2018	August 2018	December 23, 2015		October 27, 2017	Radiology Consultants, Inc., Youngstown, Ohio, United States|Institut Gustave Roussy, Service de Radiologie, Villejuif Cedex, Villejuif, France|Franziskus Hospital, Bielefeld, Germany|Universitätsmedizin Greifswald, Klinik für Frauenheilkunde und Geburtshilfe, Greifswald, Germany|University of Heidelberg, Heidelberg, Germany|Universitätsklinikum Marburg, Klinik für Gynäkologie, gyn. Endokrinologie und Onkologie Senologische Diagnostik & Gynäkologischer Ultraschall, Marburg, Germany|LMU Klinikum der Universität München, München, Germany|Universitätsklinikum Tübingen, Tubingen, Germany|Sagara Hospital, Kagoshima, Matsubaracho, Kagoshima-shi, Japan|Jeroen Bosch Hospital, 's-Hertogenbosch, Netherlands|Centro Hospitalar e Universitário de Coimbra, Departamento de Radiologia, Coimbra, Portugal		https://ClinicalTrials.gov/show/NCT02638935
291	NCT00656305	ExAblate (MRgFUS) Treatment of Metastatic Bone Tumors for the Palliation of Pain		Completed	Has Results	Bone Metastases|Multiple Myeloma	Device: ExAblate MRfFUS|Device: Sham	Number of Responders|Number of Participants With a Change in Medication Use|Quality of Life (QOL) as Measured by Change in Bodily Pain Inventory (BPI) From Baseline	InSightec	All	18 Years to 100 Years   (Adult, Older Adult)	Not Applicable	147	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	BM004	March 2008	September 2012	September 2012	April 11, 2008	November 14, 2018	November 14, 2018	University of California San Diego, La Jolla, California, United States|Stanford University Medical Center, Stanford, California, United States|University MRI & Diagnostic Imaging Centers, Boca Raton, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Weill Cornell Medical College, New York, New York, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|University of Virginia Health System, Charlottesville, Virginia, United States|Toronto General Hospital, Toronto, Ontario, Canada|Rambam medical Center -The Pain palliation unit, Haifa, Israel|Sheba Medical Center, Tel Hashomer, Israel|University of Rome "La Sapienza", Rome, Italy|Rostov State Research Institute of Oncology, Rostov on Don, Russian Federation|N. N. Petrov Institute of Oncology, St. Petersburg, Russian Federation		https://ClinicalTrials.gov/show/NCT00656305
292	NCT02787512	Preoperative Biliary Drainage With Metal Versus Plastic Stents in Periampullary Cancer		Completed	No Results Available	Jaundice|Periampullary Cancer	Device: Stent	Reintervention rate until operation|Other complication rate associated with endoscopic stent insertion and stent indwell|Rate of decrease of total bilirubin|Time to operation|Time to hospital discharge after pancreaticoduodenectomy|Mortality until 3 months after pancreaticoduodenectomy	Seoul National University Hospital|Boston Scientific Corporation	All	20 Years and older   (Adult, Older Adult)	Not Applicable	60	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	SNUBH-IMGPB-2016-01	June 2016	January 10, 2019	January 10, 2019	June 1, 2016		February 12, 2019	Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Korea, Republic of|Gachon University Gil Medical Center, Incheon, Korea, Republic of		https://ClinicalTrials.gov/show/NCT02787512
293	NCT00230295	Indirect Magnetic Resonance Lymphangiography of the Head and Neck Region Using Conventional Gadolinium-based Contrast		Completed	No Results Available	Head and Neck Cancer|Head and Neck Cancers	Procedure: IMR LAG	To determined the ability of magnetic resonance lymphangiography using conventional gadolinium injected directly into the tumor site and PET scan in detecting microscopic nodal metastasis in patients with newly diagnosed H&N cancers	Stanford University|McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	20	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ENT0010	February 2003	November 2007	November 2007	September 30, 2005		July 27, 2010	Stanford University School of Medicine, Stanford, California, United States		https://ClinicalTrials.gov/show/NCT00230295
294	NCT02201797	Reproducibility and Repeatability of Multifunctional MRI Biomarkers of the Body		Completed	No Results Available	Metastatic Liver Cancer	Other: DCE MRI	repeatability coefficient (RC)	Asan Medical Center|Bracco Diagnostics, Inc	All	18 Years and older   (Adult, Older Adult)	Not Applicable	13	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	2014-0060	October 2014	June 2015	June 2015	July 28, 2014		June 24, 2015	Asan Medical Center, Seoul, Korea, Republic of		https://ClinicalTrials.gov/show/NCT02201797
295	NCT00969124	Impact of Experience on Results With the Third Eye Retroscope		Completed	Has Results	Colorectal Neoplasms	Device: Third Eye Retroscope	Detection Rates for Adenomas|Detection Rates for All Polyps|Time Spent During Withdrawal Phase and Total Procedure	Avantis Medical Systems	All	Child, Adult, Older Adult	Not Applicable	328	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	Avantis TER 08-07	January 2009	October 2009	October 2009	September 1, 2009	July 26, 2017	July 26, 2017	Florida Hospital, Celebration, Florida, United States|University of Chicago, Chicago, Illinois, United States|NorthShore University HealthSystem, Evanston, Illinois, United States|University of Massachusetts, Worcester, Massachusetts, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|Parkland Hospital, Dallas, Texas, United States|Baylor University Medical Center, Dallas, Texas, United States|S.W. Fort Worth Endoscopy Center, Fort Worth, Texas, United States|North Hills Hospital, North Richland Hills, Texas, United States		https://ClinicalTrials.gov/show/NCT00969124
296	NCT01201850	The Role of Bevacizumab in the Treatment of Radiation Necrosis in Children With Central Nervous System Tumors		Active, not recruiting	No Results Available	Radiation Necrosis	Drug: Bevacizumab (Avastin®)	Feasibility of treating pediatric patients with CNS radiation necrosis with bevacizumab|Collect multiple aspects of the patient's clinical status and radiologic imaging	University of Colorado, Denver|Genentech, Inc.	All	1 Year to 25 Years   (Child, Adult)	Not Applicable	8	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	10-0418	July 2010	February 2019	September 2019	September 15, 2010		January 15, 2019	Children's Hospital Colorado, Aurora, Colorado, United States		https://ClinicalTrials.gov/show/NCT01201850
297	NCT03750214	Evaluation of the Biop Colposcopy System's Safety and Performance (Accuracy of Its Registration Procedure)		Not yet recruiting	No Results Available	Cervical Cancer Screening	Device: Biop Colposcopy System	Performance|frequency and incidence of all Adverse Events	BIOP Medical	Female	22 Years to 65 Years   (Adult, Older Adult)	Not Applicable	26	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening	CLP - 430	November 2019	February 2020	February 2020	November 21, 2018		July 16, 2019			https://ClinicalTrials.gov/show/NCT03750214
298	NCT03332160	A Pilot Study to Evaluate the Feasibility and Potential Effectiveness of the Flexitouch System Head and Neck Treatment		Active, not recruiting	No Results Available	Head and Neck Neoplasms|Head and Neck Cancer|Head and Neck Lymphedema	Device: Flexitouch head and neck lymphedema treatment system|Other: Standard home lymphedema care	Fidelity/Adherence via Subject Diary|Adverse Events|Treatment Satisfaction|Reduction in Swelling/Inflammation - Endoscopy|Reduction in Swelling/Inflammation - Cytokine Levels|Reduction in Swelling/Inflammation - Digital Photography|Reduction in Swelling/Inflammation - Grading of External Lymphedema|Function - Jaw Range of Motion|Function - Neck Disability Index|Function - Voice Handicap Index|Function - Cervical and Shoulder Range of Motion|Symptoms - Vanderbilt Head and Neck Symptom Survey|Quality of Life - Linear Analog Self-Assessment|Symptoms - Lymphedema Symptom Intensity and Distress Survey	Tactile Medical|Vanderbilt University	All	18 Years and older   (Adult, Older Adult)	Not Applicable	49	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	4030	January 2, 2018	June 4, 2019	July 31, 2019	November 6, 2017		July 4, 2019	SIU School of Medicine, Springfield, Illinois, United States|Vanderbilt University, Nashville, Tennessee, United States		https://ClinicalTrials.gov/show/NCT03332160
299	NCT01727570	Prehabilitation to Overcome the Stress of Surgery: the Role of Nutrition in Enhancing Postoperative Functional Capacity		Completed	No Results Available	Colorectal Cancer	Dietary Supplement: Whey Protein (Immunocal®)	Six-Minute Walk Test (6MWT)	Franco Carli|Immunotec Inc.|McGill University Health Center	All	18 Years to 85 Years   (Adult, Older Adult)	Not Applicable	60	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care	11-240-SDR	September 2012	October 2013	October 2013	November 16, 2012		November 20, 2014	Montreal General Hospital, Montreal, Quebec, Canada		https://ClinicalTrials.gov/show/NCT01727570
300	NCT03788187	Persistant Organics Pollutants in Breast Cancer.	METAPOP	Completed	No Results Available	Breast Cancer|Persistant Organic Pollutants|Lymph Node Metastases	Other: Blood test sample|Other: Peritumoral adipose tissue sample	Metastatic lymph node status based of persistant organic pollutants level measured by by gas chromatography coupled to high-resolution mass spectrometry.|Pro metastatic genes messenger ribonucleic acid (mARN) expression in the tumor based of metastatic lymph node status and persistant pollutants level.	European Georges Pompidou Hospital|Institut National de la Santé Et de la Recherche Médicale, France|ONIRIS	All	18 Years and older   (Adult, Older Adult)	Not Applicable	80	Other|Industry	Interventional	Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other	2013-A00663-42	August 2013	December 27, 2013	September 15, 2017	December 27, 2018		December 27, 2018			https://ClinicalTrials.gov/show/NCT03788187
301	NCT02158507	Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer		Active, not recruiting	No Results Available	Metastatic Triple Negative Breast Cancer	Drug: Combination of Veliparib + Lapatinib	Number of subjects experiencing study-related toxicities when taking Veliparib in Combination with Lapatinib|Number of subjects with objective response rate (ORR) at 4 years post baseline (Complete responses [CRs] plus partial responses [PRs]|Number of subjects with progression free survival (PFS) at 4 years after start of study.|DNA methylation and RNA transcriptome will be evaluated before and after therapy; baseline pattern will be compared with the post treatment pattern to identify markers of response or resistance.|Measure numbers of circulating tumor cells before and after therapy|Peak Plasma concentration of Veliparib and Palatinib when given in combination.|Measure level of the M30 before and after therapy	University of Alabama at Birmingham|Scariot Foundation|GlaxoSmithKline|AbbVie	Female	19 Years and older   (Adult, Older Adult)	Not Applicable	23	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	F131219003 (UAB 1372)|000504723	July 2014	September 1, 2019	September 1, 2020	June 9, 2014		January 7, 2019	University of Alabama at Birmingham, Birmingham, Alabama, United States		https://ClinicalTrials.gov/show/NCT02158507
302	NCT04038736	Evaluation C-Scan System in Providing Structural Information and Polypoid Lesions in the Colon of Healthy Subjects	CRC	Not yet recruiting	No Results Available	Risk for Colorectal Cancer	Device: C-Scan System	Safety- Number of incidents of trial duration above 300 hours|Safety measurments of the C-Scan System regarding SUSAR|Evaluation of the performance of the C-scan System in detecting polyps≥10 mm compared to FIT results	Ceck Cap Ltd.	All	40 Years to 80 Years   (Adult, Older Adult)	Not Applicable	300	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic	CL-SY-01-0098	August 15, 2019	August 15, 2020	August 31, 2020	July 31, 2019		August 14, 2019	Bnai Zion Medical Center, Haifa, North, Israel|Rambam Medical Center, Haifa, North, Israel|Haemek Medical Center, Afula, Israel|Tel Aviv Sorasky Medical Center, Tel Aviv, Israel		https://ClinicalTrials.gov/show/NCT04038736
303	NCT03753789	Ablation Confirmation Study		Not yet recruiting	No Results Available	Cancer of the Liver|Liver Cancer|Neoplasms, Liver	Device: Microwave Ablation	Percentage of patients where probe repositioning is suggested|Percentage of patients where re-ablation is suggested|Rate of Adverse Events|Technical Success|Technique Efficacy|Hospital Resource Utilization #1: Time to perform the ablation procedure,|Hospital Resource Utilization #2: Length of hospital stay (if applicable)	Ethicon, Inc.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	100	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NEU_2017_03	September 30, 2019	December 31, 2020	December 31, 2020	November 27, 2018		July 25, 2019	Cedars-Sinai Medical Center, Los Angeles, California, United States|Mayo Clinic, Rochester, Minnesota, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|MD Anderson Cancer Center, Houston, Texas, United States|University of Wisconsin, Madison, Wisconsin, United States|University of Frankfurt, Frankfurt, Germany|University Hospital Regensburg, Regensburg, Germany|Lausanne University Hospital, Lausanne, Switzerland|University Hospital Southampton, Southampton, United Kingdom		https://ClinicalTrials.gov/show/NCT03753789
304	NCT00507208	Dynasplint Therapy for Trismus in Head and Neck Cancer		Completed	Has Results	Trismus	Device: Dynasplint Trismus System|Other: Tongue Depressors	Number of Participants Demonstrating Improved MIO Using Either the Dynapslint System or Tongue Depressors	University of Alabama at Birmingham|Dynasplint Systems, Inc.	All	19 Years and older   (Adult, Older Adult)	Not Applicable	53	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	F070323014|HNO 0602	July 2007	July 2015	July 2015	July 26, 2007	July 25, 2016	September 13, 2016	UAB Department of Otolaryngology, Birmingham, Alabama, United States		https://ClinicalTrials.gov/show/NCT00507208
305	NCT01104181	Hybrid Capture 2 Human Papiloma Virus (HPV) High-Risk Anal DNA Test		Completed	No Results Available	Anal Canal HPV Infection Diagnosis|Anal Dysplasia Diagnosis|Anal Cancer	Device: HC2 collection kit with a swab or brush	HC2 can accurately test for oncogenic HPV in anal specimens|Sensitivity and specificity of cytology with HC2	Laser Surgery Care|QIAGEN Gaithersburg, Inc	All	18 Years to 90 Years   (Adult, Older Adult)	Not Applicable	300	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Diagnostic	R09-HPV-001	March 2010	December 2010	March 2011	April 15, 2010		June 22, 2011	Laser Surgery Care, Inc., New York, New York, United States		https://ClinicalTrials.gov/show/NCT01104181
306	NCT02221076	Probe-based and Needle-based Confocal Laser Endomicroscopy During Gynaecological Procedures.		Completed	No Results Available	Cervix Cancer|Endometrium Cancer|Ovarian Cancer|Carcinoma in Situ of Fallopian Tube	Device: Confocal Laser Endomicroscopy (CLE)	The number of participants with adverse events, their type and severity.|Number of interpretable images per organ and per pathology	Mauna Kea Technologies	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	16	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	GYN_MKT_2014|2014-A00312-45	July 2014	April 18, 2016	April 18, 2016	August 20, 2014		August 29, 2017	Institut Paoli Calmettes, Marseille, France		https://ClinicalTrials.gov/show/NCT02221076
307	NCT03684408	Radiofrequency Chip for Localization of Non-Palpable Breast Lesions		Recruiting	No Results Available	Breast Tumor	Device: RFID Localization|Device: Wire Localization|Device: RFID and Wire Localization	Success of localization|Surveys of Satisfaction|Size of Tumor Margins	University of Missouri-Columbia|Health Beacons	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	84	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other	2011684	October 18, 2018	August 31, 2020	December 31, 2020	September 25, 2018		October 23, 2018	University of Missouri, Columbia, Missouri, United States		https://ClinicalTrials.gov/show/NCT03684408
308	NCT03603587	Bioclinical Study of Scalp Photoaging of a Population Male Over 65 Years Old.	BACCHUS	Recruiting	No Results Available	Skin Aging|Skin Cancer	Procedure: biopsy|Diagnostic Test: blood sample|Diagnostic Test: questionnaire on sun exposure|Diagnostic Test: examination of the scalp|Diagnostic Test: Norwood scale|Diagnostic Test: questionnaire of clinicals signs|Diagnostic Test: scinexa score|Diagnostic Test: questionnaire of the history of the hair loss	Scalp skin biomarkers|Differential expression profile of proteomic biomarkers|Data of thickness measurements of the 3 layers of the skin|scalp microflora|Percentage of anisotropy of the tensile forces of the skin|histology|Heterogeneity of pigmentation|Scinexa score (SCore for INtrinsic and EXtrinsic skin Aging)|The measurement of the thickness of the dermis|The measurement of the morphology of the dermal junction epidermis|Solar exposure score|Norwood's scale	Centre Hospitalier Universitaire de Saint Etienne|Pierre Fabre Dermo Cosmetique	Male	65 Years and older   (Older Adult)	Not Applicable	40	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	18CH035|2018-A00714-51	February 14, 2019	February 2020	May 2020	July 27, 2018		February 19, 2019	Chu de Saint Etienne, Saint Etienne, France		https://ClinicalTrials.gov/show/NCT03603587
309	NCT02973217	Immunostimulating Interstitial Laser Thermotherapy in Pancreatic Cancer		Active, not recruiting	No Results Available	Neoplasms Pancreatic	Device: Immunostimulating Interstitial Laser Thermotherapy	Safety (adverse events)|Inflammatory response in circulation measured by quantification of inflammatory cell populations|Disease progression|Evaluation of Quality of Life (using questionnaires)|Usability of the device as evaluated by treatment logs	Clinical Laserthermia Systems AB	All	18 Years to 80 Years   (Adult, Older Adult)	Not Applicable	5	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CTP-2015-008	October 2016	October 2020	February 2021	November 25, 2016		January 30, 2019	Institut J. Paoli et L. Calmettes (IPC), Marseille, France		https://ClinicalTrials.gov/show/NCT02973217
310	NCT03187587	Percutaneous Immunostimulating Interstitial Laser Thermotherapy in Pancreatic Cancer		Active, not recruiting	No Results Available	Neoplasms Pancreatic	Device: imILT|Drug: Standard chemotherapy treatment	Treatment effect by radiology|Safety assessed by the incidence the of adverse events|Usability (user evaluation of instrument)	Clinical Laserthermia Systems AB	All	18 Years to 80 Years   (Adult, Older Adult)	Not Applicable	8	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CTP-2015-006	May 17, 2017	January 2019	April 2019	June 15, 2017		January 30, 2019	Portuguese Oncology Institute of Porto, Porto, Portugal		https://ClinicalTrials.gov/show/NCT03187587
311	NCT01944722	Clinical Evaluation of the BD Onclarity™ HPV Assay on the BD Viper™ LT System With Cervical Specimens		Completed	Has Results	Uterine Cervical Neoplasms	Device: BD Onclarity™ HPV assay on BD Viper™ LT|Procedure: Colposcopy	Sensitivity of the BD Onclarity™ HPV Assay for the Detection Cervical Disease as Defined by Cervical Intraepithelial Neoplasia (CIN)2 or Greater|Sensitivity of the BD Onclarity™ HPV Assay for the Detection of Cervical Disease as Defined by Cervical Intraepithelial Neoplasia (CIN)3 or Greater|Specificity of the BD Onclarity™ HPV Assay for Detecting Cervical Disease as Defined by Cervical Intraepithelial Neoplasia (CIN)2 or Greater|Specificity of the BD Onclarity™ HPV Assay for Detecting Cervical Disease as Defined by Cervical Intraepithelial Neoplasia (CIN)3 or Greater|Positive Predictive Value (PPV) of the BD Onclarity™ HPV Assay for Detecting Cervical Disease as Defined by Cervical Intraepithelial Neoplasia (CIN).|Negative Predictive Value (NPV) of the BD Onclarity™ HPV Assay for Detecting Cervical Disease as Defined by Cervical Intraepithelial Neoplasia (CIN).|Likelihood Ratio for the Detection of Cervical Disease as Defined by Cervical Intraepithelial Neoplasia (CIN2 or Greater).|Likelihood Ratio for the Detection of Cervical Disease as Defined by Cervical Intraepithelial Neoplasia (CIN3 or Greater).|Absolute Risk for the Detection of Cervical Disease as Defined by Cervical Intraepithelial Neoplasia (CIN2 or Greater).|Absolute Risk for the Detection of Cervical Disease as Defined by Cervical Intraepithelial Neoplasia (CIN3 or Greater).|Relative Risk of the Detection of Cervical Disease as Defined by Cervical Intraepithelial Neoplasia (CIN2 or Greater).|Relative Risk of the Detection of Cervical Disease as Defined by Cervical Intraepithelial Neoplasia (CIN3 or Greater).|Positive Percent Agreement of the BD Onclarity™ HPV Assay as Compared to a Composite HPV Comparator Incorporating Results for the Digene Hybrid Capture 2 (HC2) HPV Test and PCR/Sequencing on Both Strands of the PCR Amplicon (Bidirectional Sequencing)|Negative Percent Agreement of the BD Onclarity™ HPV Assay Compared to a Composite HPV Comparator Incorporating Results for the Digene HC2 HPV Test and PCR/Sequencing on Both Strands of the PCR Amplicon (Bidirectional Sequencing)|Non-reportable Rate of the BD Onclarity™ HPV Test|Number of Participants With Cervical Intraepithelial Neoplasia (CIN)2 or Greater and CIN3 or Greater Within Each Cytology Category.	Becton, Dickinson and Company	Female	21 Years and older   (Adult, Older Adult)	Not Applicable	33858	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	BDS-USHPV	August 2013	March 2016	March 2016	September 18, 2013	April 18, 2018	June 12, 2018	University of Alabama Birmingham, Birmingham, Alabama, United States|Mobile OB/GYN, Mobile, Alabama, United States|Women's Health Research of Arizona, Phoenix, Arizona, United States|Quality of Life Medical & Research Center, Tucson, Arizona, United States|Visions Clinical Research, Tucson, Arizona, United States|Women's Health Care Research Corp, San Diego, California, United States|West Coast Medical Research, San Diego, California, United States|Blueskies Center for Women, Colorado Springs, Colorado, United States|Health Awareness Inc, Jupiter, Florida, United States|Altus, Lake Worth, Florida, United States|Segal Institute for Clinical Research, North Miami, Florida, United States|Miami Research Associates, South Miami, Florida, United States|Comprehensive Clinical Trials, LLC, West Palm Beach, Florida, United States|Medical Network for Education and Research, Decatur, Georgia, United States|Fellows Research Associates - Savannah, Savannah, Georgia, United States|Women's Health Practice, Champaign, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|Four Rivers Clinical Research, Paducah, Kentucky, United States|Louisiana State University, New Orleans, Louisiana, United States|Saginaw Valley Medical Research, Saginaw, Michigan, United States|Transgenomics, Omaha, Nebraska, United States|Vitura / Phoenix, Moorestown, New Jersey, United States|Meridian Health, Neptune, New Jersey, United States|Q Squared Solutions, Teterboro, New Jersey, United States|TriCore Reference Laboratory, Albuquerque, New Mexico, United States|Montefiore Medical Center, Bronx, New York, United States|Research Pathology Associates, LLC, Irvington, New York, United States|LabCorp, Burlington, North Carolina, United States|Eastern Carolina Women's Center, New Bern, North Carolina, United States|Lyndhurst Clinical Research, Winston-Salem, North Carolina, United States|HWC Women's Research Center, Englewood, Ohio, United States|Center for Women's Health of Lansdale, Lansdale, Pennsylvania, United States|Clinical Research of Philadelphia, Philadelphia, Pennsylvania, United States|Reading Health Physicians Network, West Reading, Pennsylvania, United States|Fellows Research Associates - Bluffton, Bluffton, South Carolina, United States|James T Martin Jr, MD, North Charleston, South Carolina, United States|Chattanooga Medical Research, Chattanooga, Tennessee, United States|Center for Disease Detection (CDD), San Antonio, Texas, United States|Physicians Research Options, Draper, Utah, United States|Research Pathology Associates, Earlysville, Virginia, United States|Tidewater Clinical, Virginia Beach, Virginia, United States		https://ClinicalTrials.gov/show/NCT01944722
312	NCT03069846	Diagnosing Melanoma, Squamous Cell Carcinoma and Basal Cell Carcinoma Using the Spectra-Scope		Recruiting	No Results Available	Skin Cancer	Device: Spectra-Scope	The primary endpoint is to compare the aggregated emission spectra of skin cell carcinoma verses normal skin.	Sung Hyun Pyun|Speclipse Australia Pty Ltd	All	18 Years and older   (Adult, Older Adult)	Not Applicable	150	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	Speclipse-2016-10	June 5, 2017	June 18, 2018	June 18, 2018	March 3, 2017		April 20, 2018	Integrated Specialist Healthcare, Miranda, New South Wales, Australia		https://ClinicalTrials.gov/show/NCT03069846
313	NCT02061527	Breast Reconstruction With Acellular Dermal Matrix in the Setting of Breast Cancer Treatment		Completed	No Results Available	Breast Cancer	Procedure: Reconstruction with ADM.|Procedure: Skin or nipple sparing mastectomy|Procedure: Reconstruction with implant|Procedure: Total submuscular coverage|Procedure: Partial submuscular coverage	The primary endpoint of this study is number of unplanned/ unanticipated surgical breast procedures. Other endpoints in the trial will be secondary.|Aesthetic outcome|Complications|Number of surgical procedures|Cost-Benefit analysis|Quality of Life	Karolinska University Hospital|Karolinska Institutet|LifeCell	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	135	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	FL/KUH-ADM-LFC-2014	April 2014	April 2017	May 2017	February 13, 2014		April 24, 2018	Falun Hospital, Department of Breast Surgery, Falun, Sweden|Capio S:t Gorans Hospital, Stockholm, Sweden|Karolinska University Hospital, Stockholm, Sweden|Södersjukhuset AB, Stockholm, Sweden|Oxford University Hospitals, Oxford, United Kingdom		https://ClinicalTrials.gov/show/NCT02061527
314	NCT03849820	Open vs Robotic Assisted Partial Nephrectomy	OpeRa	Recruiting	No Results Available	Renal Cancer	Device: Robotic-assisted partial nephrectomy|Other: Open partial nephrectomy	30 day complications|Operative time|Ischemia time|Surgical radicality conversions|Intraoperative blood loss|Pain assessment|Pain Medication|Neuropathic pain|Kidney function via the estimated glomerular filtration rate (eGRF)|Post operative complications|Length of stay|Procedure related readmissions|Procedure related reoperations|Quality of recovery from the intervention|Quality of life questionnaire, generic measure|Quality of life questionnaire, cancer patient specific	Intuitive Surgical	All	18 Years and older   (Adult, Older Adult)	Not Applicable	606	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	OpeRa-2018	March 12, 2019	February 2021	April 2022	February 21, 2019		August 6, 2019	Universitätsklinik und Poliklinik für Urologie, Halle, Germany|Universitätsklinikum Heidelberg, Urologische Klinik, Heidelberg, Germany|Klinik für Urologie, Marien Hospital Herne, Herne, Germany|Department of Urology, University Hospital Jena, Jena, Germany|Klinik für Urologie, Marien-Hospital Marl, Marl, Germany|Department of Urology, Klinikum rechts der Isar der Technischen Universität, Munich, Germany|Dept. of Urology, University Hospital Tübingen, Tübingen, Germany		https://ClinicalTrials.gov/show/NCT03849820
315	NCT02061605	First-in-Human Safety Study Of Laser Tissue Welding For Surtureless Laparoscopic Partial Nephrectomy	LTW-KIDNEY	Active, not recruiting	No Results Available	Benign Renal Tumors|Malignant Renal Tumors	Device: Laser Tissue Welding Device	Operative Blood Loss|Postoperative Blood Loss|Secondary hemorrhage or hematoma (safety issue no. 1)|Post-operative urinary leakage/ urinoma (safety issue no. 2)|Secondary infection, intra‐abdominal abscess formation and septicemia (safety issue no. 3)|Urinary stone formation (safety issue no. 4)	Laser Tissue Welding, Inc.|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	All	18 Years and older   (Adult, Older Adult)	Not Applicable	10	Industry|NIH	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	LTW-LPN-01|R44DK094619-02	June 2016	December 2020	December 2020	February 13, 2014		March 1, 2019	St. Luke's Episcopal Hospital, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT02061605
316	NCT02387268	Evaluation of the Performance of the CleanC System-Israel		Completed	Has Results	Colorectal Cancer (CRC) Screening	Device: CleanC system	Percentage Subjects With Post Procedure Cleansing Level as Measured by the Boston Bowel Preparation Scale (BBPS) Adequate Cleansing-(BBPS>1 )|Safety as Measured by Number of Serious Adverse Events and Major Complications.|Percentage of Participants in Whom the Cecum Was Reached	Motus GI Medical Technologies Ltd	All	18 Years to 75 Years   (Adult, Older Adult)	Not Applicable	10	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening	CL00005	May 2015	June 2015	November 2015	March 12, 2015	March 7, 2016	September 20, 2017			https://ClinicalTrials.gov/show/NCT02387268
317	NCT03528863	Web-based Mindfulness Meditation in Reducing Distress in Participants With Metastatic Gastrointestinal Cancer and Their Caregivers		Active, not recruiting	No Results Available	Caregiver|Metastatic Gastrointestinal Carcinoma	Behavioral: Online Mindfulness Meditation|Other: Questionnaire Administration	Feasibility as assessed by evaluating recruitment rate|Feasibility as assessed by evaluating rate of refusal to participate|Feasibility as assessed by rate of attrition|Acceptability as assessed by adherence to practice instructions|Efficacy as assessed by NCCN Distress Thermometer|Efficacy as assessed by National Institutes of Health Patient Reported Outcomes Measurement Information System (NIH PROMIS)|Efficacy as assessed by a Five Facet Mindfulness Questionnaire Short (FFMQ-SF)|Efficacy as assessed by a "Are You at Peace?" one-item spiritual probe	University of California, San Francisco|Genentech, Inc.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	60	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	174534|NCI-2018-00622|18-24261	April 20, 2018	January 30, 2019	December 1, 2019	May 18, 2018		April 4, 2019	University of California, San Francisco, San Francisco, California, United States		https://ClinicalTrials.gov/show/NCT03528863
318	NCT03004586	Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Using a 22 vs 25-Gauge Needle		Active, not recruiting	No Results Available	Malignant Neoplasm of Respiratory and Intrathoracic Organ Carcinoma|Lung Cancer	Device: 25-Gauge Needle|Device: 22-Gauge Needle|Procedure: Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration (EBUS-TBNA)	Degree of Concordance in Determining Sample Adequacy and Diagnostic Yield Between the 25-Gauge and 22-Gauge Needle During Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration	M.D. Anderson Cancer Center|Boston Scientific Corporation	All	18 Years and older   (Adult, Older Adult)	Not Applicable	61	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Diagnostic	2016-0561|NCI-2017-00624	December 16, 2016	December 2021	December 2022	December 29, 2016		May 14, 2019	University of Texas MD Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT03004586
319	NCT03035487	Urology of Virginia Case Series		Completed	Has Results	Prostate Cancer|Cancer of the PROSTATE|Prostatic Neoplasm	Device: Ultrasound guided prostate exam using SOC ultrasound system|Device: mpMRI guided prostate examination using PI-RADS v2|Device: High-resolution micro-ultrasound guided prostate biopsy	Keyword Description of Each Biopsy Sample	Exact Imaging	Male	40 Years to 79 Years   (Adult, Older Adult)	Not Applicable	9	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility	2016-UHR-001	December 2016	December 2016	February 2018	January 30, 2017	March 4, 2019	May 15, 2019	Urology of Virginia, Virginia Beach, Virginia, United States		https://ClinicalTrials.gov/show/NCT03035487
320	NCT03213314	HepaT1ca: Quantifying Liver Health in Surgical Candidates for Liver Malignancies	Hepatica	Recruiting	No Results Available	Liver Cancer|Surgery|Liver Regeneration|Colorectal Cancer Metastatic	Diagnostic Test: Multiparameter magnetic resonance imaging	Correlation between the pre-operative liver health assessment score and the post-operative liver function composite integer-based risk score.|To compare LiverMultiScan image interpretations with histological findings|• To evaluate LiverMultiScan image interpretations correlated with post-operative length of stay.	University of Edinburgh|Hampshire Hospitals NHS Foundation Trust|Perspectum Diagnostics Ltd	All	18 Years and older   (Adult, Older Adult)	Not Applicable	200	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	AC17009|223180	September 7, 2017	August 31, 2019	December 31, 2019	July 11, 2017		September 25, 2017	Hampshire Hospitals Foundation Trust, Basingstoke, United Kingdom|NHS Lothian Royal Infirmary of Edinburgh, Edinburgh, United Kingdom		https://ClinicalTrials.gov/show/NCT03213314
321	NCT00657371	Efficacy of the Third Eye Retroscope Auxiliary Imaging System		Completed	Has Results	Colorectal Cancer	Device: Third Eye Retroscope Auxiliary Imaging System	Increase (Percent) of Polyps Detected That Would Have Been Missed Without the Third Eye Retroscope (TER)|Number Polyps Detected With the Standard Colonoscope and Third Eye Retroscope (TER)|Number Participants With Polyps Who Would Have Incorrectly Been Classified as Polyp-free Had the Third Eye Retroscope Not Been Used.	M.D. Anderson Cancer Center|Avantis Medical Systems	All	50 Years to 80 Years   (Adult, Older Adult)	Not Applicable	288	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening	2007-0246	March 2008	May 2010	May 2010	April 14, 2008	December 9, 2013	December 9, 2013	Mayo Clinic, Scottsdale, Arizona, United States|El Camino Hospital, Mountain View, California, United States|Camino Medical Group Surgi-Center, Sunnyvale, California, United States|Indiana University Medical Center, Indianapolis, Indiana, United States|University of Michigan, Ann Arbor, Michigan, United States|Washington University, St. Louis, Missouri, United States|U.T.M.D. Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT00657371
322	NCT02511678	Multicenter Study of Cryoablation for Palliation of Painful Bone Metastases	MOTION	Completed	No Results Available	Pain|Neoplasm Metastasis	Procedure: Cryoablation	Difference in worst pain scores	Galil Medical	All	18 Years and older   (Adult, Older Adult)	Not Applicable	65	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CGC15-BNE098	February 15, 2016	March 12, 2018	March 12, 2018	July 30, 2015		August 10, 2018	UCLA Ronald Reagan Medical Center, Los Angeles, California, United States|Emory University Hospital, Atlanta, Georgia, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Crittenton Hospital, Rochester, Michigan, United States|Mayo Clinic Rochester, Rochester, Minnesota, United States|Washington University in St. Louis, Saint Louis, Missouri, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Institut Bergonié, Bordeaux, France|Centre Léon Bérard, Lyon, France|University Hospital of Strasbourg, Strasbourg, France|Institut Gustave Roussy, Villejuif, France		https://ClinicalTrials.gov/show/NCT02511678
323	NCT03998345	Phase 1, First in Human, Open-Label, Dose-Escalation Study of 609A in China		Not yet recruiting	No Results Available	Solid Tumors	Drug: 609A	Treatment-Emergent Adverse Events|The MTD|AUC|Cmax|t1/2|CL|ORR|DCR|DOR|PFS|OS|ADA|PD-L1	Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.	All	18 Years to 70 Years   (Adult, Older Adult)	Not Applicable	24	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	SSGJ-609-UND-I-01	August 15, 2019	June 24, 2020	June 24, 2020	June 26, 2019		June 26, 2019	Cancer hospital Chinese academy of medical sceience, Beijing, Beijing, China		https://ClinicalTrials.gov/show/NCT03998345
324	NCT01868971	Clinical Study to Establish the Feasibility and Usability of the EndoRings™		Completed	No Results Available	Colon Cancer|Bowel Cancer|Colorectal Cancer	Device: EndoRings	The primary endpoint is reaching the cecum of the colon with the ENDORINGS™.|1. Incidence of complications (number of complications)|2. Ability to complete s therapeutic interventions as biopsies, polypectomies, APC etc.|3. Procedure time.|4. Ease of scope insertion, advancement and withdrawal.|5. Ability to center the scope inside the gastrointestinal tract.|6. Subjective evaluation of the additional area screened by the physician.|7. Patient satisfactory.	EndoAid	All	18 Years to 70 Years   (Adult, Older Adult)	Not Applicable	60	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening	CSDPR100	April 2013	October 2013	October 2013	June 5, 2013		July 28, 2017	Elisha Medical Center, Haifa, Please Select, Israel		https://ClinicalTrials.gov/show/NCT01868971
325	NCT01802567	Molecular-Guided Therapy for Relapsed and Refractory Childhood Cancer		Active, not recruiting	No Results Available	Neuroblastoma|Medulloblastoma|Brain Tumors|Rare Tumors	Device: Guided Therapy- Pediatric Gene Analysis Platform	Days to treatment will be used in order to determine feasibility of using tumor samples to assess genomic mRNA expression arrays and DNA Mutation Panels using predictive modeling|Number of Participants with Adverse Events as a Measure of Safety|Overall Response Rate (ORR) of Participants by the presence of radiologically assessable disease by cross-sectional CT or MRI imaging and/or by MIBG or PET scans.|Duration of response will be objectively documented|Biology studies to include: genomic analysis of cells pre- and post- treatment, correlation of in vitro response to in vivo response, flow cytometry of tumor burden in bone marrow and biomarker development|Progression Free Survival (PFS) interval will be measured by days and compared to the PFS of previous chemotherapy regimens since relapse for each patient.	Giselle Sholler|Dell, Inc.|Spectrum Health Hospitals	All	13 Months and older   (Child, Adult, Older Adult)	Not Applicable	48	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NMTRC008	February 2013	December 2019	December 2020	March 1, 2013		July 19, 2019	Phoenix Children's Hospital, Phoenix, Arizona, United States|Rady Children's Hospital, San Diego, California, United States|Connecticut Children's Hospital, Hartford, Connecticut, United States|Arnold Palmer Hospital for Children- MD Anderson, Orlando, Florida, United States|Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States|Helen DeVos Children's Hospital, Grand Rapids, Michigan, United States|Children's Mercy Hospitals and Clinics, Kansas City, Missouri, United States|Cardinal Glennon Children's Medical Center, Saint Louis, Missouri, United States|Levine Children's Hospital, Charlotte, North Carolina, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|Dell Children's Blood and Cancer Center, Austin, Texas, United States|Primary Children's Hospital, Salt Lake City, Utah, United States		https://ClinicalTrials.gov/show/NCT01802567
326	NCT02312167	Feasibility Study for Robotic Endomicroscopy to Better Define Resection Strategies (PERSEE)	PERSEE	Completed	No Results Available	Cancer of Digestive System|Ovarian Cancer	Device: confocal laser endomicroscopy	The number of participants with adverse events, their type and severity|The ease of manipulation of the robotized probe (grade 1 to 5)	Institut Mutualiste Montsouris|Mauna Kea Technologies	All	18 Years and older   (Adult, Older Adult)	Not Applicable	30	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MKT-2013-PERSEE-01	October 2014	October 2015	October 2015	December 9, 2014		February 11, 2016	Mutualiste Montsouris Institute, Paris, France		https://ClinicalTrials.gov/show/NCT02312167
327	NCT01442285	The Mental Health and Dynamic Referral for Oncology Protocol (MHADRO)	MHADRO	Completed	No Results Available	Cancer|Distress	Behavioral: personalized, motivational messages	Decrease in psychological stress|Reduced distress	University of Massachusetts, Worcester|National Institute of Mental Health (NIMH)|Polaris Health Directions	All	18 Years and older   (Adult, Older Adult)	Not Applicable	1000	Other|NIH|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research	MHADRO|H-13561|R42MH078432	April 2011	April 2015	April 2015	September 28, 2011		April 9, 2015	University of Massachusetts Medical School, UMass Memorial, Worcester, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT01442285
328	NCT02844504	Neurophysiological Evaluation of Training Effect on Cancer-Related Weakness		Recruiting	No Results Available	Breast Cancer	Behavioral: Low Intensity Exercise Training 1|Behavioral: Low Intensity Exercise Training 2	Hand grip force|Pre to Post changes of functional brain to muscle coupling at maximum handgrip contraction|Pre to Post changes in EMG amplitude at maximum handgrip contraction|Pre to Post changes in Brain activity during maximum handgrip contraction|Functional brain to muscle (EEG-EMG) phase coupling at low intensity handgrip muscle contraction.|EEG Brain connectivity during low intensity handgrip muscle contraction|Fatigue sustained handgrip contraction task duration|functional brain to muscle coupling during fatigue	Kessler Foundation|National Cancer Institute (NCI)|Kessler Institute for Rehabilitation	Female	40 Years to 75 Years   (Adult, Older Adult)	Not Applicable	75	Other|NIH|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	R-849-14|5R01CA189665-02	May 2016	September 2019	September 2019	July 26, 2016		January 19, 2018	Kessler Foundation, West Orange, New Jersey, United States|Kessler Institute for Rehabilitation, West Orange, New Jersey, United States		https://ClinicalTrials.gov/show/NCT02844504
329	NCT03671265	Combination of Chemotherapy Plus RT and SHR-1210 to Treat Patients With ESCC		Recruiting	No Results Available	Esophageal Cancer	Drug: SHR-1210|Radiation: IMRT or VMAT|Drug: Apatinib	Adverse events (AE), Serious Adverse Event(SAE) Adverse events|ORR|PFS|OS	Tianjin Medical University Cancer Institute and Hospital|Jiangsu HengRui Medicine Co., Ltd.	All	18 Years to 75 Years   (Adult, Older Adult)	Not Applicable	20	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	SHR-1210-CRT-ESC-IIT	September 17, 2018	September 1, 2019	September 1, 2021	September 14, 2018		January 9, 2019	Department of Radiation Oncology, Tianjin Medical University Cancer Hospital, Tianjin, Tianjin, China		https://ClinicalTrials.gov/show/NCT03671265
330	NCT03216109	Improving Supportive Care For Patients With Thoracic Malignancies		Recruiting	No Results Available	Lung Cancer|Quality of Life|Supportive Care	Behavioral: Weekly telephone symptom assessment	Symptom documentation|Emergency Department (ED) Visit (Chart Review)|Emergency Department Visit (Chart Review)|Hospitalizations (Chart Review)|Change in Quality of Life using the Functional Assessment of Cancer Therapy - Lung survey|Change in patient satisfaction with decision-making using the Satisfaction with Decision Survey|Change in Patient Activation using the validated Patient Activation Measure|Change in symptoms using the validated Edmonton Symptom Assessment Scale	Palo Alto Veterans Institute for Research|Carevive Systems, Inc.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	128	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care	PAT0001ARG	May 20, 2017	June 2021	December 2022	July 13, 2017		August 28, 2018	VA Palo Alto Health Care System, Palo Alto, California, United States		https://ClinicalTrials.gov/show/NCT03216109
331	NCT00665002	Pilot Trial of a WT-1 Analog Peptide Vaccine in Patients With Myeloid Neoplasms		Completed	Has Results	Leukemia	Biological: WT-1|Drug: Montanide|Drug: Sargramostim (GM-CSF)	Number of Participants With Adverse Events (AEs)|Participants Whose Samples Demonstrated Immunological Response After Vaccination	H. Lee Moffitt Cancer Center and Research Institute|Innovive Pharmaceuticals	All	18 Years and older   (Adult, Older Adult)	Not Applicable	16	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MCC-15025|INNO-305 WT-1|105946	June 2008	July 2013	February 2015	April 23, 2008	July 24, 2014	February 27, 2015	H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States		https://ClinicalTrials.gov/show/NCT00665002
332	NCT02444390	Molecular Alterations Associated With Resistance to Endocrine Therapy and Impacting Treatment With mTOR Inhibitor	SAFIR-TOR	Active, not recruiting	No Results Available	Metastatic Breast Cancer	Procedure: Biopsy	the predictive value of p4EBP1 for an mTOR inhibitor efficacy	UNICANCER|Novartis|Fondation ARC	All	18 Years and older   (Adult, Older Adult)	Not Applicable	150	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening	UC-0105/1403	May 19, 2015	October 2018	October 2021	May 14, 2015		October 11, 2018	Institut de Cancérologie de l'Ouest/Paul Papin, Angers, France|Centre Jean Perrin, Clermont-Ferrand, France|Centre Léon Bérard, Lyon, France|Institut de Cancérologie de l'Ouest/Rene Gauducheau, Nantes, France|Centre Antoine Lacassagne, Nice, France|Institut Curie, Paris, France|Clinique Armoricaine de Radiologie, Saint-Brieuc, France|INSTITUT DE CANCEROLOGIE Lucien Neuwirth, St PRIEST EN JAREZ, France|Centre Paul Strauss, Strasbourg, France|Institut Claudius Regaud, Toulouse, France|Institut de Cancerologie de Lorraine Alexis Vautrin, Vandoeuvre-les-nancy, France|Gustave Roussy, Villejuif, France		https://ClinicalTrials.gov/show/NCT02444390
333	NCT03418948	Comparison of AMR and ADR Between Endocuff Vision-assisted and Conventional Colonoscopy: a Multicenter Randomized Trial	EXCEED	Recruiting	No Results Available	Colorectal Neoplasms	Device: CC followed by EC|Device: EC followed by CC|Device: 2x EC|Device: 2x CC	Adenoma miss rate (%)|Adenoma detection rate (%)|Mean number of adenomas detected per colonoscopy procedure|Number of sessile serrated lesions per procedure|Total number of colon lesions found during first and second examination|Difference in ADR (learning curve first 20% and last 20% by each colonoscopist)|Cecal intubation rate|Bowel cleansing levels; using the Boston Bowel Preparation Scale (BBPS) ranging from 0-9)|Procedure times (minutes)|Number of severe adverse events|Sedation and analgesia use; type and amount|Post-polypectomy surveillance guidelines; difference in surveillance intervals after the first and second procedure.|To compare patient reported outcomes e.g. pain	Radboud University|Norgine	All	40 Years to 75 Years   (Adult, Older Adult)	Not Applicable	708	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Diagnostic	EXCEED study	December 8, 2017	September 1, 2019	November 1, 2019	February 1, 2018		February 1, 2018	"Attikon" University General Hospital,, Athens, Haidari, Greece|417 Army Veterans Hospital, Athens, Greece|Radboud University Medical Center, Nijmegen, Gelderland, Netherlands		https://ClinicalTrials.gov/show/NCT03418948
334	NCT02678442	Endoscopic Ultrasound Guided Fine Needle Biopsy (EUS-FNB-SC) Using a Novel Fork Needle		Completed	No Results Available	Pancreatic Cancer	Device: Fine Needle Biopsy (FNB)|Device: Fine Needle Aspiration (FNA)	Quantity of DNA obtained by FNB versus FNA needle|Number of passes needed for tissue sample.|Size of the core specimen.|Yield of tissue for genomic profiling|Time needed for the fine needle core biopsy portion of EUS examination|Amount of material needed for cytology analysis|Amount of material needed for malignancy analysis	Mayo Clinic|Medtronic	All	18 Years to 100 Years   (Adult, Older Adult)	Not Applicable	50	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Diagnostic	15-007801	March 2016	November 16, 2018	November 16, 2018	February 9, 2016		March 28, 2019	Mayo Clinic, Jacksonville, Florida, United States		https://ClinicalTrials.gov/show/NCT02678442
335	NCT03721484	CINtec PLUS Triage in HPV Primary Screening		Not yet recruiting	No Results Available	Cervical Cancer	Diagnostic Test: CINtec PLUS	Risk of high-grade disease|Risk of low-grade disease	Western Health and Social Care Trust|Roche Pharma AG	Female	25 Years to 64 Years   (Adult)	Not Applicable	9800	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	v1.0	January 2019	July 2020	December 2021	October 26, 2018		October 26, 2018	WHSCT, Londonderry, Northern Ireland, United Kingdom		https://ClinicalTrials.gov/show/NCT03721484
336	NCT03257670	Fractional CO2 Laser Therapy Versus 4% Topical Lidocaine Gel for Dyspareunia in Breast Cancer Survivors	BCLS	Recruiting	No Results Available	Dyspareunia	Drug: 4% Topical Lidocaine Gel|Device: CO2RE fractional laser therapy	Female Sexual Function Index (FSFI) score before and after treatment with topical lidocaine ointment or transvaginal CO2 laser among breast cancer survivors with dyspareunia.|Numeric Pain Rating Scale (NPRS) score before and after treatment with topical lidocaine ointment or transvaginal CO2 laser among breast cancer survivors with dyspareunia.|Incontinence Severity Index (ISI) score before and after treatment with topical lidocaine ointment or transvaginal CO2 laser among breast cancer survivors with dyspareunia.|3 Incontinence Questions (3-IQ) score before and after treatment with topical lidocaine ointment or transvaginal CO2 laser among breast cancer survivors with dyspareunia.|Colon Rectal Anal Distress Inventory (CRADI) score before and after treatment with topical lidocaine ointment or transvaginal CO2 laser among breast cancer survivors with dyspareunia.|Patient Global Impression of Severity (PGI-S) score before treatment with topical lidocaine ointment or transvaginal CO2 laser among breast cancer survivors with dyspareunia.|Patient Global Impression of Improvement (PGI-I) score after treatment with topical lidocaine ointment or transvaginal CO2 laser among breast cancer survivors with dyspareunia.|Satisfaction with Decision (SDS) score before and after treatment with topical lidocaine ointment or transvaginal CO2 laser among breast cancer survivors with dyspareunia.	University of Cincinnati|Syneron Candela	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	70	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	UC Laser	March 20, 2018	October 1, 2018	November 1, 2018	August 22, 2017		March 27, 2018	University of Cincinnati, Cincinnati, Ohio, United States		https://ClinicalTrials.gov/show/NCT03257670
337	NCT01103492	Treatment of Hemorrhagic Radiation Proctitis Using the Halo System		Completed	Has Results	Pelvic Neoplasms	Device: HALO90 Ablation catheter	Number of Participants With Adverse Events	University Hospitals Cleveland Medical Center|Covidien, GI Solutions	All	18 Years and older   (Adult, Older Adult)	Not Applicable	1	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	11-07-46	July 2008	June 2009	June 2009	April 14, 2010	April 27, 2011	January 5, 2015	University Hospitals Case Medical Center, Cleveland, Ohio, United States		https://ClinicalTrials.gov/show/NCT01103492
338	NCT02066064	G-Eye Advanced Colonoscopy For Increased Polyp Detection Rate-randomized Tandem Study With Different Endoscopist		Completed	No Results Available	Colorectal Cancer|Adenoma	Procedure: Standard Colonoscopy|Procedure: G-EYE(TM) Colonoscopy	G-EYE™ colonoscopy detection rate of adenomas and serrated lesions compared to the standard colonoscopy detection rate of the same.|polyp and adenoma detection, procedure times and safety	Smart Medical Systems Ltd.	All	50 Years and older   (Adult, Older Adult)	Not Applicable	58	Industry	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Screening	G-EYE	November 2013	December 2015	December 2015	February 19, 2014		February 12, 2016	St. Marienkrankenhaus Frankfurt, Frankfurt, Germany		https://ClinicalTrials.gov/show/NCT02066064
339	NCT00997529	Mini Allo Stem Cell Transplantation for the Treatment of Solid Tumors	MiniSolid	Completed	No Results Available	Metastatic Solid Tumor	Drug: nonmyeloablative stem cell transplant	To determine the percent 100-day survival of patients with metastatic solid tumors undergoing non-myeloablative allogeneic stem cell transplantation (SCT).|To determine the incidence of treatment-related toxicity and acute and chronic graft versus host disease.|To determine the overall survival of patients with metastatic solid tumors undergoing non-myeloablative allogeneic SCT.|To evaluate the tumor response in patients with metastatic solid tumors undergoing non-myeloablative allogeneic SCT.	Beth Israel Deaconess Medical Center|Amgen	All	18 Years to 60 Years   (Adult)	Not Applicable	14	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	E-00-0154-FB/2001-P-000092/8	November 2000	November 2007	June 2010	October 19, 2009		July 18, 2016	Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT00997529
340	NCT01790139	Oral Iohexol for Fecal/Fluid Tagging for CT Colonography: A Study to Improve Image Quality by Preventing Colonic Bubbles		Completed	No Results Available	Colorectal Neoplasms	Drug: Oral simethicone	Colonic bubble-related image quality|Overall image quality|diagnostic performance	Asan Medical Center|GE Healthcare	All	20 Years and older   (Adult, Older Adult)	Not Applicable	84	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic	2012-0584	February 2013	November 2013	January 2014	February 13, 2013		March 26, 2014	Asan Medical Center, Seoul, Korea, Republic of		https://ClinicalTrials.gov/show/NCT01790139
341	NCT02752932	TumorGraft- Guided Therapy for Improved Outcomes in Head and Neck Squamous Cell Cancer- A Feasibility Study	Xenograft	Completed	No Results Available	Head and Neck Squamous Cell Carcinoma	Other: Drug testing on PDX per Investigator's choice (upto 4)	To determine the rate of PDX engraftment for HNSCC and RMHNSCC samples|Time to engraftment|Percentage of models successfully undergoing drug testing|Participant status at the time of completion of drug testing	Lawson Health Research Institute|Champions Oncology	All	18 Years and older   (Adult, Older Adult)	Not Applicable	41	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	106515	November 2015	October 12, 2017	October 12, 2017	April 27, 2016		October 18, 2017	London Regional Cancer Program, London, Ontario, Canada		https://ClinicalTrials.gov/show/NCT02752932
342	NCT00144976	Study of Biological Effect of Tarceva (OSI-774) for Patients Stricken by ENT Epidermoid Carcinoma		Completed	No Results Available	Head and Neck Neoplasms	Drug: Tarceva	To evaluate the biological effect of Tarceva (OSI-774) from an inhibition of EGF tumor receptor tyrosine kinase activity's point of view, for patients who are carriers of head and neck epidermoid carcinoma.|Correlation study between pharmacokinetic and biological effect observed of molecule OSI-774.|Verification of biological effect of Tarceva's homogeneity (inhibition of EGFR-TK) according to sites, particularly from the point of view of a possible difference primary tumor/metastatic adenopathy and tumorous tissue/healthy tissue.|Characterisation of OSI-774 modes of action from the cellular cycle arrest proteinic effectors's point of view.|Constitution of frozen tissue bank for genomic (sequencing) study of tumorous EGF-R structure and for modification of in situ gene expression induction with OSI-774 by RNA microarrays technology.|Pharmacogenomics study of Tarceva's metabolism : genes studied code for cytochrome 3A5 and glycoprotein-P.	Institut Claudius Regaud|Roche Pharma AG	All	18 Years and older   (Adult, Older Adult)	Not Applicable	43	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)	03 VADS 01	October 2003	December 2006	December 2006	September 5, 2005		March 27, 2015	Center Oscar Lambret, Lille, France|Institut claudius regaud, Toulouse, France		https://ClinicalTrials.gov/show/NCT00144976
343	NCT02145143	Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study		Active, not recruiting	No Results Available	Thyroid Carcinoma	Drug: Vemurafenib|Device: serial 124I PET/CT|Drug: thyrotropin alpha	Response|objective response rate (ORR)|safety	Memorial Sloan Kettering Cancer Center|Genentech, Inc.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	12	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	14-031	May 2014	May 2020	May 2020	May 22, 2014		February 26, 2019	Memorial Sloan Kettering Cancer Center, New York, New York, United States		https://ClinicalTrials.gov/show/NCT02145143
344	NCT03607682	Tumor-Treating Fields Therapy in Preventing Brain Tumors in Participants With Extensive-Stage Small Cell Lung Cancer		Recruiting	No Results Available	Extensive Stage Small Cell Lung Carcinoma	Procedure: Tumor Treating Fields (TTF) Therapy|Device: NovoTTF-200A Device|Other: Quality-of-Life Assessment	Percentage of patients continuing therapy until intracranial tumor|Time to intracranial failure|Overall survival|Rate of intracranial failure|Rate of decline in cognitive function|Time to neurocognitive failure|Neurocognitive failure-free survival|Evaluate quality of life using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30|Incidence of adverse events	Albert Attia|NovoCure Ltd.|Vanderbilt-Ingram Cancer Center	All	22 Years and older   (Adult, Older Adult)	Not Applicable	25	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	VICC THO 1747|NCI-2018-01428	September 5, 2018	December 2021	January 2022	July 31, 2018		August 7, 2019	Johns Hopkins Suburban Hospital, Bethesda, Maryland, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States		https://ClinicalTrials.gov/show/NCT03607682
345	NCT01816256	Screening for Asymptomatic Portal Vein Thrombosis and Portal Hypertension in Patients With Philadelphia Negative Myeloproliferative Neoplasms		Completed	No Results Available	Myeloproliferative Neoplasms (MPN)|Polycythemia Vera (PV)|Essential Thrombocythemia (ET)|Myelofibrosis (MF)	Procedure: Upper gastrointestinal endoscopy and Doppler ultrasound	Incidence of asymptomatic portal vein thrombosis (PVT) and/or portal hypertension (PHTN) in patients with Philadelphia negative myeloproliferative neoplasms (MPNs)|Identify the patient, disease and treatment related risk factors associated with PVT and PHTN|Comparison of survival and number of patients with leukemic transformation in patients with or without asymptomatic PVT/PHTN	University Health Network, Toronto|Novartis Pharmaceuticals	All	Child, Adult, Older Adult	Not Applicable	102	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening	MPN 12-01	May 2013	March 11, 2019	March 11, 2019	March 22, 2013		May 21, 2019	Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada		https://ClinicalTrials.gov/show/NCT01816256
346	NCT03525236	The Oncoflavour Study		Completed	No Results Available	Cancer	Other: Tasting of flavours	Liking of 5 different oral nutritional supplements with adapted flavors	University Medical Center Groningen|Nutricia, Inc.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	50	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	201700363	June 19, 2017	November 1, 2017	November 1, 2017	May 15, 2018		May 15, 2018	University Medical Center Groningen, Groningen, Netherlands		https://ClinicalTrials.gov/show/NCT03525236
347	NCT01925573	Optune(NOVOTTF-100A)+ Bevacizumab+ Hypofractionated Stereotactic Irradiation Bevacizumab-Naive Recurrent Glioblastoma (GCC 1344)		Active, not recruiting	No Results Available	RECURRENT GLIOBLASTOMA|Brain Tumor	Device: Optune(NOVOTTF-100A)	Number of Adverse Events with a grade 3 or high toxicity (Primary Measure)	University of Maryland, Baltimore|NovoCure Ltd.	All	22 Years and older   (Adult, Older Adult)	Not Applicable	7	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HP-00056719	May 2014	December 2021	December 2026	August 19, 2013		August 14, 2019	Ummc Msgcc, Baltimore, Maryland, United States		https://ClinicalTrials.gov/show/NCT01925573
348	NCT02743741	Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors		Recruiting	No Results Available	Neuroendocrine Tumors	Drug: Lutetium-177 Octreotate	The proportion of patients progression-free using RECIST 1.1 criteria|The overall response rate as determined by structural imaging using RECIST criteria.|The biochemical response rate (as defined by biochemical responses: serum chromogranin A and 24 hr urinary 5HIAA).|The acute and late adverse effects of Lu-DOTATATE (177Lu) using CTCAE Version 4.03|Overall survival|The Quality of Life (QoL) in patients treated with Lu-DOTATATE (177Lu)	University Health Network, Toronto|Ozmosis Research Inc.|Cancer Care Ontario|Canadian Molecular Imaging Probe Consortium	All	Child, Adult, Older Adult	Not Applicable	195	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	OZM-067	July 2016	January 2024	January 2024	April 19, 2016		March 26, 2019	Juravinski Cancer Centre, Hamilton, Ontario, Canada|London Health Sciences Centre, London, Ontario, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Sunnybrook Odette Cancer Center, Toronto, Ontario, Canada		https://ClinicalTrials.gov/show/NCT02743741
349	NCT01307813	Apollo Overstitch, a Treat and Resect Model	Overstitch	Completed	No Results Available	Colon Malignant Tumor|Colon Benign Tumor	Device: Overstitch Endoscopic Suturing System	The successful suture approximation with the cinching device is measured by the depth of suture placement,evidence of perforation, and the quality of suture approximation	University Hospitals Cleveland Medical Center|Apollo Endosurgery, Inc.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	4	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)	10-10-31	February 2011	November 2011	November 2011	March 3, 2011		December 16, 2014	University Hospitals Case Medical Center, Cleveland, Ohio, United States		https://ClinicalTrials.gov/show/NCT01307813
350	NCT03867045	Development of a Cabozantinib (Cabometyx) Symptom Management Application for Use in Patients With Renal Cancer	Cabo App	Not yet recruiting	No Results Available	Metastatic Renal Cell Carcinoma Treated With Cabozantinib	Device: Usability of an electronic symptom management application	Number of comments from participants indicating ease of use of the application.|Blood pressure (BP) readings measured daily by the BP monitoring device compared with those BP readings measured at interval clinic visits within the first 12 weeks to determine similar detection of symptoms.|Movement recorded daily by the activity tracking device compared with ECOG assessment outcomes measured during interval clinic visits within the first 12 weeks to determine similar estimates of activity.|Number and frequency of adverse symptoms reported in the symptom management application compared with clinical assessment of adverse events recorded at interval clinic visits within the first 12 weeks to determine similar report of adverse symptoms.	Duke University|Exelixis	All	18 Years and older   (Adult, Older Adult)	Not Applicable	9	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility	Pro00086667	September 2019	September 2020	September 2020	March 7, 2019		August 15, 2019			https://ClinicalTrials.gov/show/NCT03867045
351	NCT02267876	Longitudinal Clinical Evaluation of the HPV Assay on the BD VIPER LT System With Cervical Specimens		Enrolling by invitation	No Results Available	Cervical Neoplasms|Human Papillomavirus	Device: BD HPV Assay on Viper LT|Procedure: Colposcopy	Cumulative Incidence Rate for greater than or equal to Cervical intraepithelial neoplasia 2 (CIN2) over 3 years|Cumulative incidence of greater than or equal to Cervical intraepithelial neoplasia 3 (CIN3) over 3 years	Becton, Dickinson and Company	Female	21 Years and older   (Adult, Older Adult)	Not Applicable	8000	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic	BDS-USLHPV	October 2014	December 12, 2018	May 2019	October 20, 2014		January 3, 2019	University of Alabama, Birmingham, Alabama, United States|Mobile OB/GYN, Mobile, Alabama, United States|Women's Health Research of Arizona, Phoenix, Arizona, United States|Quality of Life Medical & Research Center, Tucson, Arizona, United States|Visions Clinical Research, Tucson, Arizona, United States|Women's Health Care Research Corp., San Diego, California, United States|Blueskies Center for Women, Colorado Springs, Colorado, United States|Health Awareness Inc., Jupiter, Florida, United States|Altus Research, Lake Worth, Florida, United States|Segal Institute for Clinical Research, North Miami, Florida, United States|Miami Research Associates, South Miami, Florida, United States|Comprehensive Clinical Trails, LLC, West Palm Beach, Florida, United States|Medical Network for Education & Research, Decatur, Georgia, United States|Fellows Research Alliance - Savannah, Savannah, Georgia, United States|Women's Health Practice, Champaign, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|Four Rivers Clinical Research, Paducah, Kentucky, United States|Louisiana State University, New Orleans, Louisiana, United States|BD 54 Loveton, Sparks, Maryland, United States|Saginaw Valley Medical Research, Saginaw, Michigan, United States|Virtua Phoenix OB/GYN, Moorestown, New Jersey, United States|Meridian Health / Jersey Shore University Medical Center, Neptune, New Jersey, United States|Quest Laboratories, Teterboro, New Jersey, United States|TriCore, Albuquerque, New Mexico, United States|Montefiore Medical Center, Bronx, New York, United States|Research Pathology Associates, LLC, Irvington, New York, United States|Eastern Carolina Women's Center, New Bern, North Carolina, United States|Lyndhurst Clinical Research, Winston-Salem, North Carolina, United States|HWC Women's Research Center, Englewood, Ohio, United States|Center for Women's Health of Lansdale, Lansdale, Pennsylvania, United States|Clinical Research of Philadelphia, Philadelphia, Pennsylvania, United States|Reading Health Physician Network, West Reading, Pennsylvania, United States|Fellows Research Alliance - Bluffton, Bluffton, South Carolina, United States|James T. Martin Jr. OB/GYN, North Charleston, South Carolina, United States|Chattanooga Medical Research, Chattanooga, Tennessee, United States|Center for Disease Detection, LLC, San Antonio, Texas, United States|Physicians Research Options, Draper, Utah, United States|Research Pathology Associates, Charlottesville, Virginia, United States|Tidewater Clinical Research, Virginia Beach, Virginia, United States|BioVision, Outremont, Quebec, Canada		https://ClinicalTrials.gov/show/NCT02267876
352	NCT01213004	Evaluation of Respiratory Motion-Corrected Cone-Beam CT in Radiation Treatment of Thoracic and Abdominal Cancers		Completed	No Results Available	Gastric Cancer|Lung Cancer	Procedure: respiration correlated CT scan	To determine whether motion-corrected cone-beam CT (CBCT) improves the localization accuracy|To determine whether motion-corrected cone-beam CT (CBCT) can visualize and localize abdominal tumors using intravenous contrast enhancement.|To determine whether motion-corrected cone-beam CT (CBCT) derived from a respiration correlated CT (RCCT) scan on the same day improves localization accuracy|To determine whether tumor and organ-at-risk positions localized in cone-beam CT (CBCT)	Memorial Sloan Kettering Cancer Center|University of North Carolina, Chapel Hill|Varian Medical Systems	All	18 Years and older   (Adult, Older Adult)	Not Applicable	52	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	10-146	September 2010	February 2018	February 2018	October 1, 2010		February 6, 2018	Memorial Sloan Kettering Cancer Center, New York, New York, United States		https://ClinicalTrials.gov/show/NCT01213004
353	NCT02409108	Perfusion-Induced Hyperthermia for Metastatic Carcinoma		Completed	No Results Available	Metastatic Non-Small Cell Lung Carcinoma|Solid Tumor, Adult	Device: Exatherm-TBH system	Safety as measured by adverse events|Exatherm-TBH device functionality|Safety as measured by serious adverse events|Quality of Life|Complication rates associated with hyperthermic treatment|Response rate|Time to treatment failure|Progression free survival|Death	Jonathan Kiev|Exatherm, Inc|University of Kentucky	All	22 Years and older   (Adult, Older Adult)	Not Applicable	4	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility	MCC-14-0929-F3R|2014-089	July 2015	April 2018	February 16, 2019	April 6, 2015		April 12, 2019	University of Kentucky, Markey Cancer Center, Lexington, Kentucky, United States		https://ClinicalTrials.gov/show/NCT02409108
354	NCT02547480	LifePearl-Iri Pharmacokinetic Study		Completed	No Results Available	Metastatic Colorectal Cancer|mCRC	Device: TACE with irinotecan loaded LifePearl	Maximum Observed Plasma Concentration (Cmax)|Time to reach Cmax (Tmax)|Area Under the Curve (AUC)|Adverse Events (AE) (grade ≥3) and Serious AEs related with study treatment up to 30 days post initial treatment|Overall Survival|Progression-Free Survival|Response rate|Technical success - treatment delivery|Technical success - total dose delivered	Terumo Europe N.V.|Federation Francophone de Cancerologie Digestive|Universitaire Ziekenhuizen Leuven	All	18 Years and older   (Adult, Older Adult)	Not Applicable	15	Industry|Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	T126E2	November 2015	April 28, 2017	September 19, 2017	September 11, 2015		November 27, 2017	KUL, Leuven, Belgium|SLK-Kliniken Heilbronn GmbH, Heilbronn, Germany|Klinikum Bogenhausen, Städt. Klinikum München GmbH, Munich, Germany		https://ClinicalTrials.gov/show/NCT02547480
355	NCT01693159	Effects of ECA on Quality of Life in Head and Neck Cancer Patients Suffering From Cetuximab-induced Rhagades	SUPPORT	Recruiting	No Results Available	Pain	Device: ECA|Other: Standard topical treatment of the institution, e.g. Lotio	pain intensity 24 hours after application of ECA or the standard treatment quantified by the visual analogue scale (VAS)|Evaluation of QoL	National Center for Tumor Diseases, Heidelberg|Heidelberg University|iOMEDICO AG	All	18 Years and older   (Adult, Older Adult)	Not Applicable	50	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Uni-HD-2010-33-40-1003	May 2011	July 2018	November 2018	September 26, 2012		September 25, 2017	University of Heidelberg Medical Center, Heidelberg, Germany		https://ClinicalTrials.gov/show/NCT01693159
356	NCT03457506	Intra-individual Comparison of Conventional and Digital PET/CT Scanners		Recruiting	No Results Available	Breast Cancer|Lung Cancer|Esophageal Cancer|Miscellaneous Neoplasm	Diagnostic Test: Digital PET/CT scan	Diagnostic outcome of the PET/CT study|PET image quality	Isala|Philips Healthcare	All	18 Years and older   (Adult, Older Adult)	Not Applicable	225	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	NL52329.075.15	January 8, 2018	October 1, 2019	January 2, 2020	March 7, 2018		August 9, 2019	Isala, Zwolle, Overijssel, Netherlands	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/06/NCT03457506/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT03457506
357	NCT00937833	Return of Continence Following Robot-Assisted Radical Prostatectomy With or Without a Urethrovesical Sling		Completed	Has Results	Urinary Incontinence|Prostate Cancer	Procedure: Prostatectomy|Device: Surgisis Male Sling	Number of Continent Patients Post Prostatectomy	Cook Group Incorporated	Male	18 Years and older   (Adult, Older Adult)	Not Applicable	150	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention	08-015|350017	November 2009	October 2013	November 2014	July 13, 2009	November 13, 2014	December 29, 2014	Indiana University School of Medicine, Indianapolis, Indiana, United States|Urology of San Antonio Research, San Antonio, Texas, United States		https://ClinicalTrials.gov/show/NCT00937833
358	NCT03222440	Combination of Radiotherapy and SHR-1210 to Treat Patients With ESCC		Recruiting	No Results Available	Esophageal Cancer	Drug: SHR-1210	Incidence of Treatment-Emergent Adverse Events|ORR|PFS|OS	Tianjin Medical University Cancer Institute and Hospital|Jiangsu HengRui Medicine Co., Ltd.	All	18 Years to 75 Years   (Adult, Older Adult)	Not Applicable	20	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	SHR-1210-RT-ESC-IIT	July 20, 2017	July 20, 2018	July 20, 2020	July 19, 2017		July 19, 2017	Department of Radiation Oncology, Tianjin Medical University Cancer Hospital, Tianjin, Tianjin, China		https://ClinicalTrials.gov/show/NCT03222440
359	NCT03806738	Enhancing Shared Decision-Making in Breast Cancer		Recruiting	No Results Available	Shared Decision Making	Other: Intervention-specific Carevive questionnaire|Other: Standard of Care questionnaire	Impact of Shared Decision Making	University of Alabama at Birmingham|American Cancer Society, Inc.|Carevive Systems, Inc.	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	140	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research	427 BC SDM	December 11, 2018	December 2021	December 2021	January 16, 2019		January 16, 2019	University of Alabama at Birmingham, Birmingham, Alabama, United States		https://ClinicalTrials.gov/show/NCT03806738
360	NCT02460432	Comparison of Drug Eluting Stent and Covered Metal Stent in Malignant Biliary Obstruction (MIRA III)		Completed	No Results Available	Biliary Neoplasms|Biliary Obstruction|Pancreatic Neoplasms	Device: Paclitaxel-eluting metal Stent|Device: Covered Metal Stent	Cumulative stent patency during 6months after stent placement|Stent migration|Secondary stent insertion due to recurrent biliary obstruction|Mean survival|Adverse events	Taewoong Medical Co., Ltd.	All	19 Years and older   (Adult, Older Adult)	Not Applicable	106	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	MIRA-003	May 2015	December 26, 2016	December 26, 2016	June 2, 2015		April 11, 2017	Inje University Busan Paik Hospital, Busan, Bokji-ro Busanjin-gu, Korea, Republic of|Seoul National University Hospital, Seoul, Haehak-ro Jongno-gu, Korea, Republic of|In Ha University Hospital, Incheon, Inhang-ro Jung-gu, Korea, Republic of|Samsung Medical Center, Seoul, Irwon-Dong, Gangnam-Gu, Korea, Republic of|Gangnam Severance Hospital, Seoul, Korea, Republic of		https://ClinicalTrials.gov/show/NCT02460432
361	NCT02972372	Chemoradiation Versus Esophagectomy for Locally Advanced Esophageal Cancer	CELAEC	Recruiting	No Results Available	Esophagus Cancer	Procedure: CRT|Procedure: surgery	2 year disease-free survival|Treatment-related adverse events|Quality of life|2 year overall survival	The First Affiliated Hospital of Henan University of Science and Technology|Jiangsu HengRui Medicine Co., Ltd.|Anyang Tumor Hospital|150th Hospital of PLA	All	18 Years to 75 Years   (Adult, Older Adult)	Not Applicable	196	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CRTESC6111	November 2016	December 2020	June 2021	November 23, 2016		April 19, 2017	Anyang Tumor Hospital, Anyang, Henan, China|The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, Henan, China		https://ClinicalTrials.gov/show/NCT02972372
362	NCT02035475	Prevention of Lymphoceles After Robotic PLND	PLND	Completed	Has Results	Lymphoceles|Prostate Cancer	Device: Intuitive Vessel Sealer	Incidence of Lymphoceles|Surgical Complications	OhioHealth|Intuitive Surgical	Male	18 Years and older   (Adult, Older Adult)	Not Applicable	120	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention	OH1-13-00471	August 2014	December 2014	December 2014	January 14, 2014	November 15, 2016	November 15, 2016	Dublin Methodist Hospital, Columbus, Ohio, United States		https://ClinicalTrials.gov/show/NCT02035475
363	NCT02818946	Diagnostic Utility of MRI in Female Patients With Nipple Discharge: A Prospective Trial		Recruiting	No Results Available	Disorder of Nipple|Breast Neoplasms	Device: MRI	Sensitivity|Specificity|Positive predictive value|Negative predictive value	Duke University|Bracco Diagnostics, Inc	Female	22 Years and older   (Adult, Older Adult)	Not Applicable	150	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	Pro00063806	July 2016	December 31, 2020	December 31, 2020	June 30, 2016		July 18, 2019	Duke University Medical Center, Durham, North Carolina, United States		https://ClinicalTrials.gov/show/NCT02818946
364	NCT00798889	Rollover Protocol for Prior SU011248 Protocols		Completed	Has Results	Solid Tumors	Drug: Sunitinib	Duration of Treatment	Pfizer	All	18 Years and older   (Adult, Older Adult)	Not Applicable	314	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	A6181030	March 2004	December 2011	December 2011	November 26, 2008	January 21, 2013	January 21, 2013	Pfizer Investigational Site, Birmingham, Alabama, United States|Pfizer Investigational Site, Birmingham, Alabama, United States|Pfizer Investigational Site, Birmingham, Alabama, United States|Pfizer Investigational Site, Los Angeles, California, United States|Pfizer Investigational Site, Los Angeles, California, United States|Pfizer Investigational Site, San Francisco, California, United States|Pfizer Investigational Site, San Francisco, California, United States|Pfizer Investigational Site, Santa Monica,, California, United States|Pfizer Investigational Site, Aurora, Colorado, United States|Pfizer Investigational Site, Indianapolis, Indiana, United States|Pfizer Investigational Site, Boston, Massachusetts, United States|Pfizer Investigational Site, Boston, Massachusetts, United States|Pfizer Investigational Site, Boston, Massachusetts, United States|Pfizer Investigational Site, Ann Arbor, Michigan, United States|Pfizer Investigational Site, Detroit, Michigan, United States|Pfizer Investigational Site, Farmington Hills, Michigan, United States|Pfizer Investigational Site, Minneapolis, Minnesota, United States|Pfizer Investigational Site, St. Louis, Missouri, United States|Pfizer Investigational Site, Albuquerque, New Mexico, United States|Pfizer Investigational Site, Albuqurque, New Mexico, United States|Pfizer Investigational Site, New York, New York, United States|Pfizer Investigational Site, New York, New York, United States|Pfizer Investigational Site, New York, New York, United States|Pfizer Investigational Site, Durham, North Carolina, United States|Pfizer Investigational Site, Cleveland, Ohio, United States|Pfizer Investigational Site, Philadelphia, Pennsylvania, United States|Pfizer Investigational Site, Myrtle Beach, South Carolina, United States|Pfizer Investigational Site, Franklin, Tennessee, United States|Pfizer Investigational Site, Gallatin, Tennessee, United States|Pfizer Investigational Site, Hermitage, Tennessee, United States|Pfizer Investigational Site, Lebanon, Tennessee, United States|Pfizer Investigational Site, Murfreesboro, Tennessee, United States|Pfizer Investigational Site, Nashville, Tennessee, United States|Pfizer Investigational Site, Nashville, Tennessee, United States|Pfizer Investigational Site, Nashville, Tennessee, United States|Pfizer Investigational Site, Nashville, Tennessee, United States|Pfizer Investigational Site, Nashville, Tennessee, United States|Pfizer Investigational Site, Nashville, Tennessee, United States|Pfizer Investigational Site, Smyrna, Tennessee, United States|Pfizer Investigational Site, Dallas, Texas, United States|Pfizer Investigational Site, Houston, Texas, United States|Pfizer Investigational Site, Madison, Wisconsin, United States|Pfizer Investigational Site, Randwick, New South Wales, Australia|Pfizer Investigational Site, East Melbourne, Victoria, Australia|Pfizer Investigational Site, Heidelberg, Victoria, Australia|Pfizer Investigational Site, Montreal, Quebec, Canada|Pfizer Investigational Site, Villejuif Cedex, France|Pfizer Investigational Site, Thessaloniki, Greece|Pfizer Investigational Site, Milano, Italy|Pfizer Investigational Site, Milano, Italy|Pfizer Investigational Site, Nijmegen, Gld, Netherlands|Pfizer Investigational Site, Singapore, Singapore|Pfizer Investigational Site, Lund, Sweden|Pfizer Investigational Site, Stockholm, Sweden|Pfizer Investigational Site, St. Gallen, Switzerland|Pfizer Investigational Site, Leeds, United Kingdom|Pfizer Investigational Site, London, United Kingdom|Pfizer Investigational Site, London, United Kingdom|Pfizer Investigational Site, Newcastle-Upon-Tyne, United Kingdom		https://ClinicalTrials.gov/show/NCT00798889
365	NCT00125372	Study of Tarceva and Targretin in Stage I-II Lung Cancer		Completed	Has Results	Carcinoma, Non-small-cell Lung	Drug: erlotinib (Tarceva) and bexarotene (Targretin)	Number of Participants With Change in Expression Level of EGFR.|Number of Participants With Change in Expression Level of Cyclin D1|Number of Participants With Change in Expression Level of Phosphorylated EGFR (pEGFR)|Tumor Tissue Concentrations of Erlotinib and Bexarotene and Correlation With Plasma Levels|Number of Participants With EGFR Mutations and Correlation of EGFR Mutations With Response	Dartmouth-Hitchcock Medical Center|Ligand Pharmaceuticals|Genentech, Inc.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	12	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	D-0453	December 2005	August 2010	August 2010	August 1, 2005	November 12, 2018	January 8, 2019	Norris Cotton Cancer Center, Lebanon, New Hampshire, United States		https://ClinicalTrials.gov/show/NCT00125372
366	NCT03958136	Clinico-biological Data Collection Study of Metastatic Breast Cancer	EPICUREseinmet	Recruiting	No Results Available	Breast Cancer	Procedure: Metastasis biopsy|Biological: Biomarkers blood, urine and microbiota samples|Behavioral: Patient Reported Outcome (PRO)	Creation of complex prospective clinico-biological database in metastatic breast cancer|Overall survival|Progression free survival|Quality of life during treatment|Response to treatment for each therapeutic sequence	Institut Cancerologie de l'Ouest|European Regional Development Fund|AstraZeneca|Novartis|Eli Lilly and Company	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	300	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other	ICO-N-2017-12	December 24, 2018	December 24, 2033	December 30, 2034	May 21, 2019		May 24, 2019	Institut de Cacerologie de l'ouest - site Paul Papin, Angers, France|Institut de cancerologie de l'Ouest, Saint Herblain, France		https://ClinicalTrials.gov/show/NCT03958136
367	NCT03952767	The STEPP Study: Sensors To Evaluate Physical Performance	STEPP	Recruiting	No Results Available	Oncology	Other: Digital Physical Measures and Survey Assessments	Amount of mean steps per day recorded at home|Amount of mean sedentary activity time recorded at home|Amount of Light activity time recorded at home|Amount of moderate activity time recorded at home|Amount of vigorous activity time recorded at home|Self-Reported Karnofsky Performance Score (KPS)	UNC Lineberger Comprehensive Cancer Center|Pfizer	All	18 Years to 99 Years   (Adult, Older Adult)	Not Applicable	90	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	LCCC 1851	April 24, 2019	October 30, 2020	October 30, 2021	May 16, 2019		July 19, 2019	UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States		https://ClinicalTrials.gov/show/NCT03952767
368	NCT02668276	Engaging Newly Diagnosed Men About Cancer Treatment Options	ENACT	Recruiting	No Results Available	Prostatic Neoplasms	Other: Standard NCCN counseling|Other: Standard NCCN counseling and Oncotype DX results	Effect of adding Oncotype DX prostate cancer assay to usual counseling on the proportion of men adopting Active Surveillance (AS).	University of Illinois at Chicago|United States Department of Defense|Cook County Hospital|Genomic Health®, Inc.	Male	up to 76 Years   (Child, Adult, Older Adult)	Not Applicable	300	Other|U.S. Fed|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other	2015-1294|W81XWH-14-PCRP-BDA	April 2016	August 2022	August 2022	January 29, 2016		May 16, 2018	Jesse Brown V. A. Medical Center, Chicago, Illinois, United States|John H. Stroger Hospital of Cook County, Chicago, Illinois, United States|University of Illinois at Chicago, Chicago, Illinois, United States		https://ClinicalTrials.gov/show/NCT02668276
369	NCT02700971	RATIO: Rational Approach To Immuno-Oncology	RATIO	Recruiting	No Results Available	Metastatic Melanoma	Procedure: Molecular Microscope Diagnostic system	Correlation of the MMDx from pretreatment biopsy with overall response rate (ORR).|Progression Free Survival (PFS)|Overall Survival (OS)	AHS Cancer Control Alberta|Transplant Genomics, Inc.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	35	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	IIT-RATIO-CCI-01	June 23, 2016	December 2021	December 2021	March 7, 2016		December 19, 2018	Cross Cancer Institute, Edmonton, Alberta, Canada		https://ClinicalTrials.gov/show/NCT02700971
370	NCT03666104	Using Virtual Reality (VR) Models for Preoperative Planning - Mount Sinai		Completed	No Results Available	Kidney Cancer|Renal Cell Carcinoma	Device: Ceevra Reveal	Total operative time|Blood loss (measured in cubic centimeters)|Clamp time|Intraoperative conversion from robotic assisted laparoscopic procedure to open procedure|Intraoperative conversion from partial nephrectomy to radical nephrectomy|Intraoperative complication|Patient hospital stay|Positive tumor margin (assessed via standard post-operative biopsy)|Post-Op complication|Readmission	Ceevra, Inc.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	10	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment	IRB-18-00442	August 21, 2018	February 28, 2019	March 18, 2019	September 11, 2018		June 6, 2019	Mount Sinai St. Luke's and Mount Sinai Roosevelt, New York, New York, United States|The Mount Sinai Hospital, New York, New York, United States		https://ClinicalTrials.gov/show/NCT03666104
371	NCT03556943	Using Virtual Reality (VR) Models for Preoperative Planning - Mayo Clinic		Completed	No Results Available	Kidney Cancer|Renal Cell Carcinoma	Device: Ceevra Reveal	Hilum dissection time|Tumor localization time|Tumor resection time|Reconstruction time|Total operative time|Blood loss (measured in cubic centimeters)|Clamp time|Intraoperative conversion from robotic assisted laparoscopic procedure to open procedure|Intraoperative conversion from partial nephrectomy to radical nephrectomy|Intraoperative complication|Patient hospital stay|Positive tumor margin (assessed via standard post-operative biopsy)|Post-Op complication|Readmission	Ceevra, Inc.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	10	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment	20171006MAYO	May 15, 2018	February 28, 2019	March 18, 2019	June 14, 2018		June 6, 2019	Mayo Clinic Arizona, Scottsdale, Arizona, United States|Mayo Clinic Florida, Jacksonville, Florida, United States		https://ClinicalTrials.gov/show/NCT03556943
372	NCT03542565	Using Virtual Reality (VR) Models for Preoperative Planning - JWCI		Completed	No Results Available	Kidney Cancer|Renal Cell Carcinoma	Device: Ceevra Reveal	Hilum dissection time|Tumor localization time|Tumor resection time|Reconstruction time|Total operative time|Blood loss (measured in cubic centimeters)|Clamp time|8. Intraoperative conversion from robotic assisted laparoscopic procedure to open procedure|Intraoperative conversion from partial nephrectomy to radical nephrectomy|Intraoperative complication|Patient hospital stay|Positive tumor margin (assessed via standard post-operative biopsy)|Post-Op complication|Readmission	Ceevra, Inc.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	4	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment	20171006JWCI	April 30, 2018	February 28, 2019	March 18, 2019	May 31, 2018		June 6, 2019	John Wayne Cancer Institute at Providence St. John's Health Center, Santa Monica, California, United States		https://ClinicalTrials.gov/show/NCT03542565
373	NCT03534206	Using Virtual Reality (VR) Models for Preoperative Planning - University of Tennessee		Completed	No Results Available	Kidney Cancer|Renal Cell Carcinoma	Device: Ceevra Reveal	Hilum dissection time|Tumor localization time|Tumor resection time|Reconstruction time|Total operative time|Blood loss (measured in cubic centimeters)|Clamp time|Intraoperative conversion from robotic assisted laparoscopic procedure to open procedure|Intraoperative conversion from partial nephrectomy to radical nephrectomy|Intraoperative complication|Patient hospital stay|Positive tumor margin (assessed via standard post-operative biopsy)|Post-Op complication|Readmission	Ceevra, Inc.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	20	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment	20171006UTMC	April 11, 2018	February 28, 2019	March 18, 2019	May 23, 2018		June 6, 2019	University of Tennessee Medical Center, Knoxville, Tennessee, United States		https://ClinicalTrials.gov/show/NCT03534206
374	NCT03421418	Using Virtual Reality (VR) Models for Preoperative Planning - UNC		Completed	No Results Available	Kidney Cancer|Renal Cell Carcinoma	Device: Ceevra Reveal	Hilum Dissection Time|Tumor Localization Time|Tumor Resection Time|Reconstruction Time|Total Operative Time|Blood Loss|Clamp Time|Conversion to Open|Conversion to Radical|Intraoperative Complication|Patient Hospital Stay|Positive Margin|Post-Op Complication|Readmission	Ceevra, Inc.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	8	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment	17-0904	January 9, 2018	February 28, 2019	March 18, 2019	February 5, 2018		June 6, 2019	UNC Hospital, Chapel Hill, North Carolina, United States		https://ClinicalTrials.gov/show/NCT03421418
375	NCT03334344	Using Virtual Reality (VR) Models for Preoperative Planning		Completed	No Results Available	Kidney Cancer|Renal Cell Carcinoma	Device: Ceevra Reveal	Hilum Dissection Time|Tumor Localization Time|Tumor Resection Time|Reconstruction Time|Total Operative Time|Blood Loss|Clamp Time|Conversion to Open|Conversion to Radical|Intraoperative Complication|Patient Hospital Stay|Positive Margin|Post-Op Complication|Readmission	Ceevra, Inc.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	36	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment	20171006	October 24, 2017	February 28, 2019	March 18, 2019	November 7, 2017		June 6, 2019	Swedish Urology Group, Seattle, Washington, United States|Swedish Medical Center, Seattle, Washington, United States		https://ClinicalTrials.gov/show/NCT03334344
376	NCT02106143	RejuvenAir™ System Lobectomy Safety and Histology Study	Lobectomy	Completed	No Results Available	Lung Neoplasms|Airway Obstruction|Lung Cancer	Device: RejuvenAir™ Radial Spray Cryotherapy	safety|Measurement of histological changes at treatment sites	CSA Medical, Inc.	All	21 Years to 75 Years   (Adult, Older Adult)	Not Applicable	11	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility	009	September 2014	June 2015	October 2015	April 8, 2014		May 11, 2017	Galway University Hosptial, Galway, Ireland|University Medical Center Groningen, Groningen, Netherlands|Royal Brompton Hospital, London, United Kingdom		https://ClinicalTrials.gov/show/NCT02106143
377	NCT04026763	MR/TRUS Fusion Guided Prostate Biopsy		Recruiting	No Results Available	Prostate Disease|Elevated Prostate Specific Antigen|Family History of Prostate Cancer|Positive Digital Rectal Exam	Procedure: prostate biopsy|Procedure: MR US Fusion Guided Prostate Biopsy|Device: MR/TRUS Fusion Guided Prostate Biopsy	Incidence of Prostate Cancer|Incidence of adverse events|Pirads score|Gleason score	Icahn School of Medicine at Mount Sinai|Philips Healthcare	Male	18 Years and older   (Adult, Older Adult)	Not Applicable	520	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	GCO 15-0768	May 11, 2018	December 2021	December 2021	July 19, 2019		July 19, 2019	Icahn School of Medicine at Mount Sinai, New York, New York, United States		https://ClinicalTrials.gov/show/NCT04026763
378	NCT02964325	Efficacy of Mirasol-treated Apheresis Platelets in Patients With Hypoproliferative Thrombocytopenia	MIPLATE	Recruiting	No Results Available	Hematologic Malignancies|Hypoproliferative Thrombocytopenia	Device: Mirasol platelets (MIR PLTs)|Device: Reference platelets (REF PLTs)	Number of days of grade 2 or higher bleeding|Human leukocyte antigen (HLA) alloimmunization|Proportion of subjects with ≥ grade 2 bleeding|Time to first ≥ grade 2 bleed|Proportion of subjects with ≥ grade 3 bleeding|Proportion of subjects with PLT refractoriness|Immune platelet refractoriness	Terumo BCTbio|Biomedical Advanced Research and Development Authority	All	Child, Adult, Older Adult	Not Applicable	556	Industry|U.S. Fed	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care	CTS-5030	May 5, 2017	November 2021	November 2021	November 16, 2016		December 21, 2018	University of Florida Health Shands Hospital, Gainesville, Florida, United States|Emory University/Children's Hospital of Atlanta, Atlanta, Georgia, United States|University of Iowa, Iowa City, Iowa, United States|John Hopkins University School of Medicine/Johns Hopkins Kimmel Cancer Center, Baltimore, Maryland, United States|Boston Children's Hospital, Boston, Massachusetts, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Robert Wood Johnson Medical School/RWJ University Hospital, New Brunswick, New Jersey, United States|University of Washington Medical Center, Seattle, Washington, United States		https://ClinicalTrials.gov/show/NCT02964325
379	NCT03564977	CD19-targeted CAR-T Cell Therapy for MRD+ B-cell Malignancies After Autologous Stem Cell Transplantation		Recruiting	No Results Available	Lymphoma, B-Cell|Leukemia, B-Cell|Minimal Disease, Residual	Biological: CD19-targeted CAR-T cells	Objective response rate|Disease control rate|Overall survival|Progress-free survival	Qingdao Central Hospital|Yake Biotechnology Ltd.	All	18 Years to 75 Years   (Adult, Older Adult)	Not Applicable	20	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	QingdaoCH201805	July 15, 2018	June 15, 2020	June 15, 2020	June 21, 2018		July 2, 2018	Qingdao Central Hospital, Qingdao, Shandong, China		https://ClinicalTrials.gov/show/NCT03564977
380	NCT03586050	Study to Evaluate the Safety and Effectiveness of Microwave Ablation in Patients With Hepatocellular Carcinoma in Korea		Recruiting	No Results Available	Carcinoma, Hepatocellular|Hepatocellular Carcinoma|Hepatocellular Cancer|Cancer, Hepatocellular	Device: Microwave ablation	Number of subjects achieving technical Success defined a complete tumor ablation (kill)|Number of subjects achieving primary Technique Efficacy defined as complete tumor ablation (kill)|Local Tumor Progression Rate|Primary efficacy rate defined as percentage of target tumors successfully eradicated|Secondary efficacy as defined as the percentage of tumors that have undergone successful repeat ablation|Progression free survival|Overall survival|Rate of all adverse events|Patient reported quality of life|Health economics: complete procedure time|Patient reported pain|Health economics: ablation time|Health economics: number of ablations|Health economics: length of hospital stay|Health economics: number of probes used|Health economics: type of ablation probes used	Ethicon, Inc.	All	19 Years and older   (Adult, Older Adult)	Not Applicable	30	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NEU_2017_01	December 11, 2017	December 18, 2019	December 16, 2022	July 13, 2018		May 30, 2019	Samsung Medical Center, Seoul, Korea, Republic of		https://ClinicalTrials.gov/show/NCT03586050
381	NCT00713427	Study of the WallFlex™ Biliary Partially-covered Stent for the Palliative Treatment of Malignant Bile Duct Obstruction		Completed	No Results Available	Biliary Strictures Caused by Malignant Neoplasms	Device: WallFlex™ Biliary Partially-Covered Stent	The primary outcome measured will be the adequate clinical palliation of the biliary obstruction defined as absence of recurrent biliary obstruction. Recurrent biliary obstruction will be determined by treating physicians.|Secondary outcome measures include the occurrence, severity, device- and procedure-relatedness of adverse events, device deployability and removability, re-interventions, biliary obstruction symptoms, liver function, and recurrent biliary obstruction.	Boston Scientific Corporation	All	18 Years and older   (Adult, Older Adult)	Not Applicable	70	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ENDO-WALLFLEX-BIL-PALL-002|E7020	July 2007	May 2008	May 2008	July 11, 2008		September 1, 2009	ULB Erasme Hospital, Brussels, Belgium|Hopital Edouard Herriot, Lyon, Cedex 3, France|EVK Krankenhaus der Universitat Dusseldorf, Dusseldorf, Germany|Asian Institute of Gastroenterology, Hyderabaad, India|Università Cattolica del Sacro Cuore, Rome, Italy|Academisch Medisch Centrum Universiteit van Amsterdam, Amsterdam, AZ, Netherlands		https://ClinicalTrials.gov/show/NCT00713427
382	NCT03690323	Pancreatic Locally Advanced Irresectable Cancer Ablation	PELICAN	Recruiting	No Results Available	Locally Advanced Pancreatic Cancer	Procedure: Radiofrequency ablation (RFA)|Drug: FOLFIRINOX|Drug: Nab-paclitaxel plus Gemcitabine|Drug: Gemcitabine	Overall survival|Progression free survival|Complications|Radiological tumor response|Tumor marker response|Quality of Life questionnaire	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Dutch Cancer Society|Comprehensive Cancer Centre The Netherlands|Olympus	All	18 Years and older   (Adult, Older Adult)	Not Applicable	228	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NL50467.018.14	April 7, 2015	November 2019	May 2020	October 1, 2018		October 1, 2018	Amsterdam UMC, Amsterdam, Noord-Holland, Netherlands|Regionaal Academisch Kankercentrum Utrecht, Utrecht, Netherlands		https://ClinicalTrials.gov/show/NCT03690323
383	NCT03076216	A Pilot Study of OncoSil™ Given to Patients With Pancreatic Cancer Treated With Gemcitabine +/- Nab-paclitaxel.	OncoPaC-1	Active, not recruiting	No Results Available	Unresectable Locally Advanced Pancreatic Carcinoma	Device: OncoSil™	Safety / Tolerability of Device as determined by the number of treatment emergent adverse events (TEAEs) evaluated according to CTCAE V4.0|Local Progression free survival within the pancreas|Progression free survival - entire body|Overall survival|Body weight|Impaired function|Pain Scores	OncoSil Medical Limited	All	18 Years and older   (Adult, Older Adult)	Not Applicable	9	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ONC01P01	August 1, 2017	April 2019	April 2019	March 10, 2017		December 20, 2018	Cedars Sinai Department of Radiation Oncology, Los Angeles, California, United States|Moffitt Cancer Centre, Tampa, Florida, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States|MD Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT03076216
384	NCT03003078	A Pilot Study of OncoSil™ Given to Patients With Pancreatic Cancer Treated With FOLFIRINOX or Gemcitabine+Abraxane	PanCO	Active, not recruiting	No Results Available	Unresectable Locally Advanced Pancreatic Carcinoma	Device: OncoSil™	Safety / Tolerability of Device according to CTCAE V4.0|Local Progression free survival within the pancreas|Progression free survival - entire body|Overall survival|Body weight|Impaired function|Pain Scores	OncoSil Medical Limited	All	18 Years and older   (Adult, Older Adult)	Not Applicable	50	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ONC01P03	March 27, 2017	February 2020	February 2020	December 26, 2016		July 19, 2018	Corrimal Cancer Care Clinic, 20-22 Underwood St, Corrimal, New South Wales, Australia|Department of Medical Oncology, Royal North Shore Hospital, St Leonards, New South Wales, Australia|The Kinghorn Cancer Centre, St Vincent's Hospital, Sydney, New South Wales, Australia|The Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead, New South Wales, Australia|Department of Gastroenterology and Hepatology, Royal Adelaide Hospital, Adelaide, South Australia, Australia|Institute for Breathing and Sleep -Bowen CentreAustin Health, Heidelberg, Victoria, Australia|Monash Cancer Centre, Melbourne, Victoria, Australia|Institut Jules Bordet, Bruxelles, Belgium|Cambridge Cancer Trials Centre, Addenbrooke's Hospital, Cambridge, Cambridgeshire, United Kingdom|Leicester Royal Infirmary, Leicester, East Midlands, United Kingdom|Guy's and St Thomas' NHS Foundation Trust,, London, Greater London, United Kingdom|Hammersmith Hospital, London, United Kingdom		https://ClinicalTrials.gov/show/NCT03003078
385	NCT00308178	Dose Dense Abraxane in Adjuvant Chemotherapy for Breast Cancer		Completed	No Results Available	Breast Cancer	Drug: Abraxane	To evaluate the feasibility and toxicity of Abraxane after chemotherapy as part of dose-dense adjuvant chemotherapy for breast cancer.|To evaluate the feasibility of administering Abraxane on a dose dense schedule without G-CSF support|to estimate the percentage of patients with various grades of hematologic toxicity, neurotoxicity, and other non-hematologic toxicity associated with dose-dense Abraxane|to evaluate quality of life.	Harold J. Burstein, MD, PhD|Celgene Corporation|Beth Israel Deaconess Medical Center|Massachusetts General Hospital|Dana-Farber Cancer Institute	All	18 Years and older   (Adult, Older Adult)	Not Applicable	66	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	05-249	March 2006	September 2006	June 2008	March 29, 2006		February 18, 2013	Massacusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT00308178
386	NCT01833208	Radiation Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Receiving Sipuleucel-T		Active, not recruiting	No Results Available	Hormone-Resistant Prostate Cancer|Metastatic Malignant Neoplasm in the Bone|Recurrent Prostate Carcinoma|Stage IV Prostate Cancer	Other: Laboratory Biomarker Analysis|Radiation: Radiation Therapy	Capacity of T cells to proliferate in response to antigen stimulation, assessed with a tritiated thymidine incorporation assay and an interferon-gamma enzyme-linked immunosorbent spot assay|Change in antigen-specific humoral response measured via enzyme-linked immunosorbent assay|Change in the genetics of immune effectors, measured with ribonucleic acid from monocytic and lymphocytic cells|Quantification of lymphocyte subsets and NK cells|Adverse event rates assessed using National Cancer Institute Common Terminology Criteria for Adverse Events version 4|Cancer-specific survival|Change in PSA|Overall survival	Roswell Park Cancer Institute|National Cancer Institute (NCI)|Dendreon	Male	18 Years and older   (Adult, Older Adult)	Not Applicable	15	Other|NIH|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	I 223912|NCI-2013-00633|P30CA016056	July 3, 2013	August 6, 2018	August 6, 2019	April 16, 2013		February 15, 2019	Roswell Park Cancer Institute, Buffalo, New York, United States|Western New York Urology Associates LLC-Harlem, Cheektowaga, New York, United States		https://ClinicalTrials.gov/show/NCT01833208
387	NCT03302884	Circulating Tumor DNA as an Early Marker of Recurrence and Treatment Efficacy in Ovarian Carcinoma	CIDOC	Not yet recruiting	No Results Available	Ovarian Carcinoma	Other: biological sampling	Prognostic value of ctDNA increase for predicting a subsequent clinical, radiological (RECIST v1.1) or biological (CA-125 according to GCIG criteria) diagnosis of disease relapse.	Institut Paoli-Calmettes|AstraZeneca	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	150	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	CIDOC-IPC- 2016-008	December 30, 2017	October 30, 2022	October 30, 2022	October 5, 2017		December 7, 2017	Centre Jean Perrin, Clermont Ferrand, France|Centre Oscar Lambret, Lille, France|Institut Du Cancer de Montpellier, Montpellier, France		https://ClinicalTrials.gov/show/NCT03302884
388	NCT03704727	The Effects of Probiotics on Intestinal Permeability in Gastrointestinal Cancer Patients in Chemotherapy		Completed	No Results Available	Intestinal Permeability|Gastrointestinal Irritation|Mucositis	Dietary Supplement: Probiotic	Intestinal permeability|Gastrointestinal adverse events	University of Copenhagen|Actial Farmaceutica S.r.l.|Nutricia, Inc.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	5	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	H-18010425	July 1, 2018	February 1, 2019	February 1, 2019	October 15, 2018		April 18, 2019	Departmen of Oncology, Rigshospital, Copenhagen, Denmark		https://ClinicalTrials.gov/show/NCT03704727
389	NCT03530605	Use of Optune TTF With Radiation as an Alternative for Elderly Patients With Primary CNS Lymphoma		Not yet recruiting	No Results Available	Central Nervous System Neoplasms, Primary	Device: Optune TTF device	Overall Survival Time|Progression-Free Survival Time|One-Year Survival Rate|Radiographic Response Rate|Steroid & Antiepileptic Use	Scott G. Turner|NovoCure Ltd.|Saint Luke's Health System	All	70 Years and older   (Older Adult)	Not Applicable	10	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Optune TTF in PCNSL	October 2018	October 2022	October 2024	May 21, 2018		October 3, 2018	Saint Luke's Hospital of Kansas City, Kansas City, Missouri, United States|Lifespan Physician Group, Neurosurgery, Providence, Rhode Island, United States		https://ClinicalTrials.gov/show/NCT03530605
390	NCT03111368	EUS-FNA of Solid Pancreatic Mass: Comparison Between Negative Pressure and Slow-pull Technique	EUS-FNA	Completed	No Results Available	Pancreatic Neoplasm	Procedure: Endoscopic ultrasound-guided fine needle aspiration	Diagnostic yield	University of Sao Paulo General Hospital|Boston Scientific Corporation|Medi - Globe	All	18 Years and older   (Adult, Older Adult)	Not Applicable	1	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic	41620315.9.0000.0068	April 27, 2015	June 23, 2016	June 23, 2016	April 12, 2017		April 12, 2017	Hospital das Clinicas da FMUSP, Sao Paulo, SP, Brazil		https://ClinicalTrials.gov/show/NCT03111368
391	NCT03404934	Clinical Study Verifying C-REX LapAid in Clinical Practice		Recruiting	No Results Available	Cancer Colonic	Device: C-REX Ring-locking Procedure	Incidence rate of complication related to the investigational device|Time to evacuation of the short-term implant|Time to first defecation|Time to first intestinal sounds|Time to passage of gas|Number of postoperative interventions related to the investigational device|Anastomotic integrity pressure|Time of surgery	Carponovum AB|Fudan University	All	18 Years to 80 Years   (Adult, Older Adult)	Not Applicable	100	Industry|Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CREX-005	January 3, 2018	September 2019	September 2019	January 19, 2018		July 31, 2019	Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China		https://ClinicalTrials.gov/show/NCT03404934
392	NCT01887314	Efficacy Study of Ginger (Zingiber Officinale) Extract "Ginpax" to Manage Nausea in Cancer Patients Receiving High Emetogenic Treatments and Standard Anti-emetogenic Therapy		Completed	No Results Available	Cancer|Nausea|Vomiting	Dietary Supplement: Standardized Ginger extract	To evaluate the efficacy of Ginger in protecting patients from delayed nausea (incidence of no delayed nausea and non-significant delayed nausea)|Protection from delayed vomiting (number of emetic episodes in delayed phase)|Use of antiemetic rescue medication.|Overall fatigue assessment (BFI questionnaire)	Helsinn Healthcare SA	All	18 Years and older   (Adult, Older Adult)	Not Applicable	250	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care	HF01-12-69	June 2013	September 2015	October 2015	June 26, 2013		January 27, 2016	Istituto Nazionale dei Tumori, Milan, Italy|IEO -Istituto Europeo di Oncologia-, Milan, Italy|Ospedale S. Gerardo, Monza, Italy|Policlinico Umberto I, Rome, Italy|Istituti Fisioterapici Ospitalieri - Istituto Nazionale Tumori "Regina Elena", Rome, Italy|Ospedale S. Maria, Terni, Italy		https://ClinicalTrials.gov/show/NCT01887314
393	NCT03375437	RNASARC - Molecular Screening Program of Soft Tissue Sarcomas With Complex Genomic Profile to Detect NTRK1/2/3, ROS1 or ALK Gene Fusions.	RNASARC	Recruiting	No Results Available	Soft Tissue Sarcoma|Advanced Cancer|Metastatic Cancer	Genetic: Blood and tumor samples	the proportion of patients with NTRK1/2/3, ROS1 or ALK gene fusions (95% confidence interval)|Proportion of patients with NTRK1/2/3, ROS1, or ALK gene fusion per histological sub-types of STS with complex genomics|Clinical characteristics of patients with NTRK1/2/3, ROS1, or ALK gene fusion versus patients with no NTRK1/2/3, ROS1, or ALK gene fusion.|anti-cancer treatments initiated since inclusion.|Overall survival (OS)	Centre Leon Berard|Hoffmann-La Roche	All	12 Years and older   (Child, Adult, Older Adult)	Not Applicable	750	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening	ET17-080 (RNASARC)	February 15, 2018	February 15, 2020	January 15, 2021	December 18, 2017		June 6, 2019	Centre Jean Perrin, Clermont-Ferrand, France|Centre Georges-Francois Leclerc, Dijon, France|Centre Oscar Lambret, Lille, France|CHU de Limoges Hôpital Dupuytren, Limoges, France|Centre Léon Bérard, Lyon, France|Institut de Cancérologie de Lorraine, Nancy, France|Centre Eugène Marquis, Rennes, France|Institut de Cancérologie de la Loire Lucien Neuwirth, Saint-Priest-en-Jarez, France		https://ClinicalTrials.gov/show/NCT03375437
394	NCT03468244	Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Patients With Advanced Digestive System Neoplasms		Recruiting	No Results Available	Advanced Esophageal Squamous Carcinoma|Gastric Adenocarcinoma|Pancreatic Adenocarcinoma|Colorectal Adenocarcinoma	Biological: Personalized mRNA Tumor Vaccine	Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Disease Control Rate of Personalized mRNA Tumor Vaccine|Progression-free Survival of Personalized mRNA Tumor Vaccine|Time to Tumor Progression of Personalized mRNA Tumor Vaccine|Overall Survival of Personalized mRNA Tumor Vaccine	Changhai Hospital|Stemirna Therapeutics	All	18 Years to 75 Years   (Adult, Older Adult)	Not Applicable	24	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CHO-01002	May 1, 2018	December 31, 2019	December 31, 2021	March 16, 2018		February 26, 2019	Changhai Hospital, Shanghai, Shanghai, China		https://ClinicalTrials.gov/show/NCT03468244
395	NCT01852032	Computed Tomography Versus Standard 2D Mammography Versus 3D Tomosynthesis		Completed	Has Results	Breast Cancer	Radiation: Tomosynthesis Breast Scanning|Radiation: Breast CT Scanning	Beta of CT Coronal View|Beta of CT Sagittal View|Beta of CT Axial View|Beta of Tomosynthesis Craniocaudal View|Beta of Tomosynthesis Medial Lateral Oblique View	University of California, Davis|Hologic, Inc.	Female	35 Years and older   (Adult, Older Adult)	Not Applicable	23	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	221183	November 2010	March 4, 2016	March 4, 2016	May 13, 2013	March 16, 2018	April 17, 2018	UC Davis Medical Center, Sacramento, California, United States		https://ClinicalTrials.gov/show/NCT01852032
396	NCT04022772	Effect of PACK Health Support Program on Patient Reported Outcomes in Patients With Breast Cancer		Recruiting	No Results Available	Breast Carcinoma	Other: Best Practice|Other: Medical Chart Review|Other: Quality-of-Life Assessment|Other: Questionnaire Administration|Procedure: Supportive Care	Patient reported outcomes on global physical and mental health|Rate of emergency room visits and hospital admissions	M.D. Anderson Cancer Center|National Cancer Institute (NCI)|Genentech, Inc.	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	545	Other|NIH|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	2018-0473|NCI-2019-03897|P30CA016672	July 31, 2019	February 28, 2021	February 28, 2022	July 17, 2019		August 1, 2019	M D Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT04022772
397	NCT02534233	Evaluation of Effect of CryoBalloon Focal Ablation System on Human Esophageal Epithelium	ColdPlay2	Enrolling by invitation	No Results Available	Barrett's Esophagus|Esophageal Squamous Dysplasia|Esophageal Cancer	Device: CryoBalloon	Histological evaluation of treatment zone(s) for dysplasia|Number of patients with treatment-related adverse events (pain and dysphagia)|Histological evaluation of treatment zone for intestinal metaplasia (BE patients)	Johns Hopkins University|C2 Therapeutics, Inc.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	60	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NA_00075654	April 2015	August 2019	December 2019	August 27, 2015		February 1, 2019	Johns Hopkins Hospital, Baltimore, Maryland, United States		https://ClinicalTrials.gov/show/NCT02534233
398	NCT03783871	NeuWave HCC China Study	NW	Recruiting	No Results Available	Liver Tumor|Hepatocellular Carcinoma	Device: Microwave ablation	Technical Success|Primary Technical Efficacy	Ethicon, Inc.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	137	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NEU_2017_07	February 17, 2019	December 10, 2022	July 24, 2023	December 21, 2018		August 6, 2019	Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China|The First Affiliated Hospital，Sun Yat-sen University, Guangzhou, Guangdong, China|Chinese PLA General Hospital, Beijing, China|Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China		https://ClinicalTrials.gov/show/NCT03783871
399	NCT01803295	Pre-TURBT TC-3 Gel Intravesical Instillation in NMIBC	OPTIMA	Completed	No Results Available	Carcinoma of Urinary Bladder, Superficial	Device: 40 mg MMC gel|Other: Standard of care MMC mixed with water|Device: 80 mg MMC gel	ablative effect of pre-TURBT intravesical instillations of the treatments on The bladder lesion(s) of NMIBC patients|Number of Participants with Adverse Events as a Measure of Safety and Tolerability rate.	UroGen Pharma Ltd.	All	21 Years and older   (Adult, Older Adult)	Not Applicable	80	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	TAS-4M-CS-0002-0	June 2013	July 2016	June 2017	March 4, 2013		June 16, 2017	Carmel Medical Center of Haifa, Department of Urology, Haifa, Israel|Rambam Health Care Campus, Haifa, Israel|Wolfson Medical Center of Holon, Department of Urology, Holon, Israel|Meir medical center, Kfar Saba, Israel|Galil Maaravi Medical Center of Nahariya, Department of Urology, Nahariya, Israel|Rabin Medical Center of Petah Tikva, Department of Urology, Petach Tikvah, Israel|Ziv Medical Center, Zefat, Israel|Vita Salute University, San Raffaele Hospital of Milan, Department of Urology, Milan, Italy|S. Andrea Hospital of Rome, Department of Urology, Rome, Italy|Ospedaliera OO.RR. S. Giovanni di Dio e Ruggi D'Aragona, Salerno, Italy|Fundacio Puigvert, Barcelona, Spain|Hospital Universitario Infanta Sofìa of Madrid, Department of Urology, Madrid, Spain|Hôpital HUG of Geneva, Department of Urology, Geneva, Switzerland		https://ClinicalTrials.gov/show/NCT01803295
400	NCT01241565	ENDO GIA™ Stapler With ENDO GIA™ Reload With Tri-Staple™ Technology in a Pulmonary Resection		Completed	Has Results	Lung Cancer	Device: ENDO GIA™ Stapler with TRI-STAPLE™ Technology	Incidence of Prolonged Air Leaks|Incidence of Air Leaks|Duration of Air Leak|Length of Hospital Stay|Duration of Chest Tube Following Surgery|Incidence of Serosal Tearing	Medtronic - MITG	All	18 Years and older   (Adult, Older Adult)	Not Applicable	50	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	COVEGTT0027	November 2010	October 2011	October 2011	November 16, 2010	July 3, 2014	July 3, 2014	Cedar Sinai Medical Center, Los Angeles, California, United States|Advocate Christ Medical Center, Oak Lawn, Illinois, United States|Mayo Clinic, Rochester, Minnesota, United States		https://ClinicalTrials.gov/show/NCT01241565
401	NCT03448874	Seal-G MIST (Minimally Invasive Sealant/Spray Technology) System Safety Study [SEALAR Study]	SEALAR	Not yet recruiting	No Results Available	Colorectal Cancer|Diverticulitis Colon	Device: Seal-G MIST System	Incidence of overall subject pre-specified* procedure related Adverse Events|Incidence of clinical anastomotic leaks|Incidence of subclinical/ radiological leaks|Incidence of Serious Adverse Events (SAE) complications|Incidence of collection/abscess without demonstrated leak|Incidence of reoperation|Incidence of postoperative mortality|Hospital length of stay|Incidence of "deployment failure"	Sealantis Ltd.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	80	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	DLG-072-06	April 2018	April 2019	July 2019	February 28, 2018		February 28, 2018			https://ClinicalTrials.gov/show/NCT03448874
402	NCT01964677	MR-HIFU for Bone Metastases		Completed	No Results Available	Cancer|Bone Metastases	Device: Magnetic Resonance Image-guided High Intensity Focused Ultrasound (MR-HIFU)	Pain response	Institute of Cancer Research, United Kingdom|Philips Medical Systems	All	18 Years and older   (Adult, Older Adult)	Not Applicable	12	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	12/LO/0424 CCR3772	January 2014	November 14, 2016	November 14, 2016	October 17, 2013		August 22, 2017	The Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom		https://ClinicalTrials.gov/show/NCT01964677
403	NCT04008537	Daily Imaging, Target Identification, and Simulated Computed Tomography-Based Stereotactic Adaptive Radiotherapy Workflow in a Novel Ring Gantry Radiotherapy Device		Not yet recruiting	No Results Available	Cancer of Pancreas|Cancer of Pelvis|Cancer of Abdomen|Cancer of Thorax	Device: Ring gantry kV-CBCT combined with linear accelerator	Feasibility of the device as measured by successful completion of the full CBCT-guided online ART workflow, from volumetric imaging through phantom delivery in at least 90% of attempted fractions	Washington University School of Medicine|Varian Medical Systems	All	18 Years and older   (Adult, Older Adult)	Not Applicable	32	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility	201906142	September 30, 2019	September 30, 2020	September 30, 2020	July 4, 2019		July 4, 2019	Washington University School of Medicine, Saint Louis, Missouri, United States		https://ClinicalTrials.gov/show/NCT04008537
404	NCT03503162	Evaluation of the Bowel Cleansing in Hospitalized Patients Using Pure-Vu System		Completed	No Results Available	Gastrointestinal Disease|Colorectal Cancer	Device: Pure-Vu System	The rate of adequate cleansing level before and after the use of the Pure-Vu System	Motus GI Medical Technologies Ltd	All	22 Years and older   (Adult, Older Adult)	Not Applicable	95	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening	CL00044	May 17, 2018	May 20, 2019	May 20, 2019	April 19, 2018		May 21, 2019	Washington University School of Medicine, Saint Louis, Missouri, United States	"Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/62/NCT03503162/Prot_000.pdf	https://ClinicalTrials.gov/show/NCT03503162
405	NCT00196105	Malignant Obstruction ZILVER Against Routine Therapy (MOZART I)		Completed	Has Results	Biliary Tract Neoplasms|Pancreatic Neoplasms|Jaundice, Obstructive	Device: 6 mm Nitinol Zilver Stent|Device: 10 mm Nitinol Zilver Stent|Device: 10 mm Stainless Steel Wallstent	Patency|Closure or Blockage of the Stent (Occlusion)|Number of Days to Occlusion|Number of Deaths|Time to Death	Cook Group Incorporated	All	21 Years and older   (Adult, Older Adult)	Not Applicable	241	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	03-MOZ	September 2003	December 2006	December 2006	September 20, 2005	January 12, 2010	October 3, 2011	Maine Medical Center, Portland, Maine, United States		https://ClinicalTrials.gov/show/NCT00196105
406	NCT00754286	A Randomized Trial of The Effectiveness of Aromatherapy on Chemotherapy Induced Nausea and Vomiting in Children With Cancer		Completed	No Results Available	Brain Tumors|Leukemia|Sarcomas|Neuroblastoma|Lymphoma|Hodgkins Disease	Other: Aromatherapy Scented Wand|Other: Placebo wand	Examine the effect of aromatherapy on nausea and vomiting among pediatric oncology patients undergoing chemotherapy.|Effects on anxiety, depression and quality of life in this population	Albert Einstein College of Medicine|Soothing Scents, Inc.	All	7 Years to 21 Years   (Child, Adult)	Not Applicable	132	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care	08-01-017	July 2008	July 2011	July 2011	September 17, 2008		September 7, 2018	Children's Hospital at Montefiore, Bronx, New York, United States		https://ClinicalTrials.gov/show/NCT00754286
407	NCT03910699	THREE-row Circular STAPLER in Low Anterior Resection for Rectal Cancer	THREESTAPLER	Not yet recruiting	No Results Available	Anastomotic Leak|Anastomotic Haemorrhage|Anastomotic Complication|Rectal Neoplasms|Staple Misfire|Anastomosis|Anastomotic Stenosis	Device: Three-row circular stapler|Device: Two-row circular stapler	Anastomotic leakage rate|Operating time|Circular stapler misfunction rate|Anastomotic bleeding rate|Re-intervention rate|Early postoperative complications rate|The postoperative hospital stay|Complications of defunctioning stoma|Overall quality of life|Cancer-related quality of life|Manifestation of Low Anterior Resection Syndrome (LARS)|Adverse events rate|Serious adverse events rate	Russian Society of Colorectal Surgeons|Meril Life Sciences Pvt. Ltd.|I.M. Sechenov First Moscow State Medical University	All	18 Years to 85 Years   (Adult, Older Adult)	Not Applicable	154	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment	RSCS-Z0836	April 10, 2019	October 1, 2019	October 1, 2020	April 10, 2019		April 10, 2019			https://ClinicalTrials.gov/show/NCT03910699
408	NCT02025413	Isolation of Circulating Tumor Cells Using a Novel EMT-Based Capture Method	CTC-EMT	Completed	No Results Available	Metastatic Progressive Castration-resistant Prostate Cancer|Metastatic Progressive Breast Cancer	Device: Mesenchymal-marker based ferrofluid (N-cadherin or O-cadherin based)	Feasibility as measured by successfully detecting at least one CTC in at least 2 out of 10 subjects, comparing the non-detection rate over time.|Comparison of the proportion of patients with no detectable CTCs between capture methods over time|Changes in CTCs (using each method) over time during systemic therapy|Change in correlation of CTC enumeration using each method with baseline clinical and pathologic disease characteristics (for example, clinical stage, site of metastatic disease, Gleason sum for CRPC, PSA for CRPC, previous therapies)|Median number of CTCs detected by each method over time	Duke University|Prostate Cancer Foundation|United States Department of Defense|Janssen Diagnostics, LLC	All	18 Years and older   (Adult, Older Adult)	Not Applicable	46	Other|U.S. Fed|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility	Pro00032772	November 2011	December 2015	December 2015	January 1, 2014		December 20, 2018	Duke University Medical Center, Durham, North Carolina, United States		https://ClinicalTrials.gov/show/NCT02025413
409	NCT03655353	A Study of 68Ga-ABY-025 PET for Non-invasive Quantification of HER2-expression in Advanced Breast Cancer	Affibody-3	Recruiting	No Results Available	HER2-positive Breast Cancer	Diagnostic Test: ABY-PET	HER2- expression by using 68Ga-ABY-025 PET.|HER2-expression by analysing biopsy sample.	Henrik Lindman|Roche Pharma AG|Swedish Cancer Society|Affibody|Swedish Breast Cancer Group|Uppsala University Hospital	All	18 Years and older   (Adult, Older Adult)	Not Applicable	120	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	ABY-025-MI301	August 22, 2018	December 31, 2021	December 31, 2022	August 31, 2018		September 7, 2018	Section for Clinical Research & Development Unit, Uppsala, Sweden		https://ClinicalTrials.gov/show/NCT03655353
410	NCT00301145	Varenicline Tartrate With Telephone-Based Counseling and/or Internet-Based Counseling in Helping Adults Stop Smoking		Completed	No Results Available	Unspecified Adult Solid Tumor, Protocol Specific	Behavioral: smoking cessation intervention|Drug: varenicline|Other: counseling intervention|Other: internet-based intervention		SRI International|National Cancer Institute (NCI)	All	18 Years and older   (Adult, Older Adult)	Not Applicable	1200	Industry|NIH	Interventional	Allocation: Randomized|Masking: None (Open Label)|Primary Purpose: Prevention	CDR0000455745|SRI-751	October 2005	June 2008	November 2008	March 10, 2006		December 19, 2013	SRI International, Menlo Park, California, United States|Center for Health Studies, Seattle, Washington, United States|Free & Clear, Incorporated, Seattle, Washington, United States		https://ClinicalTrials.gov/show/NCT00301145
411	NCT01749722	Safety and Efficacy of the NaviAid™ G-Eye System During Colonoscopy		Completed	No Results Available	Colorectal Cancer|Polyp|Adenoma	Device: NaviAid™ G-Eye procedure	Number of adverse events	Smart Medical Systems Ltd.	All	40 Years to 75 Years   (Adult, Older Adult)	Not Applicable	50	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	G-Eye 15502	November 2012	April 2013	June 2013	December 17, 2012		July 30, 2013	Elisha Hospital, Haifa, Israel		https://ClinicalTrials.gov/show/NCT01749722
412	NCT01552200	Performance Evaluation of the NaviAid™ G-Eye System		Completed	No Results Available	Colorectal Cancer|Polyp|Adenoma	Procedure: Group A-Standard Colonoscopy, then NaviAid™ G-Eye procedure|Procedure: Group B-NaviAid™ G-Eye procedure, then Standard Colonoscopy	NaviAid™ G-Eye procedure adenoma detection rate compared to the standard colonoscopy procedure adenoma detection rate	Smart Medical Systems Ltd.	All	40 Years and older   (Adult, Older Adult)	Not Applicable	126	Industry	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	G-Eye 15501	June 2012	June 2013	June 2013	March 13, 2012		April 8, 2014	St. Marienkrankenhaus Frankfurt, Frankfurt, Germany|Hadassah Medical Organization, Jerusalem, Israel|Laniado Hospital, Netanya, Israel|Tel Aviv Sourasky Medical Center, Tel Aviv, Israel		https://ClinicalTrials.gov/show/NCT01552200
413	NCT01226914	A Trial Comparing Wound Drainage and Post-operative Complications With and Without the Use of EVICEL™ Fibrin Sealant in Thyroidectomy		Completed	Has Results	Thyroid Neoplasm|Goiter	Drug: EVICEL	To Compare the Amount of Post-operative Wound Drainage Between the Group of Patients in Which EVICEL™ Spray is Utilized (Arm A), and the Group of Patients in Which an EVICEL™ Placebo is Utilized (Arm B).	Medical University of South Carolina|Ethicon, Inc.	All	18 Years to 99 Years   (Adult, Older Adult)	Not Applicable	55	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care	EVICEL	June 2010	July 2014	July 2014	October 22, 2010	February 5, 2019	February 5, 2019			https://ClinicalTrials.gov/show/NCT01226914
414	NCT03127449	AST2818 in Advanced Non-Small Cell Lung Cancer With EGFR Mutations		Active, not recruiting	No Results Available	Advanced NSCLC	Drug: Alflutinib	Objective response rate of Alflutinib|Duration of response of Alflutinib|Progression free survival of Alflutinib|Clinical benefit rate of Alflutinib|Disease control rate of Alflutinib|Incidence and Severity of Treatment-Emergent Adverse Events|Steady state Maximum Plasma Concentration [Cmax] of multiple doses Alflutinib and 2 metabolites|Steady state peak plasma time [tmax] of multiple doses Alflutinib and 2 metabolites|Steady state Cmin (Minimum Plasma Concentration) of multiple doses Alflutinib and 2 metabolites|Steady state area under the plasma concentration versus time curve [AUC] of multiple doses Alflutinib and 2 metabolites|Steady state clearance of multiple doses Alflutinib and 2 metabolites|Accumulation ratio of multiple doses Alflutinib and 2 metabolites	Allist Pharmaceuticals, Inc.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	81	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	20170405	June 1, 2017	December 1, 2018	December 2019	April 25, 2017		July 9, 2019	cancer hospital Chinese academy of medical sciences, Beijing, China		https://ClinicalTrials.gov/show/NCT03127449
415	NCT03302403	Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors		Not yet recruiting	No Results Available	B Cell Lymphoma|B Cell Leukemia|Myeloma|Hepatocellular Carcinoma|Pancreatic Carcinoma|Adenocarcinoma of Esophagogastric Junction	Genetic: CAR-CD19 T cell|Genetic: CAR-BCMA T cell|Genetic: CAR-GPC3 T cell|Genetic: CAR-CLD18 T cell|Drug: Fludarabine|Drug: Cyclophosphamide	Number of participants with CRA T-related adverse events as assessed by CTCAE v4.03|Engraftment	Kang YU|Carsgen Therapeutics, Ltd.|First Affiliated Hospital of Wenzhou Medical University	All	18 Years to 75 Years   (Adult, Older Adult)	Not Applicable	48	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CGZ001	October 2017	June 2019	December 2020	October 5, 2017		October 5, 2017	First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China		https://ClinicalTrials.gov/show/NCT03302403
416	NCT00165308	Tamoxifen in the Prevention of Breast Cancer in Hodgkin's Disease Survivors		Completed	No Results Available	Hodgkin's Disease|Breast Cancer	Drug: Tamoxifen	To determine the feasibility of a randomized trial testing the effectiveness of tamoxifen in reducing the risk of radiogenic breast cancer.|To determine the safety and effect on quality of life in participating women.	Dana-Farber Cancer Institute|Brigham and Women's Hospital|Massachusetts General Hospital|AstraZeneca	Female	18 Years to 35 Years   (Adult)	Not Applicable	29	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	00-253	April 2001	March 2004	June 2009	September 14, 2005		July 9, 2014	Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT00165308
417	NCT01421680	The Effects of Preoperative and Postoperative Oral Nutritional Supplements in Malnourished Post-gastrectomy Patients		Completed	No Results Available	Malnourished|Stomach Neoplasms|Gastrointestinal Stromal Tumors	Dietary Supplement: Ensure powder	Postoperative complication rate|Body weight|Body composition indices|Length of hospital stay|Quality of life|Postoperative 30-day mortality|Biochemical assessment of nutritional status|Readmission rate|Patient compliance of oral nutritional supplements	Seoul National University Hospital|Abbott	All	20 Years and older   (Adult, Older Adult)	Not Applicable	144	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	ANSK1101	August 2011	December 2013	December 2013	August 23, 2011		March 14, 2014	Department of Surgery, Seoul National University Hospital, Seoul, Korea, Republic of		https://ClinicalTrials.gov/show/NCT01421680
418	NCT00464724	3T Perfluorocarbon-Filled Endorectal Magnetic Resonance Spectroscopic Imaging of Prostate		Active, not recruiting	No Results Available	Prostate Cancer	Procedure: 3T Magnetic Resonance Spectroscopic Imaging	Comparison of linewidths collected from AIR MRSI and PFC-MSRI	M.D. Anderson Cancer Center|United States Department of Defense|GE Healthcare	Male	18 Years and older   (Adult, Older Adult)	Not Applicable	80	Other|U.S. Fed|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	2006-0516|NCI-2011-00517|PC061612	March 2007	March 2020	March 2021	April 24, 2007		May 15, 2019	University of Texas MD Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT00464724
419	NCT03619993	Patient Preference for Pegfilgrastim (Neulasta®) Application Forms	CONVENIENCE	Recruiting	No Results Available	Non Hodgkin Lymphoma|Breast Cancer	Device: On-body injector|Device: Pre-filled syringe	Patient preference for type of pegfilgrastim application assessed via project specific survey answered after 4 applications.|Time point of pegfilgrastim application within a chemotherapy cycle|Patient preference for pegfilgrastim application assessed via project specific survey answered at time of enrollment|Impact of type of pegfilgrastim application on daily life of the patient assessed by direct questioning using project specific patient survey.|Percentage of nurses favoring pegfilgrastim application via On-body injector at study start and at end of study as stated via a project specific nurse survey|Preference of investigators for either type of pegfilgrastim application at study start und at end of study assessed via project specific investigator survey|Cost factors for the health care system for both types of application of pegfilgrastim	iOMEDICO AG|Amgen	All	18 Years and older   (Adult, Older Adult)	Not Applicable	400	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other	IOM-040369	June 25, 2018	November 2020	November 2020	August 8, 2018		January 17, 2019	Research Site, Aschaffenburg, Germany|Research Site, Augsburg, Germany|Research Site, Berlin, Germany|Research Site, Bonn, Germany|Research Site, Celle, Germany|Research Site, Dresden, Germany|Research Site, Dresden, Germany|Research Site, Erfurt, Germany|Research Site, Flensburg, Germany|Research Site, Frankfurt an der Oder, Germany|Research Site, Freiburg, Germany|Research Site, Georgsmarienhütte, Germany|Research Site, Goslar, Germany|Research Site, Göttingen, Germany|Research Site, Halberstadt, Germany|Research Site, Halle (Saale), Germany|Research Site, Hannover, Germany|Research Site, Heidelberg, Germany|Research Site, Herne, Germany|Research Site, Hildburghausen, Germany|Research Site, Hildesheim, Germany|Research Site, Kaiserslautern, Germany|Research Site, Kassel, Germany|Research Site, Krefeld, Germany|Research Site, Köthen, Germany|Research Site, Mannheim, Germany|Research Site, Mayen, Germany|Research Site, Moers, Germany|Research Site, Mühlhausen, Germany|Research Site, Mülheim an der Ruhr, Germany|Research Site, München, Germany|Research Site, Naunhof, Germany|Research Site, Neunkirchen, Germany|Research Site, Neustadt In Sachsen, Germany|Research Site, Nordhorn, Germany|Research Site, Offenbach am Main, Germany|Research Site, Oldenburg, Germany|Research Site, Ostfildern, Germany|Research Site, Passau, Germany|Research Site, Plauen, Germany|Research Site, Ratingen, Germany|Research Site, Rostock, Germany|Research Site, Singen, Germany|Research Site, Spremberg, Germany|Research Site, Stolberg, Germany|Research Site, Stralsund, Germany|Research Site, Sömmerda, Germany|Research Site, Würselen, Germany		https://ClinicalTrials.gov/show/NCT03619993
420	NCT03356002	Evaluation of C-Scan System in Providing Structural Information and Detection of Polypoid Lesions in High Risk Subjects		Recruiting	No Results Available	High Risk (Above Average) Subjects|Non Compliant Patients for Colo Rectal Cancer [CRC] Screening|Counterindicated Patients for Colonoscopy	Device: C-Scan System	Sensitivity and specificity of C-Scan Capsule System in detecting per segment polypoid lesions 10 mm and up as compared with Colonoscopy|Sensitivity and specificity of C-Scan Capsule System in detecting patients with polypoid lesions 6≤x≤9 mm, compared with Optical Colonoscopy|Calculation of the score of the C-Scan system to generate a 3D model of the colon|Quantify the variance of the Interpretation of the data from the C-Scan System between the reviewers	Ceck Cap Ltd.	All	40 Years to 80 Years   (Adult, Older Adult)	Not Applicable	300	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Investigator)|Primary Purpose: Diagnostic	CL-SY-01-0094	January 28, 2018	December 30, 2019	February 26, 2020	November 29, 2017		June 4, 2019	Rambam Medical Center, Haifa, North, Israel|Haemek Medical Center, Afula, Israel|Soroka Medical Center, Be'er Sheva, Israel|Bnai-Zion Medical Center, Haifa, Israel|Meir Medical Center, Kfar Saba, Israel|Laniado Medical Center, Netanya, Israel|Tel Aviv Sorasky Medical Center, Tel Aviv, Israel		https://ClinicalTrials.gov/show/NCT03356002
421	NCT02522520	Pedometer Intervention and Health Effects for Sedentary Colorectal Cancer Patients During Adjuvant Chemotherapy		Recruiting	No Results Available	Colorectal Cancer	Behavioral: Pedometer intervention|Behavioral: Pedometer + hospital based intervention|Device: Omron Walking Style pro. 20	Maximum oxygen uptake - ( VO2 peak)|Health related Quality of Life|Symptoms and side-effects|Anxiety and Depression|Lifestyle factors|Physical activity level|Dual Energy X-ray Absorptiometry scan|Blood cholesterols|Blood pressure / pulse|Pedometer Step Count	Rigshospitalet, Denmark|Copenhagen University Hospital at Herlev|Novo Nordisk A/S|Danish Cancer Society|TrygFonden, Denmark	All	18 Years and older   (Adult, Older Adult)	Not Applicable	48	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other	CIRE-15	June 2015	December 2019	June 2020	August 13, 2015		April 10, 2019	Rigshospitalet, Copenhagen, Denmark		https://ClinicalTrials.gov/show/NCT02522520
422	NCT02047305	Radiofrequency Ablation for Patients With Esophageal Squamous Cell Neoplasia		Completed	No Results Available	ESOPHAGEAL SQUAMOUS CELL CARCINOMA	Device: Radiofrequency Ablation	Complete response|Safety|Recurrences|Progressors|Sustained CR	Covidien, GI Solutions|Medtronic - MITG	All	18 Years to 80 Years   (Adult, Older Adult)	Not Applicable	100	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	B300	January 2009	August 2011	November 2016	January 28, 2014		November 30, 2016	Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China		https://ClinicalTrials.gov/show/NCT02047305
423	NCT03771833	M5 vs. M6 Comparison Study With a Sub Study Into the Dielectric Constant of Aspirated Cyst Fluid		Not yet recruiting	No Results Available	Breast Cyst|Breast Cancer Female	Device: MARIA scan	Establish the presence or absence of a difference in the MARIA(R) outputs obtained with M5 and M6 when the participants is not moved between scans and when they are moved between scans|Establish the presence or absence of a difference between MARIA(R) outputs on the same device when the participant is stationary between scans and when they are moved between scans|Measure the dielectric constant of aspirated cyst fluid and any variance between cyst type|Assess the diagnostic accuracy of both the M5 and M6 versions of the MARIA system in identifying lesions of the breast, including benign lesions such as cysts|Understand participant acceptability of the MARIA scan and obtain feedback on patient experience: questionnaire	Micrima, Ltd.	Female	18 Years to 80 Years   (Adult, Older Adult)	Not Applicable	20	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other	PROT-P2-024	December 19, 2018	March 19, 2019	April 1, 2019	December 11, 2018		December 14, 2018			https://ClinicalTrials.gov/show/NCT03771833
424	NCT02080650	Characterization of Circulating Tumor Cells Captured by c-MET (CTC-MET)		Completed	No Results Available	Prostate Cancer|Renal Cell Carcinoma|Bladder Cancer|Colorectal Cancer|Gastric Cancer|Pancreatic Cancer|Non-small Cell Lung Cancer|Advanced MET Amplified Solid Tumor	Device: Mesenchymal-marker based ferrofluid (c-MET)|Device: Epithelial cell adhesion molecule (EpCAM) ferrofluid	Feasibility|Difference in the median number of CTCs|Association of the number of detectable CTCs with baseline clinical and pathologic disease characteristics.|Kinetics of CTCs over time during treatment with c-MET targeted therapies	Duke University|Prostate Cancer Foundation|Janssen Diagnostics, LLC	All	18 Years and older   (Adult, Older Adult)	Not Applicable	62	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility	Pro00052149	March 2014	May 19, 2016	July 19, 2016	March 6, 2014		August 1, 2017	Duke University Medical Center, Durham, North Carolina, United States		https://ClinicalTrials.gov/show/NCT02080650
425	NCT03338049	All in One Study: A Prospective Trial of Electromagnetic Navigation for Biopsy of Pulmonary Nodules	AIO	Recruiting	No Results Available	Lung Cancer	Device: Veran System	Diagnostic Yield|Serious Adverse Events|Adverse Events|Rate of procedure cancellation|Procedural Factors	Veran Medical Technologies	All	21 Years and older   (Adult, Older Adult)	Not Applicable	150	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	VMT AIO 2017	February 14, 2018	December 2019	January 2020	November 9, 2017		September 26, 2018	Banner University Medical Center - Phoenix, Phoenix, Arizona, United States|Grady Memorial Hospital, Atlanta, Georgia, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States|Washington University Medical Center, Saint Louis, Missouri, United States|University of North Carolina Medical Center, Chapel Hill, North Carolina, United States|Duke University Hospital, Durham, North Carolina, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina Medical Center, Charleston, South Carolina, United States|Swedish Medical Center, Seattle, Washington, United States		https://ClinicalTrials.gov/show/NCT03338049
426	NCT02155075	Evaluation of Real Imaging's 3D Functional Metabolic Imaging and Risk Assessment (MIRA) System		Recruiting	No Results Available	Breast Cancer	Device: MIRA device imaging	Sufficient number of cancer case and controls have been imaged	Real Imaging Ltd.	Female	30 Years and older   (Adult, Older Adult)	Not Applicable	730	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening	960-CSP-ISR_ImplantsMC_ILS3	January 2015	October 2019	October 2019	June 4, 2014		June 19, 2018	The Chaim Sheba Medical Center at Tel Hashomer, Ramat-Gan, Israel		https://ClinicalTrials.gov/show/NCT02155075
427	NCT03718078	Robotic Endomicroscopy to Better Define Resection Strategies Applied to Hepatic Surgery	PERSEE	Not yet recruiting	No Results Available	Hepatocarcinoma|Hepatic Metastasis|Hepatic Tumor	Device: Confocal Laser Endomicroscopy	malignant pCLE criteria|pathological pCLE criteria|Ease of use of the endomicroscopy device|Audio/video telecommunication quality|Number of participants with CLE imaging-related adverse events as assessed by CTCAE v5.0|Stability and reproducibility of images/sequences during procedures|pCLE criteria diagnostic performance	Mauna Kea Technologies	All	18 Years and older   (Adult, Older Adult)	Not Applicable	40	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	MKT-2018-PERSEE-02-DIG|2018-A02619-46	March 2019	January 7, 2020	January 7, 2020	October 24, 2018		January 24, 2019	Institut Mutualiste Montsouris, Paris, France		https://ClinicalTrials.gov/show/NCT03718078
428	NCT02162732	Molecular-Guided Therapy for Childhood Cancer		Active, not recruiting	No Results Available	Neuroblastoma|Medulloblastoma|Glioma|Ependymoma|Choroid Plexus Neoplasms|Craniopharyngioma|Dysembryoplastic Neuroepithelial Tumor|Meningioma|Primitive Neuroectodermal Tumors (PNETs)|Germ Cell Tumors|Rhabdomyosarcoma|Non-rhabdomyosarcoma|Ewings Sarcoma|Osteosarcoma|Wilms Tumor|Renal Cell Carcinoma|Malignant Rhabdoid Tumor|Clear Cell Sarcoma|Liver Tumors	Device: Guided Therapy	Days to treatment will be used in order to determine feasibility of using tumor samples to assess genomic sequencing using predictive modeling to make real-time treatment decisions for children with relapsed/refractory cancers.|Number of Participants with Adverse Events as a Measure of Safety|Overall Response Rate (ORR) of Participants by the presence of radiologically assessable disease by cross-sectional CT or MRI imaging and/or by MIBG or PET scans.|Duration of response will be objectively documented|Biology studies to include: genomic analysis of cells pre- and post- treatment, correlation of in vitro response to in vivo response, sub analysis examination of disease types, and biomarker development.|Progression Free Survival (PFS) interval will be measured by days and compared to the PFS of previous chemotherapy regimens since relapse for each patient.	Giselle Sholler|Translational Genomics Research Institute|Dell, Inc.|Spectrum Health Hospitals	All	13 Months to 21 Years   (Child, Adult)	Not Applicable	184	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NMTRC009	June 2014	June 2020	June 2021	June 13, 2014		July 18, 2019	Arkansas Children's Hospital, Little Rock, Arkansas, United States|Rady Children's Hospital, San Diego, California, United States|Connecticut Children's Hospital, Hartford, Connecticut, United States|Arnold Palmer Hospital for Children, Orlando, Florida, United States|Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States|Helen DeVos Children's Hospital, Grand Rapids, Michigan, United States|Children's Hospital and Clinics on Minnesota, Minneapolis, Minnesota, United States|Children's Mercy Hospitals and Clinics, Kansas City, Missouri, United States|Cardinal Glennon Children's Medical Center, Saint Louis, Missouri, United States|The Children's Hospital at Montefiore, Bronx, New York, United States|Levine Children's Hospital, Charlotte, North Carolina, United States|Randall Children's Hospital, Portland, Oregon, United States|Penn State Milton S. Hershey Medical Center and Children's Hospital, Hershey, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Monroe Carrell Jr. Children's Hospital at Vanderbilt, Nashville, Tennessee, United States|Dell Children's Blood and Cancer Center, Austin, Texas, United States|Texas Children's Cancer and Hematology Centers, Houston, Texas, United States|Primary Children's Hospital, Salt Lake City, Utah, United States|American University of Beirut Medical Center, Beirut, Lebanon		https://ClinicalTrials.gov/show/NCT02162732
429	NCT03970967	Alpha Radiation Emitters Device for the Treatment of Newly Diagnosed Breast Carcinoma Patients With Distant Metastases		Not yet recruiting	No Results Available	Breast Carcinoma|Metastatic Breast Cancer|Invasive Breast Cancer|Distant Metastases.Pathology	Device: Device: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)	Tumor response to DaRT|Adverse Events|Change in tumor volume.|DaRT seeds placement|Change in quality of life: EORTC-QLQ-C30|Progression free survival|Pathological remissions.|Abscopal effects.|Change in quality of life: BR23|Abscopal effects	Alpha Tau Medical LTD.	All	45 Years and older   (Adult, Older Adult)	Not Applicable	30	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CTP-BRST-01	August 2019	August 2022	October 2022	June 3, 2019		June 3, 2019			https://ClinicalTrials.gov/show/NCT03970967
430	NCT03113799	A Study Evaluate Aqueduct's Smart External Drain	SED	Completed	No Results Available	Hydrocephalus|Hydrocephalus in Children|Tumor, Brain	Device: Smart External Drain - SED	Staff interactions|Staff Time|Safety	Aqueduct Critical Care	All	5 Years to 80 Years   (Child, Adult, Older Adult)	Not Applicable	56	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ASSESSED SED1	April 12, 2017	August 15, 2018	January 29, 2019	April 14, 2017		January 31, 2019	Seattle Children's Hospital, Seattle, Washington, United States|University of Washington School of Medicine / Harborview Medical Center, Seattle, Washington, United States		https://ClinicalTrials.gov/show/NCT03113799
431	NCT01823107	Feasibility Study of Meso BioMatrix Device for Breast Reconstruction		Completed	No Results Available	Breast Cancer	Device: Meso BioMatrix Device	Rate of breast related adverse events|Measurement of aesthetic satisfaction with the use of the Breast-Q survey	Kensey Nash Corporation	Female	21 Years and older   (Adult, Older Adult)	Not Applicable	25	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MESO-001	October 2012	June 2017	June 29, 2017	April 4, 2013		August 10, 2018	Henry Ford Health System, Detroit, Michigan, United States|Long Island Plasic Surgical Group, PC, Garden City, New York, United States|Long Island Plastic Surgical Group, PC, Garden City, New York, United States|Cancer Center of America at Eastern Regional Medical Center / Dr. Glat Plastic & Reconstructive Surgery, Bala-Cynwyd, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University of Utah (Huntsman Cancer Hospital), Salt Lake City, Utah, United States		https://ClinicalTrials.gov/show/NCT01823107
432	NCT01917513	Prospective Trial to Compare the Clinical Efficiency of G-EYE™ HD Colonoscopy With Standard HD Colonoscopy		Completed	Has Results	Adenoma|Polyps|Colorectal Cancer	Device: G-EYE™ colonoscopy|Device: Standard Colonoscopy	Detection Rate of Adenomas and Serrated Lesions|Number of Polyp and Adenoma Detection, Procedure Times and Safety (Number of Patients With Adverse Events.	Smart Medical Systems Ltd.	All	50 Years and older   (Adult, Older Adult)	Not Applicable	1000	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	G-EYE 15505	May 2014	September 2016	September 2016	August 6, 2013	January 23, 2018	January 23, 2018	Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States|NYU Langone Medical Center, New York, New York, United States|Herlev Hospital, Harlev, Denmark|Universitätsmedizin Johannes Gutenberg University Mainz, Mainz, Germany|Universitätsklinikum Tübingen, Tübingen, Germany|Helios Dr. Horst Schmidt Kliniken (HSK), Wiesbaden, Germany|Asian Institute of Gastroenterology, Hyderabad, India|Hadassah Medical Center, Jerusalem, Israel|Laniado Hospital, Netanya, Israel|Assaf Harofeh Medical Center, Tzrifin, Israel|Vita Salute San Raffaele University - Scientific Institute San Raffaele, Milan, Italy|Maastricht University Medical Centre, Maastricht, Netherlands|Radboud UMC, Nijmegen, Netherlands|Birmingham City University, Birmingham, United Kingdom|Russells Hall Hospital, Dudley, United Kingdom	"Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/13/NCT01917513/Prot_000.pdf	https://ClinicalTrials.gov/show/NCT01917513
433	NCT03924271	Prevalence Study of Iron Deficiency in Patients With Cancer	CARENFER ONCO	Not yet recruiting	No Results Available	Iron-deficiency	Diagnostic Test: Iron deficiency testing	Blood iron status	VIFORFRANCE	All	18 Years and older   (Adult, Older Adult)	Not Applicable	1200	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	CARENFER ONCO HEMATO	May 15, 2019	June 30, 2019	June 30, 2019	April 23, 2019		April 23, 2019			https://ClinicalTrials.gov/show/NCT03924271
434	NCT01394978	NeoMend ProGEL™ Pleural Air Leak Sealant Post-Approval Study		Completed	Has Results	Lung Cancer|Lung Tumor	Other: Control|Device: ProGEL Pleural Air Leak Sealant	Safety Endpoints	C. R. Bard	All	18 Years and older   (Adult, Older Adult)	Not Applicable	444	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NEO09-100	June 2011	February 2016	February 2016	July 15, 2011	July 11, 2017	July 11, 2017	St. Vincent Birmingham & St. Vincent East, Birmingham, Alabama, United States|University of Alabama in Birmingham, Birmingham, Alabama, United States|Jacksonville Center for Research, Jacksonville, Florida, United States|Moffit Cancer Center, Tampa, Florida, United States|WellStar Research Institute, Atlanta, Georgia, United States|Emory University, Atlanta, Georgia, United States|Indiana University, Indianapolis, Indiana, United States|St. Vincent Hospital and Health Care Center, Indianapolis, Indiana, United States|Greater Baltimore Medical Center, Baltimore, Maryland, United States|Mass General Hospital, Boston, Massachusetts, United States|Brigham Womens' Hospital, Boston, Massachusetts, United States|Beth Israel Deconess Medical Center, Boston, Massachusetts, United States|UMass Memorial Medical, Worcester, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Lancaster General Hospital, Lancaster, Pennsylvania, United States|Virginia Commonwealth University Medical Center, Richmond, Virginia, United States|Swedish Cancer Institute, Seattle, Washington, United States|Dean Foundation for Health, Research and Education, Inc., Madison, Wisconsin, United States		https://ClinicalTrials.gov/show/NCT01394978
435	NCT03229772	Demonstration of the "SPECT/CT System With CZT Detectors" Imaging Performance in a Clinical Setting		Completed	No Results Available	Cancer	Device: Discovery NM/CT 670 CZT Imaging Scan	Diagnostic Image Quality|Image Resolution	GE Healthcare	All	18 Years to 90 Years   (Adult, Older Adult)	Not Applicable	19	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	117.02-2015-GES-0002	September 2015	February 2016	May 2016	July 26, 2017		July 26, 2017	Rambam Health Care Center, Haifa, Israel		https://ClinicalTrials.gov/show/NCT03229772
436	NCT00867724	Clinical Study-evaluate Performance&Safety "Aer-O-Scope" in Colon of Low Risk Patients		Completed	No Results Available	Colon Cancer|Rectal Cancer	Device: Aer-O-Scope Colonoscopy	Ability to screen the entire length of the colon to the cecum.|Safety endpoints to include incidence of bowel perforation, Colonic bleeding, Damage to colon, rectum and anus mucosa or any other Adverse events	GI View Ltd.	All	18 Years to 70 Years   (Adult, Older Adult)	Not Applicable	68	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	190-CLD-AOS	September 2009	July 2013	July 2013	March 24, 2009		August 1, 2017	Sourasky Medical Center, Tel Aviv, Israel		https://ClinicalTrials.gov/show/NCT00867724
437	NCT00785369	In Vivo Confocal Microscopy for Pigmented Lesion Diagnosis		Completed	No Results Available	Skin Cancer|Melanoma|Lentigo Maligna	Device: Reflectance confocal microscopy	To assess the diagnostic accuracy of reflectance confocal scanning laser microscopy(RCM) for melanoma diagnosis when compared to the "gold standard" histopathologic diagnosis.|To assess interobserver variability associated with interpreting confocal images for detecting cutaneous melanoma and to assess confocal correlations in a qualitative manner.	Lucid, Inc.|Memorial Sloan Kettering Cancer Center|Loma Linda University|University of Rochester|VA Loma Linda Health Care System|Skin and Cancer Associates in Plantation,Fl.|Harvard University	All	18 Years and older   (Adult, Older Adult)	Not Applicable	441	Industry|Other|U.S. Fed	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	LI058054|5R44CA058054-06	August 2008	December 2009	December 2009	November 5, 2008		October 3, 2012	Loma Linda University, Loma Linda, California, United States|VA Loma Linda Health Care System, Loma Linda, California, United States|Skin and Cancer Assoicates, Plantation, Florida, United States|Memorial Sloan-Kettering Cancer Center, Hauppauge, New York, United States|Memorial Sloan-Kettering Cancer Center, Manhattan, New York, United States|University of Rochester Medical Center, Rochester, New York, United States		https://ClinicalTrials.gov/show/NCT00785369
438	NCT02307630	PET Imaging of Solid Tumors Using 124I-Humanized 3F8: A Pilot Study		Active, not recruiting	No Results Available	Melanoma|Neuroblastoma|Sarcoma	Biological: 124I-Humanized 3F8	radioactivity measured to determine pharmacokinetics of 124I-hu3F8|PET/CT scan images will be analyzed to determine bio distribution of 124I-hu3F8	Memorial Sloan Kettering Cancer Center|Y-mAbs Therapeutics	All	3 Years to 90 Years   (Child, Adult, Older Adult)	Not Applicable	7	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	13-147	November 2014	November 2019	November 2019	December 4, 2014		November 29, 2018	Memorial Sloan Kettering Cancer Center, New York, New York, United States		https://ClinicalTrials.gov/show/NCT02307630
439	NCT00392366	Laser Interstitial Thermal Therapy Under "Real Time" MRI Guidance for "Minimal Invasive" Treatment of Liver Metastasis		Completed	No Results Available	Carcinoma, Hepatocellular|Liver Neoplasms|Digestive System Neoplasms	Device: MR-guided Laser Interstitial Thermal Therapy System	Accuracy of predicted lesion geometry to histologically measured dimensions	BioTex, Inc.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	25	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	LITT / METASTASE HEPATIQUES	July 2006		July 2008	October 26, 2006		January 1, 2010	Hospital Cochin, Paris, France		https://ClinicalTrials.gov/show/NCT00392366
440	NCT02597452	Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner	iBE	Active, not recruiting	No Results Available	Breast Cancer	Device: intelligent Breast Exam, iBE	Compare the outcomes of the iBE examinations to clinical breast examinations by estimating the sensitivity of the device using imaging results|Compare the outcomes of the iBE examinations to clinical breast examinations by estimating the specificity of the device using imaging results|Position of the breast lesion|Size detection of the breast lesion|Inter-rate reliability of the iBE and the CBE number of lesions detected|Inter-rate reliability of the iBE and the CBE position of lesions detected|Post-stratification of the analysis of the reliability by Breast Imaging Reporting and Data System level	University of Pennsylvania|UE LifeSciences Inc.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	1000	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening	821412-UPCC24114	March 2014	June 2019	December 2019	November 5, 2015		June 11, 2019	Pennsylvania Hospital, Philadelphia, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT02597452
441	NCT03593122	Investigation on the Efficacy of WO 2085 Moisturising Cream for Breast Cancer Patients Suffering From Vulvovaginal Dryness		Completed	No Results Available	Vulvovaginal Atrophy	Device: WO2085 Moisturising Cream	Change from Baseline of subjective vulvovaginal atrophy symptoms (e.g. feeling of dryness, itching)|Change from Baseline of objective vulvovaginal atrophy symptoms (e.g. thinning of the vaginal epithelium, redness)|Global judgement of efficacy|Global judgement of tolerability|Adverse Events	Dr. August Wolff GmbH & Co. KG Arzneimittel|Dr. Dimitrios Chatsiproios|Dr. med. Klaus König|SAM®, Statistische Analysen und Monitoring GmbH	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	128	Industry|Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	VFAU-13/2009	January 4, 2010	July 31, 2010	July 31, 2010	July 19, 2018		July 19, 2018	Axel Gerick, Aachen, Germany|Sibylle Kaßpohl, Alzenau, Germany|Jörg Schilling, Berlin, Germany|Axel Widing, Berlin, Germany|Alexandra Coumbos, Berlin, Germany|Amin Mortazawi, Darmstadt, Germany|Kathrin von Ardenne, Dresden, Germany|Joachim Larbig, Fulda, Germany|Nidal Gazawi, Leipzig, Germany|Elke Wierick, Lohsa, Germany|Dagmar Guth, Plauen, Germany|Wolfgang Clemens, Stolberg, Germany|Carsten Hielscher, Stralsund, Germany|Christopher Wolf, Ulm, Germany|Heidi Massinger-Biebl, Waldkirchen, Germany|Klaus Doubek, Wiesbaden, Germany|Anja Obermeyer, Würselen, Germany		https://ClinicalTrials.gov/show/NCT03593122
442	NCT03796052	Study Determining Safety and Efficacy of Avena Sativa (Oat) Skincare Products for Treating Skin Dryness and Itching in Cancer Patients		Recruiting	No Results Available	Ichthyosis|Pruritus	Other: Avena Sativa Skincare Regimen	Mean Change from Baseline to Visit 2 in CTCAE Grading of Xerosis|Mean Change from Baseline to Visit 2 in CTCAE Grading of Pruritus|Mean Change from Baseline to Visit 2 in Overall Xerosis Grading|Mean Change from Baseline to Visit 2 in Overall Pruritus Grading|Mean Change from Baseline to Visit 2 in Overall Irritation Assessment|Frequency Distribution for Overall Tolerance at Visit 2 - Subject Rating|Frequency Distribution for Overall Tolerance at Visit 2 - Investigator Rating|Mean Change from Baseline to Visit 2 in PRO-CTCAE Skin Dryness|Mean Change from Baseline to Visit 2 in PRO-CTCAE Itching|Mean Change from Baseline to Visit 2 in Skindex-16 Global Score|Mean Change from Baseline to Visit 2 in Skindex-16 Emotional Subscale|Mean Change from Baseline to Visit 2 in Skindex-16 Symptoms Subscale|Mean Change from Baseline to Visit 2 in Skindex-16 Functional Subscale|Mean Change from Baseline to Visit 2 in Skin Moisture|Mean Change from Baseline to Visit 2 in Skin Water Loss|Mean Change from Baseline to Visit 2 in Self-Assessment of Dryness|Mean Change from Baseline to Visit 2 in Self-Assessment of Flakiness|Mean Change from Baseline to Visit 2 in Self-Assessment of Itchiness|Mean Change from Baseline to Visit 2 in Self-Assessment of Roughness|Mean Change from Baseline to Visit 2 in Self-Assessment of Smoothness|Mean Change from Baseline to Visit 2 in Self-Assessment of Softness|Mean Change from Baseline to Visit 2 in Self-Assessment of Comfort|Mean Change from Baseline to Visit 2 in Self-Assessment of Overall Look/Feel	Johnson & Johnson Consumer Inc. (J&JCI)|Johnson & Johnson Consumer and Personal Products Worldwide	All	18 Years to 75 Years   (Adult, Older Adult)	Not Applicable	50	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CCSSKA000844	May 23, 2019	August 30, 2019	August 30, 2019	January 8, 2019		August 1, 2019	Memorial Sloan-Kettering Cancer Center, New York, New York, United States		https://ClinicalTrials.gov/show/NCT03796052
443	NCT03455205	Shenqi Fuzheng Injection for the Treatment of Cancer-related Fatigue in Chemo Patients With Digestive Tract .		Recruiting	No Results Available	Digestive Tract	Drug: shenqifuzheng|Drug: 0.9%sodium chloride	Piper Fatigue Scale（PFS）	Livzon Pharmaceutical Group Inc.|The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine	All	18 Years to 75 Years   (Adult, Older Adult)	Not Applicable	270	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	livzon-sqfz-chemo	December 24, 2017	December 30, 2019	December 30, 2019	March 6, 2018		March 6, 2018	First affiliated hospital of guangzhou university of traditional Chinese medicine, Guangzhou, Guangdong, China		https://ClinicalTrials.gov/show/NCT03455205
444	NCT03432936	Prospective Use of Philips iSuite for Interventional Procedures		Recruiting	No Results Available	Cancer|Tumor	Device: MRI guided procedure software evaluation	Needle placement efficiency into target lesion|Software ease of use in targeting lesion for treatment	Mayo Clinic|Philips Healthcare	All	18 Years to 90 Years   (Adult, Older Adult)	Not Applicable	200	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	17-007674	July 1, 2019	March 2020	March 2021	February 14, 2018		June 4, 2019	Mayo Clinic in Rochester, Rochester, Minnesota, United States		https://ClinicalTrials.gov/show/NCT03432936
445	NCT03456609	Shenqi Fuzheng Injection for the Treatment of Cancer-related Fatigue in Patients(BCS) With Digestive Tract .		Recruiting	No Results Available	Carcinogenic Fatigue	Drug: shenqifuzheng injection|Drug: Sodium Chloride Injection 0.9%	Piper Fatigue Scale（PFS）	Livzon Pharmaceutical Group Inc.	All	18 Years to 80 Years   (Adult, Older Adult)	Not Applicable	60	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	livzon-sqfz-BCS	January 18, 2018	December 30, 2019	December 30, 2019	March 7, 2018		March 7, 2018	First affiliated hospital of guangzhou university of traditional Chinese medicine, Guangzhou, Guangdong, China		https://ClinicalTrials.gov/show/NCT03456609
446	NCT03546985	A Trial of Episil® Oral Liquid in Cancer Patients Suffering From Chemotherapy- and/or Radiation-induced Oral Mucositis		Completed	No Results Available	Chemotherapy- and/or Radiation-induced Oral Mucositis	Device: episil®|Device: Kang Su	Area under the curve (AUC) of pain score of oral mucositis|Pain intensity decrease inside the oral cavity|Peak pain intensity difference inside the oral cavity|Incidence of adverse events	Solasia Pharma K.K.|Solasia Medical Information Consulting (Shanghai) Co. Ltd.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	60	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	SP-0301	December 26, 2017	May 8, 2018	May 25, 2018	June 6, 2018		June 8, 2018	The People's Liberation Army 307 Hospital, Beijing, Beijing, China|Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China|Tongji Hospital, Wuhan, Hubei, China|Jiangsu Province Hospital, Nanjing, Jiangsu, China|The People's Liberation Army 81 Hospital, Nanjing, Jiangsu, China|The First Hospital of Jilin University, Changchun, Jilin, China|Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China		https://ClinicalTrials.gov/show/NCT03546985
447	NCT03971175	Influence of Biopsy Technique on Moleculargenetic Tumor Characterisation in NSCLC	PROFILER	Recruiting	No Results Available	Carcinoma, Non-Small-Cell Lung|Pathology, Molecular	Procedure: Forceps biopsy|Procedure: Cryobiopsy	Detection of at least one molecular and/ or genetic alteration.|Differences in the detection of total mutational burden between both techniques.|Detection of any molecular and/ or genetic alterations|Combinations of molecular and/ or genetic alterations|Differences in the quantity of total mutational burden between the different techniques	University Hospital Tuebingen|AstraZeneca	All	18 Years and older   (Adult, Older Adult)	Not Applicable	540	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic	PROFILER study	December 19, 2018	December 31, 2020	December 31, 2021	June 3, 2019		June 3, 2019	University of Tuebingen, Tuebingen, Germany		https://ClinicalTrials.gov/show/NCT03971175
448	NCT01833806	A Phase IV Post Approval Clinical Study of ExAblate Treatment of Metastatic Bone Tumors for the Palliation of Pain		Recruiting	No Results Available	Bone Metastasis	Device: ExAblate MRgFUS	Proportion of Responders|Safety Profile	InSightec	All	18 Years and older   (Adult, Older Adult)	Not Applicable	70	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	BM018|P110039/S2	September 2013	June 2020	October 2020	April 17, 2013		June 14, 2019	City of Hope, Duarte, California, United States|University of California Los Angeles, Los Angeles, California, United States|University of California San Francisco, San Francisco, California, United States|Stanford University School of Medicine, Stanford, California, United States|Mayo Clinic, Rochester, Minnesota, United States|Weill Cornell Medical Center, New York, New York, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|MD Anderson, Houston, Texas, United States|University of Virginia, Charlottesville, Virginia, United States		https://ClinicalTrials.gov/show/NCT01833806
449	NCT00443534	A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.		Completed	Has Results	Neoplasms	Drug: SU011248	Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)	Pfizer	All	18 Years and older   (Adult, Older Adult)	Not Applicable	123	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	A6181078	May 2006	December 2011	December 2011	March 6, 2007	May 24, 2013	May 24, 2013	Pfizer Investigational Site, Aurora, Colorado, United States|Pfizer Investigational Site, Littleton, Colorado, United States|Pfizer Investigational Site, Orlando, Florida, United States|Pfizer Investigational Site, Atlanta, Georgia, United States|Pfizer Investigational Site, Harvey, Illinois, United States|Pfizer Investigational Site, Harvey, Illinois, United States|Pfizer Investigational Site, Maywood, Illinois, United States|Pfizer Investigational Site, Tinley Park, Illinois, United States|Pfizer Investigational Site, Zion, Illinois, United States|Pfizer Investigational Site, Munster, Indiana, United States|Pfizer Investigational Site, Baltimore, Maryland, United States|Pfizer Investigational Site, Grand Rapids, Michigan, United States|Pfizer Investigational Site, Creve Coeur, Missouri, United States|Pfizer Investigational Site, St. Louis, Missouri, United States|Pfizer Investigational Site, St. Peters, Missouri, United States|Pfizer Investigational Site, Las Vegas, Nevada, United States|Pfizer Investigational Site, Hackensack, New Jersey, United States|Pfizer Investigational Site, Chapel Hill, North Carolina, United States|Pfizer Investigational Site, Clinton, North Carolina, United States|Pfizer Investigational Site, Goldsboro, North Carolina, United States|Pfizer Investigational Site, Hickory, North Carolina, United States|Pfizer Investigational Site, Wilson, North Carolina, United States|Pfizer Investigational Site, Oklahoma City, Oklahoma, United States|Pfizer Investigational Site, Tulsa, Oklahoma, United States|Pfizer Investigational Site, Tulsa, Oklahoma, United States|Pfizer Investigational Site, Tulsa, Oklahoma, United States|Pfizer Investigational Site, Hershey, Pennsylvania, United States|Pfizer Investigational Site, Greenville, South Carolina, United States|Pfizer Investigational Site, Greer, South Carolina, United States|Pfizer Investigational Site, Spartanburg, South Carolina, United States|Pfizer Investigational Site, Bedford, Texas, United States|Pfizer Investigational Site, Dallas, Texas, United States|Pfizer Investigational Site, Fort Worth, Texas, United States|Pfizer Investigational Site, Houston, Texas, United States|Pfizer Investigational Site, San Antonio, Texas, United States|Pfizer Investigational Site, San Antonio, Texas, United States|Pfizer Investigational Site, San Antonio, Texas, United States|Pfizer Investigational Site, San Antonio, Texas, United States|Pfizer Investigational Site, Edmonton, Alberta, Canada|Pfizer Investigational Site, Ottawa, Ontario, Canada|Pfizer Investigational Site, Montreal, Quebec, Canada|Pfizer Investigational Site, Montreal, Quebec, Canada|Pfizer Investigational Site, Montreal, Quebec, Canada|Pfizer Investigational Site, Lyon Cedex 08, France|Pfizer Investigational Site, Marseille Cedex 20, France|Pfizer Investigational Site, Villejuif, France|Pfizer Investigational Site, Berlin, Germany|Pfizer Investigational Site, Grosshansdorf, Germany|Pfizer Investigational Site, Hamburg, Germany|Pfizer Investigational Site, Wiesbaden, Germany|Pfizer Investigational Site, Bologna, Italy|Pfizer Investigational Site, Cremona, Italy|Pfizer Investigational Site, Genova, Italy|Pfizer Investigational Site, Milano, Italy|Pfizer Investigational Site, Orbassano (TO), Italy|Pfizer Investigational Site, Rozzano (MI), Italy|Pfizer Investigational Site, Elche, Alicante, Spain|Pfizer Investigational Site, Barcelona, Spain|Pfizer Investigational Site, Cordoba, Spain|Pfizer Investigational Site, Sutton, Surrey, United Kingdom|Pfizer Investigational Site, London, United Kingdom|Pfizer Investigational Site, Manchester, United Kingdom		https://ClinicalTrials.gov/show/NCT00443534
450	NCT02405819	Patient and Provider Initiated Survivorship Care Planning		Completed	No Results Available	Cancer	Other: 'My Care Plan'|Other: 'Survivorship Care Plan Builder'	Patient in receipt of a complete survivorship care plan|Change in score for the CaSUN (Cancer Survivors' Unmet Needs) assessment tool|Change in score on the PLANS (Preparing for Life as a New Survivor) assessment tool	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Genentech, Inc.|WellPoint, Inc.	All	21 Years and older   (Adult, Older Adult)	Not Applicable	41	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research	J14178|IRB00057614	February 2015	February 2016	February 2016	April 1, 2015		April 21, 2016	Sibley Memorial Hospital, Washington, District of Columbia, United States|Suburban Hospital, Bethesda, Maryland, United States		https://ClinicalTrials.gov/show/NCT02405819
451	NCT03585959	superDimension™ Navigation System Version 7.2 With Fluoroscopic Navigation Technology		Active, not recruiting	No Results Available	Lung Cancer	Device: superDimension™ Navigation System Version 7.2	Confirm the location accuracy of the local registration feature|Number of cases that are technically successful (successful completion of local registration)|Investigator confirmation that the catheter is in an "Adequate Periprocedural Location" using the electromagnetic navigation bronchoscopy (ENB) technology.	Medtronic - MITG	All	18 Years and older   (Adult, Older Adult)	Not Applicable	50	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	MDT18004ILSFNV	August 3, 2018	February 2019	February 2019	July 13, 2018		February 18, 2019	FirstHealth Moore Regional Hospital, Pinehurst, North Carolina, United States		https://ClinicalTrials.gov/show/NCT03585959
452	NCT04030104	Optoacoustic Images Versus Imagio® Ultrasound	Reader-02	Active, not recruiting	No Results Available	Breast Cancer	Device: Reader Study - Imagio Ultrasound|Device: Reader Study Imagio Ultrasound + Optoacoustic Imaging	Sensitivity and Specificity|Partial Receiver Operating Characteristic (ROC) Area under the Curve (AUC)|Model-adjusted specificities and sensitivities|Negative Likelihood Ratio|Positive Likelihood Ratio	Seno Medical Instruments Inc.	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	840	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	Reader-02 Study	July 30, 2019	October 15, 2019	December 30, 2019	July 23, 2019		August 2, 2019	American College of Radiology Center for Research and Innovation, Philadelphia, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT04030104
453	NCT03845907	Clinical Evaluation of Opto-Acoustic Image Quality With the Gen1B Duplex Probe in Breast Applications		Recruiting	No Results Available	Breast Cancer	Device: Gen 1B|Device: Gen 1	Number of Subjects with Treatment-related Events|Diagnostic Image Quality of Gen 1B|Probe performance data comparison across skin types|Image Quality between probes at reduced laser level	Seno Medical Instruments Inc.	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	100	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Other	GEN1B-01	December 19, 2018	August 30, 2019	September 30, 2019	February 19, 2019		July 18, 2019	Seno Medical, San Antonio, Texas, United States		https://ClinicalTrials.gov/show/NCT03845907
454	NCT03808116	Evaluation of the SmartBx System for Breast Biopsy		Not yet recruiting	No Results Available	Breast Cancer	Device: SmartBx	biopsy core length|biopsy core yield	UC Care, Ltd.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	30	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	EMC-0124-18	May 15, 2019	June 1, 2019	July 1, 2019	January 17, 2019		April 18, 2019	Haemek medical center, Afula, North Region, Israel		https://ClinicalTrials.gov/show/NCT03808116
455	NCT03615443	Noninvasive vs. Invasive Lung Evaluation	NILE	Active, not recruiting	No Results Available	Non-Small Cell Lung Cancer	Diagnostic Test: Guardant360	Demonstrate the non-inferiority of cfDNA-based vs. tumor tissue-based genotyping|Objective Response Rate (ORR)|Turnaround Time for cfDNA vs. Tissue Results|Time to Treatment Initiation|Quantity Not Sufficient Rate of Tissue for Complete NCCN Biomarker Testing|Tissue Incomplete Rate of Tissue for NCCN Biomarker Testing|Tumor Not Detected Rate of cfDNA in Blood|Sensitivity, Specificity, and Diagnostic Accuracy of Non-NCCN Biomarkers on the Guardant360 Panel|Rate of Discovery of Genomically Mediated, Acquired Resistance to Targeted Therapies in the Biomarker-Positive Subsets	Guardant Health, Inc.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	300	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	GH03-001	February 12, 2016	December 31, 2019	December 31, 2019	August 3, 2018		August 3, 2018			https://ClinicalTrials.gov/show/NCT03615443
456	NCT00595322	Bevacizumab in the Radiation Treatment of Recurrent Malignant Glioma		Completed	No Results Available	Brain Cancer|Recurrent Malignant Gliomas|Primary Brain Tumor	Other: bevacizumab and radiation (IMRT)	To test the safety of bevacizumab in patients with recurrent malignant gliomas in preparation for a larger study to test the efficacy of this drug used during the initial radiation treatment of these tumors if safety is affirmed.	Memorial Sloan Kettering Cancer Center|Weill Medical College of Cornell University|Genentech, Inc.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	25	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	05-092	December 2005	May 2017	May 2017	January 16, 2008		May 23, 2017	Memorial Sloan-Kettering Cancer Center @ Suffolk, Commack, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States		https://ClinicalTrials.gov/show/NCT00595322
457	NCT03627442	Post-op Outcomes of Enhanced Energy Delivery Dissection for Mastectomy With Immediate Breast Reconstruction		Not yet recruiting	No Results Available	Breast Cancer	Procedure: Mastectomy with PhotonBlade|Procedure: Mastectomy with Bovie	Flap perfusion viability|Change in Surgical Site Drainage|Post-Operative Pain Assessment|Surgical Site Complications|Surgical Site Drainage - Time	Invuity, Inc.|Montefiore Medical Center	Female	18 Years to 65 Years   (Adult, Older Adult)	Not Applicable	15	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other	2017-8737	August 15, 2018	August 15, 2019	October 15, 2019	August 13, 2018		August 13, 2018			https://ClinicalTrials.gov/show/NCT03627442
458	NCT03586583	Fujifilm Feature Comparison Reader Study to Compare Old vs New Processing		Active, not recruiting	No Results Available	Breast Cancer	Device: FBP|Device: ISR	Non-inferior	Fujifilm Medical Systems USA, Inc.|International HealthCare, LLC	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	600	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Diagnostic	FMSU2017-003	June 30, 2018	June 30, 2018	September 2018	July 13, 2018		July 13, 2018	International HealthCare, LLC, Norwalk, Connecticut, United States		https://ClinicalTrials.gov/show/NCT03586583
459	NCT02867371	Evaluation of the Archimedes™ System for Transparenchymal Nodule Access 2	EAST2	Recruiting	No Results Available	Lung Cancer	Device: Archimedes System	Proportion of biopsies yielding tissue sufficient for diagnosis|Procedure planning time|Nodule access time|Fluoroscopy time|Patient registration time	Broncus Medical Inc	All	21 Years to 80 Years   (Adult, Older Adult)	Not Applicable	200	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	Protocol 44	August 2016	December 2018	February 2019	August 15, 2016		June 25, 2018	Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Duke University, Durham, North Carolina, United States|Cancer Treatment Centers of America at Southwestern Regional Medical Center, Tulsa, Oklahoma, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|Houston Methodist Hospital, Houston, Texas, United States|The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China|Shanghai Chest Hospital, Shanghai, Shanghai, China|ThoraxKlinik, Heidelberg, Germany|Hong Kong Sanatorium & Hospital, Hong Kong, Hong Kong		https://ClinicalTrials.gov/show/NCT02867371
460	NCT03456427	Patient-Assisted Compression in 3D - Impact on Image Quality and Workflow	3D PAC	Completed	Has Results	Breast Cancer	Device: Patient-Assisted Compression (PAC)|Device: Technologist-Controlled (TC) Compression	Percentage of Acceptable Overall Image Quality|Number of Repeat Image Acquisitions|Percentage of Acceptable Mammographic Attributes	GE Healthcare	Female	40 Years and older   (Adult, Older Adult)	Not Applicable	36	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility	124.03-2017-GES-0005	January 4, 2018	January 9, 2018	January 9, 2018	March 7, 2018	April 5, 2019	April 5, 2019	Boca Raton Regional Hospital, Boca Raton, Florida, United States	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/27/NCT03456427/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT03456427
461	NCT03943368	Using Virtual Reality (VR) Models for Robotic Prostatectomy		Enrolling by invitation	No Results Available	Prostate Cancer	Device: Ceevra Reveal	Total operative time|Blood loss (measured in cubic centimeters)|Intraoperative conversion from robotic assisted laparoscopic procedure to open procedure|Intraoperative complication|Patient hospital stay|Positive tumor margin (assessed via standard post-operative biopsy)|Postoperative Gleason Score|Postoperative oncologic stage (T stage)|Readmission|Postoperative prostate-specific antigen (PSA)|Postoperative erectile function|Postoperative continence	Ceevra, Inc.	Male	18 Years and older   (Adult, Older Adult)	Not Applicable	20	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	20171006RP	April 25, 2019	March 31, 2020	March 31, 2021	May 9, 2019		August 1, 2019	UC Irvine, Orange, California, United States|Mayo Clinic Florida, Jacksonville, Florida, United States|Swedish Urology Group, Seattle, Washington, United States|Swedish Medical Center, Seattle, Washington, United States		https://ClinicalTrials.gov/show/NCT03943368
462	NCT03870269	Using Virtual Reality (VR) Models for Robotic Prostatectomy - UNC		Enrolling by invitation	No Results Available	Prostate Cancer	Device: Ceevra Reveal	Total operative time|Blood loss (measured in cubic centimeters)|Intraoperative conversion from robotic assisted laparoscopic procedure to open procedure|Intraoperative complication|Patient hospital stay|Positive tumor margin (assessed via standard post-operative biopsy)|Postoperative Gleason Score|Postoperative oncologic stage (T stage)|Readmission|Postoperative prostate-specific antigen (PSA)|Postoperative erectile function|Postoperative continence	Ceevra, Inc.	Male	18 Years and older   (Adult, Older Adult)	Not Applicable	40	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	17-0904RP	February 25, 2019	March 31, 2020	March 31, 2021	March 12, 2019		March 12, 2019	UNC Hospital, Chapel Hill, North Carolina, United States		https://ClinicalTrials.gov/show/NCT03870269
463	NCT02557906	Evaluating Outcomes of Immediate Breast Reconstruction (POBRAD-M)	POBRAD-M	Active, not recruiting	No Results Available	Breast Neoplasms|Breast Diseases	Procedure: Breast reconstruction - implant and an ADM (SurgiMend)|Procedure: Breast reconstruction- autologous tissue|Procedure: Breast reconstruction- implant + dermal sling/LD flap	Number of patients with adverse events|Aesthetic outcome measured by Photographic assessment|BREAST-Q questionnaire score	King's College London|Guy's and St Thomas' NHS Foundation Trust|Integra LifeSciences Corporation	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	209	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	153962	July 2014	January 2016	January 2020	September 23, 2015		March 13, 2018	Royal Hampshire County Hospital, Winchester, Hampshire, United Kingdom|Frimley Park Hospitals NHS Foundation Trust, Frimley, United Kingdom|Leeds Teaching Hospitals, Leeds, United Kingdom|Department of Research Oncology, King's College London, London, United Kingdom|Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom|Royal Cornwall Hospital, Truro, United Kingdom		https://ClinicalTrials.gov/show/NCT02557906
464	NCT03107156	Understanding Evidence-Based Practice Patterns in Advanced NSCLC		Recruiting	No Results Available	Non Small Cell Lung Cancer	Behavioral: Carevive CPS	Adherence (by providers) to evidence-based treatment recommendations for patients with advanced NSCLC|Components of value-based NSCLC cancer care.|Clinical practice patterns in medical oncologists managing older patients with advanced NSCLC.	Carevive Systems, Inc.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	375	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	G409	January 1, 2018	October 30, 2018	April 30, 2019	April 11, 2017		January 30, 2019	Jefferson University, Philadelphia, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT03107156
465	NCT03056300	A Prospective, Multi-Center Evaluation of a Powered Vascular Stapler in Video-Assisted Thoracoscopic Lobectomies		Completed	Has Results	Non-Small Cell Lung Cancer	Device: Video-Assisted Thoracoscopic Lobectomy with powered vascular stapler	Incidence of Intra-Operative Hemostatic Interventions|Post-operative Interventions or Procedures Related to Pulmonary Artery or Pulmonary Vein Bleeding	Ethicon, Inc.	All	18 Years to 75 Years   (Adult, Older Adult)	Not Applicable	50	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	ESC-14-006	January 11, 2017	May 26, 2017	May 26, 2017	February 17, 2017	December 17, 2018	January 30, 2019	Beijing Cancer Hospital, Beijing City, China	"Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/00/NCT03056300/Prot_000.pdf|"Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/00/NCT03056300/SAP_001.pdf	https://ClinicalTrials.gov/show/NCT03056300
466	NCT03762616	Urology San Antonio MRI/MicroUS Comparison		Recruiting	No Results Available	Prostate Cancer	Diagnostic Test: Micro-ultrasound targeted biopsy|Diagnostic Test: mpMRI targeted biopsy	Detection Rate of Cancer|Lesion size and shape comparison|Detailed Pathology Correlation|Retrospective on MRI|Retrospective on micro-ultrasound	Exact Imaging	Male	40 Years to 75 Years   (Adult, Older Adult)	Not Applicable	120	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: Single (Investigator)|Primary Purpose: Diagnostic	EVU-2018-001	November 28, 2018	November 28, 2019	November 28, 2019	December 4, 2018		December 20, 2018	Urology San Antonio - Pasteur Plaza Surgery Center, San Antonio, Texas, United States		https://ClinicalTrials.gov/show/NCT03762616
467	NCT03196635	Patient-Assisted Compression - Impact on Image Quality and Workflow		Completed	Has Results	Breast Cancer	Device: Patient-Assisted (PA) Breast Compression|Device: Technologist-Controlled (TC) Breast Compression	Number of Subjects With Acceptable Overall Clinical Image Quality for Patient-assisted (PA) and Technologist-controlled (TC) Image Sets|Repeat Image Acquisition|Acceptability of Mammographic Attributes	GE Healthcare	Female	40 Years and older   (Adult, Older Adult)	Not Applicable	31	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening	124.03-2017-GES-0002	June 19, 2017	June 29, 2017	June 29, 2017	June 23, 2017	August 31, 2018	August 31, 2018	Boca Raton Regional Hospital Christine E. Lynn Women's Health and Wellness Institute, Boca Raton, Florida, United States	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/35/NCT03196635/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT03196635
468	NCT03662958	Comparison of a Novel Leuprolide With Market Leuprolide		Recruiting	No Results Available	Prostate Cancer	Drug: Lutrate|Drug: Enantone	The rate of castration at the end of week 4 (i.e. day 29)|The time to castration (i.e Tlag) between the 2 groups after administration of leuprolide|The duration of castration (i.e Tcast)|LH concentration|FSH concentration	Lee's Pharmaceutical Limited	Male	18 Years to 40 Years   (Adult)	Not Applicable	48	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	ZK-LUT-201802	August 1, 2018	October 2018	December 2018	September 10, 2018		September 10, 2018	The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China		https://ClinicalTrials.gov/show/NCT03662958
469	NCT03561857	Clinical Trial for a Robotic Endomicroscopy to Better Define Resection Strategies Applied to Urology Surgery	PERSEE II	Recruiting	No Results Available	Prostate Cancer	Device: Confocal Laser Endomicroscopy	pCLE criteria	Mauna Kea Technologies	Male	18 Years and older   (Adult, Older Adult)	Not Applicable	100	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	MKT-2018-PERSEE-02|2018-A01242-53	January 16, 2019	June 2020	June 2020	June 19, 2018		January 28, 2019	Groupe Hospitalier Diaconesses Croix Saint-Simon, Paris, France|Institut Mutualiste Montsouris, Paris, France		https://ClinicalTrials.gov/show/NCT03561857
470	NCT03400150	ProSpace™ Balloon System Pivotal Study BP-007		Recruiting	No Results Available	Prostate Cancer	Device: ProSpace|Other: Control	Adverse Event Rate of Occurrence|Reduction in Rectal Radiation Exposure	BioProtect	Male	18 Years and older   (Adult, Older Adult)	Not Applicable	222	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care	BP-007	January 3, 2018	February 29, 2020	July 31, 2020	January 17, 2018		June 25, 2019	Urology Nevada, Reno, Nevada, United States|CUF, Porto, Portugal		https://ClinicalTrials.gov/show/NCT03400150
471	NCT02702921	Powered Vascular Stapler in Video-Assisted Thoracoscopic (VAT) Lobectomies		Completed	Has Results	Non Small Cell Lung Cancer	Device: Surgeon's 'standard of care' stapler|Device: Ethicon Powered Vascular Stapler	Incidence of Intra-Operative Hemostatic Intervention|Post-operative Interventions or Procedures Related to Pulmonary Artery or Pulmonary Vein Bleeding	Ethicon Endo-Surgery	All	18 Years and older   (Adult, Older Adult)	Not Applicable	201	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ESC-15-001	February 1, 2016	March 31, 2017	March 31, 2017	March 9, 2016	June 29, 2018	October 11, 2018	Emory University, Atlanta, Georgia, United States	"Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/21/NCT02702921/Prot_000.pdf|"Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/21/NCT02702921/SAP_001.pdf	https://ClinicalTrials.gov/show/NCT02702921
472	NCT03214835	CDx Biopsies for Detection of Laryngopharyngeal Reflux and Laryngeal Lesions		Not yet recruiting	No Results Available	Laryngeal Disease|Laryngeal Tumor|Laryngopharyngeal Reflux	Device: Endo CDx Brush biopsy	Efficacy of EndoCDx brush|Assessment of pain	CDx Diagnostics|Rambam Health Care Campus	All	18 Years and older   (Adult, Older Adult)	Not Applicable	300	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Screening	CDx Laryngeal and LPR Study	February 2018	August 2019	December 2019	July 12, 2017		January 25, 2018			https://ClinicalTrials.gov/show/NCT03214835
473	NCT02130115	LungPoint ATV for Biopsy in Patients Undergoing Lobectomy	LABEL	Completed	No Results Available	Lung Cancer	Device: LungPoint ATV System	Ability to complete procedure using system|Proportion of nodules biopsied yielding tissue sufficient for diagnosis|Number of significant adverse events	Broncus Medical Inc	All	21 Years to 75 Years   (Adult, Older Adult)	Not Applicable	12	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)	Protocol 40	March 2013	September 2013	December 2013	May 5, 2014		May 5, 2014	Thoraxklinik, Heidelberg, Germany		https://ClinicalTrials.gov/show/NCT02130115
474	NCT00476229	Thymoglobulin and Total Lymphoid Irradiation for Hematologic Malignancies		Completed	Has Results	Lymphoma|Leukemia	Drug: Thymoglobulin|Radiation: Total Lymphoid Irradiation|Procedure: Peripheral Blood Stem Cell Infusion|Drug: Rituximab	Composite Success Rate	M.D. Anderson Cancer Center|Genzyme, a Sanofi Company	All	up to 70 Years   (Child, Adult, Older Adult)	Not Applicable	20	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2005-0892	June 2006	May 2009	May 2009	May 21, 2007	August 9, 2011	August 7, 2012	U.T.M.D. Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT00476229
475	NCT02504424	AirXpanders AeroForm Tissue Expander System for Breast Reconstruction	XPAND-II	Completed	Has Results	Breast Cancer	Device: AeroForm Tissue Expander	Number of Breasts With Successful Tissue Expansion With Exchange to a Permanent Breast Implant Unless Exchange is Precluded by a Non-device Related Event|Number of Breast With Successful Tissue Expansion With Exchange to Permanent Implant Including All Breasts in the Per Protocol Cohort.	AirXpanders, Inc.	Female	18 Years to 70 Years   (Adult, Older Adult)	Not Applicable	50	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CTP-0005 AirXpanders	November 12, 2015	May 3, 2017	September 26, 2017	July 22, 2015	September 5, 2018	January 29, 2019	Marin General Hospital, Greenbrae, California, United States|Good Samaritan Hospital, San Jose, San Jose, California, United States|Broward Health Medical Center, Fort Lauderdale, Florida, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Faulkner Hospital, Boston, Massachusetts, United States|University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, United States|Columbia University, New York, New York, United States|Presbyterian Medical Center, Charlotte, North Carolina, United States	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/24/NCT02504424/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT02504424
476	NCT02406599	MarginProbe® System U.S. Post-Approval Study		Recruiting	No Results Available	Breast Cancer	Device: Margin Probe|Other: Control: Additional inspection	Diagnostic accuracy at the margin level|Incomplete Surgical Resection (ISR )|Positive Margin presence on the Outermost Shaving after the initial lumpectomy surgery|Cosmesis evaluation|Repeat lumpectomy rate|Repeat lumpectomy and mastectomy rate|Diagnostic Accuracy at the Patient Level (ignoring location)	Dune Medical Devices	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	440	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care	CP-07-001	June 2015	August 31, 2019	March 31, 2020	April 2, 2015		February 25, 2019	Baptist MD Anderson Cancer Center, Jacksonville, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|NorthShore University HealthSystem, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|John Hopkins Medicine, Baltimore, Maryland, United States|Summit Medical Group, Berkeley Heights, New Jersey, United States|New Mexico University Cancer center, Albuquerque, New Mexico, United States|Montefiore Medical Center, New York, New York, United States|PinnacleHealth Cancer Institute, Harrisburg, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT02406599
477	NCT02507765	Stereotactic Body Radiation Therapy and Transarterial Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery		Recruiting	No Results Available	Child-Pugh Class A|Child-Pugh Class B|Stage IIIA Hepatocellular Carcinoma|Stage IIIB Hepatocellular Carcinoma|Stage IIIC Hepatocellular Carcinoma|Stage IVA Hepatocellular Carcinoma|Stage IVB Hepatocellular Carcinoma	Other: Laboratory Biomarker Analysis|Radiation: Stereotactic Body Radiation Therapy|Procedure: Transarterial Chemoembolization	Feasibility of SBRT in combination with TACE, measured by the number of patients able to tolerate all study procedures|Change in diffusion|Change in hypoxia measurements|Change in perfusion|Incidence of toxicities|Local control|Objective response rate (CR + PR) as measured by modified RECIST criteria version 1|Overall survival|Progression-free survival	Ohio State University Comprehensive Cancer Center|Varian Medical Systems	All	18 Years and older   (Adult, Older Adult)	Not Applicable	15	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	OSU-15032|NCI-2015-00894	July 2015	October 31, 2018	October 31, 2018	July 24, 2015		March 5, 2018	Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States		https://ClinicalTrials.gov/show/NCT02507765
478	NCT02828839	Prostate Biopsy Access Needle & Needle Guide Feasibility Study	STABLE	Active, not recruiting	No Results Available	Prostate Cancer	Procedure: Access needle	Assessment of the handling characteristics of the access needle and needle guide.	Perineologic	Male	18 Years to 80 Years   (Adult, Older Adult)	Not Applicable	500	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening	P-101	November 2015	December 31, 2018	May 30, 2019	July 12, 2016		April 4, 2018	Corbin Clinical Resources, Cumberland, Maryland, United States		https://ClinicalTrials.gov/show/NCT02828839
479	NCT02783950	Genomics in Michigan Impacting Observation or Radiation	G-MINOR	Active, not recruiting	No Results Available	Prostate Cancer	Other: Decipher Prostate Cancer Classifier	Number of participants that receive adjuvant therapy (radiation and/or hormone therapy)	GenomeDx Biosciences Corp|Michigan Urological Surgery Improvement Collaborative (MUSIC)	Male	Child, Adult, Older Adult	Not Applicable	359	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	CU 008	August 2016	November 2020	November 2021	May 26, 2016		October 5, 2018	University of Michigan Hospital and Health Systems, Ann Arbor, Michigan, United States		https://ClinicalTrials.gov/show/NCT02783950
480	NCT03244683	A Study of the Efficacy of ONS to Reduce Postoperative Complications Associated With Pancreatic Surgery	INSPIRE	Recruiting	No Results Available	Pancreatic Cancer|Chronic Pancreatitis	Dietary Supplement: Ensure Surgical|Other: Nutrition counseling|Other: Low-intensity exercise therapy	Postoperative complications|Supplement compliance|Anthropometric measures|Length of stay and readmission	Ohio State University|Abbott Nutrition	All	40 Years to 89 Years   (Adult, Older Adult)	Not Applicable	150	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2017H0170	August 28, 2017	June 27, 2019	December 31, 2019	August 9, 2017		September 19, 2017	The Ohio State University Wexner Medical Center, Columbus, Ohio, United States		https://ClinicalTrials.gov/show/NCT03244683
481	NCT02773940	ClariCore™ Biopsy System in Patients Undergoing Radical Retropubic Prostatectomy		Active, not recruiting	No Results Available	Prostate Cancer	Device: ClariCore System	Optical spectra measurements will be correlated with biopsy tissue core samples in patients with known prostate cancer undergoing radical retropubic prostatectomy surgery to develop a prostate tissue classification database|All adverse events reported during the procedure that are related to the ClariCore System	Precision Biopsy, Inc.	Male	18 Years to 85 Years   (Adult, Older Adult)	Not Applicable	100	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	STP-1002	May 2016	December 2019	June 2020	May 16, 2016		February 15, 2019	Brady Urological Institute, Johns Hopkins Hospital, Baltimore, Maryland, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States		https://ClinicalTrials.gov/show/NCT02773940
482	NCT01955122	Polyp Detection With the EndoRings™: A Randomized Tandem Colonoscopy Study		Completed	Has Results	Colon Cancer	Device: Tandem Colonoscopy	Adenoma and Polyp Miss Rate|Total Number of Therapeutic Interventions Performed|Procedure Time A Stopwatch Will be Used for Stopping the Timing of the Procedure for Any Polypectomy Performed and Then Restarting Once the Polypectomy is Completed, Meaning That Purely Procedure Time is Measured|Sedation|Scope Centering Ability|Colon Area Screened|Patient Satisfaction	EndoAid	All	40 Years to 75 Years   (Adult, Older Adult)	Not Applicable	126	Industry	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	TSDPR100	July 2013	July 2014	July 2014	October 7, 2013	March 6, 2017	March 6, 2017	Indiana University, Indianapolis, Indiana, United States|Elisha Medical Center, Haifa, Please Select, Israel|University Medical Center Utrecht, Utrecht, Netherlands		https://ClinicalTrials.gov/show/NCT01955122
483	NCT02046278	LifeSeal™ Pilot Study in Subjects Undergoing Circular Stapled Anastomosis Created Within 10 cm of the Anal Verge		Completed	No Results Available	Rectal Cancer	Device: LifeSeal™ Kit	Assessment of the overall Subject safety by incidence of pre specified procedure related Adverse Events.|Performance Rate of anastomotic leak (both radiological and clinical leaks)	LifeBond Ltd.	All	18 Years to 90 Years   (Adult, Older Adult)	Not Applicable	70	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CLP-LS-0110	January 2014	August 2014	August 2016	January 27, 2014		August 30, 2016	OLV Ziekenhuis, Aalst, Belgium|Ziekenhuis Oost-Limburg, Genk, Belgium|University Hospital, Gent, Belgium|UZ Leuven, Leuven, Belgium|Sourasky Medical Center, Tel Aviv, Israel|Skane University Hospital, Malmo, Sweden|Karolinska Institutet, Stockholm, Sweden|Uppsala University Hospital, Uppsala, Sweden		https://ClinicalTrials.gov/show/NCT02046278
484	NCT01943916	The PIONEER-0 Study of the Imagio Breast Imaging System		Completed	No Results Available	Breast Cancer	Device: Imagio OA/US (US and OA/US)|Device: Imagio gray scale ultrasound	The objective of the study is to evaluate the sensitivity and specificity of the Imagio for the visualization of suspicious masses when compared to the Imagio ultrasound component based on the probability of malignancy (POM).	Seno Medical Instruments Inc.	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	2105	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	PIONEER-01	December 21, 2012	September 9, 2015	September 9, 2015	September 17, 2013		January 18, 2018	Radnet (Temecula), Murrieta, California, United States|Sally Jobe, Englewood, Colorado, United States|Yale University, New Haven, Connecticut, United States|Georgetown University Hospital, Department of Radiology, Washington, District of Columbia, United States|Boca Raton Regional Hospital, Boca Raton, Florida, United States|Breast Care Atlanta, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|New York Presbyterian Hospital, New York, New York, United States|Elizabeth Wende Breast Care, Rochester, New York, United States|Solis Women's Health (North Carolina), Greensboro, North Carolina, United States|Cleveland Clinic, Breast Services DDI Clinical Research, Cleveland, Ohio, United States|Weinstein Imaging Associates, Pittsburgh, Pennsylvania, United States|Austin Radiological Association, Austin, Texas, United States|MD Anderson Cancer Center, Department of Radiology and Breast Imaging, Houston, Texas, United States|Solis Women's Health, Plano, Texas, United States|Univ. Texas Health Science Center at San Antontio, Breast Imaging Center at the Cancer Therapy Research Center, San Antonio, Texas, United States		https://ClinicalTrials.gov/show/NCT01943916
485	NCT01790230	LifeSeal™ Preliminary Study in Subjects Undergoing Low Anterior Resection		Completed	No Results Available	Rectal Cancer	Device: LifeSeal™ Kit	Assessment of subject's safety by incidence of related Adverse Events|Assessment of the device's application technique	LifeBond Ltd.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	10	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CLP-LS-0105	January 2013	August 2013	August 2013	February 13, 2013		September 4, 2013	Uppsala University Hospital, Uppsala, Sweden		https://ClinicalTrials.gov/show/NCT01790230
486	NCT01369433	A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols		Completed	No Results Available	Solid Tumors	Drug: Tivozanib + paclitaxel|Drug: Tivozanib + temsirolimus|Drug: Tivozanib|Drug: Tivozanib (AV-951)|Drug: Tivozanib + capecitabine|Drug: Tivo	To assess long-term safety and tolerability of tivozanib and to determine the duration of response and progression-free survival (PFS) in subjects who continue on tivozanib, in accordance with the parent protocol.	AVEO Pharmaceuticals, Inc.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	225	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	AV-951-09-901	June 2010	June 2015	October 2015	June 9, 2011		June 21, 2017	Translational Genomics Research Institute (TGEN), Scottsdale, Arizona, United States|Institute of Urologic Oncology, Los Angeles, California, United States|Stanford University, Stanford, California, United States|Aurora, Colorado, United States|Florida Cancer Specialists, Fort Myers, Florida, United States|H. Lee Moffitt Cancer Center & Research Institute Hospital, Inc, Tampa, Florida, United States|Beech Grove, Indiana, United States|Horizon Oncology Research, Inc., Lafayette, Indiana, United States|Wichita, Kansas, United States|Medical Oncology LLC, Baton Rouge, Louisiana, United States|Jayne Gurtler MD, Laura Brinz MD, Angelo Russo MD and Janet Burroff MD APMC, Metairie, Louisiana, United States|Associates in Oncology/Hematology, Rockville, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Grand Rapids, Michigan, United States|Tupelo, Mississippi, United States|Nebraska Methodist Hospital, Omaha, Nebraska, United States|Las Vegas, Nevada, United States|Lebanon, New Hampshire, United States|Chapel Hill, North Carolina, United States|Columbus, Ohio, United States|The OU Cancer Institute, Oklahoma City, Oklahoma, United States|Philadelphia, Pennsylvania, United States|Sarah Cannon Research Institute (SCRI), Nashville, Tennessee, United States|Austin, Texas, United States|Coastal Bend Cancer Center, Corpus Christi, Texas, United States|Dallas, Texas, United States|Tacoma, Washington, United States|Hamilton, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|AVEO Investigational Site, Madurai, India|AVEO Investigational Site, Mumbai, India|Rotterdam, Netherlands|AVEO Investigational Site, Krasnodar, Russian Federation|AVEO Investigational Site - Moscow 1, Moscow, Russian Federation|AVEO Investigational Site - Moscow 2, Moscow, Russian Federation|AVEO Investigational Site - Moscow 3, Moscow, Russian Federation|AVEO Investigational Site - Moscow 4, Moscow, Russian Federation|AVEO Investigational Site - Moscow 5, Moscow, Russian Federation|AVEO Investigational Site, Obninsk, Russian Federation|AVEO Investigational Site, Rostov, Russian Federation|AVEO Investigational Site, Saint Petersburg, Russian Federation|Stavropol', Russian Federation|AVEO Investigational Site, Ufa, Russian Federation|AVEO Investigational Site, Dnipropetrovsk, Ukraine|AVEO Investigational Site, Donetsk, Ukraine|AVEO Investigational Site, Kharkiv, Ukraine|AVEO Investigational Site, Lviv, Ukraine|AVEO Investigational Site, Zaporizhya, Ukraine		https://ClinicalTrials.gov/show/NCT01369433
487	NCT01425268	Patient Controlled Tissue Expansion for Breast Reconstruction	XPAND	Completed	Has Results	Breast Cancer	Device: AeroForm Tissue Expansion|Procedure: Saline Tissue Expansion	Successful Tissue Expansion and Exchange to a Permanent Breast Implant Unless Precluded by a Non-device Related Event|Expansion Days	AirXpanders, Inc.	Female	18 Years to 70 Years   (Adult, Older Adult)	Not Applicable	158	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CTP-0003 AirXpanders	October 2011	August 2015	August 2015	August 30, 2011	June 27, 2017	June 27, 2017	Marin General Hospital, Greenbrae, California, United States|Susan Downey, Los Angeles, California, United States|University of California, Irvine Medical Center, Orange, California, United States|Sutter Healthcare-Sacramento, Sacramento, California, United States|Good Samaritan Hospital, San Jose, San Jose, California, United States|eSSe Plastic Surgery, Fort Lauderdale, Florida, United States|Baptist Medical Center South, Jacksonville, Florida, United States|Norton Healthcare Pavilion, Louisville, Kentucky, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Faulkner Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, United States|Columbia University, New York, New York, United States|South Nassau Communities Hospital, Oceanside, New York, United States|Novant Health Presbyterian Medical Center, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|The Methodist Hospital, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT01425268
488	NCT01373671	Evaluation of the Efficacy of Digital Breast Tomosynthesis Imaging	DBT	Completed	Has Results	Breast Cancer	Device: SIEMENS INSPIRATION DIGITAL BREAST TOMOSYNTHESIS (DBT) SYSTEM	Efficacy Based on the Area Under the Receiver Operating Characteristic (ROC) Curve in Breasts Analyzed With DBT as an Adjunct to FFDM vs. FFDM Alone	Siemens Medical Solutions USA - CSG	Female	30 Years and older   (Adult, Older Adult)	Not Applicable	764	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	SMS-SP09-01	May 2011	May 2014	May 2014	June 15, 2011	January 13, 2017	January 13, 2017	Siemens Medical Solutions, Malvern, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT01373671
489	NCT01692405	Semi-automatic Download of Prostate Biopsy Cores While Keeping the Orientation, Unfolding and Unity of the Sample		Completed	No Results Available	Prostate Cancer	Device: NaviGo Bx™|Procedure: biopsy sponge pad	percent of tissue loss|prostate cancer detection rate|processing time	UC Care, Ltd.	Male	18 Years and older   (Adult, Older Adult)	Not Applicable	436	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	0086-12-EMC	April 29, 2013	April 5, 2017	April 24, 2017	September 25, 2012		April 19, 2019	Haemek madical center, Afula, Israel		https://ClinicalTrials.gov/show/NCT01692405
490	NCT01331447	Pilot Bioequivalency Study of Exemestane 25 mg Tablet Under Fasted Conditions		Completed	No Results Available	Breast Cancer	Drug: exemestane	bioequivalence determined by statistical comparison Cmax	Roxane Laboratories|West-Ward Pharmaceutical	Female	18 Years to 55 Years   (Adult)	Not Applicable	12	Industry	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	EXEM-03	May 2004	May 2004	May 2004	April 8, 2011		January 23, 2018	BioKinetic Clinical Applications, Inc., Springfield, Missouri, United States		https://ClinicalTrials.gov/show/NCT01331447
491	NCT01331434	Bioequivalency Study of Exemestane 25 mg Tablet Under Fed Conditions		Completed	No Results Available	Breast Cancer	Drug: exemestane	bioequivalence determined by statistical comparison Cmax	Roxane Laboratories|West-Ward Pharmaceutical	Female	18 Years to 55 Years   (Adult)	Not Applicable	47	Industry	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	EXEM-02	October 2004	October 2004	October 2004	April 8, 2011		January 23, 2018	Bio-Kinetic Clinical Applications, Inc., Springfield, Missouri, United States		https://ClinicalTrials.gov/show/NCT01331434
492	NCT01331421	Bioequivalency Study of Exemestane 25 mg Tablet Under Fasted Conditions		Completed	No Results Available	Breast Cancer	Drug: exemestane	bioequivalence determined by statistical comparison Cmax	Roxane Laboratories|West-Ward Pharmaceutical	Female	18 Years to 55 Years   (Adult)	Not Applicable	48	Industry	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	EXEM-01	July 2004	July 2004	August 2004	April 8, 2011		January 23, 2018	BioKinetic Clinical Applications, Inc., Springfield, Missouri, United States		https://ClinicalTrials.gov/show/NCT01331421
493	NCT01155102	Bioequivalency Study of Anastrozole 1 mg Under Fasted Conditions		Completed	No Results Available	Breast Cancer	Drug: Anastrozole	bioequivalence determined by statistical comparison Cmax	Roxane Laboratories|West-Ward Pharmaceutical	All	18 Years to 45 Years   (Adult)	Not Applicable	31	Industry	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ANAS-T1-PVFS-1	April 2006	May 2006	May 2006	July 1, 2010		January 23, 2018	Bio-Kinetic Clinical Applications, Springfield, Missouri, United States		https://ClinicalTrials.gov/show/NCT01155102
494	NCT01155089	Bioequivalency Study of Anastrozole 1 mg Under Fed Conditions		Completed	No Results Available	Breast Cancer	Drug: Anastrozole	bioequivalence determined by statistical comparison Cmax	Roxane Laboratories|West-Ward Pharmaceutical	All	18 Years to 45 Years   (Adult)	Not Applicable	32	Industry	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ANAS-T1-PVFD-1	May 2006	June 2006	June 2006	July 1, 2010		January 23, 2018	Bio-Kinetic Clinical Applications, Springfield, Missouri, United States		https://ClinicalTrials.gov/show/NCT01155089
495	NCT00665912	Platelet-Rich and Concentrated Platelet-Poor Plasma to Reduce Air Leak Post-Lobectomy: A Randomized Controlled Trial		Completed	No Results Available	Lung Cancer	Procedure: Standard post-lobectomy wound care plus use of PRP and PPPc prepared by GPS and Plasmax respectively|Procedure: Standard post-lobectomy wound care	Duration of postoperative air leak|Incidence of air leak, Prolonged air leak (> days), Complications	Zimmer Biomet|University of Western Ontario, Canada	All	18 Years and older   (Adult, Older Adult)	Not Applicable	204	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Investigator)|Primary Purpose: Treatment	BBI-004	January 2008	May 2010	November 2010	April 24, 2008		March 13, 2017	University of Western Ontario: Division of Thoracic Surgery, London, Ontario, Canada		https://ClinicalTrials.gov/show/NCT00665912
496	NCT00828919	Continuing Access to Axitinib (A406- AG- 013736 ) For Patients Previously Receiving AG 013736 In Clinical Trials		Active, not recruiting	No Results Available	Solid Tumors	Drug: axitinib|Drug: crizotinib	Summary of Treatment Emergent Adverse Events (AEs) by Preferred Term Occurring In >20% Patients (All causality)|Number of Participants With Treatment Emergent Adverse Events (AEs) (Treatment Related) of axitinib|Number of Participants With Treatment Emergent Adverse Events (AEs) (Treatment Related) of crizotinib|Summary of Treatment Emergent Serious Adverse Events (SAEs) by Preferred Term (All causality)|Number of Participants With Treatment Emergent Serious Adverse Events (SAEs) (Treatment Related) of axitinib|Number of Participants With Treatment Emergent Serious Adverse Events (SAEs) (Treatment Related) of crizotinib	Pfizer	All	18 Years to 99 Years   (Adult, Older Adult)	Not Applicable	52	Industry	Interventional	Masking: None (Open Label)|Primary Purpose: Treatment	A4061008|2005-000051-15	March 7, 2003	May 31, 2021	May 31, 2021	January 26, 2009		June 3, 2019	UC Irvine Medical Center, Orange, California, United States|University of California Irvine Medical Center - Chao Family Comprehensive Cancer Center, Orange, California, United States|UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States|UCLA Hematology-Oncology-Santa Monica, Santa Monica, California, United States|University of Chicago Hospitals, Chicago, Illinois, United States|Johns Hopkins University, Baltimore, Maryland, United States|Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|The Cleveland Clinic, Cleveland, Ohio, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Providence Regional Medical Center Everett - Providence Regional Cancer Partnership, Everett, Washington, United States|Providence Regional Medical Center Everett, Everett, Washington, United States|University of Wisconsin - Hospital and Clinics, Madison, Wisconsin, United States|Fakultni nemocnice Olomouc, Olomouc, Czech Republic, Czechia|Nemocnice Na Bulovce, Praha, Czechia|Hopital de la Pitie Salpetriere, Paris Cedex 13, France|Charité - Universitaetsmedizin Berlin, Charité Campus Mitte, Berlin, Germany|Semmelweis Egyetem Altalanos Orvostudomanyi Kar, Budapest, Hungary|Fondazione IRCCS, Istituto Nazionale Tumori, Laboratorio, Milano, Italy|Fondazione IRCCS, Istituto Nazionale Tumori, S.S.D Oncologia Medica dei Tumori testa-collo, Milano, Italy|Kinki University Hospital, Osakasayama, Osaka, Japan|National Cancer Center Hospital East, Kashiwa, Tiba, Japan|Chiba Cancer Center, Chiba, Japan|Kyushu University Hospital, Fukuoka, Japan|Nagasaki University Hospital, Nagasaki, Japan|Samsung Medical Center, Seoul, Korea, Republic of|FSBSI "N.N. Blokhin Russian Cancer Research Center", Moscow, Russian Federation|Taichung Veterans General Hospital, Taichung, Taiwan|Nottingham City Hospital / Oncology Department, Nottingham, United Kingdom		https://ClinicalTrials.gov/show/NCT00828919
497	NCT03979690	Feasibility Study of a Novel Single Use Robotic Colonoscopy System		Recruiting	No Results Available	Colonic Polyp|Colon Adenoma|Colorectal Cancer	Device: NISInspire-C System	Safety: Incidence of Intra-Operative and Post-Operative Adverse Events|Feasibility: Caecal Intubation Rate (CIR)|Feasibility: Time-to-Caecum (TTC)|Feasibility: Polyp Detection Rate (PDR)|Usability	Bio-Medical Engineering (HK) Limited|The University of Hong Kong	All	40 Years to 70 Years   (Adult, Older Adult)	Not Applicable	20	Industry|Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	NISInspire-001|HKUCTR-2616|HKUCTR-2617	June 12, 2019	September 2019	September 2019	June 7, 2019		July 23, 2019	The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong		https://ClinicalTrials.gov/show/NCT03979690
498	NCT03679572	Zero-ischemia Robot-assisted Partial Nephrectomy Using Near-infrared Fluorescence	EMERALD	Recruiting	No Results Available	Renal Cancer	Procedure: Robot assisted partial nephrectomy super-selective clamping|Procedure: Robot assisted partial nephrectomy with renal artery clamping	Benefit on postoperative renal function of fluorescence-enhanced super-selective clamping during robot assisted partial nephrectomy compared with robot-assisted partial nephrectomy with renal artery clamping|Number of group conversion in the zero ischemia method.|Surgical duration in the two groups|Complications|Per-surgery blood loss|Hemoglobine rate variation|Positive surgical margins|Variation between global GFR in the two groups|Renal parenchyma preserved	University Hospital, Grenoble|Clinical Investigation Centre for Innovative Technology Network|Intuitive Surgical	All	18 Years and older   (Adult, Older Adult)	Not Applicable	50	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	38RC17.142	February 5, 2018	March 1, 2020	March 1, 2020	September 20, 2018		September 20, 2018	University Hospital Grenoble-Alps (CHU-GA), La Tronche, France		https://ClinicalTrials.gov/show/NCT03679572
499	NCT00749931	MarginProbe, a Device for Intraoperative Assessment of Margin Status in Breast Conservation Surgery	Pivotal	Completed	Has Results	Breast Cancer	Device: MarginProbe|Procedure: Lumpectomy	The Primary Effectiveness Endpoint is a Measure of Intraoperative Success in Addressing Positive Margins as Detected by Permanent Pathology)by Additional Oriented Tissue Re-excision From the Surgical Cavity.	Dune Medical Devices	Female	18 Years to 90 Years   (Adult, Older Adult)	Not Applicable	664	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	CP-03-001	October 2008	March 2010	June 2010	September 9, 2008	June 27, 2014	June 27, 2014	Pacific Breast Care, Costa Mesa, California, United States|University of Southern California, Los Angeles, California, United States|Cedars Sinai Hospital, Los Angeles, California, United States|HOAG Memorial Hospital, Newport Beach, California, United States|St. Joseph Hospital, Orange, California, United States|UCIrvine Medical Center, Orange, California, United States|Georgetown University Hospital, Washington, District of Columbia, United States|Anne Arundel Medical Center, Annapolis, Maryland, United States|Mercy Hospital Services, Baltimore, Maryland, United States|Franklin Square Hospital Center, Baltimore, Maryland, United States|Beth Israel Medical Center, New York, New York, United States|NYU Clinical Cancer Center, New York, New York, United States|St. Luke's Roosevelt, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Weill Medical College of Cornell University, New-York, New York, United States|Breast Care Center, Allentown, Pennsylvania, United States|Bryn Mawr Hospital, Bryn Mawr, Pennsylvania, United States|Virginia Hospital Center, Arlington, Virginia, United States|Haddasah Medical Organization, Jerusalem, Israel|Shaare Zedek, Jerusalem, Israel|Assaf Harofeh Medical Center, Zrifin, Israel		https://ClinicalTrials.gov/show/NCT00749931
500	NCT00380952	Intraoperative Use of the BP Device for Detecting Positive Margins During Lumpectomy Procedure		Completed	No Results Available	Breast Cancer	Device: Dune Device		Dune Medical Devices	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	300	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	CP-02-001	November 2006	October 2007	April 2008	September 27, 2006		May 28, 2008	HaEmek Mc, Afula, Israel|Rambam MC, Haifa, Israel|Haddasah Medical Organization, Jerusalem, Israel|Shaare Zedek, Jerusalem, Israel|Meir MC, Kfar Saba, Israel|Rabin MC, Petah Tikva, Israel|Souraski MC, Tel- Aviv, Israel|Poria MC, Tiberia, Israel|Rivka Ziv MC, Zefat, Israel		https://ClinicalTrials.gov/show/NCT00380952
501	NCT00955929	Pharmacological Penile Rehabilitation in the Preservation of Erectile Function Following Bilateral Nerve-Sparing Radical Prostatectomy		Active, not recruiting	No Results Available	Penile Cancer|Erectile Dysfunction|Radical Prostatectomy	Drug: Placebo QHS and sildenafil and questionnaires|Drug: Sildenafil and questionnaire|Drug: Trimix combination (Papavarine 30mg/mL Phentholamine 1mg/mL Prostaglandin E1 10 mcg/mmL) and questionnaires	Difference in the erectile function (EF) domain score of the International Index of Erectile Function (IIEF) between the 3 groups at 24 months.|The time to return of spontaneous functional erections.|The time for patients to respond to oral erectogenic therapy.|The proportion of patients who have normalization of their erectile function (normalization of the EF domain of the IIEF).	Memorial Sloan Kettering Cancer Center|Pfizer	Male	18 Years and older   (Adult, Older Adult)	Not Applicable	100	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	09-005	August 2009	August 2019	August 2019	August 10, 2009		September 5, 2018	Memorial Sloan Kettering Cancer Center, New York, New York, United States		https://ClinicalTrials.gov/show/NCT00955929
502	NCT02234479	MediHoney for Radiation Dermatitis		Completed	Has Results	Breast Cancer|Radiation Dermatitis	Biological: Hydrophor (Group A)|Biological: MediHoney (Group B)	Number of Participants Whom Received Medihoney Treatment and Were Analyzed Weekly for Skin Changes While Undergoing Radiation Therapy	University of Maryland, College Park|Integra LifeSciences Corporation|University of Maryland, Baltimore	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	34	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HP-00058645	June 2014	November 2014	December 2014	September 9, 2014	August 8, 2016	September 16, 2016	University of Maryland, Baltimore, Maryland, United States		https://ClinicalTrials.gov/show/NCT02234479
503	NCT01711710	Clinical Trial to Evaluate the Safety and Efficacy of Breast Implant		Active, not recruiting	No Results Available	Breast Cancer	Device: Cohesive Gel Breast Implant	a rate of rupture of 1%|a rate of capsular contracture of 5%|a rate of connective tissue disease|Changes in bust girth and actual measured bra-cup size|Change in life satisfaction	Seoul National University Hospital|HansBiomed Co.,Ltd.	Female	22 Years and older   (Adult, Older Adult)	Not Applicable	103	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	06-2010-095|E-1005-049-001	October 2010	October 2014	December 2020	October 22, 2012		September 10, 2018	Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of		https://ClinicalTrials.gov/show/NCT01711710
504	NCT02104076	Evolution® Biliary Stent System-Fully Covered		Completed	No Results Available	Carcinomas/Neoplasms	Device: Evolution® Biliary Stent-Fully Covered	Percentage of patients free from symptomatic recurrent of biliary obstruction requiring reintervention|Total Serum Bilirubin ≤ 3.0 mg/dL	Cook Group Incorporated	All	18 Years and older   (Adult, Older Adult)	Not Applicable	90	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	10-014	September 2014	July 2016	January 4, 2017	April 4, 2014		July 5, 2017	University of Colorado Hospital, Aurora, Colorado, United States|Borland-Groover Clinic, Jacksonville, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Indiana University Hospital, Indianapolis, Indiana, United States|Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|University of Virginia Health System, Charlottesville, Virginia, United States|St. Michael's Hospital, Toronto, Ontario, Canada|Centre Hospitalier de 1'Université, Montréal, Quebec, Canada|Hôpital Edouard Herriot, Lyon Cedex 03, France|Hôpital L'Archet 2, Nice Cedex 03, France|Erasmus Medish Centrum, Rotterdam, Netherlands		https://ClinicalTrials.gov/show/NCT02104076
505	NCT01711892	Health Effects of Soccer Training in Men With Prostate Cancer Receiving Androgen Deprivation Therapy		Completed	No Results Available	Prostatic Neoplasms|Exercise|Soccer Training|Androgen Deprivation Therapy	Behavioral: Soccer training	Baseline to post intervention (12 weeks) and follow-up (32 weeks) change in Body Composition.|Bone Mineral Density|Cardiorespiratory fitness (Vo2 peak)|Patient reported outcomes|Heart function|Glucose tolerance|Postural Balance|Physical function|Hip to waist ratio|Muscle Strength|Blood markers	University of Copenhagen|Danish Cancer Society|Novo Nordisk A/S|TrygFonden, Denmark|Beckett Foundation	Male	18 Years to 75 Years   (Adult, Older Adult)	Not Applicable	57	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	CIRE-04	March 2012	December 2013	December 2013	October 22, 2012		April 21, 2014	University of Copenhagen, Centre of Integrated Rehabilitation of Cancer Patients, Copenhagen, Denmark		https://ClinicalTrials.gov/show/NCT01711892
506	NCT03572998	Lymphatic Function in Patients Who Have Undergone Breast Cancer Treatment	LYFE-B	Recruiting	No Results Available	Secondary Lymphedema	Drug: Indocyanine Green (ICG)	Pumping pressure|Velocity|Frequency|morphology	University of Aarhus|Novo Nordisk A/S	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	28	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	220493|1-10-72-193-18	September 2018	February 2019	August 2019	June 28, 2018		June 28, 2018	Aarhus University, Aarhus C, Danmark, Denmark		https://ClinicalTrials.gov/show/NCT03572998
507	NCT00615537	Pilot Study on Laser Ablation of Symptomatic Benign Thyroid Masses		Completed	No Results Available	Thyroid Nodule|Thyroid Cancer|Thyroid Neoplasms|Nodular Goiter	Procedure: Laser Ablation of Thyroid Nodule	The primary goal of this study is to determine the local response of laser ablation of the treated lesion and its effect on size and vascularity. The objective measures will be based on serial US with Doppler.|To assess the effects of laser ablation on thyroid function testing. An estimate of time and cost associated with LITT procedure for treatment of soft tissue thyroid nodules.	BioTex, Inc.|Rhode Island Hospital	All	Child, Adult, Older Adult	Not Applicable	20	Industry|Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	BTX-07-003	February 2008	January 2011	January 2011	February 14, 2008		April 5, 2011	Rhode Island Hospital - Department of Diagnostic Imaging Research, Providence, Rhode Island, United States		https://ClinicalTrials.gov/show/NCT00615537
508	NCT02066103	Broncho-Adventitial Delivery of Paclitaxel to Extend Airway Patency in Malignant Airway Obstruction Patients	BROADWAY	Completed	No Results Available	Malignant Airway Obstruction Secondary to Non-small Cell Lung Cancer	Drug: Paclitaxel	Treatment safety|Technical success|Airway patency improvements|Quality of Life	Mercator MedSystems, Inc.|National Cancer Institute (NCI)	All	18 Years and older   (Adult, Older Adult)	Not Applicable	20	Industry|NIH	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	TSP0147|5R42CA141907-03	July 2014	June 2016	June 2016	February 19, 2014		April 20, 2018	Johns Hopkins University, Baltimore, Maryland, United States|The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Duke University, Raleigh, North Carolina, United States		https://ClinicalTrials.gov/show/NCT02066103
509	NCT03479151	Magnetic Resonance Guided High Intensity Focused Ultrasound (MRgHIFU) for Pain Palliation of Bone Metastases	HIFU-Bone	Recruiting	No Results Available	Cancer|Bone Metastases	Device: Magnetic Resonance Image-guided High Intensity Focused Ultrasound (MR-HIFU)	Measure the ablated tissue volume indicated by immediate post-treatment Gd-T1W imaging in responders and non-responders.|To report the treatment response rate.|To investigate whether ablated tissue volume indicated by Gd-T1W imaging at Day 30 remains stable at Days 60 and 90.|.To investigate whether intra-procedural PRFS metrics are different in responders and non-responders at Day 30|To investigate whether intra- or post-procedural changes in ADC are different in responders and non-responders.|To investigate whether intra- or post-procedural changes in T2 are different in responders and non-responders.|The rate of treatment-related adverse events|The effect of MRgHIFU treatment on patients' quality of life, recorded using Quality of Life Questionnaires (QLQ's).|The costs of MRgHIFU treatment.	Institute of Cancer Research, United Kingdom|Philips Medical Systems|Cancer Research UK	All	18 Years to 80 Years   (Adult, Older Adult)	Not Applicable	15	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	17/LO/1689 CCR 4733	March 16, 2018	September 2020	September 2020	March 27, 2018		August 8, 2018	The Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom		https://ClinicalTrials.gov/show/NCT03479151
510	NCT03746717	Occlusive Skin Closure May Reduce Wound Drainage After Tumor Hip Arthroplasty		Completed	No Results Available	Metastatic Bone Disease of the Proximal Femur	Device: occlusive wound closure|Device: conventional wound closure	Wound status|Antibiotic Use	Rigshospitalet, Denmark|Ethicon, Inc.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	70	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PRINEO-RCT RH-MSKTS-ORTH	January 15, 2017	August 21, 2018	November 3, 2018	November 20, 2018		November 20, 2018	Rigshospitalet, Copenhagen, Region Hovedstaden, Denmark		https://ClinicalTrials.gov/show/NCT03746717
511	NCT00500565	Pain Management Following TRAM Flap for Breast Reconstruction		Completed	No Results Available	Breast Cancer	Drug: Saline|Drug: Bupivicaine	Total Postoperative Opioid Use by Patient	M.D. Anderson Cancer Center|I-Flow	All	Child, Adult, Older Adult	Not Applicable	61	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	ID03-0046	December 2003	June 2006	June 2008	July 12, 2007		October 11, 2013	U.T.M.D. Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT00500565
512	NCT03941665	Use of Gelronate Gel vs. Aloevera in Preventing/Minimizing Radiation-induced Dermatitis in Breast Cancer Patients		Recruiting	No Results Available	Radiation Dermatitis	Device: Gelronate|Other: Aloevera	Development and degree of any skin reaction|Skin reaction requiring conventional topical therapy	Sheba Medical Center|Ferring Pharmaceuticals	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	120	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention	5652-18-SMC	April 1, 2019	July 2019	August 2019	May 8, 2019		May 31, 2019	Sheba Medical Center, Ramat Gan, Israel	"Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/65/NCT03941665/Prot_000.pdf	https://ClinicalTrials.gov/show/NCT03941665
513	NCT02409628	EktoTherix™ Regenerative Tissue Scaffold for Repair of Surgical Excision Wounds		Completed	No Results Available	Non-melanoma Skin Cancer|Basal Cell Carcinoma|Squamous Cell Carcinoma	Device: EktoTherix	Incidence of device related adverse events|Cosmesis (cosmetic outcome is assessed by the Vancouver Burn Scar Assessment Scale (VBSAS) score (clinician's assessment) and by a Visual Analogue Scale (VAS)	Neotherix Limited|Lorien Engineering Solutions (a division of GP Strategies Ltd)|Smith & Nephew Advanced Wound Management|NAMSA|Innovate UK	All	18 Years and older   (Adult, Older Adult)	Not Applicable	12	Industry|Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	EKT01	April 23, 2015	July 2017	July 2017	April 7, 2015		September 15, 2017	The James Cook University Hospital, South Tees Hospitals NHS Foundation Trust, Middlesbrough, North Yorkshire, United Kingdom|Scarborough Hospital, York Teaching Hospital NHS Foundation Trust, Scarborough, North Yorkshire, United Kingdom|The York Hospital, York Teaching Hospital NHS Foundation Trust, York, North Yorkshire, United Kingdom		https://ClinicalTrials.gov/show/NCT02409628
514	NCT03088150	COLLISION Trial - Colorectal Liver Metastases: Surgery vs Thermal Ablation	COLLISION	Recruiting	No Results Available	ColoRectal Cancer|Liver Metastasis Colon Cancer|Liver Metastases|Surgery	Procedure: Thermal ablation|Procedure: Surgical resection	Overall survival (OS)|Disease free survival|Time to progression	VU University Medical Center|Medtronic - MITG	All	18 Years and older   (Adult, Older Adult)	Not Applicable	618	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	NL58551.029.16	July 13, 2017	July 2022	December 2022	March 23, 2017		July 17, 2017	VU University Medical Center, Amsterdam, NH, Netherlands		https://ClinicalTrials.gov/show/NCT03088150
515	NCT03667560	Dermacell ADM Without Basement Membrane		Recruiting	No Results Available	Breast Cancer	Procedure: Dermacell ADM without basement membrane|Procedure: FlexHD	Seroma Formation|Capsular Contracture|Red breast syndrome|QOL|Infection|Histological Assessment	University of Virginia|LifeNet Health	Female	18 Years to 75 Years   (Adult, Older Adult)	Not Applicable	120	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	20295	September 1, 2018	May 1, 2021	May 1, 2021	September 12, 2018		September 12, 2018	University of Virginia, Charlottesville, Virginia, United States		https://ClinicalTrials.gov/show/NCT03667560
516	NCT02938104	Multimodal Prehabilitation to Enhance Functional Recovery After Lung Surgery		Completed	No Results Available	Lung Cancer	Dietary Supplement: Whey Protein Isolate Powder|Behavioral: Physical Exercise Program|Behavioral: Relaxation Techniques	Six-minute walk test|Health-related quality of life|Quality of Life|Physical activity level|Depression and anxiety|Nutritional status	Franco Carli|Immunotec Inc.|McGill University Health Center	All	18 Years and older   (Adult, Older Adult)	Not Applicable	120	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research	14-193-GEN	August 2014	September 2017	September 2017	October 19, 2016		March 22, 2018	Montreal General Hospital, Montreal, Quebec, Canada		https://ClinicalTrials.gov/show/NCT02938104
517	NCT02921022	Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma		Recruiting	No Results Available	Pancreatic Cancer|Advanced Pancreatic Ductal Adenocarcinoma	Drug: Gemcitabine|Drug: Nab-paclitaxel|Drug: PEGPH20	rate of symptomatic TE events	Memorial Sloan Kettering Cancer Center|Halozyme Therapeutics|Miami Cancer Institute	All	18 Years and older   (Adult, Older Adult)	Not Applicable	120	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	16-1066	October 2016	October 2020	October 2020	September 30, 2016		May 23, 2019	Hartford Healthcare Cancer Institute @ Hartford Hospital, Hartford, Connecticut, United States|Miami Cancer Institute, Miami, Florida, United States|Memoral Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States|Memorial Sloan Kettering Commack, Commack, New York, United States|Memorial Sloan Kettering Westchester, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering Nassau, Uniondale, New York, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT02921022
518	NCT03630393	Ultralow Versus Standard Pneumoperitoneum Pressure	Ultralow	Not yet recruiting	No Results Available	Prostate Cancer	Other: Pneumoperitoneum Pressure 6 mmHg|Other: Pneumoperitoneum Pressure 15 mmHg	Postoperative pain medication use|Postoperative pain scores|Operative ventilation	OhioHealth|ConMed Corporation	Male	18 Years and older   (Adult, Older Adult)	Not Applicable	192	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	1306218	April 2019	April 2020	March 2021	August 14, 2018		March 19, 2019	Dublin Methodist Hospital, Columbus, Ohio, United States		https://ClinicalTrials.gov/show/NCT03630393
519	NCT02628093	A ProspectiveTrial Comparing THUNDERBEAT to the Ligasure Energy Device During Laparoscopic Colon Surgery		Completed	No Results Available	Colon Cancer	Device: THUNDERBEAT|Device: LIGASURE	Overall time for dissection of the soft tissues|dissection time for each stage of the surgery	Weill Medical College of Cornell University|Olympus	All	18 Years and older   (Adult, Older Adult)	Not Applicable	60	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other	1403014955	February 17, 2016	May 2, 2019	May 2, 2019	December 11, 2015		July 23, 2019	Weill Cornell Medical Center- NYPH, New York, New York, United States		https://ClinicalTrials.gov/show/NCT02628093
520	NCT02324283	Comparison of Emergence and Oxygenation During One-lung Ventilation With Desflurane and Propofol Anesthesia		Active, not recruiting	No Results Available	Lung Cancer	Drug: desflurane|Drug: propofol	oxygenation|rapidity of emergence from anesthesia|quality of consiousness|postoperative nausea and vomiting	Juntendo University|Baxter Healthcare Corporation	All	20 Years to 75 Years   (Adult, Older Adult)	Not Applicable	80	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other	12-97	October 2012	June 2016	October 2019	December 24, 2014		March 2, 2018	University of Juntendo, Bunkyo-ku, Tokyko, Japan		https://ClinicalTrials.gov/show/NCT02324283
521	NCT00205231	A Pilot Study to Examine the Feasibility and Effect of Tumor Necrosis Factor (TNF) Inhibition on HIV Disease		Completed	No Results Available	HIV Infections	Drug: etanercept	changes in CD4 counts|changes in HIV-RNA levels|development of infections|degree of TNF inhibition by measuring TNF levels|changes in hematologic and biochemical laboratory tests	University of Wisconsin, Madison|Immunex Corporation	All	18 Years and older   (Adult, Older Adult)	Not Applicable	25	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2001-557	May 2002	May 1, 2004	May 1, 2004	September 20, 2005		March 22, 2019	University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States		https://ClinicalTrials.gov/show/NCT00205231
522	NCT03504761	ClariCore System Used in Transrectal Ultrasound Guided Prostate Biopsy for Real-Time Tissue Evaluation	SCORE	Recruiting	No Results Available	Cellular Diagnosis, Prostate Cancer	Device: ClariCore Optical Biopsy System	Validation of the tissue classification algorithm|Sensitivity and Specificity|Cancer Detection Rate	Precision Biopsy, Inc.	Male	22 Years and older   (Adult, Older Adult)	Not Applicable	325	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	CIP-1010-B	April 25, 2018	January 2020	December 2020	April 20, 2018		February 15, 2019	The Urology Center of Colorado, Denver, Colorado, United States|Brady Urological Institute, Johns Hopkins Hospital, Baltimore, Maryland, United States|NYU Langone Urology Associates, New York, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States|Urology of San Antonio, San Antonio, Texas, United States		https://ClinicalTrials.gov/show/NCT03504761
523	NCT03528733	Feasibility of Multi-Energy Digital Radiography Detector for Lung Lesions Detection		Recruiting	No Results Available	Lung Tumor|Solitary Pulmonary Nodule	Device: Multi-Energy Digital Radiography Detector System	Multi-Energy images will be compared to baseline Chest CT images for visualizing lung lesions.|Multi-Energy images will be compared to standard radiography images for visualizing lung lesions.	KA Imaging Inc.|Grand River Hospital	All	18 Years and older   (Adult, Older Adult)	Not Applicable	30	Industry|Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	KAIGRH1	October 22, 2018	January 1, 2019	March 1, 2019	May 18, 2018		November 7, 2018	Grand River Hospital, Kitchener, Ontario, Canada		https://ClinicalTrials.gov/show/NCT03528733
524	NCT03731455	Wise Cortical Strip for Intraoperative Neurophysiological Monitoring	WIN	Recruiting	No Results Available	Brain Tumor Adult|Epilepsy	Device: Wise Cortical Strip	Serious Adverse Device Effects (SADEs) of the Wise Cortical Strip.|The Signal-to-Noise Ratio percentage (SNR%) calculated on Somatosensory Evoked Potential (SEP) signals.|Impedance values measured for the Wise Cortical Strip.|Motor Evoked Potentials (MEPs).|Dedicated usability questionnaire.	Wise S.r.l.|Genae|Fondazione Don Carlo Gnocchi Onlus	All	18 Years to 75 Years   (Adult, Older Adult)	Not Applicable	28	Industry|Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	001_WCS	April 9, 2019	October 9, 2019	October 9, 2019	November 6, 2018		May 24, 2019	Klinikum der Universitat München, Munich, Germany|IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy|Inselspital, Bern, Switzerland|Luzerner Kantonsspital, Luzern, Switzerland|Universitätsspital, Zürich, Switzerland		https://ClinicalTrials.gov/show/NCT03731455
525	NCT02928640	ClariCore Optical Biopsy System Used in TRUS (Trans-Rectal Ultrasound)-Guided Prostrate Biopsy		Active, not recruiting	No Results Available	Cellular Diagnosis, Prostate Cancer	Device: ClariCore System	Primary Effectiveness|Assessment of Pain|Incidence and frequency of adverse events	Precision Biopsy, Inc.	Male	22 Years and older   (Adult, Older Adult)	Not Applicable	200	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	CIP-1010	September 2016	January 2020	December 2020	October 10, 2016		February 15, 2019	The Urology Center of Colorado, Denver, Colorado, United States|Johns Hopkins Brady Urological Institute- The Johns Hopkins Hospital, Baltimore, Maryland, United States|Comprehensive Urology, Royal Oak, Michigan, United States|Associated Professionals of New York, PLLC, Syracuse, New York, United States|Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States		https://ClinicalTrials.gov/show/NCT02928640
526	NCT01903174	Study of AeroForm Tissue Expander for Breast Reconstruction	ASPIRE	Completed	No Results Available	Breast Cancer|Breast Reconstruction	Device: AeroForm Breast Tissue Expander	Successful Tissue Expansion and Exchange to Permanent Breast Implant unless Precluded by a Non-Device Related Event|Adverse Events related to the Breast Reconstruction Procedure	AirXpanders, Inc.	Female	18 Years to 70 Years   (Adult, Older Adult)	Not Applicable	21	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CTP-0004	June 2012	September 2013	December 2013	July 19, 2013		March 26, 2014	Mount Hospital, Subiaco, Western Australia, Australia		https://ClinicalTrials.gov/show/NCT01903174
527	NCT02323555	Optimize the Requirements and Preparations in Outpatient Chemotherapy		Completed	No Results Available	Cancer|IV Anticancer Therapy	Other: Paramedic telephone consultation	Patient profile for Optima|Satisfaction	Centre Francois Baclesse|Roche Pharma AG	All	18 Years and older   (Adult, Older Adult)	Not Applicable	624	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	OPTIMA	March 2014	July 2016	September 2016	December 23, 2014		February 10, 2017	Centre François Baclese, Caen, France		https://ClinicalTrials.gov/show/NCT02323555
528	NCT03626896	Safety of BBB Disruption Using NaviFUS System in Recurrent Glioblastoma Multiforme (GBM) Patients		Completed	No Results Available	Glioblastoma Multiforme|Brain Tumor|Glioblastoma|Glioma|Neoplasms|Neoplasms, Nerve Tissue	Device: NaviFUS System	Number and severity of AE|Tolerated dose of FUS with the NaviFUS System for transient disruption of the BBB|Quantify the BBB disruption following BBB disruption by the NaviFUS System	NaviFUS Corporation|Chang Gung Memorial Hospital	All	20 Years and older   (Adult, Older Adult)	Not Applicable	6	Industry|Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility	NF-2017-01	August 17, 2018	May 20, 2019	June 19, 2019	August 13, 2018		June 21, 2019	Linkou Chang Gung Memorial Hospital, Taoyuan City, Taiwan		https://ClinicalTrials.gov/show/NCT03626896
529	NCT02222337	Nueva Vida Intervention for Latina Breast Cancer Survivors and Caregivers		Completed	Has Results	Quality of Life|Breast Cancer	Behavioral: Nueva Vida Intervention	PROMIS Physical Functioning|PROMIS Satisfaction With Social Roles|PROMIS Anxiety|PROMIS Depression|PROMIS Fatigue|Communication - Survivors Only - Patient Satisfaction With Care (PSQ-18 Communication Subscale)|Self-Efficacy - Survivors Only - Cancer Behavior Inventory (CBI)|Satisfaction With Care - Survivors Only - Experience of Care and Health Outcomes (ECHOS-NHL)	Georgetown University|Nueva Vida, Inc.|Latinas Contra Cancer|Gilda's Club NYC|SHARE	All	up to 85 Years   (Child, Adult, Older Adult)	Not Applicable	272	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	AD-13-5635	May 2013	January 24, 2017	December 2017	August 21, 2014	June 3, 2019	June 3, 2019	Latinas Contra Cancer, San Jose, California, United States|Nueva Vida, Washington, District of Columbia, United States|Gilda's Club New York City, New York, New York, United States|SHARE, New York, New York, United States	"Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/37/NCT02222337/ICF_000.pdf|"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/37/NCT02222337/Prot_SAP_001.pdf	https://ClinicalTrials.gov/show/NCT02222337
530	NCT02627976	Breast Edema Compression Vest		Completed	No Results Available	Edema|Lymphedema|Breast Neoplasm|Breast Cancer	Device: Compression vest, Thuasne	Effect of wearing a compression vest on patient reported outcome pain|Effect of wearing a compression vest on patient reported outcome pain two weeks after wearing a compression vest|Effect of wearing a compression vest on patient reported outcome pain one month after wearing a compression vest|Effect of wearing a compression vest on patient reported outcome pain three months after wearing a compression vest|Effect of wearing a compression vest on patient reported outcome pain six months after wearing a compression vest|Effect of wearing a compression vest on degree of breast edema (CTCAE score)|Effect of wearing a compression vest on patient reported quality of life	UMC Utrecht|Thuasne	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	25	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NL53275.041.15	February 2016	January 2018	January 2018	December 11, 2015		January 30, 2018			https://ClinicalTrials.gov/show/NCT02627976
531	NCT03763851	Cannabis Oil and Radiation Therapy for the Management of Pain		Not yet recruiting	No Results Available	Metastatic Prostate Cancer|Lung Cancer|Breast Cancer	Radiation: Active PPP005|Radiation: Radiotherapy	Cancer pain intensity assessed by Pain Intensity (PI) measurement a numerical rating scale|Cancer pain quality using the Brief Pain Inventory-SF (BPI-SF)|Impact of medical cannabis oil combined with radiation treatment on HRQoL as measured by the EQ-5D-5L|Functional status assessed by the Functional Assessment of Cancer Therapy for Prostate patients (FACT-P).|Fatigue burden assessed by the Brief Fatigue Inventory (BFI).|Cognitive status assessed by the Mini-Cog	Tetra Bio-Pharma|Santé Cannabis|McGill University	All	18 Years to 75 Years   (Adult, Older Adult)	Not Applicable	420	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	PPP005-Ph2/3-01	January 1, 2019	December 31, 2020	December 31, 2020	December 4, 2018		December 4, 2018			https://ClinicalTrials.gov/show/NCT03763851
532	NCT03706534	Breast Ultrasound Image Reviewed With Assistance of Deep Learning Algorithms		Recruiting	No Results Available	Breast Cancer|Breast Lesions|Breast Mass	Procedure: Ultrasound Image review with CADe|Procedure: Ultrasound Image review with CADx|Procedure: Ultrasound Image manual review|Procedure: Biopsy	Concordance rate|Reporting time|Consensus|Accuracy|Sensitivity|Specificity|Area Under Curve	Samsung Medison|University of Rochester	Female	21 Years and older   (Adult, Older Adult)	Not Applicable	300	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Diagnostic	300.08-2018-Samsungmedison-S	September 20, 2018	July 31, 2019	July 31, 2019	October 16, 2018		October 17, 2018	University of Rochester, Rochester, New York, United States		https://ClinicalTrials.gov/show/NCT03706534
533	NCT03887494	Study of the Impact of the Femoral Implant "Y-strut" on Lytic Bone Metastases of the Femoral Neck (WAZA-ARY)	WAZA-ARY	Not yet recruiting	No Results Available	Neoplasms, Bone Tissue|Pain, Intractable|Hip Fractures	Device: Implantation	Measure of Quality of Life for each patient within one month after the implantation|Target lesion fracture within one month after the implantation|Target lesion fracture within 2 months after the implantation|Non-target femoral fracture within 2 months after the implantation|Non-target femoral fracture within one month after the implantation|Analgesic medication needs (type and dose) within one month after the implantation|Analgesic medication needs (type and dose) within 2 months after the implantation|total AE/SAE within one month after the implantation|total AE/SAE within 2 months after the implantation|AE/SAE imputable to the device (number) within one month after the implantation|AE/SAE imputable to the device (number) within 2 months after the implantation|AE/SAE imputable to the implatation (number) within one month after the implantation|AE/SAE imputable to the implatation (number) within 2 months after the implantation|Morphinic mean dose per day within one month after the implantation|Morphinic mean dose per day within 2 months after the implantation|Quality of Life score (EORTC QLQ BM-22) within 2 months after the implantation|Pain score at target site within 2 months after the implantation: VAS|Length of stay within 2 months after the implantation|Exit mode of hospital within 2 months after the implantation	Assistance Publique - Hôpitaux de Paris|Hyprevention	All	18 Years and older   (Adult, Older Adult)	Not Applicable	15	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	K171014J|2018-A01901-54	April 15, 2019	May 22, 2020	June 30, 2020	March 25, 2019		March 28, 2019			https://ClinicalTrials.gov/show/NCT03887494
534	NCT00428220	A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.		Completed	Has Results	Metastatic Breast Cancer|Advanced Breast Cancer|Metastatic Castration Resistant Prostate Cancer|Metastatic Renal Cell Cancer|Non-Small Cell Lung Cancer|Thyroid Cancer|Advanced/Metastatic Non-Small Cell Lung Cancer|Advanced Gastric Cancer|Gastrointestinal Stromal Tumor|Hepatocellular Carcinoma|Pancreatic Islet Cell Carcinoma|Pancreatic Neuroendocrine Tumor	Drug: sunitinib	Number of Participants With Treatment-emergent Adverse Events (AEs) (All Causalities)|Number of Participants With Treatment-emergent AEs (Treatment-Related)	Pfizer	All	18 Years and older   (Adult, Older Adult)	Not Applicable	223	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	A6181114|2006-006538-16	July 2007	August 2014	September 2014	January 29, 2007	November 6, 2015	June 27, 2019	Emory University, Winship Cancer Institute, Atlanta, Georgia, United States|Investigational Drug Service, Atlanta, Georgia, United States|The Emory Clinic, Atlanta, Georgia, United States|Loyola University Medical Center, Maywood, Illinois, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Siteman Cancer Center-West County, Creve Coeur, Missouri, United States|Barnes Jewish Hospital, Saint Louis, Missouri, United States|Washington University School of Medicine, Siteman Cancer Center, Saint Louis, Missouri, United States|Siteman Cancer Center, Saint Peters, Missouri, United States|Comprehensive Cancer Center of Nevada, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Northwest Cancer Specialists, P.C., Portland, Oregon, United States|Northwest Cancer Specialists, P.C., Portland, Oregon, United States|US Oncology Research and Clinical Pharmacy (Drug Shipment Only), Fort Worth, Texas, United States|The Strelitz Diabetes Institute of Eastern Virginia Medical School, Norfolk, Virginia, United States|Clinica Viedma, Viedma, Rio Negro, Argentina|Centro Oncológico Rosario, Rosario, Santa Fé, Argentina|Instituto Oncologico de Cordoba, Nueva Cordoba, Argentina|Centro Medico San Roque, San Miguel de Tucuman, Argentina|Royal Brisbane & Women's Hospital, Herston, Queensland, Australia|Royal Adelaide Hospital, Department of Medical Oncology, Adelaide, South Australia, Australia|Austin Health, Heidelberg, Victoria, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|Mount Medical Centre, Perth, Western Australia, Australia|Hopital Erasme / Gastroenterologie, Bruxelles, Belgium|Cliniques Universitaires Saint Luc / Gastroentérologie, Bruxelles, Belgium|Cliniques Universitaires Saint-Luc, Oncologie, Bruxelles, Belgium|UZ Gasthuisberg, Department Internal Medicine - Gastroenterology - Gastro-intestinal Oncology, Leuven, Belgium|Centre Hospitalier Universitaire de Liege, Liege, Belgium|Algemeen Ziekenhuis Nikolaas, Sint-Niklaas, Belgium|AZ Sint-Augustinus, Oncologisch Centrum, Wilrijk, Belgium|Hospital São Lucas da PUCRS, Porto Alegre, RS, Brazil|Hospital Nossa Senhora da Conceicao, Porto Alegre, RS, Brazil|Sociedade Beneficente de Senhoras Hospital Sirio Libanes, Sao Paulo, SP, Brazil|Centro de Oncologia do Instituto de Radiologia, São Paulo, SP, Brazil|BC Cancer Agency - Vancouver Centre, Vancouver, British Columbia, Canada|QEII Health Sciences Centre - Nova Scotia Cancer Centre, Halifax, Nova Scotia, Canada|QEII Health Sciences Centre - Victoria General Site, Halifax, Nova Scotia, Canada|QEII Health Sciences Centre - Halifax Infirmary Site, Halifax, Nova Scotia, Canada|London Regional Cancer Program, London, Ontario, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|CHUM, Hopital Saint-Luc, Montreal, Quebec, Canada|Royal Victoria Hospital, Montreal, Quebec, Canada|Fundacion Centro de Investigacion Clinica CIC, Medellin, Anquioquia, Colombia|Hospital Universitario San Vicente de Paul, Medellin, Antioquia, Colombia|Clinica Astorga, Medellin, Antioquia, Colombia|Centre Antoine Lacassagne, Nice, Cedex 02, France|Hopital Beaujon, Clichy Cedex, Cedex, France|Groupe Hospitalier Cochin, Cancer Quest AP-HP, Paris, Cedex, France|CHU-Hôpital Jean Minjoz, Besancon, France|Hopital Saint-Andre, Bordeaux Cedex, France|Centre Jean Perrin, Clermont Ferrand, France|Polyclinique du Bois, Lille, France|Centre Oscar Lambret, Lille, France|Hopital Edouard Herriot, Lyon Cedex 03, France|Centre Leon Berard, Lyon, France|Chu La Timone, Marseille Cedex 5, France|Clinique Hartmann, Neuilly Sur Seine, France|Hopital Saint-Antoine, Paris, France|Centre Eugene Marquis, Rennes Cedex, France|Klinik fuer Innere Medizin, Gastroenterologie, Onkologie, Endokrinologie, Bad Berka, Germany|Universitaetsklinikum Charité, Campus Virchow Klinikum, Berlin, Germany|eps - early phase GmbH, Jena, Germany|Frauenaerzte Pruener Gang, Kiel, Germany|Klinik fuer Frauenheilkunde und Geburtshilfe, Universitaetsklinikum Schleswig-Holstein, Luebeck, Germany|Universitaetsklinikum Schleswig-Holstein, Campus Luebeck, Luebeck, Germany|Universitaetsklinikum Giessen und Marburg, Standort Marburg, Marburg, Germany|Rhoen Klinikum Meiningen, Gynaekologie und Geburtshilfe, Meiningen, Germany|Frauenklinik und Poliklinik, Klinikum rechts der Isar, Technische Universitaet Muenchen, Muenchen, Germany|Department of Clinical Oncology, Tuen Mun Hospital, Tuen Mun, New Territories, Hong Kong|Queen Mary Hospital, Hong Kong, Hong Kong|Division of Haematology/Oncology, Department of Medicine, Queen Mary Hospital,, Hong Kong, Hong Kong|Queen Elizabeth Hospital, Department of Clinical Oncology, Kowloon, Hong Kong|Tuen Mun Hospital, Department of Clinical Oncology, Tuen Mun, New Territories, Hong Kong|UNIMED Medical Institute, Wan Chai,, Hong Kong|National Cancer Center, Goyang-si, Gyeonggi-do, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of|Seoul National University Hospital / Department of Internal Medecine, Seoul, Republic Of Korea, Korea, Republic of|Asan Medical Center, Division of Oncology, Department of Internal Medicine, Seoul, Republic Of Korea, Korea, Republic of|Yeungnam University Medical Center/Department of Internal medicine, Daegu, Korea, Republic of|Severance Hospital, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea, Republic of|Hospital Universitario Dr. Jose Eleuterio Gonzalez Centro Universitario contra el cancer, Monterrey, Nuevo Leon, Mexico|Hospital Christus Muguerza del Parque, Chihuahua, Mexico|Cancer Care Clinic, Quezon City, Metro Manila, Philippines|National University Hospital/Department of Heamatology-Oncology, Singapore, Singapore|National Cancer Center/Department of Medical Oncology, Singapore, Singapore|Corporacio Sanitaria Parc Tauli, Sabadell, Barcelona, Spain|Fundacion Hospital Alcorcon, Alcorcon, Madrid, Spain|Servicio de Oncologia, Barcelona, Spain|Complexo Hospitalario Universitario A Coruña, La Coruña, Spain|Centro Oncologico Md Anderson International España, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Chang Gung Medical Foundation, Linkou Branch, Kuei-Shan, Taoyuan, Taiwan|Changhua Christian Hospital, Changhua, Taiwan|Chung-Ho Memorial Hospital, Kaohsiung Medical University/Department of Surgery, Kaohsiung, Taiwan|Chi Mei Medical Center, Liouying, Liouying Township, Tainan,, Taiwan|Taichung Veterans General Hospital, Department of Surgery, Taichung, Taiwan|National Taiwan University Hospital/Department of Oncology, Taipei, Taiwan|Koo Foundation Sun Yat-Sen Cancer Center, Div. of Hematology/Oncology, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Chi-Mei Medical Center, YungKang City, Tainan, Taiwan|Division of Surgery and Oncology, Liverpool, Merseyside, United Kingdom|Deparment of Cardiology, Glasgow, United Kingdom|The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom|Dainton Building, Leeds, United Kingdom|St James' Institute of Oncology, Leeds, United Kingdom|Management Offices, 4th Floor, Thomas Guy House, London, United Kingdom|Royal Marsden Hospital, London, United Kingdom|Department of Medical Oncology, Manchester, United Kingdom|Cardiology Department, Wythenshawe Hospital, Manchester, United Kingdom|Nottingham City Hospital, Nottingham, United Kingdom		https://ClinicalTrials.gov/show/NCT00428220
535	NCT03857958	Metal Versus Plastic Stent in Malignant Hilar Biliary Obstruction		Recruiting	No Results Available	Malignant Hepatobiliary Neoplasm	Procedure: endoscopic retrograde cholangio-pancreatography	Duration of stent patency	Seoul National University Hospital|Taewoong Medical Co., Ltd.	All	19 Years and older   (Adult, Older Adult)	Not Applicable	54	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	1812-098-996	February 15, 2019	December 31, 2020	June 30, 2021	February 28, 2019		April 4, 2019	Seoul National University Hospital, Seoul, Korea, Republic of		https://ClinicalTrials.gov/show/NCT03857958
536	NCT01320891	Effects of Different Strategy of Fluids Administration on Acid/Base Disorders and Inflammatory Mediators		Completed	No Results Available	Large Bowel Cancer	Behavioral: balanced solutions|Behavioral: not balanced	acid/base disorder|pro/antiinflammatory cytokine	Università degli Studi di Ferrara|B. Braun Melsungen AG	All	18 Years to 90 Years   (Adult, Older Adult)	Not Applicable	40	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	HC-I-H-0909	February 2010	August 2011	February 2012	March 23, 2011		May 8, 2017	S.Anna Universitary Hospital, Ferrara, Italy		https://ClinicalTrials.gov/show/NCT01320891
537	NCT00877682	Prostate Conformal Cryotherapy		Completed	No Results Available	Prostate Cancer	Procedure: Cryoablation	Patient Response	M.D. Anderson Cancer Center|Endocare, Inc.|Gen-Probe, Incorporated|FirmaMed|Envisioneering Medical Technologies	Male	Child, Adult, Older Adult	Not Applicable	48	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2008-0244|NCI-2011-01340	April 6, 2009	January 14, 2018	January 14, 2018	April 8, 2009		January 31, 2018	University of Texas MD Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT00877682
538	NCT03058107	Tight Caloric Control in the Cachectic Oncologic Patient (TiCaCONCO or CoCooN)	TiCaCONCO	Active, not recruiting	No Results Available	Metabolism and Nutrition Disorder	Dietary Supplement: Nutrition Therapy|Dietary Supplement: Control Therapy	overall survival (mortality)|hospitalisation|morbidity|weight stabilisation (kg)|body composition (%)|energy expenditure (Kcal)|complete remission	Universitair Ziekenhuis Brussel|Baxter Healthcare Corporation|Nutricia, Inc.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	60	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	BUN 143201629790	January 2017	July 2020	July 2020	February 20, 2017		July 24, 2019	UZ Brussel, Jette, Belgium		https://ClinicalTrials.gov/show/NCT03058107
539	NCT03580109	Spa Therapy of Upper Limb Lymphoedema	THERMOEDEME	Not yet recruiting	No Results Available	Lymphedema|Breast Cancer	Other: Immediate spa treatment|Other: Late spa treatment	Evolution of lymphoedema quality of life assessed by the rate of patient with an improvement of the LMS27 scale.|Evolution of lymphoedema quality of life assessed by the LMS27 scale.|Evolution of lymphoedema quality of life assessed by the most embarrassing items of the LMS27 scale.|Improvement of quality of life assessed by the generic quality of life: Euroquol EQ5D|Upper limb evaluation|Treatment follow up|Compliance of spa therapeutic|Achievement educational aims|Adverse events|Functional evaluation|Long term evaluation|Effect size|Sub group analysis	Association Francaise pour la Recherche Thermale|Floralis	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	160	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Other	THERMOEDEME	April 2019	April 2022	December 2022	July 9, 2018		March 18, 2019	Cabinet de médecine vasculaire, Albertville, France|Thermes Argelès-Gazost, Argelès-Gazost, France|Thermes Barbotan Les Bains, Barbotan-les-Thermes, France|Thermes La Léchère, La Léchère, France|Thermes Luz Saint Sauveur, Luz-Saint-Sauveur, France|Cabinet de médecine vasculaire, Lyon, France|Clinique du Tonkin, Villeurbanne, France		https://ClinicalTrials.gov/show/NCT03580109
540	NCT01032278	Effectiveness of Using Biomarkers to Detect and Identify Cardiotoxicity and Describe Treatment (PREDICT)		Active, not recruiting	No Results Available	Cardiac Toxicity|Unspecified Adult Solid Tumor, Protocol Specific	Other: Laboratory Biomarker Analysis|Behavioral: Questionnaires	Use of Cardiac Biomarkers, B-type Natriuretic Peptide (BNP) and Troponin I (TnI), for Detecting Cardiotoxicity in Patients Undergoing Anthracycline-based Chemotherapy|Sensitivity and specificity of serial LVEF measurements in detecting cardiotoxicity|Clinical management and outcomes of patients with abnormal cardiac biomarkers or clinically defined cardiotoxicity during chemotherapy|Supportive utility of patient-reported symptoms for the development of cardiac-related toxicity	M.D. Anderson Cancer Center|Alere San Diego	All	18 Years and older   (Adult, Older Adult)	Not Applicable	597	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	CDR0000660615|MDA-2007-0914A|NCI-2011-01466	January 25, 2011	January 2020	January 2021	December 15, 2009		May 21, 2019	Lyndon B. Johnson General Hospital (LBJ), Houston, Texas, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT01032278
541	NCT01047332	A Trial Comparing the Uncovered to the Covered Wallstent in the Palliation of Malignant Bile Duct Strictures	Wallstent	Completed	Has Results	Inoperable Tumors of the Bile Duct	Device: Partially Covered Wallstent|Device: Uncovered Wallstent	Time to Recurrent Biliary Obstruction|Patient Survival|Number of Participants With Serious Adverse Events (SAEs)|Number of Participants With Recurrent Biliary Obstruction Reported by Mechanism	Brigham and Women's Hospital|Boston Scientific Corporation	All	18 Years and older   (Adult, Older Adult)	Not Applicable	129	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care	BS-816	October 2002	May 2008	November 2009	January 12, 2010	April 11, 2017	April 11, 2017			https://ClinicalTrials.gov/show/NCT01047332
542	NCT03532347	Endoscopic Ultrasound Guided Tissue Sampling (The SharkBITE Study)	SharkBITE	Completed	No Results Available	Pancreas Cancer|Pancreas Neoplasm, Benign|Chronic Pancreatitis|Pancreas Adenocarcinoma	Device: EUS-FNA needle (Beacon)	The sensitivity of standard Beacon FNA needle compared with the SharkCore (FNB) core biopsy needle in the sampling of solid pancreatic mass lesions.|To compare the adequacy of the sample obtained with standard Beacon FNA needle compared with the SharkCore core biopsy needle in the sampling of solid pancreatic mass lesions.|Duration of pathologist reporting time|Cost benefit analysis of the needle types|Duration of sampling procedures	Newcastle-upon-Tyne Hospitals NHS Trust|Medtronic	All	18 Years and older   (Adult, Older Adult)	Not Applicable	108	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	8090	May 22, 2017	May 4, 2018	November 4, 2018	May 22, 2018		June 10, 2019	The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, Newcastle Upon Tyne, United Kingdom		https://ClinicalTrials.gov/show/NCT03532347
543	NCT01008774	START: Swiss Taxotere Alopecia Prevention Trial		Completed	No Results Available	Neoplasms|Alopecia	Device: Paxman Cooling Machine|Device: Cold Caps	Grade III or IV alopecia according to the WHO criteria|Compliance to scalp cooling procedure|Side effects of scalp cooling systems	Sanofi	All	18 Years and older   (Adult, Older Adult)	Not Applicable	239	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	DOCET_L_04449	July 2009	October 2011	October 2011	November 6, 2009		January 23, 2012	Sanofi-Aventis Administrative Office, Geneva, Switzerland		https://ClinicalTrials.gov/show/NCT01008774
544	NCT00118508	The Prevention of Osteoporosis in Premenopausal and Newly Postmenopausal (Up to 8 Years) Women With Breast Cancer Following Chemotherapy (REBBeCA Study)		Completed	No Results Available	Osteoporosis	Drug: risedronate (including placebo)	That bone loss, as determined through BMD every six months, will be prevented at clinically relevant sites, such as the hip & spine, through the use of bisphosphonate therapy in study subjects.|There will be a correlation between biochemical markers of bone turnover and changes in BMD.	University of Pittsburgh|Procter and Gamble|Aventis Pharmaceuticals	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	87	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention	IRB#0404173	May 2003	July 2006	July 2006	July 11, 2005		August 13, 2015	University of Pittsburgh Medical Center (GCRC), Pittsburgh, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT00118508
545	NCT03179358	Clinical Trial Verifying C-REX LapAid and C-REX DMH/DMHC		Completed	No Results Available	Cancer Colon|Polyp of Colon	Device: C-REX Ring-locking Procedure	Time to evacuation of the short-term implant|Time to first intestinal sounds|Time to first passage of gas|Time to first defecation|Number of postoperative interventions related to the device|Integrity pressure|Post-operative X-ray examination|Time of surgery	Carponovum AB|The First Affiliated Hospital of Xiamen University	All	18 Years to 70 Years   (Adult, Older Adult)	Not Applicable	20	Industry|Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CREX-003	September 29, 2016	June 10, 2017	June 10, 2017	June 7, 2017		January 17, 2018	The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China		https://ClinicalTrials.gov/show/NCT03179358
546	NCT02638298	Incisional Negative Pressure Wound Therapy for Preoperatively Irradiated Lower Extremity Soft Tissue Sarcoma Wounds		Recruiting	No Results Available	Sarcoma|Cancer|Infectious Disease	Device: Prevana Dressing|Other: Standard Dry Gauze Dressing	Wound Complication Rate|Total Costs	Medical University of South Carolina|KCI USA, Inc.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	30	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	Pro00028423	December 2015	December 2020	December 2020	December 23, 2015		May 14, 2019	Medical University of South Carolina, Charleston, South Carolina, United States		https://ClinicalTrials.gov/show/NCT02638298
547	NCT03914911	In Vivo Smart Biopsy Device Protocol In Radiology		Recruiting	No Results Available	Breast Cancer|Image Guided Biopsy	Device: Smart Biopsy Device	Incidence of adverse events (AEs) and serious adverse events (SAEs) Adverse events (AEs)|Correlation between pathology results and device readings|Ergonomic Assessment of the Smart Biopsy Device	Dune Medical Devices	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	100	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	CP-10-001	March 14, 2019	December 5, 2019	January 5, 2020	April 15, 2019		July 2, 2019	Meir Medical Center, Kfar Saba, Israel|Rabin Medical Center Campus Beilinson, Petah Tikva, Israel		https://ClinicalTrials.gov/show/NCT03914911
548	NCT03730207	Xpede Clinical Study		Recruiting	No Results Available	Pathological Fracture of Vertebra Due to Secondary Osteoporosis (Disorder)|Pathological Fracture of Vertebra Due to Neoplastic Disease (Disorder)	Device: Xpede™ Bone Cement|Device: Mendec Spine Bone Cement	The change of Numerical Rating Scale (NRS) score from baseline at 6 months postoperative|The change of Index Vertebral Body Angle from baseline at 6 months|The change of NRS score from baseline at 1 day and 3 months|The change of Oswestry Disability Index (ODI) score from baseline at 1 day, 3 months, and 6 months|The change of SF-36 from baseline at 1 day, 3 months, and 6 months|Change in vertebral body height restoration at 1 day, 3 months, and 6 months|Change in Vertebral body angle from baseline at 1 day and 3 months|The Rates of adverse events reported through 6 months	Medtronic Spinal and Biologics	All	18 Years to 80 Years   (Adult, Older Adult)	Not Applicable	180	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	MDT17075SD1707	December 18, 2018	October 2019	April 2020	November 5, 2018		December 27, 2018	The first affiliated hospital of Zhengzhou university, Zhengzhou, Henan, China|Hunan provincial people's hospital, Changsha, Hunan, China|The first affiliated hospital of Suzhou university, Suzhou, Jiangsu, China		https://ClinicalTrials.gov/show/NCT03730207
549	NCT02479100	Contrast Enhanced Spectral Mammography (CESM) Study	CONTEND	Recruiting	No Results Available	Breast Cancer	Diagnostic Test: Contrast Enhanced Spectral Mammogram	Assessment of impact the addition of CESM has on patient management - does this lead to an earlier diagnosis / treatment plan	Cambridge University Hospitals NHS Foundation Trust|University of Cambridge|GE Healthcare	Female	18 Years to 85 Years   (Adult, Older Adult)	Not Applicable	100	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	RADIOL/2015/CONTEND	March 2016	September 2019	September 2019	June 24, 2015		January 9, 2019	Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridgeshire, United Kingdom	"Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/00/NCT02479100/Prot_000.pdf|"Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/00/NCT02479100/ICF_001.pdf	https://ClinicalTrials.gov/show/NCT02479100
550	NCT03713099	NEUWAVE Flexible Probe Study #2		Not yet recruiting	No Results Available	Cancer of the Lung|Lung Cancer|Neoplasms, Lung|Carcinoma, Non-Small Cell Lung|Non-Small Cell Lung Cancer|Non-Small Cell Lung Carcinoma	Device: Microwave ablation	Device User Experience Survey|Technical Success (lesion completely ablated)|Technique Efficacy (lesion completely ablated)|Adverse Events|Primary Efficacy Rate|Secondary Efficacy Rate|Target Lesion Recurrence|Length of Hospital Stay|Hospital Readmission Rate	Ethicon, Inc.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	40	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NEU_2018_01	January 1, 2020	December 31, 2021	December 31, 2021	October 19, 2018		July 25, 2019	City of Hope, Duarte, California, United States|Mayo Clinic, Rochester, Minnesota, United States|New York Presbyterian-Weill Cornell Medicine, New York, New York, United States|FirstHealth Moore Regional Hospital, Pinehurst, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States		https://ClinicalTrials.gov/show/NCT03713099
551	NCT03418662	EndoRings Colonoscopy vs Standard Colonoscopy		Completed	No Results Available	Colorectal Adenoma|Colorectal Polyp|Colon Cancer	Device: EndoRings device	Adenoma Detection Rates|Time Comparison for Each Method|Total Number of Detections|Number of Detections per Colonoscopy|Polyp Detection Rate|Problems encountered with equipment|Patient Comfort Score|Effect on re-scope intervals|Cecal Intubation Rate	Indiana University|US Endoscopy	All	Child, Adult, Older Adult	Not Applicable	569	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening	1711224972	January 19, 2018	September 13, 2018	September 13, 2018	February 1, 2018		November 8, 2018	Indiana University, Indianapolis, Indiana, United States		https://ClinicalTrials.gov/show/NCT03418662
552	NCT02808884	Cancer DNA Screening Pilot Study (CANDACE)	CANDACE	Active, not recruiting	No Results Available	Circulating Tumor Cells	Genetic: Circulating tumor DNA assay	Measuring the positive and negative predictive value of a circulating tumor DNA blood test in detecting the presence of cancer or pre-cancerous lesions|The enrollment rates for this study|The number of repeated versus sporadic positive test results within a year of the last blood draw.|The rate of participation in the medical imaging component of the study once a positive test result has been confirmed.|The number of medical imaging scans required per thousand individuals enrolled in the study.|The number of participants with abnormal medical imaging scans and of those cohorts, what fraction is cancer found.	British Columbia Cancer Agency|University of British Columbia|University of Utah|Pathway Genomics|Boreal Genomics	All	55 Years to 75 Years   (Adult, Older Adult)	Not Applicable	1000	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening	H16-00519	September 2016	January 2020	January 2020	June 22, 2016		July 11, 2018	BC Cancer Agency- Vancouver Centre, Vancouver, British Columbia, Canada		https://ClinicalTrials.gov/show/NCT02808884
553	NCT03948958	PREMO Study: to Investigate Port REMoval Outcomes	PREMO	Recruiting	No Results Available	Neoplasms|Cystic Fibrosis	Other: Evaluation of the catheter function|Other: Catheter tip location, thrombus, sleeve and device damage visualization|Other: Catheter-related colonization|Other: patient-reported outcome measures (PROM) related to the presence of the TIVAD|Other: Macroscopic evaluation of the port chamber and catheter	TIVAD function|Catheter tip position visualization by fluoroscopy|Port chamber filling, sleeve formation, sleeve extend, catheter tip thrombosis and damage in port chamber or catheter trajectory|Catheter tip and port chamber culture	Universitaire Ziekenhuizen Leuven|B. Braun Medical SA	All	18 Years and older   (Adult, Older Adult)	Not Applicable	100	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	S62321	June 28, 2019	November 1, 2020	November 1, 2020	May 14, 2019		July 1, 2019	University Hospitals Leuven, Leuven, Belgium		https://ClinicalTrials.gov/show/NCT03948958
554	NCT01025167	The Effect of a New Specific Enteral Formula Compared to a Standard Formula on the Tolerability of a Combined Radio- and Chemotherapy in Cancer Patients		Completed	No Results Available	Enteral Nutrition	Dietary Supplement: Supportan(R) (Disease-specific enteral tube feed, food for special medical purposes)|Dietary Supplement: Fresubin(R)	Body cell mass measured by bioelectrical impedance spectroscopy (BIS)|Other parameters of body composition such as fat free mass, lipid mass, total body water, intracellular water, lean tissue mass|Hand grip strength|Quality of Life|Gastrointestinal tolerance	Fresenius Kabi	All	18 Years and older   (Adult, Older Adult)	Not Applicable	111	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care	N-SUP-09-DE	September 2006	January 2010	January 2010	December 3, 2009		August 20, 2010	Zentrum für Strahlentherapie und Radioonkologie, Ärztehaus am DIAKO, Bremen, Germany|Klinik und Poliklinik für Strahlentherapie und Radioonkologie, Universitätsklinikum Dresden, Dresden, Germany|Department of Radiotherapy, University hospital, Erlangen, Germany|Klinik für Strahlentherapie und Radioonkologie, Universitätsklinikum Frankfurt, Frankfurt, Germany|Abteilung Strahlentherapie und Radioonkologie, Universitätsmedizin Göttingen, Göttingen, Germany|Klinik für Strahlentherapie, Universitätsklinikum Halle, Halle, Germany|Klinik für Strahlentherapie und Radioonkologie, Universitätsklinikum des Saarlandes, Homburg (Saar), Germany|Klinik und Poliklinik für Strahlentherapie Universität Rostock, Rostock, Germany|Abteilung Strahlentherapie und Radioonkologie, Universitätsmedizin Tübingen, Tübingen, Germany|Klinik für Strahlentherapie und Radioonkologie, Universitätsklinikum Ulm, Ulm, Germany		https://ClinicalTrials.gov/show/NCT01025167
555	NCT03292198	Subclinical Lymphedema Treatment Study	SLT	Recruiting	No Results Available	Breast Cancer-related Subclinical Lymphedema	Other: 20-30 mmHg compression sleeve and gauntlet|Other: Manual Lymphatic Drainage	L-dex scores	Mercy Research|Mercy Foundation|St. Louis Men's Group Against Cancer|ImpediMed Limited|Juzo USA	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	267	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	1070741-1	April 1, 2018	April 2022	December 2022	September 25, 2017		February 1, 2019	Mercy David C. Pratt Cancer Center, Saint Louis, Missouri, United States		https://ClinicalTrials.gov/show/NCT03292198
556	NCT03850171	Cancer Adverse Effects PReventIon With Care & Exercise: the CAPRICE Study		Recruiting	No Results Available	Breast Neoplasm Female|Cardiotoxicity|Anthracyclines|Physical Activity	Other: Exercise Training	Changes from baseline in left ventricular (LV) global longitudinal strain (GLS)|Change in Blood biomarkers|Identification of barriers towards exercise training|Compliance with exercise training|Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F)|Vascular function|Cardiorespiratory fitness|Cardiovascular risk profile|Changes in LV global longitudinal strain	University Hospital Inselspital, Berne|Spital STS AG|Bürgerspital Solothurn|Brustzentrum Bern der Lindenhofgruppe|University of Bern	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	120	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention	CAPRICE	May 1, 2019	March 31, 2021	December 31, 2022	February 21, 2019		May 3, 2019	Lindenhofgruppe, Bern, Switzerland|University Clinic for Cardiology, Bern, Switzerland|Bürgerspital Solothurn, Solothurn, Switzerland|Spital STS AG, Thun, Switzerland		https://ClinicalTrials.gov/show/NCT03850171
557	NCT01216319	Evaluation of the Cook Biodesign® Nipple Reconstruction Cylinder (NRC)	NRC	Completed	Has Results	Breast Cancer|Breast Reconstruction|Nipple Reconstruction	Device: Nipple reconstruction	Percent Nipple Projection at 12 Months Compared to Baseline (1 Week Post-procedure)|Rate of Patient Satisfaction	Cook Group Incorporated	All	18 Years and older   (Adult, Older Adult)	Not Applicable	50	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	09-009	September 2011	April 2014	April 2014	October 7, 2010	May 15, 2015	June 23, 2016	Stanford University School of Medicine, Stanford, California, United States|Park Meadows Cosmetic Surgery, Lone Tree, Colorado, United States|Mercy Medical Center, Baltimore, Maryland, United States|Sanford Clinic Plastic and Reconstructive Surgery, Sioux Falls, South Dakota, United States		https://ClinicalTrials.gov/show/NCT01216319
558	NCT01753479	Spectroscopy From Duodenum		Completed	No Results Available	Pancreatic Adenocarcinoma	Other: Spectroscopy device	The spectral data of the normal cohort and UICC stage II pancreatic ductal adenocarcinoma cohort|The sensitivity and specificity to detect UICC stage II pancreatic ductal adenocarcinoma among all participants.	Olympus Corporation|M.D. Anderson Cancer Center|Catholic University of the Sacred Heart|Erasme University Hospital	All	18 Years and older   (Adult, Older Adult)	Not Applicable	445	Industry|Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	OMSC-Mag-1	January 2013	June 30, 2016	June 30, 2016	December 20, 2012		March 7, 2017	Mayo Clinic Florida, Jacksonville, Florida, United States|The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States|Hôpital Erasme, Bruxelles, Brussels-Capital Region, Belgium|Università Cattolica del Sacro Cuore, Rome, Lazio, Italy		https://ClinicalTrials.gov/show/NCT01753479
559	NCT03125798	Comparison of LigaSure to Conventional Electrocoagulation in Video-assisted Thoracoscopic Surgery Lobectomy		Recruiting	No Results Available	Lung Cancer|Complication of Surgical Procedure	Device: LigaSure™|Device: Monopolar electrocautery	Postoperative chest drainage volume.|Acute phase proteins levels.|Local temperature.	Wielkopolskie Centrum Pulmonologii i Torakochirurgii|Medtronic	All	18 Years to 85 Years   (Adult, Older Adult)	Not Applicable	200	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	TH-17-ML-1	May 3, 2018	September 2020	September 2020	April 24, 2017		May 4, 2018	Wielkopolskie Centrum Pulmonologii i Torakochirurgii, Poznań, Wielkopolska, Poland		https://ClinicalTrials.gov/show/NCT03125798
560	NCT02788955	Protein Recommendation to Increase Muscle	PRIMe	Recruiting	No Results Available	Colorectal Cancer	Behavioral: Dietary counselling|Other: Dietary Protein	Change/maintenance in muscle mass|Change in physical function	University of Alberta|Canada Foundation for Innovation|Government of Alberta|Nestlé Health Science Spain|Olymel|Cargill	All	18 Years to 85 Years   (Adult, Older Adult)	Not Applicable	36	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HREBA.CC-15-0193	April 2016	December 2019	December 2020	June 2, 2016		March 25, 2019	University of Alberta, Edmonton, Alberta, Canada		https://ClinicalTrials.gov/show/NCT02788955
561	NCT01644669	Safety and Efficacy Study of the Xoft® Axxent® eBx™ IORT System		Active, not recruiting	No Results Available	Invasive Ductal Carcinoma|Ductal Carcinoma in Situ	Radiation: Intra-operative Radiation Therapy - IORT	Assess the rate of ipsilateral breast tumor recurrence (IBTR) at 5 years|Assess the rate of regional breast tumor recurrence (RBTR)|Disease Free Survival Rate (DFSR) and Overall Survival rate|Cosmetic Outcome|Quality of Life (QOL)|Assess the safety of single fraction IORT at the time of breast conserving surgery for early stage breast cancer|Assess the rate of ipsilateral breast tumor recurrence (IBTR) at 10 years	Xoft, Inc.|Icad, Inc.	Female	40 Years and older   (Adult, Older Adult)	Not Applicable	1200	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CTPR-0009	May 2012	February 2023	December 2024	July 19, 2012		November 8, 2018	Cancer Treatment Services Arizona, Casa Grande, Arizona, United States|Phoenix Baptist Hospital, Phoenix, Arizona, United States|University of Arizona, Tucson, Arizona, United States|Kern Medical Center, Bakersfield, California, United States|City of Hope, Duarte, California, United States|Long Beach Memorial Medical Center, Long Beach, California, United States|UCLA, Los Angeles, California, United States|Tri-City Medical Center, Oceanside, California, United States|Breastlink, Orange, California, United States|Diablo Valley Oncology Hematology Medical Group, Pleasant Hill, California, United States|Western Surgical Care, PC, Denver, Colorado, United States|Swedish Medical Center, Englewood, Colorado, United States|Florida Hospital Celebration Health, Celebration, Florida, United States|Doctors Hospital, Coral Gables, Florida, United States|Martin Health System Center for Clinical Research, Stuart, Florida, United States|Rush University, Chicago, Illinois, United States|Lutheran Hospital of Indiana, Fort Wayne, Indiana, United States|Greater Baltimore Medical Center, Baltimore, Maryland, United States|MedStar Oncology Network - Good Samaritan Hospital, Baltimore, Maryland, United States|MedStar Oncology Network - Franklin Square, Baltimore, Maryland, United States|Exeter Hospital, Exeter, New Hampshire, United States|Staten Island University Hospital, Staten Island, New York, United States|University of Oklahoma, Oklahoma City, Oklahoma, United States|Parkridge Medical Center, Chattanooga, Tennessee, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|Sentara Northern Virginia Medical Center, Woodbridge, Virginia, United States|Monash Health / Peter MacCallum Cancer Centre, Clayton, Victoria, Australia|Hospital CUF Porto, Porto, Portugal		https://ClinicalTrials.gov/show/NCT01644669
562	NCT03881098	Atlas of Pulmonary Premalignancy		Not yet recruiting	No Results Available	Lung Cancer	Procedure: Bronchoscopies|Procedure: Sputum Sample|Procedure: Venipuncture	Determine Genomic Features of Pre-Malignant Lesions (PML) via Bronchoscopic Biopsy|Determine Microenvironmental Features of Lung Pre-Malignant Lesions (PML) via Bronchoscopic Biopsy	University of Colorado, Denver|National Cancer Institute (NCI)|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	240	Other|NIH|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening	19-0400.cc|P30CA046934	October 2019	January 2023	January 2023	March 19, 2019		July 23, 2019			https://ClinicalTrials.gov/show/NCT03881098
563	NCT03950180	Assessing The Impact Of Incorporating Charlson Comorbidity Scores On Patient Anxiety And Satisfaction		Completed	No Results Available	Prostate Cancer	Other: Prostate Cancer Comorbidity Index (PCCI) score	Traditional Decisional Conflict Scale (DCS)|The Modified 18-item Memorial Anxiety Scale for Prostate Cancer	Benaroya Research Institute|Virginia Mason Hospital/Medical Center|Axio Research Corporation	Male	18 Years and older   (Adult, Older Adult)	Not Applicable	277	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other	IRB13054	July 12, 2013	February 27, 2015	February 27, 2015	May 15, 2019		June 12, 2019			https://ClinicalTrials.gov/show/NCT03950180
564	NCT02114164	Study of CO2 Exchange Patterns During Robotic Prostatectomies		Active, not recruiting	No Results Available	Prostate Cancer|Pneumoperitoneum	Device: AirSeal System|Device: Standard Endopath	Intraoperative pneumoperitoneal pressure (mmHg).	OhioHealth|SurgiQuest, Inc.	Male	18 Years and older   (Adult, Older Adult)	Not Applicable	100	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention	OH1-13-00489	August 2016	March 2018	March 2019	April 15, 2014		July 31, 2018	Dublin Methodist Hospital, Columbus, Ohio, United States		https://ClinicalTrials.gov/show/NCT02114164
565	NCT03893539	Clinical Utility for Ion Endoluminal System		Recruiting	No Results Available	Pulmonary Nodule|Lung Cancer|Lung Diseases	Device: Ion Endoluminal System™	Navigation Success|Biopsy Success|Sensitivity for Malignancy of System-Obtained Sample|Complications	Intuitive Surgical	All	18 Years and older   (Adult, Older Adult)	Not Applicable	360	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	ISI-ION-001-2018	March 29, 2019	October 2020	December 2020	March 28, 2019		May 23, 2019	Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconness Medical Center, Boston, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|FirstHealth Moore Regional Hospital, Pinehurst, North Carolina, United States|MD Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT03893539
566	NCT01975623	Pulmonary Artery Sealing Using the HARMONIC ACE+ Shears(HS) for VATS Lobectomy		Completed	No Results Available	Lung Cancer	Device: HARMONIC ACE®+ Shears (HS)	Primary outcome for analysis will be the intergroupe comparison of mean PA burst pressures.	Centre hospitalier de l'Université de Montréal (CHUM)|Centre de Recherche du Centre Hospitalier de l'Université de Montréal|Ethicon Endo-Surgery	All	18 Years and older   (Adult, Older Adult)	Not Applicable	47	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	12.262	September 2013	December 2014	April 2015	November 4, 2013		November 26, 2015	Centre Hospitalier de l'Université de Montréal, Montréal, Quebec, Canada		https://ClinicalTrials.gov/show/NCT01975623
567	NCT02786459	Detection and Localization of Carcinoma Using High Resolution Transrectal Imaging - Proof of Concept Study	ProxiScan	Completed	No Results Available	Prostate Cancer	Device: ProxiScan|Device: Magnetic Resonance Imaging|Device: SPECT-CT	Tumor localization.	University Health Network, Toronto|Hybridyne Imaging Technologies Inc|Aytu BioScience, Inc.	Male	30 Years to 75 Years   (Adult, Older Adult)	Not Applicable	18	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	15-8723-C	April 2016	December 2018	April 2019	June 1, 2016		June 3, 2019	Princess Margaret Cancer Centre, Toronto, Ontario, Canada		https://ClinicalTrials.gov/show/NCT02786459
568	NCT03307564	Radiopaque Hydrogel in Patients Undergoing Radiotherapy for Pancreatic Cancer		Recruiting	No Results Available	Pancreatic Adenocarcinoma	Device: TraceIT tissue marker injection	TraceIT Tissue Marker	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Augmenix, Inc.	All	18 Years to 100 Years   (Adult, Older Adult)	Not Applicable	21	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	J17144|IRB00151816	June 6, 2018	December 1, 2020	December 1, 2021	October 11, 2017		October 22, 2018	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States		https://ClinicalTrials.gov/show/NCT03307564
569	NCT00355407	Darbepoetin Alfa (Aranesp) Following Allogeneic Stem Cell Transplantation		Completed	No Results Available	Hematologic Malignancies	Drug: Darbepoetin alfa	Evaluate the percentage of patients achieving a target hemoglobin of 11 g/dL or greater by day 100 following allogeneic stem cell transplantation.|Evaluate the percentage of patients achieving a greater than 1 g/dL hemoglobin increase between days 30 and 100 after allogeneic stem cell transplantation|record transfusion requirements between days 30 and 100 in patients undergoing darbepoetin alfa administration following allogeneic stem cell transplantation.	Dana-Farber Cancer Institute|Amgen|Brigham and Women's Hospital	All	18 Years and older   (Adult, Older Adult)	Not Applicable	31	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	05-420	June 2006	August 2007	August 2007	July 21, 2006		March 13, 2009	Dana-Farber Cancer Institute, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT00355407
570	NCT01969448	Study to Assess Perfusion and Patient Satisfaction in Nipple-Areola Mastectomy With Immediate Reconstruction	NASSM	Completed	Has Results	Ductal Carcinoma in Situ - Category|Breast Cancer|Prophylactic Mastectomy	Procedure: Inframammary Fold Incision or Lateral Radial Incision|Procedure: Lateral Radial Incision|Procedure: Inframammary Fold Incision|Device: Laser-assisted fluorescence angiography|Drug: Indocyanine Green	Percentage of Original Preoperative Blood Supply (Perfusion) Post Nipple Sparing Mastectomy|Percentage of Original Preoperative Blood Supply (Perfusion) Post Reconstruction|Breast Q Score|Number of Participants With Tissue Expander|Mean Operative Times for Mastectomy|Breast Weight	Washington University School of Medicine|LifeCell	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	79	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	201302004	March 28, 2013	April 27, 2016	April 17, 2017	October 25, 2013	April 18, 2018	April 18, 2018	Washington University School of Medicine, Saint Louis, Missouri, United States		https://ClinicalTrials.gov/show/NCT01969448
571	NCT03104114	Pharmacist-led Intervention on Adherence in Patients Undergoing Treatment With an Oral Oncology Medication	BSPAP	Completed	No Results Available	Adherence, Medication	Behavioral: pharmacist-intervention|Behavioral: Historical control	Medication Possession Ratio|Persistence rate|Health-belief model|Provider-patient relationship|Pharmacist-patient relationship	Boston Medical Center|Janssen Scientific Affairs, LLC	All	18 Years and older   (Adult, Older Adult)	Not Applicable	216	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research	H-35671	May 2, 2017	February 15, 2019	February 15, 2019	April 7, 2017		August 1, 2019	Boston Medical Center, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT03104114
572	NCT00121134	Bevacizumab With or Without Cyclophosphamide and Methotrexate: A Pilot Study in Women With Operable Breast Cancer		Completed	Has Results	Breast Cancer	Drug: Bevacizumab|Drug: Cyclophosphamide|Drug: Methotrexate|Drug: Capecitabine	The Completion Rate of 1 Year of Bevacizumab Therapy for All Four Cohorts	Harold J. Burstein, MD, PhD|Genentech, Inc.|Beth Israel Deaconess Medical Center|Indiana University School of Medicine|University of California, San Francisco|University of North Carolina|Dana-Farber Cancer Institute	All	18 Years and older   (Adult, Older Adult)	Not Applicable	164	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	05-055	June 2005	May 2009	May 2011	July 21, 2005	October 14, 2013	December 24, 2013	University of California, San Francisco, San Francisco, California, United States|Indiana University Cancer Center, Indianapolis, Indiana, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University of North Carolina, Durham, North Carolina, United States		https://ClinicalTrials.gov/show/NCT00121134
573	NCT02430792	Effectiveness of Community-based Football in Prostate Cancer	FC-PC	Completed	No Results Available	Prostate Cancer	Behavioral: Football	Mean change in quality of life from baseline to week 12|Mean change in quality of life from baseline to month 6|Whole-body bone mineral content percent change from baseline to month 6|Whole-body bone mineral density percent change from baseline to month 6|Whole-body lean body mass mean change from baseline to month 6|Whole-body fat mass mean change from baseline to month 6|Self-reported physical activity from baseline to week 12 and month 6|Self-reported functional well-being from baseline to week 12 and month 6|Lumbar spine bone mineral density percent change from baseline to month 6|Femoral neck bone mineral density percent change from baseline to month 6|Total hip bone mineral density percent change from baseline to month 6|Number of participants with any fracture from baseline to month 6|Number of participants with falls that resulted in seeking medical assessment from baseline to month 6	Rigshospitalet, Denmark|TrygFonden, Denmark|University of Copenhagen|Parker Research Institute|The Danish Football Association|Danish Cancer Society	Male	18 Years and older   (Adult, Older Adult)	Not Applicable	214	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care	IDnr. 106471	May 2015	September 2017	February 2018	April 30, 2015		March 13, 2018	Aarhus University Hospital, Aarhus, Aarhus N, Denmark|Rigshospitalet, København, København N, Denmark|Odense Universitets Hospital, Odense, Odense C, Denmark|Sydvestjysk Sygehus, Esbjerg, Esbjerg, Denmark		https://ClinicalTrials.gov/show/NCT02430792
574	NCT01009008	Patient Activated Controlled Expansion (PACE) Trial	PACE	Completed	No Results Available	Breast Cancer|Mastectomy|Breast Reconstruction	Device: Patient Activated Controlled Expansion Device	Expansion to and maintenance of clinically desired breast volume (not exceeding implant maximum) until permanent implant placement or 6 months (whichever comes first) unless prohibited by a non-device related failure.|Safety as evidenced by a low incidence of device-related adverse events.|Time required to achieve desired expansion results.|Overall patient treatment satisfaction.|Overall surgeon treatment satisfaction.	AirXpanders, Inc.	Female	18 Years to 65 Years   (Adult, Older Adult)	Not Applicable	40	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CTP-0001	June 2009	May 2013	June 2013	November 6, 2009		August 10, 2018	The Mount Hospital, Perth, Western Australia, Australia		https://ClinicalTrials.gov/show/NCT01009008
575	NCT01900691	Removal of the Evolution® Esophageal Stent - Fully Covered	CLARITY	Completed	No Results Available	Esophageal Fistula|Esophageal Neoplasms|Esophageal Perforation|Esophageal Stenosis|Stents	Device: Evolution® Esophageal Stent - Fully Covered	Successful removal of study stent|Clinical success	Cook Group Incorporated	All	18 Years and older   (Adult, Older Adult)	Not Applicable	130	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	11-012	September 2013	December 10, 2018	December 10, 2018	July 16, 2013		January 17, 2019	Mayo Clinic, Phoenix, Arizona, United States|Harbor-University of California Los Angeles Medical Center, Torrance, California, United States|Emory University Hospital, Atlanta, Georgia, United States|Loyola University Medical Center, Maywood, Illinois, United States|University of Louisville, Division of Surgical Oncology, Louisville, Kentucky, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Cleveland Clinic, Cleveland, Ohio, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Methodist Dallas Medical Center, Dallas, Texas, United States|University of Virginia Health System, Charlottesville, Virginia, United States|Froedtert Hospital, Milwaukee, Wisconsin, United States		https://ClinicalTrials.gov/show/NCT01900691
576	NCT03740126	Surveillance With PET/CT and Liquid Biopsies of Stage I-III Lung Cancer Patients After Completion of Definitive Therapy	SUPE_R	Recruiting	No Results Available	Carcinoma, Non-Small-Cell Lung	Diagnostic Test: Whole body 18F-FDG PET/CT	Number of relapses treatable with curative intent|Time to verified relapse|Overall survival|Overall survival for patients with relapse|Performance status at relapse|Quality of life / QLQ-C30|Quality of life / QLQ-LC13|Quality of life / Raw score|Number of procedures to assess incidental findings|Types of procedures to assess incidental findings|Adverse events due to invasive procedures done to assess incidental findings|Cost-effectiveness analysis of intervention|Type of treatment after verification of relapse	Rigshospitalet, Denmark|Novo Nordisk A/S|Danish Lung Cancer Group|Danish Comprehensive Cancer Center	All	18 Years and older   (Adult, Older Adult)	Not Applicable	750	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	H-18009536	October 25, 2018	October 2020	October 2023	November 14, 2018		November 14, 2018	Rigshospitalet, Copenhagen, Denmark|Gentofte Hospital, Gentofte, Denmark|Herlev Hospital, Herlev, Denmark		https://ClinicalTrials.gov/show/NCT03740126
577	NCT01838109	Postoperative Oral Nutritional Supplementation After Major Gastrointestinal Surgery		Completed	No Results Available	Gastric Cancer|Colon Cancer|Pancreatic Cancer|Duodenal Cancer|Biliary Cancer|Peptic Ulcer|Inflammatory Bowel Diseases	Dietary Supplement: oral nutritional supplement	Body weight decrease rate 8weeks after discharge compared with preoperative body weight|Changes in body weight before and after surgery|Change of body mass index before and after surgery|changes in PG-SGA score and grade|serum hemoglobin|serum total lymphocyte count|serum total cholesterol|serum total protein|serum albumin	Seoul National University Hospital|JW Pharmaceutical	All	20 Years to 80 Years   (Adult, Older Adult)	Not Applicable	174	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	KSSMN-01	April 2013	April 2014	April 2014	April 23, 2013		May 27, 2015	Seoul National University Hospital, Seoul, Korea, Republic of		https://ClinicalTrials.gov/show/NCT01838109
578	NCT01078415	Pilot Study of Irreversible Electroporation (IRE) to Treat Early-Stage Primary Liver Cancer (HCC)		Completed	No Results Available	Carcinoma, Hepatocellular	Device: Ablation with the NanoKnife Low Energy Direct Current (LEDC) System	Treatment efficacy as measured by modified Response Evaluation Criteria In Solid Tumors (RECIST) criteria by Computed Tomography (CT) or Magnetic Resonance (MR) imaging.|Safety using Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 criteria.	Angiodynamics, Inc.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	26	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ONC-205	February 2010	January 2013	June 2013	March 2, 2010		November 8, 2016	L'institut de cancerologie Gustave Roussy, Villejuif, Ile-de-France, France|Hopital Beaujon, Paris, France|Universitatsklinikum Magdeburg AoR, Klinik fur Radiologie und Nuklearmedizin, Magdeburg, Germany|University of Pisa School of Medicine, Pisa, Tuscany, Italy|Istituto Nazionale Tumori - Fondazione Pascale, Naples, Italy|Barcelona Clinic Liver Cancer Group, Hospital Clinic i Provincial de Barcelona, Barcelona, Spain		https://ClinicalTrials.gov/show/NCT01078415
579	NCT01840436	Efficacy of MUCIPLIQ on the Incidence of Radio-chemotherapy-induced Mucositis in Patients Suffering From Oral Cancer	MUCIPLIQ	Completed	No Results Available	Oral Mucositis|Carcinoma in Situ of Upper Respiratory Tract	Device: MUCIPLIQ|Device: Placebo	Incidence of grade 2 or higher oral mucositis|Number and Terms of grade 2 or higher oral mucositis|Administered-antalgics posology and nature|Pain experienced in time|Assessment of the Oral Health Impact Profile|Weight curve	Organ, Tissue, Regeneration, Repair and Replacement	All	18 Years and older   (Adult, Older Adult)	Not Applicable	136	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	CT11M10MURT	March 2013	January 2015	January 2015	April 25, 2013		May 5, 2016	Centre Hospitalier Intercommunal de Créteil, Créteil, Ile de France, France|APHP - Hôpital Tenon, Paris, Ile de France, France|Institut de Cancérologie Gustave Roussy, Villejuif, Ile de France, France|Centre de Cancérologie Léon Bérard, Lyon, France|CHRU de Besançon, Site du CH Belfort-Montbéliard, Montbéliard, France		https://ClinicalTrials.gov/show/NCT01840436
580	NCT02167659	Bioimpedance Spectroscopy Versus Tape Measure in Prevention of Lymphedema (PREVENT)		Active, not recruiting	No Results Available	Lymphedema	Device: 23-32 mmHg compression sleeve with gauntlet	Rate of progression of lymphedema|Number of participants with risk factors associated with lymphedema.|Time elapsed between identification of increasing fluid and referral out of study for continued swelling.|Number of participants with improved skin condition, symptoms and quality of life.	ImpediMed Limited|Vanderbilt University|Macquarie University, Australia	All	18 Years and older   (Adult, Older Adult)	Not Applicable	1100	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	VICCBRE1438	June 2014	December 2020	December 2020	June 19, 2014		September 13, 2018	Mayo Clinic, Jacksonville, Florida, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|University of Louisville, Louisville, Kentucky, United States|Southeast Health, Cape Girardeau, Missouri, United States|New York Presbyterian - University Hospital of Columbia and Cornell, New York, New York, United States|Allegheny Health Research Institute, Pittsburgh, Pennsylvania, United States|Vanderbilt University, Nashville, Tennessee, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Massey Cancer Center, Richmond, Virginia, United States|Macquarie University, Sydney, New South Wales, Australia		https://ClinicalTrials.gov/show/NCT02167659
581	NCT01060982	Observation of Histological Changes in Parathyroid Adenomas Following High Intensity Focused Ultrasound (HIFU) Treatment Procedure		Completed	No Results Available	Primary Parathyroid Adenomas	Device: Ultrasonic ablation device	Histology of excised gland.	Theraclion	All	18 Years and older   (Adult, Older Adult)	Not Applicable	5	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	HIFU/F/12.02	February 2010	January 2013	January 2013	February 2, 2010		May 6, 2014	Hôpital Privé des Peupliers, Paris, France|Cochin Hospital, Paris, France		https://ClinicalTrials.gov/show/NCT01060982
582	NCT02886572	SIMT Stereotactic Radiosurgery Outcomes Study	SIMT	Recruiting	No Results Available	Brain Metastases, Adult	Radiation: Stereotactic radiosurgery	Proportion of patients who live longer than predicted according to the Graded Prognostic Assessment (GPA) score|Proportion of patients that experience local brain recurrence within 1 year of SIMT SRS treatment.|Proportion of patients who are dead within 1 year of SIMT SRS treatment due to neurologic reasons|Proportion of patients that experience a new brain metastasis at a site different from the original brain metastasis site 1 year after SIMT SRS treatment|Proportion of patients who experience grade 3, 4, or 5 neurologic adverse events attributable to SIMT SRS	Duke University|Varian Medical Systems	All	18 Years and older   (Adult, Older Adult)	Not Applicable	40	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro00075429	May 12, 2017	October 2019	October 2019	September 1, 2016		June 11, 2019	Duke University Medical Center, Durham, North Carolina, United States		https://ClinicalTrials.gov/show/NCT02886572
583	NCT03072472	BowelScope: Accuracy of Detection Using ENdocuff Optimisation of Mucosal Abnormalities	B-ADENOMA	Completed	No Results Available	Colorectal Neoplasms|Colonic Polyp|Adenoma|Neoplasia GI|Digestive System Neoplasms|Intestinal Neoplasms|Neoplasms, Glandular and Epithelial|Digestive Disease|Intestinal Diseases|Colonic Diseases|Rectal Diseases|Intestinal Polyps|Polyps|Pathological Conditions, Anatomical	Device: Endocuff Vision	Adenoma Detection Rate|Mean adenomas detected per procedure|Rate of cuff exchange|Non-inferiority of complete withdrawal time in procedures where no polyps are detected|Compare overall procedure time between groups|Measure differences in ADR accounting for patient procedure based variables (e.g. accounting for extent of examination and bowel preparation).|Compare the rate of discovered cancers between groups|Examination extent between groups based on presumed anatomical location with a straight endoscope|Examination extent between groups based on distance of insertion in centimetres with a straight endoscope|Patient satisfaction between groups using the Gloucester scale of assessment of patient comfort|Identify any difference in future colonoscopic workload produced by increased ADR in terms of number of patients referred for full colonoscopy between the EAFS and SFS groups.|Compare the ADR of the first 20% of patients scoped by each colonoscopist with the last 20% of patients in each arm to identify any changes in ADR to assess any learning curve effect.|Compare the baseline ADR of each colonoscopist prior to trial recruitment with their individual ADR in patients where EndocuffTM Vision was not used.	South Tyneside and Sunderland NHS Foundation Trust|ARC Medical Design Ltd|Norgine	All	55 Years to 61 Years   (Adult)	Not Applicable	3221	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention	B-ADENOMA	February 14, 2017	February 13, 2018	February 13, 2018	March 7, 2017		September 6, 2018	South Tyneside NHS Foundation Trust, South Shields, Tyne And Wear, United Kingdom|Bolton NHS Foundation Trust, Bolton, United Kingdom|Gloucestershire Hospitals NHS Foundation Trust, Cheltenham, United Kingdom|Dorset Healthcare University NHS Trust, Dorchester, United Kingdom|County Durham and Darlington NHS Foundation Trust, Durham, United Kingdom|University Hospitals of Morecambe Bay NHS Foundation Trust, Kendal, United Kingdom|Kettering General Hospital NHS Trust, Kettering, United Kingdom|North West London Hospitals NHS Trust, London, United Kingdom|Northumbria Healthcare NHS Foundation Trust, North Shields, United Kingdom|Oxford Health NHS Trust, Oxford, United Kingdom|Portsmouth Hospitals NHS Trust, Portsmouth, United Kingdom|Pennine Acute Hospitals NHS Trust, Rochdale, United Kingdom|Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom|North Tees and Hartlepool NHS Trust, Stockton on Tees, United Kingdom|West Hertfordshire Hospitals NHS Trust, Watford, United Kingdom|The Royal Wolverhamptom NHS Trust, Wolverhampton, United Kingdom		https://ClinicalTrials.gov/show/NCT03072472
584	NCT00845247	The Effect of Case Management in Complex Cancer Pathways		Completed	No Results Available	Colonic Neoplasms|Rectal Neoplasms	Other: Nurse case management	Patient satisfaction with care pathways(questionnaire)|Quality of Life measures(questionnaire)|Use of health care services during "the secondary care treatment period", i.e. GPs, emergency department, planned and emergency admission, total length of hospitalisation|GPs' evaluations of continuity of care (questionnaire).|Care process measures in terms of monitoring of data from the National Patient Registry	University of Aarhus|Research Unit for General Practice, Aarhus University|The Research Council for Health and Disease, Denmark|Danish Cancer Society|Novo Nordisk A/S|Kvalitets- og efteruddannelsesudvalget for Region Midtjylland	All	Child, Adult, Older Adult	Not Applicable	280	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Health Services Research	477 980 567|Datatilsyn J.nr. 2008-41-2932	March 2009	January 2011	January 2012	February 18, 2009		August 31, 2012	Department P, Aarhus University Hospital, Aarhus C, Denmark		https://ClinicalTrials.gov/show/NCT00845247
585	NCT02620852	Women Informed to Screen Depending on Measures of Risk (Wisdom Study)	WISDOM	Recruiting	No Results Available	Breast Cancer Screening|Breast Carcinoma in Situ|Breast Cancer	Other: Complete a health questionnaire|Genetic: Provide a saliva sample for genetic testing|Other: Screening advice based on a comprehensive risk assessment|Other: Screening advice based on a basic risk assessment	Late-stage cancer|Biopsy rate|Late-stage cancers rate|Interval cancers rate|Rate of systemic therapy|Mammogram recall rate|Breast biopsy rate|DCIS rate|Chemoprevention uptake rate|Choice of risk-based versus annual screening in self-assigned cohort|Adherence to assigned screening schedule|Breast-cancer anxiety|Decisional regret|Ultra-low risk cancer rate	University of California, San Francisco|Patient-Centered Outcomes Research Institute|Robert Wood Johnson Foundation|Color Genomics, Inc.|Salesforce	Female	40 Years to 74 Years   (Adult, Older Adult)	Not Applicable	100000	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening	PCS-1402-10749	August 31, 2016	December 2020	December 2020	December 3, 2015		February 9, 2018	University of California Irvine, Irvine, California, United States|University of California Los Angeles, Los Angeles, California, United States|University of California Davis, Sacramento, California, United States|University of California San Diego, San Diego, California, United States|University of California San Francisco, San Francisco, California, United States|Edith Sanford Breast Center, Sioux Falls, South Dakota, United States		https://ClinicalTrials.gov/show/NCT02620852
586	NCT01168323	Spaced Education to Optimize Prostate Cancer Screening		Completed	No Results Available	Prostate Cancer	Behavioral: Online spaced education	Percentage of inappropriate prostate-specific antigen (PSA) screening performed by clinicians|Change in test scores between cohorts measured in weeks 1-36|Change in spaced education performance measured in weeks 1-36|Clinicians' intention to participate in future spaced education programs|Time required by clinicians to complete the spaced education questions-explanations	Harvard University Faculty of Medicine|US Department of Veterans Affairs|Agency for Healthcare Research and Quality (AHRQ)|American Urological Association|Astellas Pharma US, Inc.|National Institutes of Health (NIH)|Wyeth is now a wholly owned subsidiary of Pfizer	All	18 Years and older   (Adult, Older Adult)	Not Applicable	95	Other|U.S. Fed|Industry|NIH	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research	M15310|IRB# 1786|5K08HS017147	January 2007	February 2009	February 2009	July 23, 2010		August 9, 2010	Veterans Affairs Boston Healthcare System, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT01168323
587	NCT02977663	Imaging Multiparametric/Multimodality for Lungcancer	IRMomics	Recruiting	No Results Available	Lungcancer	Other: Magnetic Resonance Imaging (MRI)	Event-free survival of patients with lungcancer|Overall survival|Number of patients by histologic subtypes|Number of patients by mutational profile|Number of patients with metastases|Number of patients with brain metastases|Number of metastases by patient|Therapeutic responses assessed by scanner/MRI and/or Positron Emission Tomography (PET) based on consensus criteria (RECIST 1.1 and PET Response Criteria in Solid Tumors (PERCIST))	Assistance Publique - Hôpitaux de Paris|General Electric	All	18 Years and older   (Adult, Older Adult)	Not Applicable	200	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	K160701|ANSM	August 28, 2017	August 2022	August 2023	November 30, 2016		December 8, 2017	BRILLET, Bobigny, France		https://ClinicalTrials.gov/show/NCT02977663
588	NCT01015625	Primary Operation in SYnchronous meTastasized InVasivE Breast Cancer	POSYTIVE	Active, not recruiting	No Results Available	Synchronous Metastasized Breast Cancer|Circulating Tumor Cells	Procedure: Surgery|Procedure: Surgery on Demand	to evaluate the median survival of patients with synchronous metastasized breast cancer and the primary tumor in place comparing arm A with local therapy to the primary tumor versus arm B without local therapy|time to distant progression (TTPd)|time to local progression (TTPl)	Austrian Breast & Colorectal Cancer Study Group|Bayer|Amgen|Hoffmann-La Roche|AstraZeneca|Sanofi Aventis GmbH, Austria|Wyeth Lederle Pharma GmbH, Austria|GlaxoSmithKline|Merck Sharp & Dohme GmbH, Austria|Fond of the Viennese Mayor	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	254	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	ABCSG 28 / POSYTIVE|ABCSG 28	October 2010	June 2021	June 2021	November 18, 2009		December 18, 2018	Hospital Guessing, Guessing, Burgenland, Austria|Hospital Oberpullendorf, Oberpullendorf, Burgenland, Austria|Ordination Dr. Wette, St. Veit a. d. Glan, Carinthia, Austria|Gynaegological Medical University Graz, Graz, Styria, Austria|Medical University Graz, Oncology, Graz, Styria, Austria|Medical University of Innsbruck, Innsbruck, Tyrol, Austria|Hospital BHS Linz, Coop. Study Group, Linz, Upper Austria, Austria|Hospital Elisabethinen Linz, Linz, Upper Austria, Austria|General Hospital Linz, Linz, Upper Austria, Austria|Klinikum Wels-Grieskirchen GmbH, Wels, Upper Austria, Austria|State Hospital Feldkirch, Feldkirch, Vorarlberg, Austria|Paracelsus Medical University Salzburg-Oncology, Coop. Group, Salzburg, Austria|Medical University of Vienna-General Hospital Vienna, Vienna, Austria|Medical University of Vienna, Vienna, Austria		https://ClinicalTrials.gov/show/NCT01015625
589	NCT00709891	Evaluation of the Cobas® 4800 HPV Test for the Detection of High-grade Cervical Disease		Completed	Has Results	Human Papilloma Virus (HPV)	Device: cobas® 4800 HPV Test	Percentage of Participants With a Diagnosis of ≥ CIN2|Percentage of Participants With a Diagnosis of ≥ CIN3	Hoffmann-La Roche	Female	21 Years and older   (Adult, Older Adult)	Not Applicable	47208	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic	RD000649|MWP-HPV-159	May 2008	June 2013	June 2013	July 3, 2008	February 9, 2015	February 9, 2015	Enterprise, Alabama, United States|Hoover, Alabama, United States|Mobile, Alabama, United States|Phoenix, Arizona, United States|Phoenix, Arizona, United States|Tucson, Arizona, United States|Tucson, Arizona, United States|Beverly Hills, California, United States|Carmichael, California, United States|Costa Mesa, California, United States|Fountain Valley, California, United States|San Diego, California, United States|Colorado Springs, Colorado, United States|Lakewood, Colorado, United States|Boynton Beach, Florida, United States|Ft. Lauderdale, Florida, United States|Jacksonville, Florida, United States|Jacksonville, Florida, United States|Jupiter, Florida, United States|Lake Worth, Florida, United States|Miami, Florida, United States|North Miami, Florida, United States|Sarasota, Florida, United States|Tampa, Florida, United States|West Palm Beach, Florida, United States|West Palm Beach, Florida, United States|Atlanta, Georgia, United States|Decatur, Georgia, United States|Roswell, Georgia, United States|Boise, Idaho, United States|Champaign, Illinois, United States|Indianapolis, Indiana, United States|Newburgh, Indiana, United States|Louisville, Kentucky, United States|Paducah, Kentucky, United States|Covington, Louisiana, United States|Ruston, Louisiana, United States|Saginaw, Michigan, United States|Las Vegas, Nevada, United States|Lawrenceville, New Jersey, United States|Moorestown, New Jersey, United States|Albuquerque, New Mexico, United States|New Bern, North Carolina, United States|Winston-Salem, North Carolina, United States|Englewood, Ohio, United States|Lansdale, Pennsylvania, United States|West Reading, Pennsylvania, United States|Columbia, South Carolina, United States|Hilton Head, South Carolina, United States|North Charleston, South Carolina, United States|Chattanooga, Tennessee, United States|Johnson City, Tennessee, United States|Nashville, Tennessee, United States|Corpus Christi, Texas, United States|Dallas, Texas, United States|Houston, Texas, United States|McAllen, Texas, United States|Temple, Texas, United States|Salt Lake City, Utah, United States|Virginia Beach, Virginia, United States|Tacoma, Washington, United States		https://ClinicalTrials.gov/show/NCT00709891
590	NCT03988556	Feasibility and Safety of CareMin650 in Patients at Risk of or Suffering From Oral Mucositis and/or Radiation Dermatitis	SafePBM	Not yet recruiting	No Results Available	Oral Mucositis Due to Radiation|Radiation Dermatitis	Device: Photobiomodulation using CareMin650 at 6 Joules (curative intent)|Device: Photobiomodulation using CareMin650 at 3 Joules (prophylactic intent)	Occurence of adverse events|Rate of discontinuation due to AEs|Skin lesions assessment - time of lesion occurrence|Skin lesions assessment - size of lesions|Skin lesions assessment - location|Skin lesions assessment - Grade|Skin lesions assessment - Time until resolution|Oral mucosa lesions assessment - time of lesion occurrence|Oral mucosa lesions assessment - size of lesions|Oral mucosa lesions assessment - location|Oral mucosa lesions assessment - Grade|Oral mucosa lesions assessment - Time until resolution	NeoMedLight|Qualissima	All	18 Years and older   (Adult, Older Adult)	Not Applicable	72	Industry|Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other	ID-RCB: 2018-A03356-49	June 2019	March 2020	March 2020	June 17, 2019		June 17, 2019	Institut de Cancérologie de l'ouest - Paul Papin, Angers, France|Centre Oscar Lambret, Lille, France|Centre de Haute Energie, Nice, France|Institut Curie, Paris, France|Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France		https://ClinicalTrials.gov/show/NCT03988556
591	NCT01544686	Antimicrobial Catheter Securement Dressings for the Prevention of Cvc-related Bloodstream Infections in Cancer Patients	COAT	Completed	No Results Available	Bloodstream Infection	Device: 3M™ Tegaderm™ CHG IV and 3M™ Tegaderm™ Advanced IV	Incidence of definite catheter-related bloodstream infection during the first 14 days after placement of the central venous catheter|Incidence of definite catheter related bloodstream infection-related severe sepsis during the first 14 days after placement of the central venous catheter|Definite catheter-related bloodstream infection-related mortality during the first 14 days after placement of the central venous catheter|Overall incidence of catheter-related bloodstream infection|Overall catheter-related bloodstream infection-related severe sepsis|Overall catheter-related bloodstream infection-related mortality|Overall mortality|Time to removal of central venous catheter|Time to central venous catheter-related blood stream infections|Time to first neutropenic fever|Rate of unplanned changes|Tolerability/safety	University of Cologne|3M	All	18 Years and older   (Adult, Older Adult)	Not Applicable	630	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	DRKS00003368	February 2012	October 2015	October 2015	March 6, 2012		December 9, 2015	Klinikum Schwabing, Munich, Bavaria, Germany|Klinikum Neuperlach, Munich, Bavaria, Germany|Universitätsklinikum Aachen, Aachen, NRW, Germany|University Hospital Cologne, Cologne, NRW, Germany|Universitätsmedizin Berlin - Charité, Berlin, Germany		https://ClinicalTrials.gov/show/NCT01544686
592	NCT01871519	Evaluation of Outcomes for Quality of Life and Activities of Daily Living for BKP in the Treatment of VCFs	EVOLVE	Completed	Has Results	Compression Fracture of Vertebral Body|Osteoporosis|Cancer	Device: Balloon kyphoplasty	Back Pain Change From Baseline at 3 Months|Back Function Change From Baseline by Oswestry Disability Index at 3 Months|SF-36v2 Physical Component Summary Change From Baseline at 3 Months|Change From Baseline in Quality of Life by the EQ-5D Index at 3 Months|Back Pain|Back Function (ODI)|Quality of Life by SF-36v2 PCS|Quality of Life by EQ-5D Index Score|Percentage of Subjects Having Daily Living Activities Limited Due to Back Pain in the Previous 2 Weeks|The Number of Days With Limited Activities and Bed Rest Due to Back Pain in the Previous 2 Weeks;|Ambulatory Status|Barthel Index (Only for Subjects With Osteoporosis)|Karnofsky Performance Scale|Vertebral Body Height Restoration (Absolute Height Restored as Percent, AHRP)|Vertebral Body Angle|Local Cobb Angle|Subsequent Radiographic Fractures|Neurological Success Rate	Medtronic Spinal and Biologics	All	65 Years and older   (Older Adult)	Not Applicable	354	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	P12-03	May 2013	December 2015	May 2016	June 6, 2013	February 7, 2017	March 29, 2017	Alabama Clinical Therapeutics, LLC, Birmingham, Alabama, United States|University of Alabama at Birmingham, Division of Neurological Surgery, Birmingham, Alabama, United States|Washington Radiologist Medical Group, Fremont, California, United States|Sutter Health Sacramento Sierra Region, Sacramento, California, United States|Alta Orthopaedic Medical Group, Santa Barbara, California, United States|Torrance Memorial Medical Center, Torrance, California, United States|Radiology Imaging Specialist of Lakeland, Lakeland, Florida, United States|The Back Center, Melbourne, Florida, United States|Physicians & Surgeons of Pocatello, Blackfoot, Idaho, United States|St. Luke's Health System, Boise, Idaho, United States|Central Illinois Neuroscience Foundation, Bloomington, Illinois, United States|Adventist Health Partners, Hinsdale, Illinois, United States|Presence Saint Joseph Medical Center, Joliet, Illinois, United States|Illinois Bone & Joint, Morton Grove, Illinois, United States|Indiana Spine Group, Carmel, Indiana, United States|Advanced Diagnostic Imaging, PC, Saginaw, Michigan, United States|Beaumont Health System, Troy, Michigan, United States|Premier Radiology, Tupelo, Mississippi, United States|Sierra Regional Spine Institute, Reno, Nevada, United States|Consulting Orthopaedic Associates, Inc, Sylvania, Ohio, United States|Clinical Investigations, LLC, Edmond, Oklahoma, United States|James R. Webb, P.C., Tulsa, Oklahoma, United States|NeuroSpine Institute, LLC, Eugene, Oregon, United States|Scoliosis & Spine Surgery Clinic of Memphis, PLLC, Memphis, Tennessee, United States|The West Clinic, Memphis, Tennessee, United States		https://ClinicalTrials.gov/show/NCT01871519
593	NCT03741088	Study to Evaluate VORTX Rx (Theresa)	Theresa	Recruiting	No Results Available	Carcinoma, Hepatocellular|Liver Metastases	Device: VORTX Rx treatment	Acute technical performance of the VORTX Rx® medical device for the ablation of primary and metastatic liver tumors|Safety profile of the VORTX Rx. Incidence of Adverse events (serious and non-serious) that are probably or definitely device-related|Local tumor progression|Involution of the ablation zone|Assessment of liver panel.|Immunologic assessment.|Assesment of quality of life by using patient questtionaires EORTC QLQ-C30. (European Organization for Research and Treatment of Cancer)|Pain assessment by VAS scale and analgesic requirements after the ablation procedure.	HistoSonics, Inc.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	10	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility	03.CP.0.3	March 21, 2018	July 21, 2019	September 21, 2019	November 14, 2018		March 14, 2019	Clinica Diagonal, Esplugues De Llobregat, Barcelona, Spain|Hospital universitario Mutua Terrassa, Terrassa, Barcelona, Spain|Hospital Universitario Vall d´Hebrón, Barcelona, Spain		https://ClinicalTrials.gov/show/NCT03741088
594	NCT02465892	Pillars4Life Trial	Pillars4Life	Completed	No Results Available	Breast Cancer|Lung Cancer|Esophageal Cancer|Colon Cancer|Pancreatic Cancer|Liver Cancer|Renal Cancer|Bladder Cancer|Prostate Cancer|Ovarian Cancer|Cervical Cancer|Uterine Cancer	Behavioral: Pillars4Life	Chronic pain|Stress|Anxiety	Duke University|Pfizer	All	18 Years and older   (Adult, Older Adult)	Not Applicable	284	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Supportive Care	Pro00061381	May 2015	October 2016	October 2016	June 9, 2015		July 2, 2017	Duke University Medical Center, Durham, North Carolina, United States		https://ClinicalTrials.gov/show/NCT02465892
595	NCT02464904	Intrapleural Cryotherapy for Malignant Pleural Mesothelioma		Recruiting	No Results Available	Mesothelioma	Device: Cryotherapy|Other: Control	Number of Participants with Adverse Events|Mean Number of Tumor Infiltrating Immune Cells as Measured by Immunohistochemistry on Participant Tissue Samples	Mayo Clinic|CSA Medical, Inc.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	15	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	14-008715	July 2015	December 2020	December 2020	June 8, 2015		January 9, 2019	Mayo Clinic in Rochester, Rochester, Minnesota, United States		https://ClinicalTrials.gov/show/NCT02464904
596	NCT00146588	Cytoxan, Epirubicin and Capecitabine in Women With Breast Cancer		Completed	No Results Available	Breast Cancer|Stage I Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer	Drug: Cyclophosphamide|Drug: Epirubicin|Drug: Capecitabine	To determine the feasibility of administering cytoxan, epirubicin, and capecitabine to women with Stage I/II/IIIA breast cancer.	Craig A. Bunnell, MD, MPH|Dana-Farber Cancer Institute|Massachusetts General Hospital|Brigham and Women's Hospital|Beth Israel Deaconess Medical Center|Pharmacia	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	55	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	02-036	April 2002	December 2004	December 2004	September 7, 2005		March 24, 2015	Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Center, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT00146588
597	NCT03229876	Safety and Efficacy Evaluation of CD19-UCART		Recruiting	No Results Available	Acute Lymphoblastic Leukemia (ALL)|Non Hodgkin Lymphoma (NHL)	Biological: CD19-UCART	Dose Limiting Toxicities (DLTs) occurence|Objective Response Rate|Persistence of CART cells	Shanghai Bioray Laboratory Inc.|The First Affiliated Hospital of Zhengzhou University|Second Xiangya Hospital of Central South University|Shanghai 10th People's Hospital	All	6 Years to 65 Years   (Child, Adult, Older Adult)	Not Applicable	20	Industry|Other	Interventional	Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2018CAR-00CH1	June 1, 2019	August 15, 2020	December 30, 2021	July 26, 2017		July 15, 2019	First Affliated Hospital of Zhengzhou University, Zhengzhou, Henan, China|Second Xiangya Hospital of Central South University, Changsha, Hunan, China		https://ClinicalTrials.gov/show/NCT03229876
598	NCT01074177	Understanding Mechanisms of Acquired Resistance to BIBW2992		Completed	Has Results	Non-small Cell Lung Cancer|EGFR Mutations	Drug: BIBW 2992	Number of Participants That Have a T790M Mutation on Their Progression Biopsy.|Response Rate|Median Progression-free and Overall Survival|Number of Participants With Biopsy Complications From Repeat Tumor Biopsies	Massachusetts General Hospital|University of Texas|Boehringer Ingelheim	All	18 Years and older   (Adult, Older Adult)	Not Applicable	24	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	10-092	February 2011	March 2017	March 2017	February 24, 2010	March 9, 2018	March 9, 2018	Massachusetts General Hospital, Boston, Massachusetts, United States	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/77/NCT01074177/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT01074177
599	NCT03601611	Checkpoint Inhibitor Induced Colitis and Arthritis -Immunomodulation With IL-6 Blockade and Exploration of Disease Mechanisms	COLAR	Recruiting	No Results Available	Solid Tumor|Colitis|Arthritis	Drug: Tocilizumab (RoACTEMRA®)	Rate of at least one grade improvement using the NCI CTCAE v5.0|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Rate of at least one grade improvement without prednisolone using the NCI CTCAE v5.0|Rate of sustained glucocorticoid-free remission	Herlev Hospital|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Not Applicable	20	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	AA 1820	January 1, 2019	January 1, 2020	June 1, 2020	July 26, 2018		February 15, 2019	Herlev & Gentofte University Hospital, Denmark, Herlev, Denmark		https://ClinicalTrials.gov/show/NCT03601611
600	NCT01483040	PeerScope B System™ Clinical Protocol		Completed	No Results Available	Colon Cancer|Colon Diseases|Colon Polyps|Colon Adenomas	Device: colonoscopy system (PeerScope B System™)	The primary endpoint is reaching the cecum of the colon with PeerScope B S	PeerMedical Ltd.	All	18 Years to 70 Years   (Adult, Older Adult)	Not Applicable	50	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening	CD-1130	September 2011	November 2011	November 2011	December 1, 2011		November 8, 2012	Elisha Medical Center, Haifa, Israel		https://ClinicalTrials.gov/show/NCT01483040
601	NCT02694562	Microparticle Enhanced Cytotoxic Transarterial Embolization Therapy	MIRACLEIII	Completed	Has Results	Colorectal Carcinoma	Device: 40um Embozene TANDEM Microspheres	Freedom From Serious Adverse Events Rate|Local Tumor Control|Survival Rate|Time To Tumor Progression	Boston Scientific Corporation	All	19 Years and older   (Adult, Older Adult)	Not Applicable	18	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MIRACLE III	November 2013	December 2016	December 2016	February 29, 2016	February 15, 2019	February 15, 2019	European Institute of Oncology, Milan, Italy		https://ClinicalTrials.gov/show/NCT02694562
602	NCT03711916	Post-Operative Outcomes of Low Thermal Dissection vs. Traditional Electrosurgery		Completed	No Results Available	Breast Cancer|Mastectomy|Perfusion; Complications|Hemostasis	Device: PlasmaBlade 3.0S	Perfusion|Drainage|Pain Scores	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Medtronic	Female	18 Years to 75 Years   (Adult, Older Adult)	Not Applicable	20	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Investigator)|Primary Purpose: Device Feasibility	J1697|IRB00108493	March 17, 2017	October 24, 2018	December 3, 2018	October 19, 2018		June 18, 2019	Bayview Medical Center, Baltimore, Maryland, United States|Johns Hopkins Hospital Outpatient Center, Baltimore, Maryland, United States		https://ClinicalTrials.gov/show/NCT03711916
603	NCT03949777	Validation of Aer-O-Scope Colonoscope System Cecal Intubation		Not yet recruiting	No Results Available	Colonic Polyp|Colonic Neoplasms|Colonic Diseases|Colon Adenoma|Colon Disease|Colon Adenocarcinoma|Colon Cancer	Device: Aer-O-Scope Colonoscopy	Aer-O-Scope Validation of Cecal Intubation	GI View Ltd.	All	45 Years to 75 Years   (Adult, Older Adult)	Not Applicable	61	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	1056CLD	September 2019	December 2019	December 2019	May 14, 2019		May 16, 2019			https://ClinicalTrials.gov/show/NCT03949777
604	NCT03807089	Adenoma Detection Rate With a New Pediatric Colonoscope With a Short Turn Radius (Pentax Retroview) Compared With a Standard Pentax Pediatric Colonoscope		Completed	Has Results	Colonoscopy	Device: Conventional Pediatric Colonoscope|Device: Short-Turn Radius Colonoscope	Percentage of Patients With At Least One Adenoma|Overall Polyp Detection Rate|Mean Number of Adenomas Identified Per Patient With Polyps	Massachusetts General Hospital|Pentax Medical	All	40 Years and older   (Adult, Older Adult)	Not Applicable	283	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	2014P000677	July 1, 2014	May 11, 2017	May 11, 2017	January 16, 2019	July 16, 2019	July 16, 2019		"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/89/NCT03807089/Prot_SAP_001.pdf	https://ClinicalTrials.gov/show/NCT03807089
605	NCT03634696	m-Palliative Care Link: Improving Palliative Care for Late Stage Tanzanian Cancer Patients		Recruiting	No Results Available	Cancer	Other: mPCL|Other: Usual Care	Pain control|Application utility	Susan Miesfeldt|Maine Medical Center|National Institutes of Health (NIH)|Dimagi Inc.|Muhimbili University of Health and Allied Sciences|John E. Fogarty International Center (FIC)	All	21 Years and older   (Adult, Older Adult)	Not Applicable	90	Other|NIH|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research	1040841|R21TW010190	June 15, 2018	October 2019	January 1, 2020	August 16, 2018		March 27, 2019	Ocean Road Cancer Institute, Dar Es Salaam, Tanzania		https://ClinicalTrials.gov/show/NCT03634696
606	NCT03323359	Efficacy and Tolerability of Hemopatch After Hepatic Resection		Recruiting	No Results Available	Hepatectomy|Cancer, Metastatic|Hemostasis	Device: Hemopatch|Procedure: Common Surgical Techniques	Evaluated comparing the achievement of hemostasis within 3 minutes from the application of the patch|reduction of the post-operative complications|shorten the use of drainage tube after hepatic resection and the volume of the drainage|the bile leaks|any adverse event including, but not limited to, the length of hospital stay, rate of post-operative mortality|Intraoperative details	Fondazione Policlinico Universitario Agostino Gemelli IRCCS|Baxter Healthcare Corporation	All	18 Years to 75 Years   (Adult, Older Adult)	Not Applicable	98	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	PAC-HEM-16-001	March 17, 2017	November 17, 2018	March 17, 2019	October 27, 2017		November 8, 2017	Policlinico Universitario Agostino Gemelli, Rome, Italy	"Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/59/NCT03323359/Prot_000.pdf	https://ClinicalTrials.gov/show/NCT03323359
607	NCT01534897	Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436		Completed	Has Results	Papillary Thyroid Carcinoma	Drug: GSK2118436	Increased Radioiodine Uptake|Safety Analysis as Number of Participants With Adverse Events|Clinical Benefit as Measured by Change in Tumor Size|Number of Participants Who Complete the Study With Minimal Delays and no Dose Reductions|Clinical Benefit as Measured by Change in Thyroglobulin Level	Massachusetts General Hospital|GlaxoSmithKline	All	18 Years and older   (Adult, Older Adult)	Not Applicable	10	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	11-337	July 2012	March 2014	March 2014	February 17, 2012	March 15, 2017	March 15, 2017	Massachusetts General Hospital, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT01534897
608	NCT03752541	Efficacy and Safety Evaluation of BCMA-UCART		Recruiting	No Results Available	Multiple Myeloma	Biological: BCMA-UCART	Objective response rate (ORR)|Incidence and Severity of Adverse Events as a Measure of Safety and Tolerability|Duration of persistence of BCMA-UCART	Shanghai Bioray Laboratory Inc.|Second Xiangya Hospital of Central South University	All	18 Years to 65 Years   (Adult, Older Adult)	Not Applicable	20	Industry|Other	Interventional	Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2018-CAR-00CH3	November 20, 2018	November 20, 2019	November 20, 2020	November 26, 2018		November 27, 2018	Second Xiangya Hospital of Central South University, Changsha, Hunan, China		https://ClinicalTrials.gov/show/NCT03752541
609	NCT03492268	Safety and Efficacy Evaluation of BCMA-CART for Treating Multiple Myeloma		Recruiting	No Results Available	Multiple Myeloma	Biological: BCMA-CART	Objective response rate (ORR)|Incidence and Severity of Adverse Events as a Measure of Safety|Duration of persistence of BCMA-CART	Shanghai Bioray Laboratory Inc.|Shanghai 10th People's Hospital|Second Xiangya Hospital of Central South University	All	18 Years to 65 Years   (Adult, Older Adult)	Not Applicable	20	Industry|Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2018-CART-00CH3(1)	November 20, 2018	November 20, 2019	December 1, 2020	April 10, 2018		November 27, 2018	Shanghai Bioray Laboratories INC., Shanghai, Shanghai, China		https://ClinicalTrials.gov/show/NCT03492268
610	NCT03046329	Improving the Quality of Multiple Myeloma Treatment With Patient Care Plans		Completed	No Results Available	Multiple Myeloma	Behavioral: Carevive CPS	Level of provider adherence to evidence-based practices for symptom assessment/management according to chart abstractions|Degree of changes in symptom care behaviors following engagement with the supportive care intervention according to chart abstractions|Time spent delivering care plans at both baseline and follow-up using self-report by clinicians|Level of patient satisfaction and utilization of care plans using the SUS survey	Carevive Systems, Inc.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	90	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	G401	June 1, 2015	January 31, 2017	January 31, 2017	February 8, 2017		February 9, 2017			https://ClinicalTrials.gov/show/NCT03046329
611	NCT02623101	Reflectance Confocal Microscopy in Basal Cell Carcinoma		Recruiting	No Results Available	Carcinoma, Basal Cell	Device: Reflectance confocal microscopy|Procedure: Punch biopsy|Procedure: Surgical excision	The number of correctly identified basal cell carcinoma and the subtype by Reflectance confocal microscopy validated by histopathological examination of the excision specimen|Quality of life (Qol)|Cost effectiveness of Reflectance confocal microscopy as diagnostic tool to diagnose basal cell carcinoma|Quality Adjusted Live Years (QALY's)	Radboud University|ZonMw: The Netherlands Organisation for Health Research and Development|Mavig GmbH	All	18 Years and older   (Adult, Older Adult)	Not Applicable	329	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	RCM-onco ZonMw-1	January 2016	December 2018		December 7, 2015		April 23, 2018	Canisius Wilhelmina Hospital, Nijmegen, Netherlands|Radboud University Medical Center, Nijmegen, Netherlands|Rijnstate Hospital, Velp, Netherlands		https://ClinicalTrials.gov/show/NCT02623101
612	NCT02911571	PRospective Multiple Myeloma Impact Study	PROMMIS	Recruiting	No Results Available	Multiple Myeloma	Device: MMprofiler SKY92 gene signature	Change in treatment intention|3 year Progression Free Survival|3 year Overall Survival|5 year Progression Free Survival|5 year Overall Survival	SkylineDx|Medex15	All	18 Years and older   (Adult, Older Adult)	Not Applicable	250	Industry|Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	PROMMIS	February 27, 2018	June 15, 2020	December 1, 2024	September 22, 2016		June 27, 2019	Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States|Winship Cancer Institute, Emory University, Atlanta, Georgia, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Columbia University Medical Center, New York, New York, United States|Weill Cornell Medicine, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Wake Forest Baptist Medical Center,, Winston-Salem, North Carolina, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States		https://ClinicalTrials.gov/show/NCT02911571
613	NCT03647189	Randomized, Controlled Trial With Hybrid Fractional Laser		Recruiting	No Results Available	Vaginal Atrophy, Sexual Dysfunction, Vaginal Dryness, Dyspareunia	Device: Hybrid Fractional Laser	Change from baseline in Vaginal health index score (VHIS)|Change from baseline in Female sexual function index questionnaire (FSFI)|Change from baseline in day-to-day impact of vaginal aging questionnaire|Change from baseline in histology|Change from baseline in photography	Sciton	Female	40 Years to 70 Years   (Adult, Older Adult)	Not Applicable	25	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	DIVA-001	August 10, 2018	October 30, 2019	December 30, 2019	August 27, 2018		April 4, 2019	Miamim Dermatology, Miami, Florida, United States		https://ClinicalTrials.gov/show/NCT03647189
614	NCT01292486	Evaluation of the Spectra Optia® Mononuclear Cell Collection Procedure		Completed	Has Results	Multiple Myeloma	Device: Spectra Optia Apheresis System	Days Until Neutrophil Recovery Following Peripheral Blood Stem Cell Transplant Minus the Historical Median Day Until Recovery.|Days Until Platelet Recovery|CD34+ Cell Collection Efficiency.|Mononuclear Cel (MNC) Collection Efficiency|Platelet Collection Efficiency|Hematocrit of MNC Product|Granulocyte % of MNC Product	Terumo BCT	All	18 Years and older   (Adult, Older Adult)	Not Applicable	32	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	BCT10-02	February 2011	November 2011	December 2011	February 9, 2011	May 1, 2013	May 1, 2013	Emory University, Atlanta, Georgia, United States|Indiana University, Indianapolis, Indiana, United States|Duke University Medical Center, Durham, North Carolina, United States|University of Utah, Salt Lake City, Utah, United States		https://ClinicalTrials.gov/show/NCT01292486
615	NCT03105765	Acute and Chronic Pain, Especially Neuropathic Pain, After Thoracotomy and Continuous Application of Ketamine.		Completed	No Results Available	Acute Pain|Chronic Pain|Neuropathic Pain	Drug: Placebo|Drug: Ketamine	Change in perioperative opioid consumption|Change in acute pain|acute neuropathic pain|Change in chronic Pain|Chronic Neuropathic pain|Chronic Neuropathic Pain|recovery time	Dr. Horst Schmidt Klinik GmbH	All	18 Years and older   (Adult, Older Adult)	Not Applicable	200	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	HSK007	January 2011	August 2014	August 2016	April 10, 2017		April 10, 2017	Dr. Horst Schmidt Klinik, Wiesbaden, Hessen, Germany		https://ClinicalTrials.gov/show/NCT03105765
616	NCT03998722	Evaluation of VagiVital® for Treatment of Vaginal Atrophy		Not yet recruiting	No Results Available	Vaginal Atrophy	Device: Vagivital	Change in severity of VA symptom|Change in Vaginal pH|Change in severity of VA Symptom|Change in total score in the Women's Health Questionnaire|Number of AEs and assessment of intensity, causality and seriousness of Advers Events|Change in Blod pressure|Change in Heart rate|Change in degree of vaginal atrophy|Urine infections	PepTonic Medical AB	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	44	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Vagipep101	June 2019	June 2020	June 2020	June 26, 2019		June 26, 2019	Karolinska University Hospital, Stockholm, Sweden		https://ClinicalTrials.gov/show/NCT03998722
617	NCT03567798	Thrombocytopenia Induced by Chemotherapy	papayaleaf	Completed	No Results Available	Thrombocytopenia	Dietary Supplement: UPLAT|Other: Placebo	Increase in the platelet counts from baseline levels to the end of therapy.	Socrates School Of Health	All	18 Years to 55 Years   (Adult)	Not Applicable	60	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	SPL/UP/2017/01	July 18, 2017	November 20, 2017	November 20, 2017	June 25, 2018		June 27, 2018	North East Cancer Centre Hospital and research Institute, Guwahati, Assam, India		https://ClinicalTrials.gov/show/NCT03567798
618	NCT03255980	Monocenter, Open Label Clinical Investigation on the Treatment of Radiation Induced Dermatitis With Xonrid®		Completed	No Results Available	Radiodermatitis|Quality of Life	Device: Xonrid® gel|Other: Standard of Care	Proportion of patients without grade G2 skin toxicity Radiodermatitis at week 5|Median time to G2 Radiodermatitis development|Proportion of patients without G2 Radiodermatitis at week 6|Worst skin toxicity during treatment and until 2 weeks after the last radiation|Mean and worst score of Patient Reported Outcome (PRO)|Compliance to experimental treatment use|Patient's treatment global satisfaction|Treatment safety and tolerability	Helsinn Healthcare SA	All	18 Years and older   (Adult, Older Adult)	Not Applicable	80	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other	HD01-16-30	June 15, 2017	February 20, 2019	June 15, 2019	August 21, 2017		June 28, 2019	Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy		https://ClinicalTrials.gov/show/NCT03255980
619	NCT02515032	Pilot Study of Safety and Tolerability of Nutrifriend Cachexia in NSCLC Cachexia		Completed	No Results Available	Cachexia|NSCLC	Dietary Supplement: Nutrifriend Cachexia|Dietary Supplement: Isocaloric placebo	Safety and tolerability assessed by (adverse events, concomitant medication and laboratory markers) of Nutrifriend Cachexia in patients with NSCLC|Body composition assessed by fat mass and lean body mass (LBM)|Body composition assessed by weight|Body composition assessed by BMI|Body composition assessed by waist circumference|Body composition assessed by calf circumference|Function assessed by 6 minute walking test|Function assessed by grip strength|Function assessed by walking distance|Inflammation|Metabolic markers|QoL assessed by EORTC QLQ-C3|QoL assessed by Functional Assessment of Anorexia/Cachexia Therapy (FAACT) questionnaire|QoL assessed by Nutrition Appetite Questionnaire (CNAQ)|Compliance assessed by Drinks consumed|Compliance assessed by vitamin D levels|Compliance assessed by Omega-3 incorporation	Smartfish AS	All	Child, Adult, Older Adult	Not Applicable	56	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	SF-C002	July 2015	May 2017	May 2017	August 4, 2015		July 17, 2017	GH Varaždin, Varaždin, Croatia|GH Zadar, Zadar, Croatia|CHC Sestre Milosrdnice, Zagreb, Croatia|CHC Zagreb,, Zagreb, Croatia|Policlinico Universitario Campus Bio-Medico di Roma, Rome, Italy|Policlinico Tor Vergata, Rome, Italy|Azienda Ospedaliera San Camillo Forlanini, Rome, Italy|FNsP F.D. Roosvelta Banská Bystrica, Banská Bystrica, Slovakia|Nemocnica Sv. Jakuba, Bardejov, Slovakia|Východoslovenský onkologický ústav, Košice, Slovakia|NsP Štefana Kukuru Michalovce, Michalovce, Slovakia|FNsP J.A. Reimana, Prešov, Slovakia|Linkoping University Hospital, Linkoping, Sweden|Akademiska hospital, Uppsala, Sweden		https://ClinicalTrials.gov/show/NCT02515032
620	NCT03377517	Radiosurgical Hypophysectomy for Bone Metasteses Pain		Recruiting	No Results Available	Bone Metastases	Radiation: radiosurgical hypophysectomy	Change in Intensity of Bone Pain|Rate of change of disease spread|Rate of Change of Quality of Life|Rate of change in opioid use|Rate of biochemical endocrinopathy|Rate of change of optic nueropathy|Rate of change of neurologic toxicity|Rate of change of insipidus diabetes|Rate of change in costs|Rate of change of cortisol|Rate of change of pain with respect to hormones|Rate of change of pain with respect to morphine	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Accuray Incorporated	All	18 Years to 100 Years   (Adult, Older Adult)	Not Applicable	16	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	J17181|IRB00158648	May 8, 2018	May 1, 2023	March 1, 2025	December 19, 2017		November 7, 2018	The Sidney Kimmel Comprehsensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States		https://ClinicalTrials.gov/show/NCT03377517
621	NCT02252185	A Clinical Study of a Spine Fusion System in Vertebral Body Fusion Surgery		Completed	No Results Available	Disc Degenerative Disease|Spondylolisthesis|Spinal Fracture|Spinal Deformity|Spinal Stenosis|Spinal Tumor	Device: Johnson&Johnson Medical Suzhou made Spine Fusion System|Device: Imported EXPEDIUM screws and OPAL cage	Change of Japanese Orthopaedic Association score|Improvement rate of Japanese Orthopaedic Association score|Fixation stability|Visual Analogue Score of low back and leg pain|Wound healing	Johnson & Johnson Medical (Suzhou) Ltd.	All	20 Years to 70 Years   (Adult, Older Adult)	Not Applicable	106	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	DPS-201303	July 2014	September 2015	December 2015	September 30, 2014		December 3, 2015	Anhui Province Hospital, Hefei, Anhui, China|Beijing Jishuitan Hospital, Beijing, Beijing, China|Henan Provincial People's Hospital, Zhengzhou, Henan, China|Jiangxi Provincial People's Hospital, Nanchang, Jiangxi, China|Shanghai Ruijin Hospital, Shanghai, Shanghai, China|Xijing Hospital, Xi'an, Shanxi, China|The First Affiliated Hospital of Xi'an Jiaotong University Medical College, Xi'an, Shanxi, China|The First Affiliated Hospital of Kunming Medical College, Kunming, Yunnan, China		https://ClinicalTrials.gov/show/NCT02252185
622	NCT01460875	Recombinant Interferon Alfa-2b in Treating Patients With Melanoma		Completed	Has Results	Stage IA Skin Melanoma|Stage IB Skin Melanoma|Stage IIA Skin Melanoma|Stage IIB Skin Melanoma|Stage IIC Skin Melanoma|Stage IIIA Skin Melanoma|Stage IIIB Skin Melanoma|Stage IIIC Skin Melanoma|Stage IV Skin Melanoma	Biological: recombinant interferon alfa-2b|Other: laboratory biomarker analysis	Level of Activated STAT1(Phospho-STAT1)|Number of Patients With Adverse Events|Percentage of Patients With Correlation Between STAT1 Phosphorylation and Interferon Alfa Gene Regulation|Effect of Dose-reduction on Expression of Interferon Alfa Stimulated Genes|Effect of Dose-reduction on Interferon Alfa Gene Expression|Effect of Dose-reduction on Interferon Alfa Gene Expression Through Marker CD69|Effect of Dose-reduction on Interferon Alfa Gene Expression at Dose Level 4MU|Clinical Role of Tumor Sensitivity to Recombinant Interferon Alfa-2b Using Cellular Levels of Jak-STAT Signaling Intermediates	William Carson|Schering-Plough|Ohio State University Comprehensive Cancer Center	All	12 Years and older   (Child, Adult, Older Adult)	Not Applicable	34	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	OSU-07033|NCI-2011-03121	April 22, 2008	January 5, 2014	January 5, 2014	October 27, 2011	November 2, 2018	November 2, 2018	Ohio State University Medical Center, Columbus, Ohio, United States		https://ClinicalTrials.gov/show/NCT01460875
623	NCT02503111	The HPV-SAVE Study Team: HPV Screening and Vaccine Evaluation in Men Who Have Sex With Men	HPV-SAVE	Enrolling by invitation	No Results Available	Anal Dysplasia|Human Papillomavirus|Anal Cancer	Device: The Hyfrecator ® 2000 Electrosurgical System|Other: Observation Alone	Anal dysplasia treatment on a per-patient basis|Resolution of high-grade AIN at 3 and 6 months on a per-lesion basis|Acceptance rate of participants recruited into the study|Recurrence rates of high-grade AIN|Number of participants with adverse events	University Health Network, Toronto|Canadian Institutes of Health Research (CIHR)|Ontario HIV Treatment Network|CIHR Canadian HIV Trials Network|Merck Sharp & Dohme Corp.	Male	18 Years and older   (Adult, Older Adult)	Not Applicable	3000	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening	HPV-SAVE	November 2015	November 2020	December 2020	July 20, 2015		September 15, 2016	BC Centre for Disease Control, Vancouver, British Columbia, Canada|University of British Columbia, Vancouver, British Columbia, Canada|Ottawa Hospital Research Institute, Ottawa, Ontario, Canada|University Health Network - Toronto General Hospital, Toronto, Ontario, Canada		https://ClinicalTrials.gov/show/NCT02503111
624	NCT01255007	Comparison of Primovist-enhanced MRI, Diffusion Weighted MRI and Multidetector CT of Colorectal Liver Metastases		Completed	No Results Available	Colorectal Liver Metastases	Other: MR imaging	To establish superiority of Primovist-enhanced liver MRI and DWI to MDCT in the preoperative detection of colorectal liver metastases in patients who have received prior chemotherapy by comparison against pathology or Intra-operative ultrasound.|To compare diagnostic performance of MDCT, Diffusion Weighted MR and Primovist-enhanced MRI in the differentiation of viable from non-viable metastatic tumour compared to reference standard of pathology.|To investigate in the cohort of patients who have pre and post-chemotherapy MRI the role of DWI in predicting treatment response by baseline pretreatment Apparent Diffusion Coefficient (ADC) values.|To assess performance of Primovist-enhanced MRI, DW-MRI and MDCT in assessment of treatment response following chemotherapy in the cohort of patients who have pre and post-chemotherapy MRI.|To compare accuracies of Primovist-enhanced MRI and DWI to MDCT in the characterization of non-metastatic liver lesions against histopathology or intra-operative ultrasound.	University Health Network, Toronto|Bayer	All	18 Years and older   (Adult, Older Adult)	Not Applicable	50	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	UHN100405CE2010	September 2010	July 2014	December 2014	December 7, 2010		January 7, 2015	University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada		https://ClinicalTrials.gov/show/NCT01255007
625	NCT03380039	Clinical Study of CAR-BCMA T Cells in Patients With Refractory or Relapsed Multiple Myeloma		Recruiting	No Results Available	Refractory or Relapsed Multiple Myeloma	Genetic: CAR-BCMA T cells|Drug: Fludarabine|Drug: Cyclophosphamide	Number of participants with CAR-BCMA T cell therapy-related adverse events as assessed by CTCAE v4.03|Engraftment|Anti-tumor response of CAR-BCMA T cell infusion	Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|Carsgen Therapeutics, Ltd.	All	18 Years to 70 Years   (Adult, Older Adult)	Not Applicable	12	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	XH-17-018	October 13, 2017	September 30, 2019	September 30, 2020	December 20, 2017		December 20, 2017	Xin Hua Hospital of Shanghai Jiao Tong University of Medicine, Shanghai, Shanghai, China		https://ClinicalTrials.gov/show/NCT03380039
626	NCT03590808	Influenza Vaccination in Patients Receiving Immune Checkpoint Inhibitor		Active, not recruiting	No Results Available	Influenza|Solid Carcinoma	Biological: Influenza vaccination	Seroprotection rate|Seroconversion rate|Geometric mean titer of HI|Injection-related adverse events|Immune-related adverse events|T-cell mediated immune response	Seoul National University Hospital|Green Cross Corporation	All	20 Years and older   (Adult, Older Adult)	Not Applicable	143	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	1806-088-951	September 1, 2018	December 21, 2018	May 2019	July 18, 2018		April 2, 2019	Seoul National University Hospital, Seoul, Korea, Republic of		https://ClinicalTrials.gov/show/NCT03590808
627	NCT01166737	Study Comparing Tumor Debulking Surgery Versus Chemotherapy Alone in Recurrent Platinum-Sensitive Ovarian Cancer	DESKTOP III	Active, not recruiting	No Results Available	Fallopian Tube Cancer|Ovarian Cancer|Peritoneal Cavity Cancer	Procedure: Tumor Debulking Surgery (surgery in recurrent ovarian disease)	Overall survival in patients with platinum-sensitive recurrent ovarian cancer with a positive AGO-score|Quality of Life|Progression free survival	AGO Study Group|ARCAGY/ GINECO GROUP|MITO|Arbeitsgemeinschaft Gynaekologische Onkologie Austria|GlaxoSmithKline|medac GmbH|Grupo Español de Investigación en Cáncer de Ovario|NSGO|MaNGO|Cancer Research UK|Korean Gynecologic Oncology Group|Shanghai Gynecologic Oncology Group	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	408	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other	AGO-OVAR OP.4 DESKTOP III	July 2010	December 2019	December 2020	July 21, 2010		June 26, 2018	Medizinische Universität Graz, Universitätsklinik für Frauenheilkunde Graz, Abteilung Gynäkologie u. Geburtshilfe, Graz, Austria|Universitätsklinikum Innsbruck, Univ. Klinik für Gynäkologie und Geburtshilfe, Innsbruck, Austria|Medizinische Universität Wien,Universitätsklinik für Frauenheilkunde, Wien, Austria|Wilhelminenspital der Stadt Wien, Gynäkologisch und Geburtshilfliche Abteilung, Wien, Austria|UZ Leuven, Leuven, Belgium|Zhejiang Cancer Hospital, Gynecology Oncology, Hangzhou, China|Fudan University Cancer Hospital, Gynecologic Oncology, Shanghai, China|Fudan University Zhongshan Hospital, Obstetrics and Gynecology, Shanghai, China|Suzhou Municipal Hospital, Gynecologic and Obstetrics, Suzhou, China|Aalborg Hospital, Aalborg, Denmark|Aarhus University Hospital,Oncology, Aarhus, Denmark|Ringshospitalet Copenhagen University Hospital; Oncology, Copenhagen, Denmark|Herlev Hospital, Herlev, Denmark|Odense University Hospital, Gynaecology and Obstetrics, Odense, Denmark|Institut Bergonié, Gynecology, Bordeaux, France|Centre Francois Baclesse, Caen, France|Centre Jean Perrin, Clermont-Ferrand, France|Centre Antoine Lacassagne, Nice, France|Hôpital Européen Georges Pompidou, Paris, France|Hôpital Tenon, Paris, France|Insitut Jean Godinot, Service Rubis - Oncologie Médicale, Reims, France|Centre Eugène Marquis, Rennes, France|Centre Hospitalier Universitaire Charles-Nicolle, Rouen, France|Centre Henri Becquerel, Rouen, France|Centre René Gauducheau, Saint-Herblain, France|Centre Claudius Regaud, Toulouse, France|Hochtaunus-Kliniken gGmbH, Frauenklinik, Bad Homburg, Germany|Charité - Universitätsmedizin Berlin, Campus Virchow-Klinikum, Klinik für Frauenheilkunde, Berlin, Germany|Universitätsklinikum Carl Gustav Carus, Klinik für Frauenheilkunde u. Geburtshilfe, Dresden, Germany|Evangelisches Krankenhaus, Frauenklinik, Düsseldorf, Germany|Kaiserswerther-Diakonie, Florence-Nightingale Krankenhaus, Gynäkologie, Düsseldorf, Germany|Kliniken Essen Mitte, Evang. Huyssens-Stiftung, Gynäkologische Onkologie, Essen, Germany|Klinikum der JWG Universität Frankfurt, Klinik für Gynäkologie und Geburtshilfe, Frankfurt am Main, Germany|Universitätsklinikum Freiburg, Frauenklinik, Freiburg, Germany|Klinikum Fürth, Frauenklinik Nathanstift, Fürth, Germany|Gynecologic Clinic of the Ernst-Moritz-Arndt-University, Greifswald, Germany|Georg-August-Universität Göttingen, Universitäts-Frauenklinik, Göttingen, Germany|Medizinische Hochschule, Klinik für Frauenheilkunde u. Geburtshilfe, Hannover, Germany|Klinikum Kempten, Klinik für Frauenheilkunde und Geburtshilfe, Kempten, Germany|Universitätsklinikum Schleswig-Holstein Campus Kiel, Klinik f. Gynäkologie u. Geburtshilfe, Kiel, Germany|Klinikum Konstanz, Frauenklinik, Konstanz, Germany|Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Klinik für Frauenheilkunde und Geburtshilfe, Lübeck, Germany|Universitätsklinikum Mainz, Frauenklinik, Mainz, Germany|Klinikum Dritter Orden, Gynäkologie und Geburtshilfe, München, Germany|Klinikum der Universität München-Großhadern, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, München, Germany|Oberschwaben Klinik, Krankenhaus St. Elisabeth, Frauenklinik, Ravensburg, Germany|Caritas-Krankenhaus St. Josef, Klinik für Frauenheilkunde und Geburtshilfe d. Universität Regensburg, Regensburg, Germany|Leopoldina-Krankenhaus der Stadt Schweinfurt GmbH, Frauenklinik, Schweinfurt, Germany|Universitätsklinikum, Universitätsfrauenklinik, Ulm, Germany|Ammerland-Klinik GmbH, Frauenklinik, Westerstede, Germany|HSK, Dr. Horst Schmidt Klinik GmbH, Klinik für Gynäkologie u. Gynäkologische Onkologie, Wiesbaden, Germany|Centro di Riferimento Oncologico,Struttura Operativa complessa Chirurgia Oncologica Ginecologica, Aviano, Italy|Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy|Istituto Europeo di Oncologia, Divisione di Ginecologia, Milan, Italy|Istituto Nazionale Tumori di Napoli, Gynecologic Oncology, Naples, Italy|Seoul National University Hospital, Department of Obstetrics and Gynecology, Seoul, Korea, Republic of|Norwegian Radium Hospital, Oslo University Hospital, Gynecologic Oncology, Oslo, Norway|ICO Badalona - H. U. Germans Trias i Pujol, Badalona, Spain|Hospital de la Santa Creu i Sant Pau, Oncology, Barcelona, Spain|Hospital Clinic Barcelona, Oncology, Barcelona, Spain|ICO-Hospital Universitari de Girona Dr. Josep Trueta, Servicio de Oncologia de Girona, Girona, Spain|Avinguda Granvia de l'Hospitalet de Llobregat, Hospital de Bellvitge, Gynaecology, Hospitalet de Llobregat, Spain|Hospital Son Llàtzer, Oncology, Palma de Mallorca, Spain|Hospital de Navarra, Oncology, Pamplona, Spain|Fundación Instituto Valenciano de Oncologia, Valencia, Spain|Hospital Universitari i Politècnic la Fe, Oncology, Valencia, Spain|Linköping University Hospital, Department of Obstetrics and Gynecology, Linköping, Sweden|Karolinska University Hospital, Oncology, Stockholm, Sweden|Birmingham City Hospital, Cancer Research Team, Birmingham, United Kingdom|Cambridge University Hospitals NHS FT - Addenbrookes Hospital, Gynaecological Oncology, Cambridge, United Kingdom|Queen Elizabeth Hospital Gateshead, Northern gynaecological oncology centre, Gateshead, United Kingdom|Royal Surrey Country Hospital,St Lukes Cancer Centre, Guildford, United Kingdom|Lincoln County Hospital, Oncology, Lincoln, United Kingdom|St Bartholomew´s Hospital and Queen´s Hospital,Gynaecological Cancer Centre, London, United Kingdom|University College London Hospital, Cancer clinical trails unit, London, United Kingdom|Royal Marsden NHS Foundation Trust, Gynae research, Mulberry House, London, United Kingdom|Imperial College Healthcare NHS Trust Hammersmith Hospital, Medical Oncology, London, United Kingdom|Central Manchester Foundation NHS Trust, St Mary´s Hospital, Gynaecology, Manchester, United Kingdom|Queen Elizabeth the Queen Mother Hospital,East Kent Gynaeoncology Centre, Margate, United Kingdom|Northampton General Hospital, Gynaecological Oncology, Northampton, United Kingdom|East and North Hertfordhire NHS Trust,Mount Vernon Hospital,Medical Oncology, Northwood, United Kingdom|Norfolk & Norwich University Hospital,Obstetrics & Gynaecology, Norwich, United Kingdom|Nottingham University Hospital, City Campus, Oncology, Nottingham, United Kingdom|Royal Hallamshire Hospital & Weston Park Hospital, Cancer Clinical Trials Centre, Sheffield, United Kingdom|Princess Anne Hospital, gynaecology, Southampton, United Kingdom|New Cross Hospital,Oncology/Gynaecology, Wolverhampton, United Kingdom		https://ClinicalTrials.gov/show/NCT01166737
628	NCT02592837	EBUS-TBNA vs Flex 19G EBUS-TBNA		Completed	No Results Available	Lymphadenopathy|Lung Cancer|Sarcoidosis|Lymphoma	Device: Flexible 19G EBUS-TBNA needle|Device: 21G EBUS-TBNA needle	The difference in quality of diagnostic tissue obtained between the two study arms following 4 separate needle punctures per lymph node|The difference between the two study arms in the percentage of lymph nodes sampled where enough tissue is obtained for complete immunohistochemical and genetic mutation analysis.|The difference in complication rates between the two study arms|The difference between the two study arms in yield (quantity of diagnostic material) in patients ultimately diagnosed with sarcoidosis|The difference between the two study arms in yield (quantity of diagnostic material) in patients ultimately diagnosed with lymphoma|The difference in sensitivity for detecting sarcoidosis between the two study arms|The difference in sensitivity for detecting lymphoma between the two study arms	Royal Brompton & Harefield NHS Foundation Trust|Olympus Corporation	All	18 Years and older   (Adult, Older Adult)	Not Applicable	250	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Diagnostic	2015LF016B	May 2016	November 14, 2017	December 14, 2017	October 30, 2015		May 11, 2018	Royal Brompton Hospital, London, United Kingdom		https://ClinicalTrials.gov/show/NCT02592837
629	NCT02887261	Study on Indications of "Bard" PowerPort Isp Implantable Port	BPIP	Completed	No Results Available	Power Port|Image Accuracy	Device: "Bard"PowerPort sip Implantable Port|Device: Conventional Port	Chest tomography (Before and after neoadjuvant therapy)|endoscopic ultrasound (Before and after neoadjuvant therapy)|pathologic report	Chang Gung Memorial Hospital|C. R. Bard	All	20 Years to 90 Years   (Adult, Older Adult)	Not Applicable	100	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	CGMH-IRB-104-3143A3	May 2016	May 31, 2019	May 31, 2019	September 2, 2016		July 24, 2019	Chang Gung Memorial Hospital, Taoyuan, Taiwan		https://ClinicalTrials.gov/show/NCT02887261
630	NCT03356626	Comparison of Perioperative Outcomes Between Energy Device During Laparoscopic Gastrectomy		Recruiting	No Results Available	Postoperative Inflammation|Postoperative Fever	Device: ULTRACISION Harmonic Scalpel|Device: Ligasure Maryland|Device: Thunderbeat	postoperative 2nd day CRP|postoperative 4th day CRP|postoperative IL-6, IL10 level	Seoul National University Hospital|Medtronic Spine LLC	All	20 Years to 80 Years   (Adult, Older Adult)	Not Applicable	200	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Diagnostic	EBD-02	March 12, 2018	August 17, 2019	December 17, 2019	November 29, 2017		September 10, 2018	Seoul National University Hospital, Seoul, Korea, Republic of		https://ClinicalTrials.gov/show/NCT03356626
631	NCT04007835	Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI		Not yet recruiting	No Results Available	NSCLC	Drug: Anlotinib Hydrochloride	Progression free survival（PFS）|6 months and 12 months progression-free survival (PFS) Rate|objective response rate (ORR)|Disease Control Rate(DCR)|Overall survival (OS)|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|progression-free survival (PFS) for different types of EGFR mutation|Overall survival (OS) for different types of EGFR mutation	Guangdong Association of Clinical Trials|Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	All	18 Years to 75 Years   (Adult, Older Adult)	Not Applicable	120	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CTONG1803	July 2019	July 2021	December 2021	July 3, 2019		July 3, 2019	Guangdong General Hospital, Guangzhou, Guangdong, China		https://ClinicalTrials.gov/show/NCT04007835
632	NCT02475486	Role of the ANS Dysregulation in the Persistence of Fatigue in Rheumatoid Arthritis Patients Treated With Anti-TNF	ANSRA	Completed	No Results Available	Rheumatoid Arthritis	Device: VistaO2	Ratio low/high frequencies of power spectral density of R-R intervals|Number of sleep apnea syndrome|Standard deviation of all R-R intervals (SDNN)|Total Power spectral density (PSD)|PSD of Lower Frequencies|PSD of High Frequencies|normalized value of the High and Low frequencies|Physical activity|quality of sleep|depression|Correlation between fatigue and Ratio low/high frequencies of power spectral density of R-R intervals	Centre Hospitalier Universitaire de Saint Etienne|Pfizer	All	30 Years to 75 Years   (Adult, Older Adult)	Not Applicable	50	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	1508054|2015-A00655-44	February 25, 2016	October 8, 2018	October 8, 2018	June 18, 2015		June 26, 2019	Chu Saint-Etienne, Saint-etienne, France		https://ClinicalTrials.gov/show/NCT02475486
633	NCT00166361	Drainage of Malignant Extrinsic Ureteral Obstruction Using the Memokath Ureteral Stent		Completed	Has Results	Ureteral Obstruction	Device: Memokath 051 Ureteral Stent|Device: JJ Stent	Mean Stent Dwell Time	Mayo Clinic|Pnn Medical A/S	All	18 Years and older   (Adult, Older Adult)	Not Applicable	29	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	255-03	February 2004	November 2008	November 2008	September 14, 2005	July 18, 2014	July 18, 2014	Mayo Clinic, Rochester, Minnesota, United States		https://ClinicalTrials.gov/show/NCT00166361
634	NCT02944344	Four Conversations RCT		Completed	No Results Available	Breast Cancer	Behavioral: Four Conversations	Change in patient/caregiver and provider preparedness for decision making as measured by the Preparation for Decision Making Scale|Change in patient/caregiver decision making self-efficacy as measured by the Decision Self-efficacy Scale|Change in patient self-conflict as measured by the Decisional Conflict Scale|Change in provider end of life (EOL) care knowledge as measured by revised City of Hope EOL Knowledge Assessment|Change in patient and caregiver quality of life (QOL) as measured by the PROMIS Global Scale|Change in patient/caregiver and provider end of life (EOL) conversations as measured by EOL Conversations	Duke University|Duke Cancer Institute|National Comprehensive Cancer Network|Pfizer|Pillars4Life, Inc.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	357	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	Pro00070790	December 15, 2016	October 21, 2018	October 21, 2018	October 25, 2016		December 13, 2018	Duke University Medical Center, Durham, North Carolina, United States		https://ClinicalTrials.gov/show/NCT02944344
635	NCT02835391	PerClot Compared to Usual Care in Gynaecology Procedures		Completed	No Results Available	Endometriosis|Ovarian Cyst|Menorrhagia|Cancer|Uterine Fibroids	Device: PerClot|Device: Floseal, Surgicel, Surgiflo, Arista|Procedure: Electrocautery/Diatermy	achievement of haemostasis (yes/no).|Absence of re-intervention for post-operative bleeding	CryoLife Europa	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	90	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PCT1501-000-C(01/15)	November 2015	July 2017	August 2017	July 18, 2016		September 1, 2017	Bellvitge Hospital, Barcelona, Spain		https://ClinicalTrials.gov/show/NCT02835391
636	NCT03068637	Integrating Touchscreen-based Geriatric Assessment and Frailty Screening for Adults With Multiple Myeloma		Completed	No Results Available	Multiple Myeloma	Behavioral: Carevive CPS	Feasibility, usability, and acceptability of a tablet-based modified geriatric assessment using online questionnaires.|Physician use and perceived utility of the modified geriatric assessment|Description of treatment decision making patterns chosen by hematologists managing older patients with multiple myeloma|Description of rates of CTCAE Grade 3-5 toxicities in older adults with MM who receive treatment following a treatment decision making visit at which an mCGA is completed|Description of the relationship between the mCGA and toxicity in older adults with MM over 3 months of chemotherapy|Description of the relationship between the mCGA and dose modification and/or treatment discontinuation in older adults with MM over 3 months of chemotherapy.	Carevive Systems, Inc.	All	65 Years and older   (Older Adult)	Not Applicable	165	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	G405	August 23, 2016	November 8, 2017	April 1, 2018	March 3, 2017		June 15, 2018	City of Hope, Duarte, California, United States|University of Rochester Medical Center, Rochester, New York, United States		https://ClinicalTrials.gov/show/NCT03068637
637	NCT02745509	Extensive Intraoperative Peritoneal Lavage After Curative Gastrectomy for Locally Advanced Gastric Cancer (SEIPLUS)	SEIPLUS	Completed	No Results Available	Gastric Cancer	Other: Extensive Intraoperative Peritoneal Lavage	Overall survival|Disease-free survival|Peritoneal recurrence|Postoperative complications|Post-operative quality of life	Sun Yat-sen University|Anhui Provincial Hospital|The First Affiliated Hospital of Anhui Medical University|Anqing Municipal Hospital|Yuebei People's Hospital|The First Affiliated Hospital of Guangdong Pharmaceutical University|Guangdong Provincial Hospital of Traditional Chinese Medicine|Jiangsu Cancer Institute & Hospital|Jiangxi Provincial Cancer Hospital|Tianjin Medical University Cancer Institute and Hospital|First Affiliated Hospital of Wannan Medical College|Lishui hospital of Zhejiang University|Second Affiliated Hospital, School of Medicine, Zhejiang University	All	18 Years to 80 Years   (Adult, Older Adult)	Not Applicable	508	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	SEIPLUS	March 2016	November 2017	November 2017	April 20, 2016		February 21, 2019	Anqing Municipal Hospital, Anqing, Anhui, China|Anhui Provincial Hospital, Hefei, Anhui, China|The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China|First Affiliated Hospital of Wannan Medical College, Wuhu, Anhui, China|Cancer Center of Sun Yat-sen University, Guangzhou, Guangdong, China|Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, Guangdong, China|The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, Guangdong, China|Yuebei People's Hospital, Guangzhou, Guangdong, China|Jiangsu Cancer Institute & Hospital, Nanjing, Jiangsu, China|Jiangxi Provincial Cancer Hospital, Nanchang, Jiangxi, China|Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China|Lishui Hospital of Zhejiang University, Lishui, Zhejiang, China|Tianjin Medical University Cancer Institute and Hospital, Tianjin, China		https://ClinicalTrials.gov/show/NCT02745509
638	NCT01701674	Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts		Active, not recruiting	Has Results	Metastatic Melanoma	Drug: Ipilimumab|Procedure: Tumor Infiltrating Lymphocytes (TIL)|Drug: Administration of Lymphodepletion|Drug: Cyclophosphamide as Part of Lymphodepletion|Drug: Fludarabine as Part of Lymphodepletion|Drug: High Dose IL-2|Biological: Adoptive Cell Therapy with TIL	Occurrence of Dose Limiting Toxicity (DLT) Events|Rate of Meeting Feasibility Requirements|Overall Response Rate (ORR)|Progression Free Survival (PFS)	H. Lee Moffitt Cancer Center and Research Institute|Bristol-Myers Squibb|Iovance Biotherapeutics, Inc.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	13	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MCC-17057|CA184-213	October 3, 2012	April 21, 2016	December 2019	October 5, 2012	May 2, 2017	July 8, 2019	H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States		https://ClinicalTrials.gov/show/NCT01701674
639	NCT02711202	Sequential Targeting of Cluster of Differentiation 52 (CD52) and Tumor Necrosis Factor (TNF) Allows Early Minimization Therapy in Kidney Transplantation		Completed	No Results Available	Kidney Transplantation	Drug: MabCampath,|Drug: Remicade|Drug: Sirolimus|Drug: Tacrolimus	number of patients with functional graft|number of patients alive|kidney graft function (measured by serum creatinine and glomerular filtration)|the number of bioptically verified rejection episodes and their severity|fibrosis grade and presence of subclinical rejection in protocol biopsy at 12 months|intragraft gene expression (inflammatory cytokines, chemokines and protective factors)|peripheral blood gene expression (inflammatory cytokines, chemokines and protective factors)	Institute for Clinical and Experimental Medicine|Charite University, Berlin, Germany|Miltenyi Biotec GmbH	All	18 Years and older   (Adult, Older Adult)	Not Applicable	20	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening	EudraCT Number: 2006-003110-18	January 2007	March 2009	March 2009	March 17, 2016		March 17, 2016			https://ClinicalTrials.gov/show/NCT02711202
640	NCT03496844	Fluciclovine-PET/CT for Bone Metastases From Prostate Adenocarcinoma	BoneMetPETCT	Recruiting	No Results Available	Prostate Adenocarcinoma	Diagnostic Test: F-18 fluciclovine-PET/CT scan	True positive and false positive rate of positive bone findings on F-18 fluciclovine-PET/CT scan compared to gold standard of bone biopsy	University of Arizona|Blue Earth Diagnostics|Banner University Medical Center	Male	18 Years and older   (Adult, Older Adult)	Not Applicable	20	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	1803340164	April 15, 2018	April 2021	November 2021	April 12, 2018		September 11, 2018	University of Arizona, Tucson, Arizona, United States		https://ClinicalTrials.gov/show/NCT03496844
641	NCT02735291	Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Acute Non T Lymphocyte Leukemia	EECNTL	Recruiting	No Results Available	Leukemia	Biological: CD19-targeted CAR-T cells	The overall efficiency	Sinobioway Cell Therapy Co., Ltd.|The Second Hospital of Anhui Medical University	All	3 Years to 75 Years   (Child, Adult, Older Adult)	Not Applicable	24	Industry|Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2015-06-01	November 2015	November 2019	November 2019	April 12, 2016		March 14, 2017	The Second Hospital of Anhui Medical University, Hefei, Anhui, China|No. 454 Hospital of People'S Liberation Army, Nanjing, Jiangsu, China		https://ClinicalTrials.gov/show/NCT02735291
642	NCT00706641	Neoadjuvant Dasatinib and Radical Cystectomy for Transitional Cell Carcinoma of the Bladder		Completed	Has Results	Transitional Cell Carcinoma of the Bladder	Drug: Dasatinib|Procedure: Radical Cystectomy	Feasibility|Grade 3/4 Toxicities|Reduced pSFK Expression|Pathologic Complete Response (pCR) Rate|Post-Cystectomy Pathologic Stage|Reduced Ki-67 Expression|Increase in Cas3 Expression	Hoosier Cancer Research Network|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Not Applicable	25	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GU07-122	June 2008	December 2012	December 2012	June 27, 2008	January 15, 2016	January 15, 2016	Indiana University Simon Cancer Center, Indianapolis, Indiana, United States|Baylor College of Medicine, Houston, Texas, United States|Virginia Oncology Associates, Norfolk, Virginia, United States		https://ClinicalTrials.gov/show/NCT00706641
643	NCT03632005	Negative Pressure Wound Therapy vs. Sterile Dressing for Patients Undergoing Thoracolumbar Spine Surgery		Recruiting	No Results Available	Metastatic Disease|Spinal Cord Injury|Spinal Degeneration|Spinal Deformity	Device: Vacuum Assisted Closure|Other: Sterile dressing	Incidence of acute, post-operative surgical site infection (SSI) following thoracolumbar spinal surgery for a metastatic tumor, revision requiring additional instrumentation or acute traumatic spinal cord injury	John Street|KCI USA, Inc.|University of British Columbia Orthopaedics Research Excellence Fund|University of British Columbia	All	17 Years and older   (Child, Adult, Older Adult)	Not Applicable	550	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	H13-02263	March 18, 2017	August 2020	August 2020	August 15, 2018		August 15, 2018	Vancouver General Hospital, Vancouver, British Columbia, Canada		https://ClinicalTrials.gov/show/NCT03632005
644	NCT03318380	Contrast-Enhanced Ultrasound Imaging in Diagnosing Liver Cancer in Patients With Cirrhosis		Recruiting	No Results Available	Liver Cirrhosis	Procedure: Dynamic Contrast-Enhanced Ultrasound Imaging	Sensitivity of contrast-enhanced ultrasound evaluation (CEUS) for diagnosis of Hepatocellular cancer using a 95% confidence interval 95% confidence interval for HCC diagnosis using CEUS LR-5 classification|Specificity of contrast-enhanced ultrasound evaluation (CEUS) for diagnosis of Hepatocellular cancer using a 95% confidence interval|Positive Predictive Value of contrast-enhanced ultrasound evaluation (CEUS) for diagnosis of Hepatocellular cancer using a 95% confidence interval|Negative Predictive Value of contrast-enhanced ultrasound evaluation (CEUS) for diagnosis of Hepatocellular cancer using a 95% confidence interval	Sidney Kimmel Cancer Center at Thomas Jefferson University|National Cancer Institute (NCI)|GE Healthcare|Bracco Diagnostics, Inc|Thomas Jefferson University	All	21 Years and older   (Adult, Older Adult)	Not Applicable	640	Other|NIH|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	17F.310	January 19, 2018	March 2020	March 2021	October 23, 2017		May 30, 2019	University of California San Diego, San Diego, California, United States|Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Albert Einstein Medical Center, Philadelphia, Pennsylvania, United States|Vanderbilt University, Nashville, Tennessee, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Swedish Medical Center, Seattle, Washington, United States|University of Calgary, Calgary, Canada|University of Paris, Paris, France|University of Bologna, Bologna, Italy|University of Bern, Bern, Switzerland|King's College Hospital, London, United Kingdom		https://ClinicalTrials.gov/show/NCT03318380
645	NCT02687087	A Study of Patients With Dry Mouth and Sticky Saliva During Radiotherapy		Completed	No Results Available	Xerostomia	Device: Visco-ease|Device: Placebo	Change in GRIX Score	NHS Greater Glasgow and Clyde|Lamellar Biomedical Ltd|University of Glasgow	All	18 Years and older   (Adult, Older Adult)	Not Applicable	44	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care	GN14ON413|00908|44528835	March 24, 2016	February 2, 2017	February 2, 2017	February 22, 2016		February 20, 2017	Beatson West of Scotland Cancer Centre, Glasgow, Lanarkshire, United Kingdom		https://ClinicalTrials.gov/show/NCT02687087
646	NCT02558803	HPV Vaccination: Evaluation of Reminder Prompts for Doses 2 & 3		Completed	No Results Available	Human Papilloma Virus Infection Type 11|Human Papilloma Virus Infection Type 16|Human Papilloma Virus Infection Type 18|Human Papilloma Virus Infection Type 6|Cervical Cancer|Genital Warts|Oropharyngeal Cancer	Behavioral: Simple Reminder	Rate of physician-targeted automated HPV vaccination reminders on 2nd and 3rd dose HPV vaccination rates among 11-17 year old male and female patients|Assessment of Physician Acceptance of the Prompts	Regenstrief Institute, Inc.|Merck Sharp & Dohme Corp.|Indiana University	All	11 Years to 17 Years   (Child)	Not Applicable	1305	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Health Services Research	Merck 21	February 2015	May 2016	May 2016	September 24, 2015		May 25, 2016	Eskenazi Health Outpatient Care Center, Indianapolis, Indiana, United States|Eskenazi Health Center Blackburn, Indianapolis, Indiana, United States|Eskenazi Health Center Forest Manor, Indianapolis, Indiana, United States|Eskenazi Health West 38th Street, Indianapolis, Indiana, United States|Eskenazi Health Center Pecar, Indianapolis, Indiana, United States		https://ClinicalTrials.gov/show/NCT02558803
647	NCT02551887	HPV Vaccination: An Investigation of Physician Reminders and Recommendation Scripts		Completed	Has Results	Human Papilloma Virus Infection Type 11|Human Papilloma Virus Infection Type 16|Human Papilloma Virus Infection Type 18|Human Papilloma Virus Infection Type 6|Cervical Cancer|Genital Warts|Oropharyngeal Cancer	Behavioral: Automated Reminder|Behavioral: Automated Reminder Plus Script	First Dose HPV Vaccine Uptake|Second Dose HPV Vaccine Uptake	Regenstrief Institute, Inc.|Merck Sharp & Dohme Corp.|Indiana University	All	11 Years to 14 Years   (Child)	Not Applicable	647	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Health Services Research	Merck - 14	February 2014	April 2015	June 2015	September 16, 2015	February 4, 2016	March 11, 2016			https://ClinicalTrials.gov/show/NCT02551887
648	NCT01050790	Lenalidomide + Azacitidine for Adaptive Immunotherapy -> Auto SCT in Multiple Myeloma		Completed	Has Results	Multiple Myeloma	Drug: Azacitidine	Feasibility to Mobilize and Infuse Autologous Lymphocytes (ALI) After Immunomodulatory Therapy and After Stem Cell Transplant Engraftment|Complete Response Rate at 6 Months|Toxicity as Assessed by NCI CTCAE v3.0|Time to Progression Post Transplant|Progression-free and Overall Survival|Pre- and Post-ALI Immune Response to Cancer Testis Antigens (CTA)|CTA Expression Before and After Azacitidine Therapy	Virginia Commonwealth University|National Cancer Institute (NCI)|Celgene Corporation	All	18 Years to 69 Years   (Adult, Older Adult)	Not Applicable	17	Other|NIH|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CDR0000663409|P30CA016059|MCC-12430	January 2010	August 2014	September 2016	January 15, 2010	October 5, 2015	June 26, 2018	Virginia Commonwealth University, Richmond, Virginia, United States		https://ClinicalTrials.gov/show/NCT01050790
649	NCT00577096	Effects of Exercise in Combination With Epoetin Alfa		Completed	Has Results	Multiple Myeloma	Drug: Epoetin Alfa|Behavioral: Exercise|Biological: Autologous Peripheral Blood Stem Cell Transplantation|Biological: Red Blood Cell Transfusion|Drug: Thalidomide|Drug: Heparin, Low-Molecular-Weight|Biological: Platelet Transfusion|Drug: Melphalan|Drug: Total Therapy II	Number of Red Blood Cell Transfusions Needed to Maintain Hemoglobin Levels (Short Term)|Number of Red Blood Cell Transfusions Needed to Maintain Hemoglobin Levels (Long Term)|Number of Platelet Transfusions Needed to Maintain Adequate Number of Platelets.(Short Term)|Number of Platelet Transfusions Needed to Maintain Adequate Number of Platelets. (Long Term)|Number of Stem Cell Collection Attempts (Short Term)|Number of Stem Cell Collection Attempts (Long Term)|Total Number of Days of Stem Cell Collection (Short Term)|Total Number of Days of Stem Cell Collection (Long Term)|Hemoglobin Levels Before Chemotherapy and During Transplantation Period (Short Term)|Hemoglobin Levels Before Chemotherapy and During Transplantation Period (Long Term)	University of Arkansas|National Institutes of Health (NIH)|Ortho Biotech Clinical Affairs, L.L.C.	All	Child, Adult, Older Adult	Not Applicable	120	Other|NIH|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	IRB # 29287|R01NR008937|Ortho Biotech Clinical Affairs	October 2001	June 2004	June 2004	December 19, 2007	April 21, 2011	April 6, 2015	University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States		https://ClinicalTrials.gov/show/NCT00577096
650	NCT00374114	A Pilot Study to Evaluate Ultrasonic Surgical Aspiration as a Treatment Modality for Cervical Dysplasia		Completed	No Results Available	Cervical Dysplasia	Procedure: cervical conization|Procedure: ultrasonic surgical aspiration of the cervix	Adequate treatment of cervical dysplasia	University of Tennessee|Integra LifeSciences Corporation	Female	18 Years to 55 Years   (Adult)	Not Applicable	20	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	d34c09	January 2004		December 2006	September 8, 2006		December 15, 2008	University of Tennessee College of Medicine, Chattanooga, Tennessee, United States|University of Tennessee Health Sciences Center, Memphis, Tennessee, United States		https://ClinicalTrials.gov/show/NCT00374114
651	NCT03042000	Multicenter, Prospective, RCT：Investigation of Combined Modality Therapy for Locally Advanced Mid/Low Rectal Cancer.		Not yet recruiting	No Results Available	Rectal Cancer, Adenocarcinoma|Neoadjuvant Chemoradiation	Other: non-NCRT|Other: NCRT|Drug: capecitabine with oxaliplatin|Drug: capecitabine|Procedure: TEM|Procedure: radical resection	3y-DFS|3y-OS|5y-DFS|5y-OS|pCR	Peking Union Medical College Hospital|Beijing Hospital|Beijing Chao Yang Hospital|Cancer Institute and Hospital, Chinese Academy of Medical Sciences|Peking University People's Hospital|Beijing Cancer Hospital|Beijing Friendship Hospital|Geneplus-Beijing Co. Ltd.	All	18 Years to 75 Years   (Adult, Older Adult)	Not Applicable	1200	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PUMCH-Colorectal Surgery 02	February 2017	December 2020	December 2021	February 3, 2017		February 3, 2017			https://ClinicalTrials.gov/show/NCT03042000
652	NCT01830075	The Life InSight Application Study (LISA)	LISA	Completed	No Results Available	Quality of Life	Behavioral: Consultations	Quality of life|Spiritual well being|patients empowerment|spirituality	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Dutch Cancer Society|Janssen, LP	All	18 Years and older   (Adult, Older Adult)	Not Applicable	153	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	W12-143#12.17.0161	May 2014	March 2016	March 2016	April 12, 2013		July 27, 2016	Academic Medical Center, Amsterdam, Noord-Holland, Netherlands		https://ClinicalTrials.gov/show/NCT01830075
653	NCT03015883	Alpha Radiation Emitters Device for the Treatment of Squamous Cell Carcinoma	DaRT	Completed	No Results Available	Squamous Cell Carcinoma	Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)	Adverse Events|Reduction in Tumor size|Percent of NecroticTissue	Alpha Tau Medical LTD.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	27	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CTP-SCC-00	February 22, 2017	June 1, 2019	June 25, 2019	January 10, 2017		June 27, 2019	Davidof Cancer Institution at the Rabin Medical Center Israel, Petah Tiqva, Israel		https://ClinicalTrials.gov/show/NCT03015883
654	NCT03621462	Elucid Labs AIDA™ - Labelled Image Acquisition Protocol		Not yet recruiting	No Results Available	Melanoma (Skin)|Basal Cell Carcinoma of the Skin|Squamous Cell Carcinoma of the Skin	Device: Artificial Intelligence Dermatology Assistant (AIDA™)	Sensitivity of in-clinic dermatologist diagnosis using AIDA™ compared to standard dermoscopy and physical examination alone|Specificity of in-clinic dermatologist diagnosis using AIDA™ compared to standard dermoscopy and physical examination alone	Elucid Labs Inc.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	4000	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	AIDA-PRO-001	October 15, 2018	September 1, 2020	October 15, 2020	August 8, 2018		August 8, 2018	Total Skincare Centre, Calgary, Alberta, Canada		https://ClinicalTrials.gov/show/NCT03621462
655	NCT03285698	Comparing the Clinical Outcomes of DermACELL® With Integra® Bilayer Wound Matrix		Recruiting	No Results Available	Wounds|Chronic Wounds|Nonmalignant Condition	Device: DermACELL®|Device: Integra®	Time the wound bed takes to heal for split thickness skin graft application|Percentage of subjects with complete split thickness skin graft take	Georgetown University|LifeNet Health	All	18 Years to 90 Years   (Adult, Older Adult)	Not Applicable	100	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	2014-0061	April 18, 2014	August 31, 2019	October 1, 2020	September 18, 2017		February 15, 2019	Medstar Georgetown University Hospital, Washington, District of Columbia, United States		https://ClinicalTrials.gov/show/NCT03285698
656	NCT01819649	Selenium in the Prevention of Cancer	DK PRECISE	Completed	No Results Available	Cancer	Dietary Supplement: SelenoPRECISE selenium-enriched yeast tablet, Pharma Nord Denmark A/S	Viability of full scale study|AMENDMENT TO OUTCOME MEASURES: Mortality analysis.	Odense University Hospital|Danish Cancer Society|University of Southern Denmark|K. A. Rohde's and wife's Foundation|The County of Funen, Denmark|Cypress Systems, USA|The Dagmar Marshall Foundation|The N. O. Andersen Foundation|The Danish Directory of Food and Agriculture|The Foundation of Clinical Experimental Cancer Research, Odense|The Foundation of Lily Benthine Lund|The Memory Foundation of Merchant Brogaard|Pharma Nord	All	60 Years to 74 Years   (Adult, Older Adult)	Not Applicable	491	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention	OUH-DK-PILOT-PRECISE	November 1998	June 2004	June 2004	March 27, 2013		September 14, 2017	Selenium Centre, Odense University Hospital, Odense C, Denmark		https://ClinicalTrials.gov/show/NCT01819649
657	NCT00002226	Safety and Effectiveness of Giving SU5416 to HIV-Infected Patients With AIDS-Related Kaposi's Sarcoma		Completed	No Results Available	Sarcoma, Kaposi|HIV Infections	Drug: SU5416		SUGEN|NIH AIDS Clinical Trials Information Service	All	18 Years and older   (Adult, Older Adult)	Not Applicable	30	Industry	Interventional	Primary Purpose: Treatment	294A|5416.003				August 31, 2001		June 24, 2005	Norris Cancer Ctr / USC, Los Angeles, California, United States|UCLA Care Ctr / Ctr for Hlth Sciences, Los Angeles, California, United States|Saint Francis Mem Hosp / HIV Care Unit, San Francisco, California, United States|New York Univ Med Ctr, New York, New York, United States		https://ClinicalTrials.gov/show/NCT00002226
658	NCT02039232	Safety and Efficacy of the CarboFix Pedicle Screw System		Completed	No Results Available	Degenerative Disc Disease|Spondylolisthesis|Spinal Stenosis|Spinal Curvatures|Tumor	Device: Pedicle screw system	Fusion success	CarboFix Orthopedics Ltd.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	46	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CARBOFIX P CLD PPS1	January 2014	August 2017	February 2018	January 17, 2014		April 17, 2019	Hillel Yafe MC;, Hadera;, Israel|Herzliya Medical Center, Herzliya, Israel		https://ClinicalTrials.gov/show/NCT02039232
659	NCT03000998	Web App Technology for Boys and Parents: Improving HPV Vaccine Uptake		Recruiting	No Results Available	Human Papillomavirus Virus|HPV	Behavioral: Web App Intervention Group|Behavioral: Usual Customary Care Group	Vaccine Initiation|Vaccine Adherence|Attitudes towards vaccination in general|Attitudes towards the HPV vaccine|Perception of risk due to HPV and not being vaccinated|Perception of negative and positive consequences associated with HPV vaccination|Self-efficacy to make informed decisions about HPV vaccination|HPV knowledge|Spousal support and social normative and cultural perceptions of receiving the HPV vaccination	Klein Buendel, Inc.|University of New Mexico|Indiana University	All	11 Years and older   (Child, Adult, Older Adult)	Not Applicable	900	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention	1R01CA210125-01A1|0310	January 31, 2017	July 31, 2020	July 31, 2020	December 22, 2016		March 22, 2019	Klein Buendel, Inc., Golden, Colorado, United States|Indiana University, Indianapolis, Indiana, United States|University of New Mexico, Albuquerque, New Mexico, United States		https://ClinicalTrials.gov/show/NCT03000998
660	NCT03095885	A Pilot Study of Oxalate Absorption in Secondary Hyperoxaluria		Completed	No Results Available	Secondary Hyperoxaluria|Nephrolithiasis|Hyperoxaluria|Kidney Stones	Other: Oxalate-rich Test Meal	Percent oxalate absorption from oxalate-rich test meal, urinary oxalate (mg/24-hour)|Percent oxalate absorption 4-hours, 6-hours post oxalate-rich test meal and 24-hour. (mg/interval)|Percent change from baseline urinary oxalate (mg) for each collection interval.	Allena Pharmaceuticals	All	18 Years and older   (Adult, Older Adult)	Not Applicable	22	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	ALLN-177-204	November 2016	January 2017	January 2017	March 30, 2017		March 30, 2017			https://ClinicalTrials.gov/show/NCT03095885
661	NCT01892397	Pilot Study of Optune (NovoTTF-100A) for Recurrent Atypical and Anaplastic Meningioma		Active, not recruiting	No Results Available	Brain Cancer	Device: Optune (NovoTTF-100A)	progression-free survival rate|overall survival|safety and tolerability	Memorial Sloan Kettering Cancer Center|NovoCure Ltd.|Columbia University|University of Cincinnati|University of Colorado, Denver|University of Miami|Cedars-Sinai Medical Center	All	18 Years and older   (Adult, Older Adult)	Not Applicable	6	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	13-067	June 2013	June 2019	June 2019	July 4, 2013		October 24, 2018	Cedars-Sinai Medical Center, Los Angeles, California, United States|University of Colorado, Denver, Colorado, United States|University of Miami, Miami, Florida, United States|Memoral Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Cancer Center at Commack, Commack, New York, United States|Memorial Sloan Kettering West Harrison, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Columbia University, New York, New York, United States|University of Cincinnati, Cincinnati, Ohio, United States		https://ClinicalTrials.gov/show/NCT01892397
662	NCT04015765	Hybrid-APC Margin Ablation to Prevent Post EMR Adenoma Recurrence	h-APC EMR	Not yet recruiting	No Results Available	Colorectal Cancer|Polyp of Colon	Procedure: Hybrid Argon Plasma Coagulation and EMR procedure	Evaluate adenoma recurrence rate|Evaluate complete adenoma eradication rates	Centre hospitalier de l'Université de Montréal (CHUM)|Penn State University|University of Milan|Erbe Elektromedizin GmbH|Dr John levenick|Dr Alessandro Repici	All	18 Years to 89 Years   (Adult, Older Adult)	Not Applicable	100	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	h-APC EMR hybrid study	September 1, 2019	December 31, 2021	July 1, 2022	July 11, 2019		July 29, 2019			https://ClinicalTrials.gov/show/NCT04015765
663	NCT02755467	Clinical Evaluation of the Treatment of Spider Angioma		Completed	No Results Available	Spider Angioma	Device: KTP laser	The investigator will perform a baseline assessment of the spider angiomas and compare the degree of improvement for each treated lesion at 4 weeks post-final treatment using the Physician's Global Assessment scale.|At 4 weeks post-final treatment, subjects will be asked to rate their level of satisfaction with the laser treatment outcome and the overall laser treatment procedure, using the Subject Satisfaction Assessment Scale.	Cutera Inc.	All	5 Years to 65 Years   (Child, Adult, Older Adult)	Not Applicable	21	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	C-16-EV08	May 26, 2016	January 13, 2017	April 4, 2017	April 29, 2016		September 14, 2017	DuPage Medical Group, Naperville, Illinois, United States		https://ClinicalTrials.gov/show/NCT02755467
664	NCT02654418	Safety Study of SIC 8000 in Subjects Undergoing Endoscopic Mucosal Resection (EMR) of Colonic Lesions Equal to or Larger Than 2 cm		Completed	No Results Available	Adenomas	Procedure: Endoscopic Mucosal Resection of large colon polyps (greater than or equal to 20 mm in size)	Sydney Resection Quotient (size of polyp in mm divided by number of resection pieces).|Proportion of subjects with en bloc resection of all endoscopically visible lesion|Effectiveness compared to the reference comparator in terms of injected volume to provide initial polyp lift|Injected volume required to complete the procedure|Number of re-injections required to complete the procedure|Number of resection pieces|Ease of use rated on 5-point scale|Time to resect the lesion completely|Number of single session complete removal of lesions|Need for additional treatment modalities (eg coagulation, ablation, avulsion)|Pathology negative report for lateral and/or deep margins|Number of deep resections containing muscularis propria|Histologically positive or negative Free margin confirmed in en-bloc resections|Recurrent or residual neoplasia confirmed by repeat standard endoscopy and biopsy (if applicable) at the follow up visit	Cosmo Technologies Ltd	All	18 Years and older   (Adult, Older Adult)	Not Applicable	226	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment	CB-17-04/01	February 2016	May 2017	July 2017	January 13, 2016		September 5, 2017	Mayo Clinic, Jacksonville, Florida, United States|Indiana University Hospital, Indianapolis, Indiana, United States|Kansas City VA Hospital, Kansas City, Missouri, United States|Humanitas Research Hospital & Humanitas University, Milan, Italy|Queen Alexandra Hospital, Portsmouth, United Kingdom		https://ClinicalTrials.gov/show/NCT02654418
665	NCT03861221	The Technical Operations And Standard Clinical Application Protocol of CBBCT in Diagnostic Process of Breast Cancer	CBBCT	Recruiting	No Results Available	The Clinical Application Guide of Conebeam Breast CT	Device: CBBCT	Standardize the routine scanning and application criteria of CBBCT.|Summarize the breast anatomic features and lesions' characteristics on CBBCT.	Tianjin Medical University Cancer Institute and Hospital|Sun Yat-sen University|Chinese PLA General Hospital|The First Affiliated Hospital of Zhengzhou University|Guangxi Medical University|Koning Corporation	Female	35 Years and older   (Adult, Older Adult)	Not Applicable	800	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	CBBCT2018CIH	January 1, 2018	June 30, 2019	December 31, 2019	March 4, 2019		March 4, 2019	Tianjin Medical University Cancer Institute And Hospital, Tianjin, Tianjin, China		https://ClinicalTrials.gov/show/NCT03861221
666	NCT02759900	Using a Cold Atmospheric Plasma Device to Treat Skin Disorders		Recruiting	No Results Available	Actinic Keratosis|Acne|Verruca Plana|Tinea	Device: Non-thermal, atmospheric plasma	Clinical improvement	The Skin Center Dermatology Group	All	18 Years and older   (Adult, Older Adult)	Not Applicable	80	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	20130084	January 2016	March 2022	January 2023	May 3, 2016		April 9, 2019	The Skin Center Dermatology Group, New City, New York, United States		https://ClinicalTrials.gov/show/NCT02759900
667	NCT03420846	Efficiency of Presurgical Basal Cell Carcinoma Margin Mapping		Recruiting	No Results Available	Carcinoma, Basal Cell	Other: OCT Mapped	Average number of Mohs stages|Size of the surgical defect|Average time taken to perform OCT margin mapping	Michelson Diagnostics Ltd.|Skin Care Network Ltd.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	200	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	1202	July 1, 2018	April 2020	July 2020	February 2, 2018		September 5, 2018	SkinCare Network, London, United Kingdom	"Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/46/NCT03420846/ICF_000.pdf|"Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/46/NCT03420846/Prot_001.pdf	https://ClinicalTrials.gov/show/NCT03420846
668	NCT03000361	Motorized Spiral Colonoscopy Trial: A First Feasibility Trial	MSCT	Completed	No Results Available	Colonoscopy|Safety Issues|Adenoma	Procedure: Motorized Spiral Colonoscopy	Cecal intubation rate|Ileum intubation rate|Procedure time|rate of need for external compression|adenoma detection rate|success rate for removal of polyps|amount of propofol needed for sedation|maximum level of sedation during procedure|patient satisfaction score|adverse event rate|maximum pain during procedure	Evangelisches Krankenhaus Düsseldorf|Olympus	All	18 Years and older   (Adult, Older Adult)	Not Applicable	30	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MSCT	December 2016	February 1, 2017	February 1, 2017	December 22, 2016		August 1, 2017	Evangelisches Krankenhaus, Dusseldorf, Germany		https://ClinicalTrials.gov/show/NCT03000361
669	NCT03427177	Mychoice: Testing an Interactive mHealth Tool		Recruiting	No Results Available	Conflict|Decisional Conflict	Behavioral: mychoice	Perceived Efficacy in Patient-Physician Interactions (PEPPI) Self-Efficacy Scale- Change from baseline to post-test and one month follow-up|Preparation for Decision Making (PrepDM) Scale|Ottawa Decisional Conflict- Measure Change from baseline to post-test and one month follow-up|Shared Decision Making (SDM Q-9) Scale|CollaboRATE Perceived Shared Decision Making Scale|Satisfaction with Decision Scale|Experience with Clinical Trial Discussions Scale|Satisfaction with Patient Materials Scale- Change from baseline to post-test and one month follow-up|Ottawa Clinical Trial Intention Scale- Measuring change from baseline to one month follow-up|Knowledge of Clinical Trials Scale- Measuring change from baseline to follow-up|Patient Self-Advocacy (PSAS) Scale|Decision Engagement (DES-10) Patient Activation Scale- Change from baseline to post-test and one month follow-up|Clinical Trial Perceptions Measure- Change from baseline to post-test and one month follow-up|Single Item Literacy (SILS) Health Literacy Screener Scale|HINTS Technology Use Scale|Cancer and Clinical Trial Experience Scale	Fox Chase Cancer Center|Merck Sharp & Dohme Corp.|University of Pennsylvania|Temple University	All	18 Years and older   (Adult, Older Adult)	Not Applicable	270	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Health Services Research	17-014304	June 25, 2018	July 31, 2019	August 30, 2019	February 9, 2018		March 13, 2019	University of Pennsylvania, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Temple University, Philadelphia, Pennsylvania, United States|Temple University Health System, Philadelphia, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT03427177
670	NCT00283621	Aranesp and Neulasta in Patients With Sarcoma Receiving Adriamycin and Ifosfamide		Completed	No Results Available	Sarcoma	Drug: Aranesp (darbepoetin alfa)|Drug: Neulasta (pegfilgrastim)|Drug: Adriamycin|Drug: Ifosfamide	CBC diff/platelet counts|Iron Stores|Peripheral blood and bone marrows|Neurocognitive functions and Symptom burden assessment	M.D. Anderson Cancer Center|Amgen	All	18 Years to 65 Years   (Adult, Older Adult)	Not Applicable	51	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	ID02-326	June 2, 2003	April 12, 2006	April 12, 2006	January 30, 2006		November 7, 2018	UT MDAnderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT00283621
671	NCT00700531	European Trial of Free Light Chain Removal by Extended Haemodialysis in Cast Nephropathy	EuLITE	Completed	No Results Available	Multiple Myeloma|Cast Nephropathy|Kidney Failure	Device: FLC removal HD (Gambro HCO 1100)|Procedure: Standard dialysis on a high flux ployflux dialyser	Independence of haemodialysis at 3 months from enrollment (eGFR > 15mls/min/1.73m2 at 2 weeks after last dialysis session)|Efficiency of extended HD with respect to reduced sFLC concentrations; duration of HD before renal recovery; multiple myeloma response to chemotherapy and suitability for stem cell transplantation; mortality over 24 months observation period	University Hospital Birmingham|Gambro Renal Products, Inc.|Ortho Biotech, Inc.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	90	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	EudraCT 2007-003968-22|ISRCTN45967602	June 2008	January 2014	October 2015	June 18, 2008		October 5, 2016	University Hospital Birmingham, Birmingham, West Midlands, United Kingdom		https://ClinicalTrials.gov/show/NCT00700531
672	NCT02011802	Sorbact TM: Effect of a Microbial Binding Dressing on Wound Healing After Pilonidal Sinus Excision	SORKYSA	Completed	No Results Available	Sinus Pilonidal	Device: Algosteril TM|Device: Sorbact TM	Percentage of wounds healed|Total surface area measure of non-healed wounds|VAS pain|analgesic use|antibiotics use|number of dressings used	University Hospital, Strasbourg, France|INRESA Pharma	All	18 Years and older   (Adult, Older Adult)	Not Applicable	251	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	5568	December 2013	September 1, 2017	September 1, 2017	December 13, 2013		November 9, 2017	Service de Chirurgie Digestive-Hôpital Pasteur-39 av de la Liberté, Colmar, France|Service de Chirurgie Digestive-Centre Hospitalier de Mulhouse- 20 av du Dr René Laennec, Mulhouse, France|Service de Chirurgie Générale Viscérale et Digestive-Centre Hospitalier de Saverne-19 Côte de Saverne, Saverne, France|Service de Chirurgie Digestive - Hôpital de Hautepierre- Hôpitaux Universitaires de Strasbourg - France, Strasbourg, France		https://ClinicalTrials.gov/show/NCT02011802
673	NCT00683631	TheraSphere HUD For Treatment of Unresectable Hepatocellular Carcinoma (HCC)	TheraSphere	Completed	No Results Available	Hepatocellular Carcinoma	Radiation: TheraSphere HUD	Tumor Response after treatment|Incidence of toxicities / Adverse Events|Evaluate survival time|Determine proportion of patients with HCC that can be treated with Therasphere	University of Louisville|MDS Pharma Services	All	18 Years and older   (Adult, Older Adult)	Not Applicable	150	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	TheraSphere - 421.03	January 2004	July 2012	July 2012	May 23, 2008		October 21, 2013	University of Louisville Hospital / Norton Hospital, Louisville, Kentucky, United States		https://ClinicalTrials.gov/show/NCT00683631
674	NCT02356081	eSMART Trial to Evaluate ASyMS		Recruiting	No Results Available	Cancer	Other: ASyMS intervention Group	Memorial Symptom Assessment Scale (MSAS)	Louise McKean|University College Dublin|King's College London|University of California, San Francisco|University of Athens|Medical University of Vienna|University of Dundee|European Cancer Patient Coalition (ECPC)|Docobo Ltd.|University of Surrey|Sykehuset Innlandet HF|University of Strathclyde	All	18 Years and older   (Adult, Older Adult)	Not Applicable	1108	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other	CRC331	February 2015	January 2019	January 2019	February 5, 2015		November 13, 2017	Medical University Vienna Comprehensive Cancer Center, Vienna, Austria|Agioi Anargiri Cancer Hospital, Athens, Greece|Air Force General Hospital, Athens, Greece|Metropolitan Hospital, Athens, Greece|St James's Hospital, Dublin, Ireland|St Vincent's Healthcare Group, Dublin, Ireland|University Hospital Waterford, Waterford, Ireland|Innlandet Hospital Trust, Lillehammer, Norway|Royal Surrey County Hospital, Guildford, United Kingdom|Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom|St George's Healthcare Trust, London, United Kingdom|University College London, London, United Kingdom|Mount Vernon Cancer Centre, Northwood, United Kingdom		https://ClinicalTrials.gov/show/NCT02356081
675	NCT03353077	Alpha Radiation Emitters Device for the Treatment of Squamous Cell Carcinoma (DaRT)		Recruiting	No Results Available	Skin Squamous Cell Carcinoma	Device: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)	Adverse Events|Reduction in Tumor size|Percent of NecroticTissue	Alpha Tau Medical LTD.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	35	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CTP-SCC-000	November 21, 2017	April 2020	June 2020	November 27, 2017		June 27, 2019	Policlinico Umberto I Hospital Sapienza Rome University, Rome, Lazio, Italy|Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola, Italy		https://ClinicalTrials.gov/show/NCT03353077
676	NCT03497936	Marketability of a Technology-based Intervention to Increase HPV Vaccination		Recruiting	No Results Available	Human Papilloma Virus	Behavioral: Women's Stories	HPV Vaccination	Real Prevention, LLC|University of California, Irvine	Female	18 Years to 26 Years   (Adult)	Not Applicable	360	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	R44DP006291	May 1, 2018	May 31, 2020	August 30, 2020	April 13, 2018		April 30, 2019	University of California, Irvine, Irvine, California, United States|Planned Parenthood of Illinois, Chicago, Illinois, United States|Planned Parenthood of the St. Louis Region and Southwest Missouri, Saint Louis, Missouri, United States|REAL Prevention LLC, Clifton, New Jersey, United States|Public Health Management Corporation, Philadelphia, Pennsylvania, United States|Planned Parenthood of Southeastern Pennsylvania, Philadelphia, Pennsylvania, United States|St. Andrew Development, York, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT03497936
677	NCT02528266	Surgical Treatment of Symptomatic Neuroma "Stop Neuroma"		Completed	No Results Available	Neuroma	Device: Nerve Capping Device	Safety data (Serious adverse events )|Effectiveness (VAS score)|Effectiveness (QuickDASH score)|Effectiveness (Quantity and class of pain medication used)|Safety (Rate of serious adverse device effects)|Effectiveness (DN4 score)|Effectiveness (Elliot score)|Rate of recurrence of symptomatic neuroma	Polyganics BV	All	18 Years and older   (Adult, Older Adult)	Not Applicable	10	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	034A01_CIP	January 2016	March 30, 2018	March 30, 2018	August 19, 2015		June 13, 2018	Strasbourg University Hospitals, Strasbourg, France|Haga Hospital, Den Haag, Netherlands|Albert Schweitzer Hospital, Dordrecht, Netherlands|UMCG, Groningen, Netherlands|Martini Hospital Groningen, Groningen, Netherlands|MC Groep, Lelystad, Netherlands|MUMC, Maastricht, Netherlands		https://ClinicalTrials.gov/show/NCT02528266
678	NCT01988948	Dynamics of Human PApilloma Virus Interactions; Internet-based Students HeAlth Research Enterprise	DyPAVIR	Completed	No Results Available	Infection by Human Papilloma Virus	Other: Various biological sampling	Proportion of HPV detection at inclusion (all HPV genotypes)|Incidence of oncogenic HPV genotypes, co-infection with different HPV genotypes	Institut Pasteur|Université de Versailles Saint-Quentin-en-Yvelines|centre national de référence pour les Papillomavirus Humains|German Cancer Research Center	All	18 Years to 20 Years   (Adult)	Not Applicable	49	Industry|Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	2011-42|2012-A00814-39	October 2013	June 2016	June 2016	November 20, 2013		August 31, 2016	Service Universitaire de Médecine Préventive et de Promotion de la Santé (SUMPPS), Versailles, France		https://ClinicalTrials.gov/show/NCT01988948
679	NCT03892980	Da Vinci Xi NSM IDE Study		Not yet recruiting	No Results Available	Nipple Sparing Mastectomy	Device: Nipple-Sparing Mastectomy	Primary Effectiveness as measured by incidence of conversion to open surgery|Primary Safety: complication rates	Intuitive Surgical	Female	18 Years to 80 Years   (Adult, Older Adult)	Not Applicable	71	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ISI dV Xi-NSM	June 2019	July 2020	September 2020	March 27, 2019		March 27, 2019			https://ClinicalTrials.gov/show/NCT03892980
680	NCT02159898	EndoMAXX Endoluminal Valve Technology (EVT) Compared to EndoMAXX		Completed	Has Results	Malignant Esophageal Strictures	Device: EndoMAXX Endoluminal Valve Technology (EVT)|Device: EndoMAXX	Mellow and Pinkas Dysphagia Score at Baseline and 2 Weeks Following the Treatment|GERD-HRQL	Merit Medical Systems, Inc.|Geisinger Clinic|Medical College of Wisconsin|Indiana University|University of Colorado, Denver|Mayo Clinic|Weill Medical College of Cornell University|University of Florida	All	18 Years and older   (Adult, Older Adult)	Not Applicable	60	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	ESO-P3-12-02	January 2015	October 2016	December 2016	June 10, 2014	June 7, 2018	June 7, 2018	University of Colorado Denver, Aurora, Colorado, United States|University of Florida, Gainesville, Florida, United States|Indiana University, Indianapolis, Indiana, United States|Mayo Clinic, Rochester, Minnesota, United States|Weill Cornell Medical College, New York, New York, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States		https://ClinicalTrials.gov/show/NCT02159898
681	NCT03780569	TTFields Together With Temozolomide and Radiotherapy in Patients With Newly Diagnosed GBM		Active, not recruiting	No Results Available	Glioblastoma Multiforme	Device: NovoTTF-200A|Radiation: Radiotherapy|Drug: Temozolomide	Safety of concomitant Radiotherapy/Temozolomide with NovoTTF-200A: The incidence of Radiotherapy treatment delays during concomitant Radiotherapy/Temozolomide/NovoTTF-200A will be documented including severity and relationship to NovoTTF-200A.|Progression free survival|Overall survival|Adverse events, severity and frequency	NovoCure Ltd.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	10	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ICH-1	April 27, 2017	January 2019	January 2019	December 19, 2018		December 19, 2018	Tel Aviv Sourasky Medical Center, Tel Aviv, Israel		https://ClinicalTrials.gov/show/NCT03780569
682	NCT01699698	Pancreatic Juice Diagnosis From Duodenum		Completed	Has Results	Pancreatic Adenocarcinoma	Other: Tumor markers	The Concentration of the Pancreatic Cancer Markers of the Normal Cohort and UICC Stage II Pancreatic Ductal Adenocarcinoma Cohort|The Sensitivity and Specificity to Detect UICC Stage II Pancreatic Ductal Adenocarcinoma Among All Participants.	Olympus Corporation|Mayo Clinic|Kyushu University|The University of Texas Health Science Center, Houston	All	18 Years and older   (Adult, Older Adult)	Not Applicable	105	Industry|Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic	OMSC-PJD-1	October 2012	July 2014		October 4, 2012	September 3, 2015	September 21, 2015	Mayo Clinic Jacksonville, Jacksonville, Florida, United States|Kyushu University, Fukuoka-shi, Fukuoka-ken, Japan		https://ClinicalTrials.gov/show/NCT01699698
683	NCT01490060	Fosaprepitant in Patients Receiving Ifosfamide-based Regimen		Completed	Has Results	Sarcoma|Chemotherapy-induced Nausea and Vomiting|Effects of Chemotherapy|Adverse Effects of Medical Drugs	Drug: Fosaprepitant|Drug: Dexamethasone|Drug: 5HT3 receptor antagonist|Drug: Ifosfamide-based chemotherapy (AI)|Drug: Doxorubicin|Drug: Mesna|Drug: Ifosfamide|Drug: Vincristine	Complete Response	M.D. Anderson Cancer Center|Merck Sharp & Dohme Corp.	All	18 Years to 65 Years   (Adult, Older Adult)	Not Applicable	47	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2011-0620|NCI-2012-00011	May 2012	March 2016	March 2016	December 12, 2011	June 3, 2015	April 11, 2016	University of Texas MD Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT01490060
684	NCT01948661	Anthocyanin Extract and Phospholipid Curcumin in Colorectal Adenoma	MIRACOL	Active, not recruiting	No Results Available	Colorectal Adenoma|Risk Reduction	Dietary Supplement: Mirtoselect® + Meriva®|Dietary Supplement: Placebo	Change of immunohistochemical expression of beta catenin in normal and adenomatous colonic tissue|Change of IHC Nuclear Factor-Kβ (NFKβ), Ki-67 Labeling Index and P53 in normal and adenomatous mucosa.	Ente Ospedaliero Ospedali Galliera|Fondazione Umberto Veronesi|Indena S.p.A	All	18 Years to 75 Years   (Adult, Older Adult)	Not Applicable	100	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention	GAL 02	March 2014	September 2019	December 2019	September 23, 2013		August 1, 2018	ASL 3, Ospedale Villa Scassi, S.C. Gastroenterologia, Genova, Italy|Medical Oncology Ente Ospedaliero Ospedali Galliera, Genova, Italy|ASL4 Chiavarese, Ospedale di Lavagna, SSD Gastroenterologia, Lavagna, Italy		https://ClinicalTrials.gov/show/NCT01948661
685	NCT03610620	Confocal Microscopy Evaluation of Margin Clearance in Basal Cell Carcinomas in Mohs Surgery	FCM-P	Recruiting	No Results Available	Basal Cell Carcinoma	Procedure: Vivascope 2500 ex-vivo fluorescent confocal microscope	To compare the specificity and sensitivity of the ex-vivo fluorescence confocal microscopy against frozen section histopathology in detecting residual BCC in Mohs excisions.|To compare the time taken for processing and interpretation of the ex-vivo fluorescence confocal microscopy against frozen section histopathology in detecting residual BCC in Mohs excisions.	Emily Woodhouse|Mavig GmbH|Norfolk and Norwich University Hospitals NHS Foundation Trust	All	18 Years and older   (Adult, Older Adult)	Not Applicable	30	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	212591	June 12, 2017	October 11, 2019	October 11, 2019	August 1, 2018		August 23, 2018	Norfolk & Norwich University Hospitals NHS Foundation Trust, Norwich, Norfolk, United Kingdom		https://ClinicalTrials.gov/show/NCT03610620
686	NCT03025724	Photodynamic Therapy for Treatment of Cutaneous Squamous Cell Carcinoma in Situ		Not yet recruiting	No Results Available	Squamous Cell Carcinoma	Drug: Levulan Kerastick|Device: blue light source|Other: participant satisfaction survey	Evaluate the incidence of SCCis present after exposure to the experimental procedures|Physician graded scoring on a 1 to 4 scale of erythema, edema, stinging/burning, blisters/crusting, hyperpigmentation, and hypopigmentation.	Rhode Island Hospital|DUSA Pharmaceuticals, Inc.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	40	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	897494	January 2017	January 2020	January 2020	January 19, 2017		January 19, 2017			https://ClinicalTrials.gov/show/NCT03025724
687	NCT02658851	Cold Plasma for the Reduction of Lymphoceles Following PLND		Completed	No Results Available	Lymphoceles Following Pelvic Lymph Node Dissection	Device: J-Plasma	Incidence of lymphocele formation	Apyx Medical (formerly Bovie Medical Corp.)|Florida Hospital	Male	18 Years to 80 Years   (Adult, Older Adult)	Not Applicable	100	Industry|Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	808076	June 2016	June 27, 2017	June 27, 2017	January 20, 2016		September 12, 2017	Florida Hospital Global Robotics Institute, Celebration, Florida, United States		https://ClinicalTrials.gov/show/NCT02658851
688	NCT03846531	Nano-Pulse Stimulation (NPS) in Seborrheic Keratosis Study		Completed	No Results Available	Lesion Skin|Seborrheic Keratosis	Device: Nano-Pulse Stimulation (NPS)	SK Lesion Clearance	Pulse Biosciences, Inc.	All	18 Years to 75 Years   (Adult, Older Adult)	Not Applicable	60	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	NP-SK-002	May 4, 2017	November 13, 2017	May 22, 2018	February 19, 2019		February 19, 2019	Premier Plastic Surgery, San Mateo, California, United States|Skin Care Physicians, Chestnut Hill, Massachusetts, United States|Zel Skin & Laser Specialists, Edina, Minnesota, United States|Laser & Dermatologic Surgery Center, Chesterfield, Missouri, United States		https://ClinicalTrials.gov/show/NCT03846531
689	NCT01529450	Pilot LDE225 in Locally Advanced or Metastatic BCC + Previously Tx Non-LDE225 Smoothened Inhibitors		Completed	Has Results	Basal Cell Carcinoma	Drug: LDE225	Progression Free Survival (PFS) of All Participants|Molecular Markers Associated With Clinical Response	Anne Chang|Novartis|Stanford University	All	18 Years and older   (Adult, Older Adult)	Not Applicable	11	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	SKIN0009|SU-09022011-8371|21759	February 2012	August 2013	August 2013	February 8, 2012	November 2, 2016	January 16, 2017	Stanford University, School of Medicine, Stanford, California, United States		https://ClinicalTrials.gov/show/NCT01529450
690	NCT03015649	Long Term Use of SAVI SCOUT: Pilot Study		Completed	No Results Available	Breast Diseases	Device: SAVI SCOUT Surgical Guidance System	successful surgery	Sheridan Healthcare, Inc.|Cianna Medical, Inc.	Female	18 Years to 90 Years   (Adult, Older Adult)	Not Applicable	34	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research	CMI-SCOUT-001	February 3, 2017	September 10, 2018	April 4, 2019	January 10, 2017		April 16, 2019	Envision Physician Scientific Research, Inc. formerly Sheridan Healthcare, Inc., Plantation, Florida, United States		https://ClinicalTrials.gov/show/NCT03015649
691	NCT03148665	Saliva-based Detection of CD44	Detect 44	Active, not recruiting	No Results Available	Oral Cavity Squamous Cell Carcinoma|Oropharynx Squamous Cell Carcinoma|Squamous Cell Carcinoma of the Oropharynx|Squamous Cell Carcinoma of the Head and Neck	Device: OncAlert	To validate performance of the Vigilant Oral Rinse Point of Care strip in a multi-institutional clinical setting|To prospectively validate the performance of pretreatment Vigilant Oral Rinse Point of Care strip and Sol CD44 as a predictor of outcome for oral/oropharyngeal cancer in a point of care multi-institutional clinical setting|To determine the association of post treatment salivary solCD44 and the Vigilant Oral Rinse Point of Care strip with disease outcome in oral/oropharyngeal cancer	Joseph Califano|Vigilant Biosciences, Inc.|Greater Baltimore Medical Center|San Diego Veterans Healthcare System|NYU Langone Health|Johns Hopkins University|University of California, San Diego	All	18 Years and older   (Adult, Older Adult)	Not Applicable	300	Other|Industry|U.S. Fed	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening	161215	April 14, 2017	December 30, 2019	May 30, 2020	May 11, 2017		June 25, 2019	UCSD Moores Cancer Center, La Jolla, California, United States|Greater Baltimore Medical Center, Baltimore, Maryland, United States|Johns Hopkins School of Medicine, Baltimore, Maryland, United States|New York University College of Dentistry, New York, New York, United States		https://ClinicalTrials.gov/show/NCT03148665
692	NCT01236300	In Vivo nCLE Study in the Pancreas With Endosonography of Cystic Tumors	INSPECT	Completed	Has Results	Pancreatic Cysts	Device: Cellvizio needle-based Confocal Laser Endomicroscopy (nCLE) system	Sensitivity|Specificity|PPV (Positive Predictive Value)|NPV (Negative Predictive Value)|Overall Complication Rate	University of Chicago|Mauna Kea Technologies|Institut Paoli-Calmettes|Technische Universität München|Yale University|University of California, Irvine|Mayo Clinic|University of Washington|Cedars-Sinai Medical Center	All	18 Years and older   (Adult, Older Adult)	Not Applicable	66	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	MKT-2010-INSPECT|EUSFNA_02	July 2010	August 2011	May 2012	November 8, 2010	March 31, 2015	June 8, 2016	University of Chicago, Chicago, Illinois, United States		https://ClinicalTrials.gov/show/NCT01236300
693	NCT01502020	A Bioequivalence Study With Clinical Endpoints Comparing Generic Imiquimod Cream, 3.75% and Zyclara™ (Imiquimod) Cream, 3.75% in Subjects With Actinic Keratoses		Completed	No Results Available	Actinic Keratoses	Drug: imiquimod cream, 3.75%|Drug: Vehicle Cream	Complete clearance rate|Dosing Compliance|Adverse Events|Local Skin Reactions|Partial Clearance Rate|Percent Change in the AK number	Actavis Mid-Atlantic LLC	All	18 Years and older   (Adult, Older Adult)	Not Applicable	410	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	094-3152-301	February 2011	August 2011	November 2011	December 30, 2011		December 30, 2011	Total Skin and Beauty Dermatology Center, PC, Birmingham, Alabama, United States|International Dermatology Research, Inc., Miami, Florida, United States|MedaPhase, Inc., Newnan, Georgia, United States|Northwest Clinical Trials, Boise, Idaho, United States|Altman Dermatology Associates, Arlington Heights, Illinois, United States|Deaconess Clinic, Inc., Evansville, Indiana, United States|Indiana Clinical Trials Center, Plainfield, Indiana, United States|Dermatology Specialists, Louisville, Kentucky, United States|Michigan Center for Research Corp., Clinton Township, Michigan, United States|Minnesota Clinical Study Center, Fridley, Minnesota, United States|Skin Specialists, P.C., Omaha, Nebraska, United States|Academic Dermatology Associates, Albuquerque, New Mexico, United States|Dermatology, Laser & Vein Specialists of the Carolinas,, Charlotte, North Carolina, United States|Dermatology Research Center of Cincinnati, Cincinnati, Ohio, United States|Oregon Medical Research Center, PC, Portland, Oregon, United States|Philadelphia Institute of Dermatology, Fort Washington, Pennsylvania, United States|DermResearch, Inc., Austin, Texas, United States|Suzanne Bruce and Associates, P.A., Houston, Texas, United States|Dermatology Clinical Research Center of San Antonio, San Antonio, Texas, United States		https://ClinicalTrials.gov/show/NCT01502020
694	NCT03159819	Clinical Study of CAR-CLD18 T Cells in Patients With Advanced Gastric Adenocarcinoma and Pancreatic Adenocarcinoma		Recruiting	No Results Available	Advanced Gastric Adenocarcinoma|Pancreatic Adenocarcinoma	Genetic: CAR-CLD18 T Cells	Safety and tolerance|Engraftment	Changhai Hospital|Carsgen Therapeutics, Ltd.	All	18 Years to 70 Years   (Adult, Older Adult)	Not Applicable	24	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CG4003	April 1, 2017	December 31, 2019	December 31, 2021	May 19, 2017		March 12, 2018	Changhai Hospital, Shanghai, Shanghai, China		https://ClinicalTrials.gov/show/NCT03159819
695	NCT02067468	Optimal Strategy for the Management of ASCUS Cytology in Health Care Services of Medellin, Colombia	ASCUS-COL	Completed	No Results Available	Cervical Abnormalities|Cervical Intraepithelial Neoplasia Grade 2/3|Cervical Cancer	Device: HPV test|Procedure: COLPOSCOPY|Device: cytology	Cervical Intraepithelial Neoplasia Grade 2 or higher(CIN2+)	Universidad de Antioquia|International Agency for Research on Cancer|Barts and the London School of Medicine and Dentistry|Instituto Colombiano para el Desarrollo de la Ciencia y la Tecnología (COLCIENCIAS)|QIAGEN Gaithersburg, Inc|EPS SURA|EPS COMFAMA|EPS COMFENALCO|DINAMICA IPS|Laboratorio Clínico Escuela de Microbiología (Universidad de Antioquia)|Metrosalud	Female	20 Years to 69 Years   (Adult, Older Adult)	Not Applicable	3000	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research	111545921657	January 2011	April 2016	April 2016	February 20, 2014		June 6, 2016	Universidad de Antioquia, Medellin, Antioquia, Colombia		https://ClinicalTrials.gov/show/NCT02067468
696	NCT01442064	An Extension Study to Evaluate Safety and Tolerability of Ranibizumab in Macular Edema Secondary to Retinal Vein Occlusion (Cohort 2)		Completed	Has Results	Macular Edema|Retinal Vein Occlusion	Drug: Ranibizumab 0.5 mg	Number of Participants With Ocular Adverse Events in the Study Eye|Number of Participants With Non-ocular Adverse Events|Change From Baseline in the Best Corrected Visual Acuity (BCVA)|Change From Baseline in Central Foveal Thickness at Month 6 and Month 12|Change From Baseline in Visual Function Composite Score, as Measured by the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25)	Genentech, Inc.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	608	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	FVF3426g (Cohort 2)	July 2008	July 2010	July 2010	September 28, 2011	January 10, 2012	January 10, 2012			https://ClinicalTrials.gov/show/NCT01442064
697	NCT01215721	Study to Determine Effects of Vesicare on Return to Continence Post - Radical Prostatectomy (Part II)		Completed	Has Results	Urinary Incontinence	Drug: Vesicare	Time to Continence	University of California, Irvine|Astellas Pharma US, Inc.	Male	18 Years and older   (Adult, Older Adult)	Not Applicable	40	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2007-5720-2	October 2010	May 2013	May 2013	October 6, 2010	January 23, 2014	January 23, 2014	University of California, Irvine Medical Center, Orange, California, United States		https://ClinicalTrials.gov/show/NCT01215721
698	NCT03508856	Clinical and Histologic Evaluation of Picato 0.15% Gel in the Cosmetic Improvement of Photoaged Skin		Completed	No Results Available	Actinic Keratosis|Photo-aged Skin	Drug: Ingenol Mebutate (Picato®) 0.015% gel	To evaluate the improvement in actinic keratoses and photoaged skin as measured numerically by Griffiths' Photonumeric Photoaging scale and questionnaires,	Skin Laser & Surgery Specialists|LEO Pharma	All	45 Years to 75 Years   (Adult, Older Adult)	Not Applicable	23	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ENC_008776	November 9, 2015	August 9, 2016	August 9, 2016	April 26, 2018		April 26, 2018			https://ClinicalTrials.gov/show/NCT03508856
699	NCT03766490	Anlotinib Hydrochloride Combined With EGFR TKIs in Advanced Non-small Cell Lung Cancer		Not yet recruiting	No Results Available	Non-Small-Cell Lung	Drug: Anlotinib Hydrochloride|Drug: Gefitinib|Drug: Icotinib	PFS（Progress free survival）|Overall Survival (OS)|Objective Response Rate (ORR)|Quality of Life(QoL)|Disease Control Rate (DCR)	The First Affiliated Hospital of Soochow University|The First People's Hospital of Changzhou|Second Affiliated Hospital of Soochow University|Nantong University|Affiliated Hospital of Jiangnan University|Jiangyin People's Hospital|Changzhou No.2 People's Hospital|Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	All	18 Years to 75 Years   (Adult, Older Adult)	Not Applicable	66	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ALTER-L010	March 30, 2019	December 20, 2019	December 20, 2020	December 6, 2018		January 30, 2019	The First Affiliated hospital of soochow university, Suzhou, Jangsu, China		https://ClinicalTrials.gov/show/NCT03766490
700	NCT02451579	A Clinical Trial Evaluating the Role of Systemic Antihistamine Therapy in the Reduction of Adverse Effects Associated With Topical 5-aminolevulinic Acid Photodynamic Therapy		Completed	No Results Available	Actinic Keratoses	Drug: Antihistamine Cetirizine Hydrochloride|Other: Placebo	Localized Skin Response	Goldman, Butterwick, Fitzpatrick and Groff|DUSA Pharmaceuticals, Inc.	All	19 Years and older   (Adult, Older Adult)	Not Applicable	20	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	PDT-2015-01	February 2015	December 2016	January 2017	May 22, 2015		March 1, 2017	Cosmetic Laser Dermatology, San Diego, California, United States		https://ClinicalTrials.gov/show/NCT02451579
701	NCT02242747	Safety and Tolerability Study of Ingenol Mebutate Compared to 5-FU to Treat Facial Actinic Keratosis		Completed	No Results Available	Actinic Keratosis	Drug: ingenol mebutate|Drug: 5% 5-FU	Area under the LSR (local skin reactions)-Time Curve (AUC 0-43 days)|Area Under the each component of the total LSR-Time Curve (AUC 0-43 days)	University of Sao Paulo|LEO Pharma	All	18 Years and older   (Adult, Older Adult)	Not Applicable	100	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	11334	May 2014	July 2014	August 2014	September 17, 2014		September 17, 2014	Hospital das Clínicas of the University of São Paulo Medical School (HCFMUSP), Sao Paulo, Brazil		https://ClinicalTrials.gov/show/NCT02242747
702	NCT00121511	The Effect of Efudex Treatment on Photoaged Skin		Completed	No Results Available	Photo-aging|Keratosis	Drug: Efudex (5-fluorouracil)	Actinic Keratoses resolution and improvement in photoaging|Changes in p53 immunostaining intensity will be used to assess response|Collagen production will be evaluated by Western blotting, immunohistology, and RT-PCR	University of Michigan|Bausch Health Americas, Inc.	All	50 Years and older   (Adult, Older Adult)	Not Applicable	21	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Derm 549|2005-0368	July 2005		July 2007	July 21, 2005		May 27, 2015	University of Michigan Department of Dermatology, Ann Arbor, Michigan, United States		https://ClinicalTrials.gov/show/NCT00121511
703	NCT02015806	Robust Evaluation to Measure Improvements in Nonadherence From Low-cost Devices	REMIND	Completed	No Results Available	Cardiovascular Disease|Diabetes|Breast Cancer|Depression|Mental Health Disorder|Prostatic Hypertrophy, Benign|Parkinson's Disease|Epilepsy	Behavioral: RxTimerCap|Behavioral: Take-N-Slide|Behavioral: Pillbox	Optimal medication adherence to all cardiovascular or non-depression chronic disease medications|Optimal adherence to antidepressants|Optimal adherence to the targeted therapies in each randomization block independently|Optimal adherence to cardiovascular medications among subjects who are suboptimally adherent to these medications at time of randomization	Brigham and Women's Hospital|CVS Caremark	All	18 Years to 64 Years   (Adult)	Not Applicable	53480	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research	2013-P-00009085	March 2014	February 2015	February 2015	December 19, 2013		January 11, 2016	CVS Health, Woonsocket, Rhode Island, United States		https://ClinicalTrials.gov/show/NCT02015806
704	NCT02965209	European Novel Motorized Spiral Endoscopy Trial	ENMSET	Completed	No Results Available	Disorder of Small Intestine|Gastrointestinal Hemorrhage|Iron Deficiency Anaemia|Crohn`s Disease|Small Bowel Tumors|Intestinal Polyposis Syndrome|Coeliac Disease	Procedure: motorized spiral enteroscopy	Diagnostic yield of NMSE in patients with suspected small bowel diseases|Procedural success|Procedural time (minutes)|Depth of maximal insertion (cm)|Therapeutic yield|Adverse events	Evangelisches Krankenhaus Düsseldorf|Olympus	All	18 Years and older   (Adult, Older Adult)	Not Applicable	136	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ENMSET	November 2015	February 3, 2018	February 6, 2018	November 16, 2016		February 14, 2018	Universite Libre des Bruxelles, Brussels, Belgium|Evangelisches Krankenhaus, Duesseldorf, Germany		https://ClinicalTrials.gov/show/NCT02965209
705	NCT03727425	Robotic Bronchoscopy for Peripheral Pulmonary Lesions		Recruiting	No Results Available	Lung; Node	Device: Robotic assisted bronchoscopy	Incidence of device or procedure related adverse events|Successful navigation to targeted peripheral pulmonary lesions|Incidence of complications unrelated to device|Time to R-EBUS confirmation (lesion localization)|Time to the tissue acquisition confirmation|Total procedure time|Procedure interruptions|Radiographic and procedural factors that influence the ability to successfully navigate to peripheral lesions|Diagnostic yield|Conversion to conventional bronchoscopic procedure	Auris Health, Inc.	All	18 Years to 80 Years   (Adult, Older Adult)	Not Applicable	55	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	18-BR-0001	November 1, 2018	August 30, 2019	June 30, 2020	November 1, 2018		July 12, 2019	Henry Ford Health System, Detroit, Michigan, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Cleveland Clinic, Cleveland, Ohio, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Innova Fairfax Hospital, Falls Church, Virginia, United States		https://ClinicalTrials.gov/show/NCT03727425
706	NCT00897897	Therapeutic Magnetic Resonance Imaging (MRI)-Guided High Intensity Focused Ultrasound (HIFU) Ablation of Uterine Fibroids		Completed	Has Results	Uterine Fibroids	Device: Philips MRI-guided HIFU system	Adverse Events/Subject Resulting From HIFU Treatment of the Uterine Fibroids|Fibroid Symptom Severity Score (SSS) From the Uterine Fibroid Symptoms - Quality of Life (UFS-QoL) Questionnaire.	Philips Healthcare|Philips Medical Systems	Female	18 Years to 59 Years   (Adult)	Not Applicable	33	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	996233	April 2009	December 2009	December 2009	May 12, 2009	November 11, 2011	December 4, 2012	Hospital St. Andre, Bordeaux, France|University Hospital Schleswig-Holstein, Lübeck, Germany|Samsung Medical Center, Seoul, Korea, Republic of|University Medical Center, Utrecht, Netherlands		https://ClinicalTrials.gov/show/NCT00897897
707	NCT01903733	Bosutinib Treatment Extension Study Only For Subjects With Chronic Myeloid Leukemia (CML) Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008		Active, not recruiting	No Results Available	Chronic Myeloid Leukemia	Drug: bosutinib	To allow long term bosutinib treatment in patients with chronic or advanced phases of Ph+ CML	Pfizer	All	18 Years and older   (Adult, Older Adult)	Not Applicable	282	Industry	Interventional	Masking: None (Open Label)	B1871040|2013-000691-15	August 28, 2013	May 15, 2020	May 15, 2020	July 19, 2013		April 3, 2019	Orlando Health, Inc., Orlando, Florida, United States|Emory University Hospital, Atlanta, Georgia, United States|Emory University, Atlanta, Georgia, United States|Investigational Drug Service, Emory University Clinic, Atlanta, Georgia, United States|The Emory Clinic, Atlanta, Georgia, United States|Winship Cancer Institute, Emory University, Atlanta, Georgia, United States|Northside Hospital, Inc.- Central Research Department, Atlanta, Georgia, United States|Northside Hospital, Atlanta, Georgia, United States|Indiana Blood & Marrow Transplantation, Indianapolis, Indiana, United States|Indiana Blood and Marrow Transplantation, Indianapolis, Indiana, United States|Siouxland Hematology-Oncology Associates, LLP, Sioux City, Iowa, United States|Siouxland Regional Cancer Center dba June E. Nylen Cancer Center, Sioux City, Iowa, United States|Rcca Md,Llc, Bethesda, Maryland, United States|Hudson Valley Hematology and Oncology Associates, Hawthorne, New York, United States|Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|The University of Texas MD Anderson Cancer Center- Investigational Pharmacy, Houston, Texas, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|The University of Texas, MD Anderson Cancer Center, Houston, Texas, United States|Instituto Medico Especializado Alexander Fleming, Cd. Autonoma De Buenos Aires, Buenos Aires, Argentina|Hospital Italiano de la Plata, La Plata, Buenos Aires, Argentina|Hospital Dr. Jose Ramon Vidal, Corrientes,, Argentina|The Royal Brisbane and Women's Hospital, Herston, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|GHDC (Grand Hopital de Charleroi), Charleroi, Belgium|Universidade Estadual de Campinas / Centro de Hematologia e Hemoterapia, Campinas, SP, Brazil|Faculdade de Medicina do ABC - Centro de Estudos e Pesquisa em Hematologia e Oncologia (CEPHO), Santo Andre, SP, Brazil|Cross Cancer Institute, Edmonton, Alberta, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Sir Mortimer B. Davis-Jewish General Hospital, Montreal, Quebec, Canada|Instituto Oncologico, Clinica Renaca, Renaca, V Region, Chile|Instituto Oncologico Ltda, Renaca, V Region, Chile|The First affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China|Peking Union Medical College Hospital, Beijing, China|Chinese People's Liberation Army General Hospital, Beijing, China|Ruijin Hospital- Shanghai Jiaotong University School of Medicine, Shanghai, China|Blood Disease Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin, China|Fundacion Santafe de Bogota, Bogota, Cundinamarca, Colombia|Helsingin Yliopistollinen Keskussairaala, Hematologian poliklinikka, Helsinki, Finland|HUS-Apteekki, Helsinki, Finland|HUS-Kuvantaminen, Helsinki, Finland|HUSLAB, Meilahden sairaalan laboratorio, Helsinki, Finland|CHU de CAEN, Caen Cedex 9, France|CHU Hotel Dieu - Service Hematologie, Nantes cedex 1, France|CHU de Poitiers, Poitiers Cedex, France|CHU Poitiers, Poitiers, France|Strasbourg Oncologie Liberale -Centre de Radiotherapie, Clinique St. Anne, Strasbourg, France|Pamela Youde Nethersole Eastern Hospital, Chai Wan, Hong Kong|The Chinese University of Hong Kong-Prince Of Wales Hospital, Shatin, New Territories, Hong Kong|Egyesitett Szent Istvan es Szent Laszlo Korhaz-Rendelointezet, Budapest, Hungary|Somogy Megyei Kaposi Mor Oktato Korhaz, Belgyogyaszati Osztaly, Kaposvar, Hungary|Christian Medical College, Vellore, Tamil Nadu, India|A.O.U. Policlinico S.Orsola Malpighi, Bologna, BO, Italy|Azienda Ospedaliera San Gerardo di Monza, Monza, MB, Italy|A.O.U. San Luigi Gonzaga di Orbassano, Orbassano, TO, Italy|Ospedale S. Eugenio - UOC Ematologia, Roma, Italy|Toyohashi Municipal Hospital, Toyohashi, Aichi, Japan|Akita University Hospital, Akita City, Akita, Japan|National Hospital Organization Kyushu Cancer Center, Fukuoka-shi, Fukuoka, Japan|Kanazawa University Hospital, Kanazawa-shi, Ishikawa, Japan|Kindai University Hospital, Osakasayama-city, Osaka, Japan|Osaka University Hopsital, Suita-city, Osaka, Japan|Osaka University Hospital, Suita-city, Osaka, Japan|Hamamatsu University School of Medicine University Hospital, Hamamatsu-shi, Shizuoka, Japan|Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital, Tokyo, Japan|The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Korea, Republic of|Riga East Clinical University Hospital, Riga, Latvia|VU University Medical Center, Amsterdam, Netherlands|University Medical Center Groningen, Department of Hematology, Groningen, Netherlands|Unidad de Investigacion de Hematologia - Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru|Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|SP ZOZ Szpital Uniwersytecki w Krakowie, Krakow, Poland|Samodzielny Publiczny Szpital Kliniczny nr 1 w Lublinie, Lublin, Poland|State Budgetary Institution of Rostov Region - Rostov Regional Clinical Hospital, Rostov-on-Don, Rostov Region, Russian Federation|State Budgetary Institution of Healthcare of Sverdlovsk Region, Ekaterinburg, Sverdlovsk Region, Russian Federation|Federal State Budgetary Institution, Moscow, Russian Federation|State Budgetary Educational Institution of Higher Professional Education, Rostov-on-Don, Russian Federation|State Budgetary Institution of Healthcare - Leningrad Regional Clinical Hospital, Saint Petersburg, Russian Federation|Clinic "Institute of Pediatric Oncology, Hematology and Transplantation n.a. R.M. Gorbachova", Saint Petersburg, Russian Federation|Federal State Budgetary Institution "Federal Almazov Medical Research Centre", Saint Petersburg, Russian Federation|State Budgetary Institution of Healthcare Samara Regional Clinical Hospital n.a. V.D. Seredavin, Samara, Russian Federation|Singapore General Hospital, Singapore, Singapore|Wits Clinical Research-Chris Hani Baragwanath Hospital, Soweto, Gauteng, South Africa|Hospital Universitari Clinic de Barcelona, Barcelona, Spain|Hospital Universitario La Princesa, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Madrid Sanchinarro, Centro Integral Oncologico Clara Campal, Madrid, Spain|Hospital Virgen de la Salud, Toledo, Spain|Hospital Clinico Universitario De Valencia (CHUV), Valencia, Spain|Division of Hematology, Department of Medicine, Faculty of Medicine, Siriraj Hospital,, Bangkok, Thailand|Gaziantep Universitesi Tip Fakultesi Sahinbey Uygulama ve Arastirma Hastanesi, Gaziantep, Sehit Kamil, Turkey|Hacettepe Universitesi Tip Fakultesi, Ankara, Turkey|Municipal Institution "Cherkasy Regional Oncology Dispensary", Cherkasy, Ukraine|MI "Dnipropetrovsk City Multi-field Clinical Hospital #4" of DRC Hematology Center, Dnipropetrovsk, Ukraine|Clinical and diagnostic production laboratory, Kyiv, Ukraine|Laboratory of Immunogenetics, Kyiv, Ukraine|State Institution "National Research Center for Radiation Medicine of the National Academy of, Kyiv, Ukraine|SI Institute of Hematology and Transfusiology of National Academy of Medical Sciences of Ukraine, Kyiv, Ukraine|State Institution "Institute of Blood Pathology and Transfusion Medicine of, Lviv, Ukraine|Nottingham University Hospitals NHS Trust, Nottingham, Nottinghamshire, United Kingdom|Freeman Hospital, Newcastle Upon Tyne, UK, United Kingdom		https://ClinicalTrials.gov/show/NCT01903733
708	NCT00410488	Palonosetron in Sarcoma Patients Receiving Chemotherapy With Adriamycin and Ifosfamide (AI)		Completed	Has Results	Sarcoma|Nausea|Vomiting	Drug: Palonosetron - Single Dose|Drug: Palonosetron - Triple Dose|Drug: Adriamycin|Drug: Ifosfamide chemotherapy (AI)|Drug: Zinecard|Drug: Mesna|Drug: Vincristine|Drug: Dexamethasone	Palonosetron Response Rate in the 10 Day Study Cycle	M.D. Anderson Cancer Center|Eisai Inc.	All	18 Years to 65 Years   (Adult, Older Adult)	Not Applicable	51	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	2005-0664	December 2006	June 2011	June 2011	December 13, 2006	March 22, 2013	March 22, 2013	UT MD Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT00410488
709	NCT01086241	Tomosynthesis in Screening Mammography		Completed	No Results Available	Breast Density >25%	Procedure: 2D Mammogram|Procedure: Tomosynthesis	Interpretation Time of Scan|Recall Rates|Discomfort Scale	AHS Cancer Control Alberta|Hologic, Inc.	Female	40 Years to 69 Years   (Adult, Older Adult)	Not Applicable	500	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening	DX-TOM-001 25232	May 2010	April 2014	April 2014	March 15, 2010		March 11, 2016	Alberta Screen Test, Edmonton, Alberta, Canada		https://ClinicalTrials.gov/show/NCT01086241
710	NCT01035008	Confocal Endomicroscopy of Pancreatic InVivo		Completed	No Results Available	Pancreatic Cysts	Procedure: Endoscopic Ultrasound (EUS)	Differentiate between non-mucinous, mucinous non-malignant & malignant pancreatic cysts in vivo	Mayo Clinic|Mauna Kea Technologies	All	18 Years and older   (Adult, Older Adult)	Not Applicable	20	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	09-006345	December 2009	November 2011	November 2011	December 18, 2009		October 23, 2012	Mayo Clinic, Jacksonville, Florida, United States		https://ClinicalTrials.gov/show/NCT01035008
711	NCT00660400	Pre-Transplant 5-Azacitidine In Patients With High-Risk Myelodysplastic Syndrome Who Are Candidates For Allogeneic Hematopoietic Cell Transplant		Completed	Has Results	Leukemia	Drug: 5-azacitidine|Procedure: Allogeneic Hematopoietic Cell Transplantation (HCT)	Percentage of Participants With Relapse-free Survival (RFS)|Overall Response Rate (ORR)|Percentage of Participants Who Proceed to Hematopoietic Cell Transplantation (HCT)|Percentage of Participants With Overall Survival (OS)	H. Lee Moffitt Cancer Center and Research Institute|Celgene Corporation	All	18 Years to 68 Years   (Adult, Older Adult)	Not Applicable	25	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MCC-15158|106349	March 2008	December 2013	June 2014	April 17, 2008	July 16, 2014	September 22, 2014	H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States		https://ClinicalTrials.gov/show/NCT00660400
712	NCT02975700	A Study of PLX3397 in Patients With Unresectable or Metastatic KIT-mutated Melanoma		Active, not recruiting	No Results Available	Melanoma	Drug: PLX3397	Number of participants with dose-limiting toxicities [Part 1]|Area under the concentration-time curve (AUC) of PLX3397 [Part 1]|Maximum observed concentration (Cmax) of PLX3397 [Part 1]|Time to peak concentration (Tmax) of PLX3397 [Part 1]|Number of participants achieving objective response [Part 2]|Number of participants with serious and non-serious adverse events (AEs) by the end of Part 1|Duration of response [Part 2]|Progression-free survival [Part 2]|Overall survival [Part 2]|Number of participants with serious and non-serious adverse events (AEs) by the end of Part 2	Daiichi Sankyo Co., Ltd.|Daiichi Sankyo, Inc.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	44	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PLX108-13	January 2017	February 2020	February 2020	November 29, 2016		January 14, 2019	Beijing Cancer Hospital, Beijing, Beijing, China|Sun Yat-sen Hospital, Guangzhou, Guangdong, China|Samsung Medical Center, Gangnam-gu, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seodaemun-gu, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of		https://ClinicalTrials.gov/show/NCT02975700
713	NCT03395925	Evaluation of the Thyroid Volume After Radiofrequency Ablation of Thyroid Nodules and Recurrent Thyroid		Recruiting	No Results Available	Thyroid Nodule	Device: Celon Pro Surge	The primary objective of the study is to demonstrate reduction of thyroid volume following radiofrequency ablation of thyroid tissue	Olympus Surgical Technologies Europe	All	18 Years and older   (Adult, Older Adult)	Not Applicable	40	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CEL THYRO01	November 10, 2017	October 30, 2018	January 30, 2019	January 10, 2018		January 10, 2018	Johann-Wolfgang Goethe University, Frankfurt, Germany		https://ClinicalTrials.gov/show/NCT03395925
714	NCT03030066	Study of DS-1001b in Patients With Gene IDH1-Mutated Gliomas		Active, not recruiting	No Results Available	Glioma	Drug: DS-1001b	Percentage of participants with dose limiting toxicities|Percentage of participants experiencing an adverse event (AE)|Area under the concentration curve (AUC) for DS-1001b|Maximum plasma concentration (Cmax) for DS-1001b|Time to maximum plasma concentration (Tmax) for DS-1001b|Change from baseline in 2-hydroxyglutarate (2-HG) concentration in patient specimens after treatment with DS-1001b|Tumor response to DS-1001b based on Response Assessment in Neuro-Oncology Criteria (RANO)	Daiichi Sankyo Co., Ltd.|Daiichi Sankyo, Inc.	All	20 Years and older   (Adult, Older Adult)	Not Applicable	60	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	DS1001-A-J101|163479	January 19, 2017	January 2020	March 2020	January 24, 2017		April 10, 2019	National Cancer Center Hospital, Tokyo, Japan		https://ClinicalTrials.gov/show/NCT03030066
715	NCT03535610	Uterine Artery Embolization With Microspheres in Patients With Leiomyoma.	EMBOSOFT I	Recruiting	No Results Available	Uterine Leiomyoma	Device: Uterine Embolization	Uterine Volume Reduction|Fibroid Reduction|Quality of Life Improvement|Ovarian Function	Scitech Produtos Medicos Ltda	Female	18 Years to 50 Years   (Adult)	Not Applicable	30	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	SC-ES_001	August 13, 2018	November 20, 2019	December 20, 2019	May 24, 2018		April 4, 2019	Certa Centro de Referência em Tratamentos Avançados, São Paulo, SP, Brazil		https://ClinicalTrials.gov/show/NCT03535610
716	NCT03032198	"Clinical Evaluation of Opto-Acoustic Tomography for Detection and Diagnostic Differentiation of Thyroid Nodules"		Active, not recruiting	No Results Available	Feasibility Study for Thyroid Indication	Device: Imagio OA/US	Initial assessment of Imagio's ability to distinguish between benign and malignant thyroid nodules.	Seno Medical Instruments Inc.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	110	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	Thyroid-01	December 4, 2017	December 2019	December 2019	January 26, 2017		January 8, 2019	Invision Sally Jobe, Greenwood Village, Colorado, United States|UT Health Science Center, San Antonio, Texas, United States		https://ClinicalTrials.gov/show/NCT03032198
717	NCT03450421	Safety and Efficacy of Actamax™Adhesion Barrier in Women Undergoing Laparoscopic Abdominopelvic Surgery/Myomectomy		Not yet recruiting	No Results Available	Uterine Fibroid	Device: Actamax™Adhesion Barrier	Adhesion Free at Sites of Surgery at SLL	Actamax Surgical Materials LLC	Female	18 Years to 44 Years   (Adult)	Not Applicable	152	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment	ABS-03UE-2014	June 2018	November 2019	July 2024	March 1, 2018		March 1, 2018			https://ClinicalTrials.gov/show/NCT03450421
718	NCT03427671	OCL 500 Treatment of Women With Symptomatic Uterine Fibroids		Active, not recruiting	No Results Available	Uterine Fibroid|Myoma|Leiomyoma	Device: Occlusin 500 Microspheres	Fibroid volume|Uterine volume|Quality of Life Assessment	IMBiotechnologies Ltd.	Female	Child, Adult, Older Adult	Not Applicable	15	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	OCL500-P3-UFE-02	January 17, 2018	July 31, 2019	August 31, 2019	February 9, 2018		February 22, 2019	University of Alberta Hospital, Edmonton, Alberta, Canada		https://ClinicalTrials.gov/show/NCT03427671
719	NCT03219385	Directed Ablation of Uterine Fibroids Using a Noninvasive Approach	DIANA	Not yet recruiting	No Results Available	Uterine Leiomyoma	Device: Mirabilis System	Change in menstrual bleeding as measured by the Menstrual Pictogram (MP) score|Rate of reintervention|Adverse event reports|Change in Uterine Fibroid Symptom - Quality of Life (UFS-QOL) survey score|Percentage of patients achieving pre-specified reductions in Menstrual Pictogram (MP) score|Change in treated fibroid volume as assessed by gadolinium-enhanced MRI|Presence of newly-formed non-perfused volumes (NPV) in the targeted tissue	Mirabilis Medica, Inc.	Female	18 Years to 50 Years   (Adult)	Not Applicable	180	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MMI 2001	September 2018	September 2020	September 2022	July 17, 2017		March 21, 2018			https://ClinicalTrials.gov/show/NCT03219385
720	NCT02022098	Debio 1143-201 Dose-finding and Efficacy Phase I/II Trial		Active, not recruiting	No Results Available	Squamous Cell Carcinoma of the Head and Neck	Drug: Cisplatin|Radiation: Radiotherapy|Drug: Debio 1143|Drug: Placebo	Phase II: Percentage of participants achieving Locoregional Control (LRC) at 18 months from the end of chemo-radiation therapy (CRT)|Phase II: Complete Response Rate (by RECIST version 1.1) at six months after completion of chemo-radiation therapy (CRT) therapy|Phase II: Best Overall response rate, Disease Control rate and Response Rate after 10 weeks from the end of CRT|Phase II: Best Overall response rate, Disease Control rate and Response Rate after 6 months from the end of CRT|Phase II: Locoregional control rate at 6 months and one year after completion of CRT|Phase II: Progression free survival rate at one year, 18 months and at 2 years as of initiation of CRT|Phase II: Distant relapse rate at six months, one year and 18 months after completion of CRT|Phase II: Disease specific survival rate one year and at 2 years as of initiation of CRT|Phase II: Overall survival rate at one year and at 2 years as of initiation of CRT|Phase II: Number of participants with clinically significant change in vital signs during participation in the trial|Phase II: Number of participants with Serious Adverse Events|Phase II: Number of participants with Adverse Events (AEs)|Phase II: Number of participants with Laboratory Abnormalities|Phase II: Number of participants with Late Toxicity as of initiation of CRT|Phase II: Number of participants with treatment changes due to AEs	Debiopharm International SA	All	18 Years to 75 Years   (Adult, Older Adult)	Not Applicable	110	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	Debio 1143-201	October 2013	April 2020	April 2020	December 27, 2013		July 31, 2019	Centre Hospitalier de Bretagne Sud - HÔPITAL DU SCORFF, Lorient, Bp 2233, France|C.H.U. Sud Amiens, Amiens, France|ICO Paul Papin, Angers Cedex 02, France|Institut Sainte-Catherine, Avignon Cedex 9, France|CHU Côte de Nacre, CAEN Cedex 09, France|Centre Jean Perrin, Clermont-Ferrand Cedex 01, France|Centre Georges François Leclerc, Dijon, France|CHU Grenoble, Grenoble, France|CHD Vendée, La Roche Sur Yon cedex 9, France|Centre Guillaume le Conquérant, Le Havre, France|Centre Jean Bernard, Le Mans, France|Centre Léon Berard, Lyon, France|Hôpital Nord Franche-Comté, Montbéliard, France|ICM - Val D'Aurelle, Montpellier, France|Institut Curie, Paris, France|Centre Henri Becquerel, Rouen, France|Institut de Cancérologie de l'Ouest (ICO) René Gauducheau, Saint-Herblain, France|Institut de Cancérologie Lucien Neuwirth (ICLN), Saint-Priest en Jarez, France|Institut Claudius Regaud, Toulouse, France|L'Institut de Cancérologie de Lorraine (ICL) Alexis Vautrin, Vandoeuvre-lès-Nancy, France|Institut Gustave Roussy, Villejuif, France|Inselspital Bern, Universitätsklinik für Radio-Onkologie, Freiburgstrasse 4, Bern, Switzerland|Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland		https://ClinicalTrials.gov/show/NCT02022098
721	NCT02491502	Treatment of Benign Thyroid Nodules With FastScan HIFU		Active, not recruiting	No Results Available	Benign Thyroid Nodules	Device: Echopulse	Number of participants with adverse events|Change in volume of the thyroid nodule compared to Baseline at 6 months|Change from Baseline Patient pain intensity score (100mm visual analog scale) at 1 day|Change from Baseline Patient pain intensity score (100mm visual analog scale) at 3 days|Change from Baseline Patient pain intensity score (100mm visual analog scale) at 7 days|Patient satisfaction questionnaire|Number of patients with Absence of palpable lesion|Patient Cosmetic evaluation measured by questionnaire|Investigator rated evaluation of the device|Change from Baseline of gland vascularization at 3 months|Change from Baseline of gland vascularization at 6 months	Theraclion	All	18 Years and older   (Adult, Older Adult)	Not Applicable	36	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HIFU/BG/TN/FS/2015	June 2015	April 2020	July 2020	July 8, 2015		May 30, 2018	University Hospital of Endocrinology USBALE, Sofia, Bulgaria		https://ClinicalTrials.gov/show/NCT02491502
722	NCT02246504	Registry - Use of a High Intensity Focused Ultrasound (HIFU) in Patients With Non-malignant Thyroid Nodules.		Completed	No Results Available	Non-malignant Thyroid Nodule	Device: HIFU treatment	Change from baseline in thyroid nodule's volume|Change from baseline in thyroid nodule's structure and vascularisation|Number of participants with adverse events	Theraclion	All	18 Years and older   (Adult, Older Adult)	Not Applicable	10	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HIFU/BG/NT	October 9, 2012	March 7, 2017	March 7, 2017	September 22, 2014		May 28, 2018	Clinic of thyroid and metabolite bone disease of the Acad. of Ivan Penchev UDHATE - 2, Zdrave street, Sofia, Bulgaria		https://ClinicalTrials.gov/show/NCT02246504
723	NCT02520414	Symphion® System In-Office Study		Completed	Has Results	Uterine Leiomyomas|Endometrial Polyps	Device: Symphion® Bipolar Hysteroscopic Tissue Resection System	Safety Profile of the Symphion® Bipolar Hysteroscopic Tissue Resection System When Used in the Office Setting for the Removal of Intracavitary Polyps and Myomas.	Boston Scientific Corporation	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	10	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	U0524	November 2014	March 2015	April 2015	August 11, 2015	June 7, 2017	June 7, 2017	Center for Women's Surgery, Albuquerque, New Mexico, United States		https://ClinicalTrials.gov/show/NCT02520414
724	NCT02410018	Safety and Effectiveness of OCL 503 in the Treatment of Women With Leiomyomata		Completed	Has Results	Leiomyomata	Device: OCL 503 (uterine artery embolization)	Number of Participants With Serious Adverse Events|Change in Fibroid Perfusion From Baseline at 7 Days Post Treatment|Change in Fibroid Perfusion From Baseline at 28 Days Post Treatment of Women With Leiomyomata by UAE|Tissue Necrosis Assessed by Histology Graded Scale at 7 Days Post Treatment of Women With Leiomyomata by UAE|Inflammatory Response Assessed by Histology at 7 Days Post Treatment of Women With Leiomyomata by UAE|Tissue Necrosis Assessed by Histology Graded Scale at 28 Days Post Treatment of Women With Leiomyomata by UAE|Inflammatory Response Assessed by Histology at 28 Days Post Treatment of Women With Leiomyomata by UAE	IMBiotechnologies Ltd.	Female	30 Years to 55 Years   (Adult)	Not Applicable	3	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	OCL503-P1-UFE-01	April 2015	June 2016	June 2016	April 7, 2015	September 7, 2018	December 5, 2018	Albany Medical Center, Albany, New York, United States		https://ClinicalTrials.gov/show/NCT02410018
725	NCT02163525	Post Market TRUST - U.S.A. Study		Active, not recruiting	No Results Available	Symptomatic Uterine Fibroids	Procedure: Global Fibroid Ablation (GFA)|Procedure: Abdominal or Laparoscopic Myomectomy|Procedure: Uterine Artery Embolization (UAE)	Compare direct cost of GFA compared to those of myomectomy and UAE|Compare rates of acute and near-term serious complications to the acute and near-term treatment-related serious adverse events of pivotal study.|Assess the incidence and cost of post discharge procedure-related complications and reinterventions|Assess factors that influence indirect costs of the three treatment alternatives|Assess Uterine Fibroid Symptom Severity and Quality of Life (UFS-QoL) pre-treatment to post treatment in all treatment groups|Assess subjects menstrual bleeding using the MIQ|Assess subject's satisfaction with her treatment|Assess the subject's general health outcome|Assess the incidence of serious complications per investigator-surgeon during training and post training.	Acessa Health, Inc.	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	114	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CP-00-0025	June 2014	September 2019	June 2024	June 13, 2014		April 24, 2019	University of California, Los Angeles, Santa Monica, California, United States|Aspen Surgery Center/John Muir Hospital, Walnut Creek, California, United States|Augusta University, Augusta, Georgia, United States|University of Chicago Medicine and Biological Sciences, Chicago, Illinois, United States|Brigham and Women's Hospital, Jamaica Plain, Massachusetts, United States|Henry Ford Hospital, West Bloomfield, Michigan, United States|University of Rochester Medical Center, Rochester, New York, United States|Texas Fertility Center, Austin, Texas, United States|INOVA, Falls Church, Virginia, United States		https://ClinicalTrials.gov/show/NCT02163525
726	NCT01946178	Clinical Study of the Mirabilis High-Intensity Focused Ultrasound System for Non-Invasive Treatment of Uterine Fibroids		Completed	Has Results	Uterine Fibroids (Leiomyomas)	Device: Mirabilis High-Intensity Focused Ultrasound Treatment System	Evaluation of All Adverse Events Encountered|HIFU-related Non-Perfused Volume (NPV)	Mirabilis Medica, Inc.	Female	18 Years to 55 Years   (Adult)	Not Applicable	73	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	No. 1006	January 2011	May 2015	May 2015	September 19, 2013	March 25, 2016	May 30, 2017	Hospital Torre Medica, Ciudad de Mexico, Distrito Federal, Mexico|Hospital Universitario, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon, Mexico		https://ClinicalTrials.gov/show/NCT01946178
727	NCT01750008	Laparoscopic Uterine Sparing Techniques Outcomes and Reinterventions	LUSTOR	Completed	No Results Available	Uterine Fibroids|Myomas	Procedure: Global Fibroid Ablation|Procedure: Myomectomy	Compare the mean time of hospitalization following laparoscopic treatment of fibroids by myomectomy or GFA|Compare and contrast post-treatment readmission and reintervention rate|Compare and Contrast peri and post procedural safety including procedural blood loss and complications|Compare and contrast recovery rate|Compare and Contrast post-treatment changes in fibroid symptom severity.|Compare and contrast post-treatment patient satisfaction|Compare and Contrast post-treatment changes in menstrual status.|Compare and Contrast post-treatment changes concerning health-related quality-of-life.	Acessa Health, Inc.	Female	18 Years to 55 Years   (Adult)	Not Applicable	51	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	CP-00-0018	November 2012	September 2013	June 2018	December 17, 2012		November 20, 2018	Tubingen University Hospital, Tubingen, Germany		https://ClinicalTrials.gov/show/NCT01750008
728	NCT01588899	China Clinical Trial for Therapeutic MR-HIFU Ablation of Uterine Fibroids		Completed	No Results Available	Uterine Fibroids	Device: MR-HIFU uterine fibroid treatment	Change in fibroid volume|Adverse Events	Philips Healthcare	Female	18 Years to 55 Years   (Adult)	Not Applicable	107	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	907764	May 2012	December 2014	May 2015	May 1, 2012		October 22, 2015	Peking University First Hospital, Beijing, Beijing, China|First Affiliated Hospital of Medical College of Xi'an Jiaotong University, Xi'an, China		https://ClinicalTrials.gov/show/NCT01588899
729	NCT01563783	Post Market TRUST Study	TRUST	Active, not recruiting	No Results Available	Uterine Fibroids	Procedure: Global Fibroid Ablation (GFA)|Procedure: Abdominal or Laparoscopic Myomectomy|Procedure: Uterine Artery Embolization (UAE)	Compare direct cost of GFA compared to those of myomectomy and UAE|Compare rates of acute and near-term serious complications to the acute and near-term treatment-related serious adverse events of pivotal study.|Assess the comparative safety of the three treatment alternatives|Assess factors that influence indirect costs of the three treatment alternatives|Assess UFS-QoL pre-treatment to post treatment in all treatment groups|Assess subjects menstrual bleeding using the MIQ|Assess subject's satisfaction with her treatment	Acessa Health, Inc.	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	260	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CP-00-0015	December 2012	September 2017	June 2022	March 27, 2012		November 20, 2018	University of Saskatchewan, Saskatoon City Hospital, Saskatoon, Saskatchewan, Canada		https://ClinicalTrials.gov/show/NCT01563783
730	NCT01369758	MyoSure Hysteroscopic Tissue Removal System Registry Study		Completed	Has Results	Uterine Fibroids|Polyps	Device: MyoSure Tissue Removal System	Procedure Efficacy|Percentage of Subjects That Achieve 100% Removal of Target Pathology	Hologic, Inc.	Female	18 Years to 65 Years   (Adult, Older Adult)	Not Applicable	290	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	TMP 200905	November 2010	May 2013	May 2013	June 9, 2011	September 13, 2017	September 13, 2017	Hologic, Inc., Marlborough, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT01369758
731	NCT01285960	ExAblate UF V2 System for the Treatment of Symptomatic Uterine Fibroids		Completed	Has Results	Uterine Fibroids	Device: ExAblate Treatment UF V2	Percentage of Participants With Leg Pain or Lower Extremity Neuropathy Persisting or Occuring Greater Than 10 Days Following Treatment	InSightec	Female	18 Years to 64 Years   (Adult)	Not Applicable	108	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	UF031	May 2012	April 2016	April 2016	January 28, 2011	February 19, 2019	March 6, 2019	University of California, Los Angeles, Los Angeles, California, United States|University of California, San Francisco, San Francisco, California, United States|Stanford University Medical Center, Stanford, California, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Duke University, Durham, North Carolina, United States|Ohio Health Research Institute, Columbus, Ohio, United States|University of Virginia Health System, Charlottesville, Virginia, United States		https://ClinicalTrials.gov/show/NCT01285960
732	NCT01142791	Safety Study of ExAblate for the Treatment of Uterine Fibroids		Completed	Has Results	Uterine Fibroids	Device: ExAblate	Percent Occurrence of Chronic Leg Pain	InSightec	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	121	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	UF033	May 2010	April 2012	April 2012	June 11, 2010	March 6, 2019	March 6, 2019	UCLA, Los Angeles, California, United States|UCSD Department of Radiology, San Diego, California, United States|University of California San Francisco, San Francisco, California, United States|University Image Guided Therapy, Boca Raton, Florida, United States|Borgess Research Institute, Kalamazoo, Michigan, United States|Duke University, Durham, North Carolina, United States|The Methodist Hospital Research Institute, Houston, Texas, United States|University of Virginia Health System, Charlottesville, Virginia, United States		https://ClinicalTrials.gov/show/NCT01142791
733	NCT00979342	Comparative Sedation Study of the MyoSure Hysteroscopic Tissue Removal System		Completed	No Results Available	Uterine Fibroids|Polyps	Device: Hysteroscopic Morcellator	Subject tolerance of procedure-related pain rated on an 11 point scale (0-10)|Subject assessment of most severe post-procedural pain rated on an 11 point scale|Subject assessment of most severe pain experienced during 48 hours post procedure, rated on an 11 point scale	Hologic, Inc.	Female	18 Years to 65 Years   (Adult, Older Adult)	Not Applicable	40	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	TMP 200902	November 2009	July 2010	July 2010	September 18, 2009		July 23, 2010	Phoenix Gynecology Consultants, Phoenix, Arizona, United States|Florida Woman Care, Boca Raton, Florida, United States|Wayne State University, Detroit, Michigan, United States|Minnesota Gynecology and Surgery, Edina, Minnesota, United States|Carolina Women's Research and Wellness Center, Durham, North Carolina, United States		https://ClinicalTrials.gov/show/NCT00979342
734	NCT00874029	Laparoscopic Radiofrequency Ablation (RFA) of Symptomatic Uterine Fibroids	Halt	Completed	Has Results	Uterine Fibroids|Uterine Myomas	Device: Halt Procedure	Assessment of Menstrual Blood Flow (MBF) at 12 Months Post Procedure|Incidence of Device and Procedure-related Adverse Events Within 12 Months Post-procedure|Surgical Re-Intervention for Menorrhagia at 12 Months Post-treatment|Change in Uterine and Fibroid Volume at 12 Months Post-procedure Compared to Pre-procedure (Baseline) as Measured With Contrast-enhanced MRI (Magnetic Resonance Imaging)|Change in Fibroid Symptom Severity and Quality of Life Scores at 12 Months Post-procedure as Compared to Pre-procedure (Baseline) Using the Uterine Fibroid Symptom and Health Related Quality of Life (UFS-QoL) Assessment Tool.|Change in Score on Questionnaire - General Health Outcome at 12 Months Post-procedure as Compared to Pre-procedure Using the EQ-5D (a Standardized Instrument for Use as a Measure of Health Outcome)|Overall Subject Treatment Outcome and Satisfaction Using the Overall Treatment Evaluation (OTE)	Acessa Health, Inc.	Female	25 Years and older   (Adult, Older Adult)	Not Applicable	137	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CP-00-0004	March 2009	January 2012	March 2014	April 2, 2009	July 3, 2014	July 3, 2014	Women's Health Research, Phoenix, Arizona, United States|USC Medical Center, Los Angeles, California, United States|Pasadena Premier Women's Health, Pasadena, California, United States|Reproductive Science Center, San Ramon, California, United States|Wayne State University, Detroit, Michigan, United States|St. Luke's Hospital, Chesterfield, Missouri, United States|Athena Gynecology Medical Group, Reno, Nevada, United States|Montefiore Medical Center, Bronx, New York, United States|Magee-Women's Hospital, Pittsburgh, Pennsylvania, United States|Hospital Universitario Esperanza, Guatemala City, Guatemala|Hospital Universitario Dr. Jose Eleuterio Gonzalez de la Universidad Autonoma de Nuevo Leon. Facultad de Medicina, Monterrey, Nuevo Leon, Mexico		https://ClinicalTrials.gov/show/NCT00874029
735	NCT02622412	Evaluation of a Multi-professional Breathlessness Service for Patients With Breathlessness Due to Any Advanced Disease	BreathEase	Completed	No Results Available	Breathlessness|COPD|Cancer|Chronic Heart Failure|Interstitial Lung Disease	Other: Multi-professional breathlessness service (MBS)|Other: Delayed MBS Intervention	Mastery of breathlessness (CRQ mastery subscale)|Quality of Life (CRQ)|Symptom Burden (IPOS)|Carers' burden of disease (ZBI)|Breathlessness severity (NRS)|Generic health-related quality of life (EQ-5D-5L)|Costs of health service utilization in Euros|Patient survival measured in days	Ludwig-Maximilians - University of Munich|University Hospital Munich|Helmholtz Zentrum München|University of Cambridge|King's College London	All	18 Years and older   (Adult, Older Adult)	Not Applicable	183	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	01GY1331	March 2, 2015	February 1, 2019	April 30, 2019	December 4, 2015		August 9, 2019	Hospital of the University of Munich, Department of Palliative Medicine, Munich, Bavaria, Germany		https://ClinicalTrials.gov/show/NCT02622412
736	NCT00166270	MR Guided Focused Ultrasound Surgery in the Treatment of Uterine Fibroids		Completed	No Results Available	Uterine Fibroids	Device: ExAblate 2000	Measures of the clinical success of patients who elect treatment of fibroids are generally subjective, and evaluated by the patient in terms of improvement.	InSightec	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	70	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	UF014	January 2005	April 2006	January 2009	September 14, 2005		July 9, 2018	Radnet Management, Los Angeles, California, United States|University MRI, Boca Raton, Florida, United States|Brigham & Women's Hospital, Boston, Massachusetts, United States|Lahey Clinic, Burlington, Massachusetts, United States|Virtua, Voorhees, New Jersey, United States|North Texas Uterine Fibroid Institute, Plano, Texas, United States		https://ClinicalTrials.gov/show/NCT00166270
737	NCT00131365	Magnetic Resonance (MR) Guided Focused Ultrasound Surgery of Uterine Fibroids		Completed	Has Results	Leiomyoma	Device: ExAblate 2000	Number and Type of Adverse Events	InSightec	Female	Child, Adult, Older Adult	Not Applicable	9	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	UF014 - 4.1/3T	January 2006	January 2009	February 2009	August 18, 2005	June 12, 2019	June 12, 2019	Cornell Vascular, New York, New York, United States		https://ClinicalTrials.gov/show/NCT00131365
738	NCT03621319	Eradicating Barrett's Esophagus Using Radiofrequency Ablation or a Novel Hybrid Argon Plasma Coagulation Technique	BURN	Recruiting	No Results Available	Barrett's Esophagus|High-grade Dysplasia in Barrett Esophagus|Low Grade Dysplasia in Barrett Esophagus	Device: Hybrid argon plasma ablation (HAPC)|Device: Radiofrequency ablation (RFA)	Rate of stricture-free eradication of dysplastic BE|Rate of eradication of intestinal metaplasia (CE-IM)|Post-operative pain|Major complications|Minor complications|Recurrence rate of dysplasia (CE-D)|Recurrence rate of intestinal metaplasia (CE-IM)|Cost-effectiveness of HAPC vs. RFA in the treatment of dysplastic BE	Erbe Elektromedizin GmbH|Erbe USA Incorporated|Kansas City Veteran Affairs Medical Center|Emissary International LLC	All	18 Years to 86 Years   (Adult, Older Adult)	Not Applicable	144	Industry|Other|U.S. Fed	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	2015_1	July 24, 2019	July 2020	September 2020	August 8, 2018		August 5, 2019	Kansas City Veterans Affairs Hospital, Kansas City, Missouri, United States|Washington University, School of Medicine; Department of Internal Medicine; Division of Gastroenterology, Saint Louis, Missouri, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Long Island Jewish Medical Center, New Hyde Park, New York, United States|Columbia University Medical Center; Division of Digestive and Liver Diseases, New York, New York, United States|Penn State Hershey Medical Center, Hershey, Pennsylvania, United States|University of Utah School of Medicine, Salt Lake City, Utah, United States		https://ClinicalTrials.gov/show/NCT03621319
739	NCT02757989	Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelodysplastic Syndrome Low Risk		Recruiting	No Results Available	MDS	Other: transplantation	overall survival|quality of life|number of patients with complete response at 36 month|number of patients with transformation in AML at 36 month|proportion of patients with iron overload|evolution of innovative iron markers including Non-transferrin binding iron (NTBI), labile plasmatic Iron (LPI) and Hepcidine|efficiency of chelation|number of patients with adverse events grade III and IV as assessed by CTCAE v4.0	Groupe Francophone des Myelodysplasies|Novartis|Neovii Biotech	All	18 Years to 69 Years   (Adult, Older Adult)	Not Applicable	105	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MDS-ALLO-RISK|2015-A00292-47	May 31, 2016	May 2020	April 2021	May 2, 2016		May 27, 2019	CHU d'Amiens, Amiens, France|CHU d'Angers, Angers, France|Centre hospitalier Victor Dupouy, Argenteuil, France|CHU Jean Minjoz, Besançon, France|Hôpital Avicenne, Bobigny, France|CHU de Haut Lévèque, Bordeaux, France|CHRU Côte de Nacre, Caen, France|CHU Estaing, Clermont Ferrand, France|CHSF Gilles de Corbeil, Corbeil-Essonnes, France|Hôpital Henri Mondor, Créteil, France|CHU de Grenoble, Grenoble, France|CH Le Mans, Le Mans, France|Hôpital Saint Vincent de Paul, Lille, France|Hôpital Huriez, Lille, France|Hôpital Dupuytren, Limoges, France|Centre hospitalier Lyon Sud, Lyon, France|GHEF, site de Meaux, Meaux, France|CHRU de Montpellier, Montpellier, France|CHU de Nantes, Nantes, France|CHU de Nice, Nice, France|CHU de Nîmes, Nîmes, France|Hôpital Saint Louis, Paris, France|Hôpital Pitié Salpétrière, Paris, France|Hôpital Cochin, Paris, France|Hôpital Necker, Paris, France|CH Joffre, Perpignan, France|CHU de Poitiers, Poitiers, France|CH René Dubos, Pontoise, France|CHU de Reims, Reims, France|Hôpital Pontchaillou, Rennes, France|Centre Henri Becquerel, Rouen, France|Institut Curie, Saint-Cloud, France|Institut de cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France|Hôpital civil, Strasbourg, France|IUCT-Oncopole, Toulouse, France|Hôpital Bretonneau, Tours, France|Hôpital de Brabois, Vandoeuvre les nancy, France		https://ClinicalTrials.gov/show/NCT02757989
740	NCT00002439	A Study of ALRT 1057 Topical Gel in Patients With AIDS-Related Kaposi's Sarcoma		Completed	No Results Available	Sarcoma, Kaposi|HIV Infections	Drug: Alitretinoin		Anderson Clinical Research|Ligand Pharmaceuticals|NIH AIDS Clinical Trials Information Service	All	18 Years and older   (Adult, Older Adult)	Not Applicable		Industry	Interventional	Primary Purpose: Treatment	272A|L1057T-31|96ACR-LIG1				August 31, 2001		June 24, 2005			https://ClinicalTrials.gov/show/NCT00002439
741	NCT03072446	Uterine Fibroid Embolization (UFE) for Symptomatic Fibroids: Comparison of Gel-Bead to Commonly Used Embolic Agents.		Completed	No Results Available	Uterine Fibroid|Embolization|Symptoms	Device: Gel-Beads embolic material	Degree of Fibroid Tissue Infarction at 3 months|Characterization of adverse events over 3 months|Change in uterine and dominant fibroid volumes	University Hospital Southampton NHS Foundation Trust|Vascular Solutions, Inc	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	11	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	RHM RAD0041	April 24, 2017	June 30, 2018	September 30, 2018	March 7, 2017		May 9, 2019	Southampton University Hospital NHS Trust, Southampton, Hampshire, United Kingdom		https://ClinicalTrials.gov/show/NCT03072446
742	NCT01484847	A Study of PF-00299804 When Given Through a Feeding Tube in Locally Advanced Head and Neck Squamous Cell Carcinoma		Completed	No Results Available	Head and Neck Squamous Cell Carcinoma	Drug: PF-00299804	Composite (or Profile) of Pharmacokinetics Time Frame: predose, 0,1,2,3,4,6,8,12,24,48,72, 96 hours post-dose|Comparison of pharmacokinetic parameters of study subjects with existing phase I pharmacokinetic data following administration of PF-00299804.|Overall safety profile as per National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0.	University Health Network, Toronto|Pfizer	All	18 Years and older   (Adult, Older Adult)	Not Applicable	6	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	WS1544542/Pan-HER-GT-001	December 2011	March 2013	July 2015	December 2, 2011		July 10, 2015	Princess Margaret Hospital, Toronto, Ontario, Canada		https://ClinicalTrials.gov/show/NCT01484847
743	NCT01916057	Hepatosplenic CANdidiasis : PETscan and Immune Response Analysis	CANHPARI	Completed	No Results Available	Invasive Fungal Disease|Chronic Disseminated Candidiasis|Hematological Malignancies|Hematopoietic Stem Cell Transplantation|Neutropenia	Device: 18F-FDG PET Scan	Global response to therapy|18F-FDG PET scan and RMI usefulness in initial diagnosis|Serological and molecular mycological tools assessment|Inflammatory cells and mediators|Genetic susceptibility	Assistance Publique - Hôpitaux de Paris|University of Lausanne Hospitals|University Hospital, Lille|Institut Pasteur|Institut National de la Santé Et de la Recherche Médicale, France	All	18 Years and older   (Adult, Older Adult)	Not Applicable	100	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	P120115|AOM12047	November 19, 2013	June 1, 2017	February 28, 2018	August 5, 2013		May 1, 2018	Service des Maladies Infectieuses et Tropicales - Centre d'Infectiologie Necker-Pasteur, IHU Imagine - Hôpital Necker-Enfants Malades,, Paris, France		https://ClinicalTrials.gov/show/NCT01916057
744	NCT00795184	Detection Of Neoplastic Tissue in Barrett's Esophagus With In vivO Probe-based Confocal Endomicroscopy	DONTBIOPCE	Completed	Has Results	Barrett Syndrome|Barrett's Syndrome|Barrett's Esophagus|Barrett Esophagus|Adenocarcinoma	Device: Imaging procedures (NBI)|Device: HDWLE|Device: pCLE	Comparative Histopathology-confirmed Measures of Per Lesion Sensitivity and Per Lesion Specificity, by Using pCLE Associated With WLE, or WLE Alone, for the Detection of High Grade Dysplasia and Early Carcinoma in Barrett's Esophagus.	Mauna Kea Technologies|Cellvizio Inc.|Emissary International LLC	All	18 Years and older   (Adult, Older Adult)	Not Applicable	122	Industry	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	MKT-2008-BE-01	November 2008	September 2009	February 2010	November 21, 2008	May 3, 2016	May 3, 2016	Mayo Clinic, Jacksonville, Florida, United States|Veterans Affairs Hospital, Kansas City, Missouri, United States|New York Presbyterian Hospital/Columbia University Medical Center, New York, New York, United States|Centre Hospitalier Universitaire, Nantes, France|Klinikum rechts der Isar, Munich, Bayern, Germany		https://ClinicalTrials.gov/show/NCT00795184
745	NCT03870412	Evaluation of the Application of PEGylated Recombinant Human Granulocyte Stimulating Factor Injection (PEG-rhG-CSF) in Chemotherapy of Elderly Lymphoma Patients		Recruiting	No Results Available	Elderly Lymphoma Patients	Drug: PEG-rhG-CSF	Incidence of febrile neutropenia in cycles 1 to 6|The incidence of grade IV neutropenia in the first to sixth cycles of PEG-rhG-CSF.|Incidence of dose adjustment of chemotherapy drugs in each chemotherapy cycle|Incidence of chemotherapy delays in each chemotherapy cycle|The proportion of patients receiving antibiotics during the entire chemotherapy period.	CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.	All	65 Years and older   (Older Adult)	Not Applicable	485	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	CSPC-JYL-LY-03	February 22, 2019	March 22, 2021	August 22, 2021	March 12, 2019		March 14, 2019	Sun Yat-sen University Cancer Hospital, Guangzhou, China		https://ClinicalTrials.gov/show/NCT03870412
746	NCT03811457	Immunotherapy With CD19 CAR T-cells in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma		Completed	No Results Available	Lymphoma Leukemia	Genetic: Welgenaleucel	The adverse events associated with CAR T cell product infusions are assessed.	UWELL Biopharma|Liaocheng People's Hospital	All	up to 70 Years   (Child, Adult, Older Adult)	Not Applicable	9	Industry|Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	UCAR019	June 1, 2017	December 31, 2018	December 31, 2018	January 21, 2019		January 21, 2019	Liaocheng People Hospital, Liaocheng, Shandong, China		https://ClinicalTrials.gov/show/NCT03811457
747	NCT03488160	CAR-T Treatment for Relapse / Refractory Type Safety and Effectiveness of Lymphoma		Recruiting	No Results Available	Lymphoma	Biological: CD19-targeted CAR-T cells	Primary Outcome Measure: The overall efficiency	Sinobioway Cell Therapy Co., Ltd.	All	16 Years to 70 Years   (Child, Adult, Older Adult)	Not Applicable	6	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	sinobiowayCT	April 10, 2018	April 10, 2019	April 20, 2019	April 4, 2018		April 10, 2018	The west area of the First Affiliated Hospital of University of Science & Technology China, Hefei, Anhui, China		https://ClinicalTrials.gov/show/NCT03488160
748	NCT03364114	Endorotor Resection In Refractory Barrett's Dysplasia Patients		Recruiting	No Results Available	Barretts Esophagus With Dysplasia	Device: EndoRotor Mucosal Resection System|Device: Continued Ablation	Complete removal of areas of Barrett's metaplasia after no more than two treatments|Assessment of Adverse Events (incidence, relationship to device and severity) compared to the control arm and the medical literature.|Percentage of Barrett's esophagus resected or ablated during the initial treatment session through the final follow-up visits.	Interscope, Inc.	All	30 Years to 79 Years   (Adult, Older Adult)	Not Applicable	110	Industry	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CLIN-0010	February 9, 2018	October 11, 2019	October 11, 2019	December 6, 2017		April 17, 2019	The Mayo Clinic, Rochester, Minnesota, United States|University of Rochester Medical Center, Rochester, New York, United States|Hospital University of Pennsylvania, Philadelphia, Pennsylvania, United States|NHS University College Hospital, London, United Kingdom	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/14/NCT03364114/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT03364114
749	NCT03311451	C2 CryoBalloon™ 180 Ablation System Dose Escalation Study.		Recruiting	No Results Available	Barrett Esophagus	Device: C2 CryoBalloon 180° Ablation System	Safety: Incidence of Dose-related SAEs|Efficacy: Dose response|Incidence of AEs|Pain|Efficacy: Percent Regression|Efficacy: Treatment	C2 Therapeutics, Inc.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	30	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CP-0019	January 7, 2018	August 2018	October 2018	October 17, 2017		February 13, 2018	AMC Medical Research B.V., Amsterdam, Netherlands|Catharina Ziekenhuis te Eindoven, Eindhoven, Netherlands|UMC Groningen, Groningen, Netherlands|St. Antonius Hospital, Nieuwegein, Netherlands|UMC Utrecht, Utrecht, Netherlands		https://ClinicalTrials.gov/show/NCT03311451
750	NCT03097666	Evaluation of Safety and Dose Response Using C2 CryoBalloon™ Swipe Ablation System for Barrett's Esophagus		Active, not recruiting	No Results Available	Barrett Esophagus	Device: C2 CRYOBALLOON SWIPE ABLATION SYSTEM	Dose-related SAEs|Efficacy: Percent Eradication by therapeutic dose|Incidence of AEs|Post-procedure pain|Efficacy: Percent Regression|Efficacy: Treatment	C2 Therapeutics, Inc.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	24	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CP-0018	March 20, 2017	November 1, 2018	November 1, 2018	March 31, 2017		September 14, 2018	AMC Medical Research B.V., Amsterdam, Netherlands|St. Antonius Hospital Nieuwegein, Amsterdam, Netherlands|Catharina Ziekenhuis te Eindhoven, Eindhoven, Netherlands		https://ClinicalTrials.gov/show/NCT03097666
751	NCT02864043	Barrett's Dysplasia Detection Pilot Trial Using the NvisionVLE® Imaging System	DDP	Completed	No Results Available	Barrett's Esophagus	Device: NvisionVLE with Real Time Targeting	Performance of manually identified VLE features in predicting biopsy defined dysplasia|Per Patient Sensitivity and specificity for detecting dysplasia|Per Biopsy Sensitivity and specificity for detecting dysplasia|Per Biopsy performance of VLE compared to standard-of-care for detecting dysplasia	NinePoint Medical	All	18 Years and older   (Adult, Older Adult)	Not Applicable	150	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	16-01	September 2016	January 2018	January 2018	August 11, 2016		January 29, 2018	UC Irvine Medical Center, Irvine, California, United States|VA Boston, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|North Shore University Hospital, Manhasset, New York, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT02864043
752	NCT02514525	Multi-center Clinical Study to Evaluate the C2 CryoBalloon Focal Ablation System	ColdPlayIII	Recruiting	No Results Available	Barrett Esophagus	Device: CryoBalloon Ablation System	Incidence of serious, CryoBalloon Ablation System-related adverse events|Percentage of patients with baseline LGD who have complete eradication of all dysplasia|percentage of patients with baseline HGD who have complete eradication of all dysplasia|percentage of all treated patients who have complete eradication of all dysplasia (CE-D)|Percentage of subjects with complete eradication of all esophageal intestinal metaplasia (CE-IM)|Percentage of subjects with progression of dysplasia from LGD to HGD or esophageal cancer, or progression of HGD to cancer|Incidence of all treatment-related and all serious, non-treatment-related adverse events|Incidence of post procedure chest discomfort events / Pain score >0 and <5|Incidence of post procedure chest discomfort events / Pain score ≥5 and requiring narcotic analgesic|Mean and Median Pain score on Day 1 post procedure|Mean and Median Pain score on Day 7 post procedure|Rate of (CE-D) and all esophageal (CE-IM) will be reported as a percentage of all subjects enrolled, and stratified by baseline dysplasia grade|Number of CryoBalloon ablation treatments required to achieve CE-D or CE-IM	C2 Therapeutics, Inc.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	150	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CP-0011	March 2016	May 2019	May 2021	August 3, 2015		September 14, 2018	UC Irvine, Orange, California, United States|Sarasota Memorial Hospital, Sarasota, Florida, United States|University of Chicago, Chicago, Illinois, United States|John Hopkins, Baltimore, Maryland, United States|Mayo Clinic, Rochester, Minnesota, United States|Northwell Health, Manhasset, New York, United States|New York Presbyterian Hospital-Columbia University Medical Center, New York, New York, United States|University of North Carolina School of Medicine, Chapel Hill, North Carolina, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT02514525
753	NCT02395471	Cytosponge Adequacy Study Evaluation II	CASEII	Completed	Has Results	Barrett's Esophagus|GERD	Device: Cytosponge™ Cell Collection Device	Procedure Preference and Acceptability Questionnaire and Visual Analog Scale|Number of Participants With Adequate Cytosponge™ Sample|Operating Characteristics|Cytosponge™ Operating Characteristics vs Worst Histology Ever|Cytosponge™ Operating Characteristics as a Function of Baseline Histology|Summary of Abrasion, Bleeding, and Perforation Observed Via Endoscopy|Ongoing Safety Measures	Medtronic - MITG	All	18 Years and older   (Adult, Older Adult)	Not Applicable	191	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	B-271	August 2015	April 24, 2018	June 1, 2018	March 23, 2015	July 30, 2019	July 30, 2019	Univeristy of California, Los Angeles, Los Angeles, California, United States|University of Colorado, Aurora, Colorado, United States|Northwestern University, Chicago, Illinois, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Gastrointestinal Associates, Knoxville, Tennessee, United States	"Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/71/NCT02395471/Prot_000.pdf|"Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/71/NCT02395471/SAP_001.pdf	https://ClinicalTrials.gov/show/NCT02395471
754	NCT03408808	Dorsal Wrist Ganglia; Aspiration Alone vs Aspiration and Injection of Platelet Rich Plasma		Not yet recruiting	No Results Available	Ganglion of Wrist	Procedure: Platelet rich plasma|Procedure: Aspiration alone	Recurrence|PEM Score	University of Aberdeen|NHS Grampian|Arthrex, Inc.	All	16 Years and older   (Child, Adult, Older Adult)	Not Applicable	200	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	1/091/17	January 2018	December 2019	December 2019	January 24, 2018		January 24, 2018	NHS Grampian, Aberdeen, United Kingdom	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/08/NCT03408808/Prot_SAP_000.pdf|"Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/08/NCT03408808/ICF_001.pdf	https://ClinicalTrials.gov/show/NCT03408808
755	NCT03564405	Pilot Clinical Trial to Evaluate the UNI-DEB for Unresectable Hepatocellular Carcinoma		Completed	No Results Available	Hepatocellular Carcinoma Non-resectable	Device: UNI-DEB	Objective Response Rate	Jeil Pharmaceutical Co., Ltd.	All	19 Years and older   (Adult, Older Adult)	Not Applicable	10	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	UNI-DEB-Pilot	December 5, 2016	March 7, 2017	May 17, 2017	June 20, 2018		June 21, 2018	Catholic University Seoul St. Mary Hospital, Seoul, Korea, Republic of		https://ClinicalTrials.gov/show/NCT03564405
756	NCT03533920	Clinical Trial to Evaluate the Efficacy and Safety of UNI-DEB for Unresectable Hepatocellular Carcinoma		Completed	No Results Available	Hepatocellular Carcinoma Non-resectable	Device: UNI-DEB	Objective Response Rate by independent evaluator	Jeil Pharmaceutical Co., Ltd.	All	19 Years and older   (Adult, Older Adult)	Not Applicable	62	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	UNI-DEB-Pivotal	October 25, 2017	June 30, 2018	September 3, 2018	May 23, 2018		October 1, 2018	Chonnam National University Hospital, Gwangju, Korea, Republic of|Seoul National University Bundang Hospital, Gyeonggi-do, Korea, Republic of|The Catholic University of Korea, Uijeongbu ST. Mary's Hospital, Gyeonggi-do, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of|Pusan National University Hospital, Pusan, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|The Catholic University of Korea, Seoul ST. Mary's Hospital, Seoul, Korea, Republic of		https://ClinicalTrials.gov/show/NCT03533920
757	NCT02730663	A Study to Evaluate the Effectiveness and Safety of EUS-guided Transluminal Drainage With 'Niti-S SPAXUS Stent'		Completed	Has Results	Pancreatic Pseudocyst	Device: Niti-S SPAXUS Stent	Number of Participants With Clinical Success|Number of Participants With Technical Success|Number of Participants With Stent Lumen Patency|Number of Participants With Stent Removal Success|Procedure Time|Number of Participants With Procedural/Device Related Serious Adverse Events|Other Adverse Events	Taewoong Medical Co., Ltd.	All	19 Years and older   (Adult, Older Adult)	Not Applicable	36	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	SPAXUS-001	March 21, 2016	June 14, 2017	June 14, 2017	April 6, 2016	July 1, 2019	July 1, 2019	Soon Chun Hyang University Hospital Bucheon, Bucheon, Gyeonggi-do, Korea, Republic of|Hallym University Dongtan Sacred Heart Hospital, Hwaseong-si, Gyeonggi-do, Korea, Republic of|Kyungpook National University Medical Center, Daegu, Korea, Republic of|Chonbook National University Hospital, Jeonju, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/63/NCT02730663/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT02730663
758	NCT03113955	STOPPER CHINA:With Tandem Microspheres in the Treatment of Localized Hepatocellular Carcinoma		Recruiting	No Results Available	Localized Hepatocellular Carcinoma	Device: Tandem Microsphere loaded with Epirubicin	The objective response rate|Time to progression (TTP)|Tumor Response|Proportion Progression-Free|Overall survival|adverse events rate	Boston Scientific Corporation	All	18 Years to 75 Years   (Adult, Older Adult)	Not Applicable	109	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	S2382	October 24, 2017	December 7, 2018	March 31, 2020	April 14, 2017		February 5, 2019	Beijing Cancer Hospital, Beijing, Beijing, China|Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China|Guangdong Nanfang Hospital, Guangzhou, Guangdong, China|Henan Cancer Hospital, Zhengzhou, Henan, China|Zhongda Hospital Affiliated Southeast University, Nanjing, Jiangsu, China|Shengjing Hospital Affiliated China Medical University, Shenyang, Liaoning, China|Shanghai Zhongshan Hospital, Shanghai, Shanghai, China|Second Aff. Hosp. of Zhejiang University College of Medicine, Hangzhou, Zhejiang, China|The First Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang, China|Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China		https://ClinicalTrials.gov/show/NCT03113955
759	NCT00088543	Thymoglobulin to Prevent Acute Graft vs. Host Disease (GvHD) in Patients With Acute Lymphocytic Leukemia (ALL) or Acute Myelogenous Leukemia (AML) Receiving a Stem Cell Transplant		Completed	No Results Available	Acute Myelogenous Leukemia (AML)|Acute Lymphocytic Leukemia (ALL)|Graft vs. Host Disease (GvHD)	Biological: Thymoglobulin [Anti-Thymocyte Globulin (Rabbit)]	Incidence of Grade II to IV acute GvHD in the first 100 days after transplant.|Incidence of treatment related adverse events and serious adverse events at 100 days and 6 months post transplant|Patient survival at 100 days and 6 months after transplant|transplant related mortality at 100 days or 6 months after transplant|severity and outcomes of acute GvHD|any events of infection at 100 days and 6 months after transplant|incidence (or absence) of mucositis|how many days in the first month after transplant certain types of narcotics are used to reduce pain|whether the subject's blood counts after transplant reach a stable level and how quickly|incidence of re-hospitalization in the first 6 months after transplant|any recurrence of the subject's leukemic disease, and how long the subject was able to stay in remission|incidence and severity of chronic GvHD, and the extent, after 100 days and 6 months after transplant|Disease free survival	Genzyme, a Sanofi Company|Sanofi	All	18 Years to 55 Years   (Adult)	Not Applicable	60	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)	SMC-101-1026	March 2004	April 2006	April 2006	July 30, 2004		March 18, 2015	University of Alabama-Birmingham Hospital, Birmingham, Alabama, United States|UCLA Medical Center, Los Angeles, California, United States|Shands at the University of Florida, Division of Hematology/Oncology, Gainesville, Florida, United States|Emory University Hospital, Atlanta, Georgia, United States|Massachusetts General Hospital Cox Bldg Room 640, Boston, Massachusetts, United States|Dana Farber Cancer Institute Dana 1B11, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center KS121, Brookline, Massachusetts, United States|Washington University School of Medicine, St. Louis, Missouri, United States|The Nebraska Medical Center, Omaha, Nebraska, United States|Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Duke University Medical Center, Durham, North Carolina, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Ottawa Hospital - General Campus, Ottawa, Ontario, Canada|Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada		https://ClinicalTrials.gov/show/NCT00088543
760	NCT03322813	ExAblate Blood Brain Barrier Disruption (BBBD) for Planned Surgery in Suspected Infiltrating Glioma		Recruiting	No Results Available	Glioma	Device: ExAblate 4000 - Type 2	Device and procedure related adverse events|Feasibility of BBB disruption	InSightec	All	21 Years to 85 Years   (Adult, Older Adult)	Not Applicable	15	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	BT004	October 18, 2018	June 2020	June 2020	October 26, 2017		April 22, 2019	University of Maryland Medical System, Baltimore, Maryland, United States		https://ClinicalTrials.gov/show/NCT03322813
761	NCT02146352	AXIOS Stent With Electrocautery Enhanced Delivery System		Completed	Has Results	Pancreatic Pseudocyst(s)	Device: AXIOS Stent with Electrocautery Enhanced Delivery System	Safety/Adverse Event Outcome Measure 1|Safety/Adverse Event Outcome Measure 2|Safety/Adverse Event Outcome Measure 3|Safety/Adverse Event Outcome 4|Safety/Adverse Event Outcome Measure 5|Safety/Adverse Event Outcome Measure 6|Stent Retention Outcome Measure|Lumen Patency Outcome Measure|Technical Success Outcome Measure 1|Clinical Success Outcome Measure|Technical Success Outcome Measure 2	Xlumena, Inc.	All	18 Years to 75 Years   (Adult, Older Adult)	Not Applicable	30	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CP201303	June 2014	January 2015	March 2015	May 23, 2014	October 2, 2015	October 2, 2015	University of Colorado Denver, Aurora, Colorado, United States|Baptist Medical Center, Jacksonville, Florida, United States|Florida Hospital, Orlando, Florida, United States|Emory University, Atlanta, Georgia, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Johns Hopkins University, Baltimore, Maryland, United States|Washington University in St. Louis, St. Louis, Missouri, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT02146352
762	NCT02832284	iNod System Human Feasibility Assessment	iNod	Completed	Has Results	Solitary Pulmonary Nodule|Biopsy, Fine-Needle	Device: iNod System	Acquisition of Adequate Specimens of Targeted Lung Lesions|Device/Procedure-Related Safety Events|Visualization|Access|Acquisition	Boston Scientific Corporation	All	18 Years and older   (Adult, Older Adult)	Not Applicable	23	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	E7113	January 18, 2017	June 8, 2017	June 14, 2017	July 14, 2016	November 22, 2018	November 22, 2018	Johns Hopkins University Medical School, Baltimore, Maryland, United States|Washington University of St. Louis, Saint Louis, Missouri, United States|Medical University of South Carolina, Charleston, South Carolina, United States	"Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/84/NCT02832284/Prot_000.pdf|"Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/84/NCT02832284/SAP_001.pdf	https://ClinicalTrials.gov/show/NCT02832284
763	NCT02548780	LifePearl-Doxo Pharmacokinetic (PK) Study		Active, not recruiting	No Results Available	HCC|Hepatocellular Carcinoma	Device: Chemoembolization|Other: Pharmacokinetics	Maximum Tolerated Dose (MTD) of Doxorubicine|Peak Plasma Concentration (Cmax)|Adverse Events|Area under the Curve (AUC)|Angiographic Stasis|Total dose delivered|Response rate|Time to Progression|Overall Survival|Progression Free Survival	Terumo Europe N.V.|Federation Francophone de Cancerologie Digestive|Fundacion Clinic per a la Recerca Biomédica	All	18 Years and older   (Adult, Older Adult)	Not Applicable	15	Industry|Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	T125E2	April 2016	October 2018	October 2018	September 14, 2015		October 22, 2018	Evgenidio Therapeftirio "Agia Trias", Athens, Greece|Hospital Clínic i provincial de Barcelona, Barcelona, Spain|Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland		https://ClinicalTrials.gov/show/NCT02548780
764	NCT00848237	HALO Patient Registry: Ablation of Barrett's Esophagus		Completed	Has Results	Barrett Esophagus	Device: Radiofrequency Ablation (HALO Ablation Systems)	Endoscopic Clearance Rate for Barrett's Esophagus-Percentage of Patients With no Endoscopically Visible Barrett's Esophagus at 1 Year Follow-up|Histological Clearance Rate for Intestinal Metaplasia (CE-IM)|Histological Clearance Rate for Dysplasia (CE-D)|Percentage of Patients With Sub-squamous Intestinal Metaplasia at 1 Year Follow up|Patient Quality of Life Questionnaire Results: Change From Baseline to 12 Month|Adverse Event Incidence	Medtronic - MITG	All	Child, Adult, Older Adult	Not Applicable	5521	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	B-500	July 2007	July 2014	July 2014	February 20, 2009	February 5, 2016	February 5, 2016	Gastrointestinal Associates and sites across the US, Knoxville and other US cities, California, United States		https://ClinicalTrials.gov/show/NCT00848237
765	NCT02650492	Immunostimulating Interstitial Laser Thermotherapy in Malignant Melanoma		Recruiting	No Results Available	Melanoma|Malignant Melanoma	Device: Immunostimulating Interstitial Laser Thermotherapy	Safety (adverse events)|Usability of the device as evaluated by treatment logs|Usability of the device as evaluated by user questionnaire|Treatment effect (Measurement of tumor burden by irRC criteria)|Inflammatory response in tumor and circulation measured by quantification of inflammatory cell populations	Clinical Laserthermia Systems AB	All	18 Years and older   (Adult, Older Adult)	Not Applicable	5	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CTP-2015-004	October 2015	June 2020	October 2020	January 8, 2016		January 30, 2019	Karolinska University Hospital Solna, Stockholm, Sweden		https://ClinicalTrials.gov/show/NCT02650492
766	NCT03742401	Treatment of Breast Fibroadenoma With High Intensity Focused Ultrasound (HIFU)		Recruiting	No Results Available	Breast Fibroadenoma	Procedure: Surgery|Device: HIFU (Echopulse)	Evaluation of the treatment of breast fibroadenoma by HIFU compared to surgery assessing the total induced cost in both study arms|Evaluation of the clinical effectiveness in both arms.|Number of cases needing corrective surgery in case of lack of effectiveness of the primary HIFU treatment.|Safety of the procedures in both arms: Number of and severity of adverse events in both arms	Theraclion	Female	18 Years to 45 Years   (Adult)	Not Applicable	300	Industry	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HIFU-Surg-FA	June 11, 2018	July 2019	December 2019	November 15, 2018		November 15, 2018	Hopital Européen, Marseille, France|CHU de Montpellier, Montpellier, France|Polyclinique de l'Atlantique, Nantes, France|American Hospital of Paris, Neuilly-sur-Seine, France|Hopital Saint Louis, Paris, France|Groupe Hospitaliler Diaconesses, Paris, France|Hopital Pitié-salpêtrière, Paris, France|Hopital TENON, Paris, France|Clinique Mutualiste LA SAGESSE, Rennes, France|Centre Hospitalier, Valenciennes, France		https://ClinicalTrials.gov/show/NCT03742401
767	NCT02612168	Melanoma Image Analysis Algorithm (MIAA) Validation Study		Completed	No Results Available	Malignant Melanoma	Device: Melanoma Image Analysis Algorithm (MIAA)	The Area Under the Curve of a Receiver Operating Characteristic (AUROC) curve of MIAA result, using a maximum likelihood estimation (MLE) from all of the available images of biopsied lesions, compared to the biopsy result|The sensitivity of MIAA, using a MLE from all of the available images of biopsied lesions, compared to the biopsy result|The sensitivity of MIAA, using a MLE from all of the available images of non-biopsied lesions, compared to clinical assessment|The specificity of MIAA, using a MLE from all of the available images of biopsied lesions, compared to the biopsy result|The specificity of MIAA, using a MLE from all of the available images of non-biopsied lesions, compared to clinical assessment|The positive predictive value of MIAA, using a MLE from all of the available images of biopsied lesions, compared to the biopsy result|The positive predictive value of MIAA, using a MLE from all of the available images of non-biopsied lesions, compared to clinical assessment|The negative predictive value of MIAA, using a MLE from all of the available images of biopsied lesions, compared to the biopsy result|The negative predictive value of MIAA, using a MLE from all of the available images of non-biopsied lesions, compared to clinical assessment|The false positive rate of MIAA, using a MLE from all of the available images of biopsied lesions, compared to the biopsy result|The false positive rate of MIAA, using a MLE from all of the available images of non-biopsied lesions, compared to clinical assesment|The false negative rate of MIAA, using a MLE from all of the available images of biopsied lesions, compared to the biopsy result|The false negative rate of MIAA, using a MLE from all of the available images of non-biopsied lesions, compared to clinical assessment|The AUROC of MIAA, using images of biopsied lesions from each of the image capture apparatus combinations, compared to the biopsy result|The AUROC of MIAA, using images of non-biopsied lesions from each of the image capture apparatus combinations, compared to clinical assessment|The sensitivity of MIAA, using images of biopsied lesions from each of the image capture apparatus, compared to the biopsy result|The sensitivity of MIAA, using images of non-biopsied lesions from each of the image capture apparatus, compared to clinical assessment|The specificity of MIAA, using images of biopsied lesions from each of the image capture apparatus, compared to the biopsy result|The specificity of MIAA, using images of non-biopsied lesions from each of the image capture apparatus, compared to clinical assessment|The positive predictive value of MIAA, using images of biopsied lesions from each of the image capture apparatus, compared to the biopsy result|The positive predictive value of MIAA, using images of non-biopsied lesions from each of the image capture apparatus, compared to clinical assessment|The negative predictive value of MIAA, using images of biopsied lesions from each of the image capture apparatus, compared to the biopsy result|The negative predictive value of MIAA, using images of non-biopsied lesions from each of the image capture apparatus, compared to clinical assessment|The false positive rate of MIAA, using images of biopsied lesions from each of the image capture apparatus, compared to the biopsy result|The false positive rate of MIAA, using images of non-biopsied lesions from each of the image capture apparatus, compared to clinical assessment|The false negative rate of MIAA, using images of biopsied lesions from each of the image capture apparatus, compared to the biopsy result|The false negative rate of MIAA, using images of non-biopsied lesions from each of the image capture apparatus, compared to clinical assessment|The concordance of MIAA result between each of the image capture apparatus|The number of adverse events, including adverse device events and serious adverse events.|The proportion of lesions with 4 images that can be analysed by MIAA|The proportion of lesions with at least 1 readable images that can be analysed by MIAA,|The AUROC curve of the MIAA result, using MLE from all of the available images of non-biopsied PLs, compared to the clinical assessment	Skin Analytics Limited	All	18 Years and older   (Adult, Older Adult)	Not Applicable	514	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	SA-001-4ev	January 11, 2017	July 11, 2018	July 11, 2018	November 23, 2015		January 25, 2019	Royal Devon and Exeter, Exeter, Devon, United Kingdom|Whipps Corss Hospital, Leytonstone, London, United Kingdom|Royal Stoke University Hospital, Stoke, Staffordshire, United Kingdom|Russells Hall Hospital, Dudley, West Midlands, United Kingdom|Bristol Royal Infirmary, Bristol, United Kingdom|Royal Free London NHS Foundation Trust, London, United Kingdom|Churchill Hospital, Oxford, United Kingdom		https://ClinicalTrials.gov/show/NCT02612168
768	NCT03130829	To Evaluate the QoL Improvement of Oral Oligo Fucoidan in Subjects Receiving Platinum-based Chemotherapy With NSCLC		Not yet recruiting	No Results Available	NSCLC Stage IV|NSCLC, Stage III	Dietary Supplement: Oligo Fucoidan|Dietary Supplement: Placebo	Quality of Life (QoL)|Progression-Free Survival (PFS)|Objective Response Rate (ORR)|Change of Cytokines	Hi-Q Marine Biotech International, Ltd.	All	20 Years and older   (Adult, Older Adult)	Not Applicable	100	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care	HiQ002	April 30, 2017	February 28, 2020	April 30, 2020	April 27, 2017		April 28, 2017	Shuang Ho Hospital, New Taipei City, Taiwan|Wan-Fang Hospital, Taipei, Taiwan|Taipei Medical University Hospital, Taipei, Taiwan		https://ClinicalTrials.gov/show/NCT03130829
769	NCT02531646	Clinical Evaluation of CARESTREAM Dual Energy and Digital Tomosynthesis		Completed	Has Results	Solitary Pulmonary Nodules	Radiation: Radiation	Radlex Scale for Diagnostic Quality Ratings - DE Predicate PA Chest|Radlex Scale for Diagnostic Quality Ratings - DE Investigational Composite|Radlex Scale for Diagnostic Quality Ratings - DE Investigational High Energy|Radlex Scale for Diagnostic Quality Ratings - DE Investigational Low Energy|Radlex Scale for Diagnostic Quality Ratings - DT Reference 1- PA Chest|Radlex Scale for Diagnostic Quality Ratings - DT Reference 2 - PA and LAT Chest|Radlex Scale for Diagnostic Quality Ratings - DT Investigational - Scout & DT Volume|Radlex Scale for Diagnostic Quality Ratings - LT Predicate Phantom Images|Radlex Scale for Diagnostic Quality Ratings - DT Investigational Phantom Images	Carestream Health, Inc.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	66	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Diagnostic	9J8068	November 2015	April 2016	April 2016	August 24, 2015	November 2, 2016	March 9, 2017			https://ClinicalTrials.gov/show/NCT02531646
770	NCT03551249	Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption		Recruiting	No Results Available	Glioma|Glioblastoma	Device: Focused ultrasound (FUS)	Device and procedure related adverse events|Feasibility of repeated BBB disruption will be evaluated through assessment of post-procedure contrast-enhanced magnetic resonance (MR) imaging	InSightec	All	18 Years to 80 Years   (Adult, Older Adult)	Not Applicable	20	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	BT008	March 26, 2019	December 2021	December 2021	June 11, 2018		July 4, 2019	University of Maryland, Baltimore, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT03551249
771	NCT03044054	Treatment of Breast Fibroadenoma Targeted Tissue With HIFU	HIFU-003	Recruiting	No Results Available	Breast Fibroadenoma	Device: ECHOPULSE	Pain level assessment|Anxiety level assessment|Volume assessment|The short (6-item) version of the State-Trait Anxiety Inventory (STAI)|Palpability of the breast fibroadenoma|Freedom from additional procedures for fibroadenoma of the breast|Patient satisfaction|Safety endpoints include adverse events (AEs) and serious adverse events (SAEs) occurring at any time during the trial.	Theraclion	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	100	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HIFU/FA/003	January 2017	January 2020	January 2020	February 6, 2017		December 21, 2018	Bellevue Hospital Center, New York, New York, United States|New York Columbia University Medical Center, New York, New York, United States|Montefiore-Einstein Center for Cancer Care, New York, New York, United States|University of Virginia Health system, Charlottesville, Virginia, United States		https://ClinicalTrials.gov/show/NCT03044054
772	NCT01419769	AXIOS Stent & Delivery System Study		Completed	Has Results	Pancreatic Pseudocyst(s)	Device: AXIOS Stent & Delivery System	Safety - Freedom From Major Complications: Access Site-related Bleeding|Safety - Freedom From Major Complications: Access Site-related Infection|Safety - Freedom From Major Complications: Perforation|Safety - Freedom From Major Complications: Stent Migration/Dislodement|Safety - Freedom From Major Complications: Tissue Injury|Safety - Freedom From Major Complications: SAE's|Effectiveness: Stent Lumen Patency at 30 Days and/or 60 Days|Effectiveness: Stent Removability at 30 Days and/or 60 Days|Effectiveness: Technical Success|Clinical Success	Xlumena, Inc.	All	18 Years to 75 Years   (Adult, Older Adult)	Not Applicable	30	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CD00744	August 2011	June 2012	April 2013	August 18, 2011	November 19, 2014	September 21, 2015	California Pacific Medical Center (CPMC), San Francisco, California, United States|Unversity of Colorado Denver, Aurora, Colorado, United States|Borland-Groover Clinic, Jacksonville, Florida, United States|University of Chicago Medical Center (UCMC), Chicago, Illinois, United States|Cornell University, New York, New York, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Hospital Costa del Sol, Marbella, Spain		https://ClinicalTrials.gov/show/NCT01419769
773	NCT01828762	Autologous Immune Cell Therapy in Primary Hepatocellular Carcinoma Patients Following Resection and TACE Therapy	DC-TC	Completed	No Results Available	Primary Hepatocellular Carcinoma	Biological: DC-TC+GM-CSF	Vital signs，physical examinations and adverse events	Cellular Biomedicine Group Ltd.|No.85 Hospital, Changning, Shanghai, China|China Cell Technology Ltd. licensed CBMG to conduct the clinical trial as the sponsor in China	All	18 Years to 80 Years   (Adult, Older Adult)	Not Applicable	8	Industry|Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	040420100005	December 2012	December 2013		April 11, 2013		December 23, 2013	9585 Humin Road,Xuhui district, Shanghai, Shanghai, China		https://ClinicalTrials.gov/show/NCT01828762
774	NCT01798134	Microparticle Enhanced Cytotoxic Transarterial Embolization Therapy in Hepatocellular Carcinoma	MIRACLE I	Completed	Has Results	Hepatocellular Carcinoma	Device: TANDEM™	Freedom From Serious Adverse Event (SAE) at 30days|Freedom From Study Related SAE at 6 Months|Freedom From Tumor Progression at 6 Months|12 Month Survival	Boston Scientific Corporation	All	18 Years and older   (Adult, Older Adult)	Not Applicable	25	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	TANDEM 2012-001 OUS	December 2012	November 2014	March 2015	February 25, 2013	June 27, 2016	October 3, 2016	Klinikum der Universitat Heidelberg, Heidelberg, Baden-Wuerttemberg, Germany|SLK-Kliniken Heilbronn GmbH, Heilbronn, Baden-Wuerttemberg, Germany|Klinikum Stuttgart- Katharinenhospital, Stuttgart, Baden-Wuerttemberg, Germany|Klinikum Bogenhausen, Munchen, Bayern, Germany|Kilinikum Darmstadt, Darmstadt, Hessen, Germany|Universitatsklinikum Essen, Essen, Nordrhein-Westfalen, Germany|University Hospital Regensburg, Regensburg, Germany		https://ClinicalTrials.gov/show/NCT01798134
775	NCT03712293	ExAblate Blood-Brain Barrier Disruption for Glioblastoma in Patients Undergoing Standard Chemotherapy		Recruiting	No Results Available	Glioblastoma Multiforme	Device: BBB Disruption with Chemotherapy Arm	Adverse Events Safety Profile|Blood Brain Barrier Opening	InSightec	All	19 Years to 80 Years   (Adult, Older Adult)	Not Applicable	10	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	BT008K	August 28, 2018	December 31, 2021	December 31, 2021	October 19, 2018		October 19, 2018	Severance Hospital, Yonsei University Health System, Seoul, Seodaemun-gu, Korea, Republic of		https://ClinicalTrials.gov/show/NCT03712293
776	NCT03616860	Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption for Treatment of Glioma		Recruiting	No Results Available	Glioblastoma	Device: Focused Ultrasound (FUS) BBB Disruption	Device and procedure related adverse events|Feasibility of repeated BBB disruption will be evaluated through assessment of post-procedure contrast-enhanced magnetic resonance (MR) imaging|Effectiveness of BBB disruption in the treated tumor region	InSightec	All	18 Years to 80 Years   (Adult, Older Adult)	Not Applicable	20	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	BT008C|277981	October 16, 2018	December 2021	December 2021	August 6, 2018		November 30, 2018	Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada		https://ClinicalTrials.gov/show/NCT03616860
777	NCT04033627	TCDαβ/CD45RA Haploidentical Transplantation in Children With Leukemia		Not yet recruiting	No Results Available	Relapsed Pediatric ALL|Acute Graft-Versus-Host Disease (Gvhd) Grade IV (Diagnosis)|Relapsed Pediatric AML	Procedure: In Vitro T cells depletion using CliniMCAS system	Log number of In Vitro T cells depletion|Incidence of grade II-IV acute GVHD|Grade I aGVHD|cGVHD|NRM|Graft failure	Shanghai Children's Medical Center|Nanfang Hospital of Southern Medical University|Children's Hospital Of Soochow University|Chinese University of Hong Kong|Miltenyi Biotec GmbH	All	2 Months to 18 Years   (Child, Adult)	Not Applicable	30	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	TCD Haplo	September 1, 2019	August 31, 2021	August 31, 2022	July 26, 2019		July 26, 2019			https://ClinicalTrials.gov/show/NCT04033627
778	NCT02488655	Treatment of Breast Fibroadenoma With FastScan HIFU		Recruiting	No Results Available	Breast Fibroadenoma	Device: Echopulse	Number of participants with adverse events|Change from Baseline volume of the fibroadenoma at 6 months|Change from Baseline Patient pain intensity score (100mm visual analog scale) at 1 day|Change from Baseline Patient pain intensity score (100mm visual analog scale) at 3 days|Change from Baseline Patient pain intensity score (100mm visual analog scale) at 7 days|Patient satisfaction questionnaire|Number of participants with absence of palpable lesion|Patient Cosmetic evaluation as measured by questionnaire|Investigator rated evaluation of the device|Change from Baseline gland vascularization at 3 months|Change from Baseline gland vascularization at 6 months	Theraclion	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	15	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HIFU/BG/FA/FS/2015	June 2015	December 2018	December 2018	July 2, 2015		May 28, 2018	University Hospital of Endocrinology USBALE, Sofia, Bulgaria		https://ClinicalTrials.gov/show/NCT02488655
779	NCT03276286	Nativis Voyager for Newly Diagnosed GBM	NAT109	Active, not recruiting	No Results Available	Glioblastoma Multiforme	Device: Nativis Voyager	Treatment-related Adverse Events (Safety)|Clinical Utility PFS|Clinical Utility OS	Nativis, Inc.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	36	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility	NAT109	November 10, 2017	January 31, 2020	January 31, 2020	September 8, 2017		May 15, 2019	Center for Neurosciences, Tucson, Arizona, United States|California Cancer Care Associates, Encinitas, California, United States|John Wayne Cancer Institute @ Providence St Johns Health Center, Santa Monica, California, United States|Associated Neurologists of Southern CT, PC, Fairfield, Connecticut, United States|Boca Raton Regional Hospital, Boca Raton, Florida, United States|Cancer Care Collaborative, Austin, Texas, United States|Baylor Scott and White Health, Temple, Texas, United States		https://ClinicalTrials.gov/show/NCT03276286
780	NCT02919046	Study Evaluating the Efficacy and Safety With CAR-T for Relapsed or Refractory Neuroblastoma in Children		Recruiting	No Results Available	Relapsed or Refractory Neuroblastoma	Biological: GD2-targeted CAR-T cells	The overall efficiency of patients with neuroblastoma after autologous CAR-T cell therapy|Progression free survival|Overall survival|Patients-based Quality of Life Evaluation|3°or above incidence rate of serious adverse reaction related to treatment	Sinobioway Cell Therapy Co., Ltd.|Nanjing Children's Hospital|Children's Hospital of Fudan University	All	1 Year to 14 Years   (Child)	Not Applicable	22	Industry|Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	WM-CART-07	September 2016	September 2020	September 2020	September 29, 2016		March 14, 2017	Nanjing Children's Hospital, Nanjing, Jiangsu, China|Children's Hospital of Fudan University, Shanghai, Shanghai, China		https://ClinicalTrials.gov/show/NCT02919046
781	NCT02139683	Feasibility Study Assessing the Treatment of Fibroadenomata With a Circumferential Sonication Treatment With HIFU		Completed	No Results Available	Breast Fibroadenoma	Device: HIFU treatment	Changes in size of fibroadenomata as recorded on ultrasound imaging|Adverse Events|Patient recorded outcomes measures|Mean treatment time|Cost-effectiveness	Theraclion|King's College London	All	18 Years and older   (Adult, Older Adult)	Not Applicable	50	Industry|Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HIFU-F	January 2014	January 2016	January 2016	May 15, 2014		May 30, 2018	Kings College London, Guy's & St Thomas' Hospitals, Department of Research Oncology, London, United Kingdom		https://ClinicalTrials.gov/show/NCT02139683
782	NCT02011919	Treatment of Breast Fibroadenoma With High Intensity Focused Ultrasound (HIFU)	HIFU	Completed	No Results Available	Breast Fibroadenoma	Device: Echopulse	FA volume changes from baseline|Palpability|Pain assessment|Cosmetic result|Gland vascularisation|Histological outcome|Energy settings|Breast immobilization|Duration of the treatment session|Ease of implementation of treatment	Theraclion	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	27	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HIFU / TU / FA	December 2013	January 2017	January 2017	December 13, 2013		May 30, 2018	Tubingen University Hospital, Tubingen, Germany		https://ClinicalTrials.gov/show/NCT02011919
783	NCT02948790	Auditory Nerve Monitoring Using Intra-cochlear Stimulation in Subjects With Acoustic Neuroma	NeuriStim	Recruiting	No Results Available	Hearing Loss, Cochlear|Neurinoma of the Acoustic Nerve	Device: Neuristim|Device: Cochlear implant	Wave V latency|Complications|Impedance measurement|ergonomics of the Neuristim|Speech audiometry|Pure tone audiometry	Oticon Medical	All	18 Years and older   (Adult, Older Adult)	Not Applicable	34	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	PIC_05	April 7, 2017	January 2019	May 2019	October 28, 2016		September 25, 2018	University Hospital Bordeaux - Pellegrin, Bordeaux, France|University Hospital Grenoble - A. Michallon, Grenoble, France|University Hospital Lyon - Edouard Herriot, Lyon, France|University Hospital Pitié Salpétrière, Paris, France		https://ClinicalTrials.gov/show/NCT02948790
784	NCT03940963	Study of AxoGuard® Nerve Cap and Neurectomy for Treatment of Symptomatic Neuroma & Prevention of Recurrent Neuroma Pain	REPOSE	Recruiting	No Results Available	Symptomatic Neuroma|Morton's Neuroma|Chronic Nerve Pain	Device: AxoGuard® Nerve Cap|Procedure: Standard Neurectomy	Change in Visual Analog Scale (VAS) For Pain Score at 3 post-operative months in Pilot Phase Subjects|Change in Visual Analog Scale (VAS) For Pain Score at 12 post-operative months in Comparative Phase Subjects.|Safety: Serious Adverse Events (SAEs)|Safety: Adverse Events (AEs) or Unanticipated Adverse Device Effects (UADEs)|Changes in Visual Analog Scale (VAS) For Pain score through 12 post-operative months compared to baseline.|2. Change in Patient Reported Outcome Measurement Information System (PROMIS®) - Pain Related Measures through 12 post-operative months compared to baseline.|Change in Foot Health Status Questionnaire (FHSQ) Score at 1,3,6,9, and 12 post-operative months compared to baseline.|Changes in quantity, quality and class of pain medication use at 1,3,6,9 and 12 months comparted to baseline.|SAEs, AEs, and/or UADEs	Axogen Corporation	All	18 Years and older   (Adult, Older Adult)	Not Applicable	101	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment	CAP-CP-001	October 10, 2018	November 2021	November 2021	May 7, 2019		May 7, 2019	Anastasia Medical Group, Saint Augustine, Florida, United States|North Jersey Podiatry, Wayne, New Jersey, United States|Foot and Ankle Specialists of Ohio, Mentor, Ohio, United States|Austin Foot and Ankle Specialists, Austin, Texas, United States|Complete Foot and Ankle Care of North Texas, Denton, Texas, United States|JPS Health Network, Fort Worth, Texas, United States		https://ClinicalTrials.gov/show/NCT03940963
785	NCT02507102	A Feasibility Study of the Nativis Voyager® System in Patients With Recurrent Glioblastoma Multiforme (GBM) in Australia		Completed	No Results Available	Glioblastoma Multiforme	Device: Voyager	Incidence and evaluation of any serious adverse events associated with the Nativis Voyager System|Tumor Response|Overall survival at six months compared with historical response|Progression free survival	Nativis, Inc.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	11	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NAT-105	August 2015	December 2017	March 26, 2018	July 23, 2015		March 30, 2018	St. Vincent's Hospital Melbourne, Melbourne, Victoria, Australia		https://ClinicalTrials.gov/show/NCT02507102
786	NCT02649894	Safety and Effectiveness of a New Pleural Catheter for Symptomatic, Recurrent, MPEs Versus Approved Pleural Catheter	SWIFT	Completed	No Results Available	Malignant Pleural Effusion	Device: Active Comparator: Approved Uncoated PleurX Indwelling Pleural Catheter|Device: Experimental: Silver Nitrate Coated Indwelling Pleural Catheter (SNCIPC)	The proportion of subjects achieving pleurodesis without recurrence|Time to confirmed pleurodesis|Time to recurrence	CareFusion	All	18 Years and older   (Adult, Older Adult)	Not Applicable	119	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	CS-IP-VH-14-009	May 2016	April 18, 2018	April 18, 2018	January 8, 2016		May 3, 2019	Heart Center Research, Huntsville, Alabama, United States|Stanford University School of Medicine/ Stanford Cancer Institute, Stanford, California, United States|Moffitt Cancer Center, Tampa, Florida, United States|Northwestern Unversity, Chicago, Illinois, United States|St. Vincent Medical Group, Indianapolis, Indiana, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deconess Medical Center West, Boston, Massachusetts, United States|Washington Universtiy School of Medicine, Barnes Jewish Hospital, Saint Louis, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|SUNY Upstate Hospital, Syracuse, New York, United States|UNC Hospital, Chapel Hill, North Carolina, United States|Duke University, Durham, North Carolina, United States|Vanderbuilt University, Nashville, Tennessee, United States|University of Texas, MD Anderson Cancer Center, Houston, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Southmead Hospital, Bristol, United Kingdom|Oxford Center for Respiratory Medicine, Churchill Hospital, Oxford, United Kingdom|Great Western Hospital, Swindon, United Kingdom	"Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/94/NCT02649894/Prot_000.pdf|"Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/94/NCT02649894/SAP_001.pdf	https://ClinicalTrials.gov/show/NCT02649894
787	NCT02228174	Sonography Guided Transcervical Ablation of Uterine Fibroids	SONATA	Active, not recruiting	Has Results	Menorrhagia	Device: Intrauterine Ultrasound-Guided Radiofreq. Ablation System	Percentage of Subjects With ≥ 50% Reduction in Menstrual Blood Loss as Assessed by Pictorial Blood Loss Assessment Chart (PBAC)|Percentage of Subjects Without Surgical Re-intervention for Heavy Menstrual Bleeding Due to Treatment Failure|Safety - Percentage of Subjects With Adverse Device Effects (Serious or Non-serious)|Percentage Change in Total and Perfused Mean Maximal Fibroid Volumes at 12 Months|Change in the Symptom Severity Score (SSS) and Quality of Life (HR-QoL) Subscales of the Uterine Fibroid Symptom and Quality of Life (UFS-QoL) Questionnaire at 12 Months|Time to Return to Normal Activity (RTNA) in Days|Overall Treatment Effect (OTE) at 12 Months|Subject Satisfaction With Treatment at 12 Months|Subject Willingness to Recommend Procedure at 12 Months|Change in General Health State at 12 Months|Subject Pain|Procedure Tolerance|Mean Length of Stay|Occurrence of Pregnancy|Pregnancy Outcome - Gestation Age|Pregnancy Outcome - Birth Weight|Change in Work Productivity and Activity Impairment Due to Uterine Fibroid Symptoms at 12 Months	Gynesonics	Female	25 Years to 50 Years   (Adult)	Not Applicable	147	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CL04502	October 2014	October 18, 2017	October 2019	August 28, 2014	February 19, 2019	February 19, 2019	Kelly H. Roy M.D. P.C., Phoenix, Arizona, United States|Advanced Women's Health Institute, Denver, Colorado, United States|Christiana Care Health Services, Inc., Newark, Delaware, United States|George Washington University Hospital, Washington, District of Columbia, United States|KO Clinical Research, LLC, Fort Lauderdale, Florida, United States|Visions Clinical Research, Wellington, Florida, United States|The Advanced Gynecologic Surgery Institute - Charles E. Miller, MD & Associates, Naperville, Illinois, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Wayne State University, Detroit, Michigan, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Mercy Clinic, Minimally Invasive Gynecology, Saint Louis, Missouri, United States|Cooper University Hospital, Camden, New Jersey, United States|Basque Women's Care, Albuquerque, New Mexico, United States|Montefiore Medical Center, New York, New York, United States|Carolina Women's Research and Wellness Center, Durham, North Carolina, United States|Drexel University, Philadelphia, Pennsylvania, United States|Magee Women's Hospital, Pittsburgh, Pennsylvania, United States|Greenville Health System, Greenville, South Carolina, United States|Baylor Research Institute, Fort Worth, Texas, United States|Willowbend Health and Wellness Associates, Frisco, Texas, United States|Eastern Virginia Medical School, Norfolk, Virginia, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Hospital Universitario "Dr. José Eleuterio González" de la Universidad Autónoma de Nuevo León, Monterrey, N.l., Mexico	"Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/74/NCT02228174/Prot_000.pdf|"Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/74/NCT02228174/SAP_001.pdf	https://ClinicalTrials.gov/show/NCT02228174
788	NCT02296580	A Feasibility Study of the Nativis Voyager® System in Patients With Recurrent Glioblastoma Multiforme (GBM)		Active, not recruiting	No Results Available	Glioblastoma Multiforme	Device: Nativis Voyager RFE Therapy	Number of any adverse events associated with the investigational therapy.|Clinical Utility: PFS|Clinical Utility: OS	Nativis, Inc.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	32	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NAT-101	February 2014	January 31, 2020	January 31, 2020	November 20, 2014		May 15, 2019	University of Alabama at Birmingham (UAB), Birmingham, Alabama, United States|Center for Neurosciences, Tucson, Arizona, United States|cCARE - California Cancer Associates for Research & Excellence, Encinitas, California, United States|John Wayne Cancer Institute @ Providecne St. Johns Health Center, Santa Monica, California, United States|Associated Neurologists of Southern CT, P.C., Fairfield, Connecticut, United States|Boca Raton Regional Hospital, Boca Raton, Florida, United States|University of Kansas Medical Center (KUMC), Kansas City, Kansas, United States|Providence Brain & Spine Institute, Portland, Oregon, United States|Cancer Care Collaborative, Austin, Texas, United States|Baylor Scott & White Health, Temple, Texas, United States|Virginia Mason Hospital & Medical Center, Seattle, Washington, United States|Swedish Medical Center, Seattle, Washington, United States|St Vincent's Hospital Melbourne, Melbourne, Australia		https://ClinicalTrials.gov/show/NCT02296580
789	NCT01422629	High Intensity Focused Ultrasound (HIFU) to Treat Breast Fibroadenoma		Completed	No Results Available	Breast Fibroadenoma	Device: Ultrasonic ablation device	HIFU induced tissue necrosis assessed by histology of excised gland or reduction volume of fibroadenoma|Volume reduction of the fibroadenoma|- Pain score during the HIFU treatment evaluated by the Visual Analog Scale.|Percentage of patients with Adverse events	Theraclion	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	24	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	HIFU/F/FA/Dec2010	October 2011	February 2014	February 2014	August 24, 2011		April 9, 2014	Hôpital Jeanne de Flandre, CHU de Lille 2 Avenue Oscar Lambret, Lille, France|Hôpital Américain de Paris, Neuilly Sur Seine, France		https://ClinicalTrials.gov/show/NCT01422629
790	NCT02227732	A Pilot Study Evaluating the Safety and Effectiveness of a New Pleural Catheter for the Medical Management of Symptomatic, Recurrent, Malignant Pleural Effusions		Completed	No Results Available	Malignant Pleural Effusions	Device: New Indwelling Pleural Catheter	Device -related safety and the number of adverse events.|pleurodesis success|Pleurodesis success	CareFusion	All	18 Years and older   (Adult, Older Adult)	Not Applicable	10	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CS-IS-VH-13-001|CI20130054	April 2014	May 2015	May 2015	August 28, 2014		August 8, 2016	Southmead Hospital - Academic Resporatory Unit, Westbury on Severn, Bristol, United Kingdom		https://ClinicalTrials.gov/show/NCT02227732
791	NCT01331954	Treatment of Breast Fibroadenoma With High Intensity Focused Ultrasound (HIFU)		Active, not recruiting	No Results Available	Breast Fibroadenoma	Device: Ultrasonic ablation device	Reduction of breast fibroadenoma volume at ultrasonography	Theraclion	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	20	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HIFU/BG/FA/Jan2011	March 2011	September 2018	September 2018	April 8, 2011		May 28, 2018	University Hospital of Endocrinology (USBALE) "Acad. Ivan Penchev", Sofia, Bulgaria		https://ClinicalTrials.gov/show/NCT01331954
792	NCT01609179	IPI-926 Extension Protocol for Continuation of Treatment With IPI-926		Completed	No Results Available	Basal Cell Carcinoma|Chondrosarcoma	Drug: IPI-926	Incidence of adverse events (AEs) and serious adverse events (SAEs), and laboratory test results	Infinity Pharmaceuticals, Inc.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	9	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IPI-926-09	March 2012	October 2012	November 2012	May 31, 2012		November 14, 2012	University of Colorado Denver, Aurora, Colorado, United States|Johns Hopkins, Baltimore, Maryland, United States		https://ClinicalTrials.gov/show/NCT01609179
793	NCT00910312	ICE-SENSE™ Cryotherapy for Breast Fibroadenoma Trial	ICE-CRYSTAL	Completed	No Results Available	Fibroadenoma	Device: Ice-Sense	engulfment of the tumor by the ice-ball as seen under ultrasound imaging|any device related adverse events or complications that may occur	IceCure Medical Ltd.	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	54	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	AM-03|version 5.0	April 2009	January 2013	January 2013	May 29, 2009		April 22, 2016	Oncogynecological Center, Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Prague, Czech Republic|Department of Obstetrics and Gynecology, University Hospital of Heidelberg, Heidelberg, Germany|Department of Obstetrics and Gynecology, University Hospital of Tuebingen, Tübingen, Germany|Assuta medical centers, Haifa, Israel		https://ClinicalTrials.gov/show/NCT00910312
794	NCT01404520	Patient Activation, Counseling and Exercise - Acute Leukemia (PACE-AL)	PACE-AL	Completed	No Results Available	Acute Leukemia	Other: Exercise based multimodal intervention	Six Minute Walk Distance 6MWD|Estimated VO2 max Aastrand test|Timed chair stand|Timed biceps curl|EORTC QLQ-C30|FACT-An|HADS|SF36|MDASI	Universitetshospitalernes Center for Sygepleje|University of Copenhagen|Novo Nordisk A/S|Danish Cancer Society|Lundbeck Foundation	All	18 Years and older   (Adult, Older Adult)	Not Applicable	70	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care	H-4-2010-046	June 2011	May 2014	May 2015	July 28, 2011		December 2, 2015	Copenhagen University Hospital Rigshospital, Copenhagen, Denmark|Herlev Hospital, Herlev, Denmark		https://ClinicalTrials.gov/show/NCT01404520
795	NCT00891657	Post Market Study for an Adhesion Barrier Following Laparoscopic Myomectomy		Completed	Has Results	Fibroid|Myoma|Leiomyoma	Device: SprayShield™	Number of Sites Adherent to the Uterus|Mean Severity Score of Sites Adherent to the Uterus|Mean Extent Score of Sites Adherent to the Uterus|Area of Sites Adherent to the Uterus (cm^2)	Integra LifeSciences Corporation	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	15	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention	GYN-08-002	November 2008	May 2009	May 2009	May 1, 2009	August 31, 2010	September 7, 2017	Pius Clinic, Oldenburg, Germany		https://ClinicalTrials.gov/show/NCT00891657
796	NCT00087776	Study of Taxoprexin Injection vs. Dacarbazine in Patients With Metastatic Malignant Melanoma		Completed	No Results Available	Malignant Melanoma	Drug: Chemotherapy		American Regent, Inc.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	575	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	P01-02-17	October 2002	October 2007		July 16, 2004		January 24, 2018	Luitpold Pharmaceuticals, Inc., Norristown, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT00087776
797	NCT00731341	Hysteroscopic Cryomyolysis for the Treatment of Submucosal Leiomyomata		Completed	Has Results	Uterine Fibroids|Leiomyoma|Menorrhagia	Procedure: Cryoablation for the treatment of uterine fibroids	Number of Adverse Events|Hysteroscopic Cryoablation Related Pain Will be Measured by Self Reported Pain Severity Visual Analogue Scale (VAS) Completed by the Patient|Time (in Days) to Return to Normal Activity|Number of Participants Discharged on Day of Cryoablation Procedure.|Evaluation of Length of an Average Cryoablation Procedure|Physician's Satisfaction From the Ease and Convenience of the Cryoablation Procedure	Galil Medical	Female	30 Years to 50 Years   (Adult)	Not Applicable	3	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	UFHYS_WH_ 121207 VER 0.1	July 2008	February 2009	February 2009	August 11, 2008	July 1, 2011	November 2, 2011	St.Lucas Andreas Ziekenhuis, Amsterdam, Netherlands		https://ClinicalTrials.gov/show/NCT00731341
798	NCT01152112	HOME Study: Hysteroscopic Office Myomectomy Evaluation	HOME	Completed	Has Results	Uterine Fibroids|Polyps	Device: Myomectomy	Percent Reduction in Target Pathology Volume|Percent of Subjects That Achieve 100% Removal of Target Pathology|Subject Self-reported Pain Score Occurring During the Treatment Procedure	Hologic, Inc.	Female	18 Years to 55 Years   (Adult)	Not Applicable	74	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	TMP 2009003	June 2010	January 2012	June 2013	June 29, 2010	September 13, 2017	September 13, 2017	Phoenix Gynecology Consultants, Phoenix, Arizona, United States|Boulder Women's Clinic, Boulder, Colorado, United States|Women's Health Care Practice, Champaign, Illinois, United States|The Research Division for Integrated Health Services, Ann Arbor, Michigan, United States|Rubino OB/Gyn, West Orange, New Jersey, United States|Williams, Benavides, Marston, & Kaminski, Raleigh, North Carolina, United States|Complete Healthcare for Women, Columbus, Ohio, United States|Kulbresh Women's Center, Irmo, South Carolina, United States|Obstetrics and Gynecology, North Charleston, South Carolina, United States		https://ClinicalTrials.gov/show/NCT01152112
799	NCT01092988	A Clinical Study to Evaluate Safety of the ExAblate 2100 UF V2 System in the Treatment of Symptomatic Uterine Fibroids		Completed	No Results Available	Uterine Fibroids|Bleeding|Pain	Device: Exablate 2100	Safety|Initial Efficacy	InSightec	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	40	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	UF032	March 2010	February 2012	February 2012	March 25, 2010		February 22, 2012	Radiopharmaceutiques hopital Bretonneau, Tours, France|Sheba MC, Ramat Gan, Israel|Research Centre of Obstetric / Gynaecology & Perinatology, Moscow, Russian Federation|St. Mary's Hospital, London, United Kingdom		https://ClinicalTrials.gov/show/NCT01092988
800	NCT03327285	C-CAR011 Treatment in Subjects With ALL After HSCT		Not yet recruiting	No Results Available	Acute Lymphoblastic Leukemia(ALL)	Biological: C-CAR011	TEAEs|GVHD|Recurrence rate|OS|PFS|Remission rate	Peking University People's Hospital|Cellular Biomedicine Group Ltd.	All	15 Years to 65 Years   (Child, Adult, Older Adult)	Not Applicable	40	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2017PHB033-01|CBMG-C2017004	October 15, 2018	February 28, 2021	April 30, 2021	October 31, 2017		September 25, 2018	Peking University Institute of Hematology, Beijing, Beijing, China		https://ClinicalTrials.gov/show/NCT03327285
801	NCT03988309	The Cxbladder Hematuria Clinical Utility Study		Not yet recruiting	No Results Available	Hematuria|Urothelial Carcinoma	Diagnostic Test: Cxbladder	To measure the change in cystoscopy procedure use count between control and test arms when Cxbladder is used in the evaluation|To measure the change in total procedure use (and the invasive procedure sub-group) count between control and test arms when Cxbladder is used in the evaluation.|To measure the proportion of subjects who were ruled out on the test arm when Cxbladder is used in the evaluation|To measure the number of subjects who were incorrectly diagnosed associated with the integration of Cxbladder into the evaluation of subjects (or sub-cohorts on test and control arms) presenting with hematuria for evaluation of UC|Proportion of subjects (and sub-groups within test and control arms) with bladder cancer who are correctly identified as having cancer (true positives) and no cancer (true negatives) by the Cxbladder test.|To compare the total score of the anxiety and pain level associated with cystoscopy vs Cxbladder by using Patient Result Outcome questionnaire and WIWI(was it worthy it)|Comparison of the Cxbladder test's sensitivity, specificity, PPV and NPV with that of Cytology.	Pacific Edge Limited	All	18 Years and older   (Adult, Older Adult)	Not Applicable	600	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	CXB/2019/US	July 2019	July 2020	July 2021	June 17, 2019		June 19, 2019			https://ClinicalTrials.gov/show/NCT03988309
802	NCT02943070	Rezum I Pilot Study for BPH	Rezum Pilot	Completed	No Results Available	Prostatic Hyperplasia|Benign Prostatic Hyperplasia|Adenoma, Prostatic|Prostatic Adenoma|Prostatic Hyperplasia, Benign|Prostatic Hypertrophy|Prostatic Hypertrophy, Benign|Rezum	Device: Rezum System	IPSS Improvement|Major Complications|Proportion of Responders wth a ≥ 30% IPSS Iimprovement|Proportion of Responders wth a ≥ 50% IPSS Iimprovement|Proportion of Responders with improvement ≥ 8 points in IPSS|Change in Uroflow (Qmax)|Change in Sexual Function|Procedural Pain Score|Quality of Life|Subject Satisfaction|Procedural Parameters	Boston Scientific Corporation	Male	45 Years and older   (Adult, Older Adult)	Not Applicable	50	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	1189-001	March 2012	February 2013	December 2018	October 24, 2016		July 31, 2019	University Hospital, Brno, Czechia|Clinica Canela, La Romana, Dominican Republic|Urologcentrum, Stockholm, Sweden		https://ClinicalTrials.gov/show/NCT02943070
803	NCT02940392	Rezum FIM Optimization	Rezum FIM	Completed	No Results Available	Benign Prostatic Hyperplasia|Adenoma, Prostatic|Prostatic Adenoma|Prostatic Hyperplasia, Benign|Prostatic Hypertrophy|Prostatic Hypertrophy, Benign|Rezum	Device: Rezum System	Lesion Characteristics via MRI|Change in IPSS|Intra-procedure Pain|Post-Procedure Catheterization	Boston Scientific Corporation	Male	45 Years and older   (Adult, Older Adult)	Not Applicable	15	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	1633-001	February 2012	December 2012	June 2018	October 20, 2016		July 31, 2019	Clinica Canela, La Romana, Dominican Republic		https://ClinicalTrials.gov/show/NCT02940392
804	NCT01578967	Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma		Active, not recruiting	Has Results	Hodgkin Lymphoma, Adult	Drug: Brentuximab vedotin|Drug: ABVD	Percentage of Patients With Positron Emission Tomography (PET) Negative Disease|Number of Participant Who Achieved a Complete Response|Conversion Rate to Complete Response. Number of Participants Who Had a Partial Response Post ABVD Who Converted to a Complete Response.|Progression Free Survival|Time to Progression|Number of Adverse Events Attributed to Brentuximab Vedotin With a Grade 3 or Higher	UNC Lineberger Comprehensive Cancer Center|Seattle Genetics, Inc.	All	18 Years to 60 Years   (Adult)	Not Applicable	41	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	LCCC 1115	April 2012	August 10, 2016	August 10, 2021	April 17, 2012	October 12, 2017	October 3, 2018	City of Hope Comprehensive Cancer Center, Duarte, California, United States|Mayo Clinic, Rochester, Minnesota, United States|University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|Levine Cancer Istitute, Carolinas Health Care system, Charlotte, North Carolina, United States|Rex Cancer Center, Raleigh, North Carolina, United States|Vanderbilt University, Nashville, Tennessee, United States		https://ClinicalTrials.gov/show/NCT01578967
805	NCT03120195	EndoRotor® Ablation of Barrett's Esophagus: Safety and Feasibility Study		Recruiting	No Results Available	Barretts Esophagus With Dysplasia	Device: The EndoRotor®	Safety of EndoRotor® ablation of Barrett's mucosa; Number of participants with treatment related adverse events, such as bleeding, perforation or post procedural stenosis|Feasibility of EndoRotor® for the ablation of Barrett's mucosa|To assess the patient discomfort (recorded using the Numeric Rating Scale - grade 1-10)|To assess the dysphagia-score (recorded using the Ogilvie score)|To assess a variety of symptoms (recorded using a 7 point Likert scale)|Total time to resect tissue|Ease of performing the EndoRotor® procedure	Foundation for Liver Research|Interscope, Inc.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	30	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2016-688	January 27, 2017	December 2018	December 2018	April 19, 2017		May 25, 2018	Ijsselland Hospital, Capelle aan den IJssel, Netherlands|Radboud University Medical Center, Nijmegen, Netherlands|Erasmus MC, University Medical Center, Rotterdam, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands		https://ClinicalTrials.gov/show/NCT03120195
806	NCT02560623	Minimally-Invasive Detection of Barrett's Esophagus and Barrett's Esophagus Related Dysplasia/Carcinoma		Recruiting	No Results Available	Barrett's Esophagus	Device: Sponge capsule	Sensitivity and specificity of Barrett's Esophagus Diagnosis|Sensitivity and specificity of Barrett's dysplasia detection	Mayo Clinic|Exact Sciences Corporation	All	18 Years to 85 Years   (Adult, Older Adult)	Not Applicable	320	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening	15-004540	October 2015	June 2019	December 2019	September 25, 2015		January 7, 2019	Mayo Clinic Jacksonville, Jacksonville, Florida, United States|Mayo Clinic in Rochester, Rochester, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States		https://ClinicalTrials.gov/show/NCT02560623
807	NCT00002026	Treatment and Suppression of Hairy Leukoplakia in ARC Patients With Oral Acyclovir (ACV)		Completed	No Results Available	Leukoplakia, Hairy|HIV Infections	Drug: Acyclovir		Glaxo Wellcome|NIH AIDS Clinical Trials Information Service	All	18 Years and older   (Adult, Older Adult)	Not Applicable		Industry	Interventional	Primary Purpose: Treatment	033A|179				August 31, 2001		June 24, 2005	Univ of Southern California / LA County USC Med Ctr, Los Angeles, California, United States		https://ClinicalTrials.gov/show/NCT00002026
808	NCT02230410	Cryo Balloon for Residual Barrett's Esophagus	Cryoballoon	Enrolling by invitation	No Results Available	Barrett's Esophagus	Device: CryoBalloon Focal Ablation	eradication of barrett's esophagus and/or dysplasia	Mayo Clinic|C2 Therapeutics, Inc.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	10	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	14-004771	August 2014	August 2019	August 2019	September 3, 2014		January 21, 2019	Mayo Clinic in Rochester, Rochester, Minnesota, United States		https://ClinicalTrials.gov/show/NCT02230410
809	NCT02066233	Prospective Study to Compare the Efficacy of E.G.Scan to Detect Barrett's Esophagus Compared With Standard Endoscopy		Completed	Has Results	Barrett's Esophagus	Device: EG Scan II (transnasal endoscopy)|Procedure: Standard Endoscopy	Median Tolerability Score on 10-point Visual Analog Scale (VAS)|Preference for Either of the Two Procedures, EG II Scan Versus Standard Endoscopy	Mayo Clinic|IntroMedic Co., Ltd.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	100	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	13-008214	March 2014	October 2015	March 2016	February 19, 2014	July 6, 2017	July 6, 2017	Mayo Clinic, Rochester, Minnesota, United States		https://ClinicalTrials.gov/show/NCT02066233
810	NCT00651755	Aprepitant's Effect on Drug Metabolism in Multi-Day Combination (CHOP/R-CHOP) Chemotherapy Regimen in Lymphoma Patients		Completed	Has Results	Lymphoma	Drug: Aprepitant|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisone|Drug: Rituximab|Drug: Ondansetron	Geometric Mean Area Under Curve (AUC) of Analyte, Cyclophosphamide (CP), in Aprepitant Treatment and Control Group|Geometric Mean Area Under Curve (AUC) of Analyte, 2-dechloro-cyclophosphamide(2-deCI-CP), in Aprepitant Treatment and Control Group|Geometric Mean Area Under Curve (AUC) of Analyte, 4-hydroxy-cyclophosphamide (4-OH-CP), in Aprepitant Treatment and Control Group|Geometric Mean Area Under Curve (AUC) of Analyte, Vincristine (VC), in Aprepitant Treatment and Control Group|Geometric Mean Area Under Curve (AUC) of Analyte,Prednisone (PR), in Aprepitant Treatment and Control Group|Geometric Mean Area Under Curve (AUC) of Analyte, Prednisolone (PL), in Aprepitant Treatment and Control Group	M.D. Anderson Cancer Center|Merck Sharp & Dohme Corp.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	23	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2006-1033	March 2008	September 2011	September 2011	April 3, 2008	July 2, 2013	July 2, 2013	UT MD Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT00651755
811	NCT00574886	Idiotype Vaccine Following High-Dose Chemotherapy and Hematopoietic Stem Cell Transplantation for Patients With Lymphoma Who Had Failed Induction Chemotherapy		Completed	No Results Available	Lymphoma	Biological: Id-KLH	Humoral and cellular responses to idiotype vaccine with KLH and GM-CSF adjuvant given to patients with lymphoma following high-dose chemotherapy and hematopoietic stem cell transplant.|Safety and toxicity of idiotype vaccine with KLH and GM-CSF adjuvant in the post-transplant setting	University of Nebraska|Genitope Corporation	All	19 Years and older   (Adult, Older Adult)	Not Applicable	2	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	267-00	July 2000	March 2002	April 2008	December 17, 2007		January 17, 2018			https://ClinicalTrials.gov/show/NCT00574886
812	NCT00574730	CHOP/Rituximab Followed by Maintenance PEG Intron in Treatment of Indolent/Follicular Non-Hodgkin's Lymphoma		Completed	No Results Available	Non-Hodgkins Lymphoma	Drug: CHOP/Rituximab|Drug: PEG INTRON	Time to Treatment Failure/Duration of Response/Time to Treatment Failure/Survival|Biologic/Immunologic Evaluation on Study	University of Nebraska|Schering-Plough	All	19 Years to 75 Years   (Adult, Older Adult)	Not Applicable	27	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	013-01	May 2001	August 2005	June 2012	December 17, 2007		January 24, 2018			https://ClinicalTrials.gov/show/NCT00574730
813	NCT03795675	CI Following VS Removal or Labyrinthectomy		Recruiting	No Results Available	Vestibular Schwannoma|Meniere Disease	Device: Cochlear Implant	Change in Sound Detection Testing|Change in Speech Perception Testing|Change in Sound Localization Testing|Change in Speech, Spatial and Qualities of Hearing Scale (SSQ) Scores|Change in Nijmegen Cochlear Implant Questionnaire (NCIQ) Scores|Change in Tinnitus Handicap Inventory (THI) Scores	Ohio State University|Advanced Bionics	All	18 Years to 70 Years   (Adult, Older Adult)	Not Applicable	15	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2017H0273	January 14, 2019	December 2021	December 2025	January 8, 2019		March 14, 2019	The Ohio State University, Columbus, Ohio, United States	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/75/NCT03795675/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT03795675
814	NCT03847636	CryoBalloon Ablation for Treatment of Duodenal Adenomas	C2D2	Enrolling by invitation	No Results Available	Duodenal Adenomas|Familial Adenomatous Polyposis	Device: CryoBalloon ablation	Safety of cryoBalloon ablation in treating non-ampullary non-polypoid duodenal adenomas (DAs) as assessed by the incidence of adverse events in all treated patients|Safety of cryoBalloon ablation in treating non-ampullary non-polypoid duodenal adenomas (DAs) as assessed by the incidence of adverse events in all treatment procedures|Complete eradication rate of DAs|Percent change in the treated duodenal adenoma size|Technical failure rate|Change in Spigelman class score|Progression rate to high grade dysplasia or duodenal cancer|Time to complete eradication of DAs in each patient|Time to complete eradication of each treated DA lesion|Median number of CryoBalloon treatments to complete eradication.	Johns Hopkins University|Pentax Medical	All	18 Years and older   (Adult, Older Adult)	Not Applicable	50	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IRB00163804	May 13, 2019	May 2022	May 2022	February 20, 2019		May 20, 2019	Johns Hopkins Hospital, Baltimore, Maryland, United States		https://ClinicalTrials.gov/show/NCT03847636
815	NCT03692338	INTERVAL: Ipilimumab and Nivolumab Combination Therapy: A Study of a Supervised or Semi-Supervised Exercise InteRVention or Usual Care With Functional Capacity and Quality of Life Evaluations in Subjects With Advanced or Metastatic RenAL Cell Carcinoma	INTERVAL	Recruiting	No Results Available	Metastatic Renal Cell Carcinoma	Behavioral: Exercise	Change in Cardiopulmonary function|Patient-reported fatigue as measured by the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue scale|Patient-reported activity as measured by the Godin Leisure Time Exercise Questionnaire|Patient-reported symptoms as measured by the Functional Assessment of Cancer Therapy-Kidney Symptom Index-19 (FKSI-19)|Patient health outcome as measured by the EQ-5D health questionnaire|Patient-reported activity as measured by the Stanford Brief Activity Survey|Patient-reported activity as measured by the Incidental and Planned Activity Questionnaire	Duke University|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Not Applicable	30	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	Pro00082941	November 19, 2018	August 31, 2020	August 31, 2020	October 2, 2018		August 8, 2019	Duke University Medical Center, Durham, North Carolina, United States		https://ClinicalTrials.gov/show/NCT03692338
816	NCT00387023	Radioimmunotherapy With 90Y Zevalin for Orbital Lymphoma		Completed	Has Results	Non-Hodgkin's Lymphoma|Lymphoma	Drug: Rituximab|Drug: Zevalin	Number of Participants With Complete Response (CR) or Partial Response (PR)	M.D. Anderson Cancer Center|Biogen	All	18 Years and older   (Adult, Older Adult)	Not Applicable	12	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2003-0696	February 2004	July 2012	July 2012	October 12, 2006	November 18, 2013	November 18, 2013	UT MD Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT00387023
817	NCT03742453	Evaluation of Diagnostic Accuracy of CEUS for HCC Diagnosis		Recruiting	No Results Available	Hepatocellular Carcinoma	Diagnostic Test: contrast-enhanced ultrasound|Diagnostic Test: EOB-MRI	Diagnostic performance of CEUS for diagnosing HCC|Diagnostic performance of gadoxetic-acid liver MRI for diagnosing HCC using LI-RADSv2018|Diagnostic performance of gadoxetic-acid liver MRI for diagnosing HCC using KLCSG-NCC guidelinev2018	Seoul National University Hospital|Bracco Corporate	All	20 Years and older   (Adult, Older Adult)	Not Applicable	107	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	SNUH-2018-2268	October 16, 2018	December 31, 2019	December 31, 2020	November 15, 2018		November 21, 2018	Seoul National University Hospital, Seoul, Korea, Republic of		https://ClinicalTrials.gov/show/NCT03742453
818	NCT02378883	Apollo™ Onyx™ Delivery Microcatheter Post Market Safety Study		Completed	Has Results	Arteriovenous Malformations	Device: Apollo™ Onyx™ Delivery Micro Catheter	Number of Participants With Catheter-related Adverse Events at 30 Days|Number of Participants With Premature (Unintentional) Catheter Tip Detachment at 30 Days|Number of Participants With Intentional Catheter Tip Detachment at 30 Days|Number of Participants With Migration of Retained Catheter Tip Post Embolization at 30 Days|Number of Participants With Catheter/Tip Leakage From Detachment Zone at 30 Days|Number of Participants With Catheter-related Adverse Events at 12 Months|Number of Participants With Migration of Retained Catheter Tip Post Embolization at 12 Months	Medtronic Neurovascular Clinical Affairs	All	Child, Adult, Older Adult	Not Applicable	112	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NV-APL001	May 18, 2015	February 20, 2018	February 20, 2018	March 4, 2015	April 29, 2019	April 29, 2019	Radiology Imaging Associates, P.C., Englewood, Colorado, United States|Brigham's & Women Hospital, Boston, Massachusetts, United States	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/83/NCT02378883/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT02378883
819	NCT03146234	CAR-GPC3 T Cells in Patients With Refractory Hepatocellular Carcinoma		Recruiting	No Results Available	Hepatocellular Carcinoma	Genetic: CAR-GPC3 T cells	Safety and tolerance|Engraftment	RenJi Hospital|Carsgen Therapeutics, Ltd.	All	18 Years to 70 Years   (Adult, Older Adult)	Not Applicable	20	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CG1006	March 17, 2017	December 16, 2019	June 15, 2020	May 9, 2017		May 9, 2017	Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China		https://ClinicalTrials.gov/show/NCT03146234
820	NCT03261726	Maintaining Cochlear Patency After VIIIth Nerve Surgery		Recruiting	No Results Available	Acoustic Neuroma|Labyrinthitis Ossificans|Profound Hearing Impairment	Device: MedEl Test Electrode Placer	Incidence of Treatment-Emergent Adverse Events related to implanted insertion electrode|Presence or absence of fluid in the cochlea	Eric W. Sargent, MD|Med-El Corporation|Ascension South East Michigan	All	Child, Adult, Older Adult	Not Applicable	15	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IRB# 1040241	August 4, 2017	August 4, 2020	February 1, 2021	August 25, 2017		January 14, 2019	The Michigan Ear Institute, Farmington Hills, Michigan, United States		https://ClinicalTrials.gov/show/NCT03261726
821	NCT02188901	Contrast (Sonazoid)-Enhanced US as a Screening Tool for Hepatocellular Carcinoma in Cirrhosis: An Exploratory Cross-sectional Study		Completed	No Results Available	Hepatocellular Carcinoma (HCC)	Other: Sonazoid-enhanced ultrasonography	Detection rate of early stage HCC|False referral rate of HCC	Yonsei University|GE Healthcare	All	20 Years and older   (Adult, Older Adult)	Not Applicable	523	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening	4-2014-0337	October 15, 2014	August 3, 2016	August 3, 2016	July 14, 2014		April 26, 2018	Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of		https://ClinicalTrials.gov/show/NCT02188901
822	NCT02309099	Cochlear Implantation After Labyrinthectomy or a Translabyrinthine Surgical Approach		Completed	Has Results	Unilateral Acoustic Neuroma|Meniere's Disease	Device: Cochlear Implant	Change in Consonant-Nucleus-Consonant (CNC) Words Scores Over Time|Change in Arizona Biomedical Institute (AzBio) Sentences in Quiet Scores Over Time|Change in AzBio Sentences in Noise Scores (S0N0) Over Time|Change in AzBio Sentences in Noise Scores (S0NCI) Over Time|Change in AzBio Sentences in Noise Scores (S0NContra) Over Time|Change in Bamford-Kowal-Bench-Speech-in-Noise (BKB-SIN) Scores (S0N0) Over Time|Change in BKB-SIN Scores (S0NCI) Over Time|Change in BKB-SIN Scores (S0NContra) Over Time|Change in Localization Root-mean-squared (RMS) Error Over Time|Change in Reported Subjective Benefit on the Speech Domain of the Speech, Spatial and Qualities of Hearing (SSQ) Scale Over Time|Change in Reported Subjective Benefit on the Spatial Domain of the SSQ Scale Over Time|Change in Reported Subjective Benefit on the Qualities of Hearing Domain of the SSQ Scale Over Time|Change in Reported Subjective Difficulty Frequency on the Abbreviated Profile of Hearing Aid Benefit (APHAB) Over Time|Difference in AzBio Sentences in Quiet Scores With the Cochlear Implant on (Plus Contralateral Ear Open) Versus Off (Contralateral Ear Alone) Over Time|Difference in AzBio Sentences in Noise Scores (S0N0) With the Cochlear Implant on (Plus Contralateral Ear Open) Versus Off (Contralateral Ear Alone) Over Time|Difference in AzBio Sentences in Noise Scores (S0NCI) With the Cochlear Implant on (Plus Contralateral Ear Open) Versus Off (Contralateral Ear Alone) Over Time|Difference in AzBio Sentences in Noise Scores (S0NContra) With the Cochlear Implant on (Plus Contralateral Ear Open) Versus Off (Contralateral Ear Alone) Over Time|Difference in BKB-SIN Scores (S0N0) With the Cochlear Implant on (Plus Contralateral Ear Open) Versus Off (Contralateral Ear Alone) Over Time|Difference in BKB-SIN Scores (S0NCI) With the Cochlear Implant on (Plus Contralateral Ear Open) Versus Off (Contralateral Ear Alone) Over Time|Difference in BKB-SIN Scores (S0NContra) With the Cochlear Implant on (Plus Contralateral Ear Open) Versus Off (Contralateral Ear Alone) Over Time|Difference in Localization RMS Error With the Cochlear Implant on (Plus Contralateral Ear Open) Versus Off (Contralateral Ear Alone) Over Time	University of North Carolina, Chapel Hill|Med-El Corporation	All	18 Years to 99 Years   (Adult, Older Adult)	Not Applicable	10	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	14-1818	November 2014	November 8, 2017	November 8, 2017	December 5, 2014	December 10, 2018	January 7, 2019	University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/99/NCT02309099/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT02309099
823	NCT03450850	Study Of NOVOTTF-200A In Bevacizumab-Naive Subjects With Recurrent Grade III Malignant Astrocytoma		Not yet recruiting	No Results Available	Astrocytoma, Grade III	Device: NOVOTTF-200A	Number of participants showing no evidence of disease progression six months after initiating treatment with the device.|Evaluation of the safety of NOVOTTF-200A in this subject population.|Does the treatment significantly modify the patient's quality of life?|Correlations with established molecular markers (ATRX, TERT promoter and/or IDH1 mutation and MGMT promoter methylation	Daniela A. Bota|NovoCure Ltd.|University of California, Irvine	All	22 Years and older   (Adult, Older Adult)	Not Applicable	36	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	UCI 16-56|2017-4031	December 2019	June 2023	June 2023	March 1, 2018		August 5, 2019	University of California, Irvine, Orange, California, United States		https://ClinicalTrials.gov/show/NCT03450850
824	NCT03022695	Treatment of Breast Fibroadenoma With High Intensity Focused Ultrasound (HIFU)	HIFU	Completed	No Results Available	Breast Fibroadenoma	Device: High Intensity Focused Ultrasound	The efficacy is assessed by a reduction in volume of the fibroadenoma at baseline, 6 months and at 12 months after the HIFU on the ultrasonography.|Energy setting to obtain reduction in volume or total regression of the fibroadenoma at 12 months follow-up|Lack of palpable lesion|Pain free if pain at baseline (pain related to the fibroadenoma)|Gland vascularisation (compared to baseline) power Doppler at day 7, month 6 and 12 after the HIFU session|Pain during the HIFU session using a Visual Analog Pain Scale|Histological outcome through core needle biopsy after 12 month|Quality and ease of use of breast immobilization	University Women's Hospital Tübingen|Theraclion	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	27	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HIFU 1.0	October 2013	November 2015	December 2015	January 16, 2017		January 20, 2017	Department for Women's Health, Tübingen, Germany		https://ClinicalTrials.gov/show/NCT03022695
825	NCT03731923	Abbreviated MRI for HCC Surveillance		Recruiting	No Results Available	Hepatocellular Carcinoma|Liver Cirrhosis|Chronic Hepatitis	Diagnostic Test: Biannual ultrasonography|Diagnostic Test: Annual abbreviated liver MRI	Sensitivity for detecting HCC|Table time of abbreviated MRI|In-room time of abbreviated MRI|Specificity for detecting HCC|Sensitivity for detecting early stage HCC|Specificity for detecting early stage HCC|Image quality of abbreviated liver MRI	Seoul National University Hospital|Guerbet	All	18 Years and older   (Adult, Older Adult)	Not Applicable	252	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	SNUH-2018-1426	November 8, 2018	December 31, 2021	December 31, 2022	November 6, 2018		July 18, 2019	Seoul National University Hospital, Seoul, Korea, Republic of|The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Korea, Republic of		https://ClinicalTrials.gov/show/NCT03731923
826	NCT03686709	Y90 Radioembolization Dose Delivery and Radiation Exposure Assessment		Recruiting	No Results Available	Hepatocellular Carcinoma|Radiation Exposure	Diagnostic Test: Post therapy PET/CT Imaging	Feasibility of Active Dose Delivery Monitoring|Measurement and Assessment of Free, Circulating Yttrium 90|Therapy Monitoring Using Whole-Body Post-therapy PET/CT Imaging	University of Tennessee|Biocompatibles UK Ltd	All	18 Years and older   (Adult, Older Adult)	Not Applicable	20	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research	4388	June 19, 2018	June 18, 2019	December 31, 2019	September 27, 2018		September 27, 2018	University of Tennessee Medical Center, Knoxville, Tennessee, United States		https://ClinicalTrials.gov/show/NCT03686709
827	NCT02109458	Pilot Study of Navigational Bronchoscopy and Transthoracic Needle Biopsy		Completed	Has Results	Peripheral Pulmonary Nodules	Device: Navigation guided bronchoscopy	Feasibility|Incidence of Pneumothorax|Positive Diagnostic Yield of Bronchoscopic Biopsy of Electromagnetic Guidance Trans-thoracic Needle Aspiration (ETTNA) Alone|Positive Diagnostic Yield of Bronchoscopic Biopsy of ETTNA + EBUS + NB	Johns Hopkins University|Veran Medical Technologies	All	18 Years to 99 Years   (Adult, Older Adult)	Not Applicable	24	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	NA_00086035	September 2013	August 2015	August 2015	April 10, 2014	April 24, 2017	April 24, 2017	Johns Hopkins University, Baltimore, Maryland, United States		https://ClinicalTrials.gov/show/NCT02109458
828	NCT01101360	Port Wine Stains Treatment Matrix RF Study		Completed	No Results Available	Port Wine Stains	Device: Matrix RF|Device: Matrix RF followed by Pulse Dye Laser|Device: Pulse Dye Laser followed by Matrix RF	Time to complete healing|Adverse events recording and monitoring|Clearance of port wine stain|Lightening of the port wine stain|Improvement of port wine stain|Reduction in blood vessel concentration	Syneron Medical	All	18 Years to 65 Years   (Adult, Older Adult)	Not Applicable	10	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	DC75761	March 2010	September 2011		April 9, 2010		December 2, 2014	Laser and Skin Surgery Center of New York, New York, New York, United States		https://ClinicalTrials.gov/show/NCT01101360
829	NCT03211598	Surefire Institutional DEB-TACE		Recruiting	No Results Available	Hepatocellular Carcinoma	Procedure: TACE with Surefire	Stasis of flow in target vessel as seen on digital subtraction angiography or cone-beam CT, or reflux of particles despite the use of SIS.|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Tumor Assessment via MRI Imaging|Tumor Assessment via CT Imaging|FACT Hep4 Questionnaire	Alexander Kim|Surefire Medical, Inc.|Georgetown University	All	18 Years and older   (Adult, Older Adult)	Not Applicable	15	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	SF Georgetown	October 2016	December 2019	December 2019	July 7, 2017		October 24, 2018	Medstar Georgetown University Hospital, Washington, District of Columbia, United States		https://ClinicalTrials.gov/show/NCT03211598
830	NCT01543113	cKIT, BRAF/NRAS Mutations in Advanced Melanoma : Clinical Outcome in Response to Tyrosine-kinase Inhibitors - KitMel Project	KitMel	Completed	No Results Available	Melanoma	Other: sequencing	c-Kit exons 11, 13, 17 and 18 will be sequenced (direct sequencing and pyrosequencing when possible)|level of c-Kit determined by immunohistochemistry|Samples will also be analyzed for B-Raf mutations in codon 464, 466, 469 and 600, and for N-Ras mutations in codon 12, 13 and 61 (Pyrosequencing).	Rennes University Hospital|QIAGEN Gaithersburg, Inc	All	Child, Adult, Older Adult	Not Applicable	288	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	LOC/10-16 - KitMel|2010-A01310-39|10/43-785|11.272|911305	January 2011	March 2012	February 2014	March 2, 2012		February 24, 2014	Centre Eugène Marquis, Rennes, Bretagne, France|Rennes University Hospital, Rennes, Bretagne, France		https://ClinicalTrials.gov/show/NCT01543113
831	NCT01320852	PET Scan as a Screening Tool for Liver Transplant in Patients With Hepatocellular Carcinoma (HCC)		Completed	No Results Available	Hepatocellular Carcinoma	Other: PET Scan	Overall Survival	McGill University Health Center|Pfizer	All	18 Years to 75 Years   (Adult, Older Adult)	Not Applicable	100	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)	BMD-09-209	December 2010	September 2013	October 2013	March 23, 2011		October 25, 2013	McGill Univeristy Health Centre, Montreal, Quebec, Canada		https://ClinicalTrials.gov/show/NCT01320852
832	NCT00926536	Impact of C-arm CT in Patients With HCC Undergoing TACE: Optimal Imaging Guidance		Completed	Has Results	Carcinoma, Hepatocellular	Device: C-arm CT + DSA as needed|Device: DSA only	Dose Area Product (DAP)|Cumulative Dose (CD), a Measure of Radiation Dose	Stanford University|Siemens Healthcare Diagnostics Inc	All	18 Years and older   (Adult, Older Adult)	Not Applicable	84	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	IRB-15849|SU-05122009-2518|HEP0020	April 2009	March 2010	March 2010	June 23, 2009	April 4, 2016	April 4, 2016	Stanford University School of Medicine, Stanford, California, United States		https://ClinicalTrials.gov/show/NCT00926536
833	NCT02517749	Out Patient Talc Slurry Via Indwelling Pleural Catheter for Malignant Pleural Effusion Vs Usual Inpatient Management	OPTIMUM	Recruiting	No Results Available	Pleural Effusion, Malignant	Device: Chest Drain Insertion and Talc Pleurodesis|Device: Indwelling Pleural Catheter Insertion and Talc Pleurodesis	Global health-related quality of life|Pleurodesis failure rate|Improvement in symptoms of pain and breathlessness|Complication rate	Guy's and St Thomas' NHS Foundation Trust|Becton, Dickinson and Company	All	18 Years and older   (Adult, Older Adult)	Not Applicable	142	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	RJ115/N175	August 2015	January 2020	January 2020	August 7, 2015		August 8, 2018	Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom		https://ClinicalTrials.gov/show/NCT02517749
834	NCT01017250	Radiosurgery and Avastin for Recurrent Malignant Gliomas		Completed	Has Results	Malignant Glioma	Radiation: Stereotactic Radiosurgery (SRS)|Drug: Bevacizumab	Central Nervous System (CNS) Toxicity|Progression-free Survival (PFS)|Radiographic Response at Month 2|Overall Survival(OS)|Change in Quality of Life From Baseline to 2 Months After Stereotactic Radiosurgery (SRS)|Cognition at 2 Months After Stereotactic Radiosurgery (SRS)as Measured by the Mini-Mental State Exam ( MMSE)|Cognition at 2 Months After Stereotactic Radiosurgery (SRS) as Measured by the Trail Making Test (TMT)|Performance Status at 2 Months After Stereotactic Radiosurgery (SRS)|Steroid Usage After Stereotactic Radiosurgery (SRS)|Dynamic Contrasted-enhanced MRI (DCE-MRI) Perfusion Indices at 1 Week After Stereotactic Radiosurgery (SRS): K-trans|Dynamic Contrasted-enhanced MRI (DCE-MRI) Perfusion Indices at 2 Months After Stereotactic Radiosurgery (SRS): K-trans|Dynamic Contrasted-enhanced MRI (DCE-MRI) Perfusion Indices at 1 Week After Stereotactic Radiosurgery (SRS): AUC|Dynamic Contrasted-enhanced MRI (DCE-MRI) Perfusion Indices at 2 Months After Stereotactic Radiosurgery (SRS): AUC|Dynamic Contrasted-enhanced MRI (DCE-MRI) Perfusion Indices at 1 Week After Stereotactic Radiosurgery (SRS): EVF|Dynamic Contrasted-enhanced MRI (DCE-MRI) Perfusion Indices at 2 Months After Stereotactic Radiosurgery (SRS): EVF|Dynamic Contrasted-enhanced MRI (DCE-MRI) Perfusion Indices at 1 Week After Stereotactic Radiosurgery (SRS): ADC|Dynamic Contrasted-enhanced MRI (DCE-MRI) Perfusion Indices at 2 Months After Stereotactic Radiosurgery (SRS): ADC	Duke University|Genentech, Inc.	All	18 Years to 80 Years   (Adult, Older Adult)	Not Applicable	15	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro00018943	December 2009	March 2011	February 2012	November 20, 2009	May 9, 2012	February 28, 2014	Duke University Medical Center, Radiation Oncology, Durham, North Carolina, United States		https://ClinicalTrials.gov/show/NCT01017250
835	NCT01662765	Conservative Versus Surgical Treatment of Umbilical Pilonidal Disease		Completed	Has Results	Pilonidal Sinus|Sinus; Dermal, Pilonidal|Umbilical Granuloma	Procedure: Surgery|Other: conservative	Cure Rate|Healing Time|Visual Analogue Scale for Patient Satisfaction (VAS-PS)	Medical Park Gaziantep Hospital|Zeugma Saglik Hizmetleri San. Tic. Ltd. Sti.	All	Child, Adult, Older Adult	Not Applicable	84	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	MK-003-UPS	November 2003	May 2010	May 2012	August 10, 2012	February 16, 2017	February 16, 2017	Hatem Hospital, Gaziantep, Turkey|Medical Park Gaziantep Hospital, Gaziantep, Turkey|25 Aralık Familiy Physician Health Center, Gaziantep, Turkey|Dr.Ersin Arslan State Hospital, Gaziantep, Turkey|Şehitkamil State Hospital, Gaziantep, Turkey		https://ClinicalTrials.gov/show/NCT01662765
836	NCT00506311	Evaluating the Use of Fibrin Tissue Adhesive in Melanoma Patients		Completed	No Results Available	Melanoma	Drug: Fibrin Sealant	Time-to-Drain Removal	M.D. Anderson Cancer Center|Bayer	All	Child, Adult, Older Adult	Not Applicable	53	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GS01-564	February 2003	December 2007	March 2008	July 25, 2007		August 2, 2012	U.T.M.D. Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT00506311
837	NCT00489268	Micro-Layer Ablation of Barrett's Metaplasia- A Two-Phase, Multi-Center Trial - Extension of Follow-up to 5 Years	AIM	Completed	Has Results	Barrett Esophagus	Device: HALO Ablation System	Percentage of Participants With Histological Clearance of Barrett's Metaplasia|Progression of Histological Grade|Adverse Events|Percentage of Participants With Sub-squamous Intestinal Metaplasia	Covidien, GI Solutions|AstraZeneca|Medtronic - MITG	All	18 Years to 75 Years   (Adult, Older Adult)	Not Applicable	102	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	B-200	November 2003	February 2007	October 2009	June 21, 2007	June 30, 2011	March 13, 2017	Mayo Clinic Scottsdale, Scottsdale, Arizona, United States|UC Irvine Medical Center, Orange, California, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Mayo Clinic Rochester, Rochester, Minnesota, United States|Columbia University Medical Center, New York, New York, United States|Oregon Health Sciences University, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Gastrointestinal Associates, Knoxville, Tennessee, United States|Tacoma Digestive Disease and Research Center, Seattle, Washington, United States|Ponce Gastroenterology Research, Ponce, Puerto Rico		https://ClinicalTrials.gov/show/NCT00489268
838	NCT01163565	A Prospective Randomized Equivalence Trial to Evaluate the Safety of the Ligasure in Thyroid Surgery		Completed	No Results Available	Multinodular Goitre|Grave's Disease|Thyroid Nodule	Device: Ligasure Device	recurrent laryngeal nerve injury	University of Alberta|Medtronic - MITG	All	18 Years to 85 Years   (Adult, Older Adult)	Not Applicable	96	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment	Pro00004394	April 2010	September 2012	December 2012	July 15, 2010		December 3, 2014	Walter C Mackenzie Health Sciences Centre, Edmonton, Alberta, Canada		https://ClinicalTrials.gov/show/NCT01163565
839	NCT00282672	Ablation of Intestinal Metaplasia Containing Dysplasia		Completed	Has Results	Barrett Esophagus	Device: Ablation System plus anti-secretory medication|Device: Sham procedure plus anti-secretory medication	The % of Patients With Complete Eradication of Intestinal Metaplasia (IM) at 12 Month|The % of Patients With Complete Eradication of Dysplasia at 12 Month|The % of Patients With Complete Histological Clearance of Intestinal Metaplasia at 24 Months.|5 Year Extension: % of All Patients Enrolled in the Extension Protocol and Available for Analysis Demonstrating CR-IM at 5 Years|Durability of Eradication With no Additional Treatments|5 Year Extension: % of All Patients Enrolled in the Extension Protocol and Available for Analysis Demonstrating CR-D at 5 Years|The % of Patients With Complete Histological Clearance of IM at 12 Months, Comparing Treatment Versus Sham Control Groups Within a Specific Dysplasia Subgroup|Within the HGD Subgroup, the % of Patients With Complete Histological Clearance of HGD (CR-D) at 12 Months, Comparing Treatment Versus Sham Control Groups.|Histological Clearance of IM (% Biopsies)|Progression of Dysplasia (i.e., HGD to Adenocarcinoma, or LGD to HGD or Adenocarcinoma)|Subject Discomfort : Chest Pain Score on Day 1|Quality of Life Questionnaire (Baseline v. 12 and 24 Mos)|Adverse Event Incidence|For 5 Year Extension: Proportion (%) of All Patients Enrolled in This Extension and Available for Analysis at 5 Years Demonstrating Any Adenocarcinoma in Any Biopsy Obtained From the Esophageal Body Since Primary RFA (0-5 Years)|5 Year Extension: Proportion (%) of All Patients Enrolled in This Extension and Available for Analysis at 5 Years Demonstrating Any Adenocarcinoma in Any Biopsy Obtained From the Esophageal Body After 2 Years and Inclusive of the 5 Year Visit|5 Year Extension: Proportion (%) of All Patients Enrolled in This Extension Protocol and Available for Analysis Demonstrating CR-IM at 5 Year|5 Year Extension:Proportion (%) of All Patients Enrolled in This Extension Protocol and Available for Analysis Demonstrating CR-D at 5 Year|5 Year Extension: Proportion (%) of All Patients Enrolled in This Extension Protocol and Available for Analysis Demonstrating CR-IM at 4 Year|5 Year Extension: Proportion (%) of All Patients Enrolled in This Extension Protocol and Available for Analysis Demonstrating CR-IM at 3 Year|5 Year Extension: Proportion (%) of All Patients Enrolled in This Extension Protocol and Available for Analysis Demonstrating CR-D at 4 Year|5 Year Extension: Serious Adverse Event Incidence|5 Year Extension: All Cause Mortality of the Group From 2 to 5 Years.	Medtronic - MITG|AstraZeneca	All	18 Years to 80 Years   (Adult, Older Adult)	Not Applicable	127	Industry	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	B-204	February 2006	April 2014	August 2014	January 27, 2006	December 30, 2015	November 6, 2017	Mayo Clinic Scottsdale, Scottsdale, Arizona, United States|University of Arizona, VAMC, Tucson, Arizona, United States|UC Irvine Medical Center, Orange, California, United States|Mayo Clinic - Jacksonville, Jacksonville, Florida, United States|Harvard, VA Boston Healthcare W Roxbury, West Roxbury, Massachusetts, United States|Mayo Clinic Rochester, Rochester, Minnesota, United States|University of Kansas School of Medicine - Veterans Affairs Medical Center, Kansas City, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Columbia University Medical Center, New York, New York, United States|UNC Center for Functional GI & Motility Disorders, Chapel Hill, North Carolina, United States|University Hospitals of Cleveland, Cleveland, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Oregon Health Sciences University, Portland, Oregon, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Gastrointestinal Associates, Knoxville, Tennessee, United States|VAMC Dallas, Dallas, Texas, United States|Tacoma Digestive Disease Research Center, Tacoma, Washington, United States		https://ClinicalTrials.gov/show/NCT00282672
840	NCT02157623	Blue vs Red Light During Levulan Based Photodynamic Therapy in Patients With Basal Cell Nevus Syndrome		Completed	Has Results	Basal Cell Nevus Syndrome	Drug: Levulan|Other: Red Light Photodynamic Therapy|Other: Blue Light Photodynamic Therapy	Tumor Clearance Rate|Pain Score on a Visual-Analog Scale|Patient Satisfaction Survey	Edward Maytin, MD, PhD|DUSA Pharmaceuticals, Inc.|The Cleveland Clinic	All	Child, Adult, Older Adult	Not Applicable	7	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CASE 2614	February 1, 2016	September 1, 2016	December 1, 2016	June 6, 2014	June 2, 2017	June 2, 2017	Cleveland Clinic, Cleveland, Ohio, United States		https://ClinicalTrials.gov/show/NCT02157623
841	NCT03477149	EASYX-1 : A Multicenter Study on Safety and Efficacy of Easyx Liquid Embolization Agent Used in Five Separate Indications	EASYX-1	Recruiting	No Results Available	Varicocele|Endoleak|Portal Vein Thrombosis|Bleeding|Angiomyolipoma	Device: Easyx	Saefty:Total number of per-procedure Serious Adverse Events (SAE) for the safety|Efficacy for type 2 endoleaks embolization|Efficacy for portal vein embolization|Efficacy for varicocele embolization|Efficacy for angiomyolipoma embolization|Efficacy for active bleeding embolization|SAE|AE|untargeted embolization|unanticipated ischemia of the target organ|orchi-epididymitis|neural route lesion|aneurysm rupture|tumor rupture|Survival|Pain|Pain improvement|unanticipated use of another liquid agent|technical success|Easyx volume|Occlusion|Re-intervention|Interventional Radiologist (IR) satisfaction|Clinical efficacy|Other liquid embolics|Quality of life|Imaging	Assistance Publique - Hôpitaux de Paris|Antia Therapeutics AG	All	18 Years and older   (Adult, Older Adult)	Not Applicable	50	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	K170403J|2017-A02370-53	March 30, 2018	September 2019	September 2019	March 26, 2018		April 4, 2018	AP-HP - Hopital Europeen Georges-Pompidou Paris, France, Paris, Ile-de-France, France		https://ClinicalTrials.gov/show/NCT03477149
842	NCT00572832	Randomized Trial of Alternative Quadrivalent Human Papilloma Virus (HPV) Vaccination Schedules in a University Setting		Completed	Has Results	Human Papillomavirus Infection	Biological: Quadrivalent human papillomavirus vaccine on-time administration|Biological: Quadrivalent human papillomavirus vaccine delayed administration	Geometric Mean Antibody Titers Following the Third Dose of Human Papilloma Virus (HPV) Vaccine by Virus Type and by Administration Schedule	University of Pittsburgh|Merck Sharp & Dohme Corp.	Female	18 Years to 23 Years   (Adult)	Not Applicable	200	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	32090	September 2007	April 2009	August 2009	December 13, 2007	February 25, 2010	August 17, 2010	University of Pittsburgh, Pittsburgh, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT00572832
843	NCT03992339	A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma	SEARCH	Not yet recruiting	No Results Available	Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)	Drug: ATG-010 60 mg, orally, twice weekly, each 4 week (28-day) a cycle	ORR|DOR|DCR|OS|PFS	Antengene Corporation	All	18 Years and older   (Adult, Older Adult)	Not Applicable	60	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ATG-010-DLBCL-001	December 2019	December 2020	June 2021	June 20, 2019		July 18, 2019			https://ClinicalTrials.gov/show/NCT03992339
844	NCT00038675	Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate		Completed	No Results Available	Chronic Myelomonocytic Leukemia|Chronic Myeloid Leukemia|Polycythemia Vera|Hypereosinophilic Syndrome|Mastocytosis	Drug: Imatinib Mesylate (Gleevec)	Objective response rate|Duration of response and survival	M.D. Anderson Cancer Center|Novartis Pharmaceuticals	All	Child, Adult, Older Adult	Not Applicable	125	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ID01-167	June 2001	November 2013	November 2013	June 5, 2002		December 12, 2013	UT MD Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT00038675
845	NCT03700086	Efficacy of a Disposable Negative Wound Pressure Device in Reducing the Incidence of Wound Infection After HPB Surgery		Recruiting	No Results Available	Surgical Site Infection	Device: Disposable negative wound pressure device (PICO)|Device: OPsite post-op visible standard sterile dressing	Surgical Site Infection|Rate of discontinuation of negative wound pressure therapy|Incidence of seromas|Incidence of hematomas|Incidence of major morbidities|Stony Brook Scar Evaluation Scale Score|Costs	Azienda Ospedaliera Universitaria Integrata Verona|Smith & Nephew Wound Management Inc	All	18 Years and older   (Adult, Older Adult)	Not Applicable	100	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	PICO	September 30, 2018	May 10, 2019	June 10, 2019	October 9, 2018		October 9, 2018	Ospedale Policlinico GB Rossi, Verona, Italy		https://ClinicalTrials.gov/show/NCT03700086
846	NCT02800447	Procarbazine Hydrochloride Capsule (Natulan®) Clinical Trial Protocol		Active, not recruiting	No Results Available	Advanced Hodgkin's Lymphoma	Drug: Natulan|Drug: ABVD	overall response rate (ORR)|safety as measured by changes of vital signs, ECG and AE number	Lee's Pharmaceutical Limited	All	18 Years to 65 Years   (Adult, Older Adult)	Not Applicable	92	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Zhaoke-NTL-2015-01	June 2016	December 2018	December 2018	June 15, 2016		September 3, 2018			https://ClinicalTrials.gov/show/NCT02800447
847	NCT02253628	The Acute Effect of Coffee Consumption on Stomach, Self-reported Gastrointestinal Symptoms and Stress.		Completed	No Results Available	Stress|Signs and Symptoms, Digestive|Blood Pressure|Increased Secretion of Gastrin	Other: Cold espresso|Other: Hot instant coffee|Other: Cold instant coffee|Other: Hot filter coffee	Salivary gastrin and self-reported gastrointestinal symptoms|Blood pressure, energy intake and physical activity|Salivary cortisol and alpha-amylase|Self-reported sentiments, mood and stress.	Agricultural University of Athens|Nestlé	All	20 Years to 55 Years   (Adult)	Not Applicable	40	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)	340302	February 2014	June 2014	June 2014	October 1, 2014		October 1, 2014			https://ClinicalTrials.gov/show/NCT02253628
848	NCT01383759	Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis		Completed	No Results Available	Light Chain Deposition Disease (LCDD or MIDD)|Light Chain and Heavy Chain Deposition Disease (LHCDD or MIDD)|Monoclonal Immunoglobulin Deposition Disease (MIDD)|Amyloidosis	Drug: Bortezomib/Dexamethasone (BD), Followed By Autologous STC & Maintenance Bortezomib/Dexamethasone	To examine the tolerability|To examine the toxicity|To estimate the hematologic response rate|To estimate the organ response rate|To estimate the time to hematologic progression	Memorial Sloan Kettering Cancer Center|Millennium Pharmaceuticals, Inc.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	20	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	11-061	June 24, 2011	April 30, 2019	April 30, 2019	June 28, 2011		May 2, 2019	Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Commack, Commack, New York, United States|Memorial Sloan Kettering Westchester, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering Rockville Centre, Rockville Centre, New York, United States		https://ClinicalTrials.gov/show/NCT01383759
849	NCT00602134	Bioequivalence Study of 6-Mercaptopurine Under Fasting Conditions		Completed	No Results Available	Acute Lymphoblastic Leukemia	Drug: 6-Mercaptopurine	Bioequivalence	Roxane Laboratories|West-Ward Pharmaceutical	Male	18 Years to 45 Years   (Adult)	Not Applicable	54	Industry	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	439-09	November 2002	November 2002	November 2002	January 28, 2008		January 23, 2018	MDS Pharma Services, Phoenix, Arizona, United States		https://ClinicalTrials.gov/show/NCT00602134
850	NCT00890552	A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL Amyloidosis		Completed	Has Results	Leukemia|Amyloidosis	Drug: Lenalidomide|Drug: Melphalan|Drug: Dexamethasone	Hematologic Response Rate|Overall Survival (OS)|Event-free Survival (EFS)|Duration of Response	Stanford University|Celgene Corporation	All	18 Years and older   (Adult, Older Adult)	Not Applicable	25	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IRB-15213|RV-AMYL-PI-0375|SU-09192008-1300|HEM0010	April 2009	August 2012	October 2012	April 30, 2009	March 22, 2017	March 22, 2017	Stanford University Cancer Institute, Stanford, California, United States		https://ClinicalTrials.gov/show/NCT00890552
851	NCT01381952	Image Quality and Radiation Dose in Angiography		Completed	Has Results	Arteriovenous Malformations|Aneurysm|Stenosis|Dural Arteriovenous Malformations	Radiation: Low dose DSA (75% reduction compared to normal dose) with novel X-ray imaging technology.|Radiation: Normal dose DSA with conventional X-ray technology	Image Quality. For Each Included Participant 2 Images (1 AlluraXper; 1 AlluraClarity) Were Evaluated.|Radiation Dose Measurements: Dose Area Product (DAP)	Karolinska University Hospital|Philips Medical Systems	All	18 Years to 80 Years   (Adult, Older Adult)	Not Applicable	20	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic	KUH-PMS-01	June 2011	August 2011	September 2011	June 27, 2011	May 22, 2014	May 22, 2014	Karolinska University Hospital, Solna, Sweden		https://ClinicalTrials.gov/show/NCT01381952
852	NCT02626377	Multicenter Prospective Cohort of Informal Caregivers in Burgundy and Franche-Comté	ICE	Recruiting	No Results Available	Breast Cancer|Colorectal Cancer|Prostate Cancer|Alzheimer Disease|Age-related Macular Degeneration|Parkinson Disease|Cardiac Disease|Ischemic Stroke|Hemorrhagic Stroke	Behavioral: Support provided by social worker|Other: Information booklet receipt	(Interventional Study) Comparison of caregivers' HRQoL according to the allocated intervention by randomization based on summaries score the MOS SF36|(Observational study) Changes in HRQoL of patients' caregivers using the MOS SF36 questionnaire|(Observational study) Changes in HRQoL of cancer patients' caregivers using the CarGoQoL questionnaire|(Observational study) Changes in the coping strategies of patients' caregivers using the Borteyrou, Rascle and Truchot Questionnaire|(Observational study) Changes in feelings of anxiety and depression of patients' caregivers according to the HADs questionnaire|(Observational study) Changes in social support of patients' caregivers using the SSQ6 questionnaire|(Observational study) Changes in burden of patients' caregivers using the Zarit burden inventory|(Interventional Study) Comparison of caregivers' HRQoL according to the intervention allocated by randomization based on summaries score the MOS SF36|(Interventional Study) Changes in HRQoL of patients' caregivers according to the allocated intervention using the MOS SF36 questionnaire|(Interventional Study) Changes in HRQoL of cancer patients' caregivers according to the allocated intervention using the CarGoQol questionnaire|(Interventionnal Study) Changes in the coping strategies of patients' caregivers according to the allocated intervention using the Borteyrou, Rascle and Truchot Questionnaire|(Interventional Study) Changes in feelings of anxiety and depression of patients' caregivers according to the allocated intervention using the HADs Questionnaire|(Interventional Study) Changes in social supports of patients' caregivers according to the allocated intervention using the SSQ6 questionnaire|(Interventional Study) Changes in burden of patients' caregivers according to the allocated intervention using the Zarit burden inventory|(Interventional study) Efficiency of the intervention of a social worker for caregivers using a cost-utility analysis|(Observational study) Changes in the caregivers/patients' relationship using a qualitative approach (semi-structure interview)|(Observational study) Changes in the role of caregiver due to a situation generating a rupture (entry into an institution or death, disease remission) using a qualitative approach (semi-structure interview)	Centre Hospitalier Universitaire de Besancon|Methodological and quality of life unit in oncology (CHRU de Besançon)|University of Franche-Comté|University of Burgundy|Pôle de Gérontologie Interrégional Bourgogne et Franche-Comté|CARSAT Bourgogne et Franche-Comté|CCAS of Dijon|CCAS of Besançon|CCAS of Montbéliard|Burgundy Regional Council|Franche-Comté Regional Council|The Municipality of Besançon|The Municipality of Dijon|General Council of the Doubs|General Council of the Territoire de Belfort|Collectif Inter Associatif Sur la Sante Bourgogne|Union Régionale Interfédérale des Œuvres et Organismes Privés Sanitaires Bourgogne|Association Gérontopôle Pierre Pfitzenmeyer|Pôle de compétitivité Vitagora Goût-Nutrition-Santé|National Old Age Insurance Fund for Employees (CNAVTS)|Sheerbrooke Gérontopôle|France Alzheimer Côte-d’Or|Institut Régional de Vieillissement (IRV)|Novartis Pharmaceuticals|Roche Foundation|Ligue contre le cancer, France|National Cancer Institute, France|Quality of life and cancer clinical research platform|National Research Agency, France	All	60 Years and older   (Adult, Older Adult)	Not Applicable	7604	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other	P/2014/231	October 2015	October 2025	October 2025	December 10, 2015		October 12, 2017	CHRU de Besançon, Besançon, France|Centre Georges François Leclerc, Dijon, France|CHU de DIJON, Dijon, France		https://ClinicalTrials.gov/show/NCT02626377
853	NCT01276236	Effects of Maraviroc (MVC) on HIV-related Kaposi's Sarcoma (KS)		Completed	No Results Available	Kaposi's Sarcoma	Drug: Maraviroc	Change in Kaposi's Sarcoma Lesion Burden between Baseline and Week 1|Change in Kaposi's Sarcoma Lesion Burden between Baseline and Week 2|Change in Kaposi's Sarcoma Lesion Burden between Baseline and Week 4|Change in Kaposi's Sarcoma Lesion Burden between Baseline and Week 8|Change in Kaposi's Sarcoma Lesion Burden between Baseline and Week 16|Change in Kaposi's Sarcoma Lesion Burden between Baseline and Week 36|Change in Kaposi's Sarcoma Lesion Burden between Baseline and Week 56|Change in Kaposi's Sarcoma Lesion Burden between Baseline and Week 76|Change in Kaposi's Sarcoma Lesion Burden between Baseline and Week 96|Effects of Maraviroc on CCR5 and KSHV levels in lesional skin.|Change in CD4 count, and HIV viral load with Maraviroc from Baseline to Week 4|Change in CD4 count, and HIV viral load with Maraviroc from Baseline to Week 16|Change in CD4 count, and HIV viral load with Maraviroc from Baseline to Week 36|Change in CD4 count, and HIV viral load with Maraviroc from Baseline to Week 56|Change in CD4 count, and HIV viral load with Maraviroc from Baseline to Week 76|Change in CD4 count, and HIV viral load with Maraviroc from Baseline to Week 96|Effects on KSHV Viral Load with Maraviroc treatment from Baseline to Week 1|Effects on KSHV Viral Load with Maraviroc treatment from Baseline to Week 2|Effects on KSHV Viral Load with Maraviroc treatment from Baseline to Week 4|Effects on KSHV Viral Load with Maraviroc treatment from Baseline to Week 16|Effects on KSHV Viral Load with Maraviroc treatment from Baseline to Week 36|Effects on KSHV Viral Load with Maraviroc treatment from Baseline to Week 56|Effects on KSHV Viral Load with Maraviroc treatment from Baseline to Week 76|Effects on KSHV Viral Load with Maraviroc treatment from Baseline to Week 96|Effects of Maraviroc on CCR5 receptor expression in T and B lymphocytes, monocytes, and natural killer cells from Baseline to Week 1|Effects of Maraviroc on CCR5 receptor expression in T and B lymphocytes, monocytes, and natural killer cells from Baseline to Week 2|Effects of Maraviroc on CCR5 receptor expression in T and B lymphocytes, monocytes, and natural killer cells from Baseline to Week 4|Effects of Maraviroc on CCR5 receptor expression in T and B lymphocytes, monocytes, and natural killer cells from Baseline to Week 16|Effects of Maraviroc on CCR5 receptor expression in T and B lymphocytes, monocytes, and natural killer cells from Baseline to Week 36|Effects of Maraviroc on CCR5 receptor expression in T and B lymphocytes, monocytes, and natural killer cells from Baseline to Week 56|Effects of Maraviroc on CCR5 receptor expression in T and B lymphocytes, monocytes, and natural killer cells from Baseline to Week 76|Effects of Maraviroc on CCR5 receptor expression in T and B lymphocytes, monocytes, and natural killer cells from Baseline to Week 96|Changes in T Cell activation and exhaustion with Maraviroc treatment between Baseline and Week 1|Changes in T Cell activation and exhaustion with Maraviroc treatment between Baseline and Week 2|Changes in T Cell activation and exhaustion with Maraviroc treatment between Baseline and Week 4|Changes in T Cell activation and exhaustion with Maraviroc treatment between Baseline and Week 16|Changes in T Cell activation and exhaustion with Maraviroc treatment between Baseline and Week 36|Changes in T Cell activation and exhaustion with Maraviroc treatment between Baseline and Week 56|Changes in T Cell activation and exhaustion with Maraviroc treatment between Baseline and Week 76|Changes in T Cell activation and exhaustion with Maraviroc treatment between Baseline and Week 96	University of California, San Francisco|Pfizer|ViiV Healthcare	All	18 Years and older   (Adult, Older Adult)	Not Applicable	10	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	10-02850|2860798	February 2011	January 2015	April 2015	January 13, 2011		March 18, 2019	San Francisco General Hospital, Clinical Trials Unit, San Francisco, California, United States		https://ClinicalTrials.gov/show/NCT01276236
854	NCT00002284	A Study of Azidothymidine (AZT) in the Treatment of HIV Infection in Patients Receiving a Bone Marrow Transplant		Completed	No Results Available	Lymphoma, Non-Hodgkin|HIV Infections	Drug: Zidovudine		Glaxo Wellcome|NIH AIDS Clinical Trials Information Service	All	12 Years to 50 Years   (Child, Adult)	Not Applicable		Industry	Interventional	Primary Purpose: Treatment	014A|006				August 31, 2001		June 24, 2005	Johns Hopkins Hemapheresis Treatment Ctr, Baltimore, Maryland, United States		https://ClinicalTrials.gov/show/NCT00002284
855	NCT04051216	The SMART CART Study: Health Information Technology		Enrolling by invitation	No Results Available	Leukemia, Acute|Leukemia, Lymphoblastic	Behavioral: Education information system|Other: Activity monitor|Other: Interview|Other: Survey Administration|Other: Laboratory Biomarker Analysis	Percentage of caregivers that log onto the BMT Roadmap at least once per day for a minimum of 4 of the 7 days of the week while the patient is in the hospital.|Percentage of patients who are able to wear the activity monitoring device(s) approximately 12 hours of the day.|Percentage of patients from whom longitudinal samples of blood, urine and stool are collected, for correlative studies.|Caregiver activation/participation compared to reference population to measure the impact of Roadmap information system and wearable monitoring device using survey instrument scores of Parent-Patient Activation Measure (P-PAM) as a composite measure.|Care providers' satisfaction with the Roadmap information system and non-invasive, wearable activity monitoring device health IT tools for patients and their families/caregivers.|Presence of care process redesign associated with the Roadmap information system and wearable monitoring devices.|Quality of care process redesign associated with the Roadmap information system and wearable monitoring devices.	University of Michigan Rogel Cancer Center|Bristol-Myers Squibb	All	5 Years and older   (Child, Adult, Older Adult)	Not Applicable	60	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	UMCC 2016.051|HUM00115179	December 20, 2017	January 2021	January 2021	August 9, 2019		August 9, 2019	University of Michigan, Ann Arbor, Michigan, United States		https://ClinicalTrials.gov/show/NCT04051216
856	NCT00530179	FDG-PET-Stratified R-DICEP and R-Beam/ASCT For Diffuse Large B-Cell Lymphoma	PET-Chop	Completed	No Results Available	Diffuse Large B Cell Lymphoma	Procedure: Autologous Blood Stem Transplantation|Drug: R-CHOP		AHS Cancer Control Alberta|Hoffmann-La Roche	All	18 Years to 65 Years   (Adult, Older Adult)	Not Applicable	69	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	0307003	July 2007	February 2014	May 19, 2015	September 17, 2007		January 21, 2019	Tom Baker Cancer Centre, Calgary, Alberta, Canada|Ottawa General Hospital, Ottawa, Ontario, Canada|Saskatchewan Cancer Agency, Regina, Saskatchewan, Canada		https://ClinicalTrials.gov/show/NCT00530179
857	NCT03243617	Cosmetic Study of AO+Mist in Improving the Appearance of Skin Afflicted With Keratosis Pilaris		Completed	No Results Available	Keratosis Pilaris	Other: Placebo|Other: AO+Mist	Number of Participants With Treatment-Related Adverse Events as assessed by physical exam and appearance|Difference in Keratosis pilaris Investigator Score	AOBiome LLC	All	18 Years to 65 Years   (Adult, Older Adult)	Not Applicable	26	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Other	AOB2015-02	December 4, 2015	June 8, 2016	September 3, 2016	August 9, 2017		August 9, 2017	Skincare Physicians, Chestnut Hill, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT03243617
858	NCT03808272	AXIOS CHINA (E7148)		Not yet recruiting	No Results Available	Pancreatic Pseudocyst and Walled-off Necrosis	Device: HOT AXIOS Stent and Electrocautery- Enhanced Delivery System	Technical success rate|Clinical success rate	Boston Scientific Corporation	All	18 Years to 75 Years   (Adult, Older Adult)	Not Applicable	30	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	E7148	January 31, 2019	September 30, 2019	December 31, 2019	January 17, 2019		January 17, 2019			https://ClinicalTrials.gov/show/NCT03808272
859	NCT00789256	Low Dose Melphalan and Bortezomib for AML and High-Risk MDS		Completed	Has Results	Acute Myelogenous Leukemia|Myelodysplastic Syndromes	Drug: Melphalan|Drug: Bortezomib|Drug: Melphalan and bortezomib	Response Rate of the Combination of Bortezomib and Melphalan in Patients With AML and High-risk MDS.|Determine Safety Profile of the Combination of Bortezomib and Melphalan.|Number of Participants With Correlation Between in Vitro and in Vivo Activity of the Combination of Bortezomib and Melphalan.	Dartmouth-Hitchcock Medical Center|Millennium Pharmaceuticals, Inc.	All	Child, Adult, Older Adult	Not Applicable	26	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	D0337	September 2004	December 2008	December 2008	November 11, 2008	July 22, 2013	October 24, 2018	Integrated Community Oncology Network, Jacksonville, Florida, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States		https://ClinicalTrials.gov/show/NCT00789256
860	NCT03797209	Hot AXIOS System Japan Post Market Survey		Recruiting	No Results Available	Pancreatic Pseudocyst Infection|Pancreatic Pseudocyst|Walled Off Necrosis Infection|Walled Off Necrosis	Device: EUS-guided fistulization AXIOS	Safety (Adverse Events and Device Malfunction)|Placement success|Stent retention|Stent lumen patency|Decreased cyst size|Removal success	Boston Scientific Japan K.K.	All	Child, Adult, Older Adult	Not Applicable	100	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	E7121	January 15, 2019	October 30, 2020	October 30, 2020	January 9, 2019		February 20, 2019	Tokyo Medical University Hospital, Tokyo, Shinjuku-Ku, Japan		https://ClinicalTrials.gov/show/NCT03797209
861	NCT01936948	Safety of Endoscopic Resection of Large Colorectal Polyps: A Randomized Trial.		Active, not recruiting	No Results Available	Colon Polyps	Procedure: Clip closure	Delayed bleeding complications|Overall complications|Complete polyp resection|Polyp recurrence|Clip complications	White River Junction Veterans Affairs Medical Center|Dartmouth College|Boston Scientific Corporation	All	18 Years to 89 Years   (Adult, Older Adult)	Not Applicable	1257	U.S. Fed|Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CPHS-23578	April 2013	August 2018	December 2022	September 6, 2013		August 29, 2018	White River Junction VAMC, White River Junction, Vermont, United States		https://ClinicalTrials.gov/show/NCT01936948
862	NCT03928886	Discomfort Assessment of Senographe Pristina Patient-assisted Versus Standard Compression Mode and Quality Assessment of Screening Mammograms		Recruiting	No Results Available	Mammography Related Discomfort	Device: bilateral two-view (CC and MLO) FFDM (full field digital mammography) using patient-assisted compression mode|Device: bilateral two-view (CC and MLO) FFDM (full field digital mammography) using standard compression mode	Patient discomfort using an 11-point numeric pain rating scale|Technical/Clinical quality of mammogram using the PGMI system|Average glandular dose in mGy|Breast thickness in mm|Compression force in daN	Parc de Salut Mar|GE Healthcare	Female	50 Years to 69 Years   (Adult, Older Adult)	Not Applicable	500	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Screening	2017-7631	December 1, 2017	December 1, 2020	December 1, 2020	April 26, 2019		April 26, 2019	Hospital del Mar - Parc de Salut Mar, Barcelona, Catalonia, Spain		https://ClinicalTrials.gov/show/NCT03928886
863	NCT00398372	Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment		Completed	No Results Available	Lymphoma, Non-Hodgkin|Lymphomas: Non-Hodgkin|Lymphomas: Non-Hodgkin Cutaneous Lymphoma|Lymphomas: Non-Hodgkin Diffuse Large B-Cell|Lymphomas: Non-Hodgkin Follicular / Indolent B-Cell|Lymphomas: Non-Hodgkin Mantle Cell|Lymphomas: Non-Hodgkin Marginal Zone|Lymphomas: Non-Hodgkin Peripheral T-Cell|Lymphomas: Non-Hodgkin Waldenstr Macroglobulinemia	Drug: Rituximab|Drug: Epratuzumab	To characterize the molecular and cell biology of the tumor cells in lymphoma.	Stanford University|Amgen|National Institutes of Health (NIH)	All	18 Years and older   (Adult, Older Adult)	Not Applicable	500	Other|Industry|NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)	LYMNHL0031|200114861|77550|CA09287|CA111827	November 2000	June 2007	September 2009	November 10, 2006		June 2, 2011	Stanford University School of Medicine, Stanford, California, United States		https://ClinicalTrials.gov/show/NCT00398372
864	NCT00484848	Functional Evaluation of Two Types of Totally Implanted Venous Ports		Completed	No Results Available	Hematologic Disease	Device: Vortex port and Celsite port	Evaluation of the difference in difficulty in blood drawing between the 2 types of ports when accessing the port under identical maintenance procedure according to the guidelines in the University Hospitals Leuven.|Evaluation of the difference in one-way or bidirectional occlusion incidence between these 2 types of ports, when accessing the port under identical maintenance procedure according to the guidelines in the University Hospitals Leuven.|Evaluation of the difference in filling time for blood sampling between these 2 types of ports when using a standard 10 ml vacuum blood tube and a 19 G Gripper® needle.|Evaluation of the ease of use (ease of access) between these 2 types of ports when accessing the port.	Universitaire Ziekenhuizen Leuven|RITA Medical Systems|B. Braun Medical SA	All	18 Years and older   (Adult, Older Adult)	Not Applicable	200	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Supportive Care	SM007	September 2004	December 2004	March 2005	June 11, 2007		January 26, 2009	University Hospitals Leuven, Leuven, Belgium		https://ClinicalTrials.gov/show/NCT00484848
865	NCT03353896	NovoTTF-200A Device in Treating Patients With Newly Diagnosed High Risk Oligodendroglioma		Recruiting	No Results Available	Anaplastic Oligodendroglioma|Oligoastrocytoma|Oligodendroglioma	Device: Wear novoTTF-200A|Procedure: Quality-of-Life Assessment	Safety and Tolerability of the NovoTTFields treatment in patients with high risk oligodendroglioma	University of Southern California|National Cancer Institute (NCI)|NovoCure Ltd.	All	19 Years and older   (Adult, Older Adult)	Not Applicable	15	Other|NIH|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	6B-15-1|NCI-2017-02074|EF-OLIGO-15|P30CA014089	December 15, 2017	December 15, 2020	December 15, 2021	November 27, 2017		May 20, 2019	USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States		https://ClinicalTrials.gov/show/NCT03353896
866	NCT01404104	Neo-adjuvant Temsirolimus in Patients With Advanced Renal Cell Carcinoma		Completed	No Results Available	Renal Cell Carcinoma	Drug: Temsirolimus (pre surgery)	The rate of change in response of primary tumor and metastases (if applicable)in participants.|Average time for disease progression.|Quality of life data	St. Joseph's Healthcare Hamilton|McMaster University|Pfizer	All	18 Years and older   (Adult, Older Adult)	Not Applicable	11	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IIS-003-09	September 2008	August 2014	August 2014	July 27, 2011		July 27, 2016	St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada		https://ClinicalTrials.gov/show/NCT01404104
867	NCT03075514	Ketogenic Diets as an Adjuvant Therapy in Glioblastoma	KEATING	Completed	No Results Available	Glioblastoma|Glioblastoma Multiforme|Glioblastoma, Adult	Other: MKD|Other: MCT	To assess retention and drop out rates|Estimation of recruitment rates|Enrollment of patients|Long term retention|Dietary adjustments required to achieve ketosis|Self reported dietary compliance|Calculated dietary compliance|MCT compliance|Ketosis levels|Dietetic time required for interventions|Protocol refinements required|Sample size estimates for future trials|Quality of life|Food acceptability|Gastrointestinal side effects|Changes to biochemical markers|Anthropometric changes|Completeness of data	University of Liverpool|Walton Centre NHS Foundation Trust|Vitaflo International, Ltd	All	16 Years and older   (Child, Adult, Older Adult)	Not Applicable	12	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	UoL001277	April 1, 2017	March 5, 2019	March 5, 2019	March 9, 2017		April 4, 2019	Univeristy of Liverpool/ The Walton Centre NHS Foundation Trust, Liverpool, Merseyside, United Kingdom		https://ClinicalTrials.gov/show/NCT03075514
868	NCT01107509	Pilot Study of Neo-Adjuvant Everolimus to Treat Advanced Renal Cell Carcinoma - Analysis of Biomarkers		Completed	No Results Available	Carcinoma, Renal Cell	Drug: everolimus	Response of primary tumor and metastases (if applicable) to everolimus in terms of tumor size and appearance (RECIST imaging response criteria) as determined by CT or MRI|Effect of everolimus on blood and tissue biomarker expression (periodic blood testing and tissue samples from baseline renal biopsy and nephrectomy) in and among patients with locally advanced and metastatic disease with respect to baseline values	St. Joseph's Healthcare Hamilton|McMaster University|Novartis Pharmaceuticals	All	18 Years and older   (Adult, Older Adult)	Not Applicable	20	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MIURCCEVERO	October 1, 2010	October 1, 2017	October 1, 2017	April 21, 2010		April 4, 2018	St. Joseph's Healthcare, Hamilton, Ontario, Canada		https://ClinicalTrials.gov/show/NCT01107509
869	NCT03713203	PAGETEX® Photodynamic Therapy Device for the Treatment of Extra Mammary Paget's Disease of the Vulva (EMPV).	PAGETEX	Not yet recruiting	No Results Available	Paget Disease of the Vulva|Paget Disease, Extramammary	Device: pagetex PDT	disease control rate in 30% of patients included|Subject discomfort measured during each treatment using a Visual Analogic Scale Evaluation of pain|Clinical Evolution measured using an erythema 4 points scale and Chroma meter CR400 measures|Presence/absence of Paget cells in vulvar biopsy.|Change in score Dermatology Life Quality Index (DLQI)|Change in SF 36|Change in Hospital Anxiety and Depression Scale. (HADS)|Change in The Female Sexual Function Index (FSFI)|Presence or absence of fluorescence on the Dermoscope Fotofinder® photographs|number of Adverse Events	University Hospital, Lille|Galderma|Institut National de la Santé Et de la Recherche Médicale, France	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	24	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2017_71|2018-A01873-52|2018-002604-13	July 2019	July 2021	July 2021	October 19, 2018		May 29, 2019			https://ClinicalTrials.gov/show/NCT03713203
870	NCT03814824	Volumetric Laser Endomicroscopy With Intelligent Real-time Image Segmentation (IRIS)		Recruiting	No Results Available	Barrett's Esophagus Without Dysplasia|Barrett's Esophagus With Dysplasia|Barrett's Esophagus With Low Grade Dysplasia|Barrett's Esophagus With High Grade Dysplasia|Barrett's Esophagus With Dysplasia, Unspecified	Diagnostic Test: IRIS (Intelligent real-time image segmentation)|Diagnostic Test: VLE (Volumetric laser endomicroscopy)	Time for image interpretation|Biopsy yield|Number of biopsies	Northwell Health|NinePoint Medical	All	18 Years and older   (Adult, Older Adult)	Not Applicable	100	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	18-0963	January 23, 2019	January 2020	July 2020	January 24, 2019		March 25, 2019	North Shore University Hospital, Manhasset, New York, United States		https://ClinicalTrials.gov/show/NCT03814824
871	NCT00002059	A Double-Blind Placebo Controlled Study To Determine the Optimal Immunopharmacological Dose Level of Isoprinosine in Immunodepressed Volunteers		Completed	No Results Available	HIV Infections	Drug: Inosine pranobex		Newport Pharmaceuticals International|NIH AIDS Clinical Trials Information Service	Male	18 Years and older   (Adult, Older Adult)	Not Applicable		Industry	Interventional	Masking: Double|Primary Purpose: Treatment	008E|ISO-133-USA				August 31, 2001		June 24, 2005	Newport Pharmaceuticals International Inc, Laguna Hills, California, United States		https://ClinicalTrials.gov/show/NCT00002059
872	NCT00075777	Valproic Acid in Treating Patients With Kaposi's Sarcoma		Completed	No Results Available	Sarcoma	Drug: valproic acid	Toxicity-related discontinuation rate|Lytic induction rate|Clinical response rate|Accelerated KS progression rate	AIDS Malignancy Consortium|National Cancer Institute (NCI)|The Emmes Company, LLC	All	18 Years and older   (Adult, Older Adult)	Not Applicable	19	Other|NIH|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	AMC-038|U01CA070019|CDR0000349348	February 2005	July 2007	February 2008	January 13, 2004		August 29, 2014	Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States|Veterans Affairs Medical Center - San Diego, San Diego, California, United States|UCSF Comprehensive Cancer Center, San Francisco, California, United States|Georgia Cancer Center for Excellence at Grady Memorial Hospital, Atlanta, Georgia, United States|Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Siteman Cancer Center at Barnes-Jewish Hospital, Saint Louis, Missouri, United States|Albert Einstein Cancer Center at Albert Einstein College of Medicine, Bronx, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Case Comprehensive Cancer Center, Cleveland, Ohio, United States|Joan Karnell Cancer Center at Pennsylvania Hospital, Philadelphia, Pennsylvania, United States|Floyd & Delores Jones Cancer Institute at Virginia Mason Medical Center, Seattle, Washington, United States		https://ClinicalTrials.gov/show/NCT00075777
873	NCT01775722	Combined Bipolar Radiofrequency&Pulsed Dye Laser Treatment		Completed	Has Results	Port-Wine Stain	Device: Pulsed Dye Laser|Device: Combined Bipolar Radiofrequency&Pulsed Dye Laser	Percent Change in Blanching of Port Wine Stain	University of California, Irvine|Candela Corporation|Beckman Laser Institute University of California Irvine	All	12 Years and older   (Child, Adult, Older Adult)	Not Applicable	22	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NIH/LAMMP-2012-9092	December 2012	August 2015	August 2015	January 25, 2013	April 9, 2018	April 9, 2018	Beckman Laser Institute Medical Clinic, Irvine, California, United States		https://ClinicalTrials.gov/show/NCT01775722
874	NCT00749372	MRI Screening for Patients With Myelodysplastic Syndrome (MDS), Who Have Received Multiple Red Blood Cell Transfusions	T2*MRI	Completed	No Results Available	Myelodysplastic Syndrome (MDS)	Other: T2* Cardiac and Liver MRI	To evaluate the incidence of clinically significant cardiac iron overload in heavily transfused MDS patients using T2* MRI.|Evaluate left ventricular ejection fraction as assessed by T2* MRI.|Evaluate liver iron concentration as assessed by R2* MRI	Weill Medical College of Cornell University|Novartis Pharmaceuticals	All	18 Years and older   (Adult, Older Adult)	Not Applicable	15	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening	0803009687|CICL670A US23T	July 31, 2008	March 29, 2013	March 29, 2013	September 9, 2008		October 25, 2018	Weill Medical College of Cornell University, New York, New York, United States		https://ClinicalTrials.gov/show/NCT00749372
875	NCT03843073	Connected Catheter- Evaluation Study		Recruiting	No Results Available	Chronic Urinary Retention	Device: Connected Urinary Catheter	Improved bladder management without injury to genito-urinary tract|Successful Connected Catheter Acute Retention (Acute Performance- I)|Successful Bladder Emptying Using Connected Catheter (Acute Performance- II)|Successful Connected Catheter Valve Sealing (Acute Performance- III)	Spinal Singularity	Male	18 Years to 100 Years   (Adult, Older Adult)	Not Applicable	80	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	ES-01	February 1, 2019	November 2019	December 2019	February 15, 2019		June 6, 2019	Northwest Urology Associates, 9151 West Thunderbird Rd, Suite 104, Peoria, Arizona, United States|Northwest Urology Associates, 14674 W. Mountain View Blvd, Suite 210, Surprise, Arizona, United States|West Coast Urology, 11411 Brookshire Avenue, Suite 508, Downey, California, United States|West Coast Urology, 575 E. Hardy St., Suite 215, Inglewood, California, United States|Orange County Urology Associates/Research Alliance, Laguna Hills, California, United States|Tri Valley Urology, 25495 Medical Center Dr., Suite 204, Murrieta, California, United States|The Urology Center of Colorado, Denver, Colorado, United States|Clinical Research Center of Florida, Pompano Beach, Florida, United States|Chesapeake Urology, Owings Mills, Maryland, United States|Minnesota Urology, 6025 Lake Road Suite 200, Woodbury, Minnesota, United States|New Jersey Urology, 15000 Midlantic Drive, Suite 100, Mount Laurel, New Jersey, United States|New Jersey Urology, 2401 Evesham Road, Suite F, Voorhees, New Jersey, United States|Dr. Jonathan Vapnek Urology, New York, New York, United States		https://ClinicalTrials.gov/show/NCT03843073
876	NCT00624585	Study of Oral Dasatinib in Subjects With Myelodysplastic Syndrome (MDS) and Excess Marrow Blasts		Completed	Has Results	Myelodysplastic Syndromes	Drug: Dasatinib	Number of Participants With Marrow Complete Remission (CR)|Number of Participants With Hematologic Improvement|Number of Participants With Partial Remission (PR)|Number of Participants With Stable Disease (SD)	H. Lee Moffitt Cancer Center and Research Institute|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Not Applicable	18	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MCC-15276|CA180-106	February 2008	May 2012	May 2012	February 27, 2008	June 25, 2012	December 16, 2013	H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States		https://ClinicalTrials.gov/show/NCT00624585
877	NCT01657942	Focal MR-Guided Focused Ultrasound Treatment of Localized Intermediate Risk Prostate Lesions		Active, not recruiting	No Results Available	Localized Intermediate Risk Prostate Lesions	Device: ExAblate MR Guided Focused Ultrasound	Safety of ExAblate MRgFUS focal treatment of intermediate risk organ confined prostate lesions|Effectiveness of ExAblate MRgFUS focal treatment of intermediate risk organ-confined prostate lesions	InSightec	Male	50 Years and older   (Adult, Older Adult)	Not Applicable	101	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PCa003	October 2013	December 2019	December 2020	August 6, 2012		May 27, 2019	City of Hope, Duarte, California, United States|University of California Los Angeles, Los Angeles, California, United States|Stanford University School of Medicine, Stanford, California, United States|Sperling Prostate Center, Delray Beach, Florida, United States|Brigham & Women's Hospital, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Weill Cornell Medical Center, New York, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|University of Virginia, Charlottesville, Virginia, United States		https://ClinicalTrials.gov/show/NCT01657942
878	NCT02703064	Furocyst - Poly Cystic Ovary Syndrome Study		Completed	No Results Available	PCOS	Dietary Supplement: Furocyst	Reduction in Overian volume & Number of overian Cysts|Restoration of normal menstrual cycle	Chemical Resources	Female	18 Years to 45 Years   (Adult)	Not Applicable	107	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	Protocol No. CR-PCOS/1-15	March 26, 2015	July 2017	July 2017	March 9, 2016		September 15, 2017	Dept of Obs & Gynae, King George's Medical University, Lucknow, UP, India, Lucknow, Uttar Pradesh, India		https://ClinicalTrials.gov/show/NCT02703064
879	NCT03673995	Myoinositol Plus L-tyrosine, Selenium and Chromium in PCOS		Active, not recruiting	No Results Available	Polycystic Ovary Syndrome|Menstrual Problem|Hirsutism	Dietary Supplement: Myo-inositol+L-tyrosine	Restore of regular mestrual period|Improving Hyrsutism|Restore ovulation	Pharmarte srl	Female	16 Years to 38 Years   (Child, Adult)	Not Applicable	186	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PharmarteLtyrosine1	May 2, 2017	August 22, 2018	September 30, 2018	September 17, 2018		September 17, 2018	Altamedica Reproductive Medicine, Roma, Italy		https://ClinicalTrials.gov/show/NCT03673995
880	NCT03422289	Improved Effects of MI Plus Alpha-LA in PCOS		Completed	No Results Available	Polycystic Ovary Syndrome	Dietary Supplement: myo-inositol plus folic acid|Dietary Supplement: myo-inositol plus folic acid plus alpha-lactalbumin	Restoration of ovulation|Increase of myo-inositol plasma levels after the treatment with myo-inositol plus alpha-lactalbumin compared to the levels at the baseline	Lo.Li.Pharma s.r.l	Female	20 Years to 35 Years   (Adult)	Not Applicable	37	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MI + alpha-LA	November 2, 2016	October 12, 2017	December 15, 2017	February 5, 2018		February 6, 2018	Department of Woman Health and Reproductive Medicine of Santo Spirito Hospital, Rome, Italy		https://ClinicalTrials.gov/show/NCT03422289
881	NCT02301494	Effectiveness of Imiquimod Topical Cream in Early Stage Cutaneous T-cell Lymphoma	CTCL	Not yet recruiting	No Results Available	Mycosis Fungoides	Drug: 3.75% Imiquimod Cream|Drug: 0.1% Fluocinonide Cream	Response Rate between baseline and week 16|Response Rate 24 and 52 weeks after baseline|Safety and tolerabiliy of Imiquimod in patients with CTCL (adverse events)|Learn about T cell dysregulation in the skin from patients with CTCL (Using left over tissue from biopsies)	Rochester General Hospital|Bausch Health Americas, Inc.|Rochester Skin Lymphoma Medical Group, PLLC	All	18 Years and older   (Adult, Older Adult)	Not Applicable	40	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	48861	August 2019	August 2019	August 2019	November 26, 2014		April 3, 2019			https://ClinicalTrials.gov/show/NCT02301494
882	NCT03154710	Relevance of a Web-mediated Follow up in Patients Having a Lymphoma With a High Risk of Relapse in Complete or Partial Response		Recruiting	No Results Available	Lymphoma, T-Cell|Lymphoma, Large B-Cell, Diffuse|Lymphoma, Hodgkin	Device: SENTINEL	Number of significant complications detected and confirmed by a medical consultation performed outside the standard follow-up|Complication detection time|Number of complication observed|Rate of hospitalization for vital emergency|Sensibility of the web-application|Compliance|Performances status (PS) at relapse|Quality of life|Depression|Satisfaction|Progression free survival|Overall survival	Weprom|SIVAN Innovation|Takeda	All	18 Years and older   (Adult, Older Adult)	Not Applicable	80	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	ILC-1-2016|2016-A01024-47	July 12, 2017	January 2020	July 2021	May 16, 2017		July 31, 2019	CHBA Vannes, Vannes, Bretagne, France|Institut Bergonié, Bordeaux, Gironde, France|Polyclinique du Parc, Caen, Normandie, France|Institut d'Hématologie de Basse Normandie, Caen, Normandie, France|Hôpital Privé du Confluent, Nantes, Pays De Loire, France|Centre Hospitalier Universitaire Jean Minjoz, Besançon, France|Polyclinique Bordeaux Nord, Bordeaux, France|Centre Hospitalier Univeritaire, Dijon, France|CHU Grenoble, Grenoble, France|Centre Jean Bernard, Le Mans, France|Ch Mont de Marsan, Mont-de-Marsan, France|Centre d'Oncologie de Gentilly, Nancy, France|Hopital Saint Louis, Paris, France|Clinique Saint Anne, Strasbourg, France|Centre Hospitalier Universitaire, Tours, France		https://ClinicalTrials.gov/show/NCT03154710
883	NCT03760926	A Trial of the AblaCare Device in Transvaginal Ablation of Ovarian Tissue Under ULTRAsound Visualization in Women With PCOS Infertility		Recruiting	No Results Available	Polycystic Ovary Syndrome	Device: AblaCare Kit	Adverse Events (AEs) in terms of type (device/procedure related), seriousness, level of severity. Rate of occurence of intra-procedural and post-procedural adverse events, and device related complications|Achievement of the desired number of ablations (assessed ahead of the procedure based on the ovarian volume of the patient and determined by the clinician) within each ovary under ultrasound visualization.|Occurrence of ovulation following the procedure|AblaCare Procedure time|Pain level using the Visual Analogue Scale (VAS - 0 : no pain - 10 : worse pain possible), record of pain medications with doses administered during procedure|Technical ease of the procedure (usability): scale of 1(very easy) - 5 (impossible)|Pain level using the Visual Analogue Scale (VAS - 0 : no pain - 10 : worse pain possible), record of pain medications with doses administered post-procedure	AblaCare	Female	18 Years to 40 Years   (Adult)	Not Applicable	30	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility	ULTRA	February 14, 2019	October 2019	September 2020	December 3, 2018		February 18, 2019	Royal Derby Hospital, Derby, United Kingdom		https://ClinicalTrials.gov/show/NCT03760926
884	NCT03076138	Gene-activated Bone Substitute for Maxillofacial Bone Regeneration		Completed	No Results Available	Bone Cysts|Bone Atrophy|Bone Deformity|Bone Fracture|Bone Loss|Tooth Loss	Device: Gene-activated matrix (OCP + plasmid DNA with VEGF gene)	Bone tissue formation in the field of gene-activated bone substitute implantation|Adverse Events and Serious Adverse Events|Surgical failure rate	Histograft Co., Ltd.|Moscow State University of Medicine and Dentistry	All	18 Years to 60 Years   (Adult)	Not Applicable	20	Industry|Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	RU-Histograft-20-08-2016	March 6, 2017	December 14, 2018	December 14, 2018	March 10, 2017		May 7, 2019	A.I. Moscow State University of Medicine and Dentistry, Moscow, Russian Federation		https://ClinicalTrials.gov/show/NCT03076138
885	NCT01540799	Pathway M-1: Sphenopalatine Ganglion Stimulation for the AcuteTreatment of High Disability Migraine Headache	Pathway M-1	Completed	No Results Available	High Frequency, High Disability Migraine	Device: ATI Neurostimulation System	Major Device- and Surgical-Related Complications|Effective Therapy	Autonomic Technologies, Inc.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	80	Industry	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	Pathway M-1 (CIP-003)	February 2012	May 2018	May 2018	February 29, 2012		June 26, 2018	Dept. of Neurology, K12 Bldg. 1st fl, De Pintelaan 185 B-9000, Ghent, Belgium|Danish Headache Center & Department of Neurology, Glostrup Hospital, University of Copenhagen, Glostrup, Copenhagen, Denmark|Servicio de Neurologia, Hospital Clinico Universitario, Valencia, Spain		https://ClinicalTrials.gov/show/NCT01540799
886	NCT00021151	Compassionate Use of Campath-1H in Treating Patients With Refractory Prolymphocytic Leukemia or Chronic Lymphocytic Leukemia		Completed	No Results Available	Leukemia	Biological: alemtuzumab		Case Comprehensive Cancer Center|National Cancer Institute (NCI)|Genzyme, a Sanofi Company	All	18 Years and older   (Adult, Older Adult)	Not Applicable	2	Other|NIH|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ILEX1999|CWRU-ILEX-1999|ILEX-CAM511-A1|NCI-G01-1977	January 2000	April 2001	May 2002	April 13, 2004		January 9, 2014	Ireland Cancer Center, Cleveland, Ohio, United States		https://ClinicalTrials.gov/show/NCT00021151
887	NCT00832130	Treatment of Meibomian Gland Dysfunction and Evaporative Dry Eye		Completed	Has Results	Chalazion|Dry Eye Syndromes	Device: Manual Mini System|Device: iHeat Portable Warm Compress Therapy	Meibomian Gland Assessment (Total Meibomian Gland Secretion Score)|Incidence of Device-related Adverse Events|Tear Break-up Time|Dry Eye Symptoms (Total SPEED Score)|Ocular Surface Staining (Corneal Staining Sum Score)|Intraocular Pressure|(LogMAR) Best Spectacle Corrected Visual Acuity|Discomfort Evaluation (Discomfort/Pain Score)	TearScience, Inc.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	139	Industry	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	LF001	February 2009	June 2009	August 2009	January 29, 2009	December 6, 2011	December 12, 2011	Fayetteville, Arkansas, United States|Morrow, Georgia, United States|Highland Park, Illinois, United States|Edgewood, Kentucky, United States|Lexington, Kentucky, United States|Winchester, Massachusetts, United States|Jackson, Michigan, United States|Bloomington, Minnesota, United States|Stillwater, Minnesota, United States|Charlotte, North Carolina, United States|Lancaster, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT00832130
888	NCT00472290	Evaluating the Safety of Long Term Dosing of Romiplostim (Formerly AMG 531) in Thrombocytopenic Subjects With Myelodysplastic Syndromes (MDS)		Completed	Has Results	Hematology|MDS|Myelodysplastic Syndromes|Thrombocytopenia	Drug: Romiplostim (formerly AMG 531)	Overall Summary of Adverse Events|Incidence of Antibody (AB) Formation|Weekly Bleeding Events Per 100 Subject Years|Platelet Transfusion Events Per 100 Subject Years|Weeks With Platelet Response Per Year|Time to First Platelet Response|Duration of Platelet Response	Amgen	All	18 Years and older   (Adult, Older Adult)	Not Applicable	72	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	20060197	April 1, 2007	July 18, 2011	December 26, 2011	May 11, 2007	July 15, 2013	December 29, 2017			https://ClinicalTrials.gov/show/NCT00472290
889	NCT02619604	A Quality Improvement Approach to the Management of Chronic Lymphocytic Leukemia	Med-IQ CLL	Completed	No Results Available	Chronic Lymphocytic Leukemia	Other: Education Intervention	Change in provider knowledge with management of Quality of Life Concerns for CLL patients, as measured by survey|Change in provider confidence with management of Quality of Life Concerns for CLL patients, as measured by survey	Duke University|Med-IQ|Gilead Sciences|Genentech, Inc.	All	Child, Adult, Older Adult	Not Applicable	50	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research	Pro00063975	May 2016	February 2017	February 2017	December 2, 2015		February 15, 2017	Duke Cancer Network, Durham, North Carolina, United States		https://ClinicalTrials.gov/show/NCT02619604
890	NCT02809222	Plasmatic L-AScorbic Acid in MYelodyplastic Syndroms and Controls	PLASMYC	Recruiting	No Results Available	Myelodysplastic Syndrome|Secondary Acute Myeloid Leukemia	Other: Samples|Other: Quality of life questionnaire	Plasmatic ascorbic acid concentration at baseline|Plasmatic ascorbic acid concentration during follow-up|Plasmatic antioxidants concentrations|Collection of plasma|Complete blood count and blood blasts cells|Polyunsaturated fatty acids|Plasmatic ascorbic acid concentration and number of adverse events|Oxidative stress parameters and number of adverse events|Plasmatic ascorbic acid concentration and parameters of iron metabolism|Plasmatic ascorbic acid concentration and quality of life|Collection of frozen cells	University Hospital, Tours|Tours Autogreffe|Novartis	All	60 Years and older   (Adult, Older Adult)	Not Applicable	180	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research	PHAO16-EG/PLASMYC|2016-A00539-42	October 25, 2016	March 2019	March 2019	June 22, 2016		October 27, 2017	Clinical Research Center, University Hospital, Tours, Tours, France|Department of Haematology and Cell Therapy, University Hospital, Tours, Tours, France		https://ClinicalTrials.gov/show/NCT02809222
891	NCT01222390	Tissue Expander Breast Reconstruction Study on Breast Volume and Shape Change	CPX3	Completed	Has Results	Contour Irregularity of Reconstructed Breast	Device: Contour Profile Tissue Expander	Breast Projection|Aesthetic Outcomes|Complication Rate|Emotional Outcomes|Location of Volume Change	Northwestern University|Mentor Worldwide, LLC	Female	25 Years to 85 Years   (Adult, Older Adult)	Not Applicable	12	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	G10-0056	November 2010	July 2013	April 2014	October 18, 2010	November 17, 2014	November 17, 2014	Northwestern University, Chicago, Illinois, United States		https://ClinicalTrials.gov/show/NCT01222390
892	NCT00487409	Random Comparison of LigaSure and Disposable Staples for Laparoscopic Surgery		Completed	No Results Available	Colonic Diseases|Rectal Diseases	Procedure: Bipolar electrosurgical generator and instruments|Procedure: Disposable stapling instruments	this study will evaluate the surgical approach using the Ligasure device at six weeks post operative.|Will evaluate the surgical approach using electrocautery with surgical clips and staples	University Hospitals Cleveland Medical Center|Tyco Healthcare Group	All	18 Years to 80 Years   (Adult, Older Adult)	Not Applicable	100	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	10-06-33	December 2006	November 2010	November 2010	June 18, 2007		December 15, 2014	University Hospitals of Cleveland Case Medical Center, Cleveland, Ohio, United States		https://ClinicalTrials.gov/show/NCT00487409
893	NCT03129373	Clinical Study : Efficacy and Safety of Three Cryotherapy Devices for Wart Treatment		Completed	No Results Available	Warts	Device: Cryogenic treatment of warts	Comparison of the percentage of subjects with clinical wart remission after 1 treatment in the Pixie® group versus comparators groups (Wartner® and Wortie®), as observed during a clinical evaluation of the treated wart by the dermatologist.|Comparison of the number of treatments needed for clinical remission of warts with the three products.|Surface area measurements of frostbite area to evaluate the efficacy of the freezing process, during the three applications if applicable.|Illustration of the visual aspects of the wart remission with macrophotographs.|Evaluation of the skin conditions at study end, assessed by the investigator by clinical evaluation.|Recording of adverse events.|Comparison of the percentage of subjects with clinical wart remission after 1, 2 and 3 treatments in the Pixie® group versus comparators groups (Wartner® and Wortie®), as observed during a clinical evaluation of the treated wart by the dermatologist.	Oystershell NV	All	4 Years and older   (Child, Adult, Older Adult)	Not Applicable	138	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment	14E2344	July 2015	November 2016	November 2016	April 26, 2017		September 19, 2017			https://ClinicalTrials.gov/show/NCT03129373
894	NCT01536834	Safety & Performance Study of Verruca Treatment Device		Completed	No Results Available	Verruca|Plantar Wart	Device: Medical Device	Safety Endpoint|Efficacy endpoint presence/absence of verruca by podiatrist|Efficacy endpoint presence/absence of verruca and pain by patient	Reckitt Benckiser LLC	All	18 Years and older   (Adult, Older Adult)	Not Applicable	35	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NPD396 02	June 2012	January 2013	February 2013	February 22, 2012		October 11, 2017	Mr. Andrew Ryals, Wakefield, Yorkshire, United Kingdom		https://ClinicalTrials.gov/show/NCT01536834
895	NCT02823158	Bilateral Pallidal Stimulation in Patients With Advanced Parkinson's Disease-LATESTIM	LATESTIM	Recruiting	No Results Available	Central Nervous System Disease|Basal Ganglia Disease|Movement Disorders|Neurodegenerative Disorders|Parkinson Disease	Procedure: Deep brain stimulation (DBS) of Globus Pallidus internus (GPi) and Best medical treatment (BMT)|Procedure: Best medical treatment	Difference of change of the score of the Parkinson's disease questionnaire 39 (PDQ-39-SI) from baseline to follow-up between the two treatment groups.|Difference of change in number of hours per day spent in motor "on" without troublesome dyskinesia from baseline to follow-up between the two treatment groups.|Difference of change of the score of the MDS-UPDRS part III (Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale, part III) from baseline to follow up between the two trial groups.|Difference of change of the score of the MDS-UPDRS part IV (Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale, part IV) (MDS-UPDRS) from baseline to follow up between the two trial groups.|Difference of change in number of hours per day spent in motor "on" with troublesome dyskinesia from baseline to follow-up between the two treatment groups.	University Hospital Inselspital, Berne|Boston Scientific Corporation	All	18 Years to 85 Years   (Adult, Older Adult)	Not Applicable	55	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	2016-000334	September 2016	September 2020	September 2020	July 6, 2016		October 12, 2018	Inselspital University Hospital Bern, Bern, Switzerland		https://ClinicalTrials.gov/show/NCT02823158
896	NCT01072097	The Effect of Atorvastatin on Androgens, Glucose Metabolism and Inflammation in Polycystic Ovary Syndrome (PCOS) Women		Completed	No Results Available	Polycystic Ovary Syndrome	Drug: Atorvastatin|Drug: Placebo	Androgen secretion|Glucose metabolism|Inflammatory markers	University of Oulu|Pfizer	Female	30 Years to 50 Years   (Adult)	Not Applicable	30	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	85/2006	September 2006	January 2011	January 2011	February 19, 2010		September 7, 2011	Department of Obstetrics and Gynaecology, University of Oulu, Oulu, Finland		https://ClinicalTrials.gov/show/NCT01072097
897	NCT03311152	Circulating Cell-free DNA-based Epigenetic Biomarker mSEPT9 for Hepatocellular Carcinoma Detection in Cirrhosis	SEPT9-CROSS	Recruiting	No Results Available	Hepatocellular Carcinoma|Cirrhosis	Diagnostic Test: "Epi proColon 2.0 CE" test from Epigenomics, Inc (Berlin, Germany)	Presence of hepatocellular carcinoma.|Presence of early hepatocellular carcinoma. Early hepatocellular carcinoma will be defined as a tumor smaller than 30 mm according to Kudo M (Liver Cancer. 2013;2:69-72).	Central Hospital, Nancy, France|Institut National de la Santé Et de la Recherche Médicale, France|Groupement Interrégional de Recherche Clinique et d'Innovation|Epigenomics, Inc	All	18 Years and older   (Adult, Older Adult)	Not Applicable	440	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Diagnostic	2017-A01885-48	February 12, 2018	February 12, 2021	February 12, 2022	October 17, 2017		February 16, 2018	University Hospital of Nancy (CHRU de Nancy), Vandoeuvre-lès-Nancy, France		https://ClinicalTrials.gov/show/NCT03311152
898	NCT02147353	Treatment of External Genital Warts With Cryotherapy and Sinecatechins 15% Ointment		Completed	Has Results	External Genital Warts	Drug: Sinecatechins 15% Ointment|Drug: Cryotherapy alone	Number of Participants With Complete Clearance,|Number of Participants With Recurrence of Previously Treated EGW Lesions|Local Skin Reactions|Subjects With Partial Clearance of Lesions|Mean Change in Number of Lesions	Icahn School of Medicine at Mount Sinai|Fougera Pharmaceuticals Inc.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	42	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment	GCO 11-0860	September 2011	December 2012	December 2012	May 26, 2014	June 14, 2019	June 14, 2019	Icahn School of Medicine at Mount Sinai, New York, New York, United States		https://ClinicalTrials.gov/show/NCT02147353
899	NCT01746056	A Comparative Study of Occlusive Heat Patch in the Treatment of Warts		Active, not recruiting	No Results Available	Verruca (Warts)	Device: Occlusive Heat Patch	Percent reduction in verrucae diameter	Yale University|Ferndale Laboratories, Inc.	All	5 Years and older   (Child, Adult, Older Adult)	Not Applicable	31	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	1209010850	December 2012	December 2017	December 2018	December 10, 2012		March 15, 2018	Yale School of Medicine, New Haven, Connecticut, United States		https://ClinicalTrials.gov/show/NCT01746056
900	NCT00749320	Arterial Spin Labeling Blood Flow MRI for Evaluation of Response to Antiangiogenic and Targeted Therapies of Renal Cell Carcinoma (RCC)		Active, not recruiting	No Results Available	Renal Cell Carcinoma	Other: Arterial Spin Labeling Magnetic Resonance Imaging	To explore the association of baseline blood flow in renal cell carcinoma measured by ASL MRI and tumor response to treatment with sunitinib or pazopanib|To explore the association of changes in tumor blood flow that occur early in the course of therapy compared to baseline and response of RCC to treatment with sunitinib or pazopanib|To evaluate the association between canges in tumor blood flow on ASL over the course of therapy and at the time of disease progression and resistance to therapy	Beth Israel Deaconess Medical Center|Dana-Farber Cancer Institute|Brigham and Women's Hospital|Pfizer|Novartis	All	18 Years and older   (Adult, Older Adult)	Not Applicable	40	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	08-078	September 2008	December 2019	December 2019	September 9, 2008		June 25, 2019	Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT00749320
901	NCT02530619	Alisertib in Treating Patients With Myelofibrosis or Relapsed or Refractory Acute Megakaryoblastic Leukemia		Active, not recruiting	No Results Available	Acute Megakaryoblastic Leukemia|Myelofibrosis|Primary Myelofibrosis	Drug: Alisertib|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study	Incidence of adverse events|Response to treatment	Northwestern University|The Leukemia and Lymphoma Society|Millennium Pharmaceuticals, Inc.|National Cancer Institute (NCI)	All	18 Years and older   (Adult, Older Adult)	Not Applicable	26	Other|Industry|NIH	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NU 15H10|NCI-2015-01219|STU00200682|P30CA060553	October 2015	July 2019	March 2020	August 21, 2015		February 16, 2018	University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States|Northwestern University, Chicago, Illinois, United States|Mayo Clinic, Rochester, Minnesota, United States		https://ClinicalTrials.gov/show/NCT02530619
902	NCT03850028	Molecular Imaging Using Radiolabeled Atezolizumab to Assess Atezolizumab Biodistribution in Lymphoma Patients		Recruiting	No Results Available	Diffuse Large B-Cell Lymphoma, Not Otherwise Specified	Other: 89Zr-atezolizumab PET scans	Biodistribution of 89Zr-atezolizumab|PDL1 and human leukocyte antigen (HLA) expression using immunohistochemistry (IHC)|Soluble programmed death ligand 1 (sPDL1) measurement using an enzyme-linked immunosorbent assay (ELISA).|Gene expression profiling (GEP) via Nanostring|Next generation sequencing (NGS) data	University Medical Center Groningen|VU University Medical Center|Stichting Hemato-Oncologie voor Volwassenen Nederland|Hoffmann-La Roche	All	18 Years to 75 Years   (Adult, Older Adult)	Not Applicable	20	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	201700599|2017-003511-20|NL63047.042.18	May 22, 2019	April 2, 2025	April 2, 2025	February 21, 2019		June 18, 2019	VU University Medical Center, Amsterdam, Noord-Holland, Netherlands|University Medical Center Groningen, Groningen, Netherlands		https://ClinicalTrials.gov/show/NCT03850028
903	NCT01289171	Acquired Epidermodysplasia Verruciformis (EV) Syndrome in HIV-infected Pediatric Patients		Completed	No Results Available	Flat Warts (Diagnosis)|HIV Infections	Drug: Glycolic acid	Treatment efficacy of 15% glycolic acid lotion for flat warts|Safety and tolerability of 15% glycolic acid lotion for flat warts|HPV typing in EV-like flat warts	University of Pennsylvania|NeoStrata Company, Inc.|Penn Center for AIDS Research (CFAR)	All	7 Years and older   (Child, Adult, Older Adult)	Not Applicable	38	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	P30AI045008	January 2009	June 2009	October 2010	February 3, 2011		February 3, 2011	Princess Marina Hospital, Gaborone, Botswana		https://ClinicalTrials.gov/show/NCT01289171
904	NCT01868451	Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma		Recruiting	No Results Available	Hodgkin Lymphoma	Drug: Brentuximab vedotin (SGN-35)|Drug: Doxorubicin HCL|Drug: Vinblastine Sulfate|Drug: Dacarbazine|Radiation: Involved-Site Radiation Therapy (ISRT)|Procedure: Interim PET|Radiation: consolidation volume RT (CVRT)	development of significant pulmonary toxicity|complete responses (all cohorts)|Evaluate the prognostic significance	Memorial Sloan Kettering Cancer Center|Seattle Genetics, Inc.|University of Rochester|City of Hope Medical Center|Stanford University	All	18 Years and older   (Adult, Older Adult)	Not Applicable	117	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	13-034	May 2013	May 2020	May 2020	June 4, 2013		July 15, 2019	City of Hope, Duarte, California, United States|Stanford University Medical Center, Stanford, California, United States|Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States|Memoral Sloan Kettering Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States|Memorial Sloan Kettering Commack, Commack, New York, United States|Memorial Sloan Kettering Westchester, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Memorial Sloan Kettering Nassau, Uniondale, New York, United States		https://ClinicalTrials.gov/show/NCT01868451
905	NCT01790633	Pilot Study Evaluating the Use of Simultaneous HBV, HCV, and HIV Rapid Tests	OPTISCREEN-III	Completed	Has Results	HIV|Hepatitis B|Hepatitis C|Carcinoma, Hepatocellular|AIDS	Other: ELISA|Other: Rapid Test	Accessibility of Testing Results|Access to Care	Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Gilead Sciences|Roche Pharma AG|Mairie de Paris|BioMérieux	All	18 Years and older   (Adult, Older Adult)	Not Applicable	327	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening	IMEA 38B|2012-A01681-42	February 2013	June 2013	October 2013	February 13, 2013	December 13, 2016	December 13, 2016	Consultation d'Accueil, de Soins et d'Orientation (CASO) de Médecins du Monde (MDM), Paris, France		https://ClinicalTrials.gov/show/NCT01790633
906	NCT01767597	Application of HBV Rapid Tests as a Tool for Wide-Use Screening	OPTISCREEN-B	Completed	Has Results	Hepatitis B|Liver Cirrhosis|Carcinoma, Hepatocellular	Other: ELISA testing|Other: Rapid testing	Percentage of Patients Appropriately Seeking Care	Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Gilead Sciences|Roche Pharma AG|Mairie de Paris|BioMérieux	All	18 Years and older   (Adult, Older Adult)	Not Applicable	1000	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening	IMEA 38|2011-A01603-38	February 2012	July 2012	January 2013	January 14, 2013	December 13, 2016	December 13, 2016	Centre de Santé au Maire-Volta, Paris, France|Centre d'examen de santé de la CPAM, antenne rue du Maroc, Paris, France|Consultation Policlinique de l'hôpital Saint-Antoine, Paris, France|Consultation Voyage de l'hôpital Saint-Antoine, Paris, France|CDAG de Belleville, Paris, France		https://ClinicalTrials.gov/show/NCT01767597
907	NCT02440906	Evaluation of the Texas Wellness Incentives and Navigation (WIN) Project	WIN	Completed	No Results Available	Chronic Mental Illness|Chronic Physical Illness	Behavioral: Patient-Directed Wellness Account|Behavioral: Health Navigator	Self-reported physical health related quality of life (HRQOL) using the Short Form-12 (SF-12)|Self-reported mental health related quality of life (HRQOL) using the Short Form-12 (SF-12)|Change in Total Healthcare expenditures as measured through Medicaid claims data|Changes in Inpatient Hospitalization expenditures as measured through Medicaid claims data|Changes in Outpatient expenditures as measured through Medicaid claims data|Changes in Emergency Department expenditures as measured through Medicaid claims data	University of Florida|Centers for Medicare and Medicaid Services|RTI International|Econometrica, Inc.	All	21 Years to 55 Years   (Adult)	Not Applicable	1663	Other|U.S. Fed|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	168-2012	June 2012	December 2015	December 2016	May 12, 2015		October 3, 2017	University of Florida, Institute for Child Health Policy, Gainesville, Florida, United States		https://ClinicalTrials.gov/show/NCT02440906
908	NCT02595645	GENESIS: Genetic Biopsy for Prediction of Surveillance Intervals After Endoscopic Resection of Colonic Polyps	GENESIS	Completed	No Results Available	Colonic Polyps	Genetic: Polypectomy and NGS	Genetic landscape of colonic polyps based on NGS-analysis	University of Ulm|Technische Universität München|Medical University of Graz|Specialized Medical Office for Gastroenterology Dornstadt|QIAGEN Gaithersburg, Inc	All	18 Years and older   (Adult, Older Adult)	Not Applicable	101	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening	GENESIS	August 2015	August 2016	October 2016	November 3, 2015		November 3, 2016	Medical University Graz, Graz, Steiermark, Austria|Specialized Medical Office for Gastroenterology, Dornstadt, Baden-Württemberg, Germany|University Ulm, Internal Medicine I, Interventional and Experimental Endoscopy (InExEn), Ulm, Baden-Württemberg, Germany|Technical University Munich, Munich, Bavaria, Germany		https://ClinicalTrials.gov/show/NCT02595645
909	NCT02146131	Ultrathin Bronchoscope and Radial Endobronchial Ultrasound (R-EBUS) With Fluoroscopy Versus Standard Fiberoptic Bronchoscopy (FB) (P00029233 )		Completed	Has Results	Pulmonary Lesions|Pulmonary Nodules|Pulmonary Mass	Device: Standard FB with fluoroscopy|Device: R-EBUS with ultrathin bronchoscope	Diagnostic Yield of Procedures; Number of Positive Diagnosis of Pulmonary Lesions	Medical University of South Carolina|Olympus|Johns Hopkins University|Washington Hospital Center|Mayo Clinic|Washington University School of Medicine	All	22 Years and older   (Adult, Older Adult)	Not Applicable	339	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	00029233	July 2014	July 14, 2017	July 14, 2017	May 23, 2014	September 25, 2018	September 25, 2018	Medstar Washington Hospital Center, Washington, District of Columbia, United States|University of Florida, Gainesville, Florida, United States|Johns Hopkins University, Baltimore, Maryland, United States|Washington University Saint Louis, Saint Louis, Missouri, United States|Medical University of South Carolina, Charleston, South Carolina, United States	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/31/NCT02146131/Prot_SAP_000.pdf|"Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/31/NCT02146131/ICF_001.pdf	https://ClinicalTrials.gov/show/NCT02146131
910	NCT03437382	Holmium Radioembolization as Adjuvant Treatment to RFA for Early Stage HCC: Dose Finding Study	HORA EST HCC	Recruiting	No Results Available	HCC|Early Stage HCC	Device: Quirem Medical Holmium-166 radioembolization microspheres	Dose-finding|Toxicity|Local tumor recurrence|Time to progression|Progression-free survival|Quality of Life	Leiden University Medical Center|ZonMw: The Netherlands Organisation for Health Research and Development|Health Holland|Quirem Medical B.V.|Medtronic|Maag Lever Darm Stichting	All	18 Years and older   (Adult, Older Adult)	Not Applicable	20	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	P17.161|ZonMW	July 1, 2018	August 1, 2019	August 1, 2020	February 19, 2018		August 8, 2018	Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands		https://ClinicalTrials.gov/show/NCT03437382
911	NCT02658279	Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype		Recruiting	No Results Available	Glioma|Recurrent Malignant Glioma	Drug: Pembrolizumab	response rate	Memorial Sloan Kettering Cancer Center|Merck Sharp & Dohme Corp.|M.D. Anderson Cancer Center|Dana-Farber Cancer Institute|University of California, San Francisco|Huntsman Cancer Institute/ University of Utah|University of California, Los Angeles|University of Miami	All	18 Years and older   (Adult, Older Adult)	Not Applicable	44	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	15-227	January 22, 2016	January 2020	January 2020	January 18, 2016		January 16, 2019	University of California, Los Angeles, Los Angeles, California, United States|University of California San Francisco, San Francisco, California, United States|University of Miami, Miami, Florida, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Memoral Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States|Memorial Sloan Kettering Cancer Center at Commack, Commack, New York, United States|Memorial Sloan Kettering Westchester, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Md Anderson Cancer Center, Houston, Texas, United States|University of Utah, Salt Lake City, Utah, United States		https://ClinicalTrials.gov/show/NCT02658279
912	NCT03880435	HYALOBARRIER® GEL ENDO Versus no HYALOBARRIER® GEL ENDO Following Operative Hysteroscopy for Improving Reproductive Outcome in Women With Intrauterine Pathology Wishing to Become Pregnant	AGNOHSTIC	Recruiting	No Results Available	Infertility|Polyp Uterus|Myoma;Uterus|Adhesion|Hysteroscopy|Uterine Septum|Retained Products of Conception	Device: Hyalobarrier® gel endo	Conception leading to live birth|Time to conception|Clinical pregnancy|Miscarriage|Ectopic pregnancy|Adhesions|Pre-eclampsia in women who conceived during the study period, leading to an ongoing pregnancy beyond 20 weeks of gestation|Preterm birth in women who conceived during the study period, leading to an ongoing pregnancy beyond 20 weeks of gestation|Stilbirth in women who conceived during the study period, leading to an ongoing pregnancy beyond 20 weeks of gestation|Low/very low birth weight (gram) in women who conceived during the study period, leading to an ongoing pregnancy beyond 20 weeks of gestation|Caesarean section rates in women who conceived during the study period, leading to an ongoing pregnancy beyond 20 weeks of gestation|Neonatal complications in women who conceived during the study period, leading to an ongoing pregnancy beyond 20 weeks of gestation|Direct health-related costs	University Hospital, Ghent|Belgium Health Care Knowledge Centre|Nordic Pharma SAS|Universitaire Ziekenhuizen Leuven|Universitair Ziekenhuis Brussel|Imelda Hospital, Bonheiden|CTC BIMETRA|University of Liège|UCL Bruxelles	Female	18 Years to 47 Years   (Adult)	Not Applicable	420	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention	AGNOHSTIC	April 1, 2019	November 1, 2019	May 26, 2024	March 19, 2019		May 9, 2019	University hospital Ghent, Ghent, East-Flanders, Belgium		https://ClinicalTrials.gov/show/NCT03880435
913	NCT03327597	Iceland Screens, Treats or Prevents Multiple Myeloma	iStopMM	Active, not recruiting	No Results Available	Monoclonal Gammopathy of Undetermined Significance	Other: Clinical follow-up 1|Other: QoL questionnaire|Other: Standard follow-up or treatment.|Other: Clinical follow-up 2|Other: Clinical follow-up 3|Other: Clinical follow-up control	Overall survival|Cause specific survival|Quality of life (QoL)|Cost-effectiveness of screening for MGUS	University of Iceland|Landspitali University Hospital|Union for International Cancer Control|Icelandic Heart Association|deCODE genetics|International Myeloma Foundation/Black Swan Research Initiative|The Binding Site|Memorial Sloan Kettering Cancer Center|European Research Council|The Icelandic Centre for Research	All	40 Years and older   (Adult, Older Adult)	Not Applicable	80761	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Screening	UI-2017-MGUS	September 1, 2016	September 1, 2021	September 1, 2021	October 31, 2017		March 26, 2019	University of Iceland, Reykjavík, Iceland		https://ClinicalTrials.gov/show/NCT03327597
